<SEC-DOCUMENT>0000950123-24-011929.txt : 20250310
<SEC-HEADER>0000950123-24-011929.hdr.sgml : 20250310
<ACCEPTANCE-DATETIME>20241114210250
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-24-011929
CONFORMED SUBMISSION TYPE:	DRS
PUBLIC DOCUMENT COUNT:		7
FILED AS OF DATE:		20241115
<PUBLIC-REL-DATE>20250310
DATE AS OF CHANGE:		20241115

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Hinge Health, Inc.
		CENTRAL INDEX KEY:			0001673743
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMPUTER PROCESSING & DATA PREPARATION [7374]
		ORGANIZATION NAME:           	06 Technology
		IRS NUMBER:				811884841
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-07560
		FILM NUMBER:		241465556

	BUSINESS ADDRESS:	
		STREET 1:		455 MARKET STREET
		STREET 2:		7TH FLOOR
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94105
		BUSINESS PHONE:		415-689-8429

	MAIL ADDRESS:	
		STREET 1:		455 MARKET STREET
		STREET 2:		7TH FLOOR
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94105
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>DRS</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>As confidentially submitted to the U.S. Securities and Exchange Commission on
November&nbsp;14, 2024. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>This draft registration statement has not been filed publicly with the Securities and Exchange Commission and
all information contained herein remains confidential. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="right"><B>Registration
<FONT STYLE="white-space:nowrap">No.&nbsp;333-&#8194;&#8194;&#8194;&#8194;&#8194;</FONT> </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES
AND EXCHANGE COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-1</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Hinge Health, Inc. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>7370</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">81-1884841</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>455 Market Street, Suite 700 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>San Francisco, California 94105 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(415) <FONT STYLE="white-space:nowrap">726-2206</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of registrant&#146;s principal executive offices) </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Daniel Perez </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Chief
Executive Officer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Hinge Health, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>455 Market Street, Suite 700 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>San Francisco, California 94105 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(415) <FONT STYLE="white-space:nowrap">726-2206</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for service) </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Tad J. Freese</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Erica D. Kassman</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Latham&nbsp;&amp; Watkins LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>140 Scott Drive</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Menlo Park,
California 94025</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(650) <FONT STYLE="white-space:nowrap">328-4600</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>David Wood</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Hinge Health, Inc.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>455
Market Street, Suite 700</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>San Francisco, California 94105</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(415) <FONT STYLE="white-space:nowrap">726-2206</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Alan Denenberg</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Shane Tintle</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Davis
Polk&nbsp;&amp; Wardwell LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>900 Middlefield Road, Suite 200</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Redwood City, California 94063</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(650) <FONT STYLE="white-space:nowrap">752-2000</FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman" ALIGN="justify"><B>Approximate date of commencement of proposed sale to the public:</B> As soon as practicable after the effective date of this
registration statement. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman" ALIGN="justify">If any of the securities being registered on this Form are to be offered on a delayed or continuous
basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.&#8194;&#9744; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman" ALIGN="justify">If this Form is filed
to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&#8194;&#9744; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman" ALIGN="justify">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act,
check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman" ALIGN="justify">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and
list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman" ALIGN="justify">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT
STYLE="white-space:nowrap">non-accelerated</FONT> filer, a smaller reporting company or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company&#148; and
&#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt">Large&nbsp;accelerated&nbsp;filer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt">&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt">Accelerated filer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt">&#9744;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt">&#9746;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt">Smaller&nbsp;reporting&nbsp;company</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt">&#9744;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt">Emerging&nbsp;growth&nbsp;company</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt">&#9746;</P></TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman" ALIGN="justify">If an emerging growth company, indicate by check mark if the registrant has elected not to use
the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&#8194;&#9744; </P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman" ALIGN="justify"><B>The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective
date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until the
registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Explanatory Note: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the applicable provisions of the Fixing America&#146;s Surface Transportation Act, we are omitting our audited
financial statements as of and for the year ended December&nbsp;31, 2022, and our unaudited financial statements as of and for the nine months ended September&nbsp;30, 2024 and 2023 because they relate to historical periods that we believe will not
be required to be included in the prospectus at the time of the contemplated offering. We intend to amend this registration statement to include all financial information required by Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> at the date
of such amendment before publicly filing this registration statement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Arial Narrow" ALIGN="justify"><FONT COLOR="#de1a1e"><B>The information in this preliminary prospectus is not complete and
may be changed. We and the selling stockholders may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and
neither we nor the selling stockholders are soliciting offers to buy these securities in any jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><FONT COLOR="#de1a1e"><I>PRELIMINARY PROSPECTUS (Subject to Completion) </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><FONT COLOR="#de1a1e"><I>Issued&#8195;&#8195;&#8195;&#8195;, 2025 </I></FONT></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><I>&#8195;&#8195;&#8195;&#8195;Shares </I></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g829170g70a03.jpg" ALT="LOGO" STYLE="width:2.32843in;height:0.925811in;">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><I>Class&nbsp;A Common Stock </I></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:9pt; font-family:Bodoni MT" ALIGN="justify"><I>Hinge Health, Inc. is offering &#8195;&#8195;&#8195;&#8195;shares of its Class&nbsp;A common stock and the selling stockholders identified in this
prospectus are offering an aggregate of &#8195;&#8195;&#8195;&#8195;shares of Class&nbsp;A common stock. This is our initial public offering and no public market currently exists for shares of our Class&nbsp;A common stock. We will not receive any
proceeds from the sale of shares of Class&nbsp;A common stock by any of the selling stockholders. We anticipate that the initial public offering price per share of our Class&nbsp;A common stock will be between $&#8195;&#8195; and $&#8195;&#8195;.
</I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:9pt; font-family:Bodoni MT" ALIGN="justify"><I>We intend to apply to list our Class&nbsp;A common stock on the &#8195;&#8195;&#8195;&#8195; under the symbol
&#147;&#8195;&#8195;&#8195;&#8195;.&#148; </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:9pt; font-family:Bodoni MT" ALIGN="justify"><I>Following this offering, we will have two classes of common stock, Class&nbsp;A common stock and
Class&nbsp;B common stock (collectively, our &#147;common stock&#148;). The rights of holders of Class&nbsp;A common stock and Class&nbsp;B common stock will be identical, except with respect to voting and conversion rights. Each share of
Class&nbsp;A common stock will be entitled to one vote. Each share of Class&nbsp;B common stock will be entitled to 15 votes and will be convertible at any time into one share of Class&nbsp;A common stock. The holders of outstanding shares of
Class&nbsp;B common stock will hold approximately &#8195; % of the voting power of our outstanding capital stock after the completion of this offering, with our directors, executive officers, and 5% stockholders and their respective affiliates
holding approximately &#8195;% of the voting power, assuming no exercise of the underwriters&#146; option to purchase additional shares, if any. </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:9pt; font-family:Bodoni MT" ALIGN="justify"><I>We are an &#147;emerging growth company&#148; as defined under the U.S. federal securities laws and, as such, may elect to comply with certain
reduced public company reporting requirements for this prospectus and future filings. </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify"><B><I>Investing in our Class&nbsp;A common stock
involves risks. See &#147;<A HREF="#rom829170_4">Risk Factors</A>&#148; beginning on page&nbsp;21 to read about factors you should consider before deciding to invest in our Class&nbsp;A common stock. </I></B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><I>PRICE $&#8195;&#8195;&#8195;&#8195; A SHARE </I></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Bodoni MT; " ALIGN="center"><B><I>Price
to<BR>Public</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Bodoni MT; " ALIGN="center"><B><I>Underwriting<BR>Discounts<BR>and<BR>Commissions&nbsp;(1)</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Bodoni MT; " ALIGN="center"><B><I>Proceeds
to<BR>Hinge&nbsp;Health&nbsp;(2)</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Bodoni MT; " ALIGN="center"><B><I>Proceeds
to<BR>Selling<BR>Stockholders&nbsp;(2)</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><I>Per share</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>$&#8195;&#8195;&#8194;&#8201;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>$&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8194;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>$&#8195;&#8195;&#8195;&#8195;&#8195;&#8201;&#8195;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>$&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><I>Total</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>$&#8195;&#8195;&#8194;&#8201;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>$&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8194;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>$&#8195;&#8195;&#8195;&#8195;&#8195;&#8201;&#8195;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>$&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(1)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="justify"><I>See the section titled &#147;Underwriters&#148; for additional information regarding compensation payable
to the underwriters. </I></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(2)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="justify"><I>Before expenses. </I></P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="justify"><I>We have granted the underwriters an option for a period of 30 days to purchase up to an additional &#8195;&#8195;&#8195;&#8195; shares of our
Class&nbsp;A common stock at the initial public offering price less the underwriting discounts and commissions. </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="justify"><I>The Securities and
Exchange Commission and state securities regulators have not approved or disapproved these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="justify"><I>The underwriters expect to deliver the shares of Class&nbsp;A common stock to purchasers on &#8195;&#8195;&#8195;&#8195;&#8195;, 2025.
</I></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:15pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="36%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:15pt">
<TD VALIGN="top"><I>MORGAN&nbsp;STANLEY</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><I>BARCLAYS</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><I>BOFA&nbsp;SECURITIES</I></TD></TR>
</TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="justify"><I>&#8195;&#8195;&#8195;&#8195;, 2025 </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom829170_1a">Glossary of Terms</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">iii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom829170_1">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom829170_2">The Offering</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom829170_3">Summary Consolidated Financial Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom829170_4">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom829170_5">Special Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom829170_6">Market and Industry Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom829170_7">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom829170_8">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom829170_9">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom829170_10">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom829170_11">Management&#146;s Discussion and Analysis of Financial Condition and Results
 of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom829170_12">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
</DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom829170_13">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom829170_14">Executive and Director Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom829170_15">Certain Relationships and Related-Party Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom829170_16">Principal and Selling Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom829170_17">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom829170_18">Shares Eligible for Future Sale</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom829170_19">Material U.S. Federal Income Tax Consequences to <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom829170_20">Underwriters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom829170_21">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom829170_22">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom829170_23">Where You Can Find Additional Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom829170_24">Index to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> </div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As used in this prospectus, unless the context otherwise requires, references to &#147;Hinge Health,&#148; the
&#147;company,&#148; &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; and similar terms refer to Hinge Health, Inc., and, where appropriate, its subsidiaries, taken as a whole, and its predecessor, Marblar Limited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Hinge Health,&#148; the Hinge Health logos, and other trade names, trademarks, or service marks of Hinge Health
appearing in this prospectus are the property of Hinge Health, Inc. Other trade names, trademarks, or service marks appearing in this prospectus are the property of their respective holders. We do not intend our use or display of other
companies&#146; trade names, trademarks, or service marks to imply a relationship with, or endorsement or sponsorship of us by, these other companies. Solely for convenience, trade names, trademarks, and service marks referred to in this prospectus
appear without the <SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, <SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>, and <SUP STYLE="font-size:75%; vertical-align:top">SM</SUP> symbols, but those references are not intended to
indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner will not assert its rights, to these trade names, trademarks, and service marks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Numerical figures included in this prospectus have been subject to rounding adjustments. Accordingly, numerical figures shown
as totals in various tables may not be arithmetic aggregations of the figures that precede them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">References to
www.hingehealth.com in this prospectus are inactive textual references only, and the information contained on, or that can be accessed through, our website does not constitute part of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Neither we, the selling stockholders, nor the underwriters have authorized anyone to provide you any information or to make
any representations other than those contained in this prospectus or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. Neither we, the selling stockholders, nor the underwriters take responsibility for,
or provide any assurance as to the reliability of, any other information others may give you. This prospectus is an offer to sell only the shares offered hereby, and only under circumstances and in jurisdictions where it is lawful to do so. We are
not, the selling stockholders are not, and the underwriters are not, making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. The information contained in this prospectus is accurate only as of the date
of this prospectus, regardless of the time of delivery of this prospectus or any sale of the shares of our common stock. Our business, results of operations, and financial condition may have changed since that date. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>For investors outside the United States</I>: Neither we, the selling
stockholders, nor the underwriters have done anything that would permit this offering or the possession or distribution of this prospectus or any free writing prospectus in connection with this offering in any jurisdiction where action for that
purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of our common
stock and the distribution of this prospectus outside the United States. See the section titled &#147;Underwriters&#148; for additional information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Through and including &#8195;&#8195;&#8195;&#8195;, 2025 (the 25th day after the date of this prospectus), all dealers that
buy, sell, or trade our Class&nbsp;A common stock, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to the obligation of dealers to deliver a prospectus when acting as
underwriters and with respect to their unsold allotments or subscriptions. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom829170_1a"></A>GLOSSARY OF TERMS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following are abbreviations, acronyms, and definitions of certain terms used in this prospectus: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="76%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Term</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Definition</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Calculated Billings</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Total revenue, plus the change in deferred revenue, less the change in contract assets for the period.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Clients</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Businesses or organizations, which we call entities, that have at least one active agreement with us at the end of a particular period. Entities that procure our platform through our partners are counted as individual clients. We
do not count our partners as clients unless they also separately have at least one active client agreement with us. When a partner has an agreement with us for their fully-insured population, that partner is deemed to be one client, despite there
being multiple fully-insured employers within that partner that have access to our platform.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Contracted Lives</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Individuals within our contracted clients who have, or will have, the ability to enroll in our programs, typically employees and their adult dependents. Contracted lives include individuals within contracted clients that have not
yet launched our platform, and thus such individuals are not yet eligible to be billed. Contracted lives include eligible lives.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Electronic&nbsp;Health&nbsp;Record (&#147;EHR&#148;)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Collection of patient health records electronically stored in a digital format.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Eligible Lives</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Individuals within our clients that have launched our platform, and thus such individuals have the ability to enroll in our programs and are eligible to be billed. Eligible lives are a subgroup of our contracted lives.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Fully-Insured Employers</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Employers that pay a group health insurance provider for the employees enrolled in the insurance provider&#146;s health plan, and the insurance provider is responsible for those employees&#146; medical claims.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>HingeConnect</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">A proprietary member identification and engagement engine based on an <FONT STYLE="white-space:nowrap">AI-driven</FONT> database that integrates external EHRs and other data sources into Hinge Health&#146;s technology platform.
HingeConnect informs care and enables highly personalized care and coordination with external providers.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>LTM&nbsp;Average&nbsp;Eligible Lives</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">The average number of eligible lives calculated as the sum of eligible lives as of the first quarter and eligible lives as of the end of the last quarter in a given <FONT STYLE="white-space:nowrap">12-month</FONT> period, divided
by two.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Medicare Advantage</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Health plan for people aged 65 and older that is managed by private insurance companies that contract with the federal government. These private insurance companies receive a set payment from Medicare, administer benefits, and
bear the financial risk of claims made by plan beneficiaries.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Member</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">An eligible life, including employees and adult dependents of our clients, who has engaged with our platform at any point and whose engagement has been billed or is contractually eligible to be
billed.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="75%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>MSK</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Musculoskeletal system, which refers to the performance of the locomotor system composed of intact muscles, bones, joints, and adjacent connective tissues.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Net Dollar Retention (&#147;NDR&#148;)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Total revenue generated from our clients during a particular <FONT STYLE="white-space:nowrap">12-month</FONT> period divided by total revenue generated from such clients during the prior
<FONT STYLE="white-space:nowrap">12-month</FONT> period. This metric compares revenue from the same cohort of clients across comparable periods and reflects renewals, expansion, contraction, and churn.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Partners</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Health plans, Pharmacy Benefit Managers (&#147;PBMs&#148;), Third-Party</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Administrators (&#147;TPAs&#148;), and other ecosystem entities such as centers of excellence and healthcare navigation companies.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Pharmacy Benefit Managers (&#147;PBMs&#148;)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Third-party companies that act as an intermediary between insurance providers and pharmaceutical companies.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Return on Investment (&#147;ROI&#148;)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Return on investment for a client is calculated as the average medical claim cost savings divided by the average subscription fee, on a per member per year basis for a given period.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Self-Insured Employers</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Employers who bear the financial risk of medical claims for their employees and their dependents and utilize health plans for their administrative services only.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I><FONT STYLE="white-space:nowrap">Third-Party&nbsp;Administrator</FONT> (&#147;TPA&#148;)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Company or organization that collects and processes insurance claims and delivers support for health plans and employers.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iv </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom829170_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>This summary highlights information contained elsewhere in this prospectus and does not contain all of the information that
you should consider in making your investment decision. Before investing in our Class&nbsp;A common stock, you should carefully read this entire prospectus, including our consolidated financial statements and the related notes included elsewhere in
this prospectus and the information set forth under the sections titled &#147;Risk Factors,&#148; &#147;Special Note Regarding Forward-Looking Statements,&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results
of Operations.&#148; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our vision is to create a vertically integrated healthcare system powered by innovative technology &#150; and we are starting
with MSK care. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Hinge Health is a leading technology platform for individuals seeking to treat and prevent joint and
muscle pain. We leverage AI and software to deliver an outstanding member experience, improved member outcomes, and cost reductions for our clients. We have designed our platform to address a broad spectrum of joint and muscle care&#151;from acute
injury, to chronic pain, to post-surgical rehabilitation. Our platform integrates <FONT STYLE="white-space:nowrap">AI-powered</FONT> motion tracking technology, a proprietary electrical nerve stimulation wearable device, and an <FONT
STYLE="white-space:nowrap">AI-supported</FONT> care team of licensed physical therapists, physicians, and board-certified health coaches to address our members&#146; MSK conditions while reducing the need for surgeries or pain medications. Our
platform is driving equity in care access by meeting our members where they are, allowing them to choose where, when, and how often they engage in their exercise therapy sessions and embrace movement as a way of life. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There is no shortage of new technologies in the healthcare industry, yet the cost of care continues to rise. In other
industries, the launch of new technologies has generally improved user experiences and lowered costs. In healthcare, however, new technologies have not always been successful in lowering the cost of care or improving clinical outcomes. We believe
the key reasons healthcare&#146;s response to technology has been idiosyncratic are because: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Previous technologies often delivered care digitally, but without significantly differentiating the member
experience, outcomes, or cost savings as compared to offline providers; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The current framework for healthcare reimbursement has specific pathways to pay for care, which means new
technologies are constrained to deliver within this framework. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At Hinge Health, we have taken a
different approach to solving these problems. Our platform uses AI and software to deliver effective MSK care with an <FONT STYLE="white-space:nowrap">AI-supported</FONT> care team. We developed novel billing methods for our innovative technology by
partnering with health plans, pharmacy benefit managers (&#147;PBMs&#148;), third-party administrators (&#147;TPAs&#148;), and other ecosystem entities such as centers of excellence and healthcare navigation companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While the MSK market is massive, the existing solutions have fallen short as they are often expensive and ineffective.
Effective MSK care should be engaging, easy to use, and accessible anytime, anywhere. We developed Hinge Health to address the inefficiencies in the legacy system that treats MSK conditions today. We designed our platform to be simple, accessible,
complete, and personalized. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Simple and accessible</B>: Traditional MSK care can be difficult to access. While digital physical therapy
that provides basic teleconferencing capabilities may address certain barriers to access, such as reducing the distance to care, effective accessible care must provide the right type of care at the right time with the right people. Members can
access our broad spectrum of MSK care through a single <FONT STYLE="white-space:nowrap">on-demand</FONT> app, designed to provide an engaging, seamless, and convenient digital experience whenever and wherever the member chooses.
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Complete</B>: Our platform offers a wide range of support with multiple programs across many affected areas
to provide a continuum of care from prevention to treatment of acute injury and chronic pain, as well as surgery decision support and post-surgical recovery. We also offer <FONT STYLE="white-space:nowrap">non-addictive</FONT> and <FONT
STYLE="white-space:nowrap">non-invasive</FONT> pain relief via electrostimulation through our proprietary <FONT STYLE="white-space:nowrap">FDA-cleared</FONT> wearable device, Enso, that is seamlessly integrated into our platform.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Personalized</B>: Our platform delivers smarter care through AI and machine learning. Our AI model is
trained on a large, proprietary MSK data set, and our technology is continuously learning and improving as each new member enrolls and engages with our programs, which creates a positive feedback loop. As of September&nbsp;30, 2024, we have treated
over one million members and our programs have tracked over 59&nbsp;million activity sessions and 27&nbsp;million member-reported outcome logs. We focus on personalization to keep members moving: from customized care plans to real-time <FONT
STYLE="white-space:nowrap">in-app</FONT> exercise adjustments based on the member&#146;s feedback and our proprietary motion tracking technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have developed an efficient <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">go-to-market</FONT></FONT>
model by working directly with our partners and clients. Our clients are primarily self-insured employers and include many of the nation&#146;s leading enterprises across a broad range of industries and sizes. Within this segment, we also serve many
public sector self-insured employers, such as state and local city governments. In most instances, we partner with clients&#146; health plans, TPAs, PBMs, or other ecosystem entities to reduce the friction of contracting, pricing, security and IT
compliance, onboarding, and billing. We are also in the early stages of expanding to serve health plans&#146; fully-insured and Medicare Advantage populations and federal insurance plans. As of September&nbsp;30, 2024, we had approximately
18&nbsp;million contracted lives across more than 2,000 clients. We had active client agreements with 48% of the Fortune 100&nbsp;companies and 42% of the Fortune 500 companies, as of September&nbsp;30, 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that we grow efficiently because of our scalable, repeatable <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">go-to-market</FONT></FONT> model. We sell through our direct sales force and our partners. Once we contract with a client, we are typically the sole digital MSK care provider to their contracted lives for an average
contract term of three years. For the term of each contract, we are able to enroll, engage, and <FONT STYLE="white-space:nowrap">re-engage</FONT> the client&#146;s eligible lives, driving a recurring, repeatable revenue model, which is demonstrated
in our net dollar retention of&#8195;&#8195;% as of December&nbsp;31, 2024. Our <FONT STYLE="white-space:nowrap">12-month</FONT> client retention rate was 98% as of September&nbsp;30, 2024, and as of October&nbsp;31, 2024, our client net promotor
score (&#147;NPS&#148;) was 87, which demonstrates our high level of client satisfaction. We also invested early in building our partner network. As of September&nbsp;30, 2024, we had over 50 partners, including four out of the five largest national
health plans by self-insured lives and the top three PBMs by market share, and we had retained 100% of our partners that we choose to work with since inception, excluding partners who were acquired. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have experienced significant growth since our inception, with a recurring revenue business model and an efficient <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">go-to-market</FONT></FONT> motion. As of December&nbsp;31, 2024, we had approximately&#8195;&#8195;&#8195;&#8195;members and approximately&#8195;&#8195;&#8195;&#8195;clients, compared to
approximately 371,000 members and approximately 1,650 clients as of December&nbsp;31, 2023. Our revenue was $&#8195;&#8195;million and $293&nbsp;million for the years ended December&nbsp;31, 2024 and 2023, respectively, representing a year-over-year
growth rate of&#8195;&#8195;%. Gross profit was $&#8195;&#8195;million and $194&nbsp;million for the years ended December&nbsp;31, 2024 and 2023, respectively. For the year ended December&nbsp;31, 2024, we achieved a gross margin of&#8195;&#8195;%
compared to 66% for the year ended December&nbsp;31, 2023. For the year ended December&nbsp;31, 2024, our <FONT STYLE="white-space:nowrap">non-GAAP</FONT> adjusted gross margin was&#8195;&#8195;%, compared to 70% for the year ended December&nbsp;31,
2023. Net cash used in operating activities was $&#8195;&#8195;million and $63.9&nbsp;million for the years ended December&nbsp;31, 2024 and 2023, respectively, and free cash flow was an outflow of $&#8195;&#8195;million and $68.5&nbsp;million for
the years ended December&nbsp;31, 2024 and 2023, respectively. See the section titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#151;Non-GAAP Financial Measures&#148; for a reconciliation of
non-GAAP gross profit and gross margin to GAAP gross profit and free cash flow to net cash used in operating activities. We incurred net losses of $&#8195;&#8195; million and $108.1&nbsp;million for the years ended December&nbsp;31, 2024 and 2023,
respectively. As of December&nbsp;31, 2023, we had an accumulated deficit of $510.8&nbsp;million. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Industry Background </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>MSK Conditions Are Widespread and Significantly Impact Quality of Life. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">MSK pain is pervasive &#150; it affects people around the world, across all ages, genders, and socioeconomic backgrounds. MSK
conditions impact an estimated 1.7&nbsp;billion people worldwide and are a leading contributor to disability. Within the United States alone, our current core market, approximately 40% of adults suffered from an MSK disorder in 2021, according to
the WHO Estimator. The pain caused by MSK conditions can have debilitating effects on one&#146;s quality of life, comorbidities, mental well-being, and ability to work. In 2023, we and a third-party research firm conducted a study of 7,291
individuals in the United States that suffered from chronic and acute MSK pain (the &#147;MSK Care 2024 Survey&#148;). Findings from the survey indicate that pain, especially chronic pain, can create a vicious cycle of fear, depression, sleep
issues, activity avoidance, and more. Among the takeaways from the State of MSK Care 2024 Survey: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Barriers to traditional physical therapy include cost and access</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>People in pain want to avoid costly, risky interventions</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Pain is a mental health issue</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Pain rarely exists in isolation</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Pain negatively impacts everyday life and work</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Rising Costs Related to MSK Conditions Are Too Big to Ignore. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The U.S. economy suffers from the weight of MSK medical costs, which rose to an estimated $381&nbsp;billion in 2016. MSK
conditions are one of the top drivers of healthcare spending in the United States and accounted for nearly one in seven dollars spent on healthcare expenses in 2016. Because of population growth and aging, the number of people living globally with
MSK conditions and associated functional limitations is increasing. Employers notice the costs: for example, approximately 74% of employers reported that MSK conditions were a top driver of their healthcare spending in 2024, according to a survey
conducted by Business Group on Health. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The Existing Approach to MSK Pain Is Inadequate and Leaves Individuals
Seeking More Effective Alternatives. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Medical literature indicates that conservative care management through
physical therapy can be an effective route for addressing many chronic MSK conditions. However, there is often a disconnect between the MSK care that is needed and the care that is received. According to the Hinge Health People in Pain Survey
conducted by us and a third-party research firm in 2022 of individuals that suffered from chronic and acute MSK pain (the &#147;Hinge Health People in Pain Survey&#148;), almost half of respondents reported that they wouldn&#146;t be able to manage
pain without professional help. However, our analysis of Health Claims Data indicates that only 9% of adults in the United States pursued <FONT STYLE="white-space:nowrap">in-person</FONT> physical therapy in 2023. While the Hinge Health People in
Pain Survey found that 70% of respondents reported that they understood the health benefits available to them, 64% of respondents reported that they were not currently using a care plan created by a professional. We believe the reason for the
disparities and disconnect between the MSK care needed and the MSK care received is that the legacy system for treating MSK conditions is often difficult to access, incomplete, and can drive people to potentially avoidable surgeries, injections, and
pain medications. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Difficult to access</B>: <FONT STYLE="white-space:nowrap">In-person</FONT> physical therapy can be
difficult to access due to barriers such as the limited supply of providers and their availability, the location of providers, and an individual&#146;s ability to commit time to the process. For instance, physical therapy appointments may take time
to schedule, depending on the availability of the provider, and the experience can be highly dependent on the expertise of the particular provider. In order to make care more accessible, there is a need to reduce potential points of friction.
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Incomplete</B>: According to a 2022 Acceptance Questionnaire survey we conducted (the &#147;Hinge Health
2022 AQ Survey&#148;), four in five respondents needed more than physical therapy to improve their recovery. Whether there is too much pain to begin a physical therapy program or a <FONT STYLE="white-space:nowrap">co-existing</FONT> health
condition, providing physical care alone often leaves a gap in the care needed and mental health or other supportive care is also required. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Avoidable surgery</B>: Whether <FONT STYLE="white-space:nowrap">in-person</FONT> or digital, siloed care
within the legacy treatment system means that a physician visit could quickly escalate to a nearly $100,000 surgery because divisional units within the system can result in disjointed care. According to our analysis of Health Claims Data,
approximately 62% of spending on the treatment of MSK conditions in 2022 was attributed to surgery intervention and related costs. A review of high-quality clinical practice guidelines demonstrated that patients should address education, physical
activity, and exercise as a first line of treatment for the most common MSK pain. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Market Opportunity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe there is a substantial opportunity to use technology and AI to transform how individuals approach physical therapy,
treatment of chronic and acute pain, and care management for MSK conditions. In the United States, approximately 40% of adults suffered from an MSK disorder in 2021, according to the WHO Estimator, leading to an estimated $381&nbsp;billion spent in
that year on MSK treatments. Based on our analysis of Health Claims Data, we believe that approximately $42&nbsp;billion is spent annually on physical therapy, which is a subset of MSK treatment. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Self-insured employers</B>: According to AIS Health, approximately 120&nbsp;million individuals received
healthcare coverage from self-insured U.S. employers as of 2021. Based on our analysis of Health Claims Data and our finding that approximately 9% of adults in the United States pursued <FONT STYLE="white-space:nowrap">in-person</FONT> physical
therapy in 2023, combined with our pricing methodology, we believe that the addressable market opportunity for our platform and programs is approximately $10&nbsp;billion based on our current platform and programs. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Fully-insured employers, Medicare Advantage, and federal insurance plans</B>: We believe that by further
expanding into these segments, an additional 96&nbsp;million lives can be addressed by our platform and programs, which, combined with our pricing methodology, represent an additional addressable market opportunity of $8&nbsp;billion. We also
developed a fall prevention program to help us better address the needs of the Medicare Advantage population. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Government agencies and government healthcare programs (Medicare and Medicaid)</B>: We further believe that
government agencies and government healthcare programs, such as Medicare and Medicaid, can provide an additional 112&nbsp;million lives that can be addressed by our platform and programs, which, combined with our pricing methodology, represent an
additional addressable market opportunity of $9&nbsp;billion. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>International expansion</B>: We are strategically expanding into international markets. Initially, we are
expanding through the global footprint of our current clients&#146; employee base with the objective of supporting our clients&#146; employees in geographies that are key to them. We also plan to expand to
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> based employers in other countries. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Product innovation</B>: We have a history of product innovation, and we plan to continue to expand our
programs. We recently launched a program that delivers specialized care for women&#146;s pelvic health, a segment that is historically underserved. Another segment that we have identified as being underserved is specialized MSK care for women in
their perimenopause, menopause, and postmenopausal phases. An estimated 71% of perimenopausal women experience MSK pain, according to a 2020 study on </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
MSK pain during the menopausal transition published in the Neural Plasticity journal. As we introduce new programs, we further expand our addressable market opportunity by increasing the eligible
lives that can benefit from our technology platform. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">According to the U.S. Bureau of Labor Statistics,
the demand for physical therapy is expected to increase due to an aging population and increased prevalence of chronic conditions such as diabetes and obesity. We believe that these trends will continue, and that our technology platform enables more
accessible and affordable MSK care, driving the expansion of the broader physical therapy market as utilization and adherence increase. We believe we are well positioned to address the large and durable market opportunity for our platform and
products and continue to grow our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Platform </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are a leading technology platform for individuals seeking to treat and prevent joint and muscle pain. We leverage technology
and AI to automate the key aspects of care while delivering improved member outcomes, personalized member experiences, and cost reductions for our clients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We designed our platform to treat and prevent a broad spectrum of joint and muscle pain through scalable and personalized
care. We offer a wide range of support with multiple programs, including for those suffering from chronic pain to those considering surgical interventions or undergoing post-surgery rehabilitation. Our platform and programs aim to treat and prevent
MSK pain and injuries across the body, including the neck, upper back, shoulders, elbows, forearms, wrists, hands, lower back, hips, pelvic region, thighs, knees, shins, calves, ankles, and feet. Our
<FONT STYLE="white-space:nowrap">AI-powered</FONT> motion tracking technology allows us to provide exercise adjustments in real-time remotely, which reduces the human hours associated with traditional physical therapy and results in a more scalable
model of care. We also use AI and machine learning to provide personalized care through our programs, which are customized based on a member&#146;s affected areas and movement threshold. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We routinely expand our platform with new programs, capabilities, and features. Over the last three years, we have launched
new programs to address six additional affected areas, including specialized programs to address women&#146;s pelvic health and fall prevention. We also launched Enso to deliver a <FONT STYLE="white-space:nowrap">non-addictive,</FONT> <FONT
STYLE="white-space:nowrap">non-invasive</FONT> alternative for pain relief, developed HingeConnect for real-time care interventions and external provider coordination, and integrated TrueMotion technology to replace wearable sensors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Value Proposition </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Value to Our Members: </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At Hinge Health, we put our members first. Pain is personal. When a member reports a reduction in pain, they often share their
experience with others. As of September&nbsp;30, 2024, approximately nine out of ten members surveyed by us have reported being satisfied with our programs. We believe that our platform can address needs across demographics, occupations, and
lifestyles. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Substantial outcomes</B>: The research related to our programs spans 18 peer-reviewed research articles and
studies and outcomes analyses, including the 2020 Longitudinal Study that evaluated the efficacy of our platform in a large population of participants with chronic knee and back pain where participants reported a 68% average improvement in reported
pain and a 58% reduction in reported depression and anxiety after 12 weeks. We believe that what makes these results possible is the high-quality care that our programs are designed to enable, coupled with the convenience and simplicity of our
technology platform. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Accessible</B>: We have designed our platform to allow members to access MSK care resources directly from
their phone or tablet at their convenience. Because we provide care that is facilitated by software </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
and AI, members can engage with our platform and programs on demand. Our platform is typically offered at no direct cost to our members and is fully paid for by their employers or health plans.
We have redesigned the exercise therapy experience to encourage adherence through increased accessibility and affordability, and we continually look for ways to further health equity. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Comprehensive care</B>: Our platform allows us to track over 100 unique points on the body to address an
individual&#146;s range of motion. In order to address physical and behavioral needs, we combat care gaps by pairing technology with a care team. We provide physical therapists, physicians, and health coaches, which are recognized for their value by
the American Medical Association, to address member needs and enable favorable member outcomes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Personalized</B>: Our AI personalization engine estimates a member&#146;s risk profile and develops a
tailored care program for each member, which is overseen by our care team. We deliver members a specific care plan designed to align with their focus areas, meet their goals, and improve their overall quality of life. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Educational</B>: For those with chronic pain, lasting behavioral change is critical in order for people to
recover from their pain and achieve improved long-term outcomes. Our education helps members understand the causes of their chronic pain, the benefits of exercise therapy, and the lifestyle and behavioral health factors that influence their pain, as
well as how to address and improve them. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Seamless and simple</B>: We are dedicated to creating seamless healthcare experiences that are designed to
be easy to use and even fun, regardless of a member&#146;s background. We design our member experience to be streamlined with access to a single app where our platform is accessible on a device of a member&#146;s choosing. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Value to Our Clients: </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our clients are the businesses and organizations that pay for our platform for their covered employees and adult dependents,
either by contracting with us directly or by contracting for access to our platform through one of our partners. Our clients are primarily self-insured employers and include many of the nation&#146;s leading enterprises across a broad range of
industries and sizes. Much of the value to our members is aligned with the value to our client. Below are the added benefits that our clients receive through our platform. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Measurable outcomes and cost savings</B>: We demonstrate medical claims-backed cost savings to our clients
coupled with measurable outcomes for our members. Our platform is supported by the results from 18 studies, including our 2023 Employer Claims Study that estimated an ROI of 2.4x for clients included in the study, based on the estimated $2,387
average cost savings per member over a <FONT STYLE="white-space:nowrap">12-month</FONT> period divided by the cost of our chronic program, as well as the 2020 Longitudinal Study that evaluated the efficacy of our platform in a large population of
participants with chronic knee and back pain where participants reported a 68% average improvement in reported pain and a 58% reduction in reported depression and anxiety after 12 weeks. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Employee wellbeing and productivity</B>: We think bigger about MSK pain by addressing both the physical and
mental strain of MSK pain in a way that is designed to lead to happier, healthier, and more productive employees. We provide outcomes information to our clients such as reported pain-related work absenteeism or impaired work productivity in order to
quantify the impact of our program on our members. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Ability to attract and retain talent</B>: Healthcare benefits have gained greater significance in the
recruitment and retention of employees, particularly in tight labor markets. Through technology, we aim to equip our members with the ability to lead more enriching lives with improved health outcomes, which in turn may serve as a draw for our
clients when recruiting talent. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Simplicity of implementation</B>: We are dedicated to streamlining processes for our clients and focus on
eliminating the time-related impairments associated with implementation. Through our strategic partnerships with health plans, PBMs, TPAs, and other ecosystem partners (entities such as centers of excellence and healthcare navigation companies), we
have streamlined the contracting and implementation process to enable launch in as little as weeks compared to typically much longer implementation periods that are common within healthcare. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Value to Our Ecosystem Partners: </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have a vast ecosystem partner network that includes: health plans, PBMs, TPAs, digital health providers, centers of
excellence, healthcare navigation partners, brokers, and consultants. Similar to our approach with members and clients, we strive to create value for ecosystem partners. Examples of the value we help create with our partners include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Source of innovation</B>: In addition to the core medical and pharmacy products that clients purchase,
clients have grown to expect their health plans and PBMs to survey, vet, and select leading solutions that address their highest medical cost categories, such as MSK conditions. We designed our platform to create superior member experiences that
result in positive outcomes across a wide range of clients and demographics, allowing us to validate outcomes at scale. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Cost savings</B>: In addition to removing the administrative burden of selecting, contracting, and
integrating with healthcare solutions, ecosystem partners have selected our platform and programs for their fully-insured and Medicare Advantage plan populations to potentially increase their cost savings and optimize their star ratings.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Ease of client implementation</B>: With the proliferation of digital health providers, ecosystem partners
have become increasingly flexible at implementing <FONT STYLE="white-space:nowrap">one-off</FONT> solutions at the request of their clients. By taking a more proactive approach in selecting preferred providers, ecosystem partners can better
streamline integrations for their clients as opposed to a series of <FONT STYLE="white-space:nowrap">one-off</FONT> solutions that are disconnected and siloed. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>High-risk member engagement</B>: Given growing data indicates that a small percentage of individuals drive
the majority of the healthcare costs, the imperative to identify, intervene, and treat high-risk members has become a top priority across our partners.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>Together with our data and interventions,
our partners&#146; claims and prior authorization data help us serve high-risk members more immediately. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Competitive Strengths
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We seek to be the best solution on the market, the most validated solution on the market, and the easiest to buy. We
believe the following strengths differentiate our platform and programs, which will drive our continued success with new and existing clients and members. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Scale and market leadership</B>: We are a leading digital MSK platform in the United States, with over
2,000 clients and approximately 18&nbsp;million contracted lives as of September&nbsp;30, 2024. As of September&nbsp;30, 2024, we had over 50 partners, consisting of health plans (including four out of the five largest national health plans based on
self-insured lives), PBMs (including the top three PBMs by market share), TPAs, and other ecosystem partners. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Member-first, <FONT STYLE="white-space:nowrap">software-led</FONT> digital care delivery</B>: Hinge Health
is designed to provide a seamless member experience accessible <FONT STYLE="white-space:nowrap">on-demand</FONT> via a single app, which offers members the ability to access care from a member&#146;s personal smartphone or tablet. Our <FONT
STYLE="white-space:nowrap">software-led,</FONT> <FONT STYLE="white-space:nowrap">AI-powered</FONT> delivery model also enables us to deliver care at scale&#151;where members have the potential to benefit from the technology and expertise of our
entire platform. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>AI technology and data advantage</B>: We actively deploy large language models across our databases and
implement new uses of AI on our platform. Our proprietary exercise personalization engine leverages machine-learning from more than one million lifetime members that have used our platform and has tracked over 59&nbsp;million activity sessions and
27&nbsp;million member-reported outcome logs as of September&nbsp;30, 2024. We leverage <FONT STYLE="white-space:nowrap">AI-powered</FONT> motion tracking technology to provide members with real-time audio and visual feedback during their exercise
sessions to help correct their form. Our proprietary <FONT STYLE="white-space:nowrap">AI-driven</FONT> database, HingeConnect, helps us identify and target the cost-driving individuals by leveraging a vast array of data, including demographics,
comorbidities, exercise forms, and pain scores, as well as EHR data with daily claims feeds across over 750,000 providers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Scalable and efficient
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">go-to-market</FONT></FONT> strategy</B>: Our partner relationships provide us with an important competitive advantage. Our partners collaborate with our sales force to win new
clients. When we enter into an agreement with a partner, we typically win a large majority of the employers using that partner who go on to select a digital MSK solution. Our partners also assist us in identifying and encouraging enrollment on our
platform. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Outcomes for members and ROI to clients</B>: Members report measurable and significant improvements after
the use of our programs, including the 2020 Longitudinal Study that evaluated the efficacy of our platform in a large population of participants with chronic knee and back pain where participants reported a 68% average improvement in reported pain
and a 58% reduction in reported depression and anxiety after 12 weeks. Since 2017, we have published 14 peer-reviewed research articles in established journals on program engagement, clinical outcomes, medical care, and prescription drug
utilization, in addition to four reviewed medical claims-based studies. Such studies examined how member outcomes can lead to cost savings for our clients. Our 2023 Employer Claims Study estimated a 2.4x ROI for clients, based on the estimated
$2,387 average cost savings per member over a <FONT STYLE="white-space:nowrap">12-month</FONT> period divided by the cost of our chronic program. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Platform extensibility and proven record of innovation</B>: We are committed to continuous innovation. We
have increased the number of affected areas addressed by our programs, from two at our inception, to sixteen as of September&nbsp;30, 2024. We have also introduced Enso, an <FONT STYLE="white-space:nowrap">FDA-cleared,</FONT> wearable device,
developed HingeConnect, our proprietary <FONT STYLE="white-space:nowrap">AI-driven</FONT> database for real-time care interventions and external provider coordination, and integrated our proprietary <FONT STYLE="white-space:nowrap">AI-powered</FONT>
motion tracking technology to replace wearable sensors and provide motion guidance during exercise therapy. We recently launched a program that delivers specialized care for women&#146;s pelvic health and a fall prevention program for eligible lives
in our Medicare Advantage population. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Growth Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have experienced significant growth since inception, which we attribute to expanding our client base, increasing adoption
across our existing client base, launching new programs, and expanding into new markets. We believe we are well positioned for continued growth, as we believe our current total contracted lives only represent approximately 5% of our target
addressable market. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Expand our client base in our core markets</B>: Our core client base is self-insured employers. We believe
the addressable market for self-insured employers in the United States is approximately 120&nbsp;million lives according to our analysis of data from AIS Health, of which approximately 17&nbsp;million were contracted in our existing client base as
of September&nbsp;30, 2024. This provides a sizable growth opportunity, which we can address by leveraging our experienced sales force and strong relationships with health plans, benefits consultants, and other ecosystem partners.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Expand into new markets</B>: We have expanded beyond our core self-insured employer market and will
continue to evaluate opportunities to do so in the future. In addition to self-insured employers, we also </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
offer our platform to fully-insured health plan populations and Medicare Advantage populations. In many cases, after we have delivered positive outcomes for our partners&#146; self-insured
employers, they decide to contract with us for their fully-insured and Medicare Advantage lines of business. These two populations, combined with the federal insurance populations we are also expanding into, represent an estimated 96&nbsp;million
additional lives in the United States. We expanded into Canada in 2024 and expect to offer a global program to individuals in several additional countries outside of the United States that are employees of U.S.-based multinational corporations by
the end of 2024 and grow that program in 2025. We also plan to expand to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> based employers in other countries. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Increase adoption across existing client base</B>: We expect to leverage our partner integrations, our
proprietary HingeConnect <FONT STYLE="white-space:nowrap">AI-driven</FONT> database, and our growth team&#146;s capabilities to reach out to eligible lives when we believe they are most likely to benefit from our platform. We have dedicated research
and development resources to continuously optimize our targeting to maximize the number of eligible lives that enroll in our programs. We have also created programs for many different types of care by expanding from chronic care to include acute, <FONT
STYLE="white-space:nowrap">pre-</FONT> and post-surgery, and preventative care. These developments allow us to reach and engage more members. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Launch new programs and capabilities driven by investment in our platform</B>: We have a history of
innovation and expect to continue to develop and invest in our platform to provide more value to our members, clients, and partners over time. We believe we have a promising product roadmap ahead of us, including an expansion of our women&#146;s
pelvic health and fall prevention programs and further AI use cases. Given the broad potential of our platform, we believe that we have a truly significant opportunity to launch new programs and capabilities to attract new clients and increase
adoption by eligible lives within our existing clients, as well as to improve programs and optimize engagement with our care team given our proprietary data and AI advantage. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risk Factors Summary </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our
business is subject to a number of risks and uncertainties of which you should be aware before making a decision to invest in our Class&nbsp;A common stock.&nbsp;These risks are more fully described in the section titled &#147;Risk Factors&#148;
immediately following this prospectus summary. These risks include, among others, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have a history of net losses, we anticipate increasing expenses in the future, and we may not be able to
achieve or maintain profitability. Although we have experienced rapid growth recently, if we fail to effectively manage our growth, we may be unable to execute our business plan and adequately address competitive challenges, and our business,
results of operations, and financial condition could be materially adversely affected. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may be unable to successfully execute on our growth initiatives, business strategies, or operating plans.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have a limited operating history, which makes it difficult for you to evaluate our business, future
prospects, and your investment, and makes it difficult to predict our future results of operations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our results of operations have in the past fluctuated and may in the future continue to fluctuate on a
quarterly and annual basis. If we fail to meet the expectations of analysts or investors, our stock price and the value of your investment could decline substantially. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to attract new clients, if existing clients do not renew their agreements or renew on less
favorable terms, or if we do not achieve our performance guarantees, it could have a material adverse effect on our business, results of operations, and financial condition. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we fail to retain existing members or add new members, our revenue, business, results of operations, and
financial condition may be materially adversely affected. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A substantial portion of our client relationships are contracted through a limited number of health plans and
other partners. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our increasing reliance on AI and machine learning technologies may expose us to significant risks, including
development and deployment challenges, regulatory uncertainties, and potential third-party claims, which could adversely affect our reputation, business, results of operations, and financial condition. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may be unable to establish, maintain, protect, and enforce our intellectual property and proprietary rights
or prevent third parties from making unauthorized use of our technology, or we may in the future become subject to claims of infringement, misappropriation, or violation of third parties&#146; intellectual property rights. Our failure to protect our
intellectual property and any potential intellectual property infringement claims could harm our brand, devalue our proprietary content, and affect our ability to compete effectively. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our business operates in a highly regulated industry and changes over time in regulations, or the
implementation of existing regulations, could affect our operations and subject us to increased compliance costs and liabilities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and our affiliated professional entities are subject to federal, state, and foreign healthcare laws and
regulations, and a finding of failure to comply with such laws and regulations could have a material adverse effect on our business. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Legislative or regulatory healthcare reform measures may make it more difficult and costly to operate our
business, or to do so profitably. Accordingly, such legislative or regulatory healthcare reform measures may have a material adverse effect on our business, results of operations, and financial condition. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Enso device is subject to extensive government regulation. We may not receive, or may be delayed in
receiving, the necessary marketing authorizations for modifications to our Enso device or any device products we may offer, and failure to timely obtain necessary marketing authorizations or certifications for any medical devices we may offer could
have a material adverse effect on our business, results of operations, and financial condition. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The FDA may modify its enforcement policies with respect to medical software products, and our programs may
become subject to extensive regulatory requirements, which may increase the cost of conducting, or otherwise harm, our business. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The price of our Class&nbsp;A common stock may be volatile or may decline regardless of our operating
performance, resulting in substantial losses for investors purchasing shares in this offering. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The dual class structure of our common stock will have the effect of concentrating voting control with the
holders of our Class&nbsp;B common stock and our executive officers and directors, including our Founders, and significant stockholders, who will collectively hold in the aggregate % of the voting power of our capital stock following the completion
of this offering. This ownership will limit or preclude your ability to influence corporate matters, including the election of directors, amendments of our organizational documents, and any merger, consolidation, sale of all or substantially all of
our assets, or other major corporate transaction requiring stockholder approval. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We were originally established as a private limited company under the laws of England and Wales in January 2012 under the name
Marblar Limited. In March 2016, we incorporated Hinge Health, Inc. as a Delaware corporation. In April 2016, Marblar Limited and Hinge Health, Inc. entered into a Share Exchange </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Agreement pursuant to which Hinge Health, Inc. purchased the outstanding equity of Marblar Limited in exchange for capital stock of Hinge Health, Inc. As a result, Hinge Health, Inc. assumed the
business and operations of Marblar Limited. Our principal executive offices are located at 455 Market Street, Suite 700, San Francisco, California 94105, and our telephone number is (415) <FONT STYLE="white-space:nowrap">726-2206.</FONT> Our website
address is <I>www.hingehealth.com</I>. Information contained on, or that can be accessed through, our website does not constitute part of this prospectus, and the inclusion of our website address in this prospectus is an inactive textual reference
only. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Channels for Disclosure of Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After the completion of this offering, we intend to announce information to the public through filings with the U.S. Securities
and Exchange Commission (&#147;SEC&#148;), the investor relations page on our website, press releases, public conference calls, and webcasts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The information disclosed on the foregoing channels could be deemed to be material information. As such, following this
offering, we encourage investors, the media, and others to follow the channels listed above and to review the information disclosed through such channels. Our disclosure of information on the foregoing channels does not limit our obligations to make
required disclosures as prescribed by U.S. federal securities laws, including in SEC filings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any updates to the list of
disclosure channels through which we will announce information will be posted on the investor relations page on our website. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an
Emerging Growth Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are an emerging growth company as defined in the Jumpstart Our Business Startups Act of
2012 (the &#147;JOBS Act&#148;). We will remain an emerging growth company until the earliest of: (i)&nbsp;the last day of the fiscal year following the fifth anniversary of the consummation of this offering; (ii)&nbsp;the last day of the fiscal
year in which we have total annual gross revenue of at least $1.235&nbsp;billion; (iii)&nbsp;the last day of the fiscal year in which we are deemed to be a &#147;large accelerated filer&#148; as defined in Rule
<FONT STYLE="white-space:nowrap">12b-2</FONT> under the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), which would occur if the market value of our common stock held by
<FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeded $700.0&nbsp;million as of the last business day of the second fiscal quarter of such year; or (iv)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in <FONT
STYLE="white-space:nowrap">non-convertible</FONT> debt securities during the prior three-year period. An emerging growth company may take advantage of specified reduced reporting requirements and is relieved of certain other significant requirements
that are otherwise generally applicable to public companies. As a result, the information that we provide to our stockholders may be different than you might receive from other public reporting companies in which you hold equity interests. As an
emerging growth company, we have elected to take advantage of certain of the reduced disclosure obligations in the registration statement of which this prospectus is a part and may elect to take advantage of other reduced reporting requirements in
future filings. In particular: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we will present in this prospectus only two years of audited annual consolidated financial statements, plus
any required unaudited condensed consolidated financial statements, and related management&#146;s discussion and analysis of financial condition and results of operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we will avail ourselves of the exemption from the requirement to obtain an attestation and report from our
independent registered public accounting firm on the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we will provide less extensive disclosure about our executive compensation arrangements; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we will not require stockholder <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory votes on
executive compensation or golden parachute arrangements. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the JOBS Act provides that an emerging growth company can take
advantage of an extended transition period for complying with new or revised accounting standards. This provision allows an emerging growth company to delay the adoption of some accounting standards until those standards would otherwise apply to
private companies. We have elected to use the extended transition period for any other new or revised accounting standards until the date that we are no longer an emerging growth company or affirmatively and irrevocably opt out of the extended
transition period. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom829170_2"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;A common stock offered by us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195;shares.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;A common stock offered by the selling stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:pt"><BR></P> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195;shares.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Option to purchase additional shares of Class&nbsp;A common stock offered by us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:pt"><BR></P> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195;shares.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;A common stock to be outstanding immediately after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:pt"><BR></P> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195;shares (or
&#8195;&#8195;&#8195;&#8195;shares if the underwriters exercise their option to purchase additional shares of Class&nbsp;A common stock in full).</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;B common stock to be outstanding immediately after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:pt"><BR></P> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195;shares.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Class&nbsp;A and Class&nbsp;B common stock to be outstanding immediately after this
offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:pt"><BR></P> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares (or
&#8195;&#8195;&#8195;&#8195;shares if the underwriters exercise their option to purchase additional shares of Class&nbsp;A common stock in full).</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Voting rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Following this offering, we will have two classes of common stock, Class&nbsp;A common stock and Class&nbsp;B common stock.
The rights of holders of Class&nbsp;A common stock and Class&nbsp;B common stock will be identical, except with respect to voting and conversion rights. Each share of Class&nbsp;A common stock will be entitled to one vote. Each share of Class&nbsp;B
common stock will be entitled to 15 votes and will be convertible at any time into one share of Class&nbsp;A common stock.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Holders of our Class&nbsp;A common stock and Class&nbsp;B common stock will generally vote together as a single class, unless otherwise
required by law or our amended and restated certificate of incorporation or amended and restated bylaws, which will be in effect immediately prior to the completion of this offering. The holders of our outstanding Class&nbsp;B common stock will
hold&#8195;% of the voting power of our outstanding capital stock after the completion of this offering, with our directors, executive officers, and 5% stockholders and their respective affiliates holding approximately&#8195;% of the voting power,
assuming no exercise of the underwriters&#146; option to purchase additional shares, if any. Accordingly, such holders will have the ability to control the outcome of matters submitted to our stockholders for approval, including the election of our
directors and the approval of any change of control transaction. See the sections titled &#147;Principal and Selling Stockholders&#148; and &#147;Description of Capital Stock&#148; for additional
information.</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Use of proceeds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We estimate that we will receive net proceeds from this offering of approximately $&#8195;&#8195; (or $&#8195;&#8195; if the
underwriters exercise their option to purchase additional shares of Class&nbsp;A common stock in full), based upon the assumed initial public offering price of $&#8195;&#8195; per share of Class&nbsp;A common stock, which is the midpoint of the
price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We will not receive any proceeds from the sale of
Class&nbsp;A common stock in this offering by the selling stockholders.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We currently intend to use the net proceeds of this offering for general corporate purposes, working capital, and to fund our growth strategies
discussed in this prospectus. We may also use a portion of the net proceeds to us to acquire or invest in complementary businesses, products, services, technologies, or other assets. We do not, however, have agreements or commitments to enter into
any acquisitions or investments at this time.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We will
have broad discretion in the way that we use the net proceeds of this offering. See the section titled &#147;Use of Proceeds&#148; for additional information.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk factors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">See the section titled &#147;Risk Factors&#148; and other information included in this prospectus for a discussion of
factors you should carefully consider before deciding whether to invest in our Class&nbsp;A common stock.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proposed trading symbol</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;&#8195;&#8195;&#8195;&#8195;&#148;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The number of shares of our common stock to be outstanding after this offering is based on
&#8195;&#8195;&#8195;&#8195; shares of our Class&nbsp;A common stock outstanding and &#8195;&#8195;&#8195;&#8195; shares of our Class&nbsp;B common stock outstanding as of December&nbsp;31, 2024, after giving effect to the Transactions (as defined
below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The number of shares of our common stock to be outstanding after this offering does not include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of our Class&nbsp;A common stock issuable upon the exercise of outstanding
stock options to purchase shares of our Class&nbsp;A common stock as of December&nbsp;31, 2024, with a weighted-average exercise price of $&#8195;&#8195; per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of our Class&nbsp;B common stock issuable upon the exercise of outstanding
stock options to purchase shares of our Class&nbsp;B common stock as of December&nbsp;31, 2024, with a weighted-average exercise price of $&#8195;&#8195; per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of our Class&nbsp;A common stock issuable upon the exercise of outstanding
stock options to purchase shares of our Class&nbsp;A common stock granted after December&nbsp;31, 2024, with a weighted-average exercise price of $&#8195;&#8195; per share; </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of our Class&nbsp;B common stock issuable upon the exercise of outstanding
stock options to purchase shares of our Class&nbsp;B common stock granted after December&nbsp;31, 2024, with a weighted-average exercise price of $&#8195;&#8195; per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of our Class&nbsp;A common stock issuable upon the vesting of restricted
stock units (&#147;RSUs&#148;) for shares of our Class&nbsp;A common stock subject to service-based and liquidity-based vesting conditions outstanding as of December&nbsp;31, 2024, for which the service-based vesting condition was not yet satisfied
as of December&nbsp;31, 2024 and for which the liquidity-based vesting condition will be satisfied in connection with this offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of our Class&nbsp;A common stock issuable upon the vesting of
performance-based restricted stock units (&#147;PRSUs&#148;) for shares of our Class&nbsp;A common stock subject to performance-based and liquidity-based vesting conditions outstanding as of December&nbsp;31, 2024, for which the performance-based
vesting condition was not yet satisfied as of December&nbsp;31, 2024 and for which the liquidity-based vesting condition will be satisfied in connection with this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of our Class&nbsp;B common stock issuable upon the vesting of RSUs for
shares of our Class&nbsp;B common stock subject to service-based and liquidity-based vesting conditions outstanding as of December&nbsp;31, 2024, for which the service-based vesting condition was not yet satisfied as of December&nbsp;31, 2024 and
for which the liquidity-based vesting condition will be satisfied in connection with this offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of our Class&nbsp;B common stock issuable upon the vesting of PRSUs for
shares of our Class&nbsp;B common stock subject to performance-based and liquidity-based vesting conditions outstanding as of December&nbsp;31, 2024, for which the performance-based vesting condition was not yet satisfied as of December&nbsp;31,
2024 and for which the liquidity-based vesting condition will be satisfied in connection with this offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of our Class&nbsp;A common stock reserved for future issuance under our
2025 Incentive Award Plan (the &#147;2025 Plan&#148;), which will become effective on the business day immediately prior to the date of effectiveness of the registration statement of which this prospectus forms a part, including
&#8195;&#8195;&#8195;&#8195; new shares and the number of shares (i)&nbsp;that remain available for grant of future awards under our 2017 Equity Incentive Plan (as amended, the &#147;2017 Plan&#148;) at the time the 2025 Plan becomes effective,
which shares will cease to be available for issuance under the 2017 Plan at such time, (ii)&nbsp;underlying outstanding stock-based compensation awards granted under the 2017 Plan, and (iii)&nbsp;underlying the outstanding awards under the 2016
Hinge Health EMI Share Option Scheme (the &#147;EMI Scheme,&#148; and together with the 2017 Plan, the &#147;Prior Plans&#148;) (such awards outstanding under such plans, the &#147;Prior Plan Awards&#148;) that expire, or are cancelled, forfeited,
reacquired, or withheld; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of our Class&nbsp;A common stock reserved for future issuance under our
2025 Employee Stock Purchase Plan (the &#147;ESPP&#148;), which will become effective on the business day immediately prior to the date of effectiveness of the registration statement of which this prospectus forms a part. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The 2025 Plan and the ESPP also provide for automatic annual increases in the number of shares reserved thereunder. See the
section titled &#147;Executive and Director Compensation&#151;Equity Incentive Plans&#148; for additional information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Except as otherwise indicated, all information in this prospectus assumes or gives effect to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the adoption, filing, and effectiveness of our amended and restated certificate of incorporation and the
adoption of our amended and restated bylaws, each of which will occur immediately prior to the completion of this offering; </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i) the reclassification of &#8195;&#8195;&#8195;&#8195;, or all outstanding shares of our common stock (other
than those held by Daniel Perez and Gabriel Mecklenburg (our &#147;Founders&#148;)), as of &#8195;&#8195;&#8195;&#8195;, 2024 into an equal number of shares of our Class&nbsp;A common stock, (ii)&nbsp;the reclassification of
&#8195;&#8195;&#8195;&#8195;, or all outstanding shares of common stock held by our Founders, as of &#8195;&#8195;&#8195;&#8195;, 2024 into an equal number of shares of our Class&nbsp;B common stock, (iii)&nbsp;the reclassification of all shares of
common stock underlying outstanding equity awards under our Prior Plans (other than those held by our Founders) into shares of Class&nbsp;A common stock pursuant to an amendment to our Prior Plans, (iv)&nbsp;the amendment of the terms of all
outstanding stock options to purchase shares of common stock, RSUs and PRSUs under our 2017 Plan held by our Founders to provide that such awards are exercisable for or settle into shares of Class&nbsp;B common stock, and (v)&nbsp;the amendment of
the terms of our outstanding convertible preferred stock to provide that such shares are initially convertible into shares of Class&nbsp;B common stock, each of which will occur prior to completion of this offering (collectively, the &#147;Common
Stock and Preferred Stock Reclassification&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the automatic conversion of all outstanding shares of our redeemable convertible preferred stock outstanding
into an aggregate of &#8195;&#8195;&#8195;&#8195; shares of our Class&nbsp;B common stock, which will occur prior to the completion of this offering (the &#147;Preferred Stock Conversion&#148;); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the conversion of &#8195;&#8195;&#8195;&#8195;shares of our Class&nbsp;B common stock into
&#8195;&#8195;&#8195;&#8195;shares of Class&nbsp;A common stock by certain holders of Class&nbsp;B common stock, including shares that are being converted in connection with the sale of shares of Class&nbsp;A common stock by certain selling
stockholders in this offering as described in the section titled &#147;Principal and Selling Stockholders&#148; (the &#147;Class&nbsp;B Conversion&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise of outstanding stock options or settlement of outstanding RSUs or PRSUs described above after
&#8195;&#8195;&#8195;&#8195;, 2025; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise by the underwriters of their option to purchase &#8195;&#8195;&#8195;&#8195; additional shares of
our Class&nbsp;A common stock in this offering. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unless otherwise specified or context otherwise requires, we refer to
the Common Stock and Preferred Stock Reclassification, the Preferred Stock Conversion, and the Class&nbsp;B Conversion, collectively as the &#147;Transactions.&#148; See the section titled &#147;Description of Capital Stock&#148; for additional
information regarding the Transactions. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom829170_3"></A>SUMMARY CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following tables set forth our summary consolidated financial data. The summary consolidated statement of operations data
for the years ended December&nbsp;31, 2024 and 2023 and balance sheet data as of December&nbsp;31, 2024, except for pro forma and pro forma as adjusted amounts, have been derived from our audited consolidated financial statements and related notes
included elsewhere in this prospectus. Our audited consolidated financial statements included elsewhere in this prospectus have been prepared in accordance with U.S. generally accepted accounting principles (&#147;GAAP&#148;). Our historical results
are not necessarily indicative of the results that may be expected for any period in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">You should read the
following summary consolidated financial data in conjunction with the section titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our audited consolidated financial statements and related
notes included elsewhere in this prospectus. The summary consolidated financial data in this section are not intended to replace, and are qualified in their entirety by, the audited consolidated financial statements and related notes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidated Statements of Operations and Comprehensive Loss Data </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2023&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2024&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except&nbsp;per&nbsp;share<BR>data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">292,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">194,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">324,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(130,514</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(108,546</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Benefit from)<B> </B>income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(405</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(108,141</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders, basic and diluted<SUP
STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8.31</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares used to compute net loss per share attributable to common stockholders<SUP
STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Pro forma net loss per share attributable to common stockholders, basic and diluted (unaudited)<SUP
STYLE="font-size:75%; vertical-align:top">(3)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Includes stock-based compensation expense as follows: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">See Note 11 to our audited financial statements included elsewhere in this prospectus for details on the
calculations of historical basic and diluted net loss per share and the weighted-average number of attributable common stockholders in computation of these per share amounts. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The unaudited pro forma basic and diluted net loss per share have been prepared to give effect to the filing
and effectiveness of our amended and restated certificate of incorporation, which will occur immediately prior to the completion of this offering and the Transactions. The pro forma net loss used to calculate pro forma net loss per share reflects
stock-based compensation expense of approximately $&#8195;&#8195; that we will recognize upon the completion of this offering related to RSUs and PRSUs subject to service-based or performance-based and liquidity-based vesting conditions for which
the service-based or performance-based vesting condition was satisfied as of December&nbsp;31, 2024 and for which the liquidity-based vesting condition will be satisfied in connection with this offering. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidated Balance Sheet Data </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro<BR>Forma&nbsp;As<BR>Adjusted<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The pro forma column above gives effect to (i)&nbsp;the filing and effectiveness of our amended and restated
certificate of incorporation, which will occur immediately prior to the completion of this offering, (ii)&nbsp;the Transactions, and (iii)&nbsp;stock-based compensation expense of approximately $&#8195;&#8195;that we will recognize upon the
completion of this offering related to RSUs and PRSUs subject to service-based or performance-based and liquidity-based vesting conditions for which the service-based or performance-based vesting conditions were satisfied as of December&nbsp;31,
2024 and for which the liquidity-based vesting condition will be satisfied in connection with this offering. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The pro forma as adjusted column above gives further effect to (i)&nbsp;the pro forma adjustments set forth
above and (ii)&nbsp;the issuance and sale of&#8195;&#8195;&#8195;&#8195; shares of Class&nbsp;A common stock by us in this offering at an assumed initial public offering price of $&#8195;&#8195;per share, which is the midpoint of the price range set
forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Working capital is defined as total current assets less total current liabilities. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key Metrics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We monitor the following key metrics to help us evaluate our business, identify trends affecting our business, formulate
business plans and make strategic decisions. We believe the following metrics are useful in evaluating our business: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of clients</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Members</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">370,526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LTM average eligible lives (in thousands)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LTM calculated billings (in thousands)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">328,827</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">See the section titled &#147;Management&#146;s Discussion and Analysis of Financial Condition
and Results of Operations&#151;Key Metrics&#148; for information on how we define and calculate these metrics. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-GAAP</FONT> Financial Measures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to our results prepared in accordance with GAAP, we believe the following
<FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures, including <FONT STYLE="white-space:nowrap">non-GAAP</FONT> gross profit and <FONT STYLE="white-space:nowrap">non-GAAP</FONT> gross margin,
<FONT STYLE="white-space:nowrap">non-GAAP</FONT> loss from operations and <FONT STYLE="white-space:nowrap">non-GAAP</FONT> operating margin, and free cash flow, each of which are included in this prospectus, provide those that review our financial
information with additional useful information in evaluating our performance and liquidity and allow them to more readily compare our results across periods without the effect of <FONT STYLE="white-space:nowrap">non-cash</FONT> and other items as
detailed below. Additionally, our management and board of directors use <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures to evaluate our performance and liquidity, identify trends, and make strategic decisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There are limitations to the use of the <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures presented in this
prospectus. For example, our <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures may not be comparable to similarly titled measures of other companies. Other companies, including companies in our industry, may calculate <FONT
STYLE="white-space:nowrap">non-GAAP</FONT> financial measures differently than we do, limiting the usefulness of those measures for comparative purposes. Our <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures should not be
considered in isolation or as alternatives to gross profit, gross margin, income (loss) from operations, net cash provided by (used in) operating activities or any other measure of financial performance calculated and presented in accordance with
GAAP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">See the section titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of <FONT
STYLE="white-space:nowrap">Operations&#151;Non-GAAP</FONT> Financial Measures&#148; for additional information about these <FONT STYLE="white-space:nowrap">non-GAAP</FONT> measures, including their limitations, and a reconciliation of our <FONT
STYLE="white-space:nowrap">non-GAAP</FONT> financial measures to the most directly comparable financial measures stated in accordance with GAAP. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2023&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2024&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except&nbsp;percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GAAP gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">194,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-GAAP</FONT> gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">204,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GAAP gross margin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-GAAP</FONT> gross margin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GAAP loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(130,514</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-GAAP</FONT> loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(118,227</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GAAP operating margin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-GAAP</FONT> operating margin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(63,909</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Free cash flow</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(68,524</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I><FONT STYLE="white-space:nowrap">Non-GAAP</FONT> Gross Profit and <FONT
STYLE="white-space:nowrap">Non-GAAP</FONT> Gross Margin </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We define <FONT STYLE="white-space:nowrap">non-GAAP</FONT>
gross profit as gross profit presented in accordance with GAAP, adjusted to exclude <FONT STYLE="white-space:nowrap">non-cash,</FONT> <FONT STYLE="white-space:nowrap">non-operational</FONT> and <FONT STYLE="white-space:nowrap">non-recurring</FONT>
items, including excess and obsolete inventory charges related to our <FONT STYLE="white-space:nowrap">AI-powered</FONT> motion tracking technology transition, stock-based compensation expenses and amortization of intangible assets. We define <FONT
STYLE="white-space:nowrap">non-GAAP</FONT> gross margin as <FONT STYLE="white-space:nowrap">non-GAAP</FONT> gross profit divided by revenue. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I><FONT STYLE="white-space:nowrap">Non-GAAP</FONT> Loss from Operations and
<FONT STYLE="white-space:nowrap">Non-GAAP</FONT> Operating Margin </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We define
<FONT STYLE="white-space:nowrap">non-GAAP</FONT> loss from operations as loss from operations presented in accordance with GAAP, adjusted to exclude <FONT STYLE="white-space:nowrap">non-cash,</FONT>
<FONT STYLE="white-space:nowrap">non-operational</FONT> and <FONT STYLE="white-space:nowrap">non-recurring</FONT> items, including excess and obsolete inventory charges related to our computer vision technology transition, stock-based compensation
expenses and amortization of intangible assets. We define <FONT STYLE="white-space:nowrap">non-GAAP</FONT> operating margin as <FONT STYLE="white-space:nowrap">non-GAAP</FONT> loss from operations divided by revenue.</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Free Cash Flow </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We define free cash flow as net cash provided by (used in) operating activities less cash used for purchases of property and
equipment and capitalized <FONT STYLE="white-space:nowrap">internal-use</FONT> software. We believe that free cash flow is a helpful indicator of liquidity that provides information to management and investors about the amount of cash generated or
used by our operations that, after the investments in property and equipment and capitalized <FONT STYLE="white-space:nowrap">internal-use</FONT> software, can be used for strategic initiatives, including investing in our business and strengthening
our financial position. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom829170_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Investing in our Class&nbsp;A common stock involves a high degree of risk. You should carefully consider the risks and
uncertainties described below, together with all of the other information in this prospectus, before making a decision to invest in our Class&nbsp;A common stock. If any of the risks occur, our business, results of operations, and financial
condition could be materially adversely affected. In that event, the trading price of our Class&nbsp;A common stock could decline, and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that
we currently deem immaterial also may impair our business and materially adversely affect our business, results of operations, and financial condition. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Business, Operations, and Industry </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We have a history of net losses, we anticipate increasing expenses in the future, and we may not be able to achieve or
maintain profitability. Although we have experienced rapid growth recently, if we fail to effectively manage our growth, we may be unable to execute our business plan and adequately address competitive challenges, and our business, results of
operations, and financial condition could be materially adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While we have experienced revenue
growth over recent periods, we may not be able to sustain or increase our growth or achieve or maintain profitability in the future. We incurred net losses of $&#8195;&#8195;million and $108.1&nbsp;million for the years ended December&nbsp;31, 2024
and 2023, respectively. Our cash flow from operations was negative for the year ended December&nbsp;31, 2023. As of December&nbsp;31, 2023, we had an accumulated deficit of $510.8&nbsp;million. We have incurred net losses on an annual basis since
our inception. We expect our costs will continue to increase in the foreseeable future as we expect to invest additional funds to grow our business, maintain and increase our members and clients, expand our engagement with partners, hire additional
employees, including our care team, develop new programs and enhance our platform. We may not be able to sustain our growth or achieve or maintain profitability in the future. Our efforts to maintain and increase our client base and our members may
be more challenging than we anticipate, and we may not be able to maintain the historical growth rate of our client base and our members. Our efforts to grow our business may prove more expensive than we currently anticipate, and we may not succeed
in increasing our revenue sufficiently to offset these expenses. Our limited operating history may make it difficult to evaluate our current business and our future prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have encountered and will continue to encounter risks and difficulties frequently experienced by growing companies in
rapidly changing industries. We have recently experienced, and expect to continue to experience, rapid growth in our operations. This growth has placed, and will continue to place, a significant strain on our operational and financial resources and
our personnel. We may not be able to manage our anticipated future growth effectively, including due to a failure to maintain or enhance our information technology infrastructure, financial and accounting systems and controls, and regulatory
compliance framework, or a failure to manage expanded operations and employees in geographically distributed locations. In addition to the expected costs to grow our business, we also expect to incur additional legal, accounting, and other expenses
as we grow and operate as a publicly traded company. These expenditures may be more costly than we expect, and if we do not achieve the benefits anticipated from these investments, or if the realization of these benefits is delayed, they may not
result in increased revenue or growth in our business. If we are unable to successfully address any of these risks and challenges as we encounter them, our business, results of operations, and financial condition could be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may be unable to successfully execute on our growth initiatives, business strategies, or operating plans.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our growth initiatives, strategies, and operating plans are designed to enhance our business and expand our
platform and programs. The anticipated benefits from our growth initiatives, strategies and operating efforts are based on assumptions that may prove to be inaccurate. Moreover, we may not be able to successfully complete
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
these growth initiatives, strategies, and operating plans and realize all of the benefits, including growth targets and cost savings, that we expect to achieve, or it may be more costly to do so
than we anticipate. A variety of risks could cause us not to realize any or all of these expected benefits. These risks include, among others: delays in the anticipated timing of activities related to such growth initiatives, business strategies,
and operating plans; increased difficulty and cost in implementing our initiatives, strategy and operating efforts, including difficulties in complying with new and evolving regulatory requirements; and the incurrence of other unexpected costs
associated with operating our business. Moreover, our continued implementation and investment in these initiatives, strategies, and plans may disrupt our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT>
operations and performance. Additionally, our planned expansion into fully insured health plan and Medicare Advantage populations may result in changes to our business model, which could impact our financial performance. The fully insured and
Medicare Advantage markets operate under different financial dynamics compared to our core self-insured employer channel, and we may experience variability in our revenue and gross margin as a result. As a result, we cannot assure you that we will
realize any benefits from executing on our growth initiatives, business strategies, or operating plans. If, for any reason, the benefits we realize are less than our estimates or the implementation of these growth initiatives, strategies, and
operating plans adversely affects our operations or costs more or takes longer to effectuate than we expect, or if our assumptions about their impact to our business prove inaccurate, our business, results of operations, and financial condition
could be materially adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We have a limited operating history, which makes it difficult for you to
evaluate our business, future prospects, and your investment, and makes it difficult to predict our future results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We were formed in 2012 and launched our first U.S. client in 2016. Accordingly, we have a limited operating history, which
makes it difficult to evaluate our operations and future prospects. As a result of our limited operating history, we have limited insight into trends that may emerge and affect our business. As such, we face risks and uncertainties relating to our
ability to implement our business plan successfully, including, without limitation, our ability to maintain and increase our clients, members, contracted lives, and partners, expand our business in existing markets and enter new markets, and our
ability to accurately forecast our future results of operations, including revenue, margins, cash flow, and net income (loss), as well as plan our operating expenses. In addition, our business is affected by general macroeconomic and business
conditions in the United States and around the world, including fluctuating interest rates, political and market instability and uncertainty, inflationary pressures, terrorist activities and armed conflicts, and other health crises and natural
disasters that affect us and our clients, members, and partners. If our assumptions regarding these risks and uncertainties are incorrect or change due to changes in our markets or changes in business and economic conditions generally, or if we do
not address these risks successfully, our results of operations and financial results may differ materially from our expectations and our business may suffer. These risks and challenges could affect fundamental aspects of our business, including our
ability to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain and increase our contracted lives and members; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain and increase our clients and partners; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain and increase revenue from our platform; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enhance our platform, develop new or enhanced programs, and effectively manage our growth;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">comply with existing and new laws and regulations applicable to our business and our industry, including,
without limitation, any healthcare regulatory laws and compliance regulations that govern our platform and programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successfully compete with other companies that are currently in, or may in the future enter, our markets or
that offer MSK treatments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain and improve the infrastructure underlying our platform, including our apps and website, including
with respect to data protection and cybersecurity; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain and enhance the value of our reputation and brand. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may not be able to address these risks and challenges in a cost-effective
manner, or at all. Our potential for future profitability and growth must be considered in light of these and other risks, uncertainties, expenses, and difficulties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our results of operations have in the past fluctuated and may in the future continue to fluctuate on a quarterly and
annual basis. If we fail to meet the expectations of analysts or investors, our stock price and the value of your investment could decline substantially. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our results of operations have in the past, and may in the future, continue to fluctuate significantly on a quarterly and
annual basis, driven in part by the cyclical nature of our business and the seasonal nature of our sales cycle. For example, a majority of our clients enter into contracts with us in the third and fourth quarters of each calendar year, in line with
the typical employee benefit enrollment period. Most of these clients are then launched in the first or second quarter of the following calendar year. Macroeconomic conditions, however, may delay or halt the launch process. We may be affected by
different seasonal trends in the future, particularly as our business matures. For example, we expect that, from time to time due to macroeconomic factors outside of our control, certain clients or potential clients may not engage with us until
later in the fourth quarter of a calendar year, which may delay the timing of our billings and the start of revenue recognition. We may experience unexpected fluctuations in our results of operations and financial metrics and make forecasting our
future results of operations and financial metrics more difficult. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Further, while we sometimes offer a flat annual fee
per member for our platform, many client agreements reflect milestone-based payments. Accordingly, there is a risk that we may not be able to monetize engagement by members in the manner we predict or expect based on this pricing model. In addition,
we are implementing an alternative engagement-based pricing model in the near term based on member engagement, which may take more time and require more effort to implement than anticipated, may have results that are difficult to predict, and may
result in decreased revenue from some clients. Additionally, since we recognize revenue ratably over the course of an annual subscription, any decreases in our sales to new clients or renewals of existing clients in any one period may not
immediately be fully reflected as a decrease in revenue for that period, but would negatively affect our revenue in future quarters. This dynamic also makes it difficult for us to rapidly increase our revenue through the sale of additional
subscriptions in any period. If we fail to match our past performance, if our quarterly performance fluctuates due to macroeconomic factors outside of our control, or if we fail to meet or exceed the expectations of securities analysts or investors,
the trading price of our Class&nbsp;A common stock could decline. Moreover, our stock price may be based on expectations of our future performance that may be unrealistic or that may not be met. Some of the important factors that could cause our
revenue and results of operations to fluctuate from quarter to quarter include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain and increase our contracted lives and members; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain and increase our clients and partners; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the termination or renegotiation by our significant partners of their agreements with us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to develop and deploy new or enhanced programs, expand our platform, and effectively manage our
growth; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to deliver on performance guarantees, which may include engagement thresholds, member reported
outcomes, and client return on investment, that are offered to the vast majority of our clients; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of our alternative engagement-based pricing model; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to comply with existing and new laws and regulations applicable to our business and our industry,
including, without limitation, any healthcare regulatory laws and compliance regulations that govern our platform and programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disruptions or outages in our app and website availability, actual or perceived breaches of privacy, and
compromises of the data of our contracted lives; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully compete with other companies that are currently in, or may in the future enter,
our markets or offer MSK treatments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shifts in healthcare benefits trends and reimbursement arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to manage reputational risks; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general industry and macroeconomic conditions that would adversely impact sales. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we are unable to attract new clients, if existing clients do not renew their agreements or renew on less favorable
terms, or if we do not achieve our performance guarantees, it could have a material adverse effect on our business, results of operations, and financial condition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In order to grow our business, we must continually attract new clients and reduce the level of
<FONT STYLE="white-space:nowrap">non-renewals</FONT> in our business. Our ability to do so depends in large part on the success of our sales and marketing efforts and on our relationships with clients and partners. We aim to enter into long-term
relationships with clients and with partners. The majority of our clients enter into contracts with us through our relationships with health plans. Most of our agreements with health plans are three-year contracts; however, health plans can
generally unilaterally terminate their relationship with us pursuant to the terms of their agreements with us or can seek to renegotiate their agreements prior to the end of the contract term. Additionally, our client contracts often include a
performance guarantee, which may include engagement thresholds, member reported outcomes, and client return on investment, and, if we are unable to achieve these performance guarantees on a consistent basis, our business, results of operations, and
financial condition could be materially adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Even if we are successful in attracting new clients, our
success with clients will depend in part on how many of their contracted lives engage with and desire to use, and continue to use, our platform and programs, which is a factor for whether such clients continue to renew their agreements with us.
Under our client agreements, our revenue depends on the fees we collect based on the number of, and engagement of, members. The more contracted lives a client has, the larger the number of potential members, which increases the potential for the
fees we can collect from that client. Many factors may lead to a decrease in the contracted lives at a given client, including, but not limited to, the natural attrition of a client&#146;s contracted lives and the impact of macroeconomic conditions
on our clients or potential clients that may result in a decrease in their employee population, and continued acceptance of our platform and programs for existing and new areas affected by MSK such that clients expand their base of contracted lives.
Further, larger clients may have complex decision-making processes to offer our platform and programs to their contracted lives, which could limit or delay our ability to engage with members or contracted lives. For example, a client may take time
to review and implement our new programs, which may delay our ability to market them to members and contracted lives, or a client may decide not to implement our new programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our client base may decline or fluctuate due to a number of factors, including our pricing, the prices of products and
services offered by our competitors, reduced hiring by our clients or reductions in their contracted lives due to macroeconomic or other factors, the efficacy of our platform and programs for members, the desirability of our platform and programs to
members and contracted lives, cost-effectiveness of our platform and programs for our clients, our ability to satisfy our obligations under our client contracts, and consolidation of our client base. In particular, our overall performance depends,
in part, on economic conditions. In recent periods, we have observed increased economic uncertainty in the United States and abroad. As our clients react to global economic conditions, including the impact of inflation on wages and labor costs,
reduced discretionary spending, and the potential for a global recession, we may see them reduce spending, reduce contracted lives, and take additional precautionary measures to limit or delay expenditures and preserve capital and liquidity. In
addition, if any of our clients are unable to access funds pursuant to instruments or lending arrangements with a financial institution that falls into receivership or experiences similar liquidity issues, such parties&#146; ability to pay their
obligations to us or to enter into new arrangements requiring additional payments to us could be adversely affected. Any future changes to the price or the timing of payment collection for use of our platform and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
programs pursuant to the terms of our agreements, including changes under our alternative engagement-based pricing model, may adversely affect our business, results of operations, and financial
condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Reductions in spending by clients on our platform and programs, delays in purchasing decisions, lack of
renewals, and an inability to attract new clients, as well as pressure for extended billing terms or pricing discounts, could limit our ability to grow our business and could adversely affect our business, results of operations, and financial
condition. In addition, we are implementing an alternative engagement-based pricing model based on member engagement, which may take more time and require more effort to implement than anticipated and may have results that are difficult to predict.
If we are unable to retain and increase our engagement of existing clients or attract new clients for any of the reasons above or for other reasons, our business, results of operations, and financial condition could be materially adversely affected.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we fail to retain existing members or add new members, our revenue, business, results of operations, and
financial condition may be materially adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The number of members and such members&#146; continued
engagement are critical to our success. Our financial performance has been and will continue to be significantly determined by our success in adding, retaining, and engaging members. Our members join through their employers, health plans, and other
purchasers of healthcare for beneficiaries, who are our clients, and our ability to retain or attract new members depends on our ability to successfully engage with such clients or potential clients that provide their contracted lives access to our
platform and programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our ability to maintain members depends on our ability to provide an engaging, effective,
accessible, and competitive platform. In addition, we believe our future success will depend in part on our ability to increase both the speed and success of member enrollment, by improving our outreach to contracted lives, engagement with
contracted lives and members, and enrollment methodology, hiring and training qualified professionals, and increasing our ability to integrate into large-scale, complex technology environments. Such members or contracted lives rely on various
sources to determine the effectiveness of our platform and programs. For example, if PBMs at our clients do not perceive our platform and programs to be useful, effective, reliable, and trustworthy, we may not be able to attract or retain members or
otherwise maintain or increase the frequency and duration of their engagement. Lack of support for our platform and programs from PBMs can affect how receptive potential clients will be to engage with us and offer our platform and programs to their
contracted lives. Subsequently, such a decrease in our ability to engage new members or retain existing members due to negative perception could render us less attractive to our potential clients that could provide direct access to additional
contracted lives and members, which may have a material and adverse impact on our revenue, business, results of operations, and financial condition. Moreover, members who may benefit from our platform and programs may lose interest and disengage,
and ultimately not <FONT STYLE="white-space:nowrap">re-enroll,</FONT> for reasons outside of our control that are not in response to the effectiveness or utility of our platform and programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Moreover, even if our platform and programs are effective, members may decide not to enroll in future periods and may stop
using our platform and programs until additional or a recurrence of MSK conditions cause them to <FONT STYLE="white-space:nowrap">re-enroll.</FONT> Our forecasts may not accurately estimate enrollment rates or the number of members. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any other number of factors could potentially negatively affect new member engagement and growth or existing member retention,
including if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our platform and programs are deemed ineffective by PBMs, existing members, or publications;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we fail to introduce new and enhanced programs or expand our platform, or if we introduce new or enhanced
programs or expand our platform for our existing members that are not favorably received; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there are changes in member sentiment about the quality, effectiveness, or accessibility of our platform and
programs or concerns related to privacy and data sharing, safety, security, or other factors; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there are adverse changes in our platform and programs that are mandated by legislation, regulatory
authorities, or litigation, including settlements or consent decrees; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there are shifts in healthcare benefits trends; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clients offer their members or employees a significant volume of optional health benefits that result in
contracted lives overlooking our platform and programs or choosing to focus on others; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">partners or clients do not consent to the implementation of our new programs and do not offer them to their
contracted lives; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our marketing efforts to contracted lives are ineffective or limited by our clients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">technical or other problems prevent us from delivering our platform and programs in an efficient, accessible,
and reliable manner or otherwise affect the member experience; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we adopt policies or procedures related to areas such as sharing the data of our contracted lives that are
perceived negatively by our members or the general public; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">new offerings from our competitors are introduced to the market, including those that have features or
functionality that may be superior to ours or that are lower-cost alternatives. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In some cases, clients
initially enter into an agreement with us to provide our platform and programs to their contracted lives, but, for a variety of possible reasons, contracted lives ultimately fail to engage with our platform and programs at the expected volume. Our
forecasts may not accurately estimate engagement rates, the amount of member engagements, and other assumptions we rely on to anticipate expected growth for our business and revenue, including under our alternative engagement-based pricing model.
Additionally, if we are unable to achieve the expected volume of members based on our engagement with clients, or are unable to do so in a timely manner and, as a result, contracted lives do not utilize our platform and programs, clients are
unlikely to renew their agreement with us and we may not be able to generate future revenue from such clients, which may adversely impact our future business, results of operations, and financial condition. If we are unable to maintain and increase
our existing members and member engagement, our revenue, business, results of operation, and financial condition could be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Individuals covered by high deductible health plans are typically ineligible to make health savings account (&#147;HSA&#148;)
contributions if they receive any coverage before their deductible is satisfied. However, an exception to this rule that is currently scheduled to expire at the end of 2024 for most plans allows these individuals to retain their <FONT
STYLE="white-space:nowrap">HSA-eligibility</FONT> if they receive telehealth or other remote services before their deductible is met. If this exception is not renewed, it could materially affect our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>A substantial portion of our client relationships are contracted through a limited number of health plans and other
partners. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Historically, a limited number of health plans and other partners have been responsible for contracting
and support with a majority of our clients. Client contracts through our top&#8195;&#8195;&#8195;&#8195;partners accounted for &#8195;% of our revenue for the year ended December&nbsp;31, 2024. These partners are not required to work with us
on&#8195;&#8195;&#8195;&#8195; an&nbsp;exclusive&nbsp;basis. If we are unable to establish, maintain, or grow these relationships over time or if the partners refer business to our competitors instead, we are likely to lose a portion of our clients
and our business, results of operations, and financial condition will suffer. The loss of any of our key partners could impact the growth rate of our revenue, business, and results of operations as we work to obtain new partners or replacement
relationships. Additionally, if the financial terms of our agreements with key partners, particularly major health plans, become less favorable to us as they are renewed, our business, results of operations, and financial condition could be
adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Contracts with our key partners may be terminated before their term expires for various reasons,
subject to certain conditions, and our partners may seek to renegotiate the terms of their agreements before their term </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
expires. For example, after a specified period, certain of our contracts are terminable for convenience by our partners, subject to a notice period. In our negotiations with health plan
contracts, we may also agree to terms in favor of the health plans that could expose us to potentially high expenses or liabilities, including unfavorable indemnification clauses that promise to indemnify the plans if the use of our platform and
programs does not qualify for &#147;first-dollar&#148; coverage due to legislative changes. See the risk factor titled &#147;Risks Related to Legal and Regulatory Matters&#151;Our business operates in a highly regulated legislative or regulatory
healthcare reform measures may make it more difficult and costly to operate our business, or to do so profitably. Accordingly, such legislative or regulatory healthcare reform measures may have a material adverse effect on our business, results of
operations, and financial condition.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Further, while we collect revenue from our clients, if the client is
contracted through a health plan partner, then the health plan partner remits payment to us. In addition, while we have agreements with our partners that indicate the terms of payment, our partners may audit or dispute our contracts and billing
practices because they differ from traditional health plan contracting and billing practices, which could lead to delays in payment or <FONT STYLE="white-space:nowrap">non-payment</FONT> of certain fees, deterioration in the partner relationship, or
renegotiation of partner agreements. Such risks may increase as we shift to our alternative engagement-based pricing model. In order to grow our business, we anticipate that we will continue to depend on our relationships with third parties,
including our partners. Identifying partners, and negotiating and documenting relationships with them, requires significant time and resources. Our competitors may be effective in providing incentives to third parties to favor their products or
services or to prevent or reduce utilization of our platform and programs. If we are unsuccessful in establishing or maintaining our relationships with third parties, our ability to compete in the marketplace or to grow our revenue could be impaired
and our business, results of operations, and financial condition may be materially adversely affected. Even if we are successful, our relationships with third parties may not result in an increase in clients, members, contracted lives, or revenue.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We incur upfront costs in our client and partner relationships, and if we are unable to maintain and grow these
relationships over time, we are likely to fail to recover these costs, which could have an adverse effect on our business, results of operations, and financial condition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We devote resources to establish relationships with our partners, including health plans in particular, in order to implement
our platform, and have a relatively long sales cycle. Accordingly, our results of operations will depend in substantial part on our ability to enroll our clients&#146; contracted lives as members, deliver a successful experience for clients and
members, and persuade our clients and partners to maintain and grow their relationships with us over time. We also invest in expanding our partner relationships, particularly with health plans. Additionally, if our business grows significantly, our
client, partner, and member acquisition costs could outpace <FONT STYLE="white-space:nowrap">our&nbsp;build-up&nbsp;of</FONT> recurring revenue, and we may be unable to reduce our total operating costs through economies of scale such that we are
unable to achieve profitability. We incur upfront costs in establishing our client and partner relationships. If we fail to achieve appropriate economies of scale, if our investments in these relationships fail to materialize or if we fail to manage
or anticipate the evolution and demand of our platform and programs, our enrollment rate may decrease, and our business, results of operations, and financial condition could be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we are not able to develop and release new programs, or successful enhancements, new features, and modifications to
our existing platform and programs, or if our clients do not consent to the inclusion of platform and program enhancements in their agreements, our business, results of operations, and financial condition could be adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The markets in which we operate are characterized by rapid technological change, frequent new product and service introductions
and enhancements, changing client and member demands, and evolving industry standards. The introduction of products and services embodying new technologies can quickly make existing products and services obsolete and unmarketable. Additionally,
changes in laws and regulations could impact the usefulness of our platform and programs and could necessitate changes or modifications to our platform and programs to accommodate such changes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We invest substantial resources in researching and developing new programs
and enhancing our existing platform and programs by incorporating additional features, improving functionality, and adding other improvements to meet our members&#146; evolving needs. The success of any enhancements or improvements to our platform
and programs or any new programs, including those in markets beyond the MSK market, depends on several factors, including timely completion, competitive pricing, adequate quality testing, integration with new and existing technologies in our
platform and third-party partners&#146; technologies and overall market acceptance. We may not succeed in developing, marketing, and delivering on a timely and cost-effective basis enhancements or improvements to our platform and programs or any new
programs that respond to continued changes in market demands or new client or member requirements, and any enhancements or improvements to our platform and programs or any new programs may not achieve market acceptance. In addition, many partners
and clients require additional consent before we can offer new programs to their members, which can delay the process and adversely affect potential revenues. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since developing or enhancing our platform and programs is complex, the timetable for the release of new programs and
enhancements to our existing platform and programs is difficult to predict, and we may not offer new programs or enhancements to our platform as rapidly as our clients require or expect. Any new programs and enhancements to our platform that we
develop or acquire may not be introduced in a timely or cost-effective manner, may not have actual or perceived effectiveness or may not achieve the broad market acceptance necessary to generate sufficient revenue. Moreover, even if we introduce new
programs or enhancements to our platform, we may experience a decline in revenue from our programs that is not offset by revenue from the new programs or enhancements to our existing platform and programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The introduction of new products and services by competitors, the development of entirely new technologies to replace existing
offerings, or shifts in healthcare benefits trends could make our platform and programs obsolete or adversely affect our business, results of operations, and financial condition. We may experience difficulties with software development, industry
standards, design, or marketing that could delay or prevent our development, introduction, or implementation of new programs, enhancements, additional features, or capabilities. If clients do not widely engage with us and their contracted lives do
not adopt our platform and programs, we may not be able to realize a return on our investment. If we do not accurately anticipate client and member demand or we are unable to develop, license, or acquire new features and capabilities on a timely and
cost-effective basis, or if such enhancements do not achieve market acceptance, it could result in adverse publicity and loss of revenue or market acceptance, each of which could have a material adverse effect on our reputation, business, results of
operations, and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The failure of our platform and programs to achieve and maintain market
acceptance or to effectively compete against other technological breakthroughs for the treatment or prevention of MSK conditions could result in us achieving sales below our expectations, which would cause our business, results of operations, and
financial condition to be materially adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our current business strategy is highly dependent on our
platform and programs achieving and maintaining market acceptance. Market acceptance and adoption of our platform and programs depends on educating people with MSK conditions, including existing and potential clients, members, and contracted lives,
as to the accessibility, distinct <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">features,&nbsp;ease-of-use,&nbsp;positive</FONT></FONT> lifestyle impact, cost savings, and other real and perceived benefits of our platform and
programs as compared to other solutions. Additionally, our ability to achieve our strategic objectives and remain competitive will depend, among other things, on our ability to develop and commercialize programs that are market-accepted for the
treatment of MSK conditions that offer accessibility, have distinct features, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">are&nbsp;easy-to-use,&nbsp;provide</FONT></FONT> measurable and meaningful cost savings to clients, and
are more appealing than available alternatives. Our competitors, as well as a number of other companies, within and outside the healthcare industry, are pursuing new delivery devices, delivery technologies, sensing technologies, procedures, drugs,
and other therapies, including solutions driven by artificial intelligence (&#147;AI&#148;) and machine learning, for the monitoring and treatment of MSK conditions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Achieving and maintaining market acceptance of our platform and programs
could be negatively impacted by many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the failure of our platform and programs to achieve wide acceptance among key opinion leaders in the treatment
community and among people living with or at risk for MSK conditions, health plans, or other existing or potential clients, partners, and members; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lack of sufficient evidence or peer-reviewed publication of clinical evidence supporting the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">safety,&nbsp;ease-of-use,&nbsp;cost-savings,</FONT></FONT> or other real or perceived benefits of our platform and programs over competitive products or other currently available
methodologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">perceived risks associated with the use of our platform and programs or similar products or technologies
generally, including those that incorporate AI and machine learning; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">individual and healthcare industry concerns or negative publicity regarding patient confidentiality and
privacy in the context of digital health; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the introduction of competitive solutions and the rate of acceptance of those solutions as compared to our
platform and programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">challenges to our platform and programs by traditional care providers and affiliated professional entities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the pace of innovation in AI and machine learning, which may lead to the development of superior or more
cost-effective solutions that could render our platform and programs obsolete or less competitive; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">uncertainty around new and emerging AI and machine learning technologies, and the risks involved in the
development and deployment of such technologies; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">results of clinical and financial studies relating to MSK solutions or similar competitive solutions,
including those prepared by our potential clients and partners. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we are not successful in
demonstrating to existing and potential clients, members, and partners, including health plans, the benefits of our platform and programs, or if we are not able to achieve the support of existing and potential clients, members, and partners for our
platform and programs, our revenue may decline or we may fail to increase our revenue in line with our forecasts, and our business, results of operations, and financial condition could be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We operate in an evolving and competitive industry and if we fail to compete effectively against our existing or
potential competitors, our business, results of operations, and financial condition could be adversely affected.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We compete across various segments within the healthcare market, including with respect to traditional healthcare providers,
physical therapy providers and medical practices, technology platforms, care management and coordination, digital health, telehealth and telemedicine, medical devices, and health information exchanges. Larger and more established companies, which
could include our partners, may focus on our markets and could directly compete with us by implementing their own solutions for MSK care. Smaller companies could also launch new products and services that compete with us and that could gain market
acceptance quickly. Our competitors and potential competitors include both enterprise companies that are focused on, or may enter, the healthcare industry, including initiatives and partnerships launched by these large companies, and private
companies that offer point solutions for a single MSK condition. We currently face competition from a range of companies, including digital platforms that provide broad care or programs that address a segment of MSK care, such as Kaia Health
Software, Inc., Omada Health, Inc., Sword Health Technologies, Inc., and Vori Health, Inc. These companies, which may offer their solutions at lower prices, are continuing to develop additional products and are becoming more sophisticated and
effective. We also currently face competition from health plans and health systems that may offer or develop products or services with features or benefits that overlap with our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
platform and programs. Large, well-financed healthcare providers and insurance carriers have in some cases developed their own products and services and may provide them to their clients at
discounted prices and as supplements to traditional healthcare services. Competition could also result in pricing pressures, which could negatively impact our sales, profitability, and market share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our ability to compete effectively depends on our ability to distinguish our company and our platform and programs from our
competitors and their products and services, and includes factors such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">long-term outcomes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ease of use and convenience; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">price; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">greater name and brand recognition; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">longer operating histories; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">greater market penetration; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">larger and more established client and partner relationships; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">larger sales forces and more established products and networks; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">larger marketing budgets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">access to significantly greater financial, human, technical, and other resources; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">breadth, depth, and efficacy of products and services; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">perceived, actual, and measurable quality, reliability, and effectiveness of products and services; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">client and member acceptance. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Some of our competitors or potential competitors may have greater name and brand recognition, longer operating histories, and
significantly greater resources than we do, and may be able to offer solutions similar to ours at a more attractive price than we can. Further, our current or potential competitors may be acquired by third parties with greater available resources.
As a result, our competitors may be able to respond more quickly and effectively than we can to new or changing opportunities, technologies, such as AI and machine learning, standards, or client or eligible life requirements or expectations and may
have the ability to initiate or withstand substantial price competition. In addition, our current or potential competitors have established, or may in the future establish, cooperative relationships with providers of complementary products,
technologies, or services to increase the availability of their products and services in the marketplaces in which we compete. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">New competitors or alliances may emerge that have greater market share, a larger number of clients or contracted lives, more
widely adopted proprietary technologies, greater marketing expertise, greater financial resources, and larger sales forces than we have, which could put us at a competitive disadvantage. Our competitors could also be better positioned to serve
certain segments of our markets, which could create additional price pressure. There is no guarantee that we will possess the resources, either financial or personnel, for the research, design, and development of new programs or the expansion of our
platform, or that we will be able to utilize these resources successfully and avoid technological or market obsolescence. In light of these factors, even if our platform and programs are more effective than those of our competitors, current or
potential clients and their contracted lives may accept competitive products and services in lieu of purchasing our platform and programs, or potential clients may choose to purchase different health benefits. If we are unable to successfully
compete, our business, results of operations, and financial condition could be adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The markets for
our platform and programs are new, rapidly evolving, and increasingly competitive, as the healthcare industry in the U.S. is undergoing significant structural change. If the digital health and
</I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>
MSK markets in which we operate develop more slowly than we expect or if they encounter negative publicity, our business, results of operations, and financial condition could be adversely
affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The digital health market is relatively new, unproven, rapidly evolving, and it is uncertain whether it
will achieve and sustain high levels of demand, consumer acceptance, and market adoption. Competition in the digital health market involves rapidly changing technologies, evolving regulatory requirements and industry expectations, frequent new
product and service introductions, evolving industry standards, short product lifecycles, and changes in consumer demands. Moreover, the MSK market, including MSK care generally and MSK pain management medical devices in particular, is new and
rapidly evolving. Our success will depend to a substantial extent on the willingness of our members and contracted lives to use, and to increase the frequency, extent, and duration of their utilization of, our platform and programs, as well as on
our ability to demonstrate the value of digital health to existing and new clients, members, and contracted lives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Negative publicity regarding patient confidentiality, data privacy, and cybersecurity in the context of technology-enabled
healthcare or concerns experienced by our competitors could limit market acceptance of our programs. Additionally, the integration and reliance on AI and machine learning technologies in our platform and programs introduce further risks. These
technologies are rapidly evolving and may not perform as expected, which could lead to inaccuracies or inefficiencies in our platform and programs. Negative publicity or regulatory scrutiny related to AI and machine learning could also impact
consumer trust and acceptance. Furthermore, the competitive landscape may shift as new AI and machine learning advancements emerge, potentially rendering our current technologies obsolete or less effective. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we fail to adapt and respond effectively to the changing healthcare landscape, changing laws, regulations, and
government enforcement priorities, changing client needs and member needs, requirements, or preferences, our platform and programs may become less competitive. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The markets in which we compete are subject to a changing healthcare landscape and changing laws, regulations, and government
enforcement priorities, as well as changing client and member needs, requirements, and preferences. The success of our business will depend on our ability to adapt and respond effectively to these changes on a timely basis. Our business strategy may
not effectively respond to these changes, and we may fail to recognize and position ourselves to capitalize upon market opportunities. We may not have sufficient advance notice or resources to develop and effectively implement an alternative
strategy. There may be scientific or clinical changes that require us to change our platform and programs or that make our platform and programs less competitive in the marketplace. If there are sensitivities to our business model or our existing
competitors and new entrants create new disruptive business models or develop new products and services that clients, members, and contracted lives prefer to our platform and programs, we may lose clients, members, and contracted lives, and our
business, results of operations, and financial condition could be adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We rely on our sales and
marketing force. If we are unable to maintain or expand our sales and marketing infrastructure, it could impede our growth, harm our business, and we may fail to attract adequate numbers of clients or members. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our business, results of operations, and financial condition are and will continue to be highly dependent on the ability of our
sales and marketing force to adequately promote and engage with clients who in turn offer our platform and programs to their contracted lives. If our sales and marketing representatives fail to achieve their objectives, we may not enter into
agreements with new clients, and member enrollment and use of our platform and programs could decrease or may not increase at levels that are in line with our forecasts. A key element of our business strategy is the continued expansion of our sales
and marketing infrastructure to maintain and increase our client base and members. In particular, we expect to increase our enterprise marketing efforts directly to contracted lives at our clients. Our sales and marketing efforts may not be
effective and may not lead to increases in the number of our clients and members. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As we increase our sales and marketing
efforts with respect to our existing platform and programs or planned expansions of our platform and programs, we will need to further expand the reach of our sales and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
marketing networks. Our future success will depend largely on our ability to continue to hire, train, retain, and motivate skilled sales and marketing representatives with significant
industry-specific knowledge in various areas, such as MSK pain management and digital health, as well as the competitive landscape for our platform and programs. Recently hired sales representatives require training and take time to achieve full
productivity. If we fail to train recent hires adequately, or if we experience high turnover in our sales force in the future, we cannot be certain that new hires will become as productive as may be necessary to maintain or increase our sales. In
addition, the expansion of our sales and marketing personnel will continue to place significant burdens on our management team. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we are unable to expand our sales and marketing capabilities, we may not be able to effectively commercialize our existing
platform and programs or planned expansions of our platform and programs, which could result in reduced client engagement and the failure of our member enrollment rates to increase in line with our forecasts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Any failure to offer high-quality implementation, member enrollment, or ongoing support may adversely affect our
relationships with our clients and members, or existing or prospective clients and members, and in turn our business, results of operations, and financial condition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Though we prepare targeted marketing campaigns, we do not control our clients&#146; deployment schedules. As a result, if our
clients do not permit and facilitate our marketing efforts, which may be necessary for successful enrollment of their contracted lives as members, or an enrollment launch date is delayed, we could incur significant costs, our enrollment rate may
decline, clients and members could become dissatisfied and decide not to use our platform and programs or not to implement our platform or programs in future periods. In addition, competitors with more efficient operating models or lower
implementation costs could jeopardize our client relationships as well as our partner relationships. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In implementing and
using our platform and programs, our clients and members depend on our support teams to resolve issues in a timely manner. High-quality support is also important for the renewal and expansion of our platform and programs by existing clients as well
as enrollment by contracted lives and <FONT STYLE="white-space:nowrap">re-enrollment</FONT> by current members. We may be unable to respond quickly enough to accommodate short-term increases in demand for support. We also may be unable to modify the
nature, scope, and delivery of our platform and programs or support to compete with changes in solutions provided by our competitors. We have also expanded our technical support team internationally and clients and members may view such support as
less effective than support based in the United States. Furthermore, clients are able to decide whether members receive support from an international team, and if we are unable to successfully transition most clients to the more cost-effective
international support structure, we may not achieve anticipated savings on support labor costs. Increased client and member demand for support could increase costs and adversely affect our business, results of operations, and financial condition.
Our sales are highly dependent on our reputation and on positive recommendations from our existing members, clients, and partners. The importance of our support functions will increase as we expand our business and pursue new clients, members, and
contracted lives. Any failure to maintain high-quality support, or a market perception that we do not maintain high-quality support, could materially adversely affect our reputation, our ability to sell our platform and programs, our ability to
enable members and contracted lives to re-enroll or enroll in our platform and programs, and, in turn, our business, results of operations, and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We believe our corporate culture has contributed to our success, and if we fail to maintain this culture as we grow, we
could lose the capabilities fostered by our culture and our business, results of operations, and financial condition could be materially adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe our culture has been a key contributor to our success to date. We have invested substantial time and resources in
building our team and investing in our corporate culture. As we continue to grow, including geographically, and develop the infrastructure of a public company, we may find it difficult to maintain our
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
corporate culture. We may not be able to effectively integrate, develop, and motivate a large number of new employees across geographies, including our growing employee base in India, and we may
not be able to maintain the beneficial aspects of our corporate culture. Any failure to preserve our culture could negatively affect our ability to retain and recruit qualified personnel. If we fail to attract new personnel or fail to retain and
motivate our current personnel, our business, results of operations, and financial condition could be materially adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, in order to attract employees that contribute to our corporate culture, we have had to offer, and believe we will
need to continue to offer, highly competitive compensation packages before we can validate the productivity of those employees. In addition, fluctuations in the price of our Class&nbsp;A common stock may make it more difficult or costly to use
equity compensation to motivate, incentivize, and retain our employees. Our stock price volatility or lack of positive performance may cause periods of time during which option exercise prices might be less than the sale price of our Class&nbsp;A
common stock or the value of RSUs we grant might be less competitive, which may lessen the retentive attributes of these awards. As a result, we may have to incur increased compensation costs, change our equity compensation strategy, or find it
difficult to motivate, incentivize, and retain our employees. Moreover, we face significant competition for talent from other healthcare, technology, and high-growth companies, which includes large enterprises and privately held companies. We may
not be able to hire new employees quickly enough to meet our needs, and any change in our hiring abilities may affect our corporate culture. If we fail to effectively manage our hiring needs and successfully integrate our new hires, our efficiency
and our employee morale, productivity, and retention could suffer, and our business, results of operations, and financial condition could be materially adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We depend on our executive officers and other key employees, and the loss of one or more of these employees or an
inability to attract and retain other highly skilled employees could materially adversely affect our business, results of operations, and financial condition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our performance depends upon the efforts and abilities of our executive team, particularly Daniel Perez, our Chief Executive
Officer and <FONT STYLE="white-space:nowrap">Co-Founder,</FONT> certain key technical and management personnel, and other highly skilled employees. The loss of the services of one or more such people could have a material adverse effect on our
business, results of operations and financial condition. Our success also depends on our ability to attract and retain other highly skilled employees and key management personnel. Qualified individuals are in high demand, and we may incur
significant costs to attract them. Competition for such personnel is intense, and we may not be able to attract or retain such personnel in the future. The loss of even a few qualified employees, or an inability to attract, retain, and motivate
additional highly skilled employees required for the planned growth of our business, could harm our results of operations and impair our ability to grow. To attract and retain key personnel, we use various measures, including an equity incentive
program for key executive officers and most employees. These measures may not be enough to attract and retain the personnel we require to operate our business effectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In April 2024, we reduced our workforce by approximately 160 people, or approximately 10% of our workforce. The expense
reduction measures taken in connection with such reduction in force may result in unintended consequences and costs, including costs associated with attrition beyond our intended reduction in force, a decrease in morale among our personnel, adverse
impacts in our ability to recruit and hire qualified personnel in the future, and the loss of institutional knowledge and expertise, which could result in losses in future periods or otherwise prevent us from realizing, in full or in part, the
anticipated benefits and savings from the reduction in force. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All of our employees are
<FONT STYLE="white-space:nowrap">at-will</FONT> employees, meaning that they may terminate their employment relationship with us at any time, and their knowledge of our business and industry would be extremely difficult to replace. If we fail to
retain talented senior management, our executive team, and other key technical and management personnel, or if we do not succeed in attracting well-qualified employees or retaining and motivating existing employees, our business, results of
operations, and financial condition may be materially adversely affected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may require additional capital to support the growth of our
platform and programs, and this capital may not be available on terms favorable to us, or at all, and may dilute existing stockholders&#146; ownership of our Class&nbsp;A common stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We intend to continue to make investments to support the growth of our platform and programs and may require additional funds
for such development. We may need additional funding for marketing expenses, to develop and expand sales resources, develop new features, or enhance our platform and programs, or acquire complementary businesses and technologies to further grow our
business and the platform and programs we can offer. Accordingly, we may need or want to engage in future equity or debt financings to secure additional funds. If we raise additional funds through issuances of equity or convertible debt securities,
our existing stockholders could suffer significant dilution, and any new equity securities we issue could have rights, preferences, and privileges superior to those of holders of our Class&nbsp;A common stock. Any debt financing that we may secure
in the future could involve restrictive covenants relating to our capital raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital and to pursue business opportunities.
Volatility in capital markets and lower market prices for many securities may, among other things, affect our ability to access new capital on terms favorable to us, if at all. If we are unable to obtain adequate financing or financing on terms
satisfactory to us, our ability to develop our platform and programs, support our business growth, and respond to business challenges could be significantly impaired, and our business, results of operations, and financial condition could be
adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we are not able to maintain and enhance our reputation and brand recognition, our business,
results of operations, and financial condition will be materially adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that maintaining
and enhancing our reputation and brand recognition is critical to our relationships with existing clients and members and our ability to attract new clients and members. The promotion of our brand may require us to make substantial investments and
we anticipate that, as our market becomes increasingly competitive, these marketing initiatives may become increasingly critical, difficult, and expensive. Our marketing activities may not be successful or yield increased revenue, and to the extent
that these activities yield increased revenue, the increased revenue may not offset the expenses we incur, and our results of operations could be materially adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, any factor that diminishes our reputation or that of our management, including failing to meet the expectations
of our clients and members, could make it substantially more difficult for us to attract new clients and members. Similarly, because our clients and members often act as references for us with prospective new clients, members, and contracted lives,
any existing clients or members that question the quality of our work or that of our employees, including our care team, could impair our ability to secure additional new clients, members, and contracted lives. If we do not successfully maintain and
enhance our reputation and brand recognition with our clients and members, our business may not grow and we could lose these relationships, which would make it more difficult to acquire new clients, members, and contracted lives, all of which could
materially adversely affect our business, results of operations, and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Acquisitions and
investments could result in operating difficulties, dilution, and other harmful consequences that may materially adversely impact our business, results of operations, and financial condition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have in the past and may in the future make acquisitions to add employees, complementary companies, programs, technologies,
or revenue. These transactions entail numerous risks and could be material to our business, results of operations and financial condition. We also expect to continue to evaluate and enter into discussions regarding a wide array of potential
strategic transactions. The identification of suitable acquisition candidates can be difficult, time-consuming, and costly, and we may not be able to complete acquisitions on favorable terms, if at all. The process of integrating an acquired
company, business or technology has created, and will continue to create, unforeseen operating difficulties and expenditures. Furthermore, an acquisition may not result in the benefits we anticipate.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Future acquisitions could also result in expenditures of significant cash,
dilutive issuances of our securities, the assumption or incurrence of debt, restrictions on our business, contingent liabilities, amortization expenses or write-offs of goodwill, any of which could harm our financial condition. In addition, any
acquisitions we announce could be viewed negatively by partners, clients, members, or investors. Moreover, acquisitions or investments could result in costly litigation or liabilities for any breach of representations and warranties made in the
course of such acquisitions or investments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, competition within our industry for acquisitions of businesses,
technologies, and assets may become intense. Even if we are able to identify an acquisition that we would like to consummate, we may not be able to complete the acquisition on commercially reasonable terms or the target may be acquired by another
company. We may enter into negotiations for acquisitions that are not ultimately consummated. Those negotiations could result in diversion of management time and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">significant&nbsp;out-of-pocket&nbsp;costs.</FONT></FONT> If we fail to evaluate and execute acquisitions successfully, we may not be able to realize the benefits of these
acquisitions, and our results of operations could be adversely affected. If we are unable to successfully address any of these risks, our business, results of operations, and financial condition could be materially adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may enter into collaborations, <FONT STYLE="white-space:nowrap">in-licensing</FONT> arrangements, joint ventures,
strategic alliances, or partnerships with third parties that may not result in the development of commercially viable solutions or the generation of significant future revenue. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the ordinary course of our business, we may enter into collaborations, <FONT STYLE="white-space:nowrap">in-licensing</FONT>
arrangements, joint ventures, strategic alliances, or technology partnerships to develop proposed programs, to enhance our platform, and to pursue new markets. Proposing, negotiating, and implementing collaborations,
<FONT STYLE="white-space:nowrap">in-licensing</FONT> arrangements, joint ventures, strategic alliances, or partnerships may be a lengthy and complex process. Other companies, including those with substantially greater financial, marketing, sales,
technology, or other business resources, may compete with us for these opportunities or arrangements. We may not identify, secure, or complete any such transactions or arrangements in a timely manner, on a cost-effective basis, on acceptable terms,
or at all. We have limited institutional knowledge and experience with respect to these business development activities, and we may also not realize the anticipated benefits of any such transaction or arrangement. Collaborations are also complex and
time-consuming to negotiate and document. In particular, these collaborations may not result in the development of solutions that achieve commercial success or result in significant revenue and could be terminated prior to developing any solutions.
If we are unable to successfully address any of these risks, our business, results of operations, and financial condition could be materially adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>A decline in the prevalence of employer-sponsored healthcare could cause our revenue to be reduced. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We currently derive a large portion of our revenue from our agreements with clients that purchase healthcare for their
employees, including through insurance or self-funded benefit plans. These clients offer all of or a portion of their employees enrollment in our platform who, in turn, become contracted lives. A large part of the demand for our platform and
programs among clients depends on the need of these clients to manage the costs of healthcare services that they pay on behalf of their employees. Various factors, including changes in the healthcare insurance market or in government regulation of
the healthcare industry, could cause a decline in employer-sponsored healthcare, which could adversely affect the market for our platform and programs and negatively affect our business, results of operations, and financial condition. Some experts
have predicted that future healthcare reform will encourage employer sponsored health insurance to become significantly less prevalent as employees, including current or potential contracted lives of our clients or potential clients, or current or
potential members, migrate to obtaining their own insurance through state sponsored insurance marketplaces. Were this to occur, there is no guarantee that we would be able to compensate for the loss in revenue derived from clients that purchase
healthcare for their contracted lives by increasing the acquisition of members by other means and our business, results of operations, and financial condition will be materially adversely affected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Use of AI and Machine Learning </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our increasing reliance on AI and machine learning technologies may expose us to significant risks, including
development and deployment challenges, regulatory uncertainties, and potential third-party claims, which could adversely affect our reputation, business, results of operations, and financial condition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We use AI and generative AI, machine learning, and automated decision-making technologies, including proprietary AI and machine
learning algorithms and models, (collectively, &#147;AI Technologies&#148;) throughout our business, and are making significant investments in this area. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For example, we use AI Technologies to support our care team and to assist with developing personalized exercise therapy
plans, providing real-time feedback on an exercise form, identifying high-risk members for targeted interventions, and generally enhancing our operational efficiency and competitiveness. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect that increased investment will be required in the future to continuously improve our use of AI Technologies. As with
many technological innovations, there are significant risks involved in developing, maintaining, and deploying these technologies and there can be no assurance that the usage of or our investments in such technologies will always enhance our
platform and programs or be beneficial to our business, including our efficiency or profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">AI Technologies have
been known to produce false or &#147;hallucinatory&#148; inferences or outputs and may subject us to new or heightened legal, regulatory, ethical, or other challenges. In particular, if the models underlying our AI Technologies are: incorrectly
designed or implemented; trained or reliant on incomplete, flawed, inadequate, inaccurate, biased, or otherwise poor quality data, or on data to which we do not have sufficient rights or in relation to which we and/or the providers of such data have
not implemented sufficient legal compliance measures; used without sufficient oversight and governance to ensure their responsible use; and/or adversely impacted by unforeseen defects, technical challenges, cybersecurity threats or material
performance issues, any of which may not be easily detectable, the performance of our platform and programs, and business, as well as our reputation and the reputations of our customers, could suffer or we could incur liability resulting from the
violation of laws or contracts to which we are a party or civil claims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, market acceptance, understanding,
and valuation of and consumer perceptions of platforms and programs that incorporate AI Technology is uncertain and the perceived value of our AI Technologies could be inaccurate. For example, inappropriate or controversial data practices by
developers and <FONT STYLE="white-space:nowrap">end-users,</FONT> or other factors adversely affecting public opinion of AI Technologies, could impair the acceptance of such AI Technologies, including those incorporated in our platform and programs.
Our failure to successfully develop AI Technologies in our platform could depress the market price of our stock and impair our ability to: raise capital; expand our business; provide, improve, and diversify our platform and programs; continue our
operations and efficiently manage our operating expenses; and respond effectively to competitive developments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In
addition to our proprietary AI Technologies, we use AI Technologies licensed from third parties in our platform and programs and our ability to continue to use such technologies at the scale we need may be dependent on access to specific third-party
software and infrastructure. We cannot control the availability or pricing of such third-party AI Technologies, especially in a highly competitive environment, and we may be unable to negotiate favorable economic terms with the applicable providers.
If any such third-party AI Technologies become incompatible with our platform and programs or unavailable for use, or if the providers of such models unfavorably change the terms on which their AI Technologies are offered or terminate their
relationship with us, our platform and programs may become less appealing to our customers and our business will be harmed. In addition, to the extent any third-party AI Technologies are used as a hosted service, any disruption, outage, or loss of
information through such hosted services could disrupt our operations or solutions, damage our reputation, cause a loss of confidence in our platform and programs, or result in legal claims or proceedings, for which we may be unable to recover
damages from the affected provider. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Moreover, the regulatory framework for AI Technologies is rapidly evolving
as many federal, state, and foreign government bodies and agencies have introduced or are currently considering additional laws and regulations. Additionally, existing laws and regulations may be interpreted in ways that would affect the operation
of our AI Technologies. As a result, implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or market perception of
their requirements may have on our business and may not always be able to anticipate how to respond to these laws or regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Already, certain existing legal regimes, such as various U.S. governmental and regulatory agencies relating to data privacy,
regulate certain aspects of AI Technologies, and various U.S. states and other foreign jurisdictions are applying, or are considering applying, their platform moderation, cybersecurity, and data protection laws to AI Technologies or are considering
general legal frameworks for the regulation of AI Technologies. In the United States, the Biden administration issued a broad Executive Order on the Safe, Secure, and Trustworthy Development and Use of Artificial Intelligence (the &#147;2023 AI
Order&#148;), that sets out principles intended to guide AI design and deployment for the public and private sector and signals the increase in governmental involvement and regulation over AI Technologies. The 2023 AI Order established certain new
requirements for the training, testing and cybersecurity of sophisticated AI models and large-scale computer centers used to train AI models. The 2023 AI Order also instructed several other federal agencies to promulgate additional regulations and
publish guidelines within specific time frames from the date of the 2023 AI Order regarding the use and development of AI Technologies. Already agencies such as the Department of Commerce, the Department of Health and Human Services
(&#147;HHS&#148;), and the Federal Trade Commission (&#147;FTC&#148;) have issued proposed rules governing the use and development of AI Technologies. Legislation related to AI Technologies has also been introduced at the federal level and is
advancing at the state level. For example, the California Privacy Protection Agency is currently in the process of finalizing regulations under the California Consumer Privacy Act of 2018 (&#147;CCPA&#148;) regarding the use of automated
decision-making. Such additional regulations may impact our ability to develop and use AI Technologies in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In
the European Union, the EU Artificial Intelligence Act (the &#147;EU AI Act&#148;), which establishes broad obligations for the development and use of AI Technologies in the European Union based on their potential risks and level of impact, came
into force in August 2024. The EU AI Act includes requirements around transparency, conformity assessments and monitoring, risk assessments, human oversight, security, accuracy, general purpose AI, and foundation models, and provides for fines of up
to the greater of &#128;35&nbsp;million or 7% of worldwide annual turnover for violations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">It is possible that further
new laws and regulations will be adopted in the United States and in other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions, or that existing laws and regulations, including competition and antitrust as well as scope of practice laws,
may be interpreted in ways that would limit our ability to use AI Technologies for our business, or require us to change the way we use AI Technologies in a manner that negatively affects the performance of our platform, programs, and business and
the way in which we use AI Technologies. We may not be able to anticipate how to respond to these rapidly evolving frameworks, and we may need to expend resources to adjust our platform and programs in certain jurisdictions if the laws, regulations,
or decisions are not consistent across jurisdictions. Further, because AI Technology itself is highly complex and rapidly developing, it is not possible to predict all of the legal, operational, or technological risks that may arise relating to the
use of AI. The cost to comply with such laws, regulations, or decisions and/or guidance interpreting existing laws, could be significant and would increase our operating expenses (such as by imposing additional reporting obligations regarding our
use of AI Technologies or limiting our use of AI Technologies to support our care team). Such an increase in operating expenses, as well as any actual or perceived failure to comply with such laws and regulations, could adversely affect our
business, results of operations, and financial condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Intellectual Property, Data Privacy, Information Technology, Cybersecurity </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may be unable to establish, maintain, protect, and enforce our intellectual property and proprietary rights or
prevent third parties from making unauthorized use of our technology, or we may in the future become subject to claims of infringement, misappropriation, or other violation of third parties&#146; intellectual property rights. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our business depends on a combination of intellectual property and other proprietary rights, including patents, trademarks,
copyrights, and trade secrets, as well as license agreements, confidentiality agreements and other contractual arrangements with our employees, affiliates, clients, strategic partners, and others. Our success and ability to compete may depend in
part on our ability to maintain and enforce existing intellectual property rights and to obtain, maintain, and enforce further intellectual property protection for our platform and programs, both in the United States and in other countries. The
protective steps we have taken and plan to take may be inadequate to deter infringement, misappropriation, or other violations of our intellectual property rights. We may be unable to detect the unauthorized use of, or take appropriate steps to
enforce, our intellectual property rights. Effective intellectual property rights protections may not be available to us or available in every jurisdiction in which we offer or intend to offer our platform and programs. Failure to adequately obtain,
maintain, protect, or enforce our intellectual property rights could harm our brand, devalue our proprietary content, and affect our ability to compete effectively. Further, defending our intellectual property rights could result in the expenditure
of significant financial and managerial resources, which could materially adversely affect our business, results of operations, and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our most material trademark asset is the United States registered trademark &#147;Hinge Health.&#148; Our trademarks, trade
names, and brand names are valuable assets that support our brand and perception of our platform and programs and distinguish our platform and programs from those of our competitors. We have registered or applied to register many of these
trademarks. However, there can be no assurance that our trademark applications will be approved. Third parties may also oppose our trademark applications or otherwise challenge our use of such trademarks, and our trademarks may be circumvented or
declared generic. Further, there can be no assurance that competitors will not infringe our trademarks or that we will have adequate resources to enforce our trademarks. Third parties may file for registration of trademarks similar or identical to
our trademarks, thereby impeding our ability to build brand identity and possibly leading to market confusion. Moreover, third parties may file first for our trademarks in certain countries. If they succeed in registering or developing common law
rights in such trademarks, and if we are not successful in challenging such third-party rights, we may not be able to use these trademarks to develop brand recognition in those jurisdictions. We also hold the rights to the
&#147;hingehealth.com&#148; internet domain name, which is subject to regulation by internet regulatory bodies and trademark and other related laws of each applicable jurisdiction. If we are unable to protect our trademarks or internet domain names
in the United States or in other jurisdictions in which we currently and may ultimately operate, our brand recognition and reputation would suffer, we would incur significant <FONT STYLE="white-space:nowrap">re-branding</FONT> expenses and our
results of operations could be adversely impacted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of September&nbsp;30, 2024, we owned 11 issued patents and 37
pending patent applications in the United States as well as 11 pending PCT applications, 13 foreign issued patents and 61 pending foreign patent applications. Our patents issued in the United States begin expiring in July 2033, excluding any patent
term adjustment. The patent positions of technology and virtual care companies, including our patent position, may involve complex legal and factual questions, and, therefore, the scope, validity, and enforceability of any patent claims that we may
obtain cannot be predicted with certainty. Our issued patents and those that may be issued in the future may not provide us with competitive advantages, may be of limited territorial reach, and may be held invalid or unenforceable if successfully
challenged by third parties, and our patent applications may never be issued. Even if issued, there can be no assurance that these patents will adequately protect our intellectual property or survive a legal challenge, as the legal standards
relating to the inventorship, validity, enforceability, and scope of protection of patent and other intellectual property rights are uncertain. Our limited patent protection may restrict our ability to protect our technologies and processes from
competition. It is also possible </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
that third parties, including our competitors, may have or obtain patents relating to technologies that overlap or compete with our platform and programs. If third parties obtain patent
protection with respect to such technologies, they may assert that our technology infringes their patents and seek to charge us a licensing fee or otherwise preclude the use of our technology. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We could incur substantial costs as a result of any claim of infringement, misappropriation or violation of another
party&#146;s intellectual property rights. If we infringe, misappropriate, or otherwise violate the intellectual property rights of third parties or are subject to an intellectual property infringement or misappropriation claim, our ability to grow
our business may be severely limited, and our business could be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Companies, organizations, or
individuals, including our competitors, may hold or obtain patents, trademarks, or other proprietary or intellectual property rights that would prevent, limit, or interfere with our ability to develop or enhance our platform and programs, which
could make it more difficult for us to operate our business. We have received and may in the future receive communications from holders of patents, trademarks, trade secrets, or other intellectual property or proprietary rights alleging that we are
infringing, misappropriating, diluting, or otherwise violating such rights. Such parties may in the future bring suits against us alleging infringement or other violation of such rights, or otherwise assert their rights and urge us to take licenses
to their intellectual property. If a patent infringement or other intellectual property-related lawsuit is brought against us, we could be forced to stop or delay sales of the program that is the subject of the suit or cease use of our technology
altogether. As the market for digital health solutions in the United States expands and more patents are issued, the risk increases that there may be patents issued to third parties that relate to our platform and programs of which we are not aware
or that we must challenge to continue our operations as currently contemplated. Litigation or other legal proceedings relating to intellectual property claims, regardless of merit, may cause us to incur significant expenses and could distract our
technical and management personnel from their normal responsibilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Patent and other types of intellectual property
litigation can involve complex factual and legal questions, and their outcome is uncertain. We cannot be certain or guarantee that we do not infringe existing patents or that we will not infringe patents that may be granted in the future. Third
parties that may own or control such patents and patent applications may bring claims against us that would cause us to incur substantial expenses and, if successfully asserted against us, could cause us to pay substantial damages. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Further, if we are determined to have infringed upon a third party&#146;s intellectual property rights, we may also be
required to do one or more of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek a license from the holder of the infringed intellectual property right, which license may not be
available on commercially reasonable terms, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay substantial royalty or license fees or other monetary damages, including treble damages and
attorneys&#146; fees if we are found to have willfully infringed a patent or other intellectual property right; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">redesign or reengineer our platform and programs, or other technology in a
<FONT STYLE="white-space:nowrap">non-infringing</FONT> manner, which may be costly, time-consuming, commercially infeasible, or impossible; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish and maintain alternative branding for our platform and programs. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Even if we were able to obtain a license to intellectual property owned by third parties, any such rights may be <FONT
STYLE="white-space:nowrap">non-exclusive,</FONT> which could result in our competitors gaining access to the same intellectual property. In the event of a successful claim of infringement against us and our failure or inability to obtain a license
(whether exclusive or <FONT STYLE="white-space:nowrap">non-exclusive)</FONT> to the infringed technology or other intellectual property right, we could be forced to cease aspects of our business operations and our business, results of operations,
and financial condition could be materially adversely affected. In addition, any litigation or claims, whether or not valid, could result in substantial costs, negative publicity and diversion of resources and management attention. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We could incur substantial costs in protecting, defending, or
enforcing our intellectual property or other proprietary rights. Failure to adequately protect, defend, or enforce our rights could impair our competitive position and we could lose valuable assets, experience reduced revenue, and incur costly and
time-consuming litigation. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Third parties, including our competitors, could be infringing, misappropriating, or
otherwise violating our intellectual property rights. In order to protect our intellectual property rights, we may be required to spend significant resources to monitor and protect these rights, which may be difficult and costly. The steps we have
taken or will take to detect unauthorized use and prevent infringement, misappropriation or other violation of our intellectual property or proprietary rights may not be successful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From time to time, we may have to resort to litigation to protect or enforce our intellectual property and proprietary rights,
which could result in substantial costs, distraction to management and diversion of our resources. Such litigation could result in the impairment or loss of portions of our intellectual property or proprietary rights. Enforcement of our intellectual
property or proprietary rights may be met with defenses, counterclaims, and countersuits attacking the validity and enforceability of such intellectual property or proprietary rights. An adverse determination of any litigation proceedings could put
our intellectual property or proprietary rights at risk of being invalidated or interpreted narrowly, could risk the issuance or cancellation of pending patent and trademark filings, and could harm our business. Further, intellectual property law,
including statutory and case law, particularly in the United States, is constantly developing. Changes in the law could make it harder for us to enforce our rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In any lawsuit that we bring to enforce our intellectual property or proprietary rights, a court may refuse to prevent the
other party from using the technology at issue on grounds that our intellectual property rights do not cover the technology in question. If we initiate legal proceedings against a third party to enforce a patent covering a program, the defendant
could counterclaim that such patent is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure
to meet any of several statutory requirements, including lack of novelty, obviousness, or <FONT STYLE="white-space:nowrap">non-enablement.</FONT> Grounds for an unenforceability assertion could be an allegation that someone connected with
prosecution of the patent withheld relevant information from the U.S. Patent and Trademark Office (&#147;USPTO&#148;) or made a misleading statement during prosecution. Third parties also may raise similar claims before administrative bodies in the
United States or abroad, even outside the context of litigation. Mechanisms for such challenges include <FONT STYLE="white-space:nowrap">re-examination,</FONT> post-grant review, <I>inter partes</I> review, interference proceedings, derivation
proceedings, and equivalent proceedings in foreign jurisdictions, such as opposition proceedings. Such proceedings could result in the revocation of, cancellation of, or amendment to our patents in such a way that they no longer cover our programs,
or any future programs that we may develop. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The outcome following legal assertions of invalidity and unenforceability is
unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal
assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our programs. Such a loss of patent protection could have a material adverse effect on our business, financial condition, results
of operations, and prospects. Even if we ultimately prevail, a court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may not be an adequate remedy. Furthermore, the monetary
cost of such litigation and the diversion of the attention of our management could outweigh any benefit we receive as a result of the proceedings. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings
could have a material adverse effect on our business, financial condition, results of operations, and prospects. Because of the substantial discovery required in connection with intellectual property litigation, our confidential or sensitive
information could be compromised by disclosure in litigation. Litigation could result in public disclosure of results of hearings, motions, or other interim developments. If securities analysts or investors perceive these results to be negative, it
could have a substantial adverse effect on the price of our Class&nbsp;A common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, our inability to detect and protect our proprietary technology
against unauthorized copying or use, as well as any costly litigation or diversion of our management&#146;s attention and resources, could delay further sales of our platform, impair the functionality of our platform, delay introductions of new
functionality to our platform, result in the substitution of inferior or more costly technologies into our platform and programs, or harm our reputation. Policing unauthorized use of our technologies, trade secrets, and intellectual property may be
difficult, expensive, and time-consuming, particularly in foreign countries where the laws may not be as protective of intellectual property rights as those in the United States and where mechanisms for enforcement of intellectual property rights
may be weak. If we fail to meaningfully protect our intellectual property and proprietary rights, our business, results of operations, and financial condition could be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If our patents expire or are not maintained, our patent applications are not granted, or our patent rights are
contested, circumvented, invalidated, or limited in scope, it may have a material adverse effect on our ability to prevent others from selling, developing, or exploiting platforms or programs similar to ours. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We cannot be certain that we are the first inventor of the subject matter to which we have filed a particular patent
application or that we are the first party to file such a patent application. If another party has filed a patent application for the same subject matter as we have, we may not be entitled to the protection sought by the patent application. Further,
the scope of protection of issued patent claims is often difficult to determine. As a result, we cannot be certain that the patent applications that we file will issue or that our issued patents will afford protection against competitors with
similar technology. In addition, our competitors may design around our issued patents, which may materially adversely affect our business, results of operations, and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our patents may expire if they are not maintained, our patent applications may not be granted, or our patent rights may be
contested, circumvented, invalidated, or limited in scope. Any expiration or invalidation of our patents may cause us to not be able to prevent others from selling, developing, or exploiting competing technologies, platforms, programs, or services,
which could have a material adverse effect on our business, results of operations, and financial condition. Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and/or applications will be due to be paid
to the USPTO and various government patent agencies outside of the United States over the lifetime of our owned or licensed patents and patent applications. We rely on our outside counsel or our licensing partners to pay these fees due to U.S. and <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> patent agencies. The USPTO and various <FONT STYLE="white-space:nowrap">non-U.S.</FONT> government patent agencies require compliance with several procedural, documentary, fee payment and other similar
provisions during the patent application process. We also depend on our licensors whose intellectual property we license to take the necessary action to comply with these requirements with respect to such
<FONT STYLE="white-space:nowrap">in-licensed</FONT> intellectual property. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which
noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market and
this circumstance could have a material adverse effect on our business, results of operations, and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We cannot guarantee that our pending patent applications will issue as patents. Even if our patent applications issue into
patents, these patents may be contested, narrowed, circumvented, held unenforceable, or invalidated in the future. Such proceedings could include supplemental examination or contested post-grant proceedings such as review, reexamination,
interference, or derivation proceedings challenging our patent rights. In addition, the rights granted under any issued patents may not provide us with adequate protection or competitive advantages. The claims under any patents that issue from our
patent applications may not be broad enough to prevent others from developing technologies that are similar or that achieve results similar to ours. The intellectual property rights of others could also bar us from licensing and exploiting any
patents that issue from our pending applications. Numerous patents and pending patent applications owned by others exist in the fields in which we have developed and are developing our technology. Many of these existing patents and patent
applications may have priority over our patent applications and could subject our patents to invalidation or our </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">patent applications to
rejection. Finally, in addition to patents and patent applications that were filed before our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
patents and patent applications, any of our existing or future patents may also be challenged by others on the basis that they are invalid or unenforceable. Any expiration, invalidation, or
devaluation of our patents may adversely affect our business, results of operations, and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The
confidentiality and invention assignment agreements that we enter into with our employees, consultants, and contractors involved in the development of intellectual property may not provide meaningful protection for our trade secrets or other
confidential information, and if we are unable to protect the confidentiality of our trade secrets or other confidential information, the value of our platform and programs and our business and competitive position could be materially adversely
affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We rely heavily on trade secret laws and confidentiality agreements to protect our unpatented <FONT
STYLE="white-space:nowrap">know-how,</FONT> technology, and other proprietary information, including our platform and programs, and to maintain our competitive position. With respect to our platform and programs, we consider trade secrets and <FONT
STYLE="white-space:nowrap">know-how</FONT> to be one of our primary sources of intellectual property. Trade secrets and <FONT STYLE="white-space:nowrap">know-how,</FONT> however, can be difficult to protect. We seek to protect these trade secrets
and other confidential information in part by entering into <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to them, such as our employees, outside contractors, advisors, and other
third parties. We also enter into confidentiality and invention assignment agreements with our employees, contractors, consultants, and other third parties who develop intellectual property on our behalf or who may have access to our proprietary
information, <FONT STYLE="white-space:nowrap">know-how</FONT> or trade secrets. These confidentiality agreements are designed to protect our proprietary information and, in the case of agreements or clauses containing invention assignment, to grant
us ownership of technologies that are developed through a relationship with employees or third parties. These agreements, however, may not be self-executing and may not provide meaningful protection against the unauthorized use or disclosure of our
trade secrets or other confidential information, and adequate remedies may not exist if unauthorized use or disclosure were to occur, or we may not have executed, or may in the future fail to execute, invention assignment agreements with employees,
contractors, consultants, and third parties who may be involved in the development of our intellectual property. Furthermore, individuals executing agreements with us may have preexisting or competing obligations to third parties, and thus an
agreement with us may be ineffective in perfecting ownership of intellectual property developed by those individuals. The exposure of our trade secrets and other proprietary information would impair our competitive advantages and could have a
material adverse effect on our business, results of operations, and financial condition. In particular, a failure to protect our confidential information may allow competitors to copy our technology, which could adversely affect our pricing and
market share. Further, other parties may independently develop substantially equivalent <FONT STYLE="white-space:nowrap">know-how</FONT> and technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to contractual measures, we seek to protect the confidential nature of our proprietary information using commonly
accepted physical and technological security measures. Such measures may not, for example, in the case of misappropriation of a trade secret by an employee, consultant, or other third party with authorized access, provide adequate protection for our
proprietary information. Our security measures may not prevent an employee, consultant, contractor, or other third party from misappropriating our trade secrets and providing them to a competitor, and the recourse we take against such misconduct may
not provide an adequate remedy to protect our interests fully. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our intellectual property, trade secrets or confidential
information will be effective. Unauthorized parties may also attempt to copy or reverse engineer certain aspects of our platform and programs that we consider proprietary. Enforcing a claim that a party illegally disclosed or misappropriated a trade
secret can be difficult, expensive, and time-consuming, and the outcome is unpredictable. Although we use commonly accepted security measures, trade secret violations are often a matter of state law, and the criteria for protection of trade secrets
can vary among different jurisdictions. In addition, trade secrets may otherwise become known or be independently developed by others, including our competitors, in a manner that could prevent legal recourse by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We are, and may in the future become, subject to claims that we or our
employees have wrongfully used or disclosed alleged trade secrets of our employees&#146; former employers. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Many of
our employees were previously employed by our competitors or other companies with similar or related technology, products, or services. We are, and may in the future become, subject to claims that we or these employees have inadvertently or
otherwise used or disclosed trade secrets or other proprietary information of former employers. Litigation may be necessary to defend against these claims. If we fail in defending such claims, we may be forced to pay monetary damages or be enjoined
from using certain technology, aspects of our platforms, aspects of our programs, or knowledge. Even if we are successful in defending against these claims, litigation could result in substantial costs and demand on management resources. See the
risk factors titled &#147;&#151;We may be unable to establish, maintain, protect, and enforce our intellectual property and proprietary rights or prevent third parties from making unauthorized use of our technology, or we may in the future become
subject to claims of infringement, misappropriation, or other violation of third parties&#146; intellectual property rights. Our failure to protect our intellectual property and any potential intellectual property infringement claims could harm our
brand, devalue our proprietary content, and affect our ability to compete effectively&#148; and &#147;&#151;We could incur substantial costs in protecting, defending, or enforcing our intellectual property or other proprietary rights. Failure to
adequately protect, defend or enforce our rights could impair our competitive position and we could lose valuable assets, experience reduced revenue, and incur costly and time-consuming litigation.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Defects, errors or vulnerabilities in our platform and programs could harm our reputation and brand and adversely impact
our business, results of operations, and financial condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Software such as the one used in our platform and
programs often contains errors, defects, security vulnerabilities, or software bugs that are difficult to detect and correct, particularly when first introduced or when new versions or enhancements are released. Despite internal testing, our
platform may contain serious errors, defects, security vulnerabilities, or software bugs that we may be unable to successfully correct in a timely manner or at all, which could result in lost revenue, significant expenditures of capital, a delay or
loss in market acceptance and damage to our reputation and brand, any of which could have an adverse effect on our business, results of operations, and financial condition. Furthermore, our platform and programs are on a cloud-based system that
allows us to deploy new versions and enhancements to all of our members simultaneously. To the extent we deploy new versions or enhancements that contain errors, defects, security vulnerabilities, or software bugs to all of our members
simultaneously, the consequences would be more severe than if such versions or enhancements were only deployed to a smaller number of members. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since our members use our platform and programs for medical, health, and well-being purposes, any errors, defects, failures,
security vulnerabilities, software bugs, or disruptions to our platform and programs, or any other performance problems with our platform and programs, could result in serious harm to our members and, in turn, hurt our brand and reputation and erode
member and client trust. We make regular updates to our platform and programs, which have in the past contained, and may in the future contain, undetected errors, defects, failures, security vulnerabilities, and software bugs when first introduced
or released. Real or perceived errors, defects, failures, security vulnerabilities, or software bugs in our platform and programs could result in loss of or delay in market acceptance of our platform and programs, loss of competitive position, lower
client and member retention rates or negative publicity (for example, a member could share information about a negative experience on social media, which could result in damage to our reputation and loss of future sales and acquisition of new
clients and members). In such an event, we may be required, or may choose, for client relations, member relations, or other reasons, to expend additional resources in order to seek to correct the problem. Our members may also seek significant
compensation from us for any losses they suffer or cease using our platform and programs, or our clients could cease conducting business with us. There can be no assurance that provisions typically included in our agreements with our clients that
attempt to limit our exposure to claims would be enforceable or adequate or would otherwise protect us from liabilities or damages with respect to any particular claim. Even if not successful, a claim brought against us by any of our members or
clients would likely be time-consuming and costly to defend and could seriously damage our reputation and brand, making it harder for us to sell our platform </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
and programs and to enroll and retain members. In addition, we may not carry insurance sufficient to compensate us for any losses that may result from claims arising from defects or disruptions
in our platform and programs. As a result, our reputation and our brand could be harmed, and our business, results of operations, and financial condition could be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our proprietary technology and solutions may not operate properly, which could damage our reputation, give rise to
claims against us, or divert application of our resources from other purposes, any of which could harm our business, results of operations, and financial condition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Proprietary software and hardware development is time-consuming, expensive, and complex and may involve unforeseen
difficulties. We may encounter technical obstacles, and it is possible that we discover additional problems or design defects that prevent our proprietary platform and programs, including our app and our Enso device, from operating properly. If our
platform and programs, including our app and our Enso device, do not function reliably, malfunction, or fail to achieve member expectations in terms of performance, clients and members could assert liability claims against us or our clients could
cancel their contracts with us. This could damage our reputation and impair our ability to attract or retain clients and members. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The software underlying our platform and programs is highly complex and may contain undetected errors or vulnerabilities, some
of which may only be discovered after the software has been used by our members. Any real or perceived errors, failures, bugs, or other vulnerabilities discovered in our software, platform and programs could result in negative publicity and damage
to our reputation, loss of clients, loss of members, loss of contracted lives, loss of, or delay in, market acceptance of our platform and programs, loss of competitive position, loss of revenue or liability for damages, overpayments, and/or
underpayments, any of which could harm our member enrollment rates. Similarly, any real or perceived errors, failures, design flaws, or defects in our Enso device or in the platform and programs we offer, including our app, could have similar
negative results. In such an event, we may be required or may choose to expend additional resources in order to help correct the problem. Such efforts could be costly, or ultimately unsuccessful. Even if we are successful at remediating issues, we
may experience damage to our reputation and brand. There can be no assurance that provisions typically included in our agreements with clients or in agreements with members that attempt to limit our exposure to claims would be enforceable or
adequate or would otherwise protect us from liabilities or damages with respect to any particular claim. Even if unsuccessful, a claim brought against us by any clients or members would likely be time-consuming and costly to defend and could
seriously damage our reputation and brand. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We depend on our information technology systems, and those of our
third-party vendors, contractors, and consultants, and any failure or significant disruptions of these systems, security breaches, or loss of data could expose us to liability or materially adversely affect our business, results of operations, and
financial condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We collect and maintain information in digital form that is necessary to conduct our
business, and we are increasingly dependent on information technology systems and infrastructure (&#147;IT Systems&#148;) to operate our business. In the ordinary course of our business, we collect, store, and transmit large amounts of confidential
information, including but not limited to intellectual property, proprietary business information, protected health information, and personal information about our clients, members, contracted lives, partners, employees, consultants, or contractors.
It is critical that we do so in a secure manner to maintain the confidentiality, availability, and integrity of such confidential information. We have established physical, electronic, and organizational measures to safeguard and secure our systems
to prevent a data compromise, and rely on commercially available and internal systems, software, tools, and monitoring to provide security for our IT Systems and the processing, transmission, storage and other processing of digital information. We
have also outsourced elements of our IT Systems and data storage systems, and as a result a number of third-party vendors, contractors and consultants may or could have access to our confidential information. We cannot conduct audits or formal
evaluations of all aspects of all of our third-party vendors&#146;, contractors&#146;, and consultants&#146; IT Systems, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
and even where we do conduct audits or evaluations, we cannot be sure that our audits or evaluations will be comprehensive or that such third-party vendors, contractors, and consultants have
sufficient measures in place to ensure the confidentiality, integrity, and availability of their IT systems and confidential information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Despite the implementation of preventative and detective security controls, such IT Systems are vulnerable to damage or
interruption from a variety of sources, including telecommunications or network failures or interruptions, system malfunction, natural disasters, malicious human acts, terrorism, and war. Such IT Systems, including our servers, are additionally
vulnerable to physical or electronic <FONT STYLE="white-space:nowrap">break-ins,</FONT> security breaches from inadvertent or intentional actions by our employees, third-party service providers, contractors, consultants, business partners, and/or
other third parties, or from cyberattacks by malicious third parties (including the deployment of harmful malware, ransomware, phishing attacks, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">denial-of-service</FONT></FONT>
attacks, social engineering, sophisticated nation-state and nation-state-supported actors and other means to affect service reliability and threaten the confidentiality, integrity, and availability of information). As we continue to embrace both
hybrid and remote working, we may face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit
vulnerabilities. The risk of a security breach or disruption has generally increased as the number, intensity, and sophistication of attempted attacks and intrusions from around the world have increased. We may not be able to anticipate all types of
security threats, and we may not be able to implement preventive measures effective against all such security threats. The techniques used by cyber criminals change frequently, may not be recognized until launched, and can originate from a wide
variety of sources, including outside groups such as external service providers, organized crime affiliates, terrorist organizations, or hostile foreign governments or agencies. In addition, the prevalent use of mobile devices that access
confidential information increases the risk of data security breaches, which could lead to the loss of confidential information or other intellectual property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We can provide no assurance that our current IT Systems, or those of the third parties upon which we rely, are fully protected
against cybersecurity threats. It is possible that we or our third-party vendors, contractors, and consultants may experience cybersecurity and other breach incidents that remain undetected for an extended period. We and certain of our service
providers from time to time are subject to cyberattacks and security incidents. Even when a security incident is detected, the full extent of the breach may not be determined immediately. The costs to us to mitigate network security problems, bugs,
viruses, worms, malicious software programs, and security vulnerabilities could be significant, and while we have implemented security measures to protect our data security and IT Systems, our efforts to address these problems may not be successful,
and these problems could result in unexpected interruptions, delays, cessation of service, and other harm to our business and our competitive position. While we do not believe that we have experienced any significant system failure, accident, or
security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our offerings to clients and members. Moreover, we and our third-party vendors, contractors, and
consultants collect, store, and transmit sensitive data, including health-related information, personally identifiable information, intellectual property, and proprietary business information in the ordinary course of our business. If a computer
security breach affects our systems or results in the unauthorized release of personally identifiable information, our reputation could be materially damaged. In addition, such breaches may in the future require notification to governmental
agencies, the media, or individuals pursuant to various federal and state privacy and security laws, if applicable, including HIPAA as well as regulations promulgated by the FTC and state breach notification laws. We would also be exposed to a risk
of loss or litigation and potential liability, which could materially adversely affect our business, results of operations, and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We and certain of our third-party vendors are from time to time subject to cyberattacks and security incidents. While we do
not believe that we have experienced any significant system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in unauthorized access to confidential and
proprietary business information, intellectual property, sensitive client </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">and member data (including health-related information such as
protected health information), or other personally </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
identifiable information of our members, clients, employees, partners, or contractors, loss or misappropriation of or damage to our data, or an inability to access data sources and critical
information, process data, or provide our platform and programs. Such failures or breaches of our or our third-party vendors&#146; security measures, or our or our third-party vendors&#146; inability to effectively resolve such failures or breaches
in a timely manner, could severely damage our reputation, adversely impact member, client, or investor confidence in us, and reduce the demand for our platform and programs. In addition, we could face litigation, significant damages for contract
breach or other breaches of law, significant monetary penalties, or regulatory actions for violation of applicable laws or regulations, and we could incur significant costs for remedial measures to prevent future occurrences and mitigate past
violations. The costs related to significant security breaches or disruptions could be material and exceed the limits of the cybersecurity insurance we maintain against such risks. If the IT Systems of our third-party vendors, contractors, or
consultants become subject to disruptions or security breaches, we may have insufficient recourse against such third parties and we may have to expend significant resources to mitigate the impact of such an event, and to develop and implement
protections to prevent future events of this nature from occurring. Any disruption or loss to IT Systems on which critical aspects of our operations depend could have an adverse effect on our business, results of operations, and financial condition.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Actual or perceived failures to comply with applicable data protection, privacy, and security, advertising, and
consumer protection laws, regulations, standards, and other requirements could adversely affect our business, results of operations, and financial condition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The global data protection landscape is rapidly evolving, and we are or may become subject to numerous state, federal, and
foreign laws, requirements, and regulations governing the collection, use, disclosure, retention, and security of personal information. These requirements may be interpreted and applied in a manner that varies from one jurisdiction to another and/or
may conflict with other laws, regulations, and regulatory interpretations. As such, our practices may not have complied or may not comply in the future with all such laws, regulations, requirements, and obligations. Any failure, or perceived
failure, by us or any of our third-party partners, data centers, or service providers to comply with privacy policies or federal or state privacy or consumer protection-related laws, regulations, regulatory interpretations, industry self-regulatory
principles, industry standards or codes of conduct, regulatory guidance, orders to which we may be subject, or other legal obligations relating to privacy or consumer protection, could adversely affect our reputation, brand, and business, and may
result in claims, proceedings, or actions against us by governmental entities, clients, members, suppliers, or others. These proceedings may result in financial liabilities or may require us to change our operations, including ceasing the use or
sharing of certain data sets, or modifying marketing and other engagement programs and plans. Any such claims, proceedings or actions could hurt our reputation, brand, and business, force us to incur significant expenses in defense of such
proceedings or actions, distract our management, increase our costs of doing business, result in a loss of clients, members, contracted lives, partners, and others and result in the imposition of monetary penalties. We are also contractually
required to indemnify and hold harmless certain third parties from the costs or consequences of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with any laws, regulations, regulatory interpretations, or other legal obligations relating to
privacy or consumer protection or any inadvertent or unauthorized use or disclosure of data that we store or handle as part of operating our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We rely on a variety of marketing techniques, including email, text message, social media marketing, and postal mailings, and
we are subject to various laws, regulations, and regulatory interpretations that govern such marketing and advertising practices. A variety of federal and state laws, regulations, and regulatory interpretations govern the collection, use, retention,
sharing, and security of consumer data, particularly in the context of online advertising, which we rely upon to attract new clients, members, and contracted lives. Federal and state governmental authorities continue to evaluate the privacy
implications inherent in the use of third-party cross-site behavioral advertising technologies and other methods of online tracking for behavioral advertising and other purposes. Various U.S. federal and state laws regulate the level of consumer
notice and consent required before a company can employ cross-site behavioral advertising technologies or other electronic tracking tools or the use of data gathered with such tools. The regulation of the use of these cross-site behavioral </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">advertising technologies and other current online tracking and advertising practices or a loss in our ability to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
make effective use of services that employ such technologies could increase our costs of operations and limit our ability to acquire new clients, members, and contracted lives on cost-effective
terms and consequently, materially and adversely affect our business, results of operations, and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Further, parts of our business are subject to HIPAA, as amended by the Health Information Technology for Economic and Clinical
Health Act, and the regulations promulgated thereunder (collectively, &#147;HIPAA&#148;). HIPAA limits the use and disclosure of individually identifiable health information, or protected health information, and imposes privacy, security, and breach
notification obligations on certain healthcare providers, health plans, and health care clearinghouses, known as covered entities, as well as their business associates that perform certain services that involve creating, receiving, maintaining, or
transmitting individually identifiable health information for or on behalf of such covered entities, and their covered subcontractors. It also mandates the reporting of certain breaches of health information to the HHS, affected individuals and if
the breach is large enough, the media. The HHS has the discretion to impose penalties without attempting to first resolve violations. HHS enforcement activity can result in financial liability and reputational harm, and responses to such enforcement
activity can consume significant internal resources. We have experienced such breaches in the past and could be exposed to a risk of loss or litigation and potential liability, which could materially adversely affect our business, results of
operations, and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Certain states have also adopted comparable privacy and security laws and
regulations, which govern the privacy, processing, and protection of health-related and other personal information. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating
potentially complex compliance issues for us and our future clients and strategic partners. For example, the CCPA, as amended by the California Privacy Rights Act (collectively, the CCPA), requires covered businesses that process the personal
information of California residents to, among other things, (i)&nbsp;make certain disclosures to California consumers about the business&#146;s data collection, use, and sharing practices; (ii)&nbsp;receive and respond to requests from California
residents to access, delete, and correct their personal information, or to opt out of certain disclosures of their personal information; and (iii)&nbsp;enter into specific contractual provisions with service providers that process California
resident personal information on the business&#146;s behalf. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additional compliance investment and potential business
process changes may be required. Similar laws have been passed in other states and are continuing to be proposed at the state and federal level, reflecting a trend toward more stringent privacy legislation in the United States. The enactment of such
laws could have potentially conflicting requirements that would make compliance challenging. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We also expect that there
will continue to be new laws, regulations, and industry standards concerning privacy, data protection, and information security proposed and enacted in various jurisdictions. Such laws may differ from each other, which may complicate compliance
efforts. For example, Washington State enacted a broadly applicable law to protect the privacy of personal health information known as the &#147;My Health My Data Act,&#148; which generally requires affirmative consent for the collection, use, or
sharing of any &#147;consumer health data.&#148; Consumer health data is defined to include personal information that is linked or reasonably linkable to a consumer and that identifies a consumer&#146;s past, present, or future physical or mental
health status; consumer health data also includes information that is derived or extrapolated from <FONT STYLE="white-space:nowrap">non-health</FONT> information, such as algorithms and machine learning. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, the interpretations of existing federal and state consumer protection laws relating to online collection, use,
dissemination, and security of health related and other personal information adopted by the FTC state Attorneys General, private plaintiffs, and courts have evolved, and may continue to evolve, over time. Consumer protection and certain state data
privacy laws like the CCPA and CPRA require us to publish statements that describe how we handle personal information and choices individuals may have about the way we handle or provide access to their personal information. If such information that
we publish is considered untrue, we may be subject to government claims of unfair or deceptive trade practices, which could lead to significant liabilities and consequences. Furthermore, according to the FTC, violating consumers&#146; privacy rights
or failing to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
take appropriate steps to keep consumers&#146; personal information secure may constitute unfair acts or practices in or affecting commerce and thus violate Section&nbsp;5(a) of the FTC Act. It
may also violate one or more <FONT STYLE="white-space:nowrap">FTC-enforced</FONT> rules. The FTC expects a company&#146;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it
holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards. The FTC&#146;s
current guidance for appropriately securing consumers&#146; personal information is similar to what is required by the HIPAA security regulations, but this guidance may change in the future, resulting in increased complexity and the need to expend
additional resources to ensure we are complying with the FTC Act. For information that is not subject to HIPAA and deemed to be &#147;personal health records,&#148; the FTC may also impose penalties for violations of the Health Breach Notification
Rule (&#147;HBNR&#148;) to the extent we are considered a &#147;personal health record-related entity&#148; or &#147;third-party service provider.&#148; The FTC has taken several enforcement actions under HBNR recently and indicated that the FTC
will continue to protect consumer privacy through greater use of the agency&#146;s enforcement authorities. As a result, our operations may be subject to greater scrutiny by federal and state regulators, partners, and consumers with respect to our
collection, use, and disclosure of health information. Additionally, federal and state consumer protection laws are increasingly being applied by FTC and states Attorneys General to regulate the collection, use, storage, and disclosure of personal
or personally identifiable information, through websites or otherwise, and to regulate the presentation of website content. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are also or may become subject to rapidly evolving data protection laws, rules, and regulations in foreign jurisdictions.
For example, in Europe, the European Union General Data Protection Regulation (&#147;GDPR&#148;) imposes strict requirements for processing the personal data of individuals within the European Economic Area (&#147;EEA&#148;) or in the context of our
activities within the EEA. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for
<FONT STYLE="white-space:nowrap">non-compliance</FONT> of up to &#128;20&nbsp;million or 4% of the annual global revenues of the <FONT STYLE="white-space:nowrap">non-compliant</FONT> company, whichever is greater. In addition to fines, a breach of
the GDPR may result in regulatory investigations, reputational damage, orders to cease, changes to our data processing activities, enforcement notices, assessment notices (for a compulsory audit) and/or civil claims (including class actions). The
GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not
been found to provide adequate protection to such personal data, including the United States, and the efficacy and longevity of current transfer mechanisms between the EEA, and the United States remains uncertain. Case law from the Court of Justice
of the European Union (&#147;CJEU&#148;) states that reliance on the standard contractual clauses&#151;a standard form of contract approved by the European Commission as an adequate personal data transfer mechanism&#151;alone may not necessarily be
sufficient in all circumstances and that transfers must be assessed on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis. On July&nbsp;10, 2023, the European Commission adopted its Adequacy Decision
in relation to the new <FONT STYLE="white-space:nowrap">EU-US</FONT> Data Privacy Framework (&#147;DPF&#148;), rendering the DPF effective as a GDPR transfer mechanism to U.S. entities self-certified under the DPF. We expect the existing legal
complexity and uncertainty regarding international personal data transfers to continue. In particular, we expect the DPF Adequacy Decision to be challenged and international transfers to the United States and to other jurisdictions more generally to
continue to be subject to enhanced scrutiny by regulators. As a result, we may have to make certain operational changes and we will have to implement revised standard contractual clauses and other relevant documentation for existing data transfers
within required time frames. As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the SCCs cannot be used, and/or start taking enforcement action, we could suffer additional costs,
complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our platform and programs,
the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since the beginning of 2021, after the end of the transition period
following the UK&#146;s departure from the European Union, we are also subject to the United Kingdom General Data Protection Regulation and Data Protection Act 2018 (collectively, the &#147;UK GDPR&#148;), which imposes separate but similar
obligations to those under the GDPR and comparable penalties, including fines of up to &pound;17.5&nbsp;million or 4% of a <FONT STYLE="white-space:nowrap">non-compliant</FONT> company&#146;s global annual revenue for the preceding financial year,
whichever is greater, as well as other potentially divergent enforcement actions for certain violations. On October&nbsp;12, 2023, the UK Extension to the DPF came into effect (as approved by the UK Government), as a data transfer mechanism from the
UK to U.S. entities self-certified under the DPF. As we continue to expand into foreign countries and jurisdictions, we may be subject to additional laws and regulations that may affect how we conduct business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The GDPR also provides that EEA member states and the UK may make their own further laws and regulations to introduce specific
requirements in certain areas, including related to the processing of special categories of personal data, including personal data related to health data. This fact may lead to greater divergence on the law that applies to the processing of personal
data across the EEA and UK, compliance with which, as and where applicable, may increase our costs and could increase our overall compliance risk. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Failure or perceived failure to comply with HIPAA, the CCPA, GDPR, the UK GDPR, and other U.S. or foreign privacy or data
security-related laws, rules or regulations could result in significant regulatory penalties and fines, affect our compliance with contracts entered into with our partners, collaborators and other third-party payors, and could have an adverse effect
on our reputation, business and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Further, as a result of regulatory enforcement proceedings and
inquiries, there may be settlements, enforcement actions, or related litigation that could include monetary penalties and/or compliance requirements that may impose significant and material costs, require us to make modifications to our data
practices and our marketing programs, result in negative publicity, or have a negative impact on consumer demand for our platform and programs, or on our commercial or industry relationships. Any of these events could adversely affect our ability to
operate our business, results of operations, and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Although we work to comply with applicable laws,
regulations, and standards, our contractual obligations, and other legal obligations, these requirements are evolving and may be modified, interpreted, and applied in an inconsistent manner from one jurisdiction to another, and may conflict with one
another or other legal obligations with which we must comply. Any failure or perceived failure by us or our employees, representatives, contractors, consultants, collaborators, or other third parties to comply with such requirements or adequately
address privacy and security concerns, even if unfounded, could result in additional cost and liability to us, damage our reputation, and adversely affect our business, results of operations, and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we fail to comply with applicable data interoperability and information blocking rules, our business, results of
operations, and financial condition could be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The 21<SUP
STYLE="font-size:75%; vertical-align:top">st</SUP> Century Cures Act (the &#147;Cures Act&#148;), which was passed and signed into law in December 2016, includes provisions related to data interoperability, information blocking and patient access.
In March 2020, the HHS Office of the National Coordinator for Health Information Technology (&#147;ONC&#148;), and Centers for Medicare&nbsp;&amp; Medicaid Services (&#147;CMS&#148;) finalized and issued complementary rules that are intended to
clarify provisions of the Cures Act regarding interoperability and information blocking, and include, among other things, requirements surrounding information blocking, changes to ONC&#146;s health IT certification program and requirements that CMS
regulated payors make relevant claims/care data and provider directory information available through standardized patient access and provider directory application programming interfaces that connect to provider EHR systems. The companion rules
transform the way in which healthcare providers, health IT developers, health information exchanges/health information networks (&#147;HIEs/HINs&#148;), and health plans share patient information, and create significant new requirements for
healthcare industry participants. For example, the ONC rule, which went into effect on April&nbsp;5, 2021, prohibits healthcare providers, health IT developers of certified health IT, and HIEs/HINs from engaging in practices that are likely to
interfere with, prevent, materially </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
discourage, or otherwise inhibit the access, exchange or use of electronic health information (&#147;EHI&#148;), also known as &#147;information blocking.&#148; To further support access and
exchange of EHI, the ONC rule identifies eight &#147;reasonable and necessary activities&#148; as exceptions to information blocking activities, as long as specific conditions are met. Any failure to comply with these rules could have a material
adverse effect on our business, results of operations and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we fail to comply with our
obligations under license or technology agreements with third parties, we may be required to pay damages and we could lose license rights that are critical to our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We license certain intellectual property, including technologies and software from third parties, which is important to our
business, and in the future, we may enter into additional agreements that provide us with licenses to valuable intellectual property or technology. Disputes may arise between us and our licensors regarding the intellectual property licensed to us
under any license agreement, including disputes related to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our compliance with reporting, financial, or other obligations under the license agreement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amounts of royalties or other payments due under the license agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and the extent to which we infringe, misappropriate, or otherwise violate intellectual property rights
of the licensor that are not subject to the license agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right to sublicense applicable rights to third parties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right to transfer or assign the license; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ownership of intellectual property and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the
joint creation or use of intellectual property by our licensors and us and our partners. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we do not
prevail in such disputes or if we fail to comply with any of the obligations under our license agreements, we may lose any or all of our rights under such license agreements or be required to pay damages, and the licensor may have the right to
terminate the license. Termination by the licensor would cause us to lose valuable rights and could prevent us from selling our platform and programs, or adversely impact our ability to commercialize future platforms and programs. Our business would
suffer if any current or future licenses terminate, if the licensors fail to abide by the terms of the license, if the licensors fail to enforce licensed patents against infringing third parties, if the licensed intellectual property is found to be
invalid or unenforceable, or if we are unable to enter into necessary licenses on acceptable terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, our
rights to certain technologies are licensed to us on a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> basis. The owners of these <FONT STYLE="white-space:nowrap">non-exclusively</FONT> licensed technologies are therefore free to license them
to third parties, including our competitors, on terms that may be superior to those offered to us, which could place us at a competitive disadvantage. In addition, the agreements under which we license intellectual property or technology from third
parties are generally complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our
rights to the relevant intellectual property or technology or increase what we believe to be our financial or other obligations under the relevant agreement. Any of the foregoing could harm our competitive position, business, results of operations,
and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We rely on third-party and open-source software for our platform and programs. Our
inability to obtain third-party licenses for such software, or obtain them on favorable terms, or any errors, bugs, defects, or failures caused by such software could adversely affect our business, results of operations, and financial condition.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We use open-source software in connection with our software platform and anticipate using open-source software in
the future. The terms of certain open-source licenses to which we are subject have not been </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
interpreted by U.S. or foreign courts, and there is a risk that open-source software licenses could be construed in a manner that imposes unanticipated conditions or restrictions on our platform,
including requiring us to disclose or license some or all of our proprietary source code to the public or distribute our software platform that uses particular open-source software at no cost to the user. While we monitor our use of open-source
software and try to ensure that none is used in a manner that would require us to disclose or license our proprietary source code or that would otherwise breach the terms of an open-source agreement, there can be no assurance that such efforts will
be successful and such a use could inadvertently occur, or could be claimed to have occurred, in part because open-source license terms can be ambiguous. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, we could face claims from third parties claiming ownership of, or demanding the release of, any open-source
software or derivative works that we have developed using such software, which could include proprietary source code, or otherwise seeking to enforce the terms of the applicable open-source license. These claims could result in litigation and could
require us to make our software source code freely available, purchase a costly license, or cease offering our platform unless and until we can <FONT STYLE="white-space:nowrap">re-engineer</FONT> such source code in a manner that avoids
infringement. This <FONT STYLE="white-space:nowrap">re-engineering</FONT> process could require us to expend significant additional research and development resources, and we may not be able to complete the
<FONT STYLE="white-space:nowrap">re-engineering</FONT> process successfully. In addition to risks related to license requirements, use of certain open-source software can lead to greater risks than use of third-party commercial software, as
open-source licensors generally do not provide support, warranties, indemnification, or other contractual protection regarding infringement claims or the quality of the code. There is little legal precedent in this area, and any actual or claimed
requirement to disclose our proprietary source code or pay damages for breach of contract could harm our business and could help third parties, including our competitors, develop technology that is similar to or superior to ours. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our platform includes software or other intellectual property licensed from third parties. It may be necessary in the future
to renew licenses relating to various aspects of these applications or to seek new licenses for existing or new applications. Necessary licenses may not be available on acceptable terms or under open-source licenses permitting redistribution in
commercial offerings, if at all. Our inability to obtain certain licenses or other rights or to obtain such licenses or rights on favorable terms could result in delays in platform and program releases until equivalent technology can be identified,
licensed, or developed, if at all, and integrated into our platform and services, which therefore may have a material adverse effect on our business, results of operations, and financial condition. In addition, third parties may allege that
additional licenses are required for our use of their software or intellectual property. We may be unable to obtain such licenses on commercially reasonable terms or at all. The inclusion in our platform and programs of software or other
intellectual property licensed from third parties on a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> basis could limit our ability to differentiate our platform and programs from those of our competitors. To the extent that our platform and
programs depend upon the successful operation of third-party software, any undetected errors, bugs, defects, or failures in such third-party software could impair the functionality of our platform and programs and delay new feature introductions,
which could adversely affect our business, results of operations, and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We rely on internet
infrastructure, bandwidth providers, third-party computer hardware and software, and other third parties for providing services to our clients and members, and any failure or interruption in the services provided by these third parties could expose
us to litigation and negatively impact our relationships with clients and members, adversely affecting our business, results of operations, and financial condition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our ability to deliver our digital platform and programs depends on the development and maintenance of the infrastructure of
the internet by third parties. This includes maintenance of a reliable network backbone with the necessary speed, data capacity, bandwidth capacity, and security. Our platform and programs are designed to operate without interruption, and in some
cases, we provide certain uptime guarantees to our clients and members. However, we have experienced in the past and may experience future interruptions and delays on our website and app and the availability of our platform and programs from time to
time. In the event of a catastrophic event with respect to one or more of our systems, we may experience an extended period of system </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
unavailability, which could negatively impact our relationship with clients and members and could result in potential liabilities or claims with respect to any uptime guarantees we have made to
clients and members. To operate without interruption, both we and our service providers must guard against: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">damage from fire, power loss, natural disasters, and other force majeure events outside our control;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">communications failures; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">software and hardware errors, failures, and crashes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">security breaches, computer viruses, hacking,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">denial-of-service</FONT></FONT> attacks, and similar disruptive problems; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other potential interruptions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We also rely on software licensed from third parties in order to offer our platform and programs. These licenses are generally
commercially available on varying terms. However, it is possible that this software may not continue to be available on commercially reasonable terms, or at all. Any loss of the right to use any of this software could result in delays in the
provisioning of our platform and programs until equivalent technology is either developed by us, or, if available, is identified, obtained, and integrated. Furthermore, our use of additional or alternative third-party software would require us to
enter into license agreements with third parties, and integration of our software with new third-party software may require significant work and require substantial investment of our time and resources. Also, any undetected errors or defects in
third-party software could prevent the deployment or impair the functionality of our software, delay new updates or enhancements to our platform and programs, result in a failure of our platform and programs, and materially adversely affect our
reputation and well as our business, results of operations, and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Legal and Regulatory Matters </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our business operates in a highly regulated industry and changes over time in regulations, or the implementation of
existing regulations, could affect our operations and subject us to increased compliance costs and liabilities. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our business is subject to rigorous laws, rules, and regulations in the jurisdictions in which we operate. These laws, rules,
and regulations include, without limitation, federal and state laws, and country specific laws, governing health information privacy, scope of practice, licensure, the corporate practice of medicine and physical therapy, fraud and abuse, exclusion
and debarment, anti-kickback obligations, false claims, patient referrals, fee splitting, regulation of devices, and other aspects of healthcare delivery. Changes, implementation, and other legal uncertainties related to such laws, rules, and
regulations may adversely affect our business, results of operations, and financial condition. The cost of compliance with the ever-changing legal and regulatory environment may be significant. Our failure to comply with existing or future laws,
rules, and regulations could subject us to fines, civil liability, including tort and product liability, mandatory injunctions that change how we operate, or the cessation of operations. As our business matures and we expand geographically, we may
become subject to new laws and regulations in new jurisdictions. It is difficult to predict how existing laws will be applied to our business, as it exists today and may exist in the future, and the new laws to which we may become subject. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We and our affiliated professional entities are subject to federal, state, and foreign healthcare laws and regulations,
and a finding of failure to comply with such laws and regulations could have a material adverse effect on our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We and our affiliated professional entities are subject to healthcare fraud and abuse regulations and enforcement by federal,
state, and foreign governments. These laws may constrain the business or financial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
arrangements and relationships through which we and our affiliated professional entities conduct our operations. In the United States, the laws that may affect our ability to operate include, but
are not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly
and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in cash or in kind, in exchange for or to induce either the referral of an individual for, or the purchase, lease, order, or recommendation of, any good,
facility, item, or service for which payment may be made, in whole or in part, under federal healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of this statute or specific intent to violate
it in order to have committed a violation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal physician self-referral law (&#147;Stark Law&#148;), which, subject to limited exceptions,
prohibits physicians from referring Medicare or Medicaid patients to an entity for the provision of certain designated health services (&#147;DHS&#148;) if the physician or a member of such physician&#146;s immediate family has a direct or indirect
financial relationship (including an ownership interest or a compensation arrangement) with the entity, and prohibits the entity from billing Medicare or Medicaid for such DHS; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal civil and criminal false claims laws, including the False Claims Act, that prohibit, among other
things, knowingly presenting, or causing to be presented, claims for payment or approval to the federal government that are false or fraudulent, knowingly making a false statement material to an obligation to pay or transmit money or property to the
federal government or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay or transmit money or property to the federal government. In addition, a claim including items or services resulting from a violation
of the federal Anti-Kickback Statute or Stark Law constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Civil Monetary Penalties Law, which prohibits, among other things, an individual or entity from offering
remuneration to a federal healthcare program beneficiary that the individual or entity knows or should know is likely to influence the beneficiary to order or receive healthcare items or services from a particular provider; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, which created federal criminal laws that prohibit executing a scheme to defraud any federal healthcare
benefit program or making false statements relating to healthcare matters submitted for payment. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of these statutes or specific intent to violate
them in order to have committed a violation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices,
biologics, and medical supplies to report annually to the U.S. Department of Health and Human Services information related to payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and
chiropractors), certain other healthcare professionals (physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists, anesthesiology assistants and certified nurse
midwives), and teaching hospitals, and ownership and investment interests held by physicians and their immediate family members; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Section&nbsp;1128J(d) of the Social Security Act (commonly known as the
<FONT STYLE="white-space:nowrap">60-Day</FONT> Overpayment Rule) that imposes criminal penalties on healthcare providers who fail to disclose or refund known overpayments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Federal Trade Commission Act and federal and state consumer protection, advertisement, and unfair
competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Foreign Corrupt Practices Act, which prohibits, among other things, U.S. companies and their employees and
agents from authorizing, promising, offering, or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations and foreign government owned
or affiliated entities, candidates for foreign political office, and foreign political parties or officials thereof; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">state and foreign law equivalents of each of the above federal laws, such as state anti-kickback and false
claims laws that may apply to items or services reimbursed by any third-party payor, including commercial insurers; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal and state laws and regulations that prohibit providers from billing and receiving payment from
Medicare and Medicaid for services unless the services are medically necessary, adequately and accurately documented, and billed using codes that accurately reflect the type and level of services rendered. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of
healthcare reform, especially in areas where there is a lack of applicable precedent and regulation. Federal and state enforcement bodies have increased their scrutiny of interactions between healthcare companies and healthcare providers, which has
led to a number of investigations, prosecutions, convictions, and settlements in the healthcare industry. Responding to investigations can be time and resource-consuming and could divert management&#146;s attention from our business. Additionally,
as a result of these investigations, we may have to agree to additional onerous compliance and reporting requirements as part of a consent decree or corporate integrity agreement. Any such investigation or settlement could increase our costs or
otherwise have an adverse effect on our business, results of operations, and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">It is possible that
governmental authorities will conclude that our business practices, including certain revenue-sharing and lead generation agreements with our partners or equity arrangements with our physicians, physical therapists, health coaches, and other
licensed healthcare professionals, do not comply with current or future statutes, regulations, agency guidance, or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our or our affiliated professional
entities&#146; operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us or our affiliated professional entities now or in the future, we may be subject to penalties, including
civil and criminal penalties, damages, fines, disgorgement, exclusion from governmental health care programs, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business, results of
operations, and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Legislative or regulatory healthcare reform measures may make it more
difficult and costly to operate our business, or to do so profitably. Accordingly, such legislative or regulatory healthcare reform measures may have a material adverse effect on our business, results of operations, and financial condition.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Federal and state governments in the U.S. and foreign governments have and continue to propose and pass a number
of legislative and regulatory initiatives to contain or reduce healthcare costs. For example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the &#147;ACA&#148;), made
major changes in how healthcare is delivered and reimbursed, including comparative effectiveness research initiatives and payment system reforms such shared savings pilots and other provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. These
changes included an aggregate reduction in Medicare payments to providers, which went into effect on April&nbsp;1, 2013 and will remain in effect through 2032, unless additional congressional action is taken. In addition, on January&nbsp;2, 2013,
the American Taxpayer Relief Act of 2012, was signed into law which, among other things, further reduced Medicare payments to certain providers, including hospitals. The Medicare Access and CHIP Reauthorization Act of 2015, enacted on April&nbsp;16,
2015 (&#147;MACRA&#148;), repealed the formula by which Medicare made annual payment adjustments to physicians and replaced the former formula with fixed annual updates and a new system of incentive payments that began in 2019 that are based on
various performance measures and physicians&#146; participation in alternative payment models such as accountable care organizations. Certain of these provisions are still being implemented, and the full impact of these changes on us cannot be
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
determined at this time. The Coronavirus Aid, Relief, and Economic Security Act (&#147;CARES Act&#148;), enacted in response to the <FONT STYLE="white-space:nowrap">Covid-19</FONT> pandemic on
March&nbsp;27, 2020, temporarily allowed patients covered by high-deductible health plans (&#147;HDHPs&#148;) to contribute to HSAs even if they received coverage for telehealth services before first satisfying their deductibles. This provision
regarding telehealth coverage on a &#147;first-dollar&#148; basis is set to expire at the end of 2024 unless additional congressional action is taken. If the exemption under the CARES Act for first-dollar coverage for telehealth services is no
longer available to patients with high deductible health plans, those individuals would not be able to make HSA contributions, which means they may have higher
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs for using our platform. Additionally, certain health plans may cease being clients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit
the amounts that federal and state governments and other third-party payers will pay for healthcare products and services and could limit or make it more difficult to operate our business, which could materially adversely affect our business,
financial condition, and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We are dependent on our relationships with our affiliated
professional entities, which we do not own, to provide some of the healthcare services we offer to our members, and our business would be harmed if those relationships were disrupted or if our arrangements with our affiliated professional entities
become subject to legal challenges. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our contractual relationships with our affiliated professional entities may
implicate certain state laws that generally prohibit the practice of medicine or other licensed professions, including physical therapy, by lay persons or entities and are intended to prevent unlicensed persons or entities from interfering with or
inappropriately influencing providers&#146; professional judgment (such activities generally referred to as the corporate practice of medicine) or engaging in certain practices such as fee splitting with such licensed professionals. These
prohibitions exist in some form, by statute, regulation, board of medicine or physical therapy, or attorney general guidance, or case law, in certain of the states in which we operate. The interpretation and enforcement of these laws vary
significantly from state to state. There can be no assurance that these laws will be interpreted in a manner consistent with our practices or that other laws or regulations will not be enacted in the future that could have a material and adverse
effect on our business, results of operations, and financial condition. Regulatory authorities, state boards of medicine, state attorneys general, and other parties may assert that, despite the agreements through which we operate, we are engaged in
the provision of medical services or that our arrangements with our affiliated professional entities constitute unlawful fee splitting. If a jurisdiction&#146;s prohibition on the corporate practice of medicine or fee splitting is interpreted in a
manner that is inconsistent with our practices, we would be required to restructure or terminate our arrangements with our affiliated professional entities to bring our activities into compliance with such laws. A determination of noncompliance, or
the termination of or failure to successfully restructure these relationships, could result in disciplinary action, penalties, damages, fines, or a loss of revenue, any of which could have a material and adverse effect on our business, results of
operations, and financial condition. State corporate practice and fee splitting prohibitions also often impose penalties on healthcare professionals for aiding in the improper rendering of professional services, which could discourage physicians and
other healthcare professionals from providing clinical services to members of the health plans with whom we contract. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In
order to comply with the corporate practice of medicine doctrine in states in which we operate, we have entered into a management or administrative services agreement (an &#147;MSA&#148;) with each of our affiliated professional entities. Under the
MSAs, we provide various administrative and operations support services in exchange for scheduled fees for our services. As a result, our ability to receive cash fees from our affiliated professional entities generally may be limited to the fair
market value of the services provided under the MSAs. To the extent our ability to receive cash fees from our affiliated professional entities may be limited in certain states in which we operate, our ability to use that cash for growth, debt
service, or other uses may be impaired and, as a result, our results of operations and financial condition may be adversely affected. In addition, while the MSAs prohibit us from controlling, influencing, or otherwise interfering with the
professional practice of any affiliated professional entity and provide that the licensed professionals retain exclusive control and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
responsibility for all aspects of the professional practice and the delivery of medical services, there can be no assurance that our contractual arrangements and activities with our affiliated
professional entities will be free from scrutiny from regulatory authorities, and we cannot guarantee that subsequent interpretation of the corporate practice of medicine and fee splitting laws will not circumscribe our business operations. If a
successful legal challenge or an adverse change in relevant laws were to occur, and we were unable to adapt our business model accordingly, our operations in affected jurisdictions would be disrupted, which could harm our business, results of
operations, and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While we expect that our relationships with our affiliated professional entities
will continue, a material change in our relationship with these entities, whether resulting from a dispute among the entities, a challenge from a governmental regulator, a change in government regulation, or the loss of these relationships or
contracts, could impair our ability to provide services to our members and could harm our business. For example, the succession arrangements in place with the owners of the professional entities include provisions to help ensure an orderly
succession of the owner or owners of such professional entities upon the occurrence of certain events. Such succession arrangements may be challenged, which may impact our relationship with the affiliated professional entities and harm our business,
results of operations and financial condition. The MSAs and succession arrangements, including any stock transfer restriction agreements, could also subject us to additional scrutiny by federal and state regulatory bodies regarding federal and state
fraud and abuse laws. Any scrutiny, investigation, or litigation with regard to these agreements or arrangements, and any resulting penalties, including monetary fines and restrictions on or agreements or arrangements, and any resulting penalties,
including monetary fines and restrictions on or mandated changes to our current business and operating arrangements, could materially adversely affect our business, results of operations, and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our business could be adversely affected by legal challenges to our ability to offer our platform and full range of
programs in certain jurisdictions. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The ability to offer our platform and full range of programs in a particular
state is directly dependent upon the applicable laws governing remote healthcare, the practice of medicine or other licensed professions, including physical therapy, and healthcare delivery in general in such location, which are subject to changing
political, regulatory, and other influences. These laws and their interpretations vary from state to state and are enforced by state courts and regulatory authorities, each with broad discretion, and are subject to change and to evolving
interpretations by state boards of medicine and physical therapy and state attorneys general, among others. With respect to remote healthcare services, in the past, state medical and physical therapy boards implemented new rules or interpreted
existing rules in a manner that has limited or restricted our affiliated professional entities&#146; ability to conduct their business as it has been conducted in the past, such as laws that require a provider to be licensed or physically located in
the same state where the patient is located. For example, certain of the jurisdictions in which we operate, including Oregon, California, New York, Virginia, New Jersey, and Massachusetts, among others, are not members of the Interstate Medical
Licensure Compact, which streamlines the process by which physicians licensed in one state are able to practice in other participating states. However, during the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, many states enacted waivers
and adopted other temporary measures that lifted certain restrictions on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-state</FONT></FONT> providers and waived certain license requirements to allow greater access to
telehealth services during the public health emergency period. Many of these waivers and temporary measures with respect to licensure have expired since the end of the public health emergency and those that have not yet expired may not be
reapproved. Accordingly, we must continuously monitor our compliance with laws in every jurisdiction in which we operate and a failure to monitor compliance may have a negative impact on our business. We cannot provide any assurance that our
platform and programs, if challenged, will be found to be in compliance with applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, it is possible
that the laws and rules governing the practice of medicine and the practice of physical therapy, including telehealth, in one or more jurisdictions in which we operate may change in a manner deleterious to us and our business. For example, in April
2021, West Virginia adopted an amendment to the West Virginia Administrative Code that, among other things, provided that physical therapy via telehealth may be used </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
to establish a new patient relationship only if the physical therapist is physically available to perform an <FONT STYLE="white-space:nowrap">in-person</FONT>
<FONT STYLE="white-space:nowrap">hands-on</FONT> examination or <FONT STYLE="white-space:nowrap">re-examination</FONT> throughout the course of the patient&#146;s care. We continue to assess and address the impact of this amendment on our business
in order to continue to be able to offer our platform and programs in West Virginia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Furthermore, in August 2024,
Illinois passed an amendment to the Illinois Physical Therapy Act, that limits physical therapists&#146; ability to provide physical therapy via telehealth to patients in Illinois and that will become effective in January 2025. The amendment
requires, among other things, that initial physical therapy evaluations without a referral or established diagnosis be performed in person and cannot be performed via telehealth unless necessary if there is a documented hardship, including
geographical, physical, or weather-related conditions. Further, the amendment states that the use of telehealth as a primary means of delivering physical therapy must be an exception and documentation must support the clinical justification. The
amendment also requires that a physical therapist providing remote care must have the capacity to provide <FONT STYLE="white-space:nowrap">in-person</FONT> care within Illinois. We are currently assessing the potential impact of this new amendment
on our business and the manner in which we offer our platform and programs in Illinois. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Increased regulation and
legislative review of remote health care practices could further increase our costs of doing business. Authorities may not agree with our interpretation of existing or future legislation and regulation, which may require us to incur additional
costs. Further states may require that members receiving physical therapy have the right to request and receive <FONT STYLE="white-space:nowrap">in-person</FONT> care, as is the case in West Virginia and Illinois, and, if so, we will need to offer <FONT
STYLE="white-space:nowrap">in-person</FONT> care options to members in those states, which could increase the cost of offering our platform and programs. If other states were to pass similar measures, it could make it difficult and more expensive to
operate our business in general or to operate our business in those states, which could materially adversely affect our business, financial condition, and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If a successful legal challenge or an adverse change in the relevant laws were to occur, and we were unable to adapt our
business model accordingly, our operations as well as the operations of our affiliated professional entities in the affected jurisdictions could be disrupted, which could have a material adverse effect on our business, results of operations, and
financial condition. Failure to comply with these laws could also result in professional discipline for the affiliated professional entities&#146; providers or civil or criminal penalties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Government laws and regulation of the internet is evolving, and unfavorable changes or failure by us to comply with
these laws and regulations could substantially harm our business, results of operations, and financial condition.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are subject to general business regulations and laws specifically governing the internet. Furthermore, the regulatory
landscape impacting this area is constantly evolving. Existing and future regulations and laws could impede the growth of the internet or other online services. These regulations and laws may involve taxation, tariffs, privacy and data security,
anti-spam, data protection, content, copyrights, distribution, electronic contracts, electronic communications, money laundering, electronic payments, and consumer protection. It is not clear how existing laws and regulations governing issues such
as property ownership, sales, and other taxes, libel, and personal privacy apply to the internet as the vast majority of these laws and regulations were adopted prior to the advent of the internet and do not contemplate or address the unique issues
raised by the internet. It is possible that general business regulations and laws, or those specifically governing the internet may be interpreted and applied in a manner that is inconsistent from one jurisdiction to another and may conflict with
other rules or our practices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We cannot assure you that our practices have complied, comply, or will in the future comply
with all such laws and regulations. Any failure, or perceived failure, by us to comply with any of these laws or regulations could result in damage to our reputation, a loss in business, and proceedings or actions against us by governmental entities
or others. For example, recent automatic renewal laws, which require companies to adhere to enhanced disclosure requirements when entering into automatically renewing contracts with consumers, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
resulted in class action lawsuits against companies that offer online products and services on a subscription or recurring basis. These and similar proceedings or actions could hurt our
reputation, force us to spend significant resources in defense of these proceedings, distract our management, increase our costs of doing business, cause members to decrease their use of our platform and programs, and may result in the imposition of
monetary liability. We may also be contractually required to indemnify and hold harmless third parties from the costs or consequences of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with any such laws or regulations. Adverse legal or
regulatory developments could substantially harm our business, results of operations, and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Changes or developments in the health insurance markets in the United States, including passage and implementation of a
law to create a single-payer or <FONT STYLE="white-space:nowrap">government-run</FONT> health insurance program, could adversely harm our business, results of operations, and financial condition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our business operates within the public and private sectors of the U.S. health insurance system, which are evolving quickly and
subject to a changing regulatory environment, and our future financial performance will depend, in part, on growth in the market for private health insurance, as our platform and programs are integrated with health insurance plans offered by our
clients, as well as our ability to adapt to regulatory developments. Changes and developments in the health insurance system in the United States could reduce demand for our platform and programs and harm our business. For example, there has been an
ongoing national debate relating to the health insurance system in the United States. Certain elected officials have introduced proposals that would create a new single-payer national health insurance program for all United States residents,
replacing virtually all other sources of public and private insurance, to more incremental approaches, or creating a new public health insurance option that would compete with private insurers. Additionally, proposals to establish a single-payer or <FONT
STYLE="white-space:nowrap">government-run</FONT> healthcare system at the state level are regularly introduced, such as in New York and California. At the federal level, the president and Congress may consider other legislation or executive orders,
including changes to the elements of the ACA. Areas of focus include policies or practices that may reduce affordability of coverage, present unnecessary barriers to coverage, or undermine protections for people with preexisting conditions. We
continue to evaluate the effect that the ACA and its possible modification, repeal, and replacement has on our business. We cannot predict the timing or impact of any future rulemaking, court decisions or other changes in the law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event that laws, regulations or rules that eliminate or reduce private sources of health insurance or require such
benefits to be taxable are adopted, the subsequent impact on the insurance carriers or self-insured plans may in turn adversely impact our ability to accurately forecast future results and harm our business, results of operations, and financial
condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We and our affiliated professional entities may become subject to medical liability claims, which could
cause us to incur significant expenses and may require us to pay significant damages if not covered by insurance. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our business entails the risk of medical liability claims against both us and our affiliated professional entities. Although we
carry insurance covering medical malpractice claims, successful medical liability claims could result in substantial damage awards that exceed the limits of our insurance coverage. In addition, professional liability insurance is expensive and
insurance premiums may increase significantly in the future, particularly as we expand our platform and programs. As a result, adequate professional liability insurance may not be available in the future at acceptable costs or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any claims made against us or our affiliated professional entities may adversely affect our business or reputation, and any
claims that are not fully covered by insurance could be costly to defend against, result in substantial damage awards against us and divert the attention of our management and our partners from our operations, which could have a material adverse
effect on our business, results of operations, and financial condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We have been, and may in the future be, subject to legal proceedings
in the ordinary course of our business. If the outcomes of these proceedings are adverse to us, it could have a material adverse effect on our business, results of operations, and financial condition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have been, and may in the future be, subject to various litigation matters from time to time, the outcome of which could
have a material adverse effect on our business, results of operations, and financial condition. Claims arising out of actual or alleged violations of law could be asserted against us by individuals, either individually or through class actions, by
governmental entities in civil or criminal investigations and proceedings, or by other entities. These claims could be asserted under a variety of laws, including but not limited to consumer finance laws, consumer protection laws, healthcare privacy
laws, tort laws, environmental laws, intellectual property laws, privacy laws, labor and employment laws, securities laws, and employee benefit laws. We may also become subject to allegations of discrimination or other similar misconduct, which,
regardless of the ultimate outcome, may result in adverse publicity that could harm our brand, reputation, and operations. Claims may also arise out of actual or alleged breaches of contract or other actual or alleged acts or omissions by or on
behalf of us. The scope, determination, and impact of claims, lawsuits, government and regulatory investigations, enforcement actions, disputes, and proceedings to which we are subject cannot be predicted with certainty, and may result in: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">substantial payments to satisfy judgments, fines, or penalties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">substantial outside counsel legal fees and costs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additional compliance and licensure requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loss or <FONT STYLE="white-space:nowrap">non-renewal</FONT> of existing licenses or authorizations, or
prohibition from or delays in obtaining additional licenses or authorizations, required for our business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loss of productivity and high demands on employee time; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">criminal sanctions or consent decrees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">termination of certain employees, including members of our executive management team; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">barring of certain employees from participating in our business in whole or in part; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">orders that restrict our business or prevent us from offering our platform or certain programs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes to our business model and practices; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">damage to our reputation and brand. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The number and significance of these potential claims and disputes may increase as our business expands. Any claim against us,
regardless of its merit, could be costly, divert management&#146;s attention and operational resources, and harm our reputation and brand. As litigation is inherently unpredictable, we cannot assure you that any potential claims or disputes will not
have a material adverse effect on our business, results of operations, and financial condition. Even if we are successful in defending against legal claims, litigation could result in substantial costs and demands on management&#146;s attention and
operational resources. See the section titled &#147;Business&#151;Legal Proceedings.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We are subject to
anti-corruption, anti-bribery, anti-money laundering, financial and economic sanctions, and similar laws and regulations, and <FONT STYLE="white-space:nowrap">non-compliance</FONT> with such laws and regulations can subject us to administrative,
civil and criminal fines and penalties, collateral consequences, remedial measures, and legal expenses, all of which could materially adversely affect our business, results of operations, and financial condition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are subject to anti-corruption, anti-bribery, anti-money laundering, financial and economic sanctions, and similar laws and
regulations in various jurisdictions in which we currently or may in the future conduct activities, including the U.S. Foreign Corrupt Practices Act (&#147;FCPA&#148;), the U.K. Bribery Act, and other
anti-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
corruption laws and regulations. The FCPA and the U.K. Bribery Act prohibit us and our officers, directors, employees, and business partners acting on our behalf, including agents, from corruptly
offering, promising, authorizing, or providing anything of value to a &#147;foreign official&#148; for the purposes of influencing official decisions or obtaining or retaining business or otherwise obtaining favorable treatment. The FCPA also
requires companies to make and keep books, records, and accounts that accurately reflect transactions and dispositions of assets and to maintain a system of adequate internal accounting controls. The U.K. Bribery Act also prohibits <FONT
STYLE="white-space:nowrap">non-governmental</FONT> &#147;commercial&#148; bribery and soliciting or accepting bribes. A violation of these laws or regulations could adversely affect our business, results of operations, financial condition, and
reputation. Our policies and procedures may not be sufficient to ensure compliance with these regulations and our directors, officers, employees, representatives, consultants, agents, and business partners could engage in improper conduct for which
we may be held responsible, even if we do not explicitly authorize or have actual knowledge of such activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are
also subject to certain economic and trade sanctions programs that are administered by the U.S. Department of the Treasury&#146;s Office of Foreign Assets Control (&#147;OFAC&#148;), and which prohibit or restrict transactions to or from or dealings
with certain countries that are subject to comprehensive sanctions, their governments, and in certain circumstances, their nationals, and with individuals and entities that are named on OFAC&#146;s list of specially designated nationals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">Non-compliance</FONT> with anti-corruption, anti-bribery, anti-money laundering, or financial
and economic sanctions laws could subject us to whistleblower complaints, adverse media coverage, investigations, and severe administrative, civil and criminal sanctions, collateral consequences, remedial measures, and legal expenses, all of which
could materially adversely affect our business, results of operations, and financial condition. In addition, changes in economic sanctions laws in the future could materially adversely impact our business and the trading price of our Class&nbsp;A
common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Medical Device Compliance and Regulations </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our Enso device is subject to extensive government regulation. We may not receive, or may be delayed in receiving, the
necessary marketing authorizations for modifications to our Enso device or any device products we may offer, and failure to timely obtain necessary marketing authorizations or certifications for any medical devices we may offer could have a material
adverse effect on our business, results of operations, and financial condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the United States, before we
can market a new medical device, or a new use of, or other significant modification to an existing, marketed medical device, such as our Enso device, we must first receive either clearance under Section&nbsp;510(k)&nbsp;of the Federal Food, Drug,
and Cosmetic Act (&#147;FDCA&#148;), approval of a premarket approval application (&#147;PMA&#148;), or grant of a <I>de novo </I>classification request from the U.S. Food and Drug Administration (&#147;FDA&#148;), unless an exemption applies. For
example, we have obtained 510(k) clearance of our Enso device for the symptomatic relief and management of chronic intractable pain, and for temporary relief of pain associated with sore and aching muscles in the shoulder, waist, back, neck, upper
extremities (arm) and lower extremities (leg) due to strain from exercise or normal household work activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the
510(k)&nbsp;clearance process, before a device may be marketed, the FDA must determine that a proposed device is &#147;substantially equivalent&#148; to a legally-marketed &#147;predicate&#148; device, which includes a device that has been
previously cleared through the 510(k)&nbsp;process, a device that was legally marketed prior to May&nbsp;28, 1976 <FONT STYLE="white-space:nowrap">(pre-amendments</FONT> device), a device that was originally on the U.S. market pursuant to an
approved PMA and later down-classified, or a 510(k)-exempt device. To be &#147;substantially equivalent,&#148; the proposed device must have the same intended use as the predicate device, and either have the same technological characteristics as the
predicate device or have different technological characteristics and not raise different questions of safety or effectiveness than the predicate device. Clinical data are sometimes required to support substantial equivalence. In the process of
obtaining PMA approval, the FDA must determine that a proposed device is safe and effective for its intended </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
use based, in part, on extensive data, including, but not limited to, technical, <FONT STYLE="white-space:nowrap">pre-clinical,</FONT> clinical trial, manufacturing, and labeling data. The PMA
process is typically required for devices that are deemed to pose the greatest risk, such as life-sustaining, life-supporting, or implantable devices. In the <I>de novo </I>classification process, a manufacturer whose novel device under the FDCA
would otherwise be automatically classified as Class&nbsp;III and require the submission and approval of a PMA prior to marketing is able to request down-classification of the device to Class&nbsp;I or Class&nbsp;II on the basis that the device
presents a low or moderate risk. If the FDA grants the <I>de novo </I>classification request, the applicant will receive authorization to market the device. This device type may be used subsequently as a predicate device for future
510(k)&nbsp;submissions. We have not sought or obtained PMA approval or <I>de novo</I> classification for any products to date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The PMA approval, 510(k)&nbsp;clearance, and <I>de novo </I>classification processes can be expensive, lengthy, and uncertain.
In addition, a PMA generally requires the performance of one or more clinical trials. Clinical data may also be required in connection with an application for 510(k)&nbsp;clearance or a <I>de novo </I>request. Despite the time, effort, and cost, a
device may not obtain marketing authorization by the FDA. Any delay or failure to obtain necessary regulatory marketing authorizations could harm our business. Furthermore, even if we are granted such marketing authorizations, they may include
significant limitations on the indicated uses for the device, which may limit the potential commercial market for the device. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have obtained 510(k) clearance for our Enso device, and we expect we will pursue similar regulatory pathways in the United
States with respect to potential modifications of our Enso device, where required, as well any future device products, including any applications we may develop that otherwise meet the FDA&#146;s definition of a medical device. However, if the FDA
requires us to pursue alternate pathways, or otherwise go through a lengthier, more rigorous premarket review for our products than we had expected, our product introductions or modifications could be delayed or prevented, which would have a
material impact on our business, results of operations and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the United States, any modification to
a product candidate for which we receive marketing authorization may require us to submit a new 510(k)&nbsp;premarket notification and obtain clearance, to submit a PMA and obtain FDA approval, or to submit a <I>de novo </I>request prior to
implementing the change. For example, any modification to a 510(k)-cleared device that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, design, or manufacture, generally requires a
new 510(k)&nbsp;clearance or other marketing authorization. The FDA requires every manufacturer to make such determinations in the first instance, but the FDA may review any manufacturer&#146;s decision. The FDA may not agree with a
manufacturer&#146;s decisions regarding whether new clearances or approvals are necessary. We have in the past made modifications to our 510(k)-cleared product that we believe did not require a new 510(k)&nbsp;clearance, and we may do so in the
future. If the FDA disagrees with our determinations and requires us to seek new marketing authorizations for any implemented product modifications, we may be required to cease marketing or to recall the modified product until we obtain such
marketing authorization, and we may be subject to significant regulatory fines or penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA or an applicable
foreign regulatory authority can delay, limit, or deny marketing authorization or certification of a device for many reasons, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to demonstrate to the satisfaction of the FDA or the applicable regulatory authority that our
device products are substantially equivalent to a predicate device or are safe and effective for their intended uses; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the disagreement of the FDA or foreign regulatory authorities or notified body that our available data support
the intended uses of our device products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">serious and unexpected adverse device effects experienced by clinical trial participants or device users;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the data from preclinical studies and clinical trials may be insufficient to support clearance, <I>de novo
</I>classification, approval, or certification, where required; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to demonstrate that the clinical and other benefits of the device outweigh the risks;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manufacturing process or facilities we use may not meet applicable requirements; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential for marketing authorization or certification policies or regulations of the FDA or applicable
foreign regulatory authorities to change significantly in a manner rendering our data or regulatory filings insufficient for continued marketing authorization or certification. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The FDA may modify its enforcement policies with respect to medical software products, and our programs may become
subject to extensive regulatory requirements, which may increase the cost of conducting, or otherwise harm, our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We develop and offer certain digital applications to our members. The FDA may regulate medical or health-related software,
including machine learning functionality and predictive algorithms, if such software falls within the definition of a &#147;medical device&#148; under the FDCA. However, historically, the FDA has exercised enforcement discretion for certain <FONT
STYLE="white-space:nowrap">low-risk</FONT> software functions and has issued several guidance documents outlining its approach to the regulation of software as a medical device. In addition, the 21st Century Cures Act amended the FDCA to exclude
from the definition of &#147;medical device&#148; certain medical-related software, including software used for administrative support functions at a healthcare facility, software intended for maintaining or encouraging a healthy lifestyle, software
designed to store EHRs, software for transferring, storing, or displaying medical device data or in vitro diagnostic data, and certain clinical decision support software. Accordingly, we believe some of our currently marketed software, including our
Hinge Health application and related algorithms are not currently regulated by the FDA as medical devices, or that such products are otherwise subject to FDA&#146;s current enforcement discretion policies applicable to software products. However,
there is a risk that the FDA could disagree with our determinations, or that the FDA could alter its enforcement discretion policies, and in each case, subject our digital applications to more stringent medical device regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the FDA determines that any of our current or future platform and programs, including the functions available within our
Hinge Health application, constitute medical devices and are not otherwise subject to enforcement discretion, such platform and programs would become subject to various requirements under the FDCA and the FDA&#146;s implementing regulations. If this
occurs, we may be required to cease marketing or to recall the affected platform and programs until we obtain the requisite clearances or approvals and may otherwise be subject to enforcement action, which would entail significant cost and could
harm our reputation, business, results of operations, and financial condition. The process of seeking clearance or approval can be expensive and time-consuming, and there is no guarantee that we would be successful in obtaining the necessary
approvals. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Failure to comply with regulatory requirements for medical devices could subject us to enforcement
actions, including substantial penalties, and might require us to recall or withdraw a product from the market. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Because we have obtained 510(k) clearance for our Enso device in the United States, we are subject to ongoing and pervasive
regulatory requirements governing, among other things, the manufacture, marketing, advertising, medical device reporting, sale, promotion, import, export, registration, and listing of devices. For example, we must submit periodic reports to the FDA
as a condition of 510(k) clearance for our Enso device. These reports include information about failures and certain adverse events associated with the device after its clearance. Failure to submit such reports, or failure to submit the reports in a
timely manner, could result in enforcement action by the FDA. Following its review of the periodic reports, the FDA might ask for additional information or initiate further investigation. In addition, any marketing authorizations we are granted are
limited to the cleared or approved indications for use. Further, the manufacturing facilities for a product are subject to periodic review and inspection. Subsequent discovery of problems with a product, manufacturer, or manufacturing facility may
result in restrictions on the product, manufacturer, or manufacturing facility, including withdrawal of the product from the market or other enforcement actions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Regulatory changes could result in restrictions on our ability to continue or expand our operations, higher than anticipated
costs, or lower than anticipated sales. Even after we have obtained the proper regulatory </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
clearance to market a device, we have ongoing responsibilities under FDA regulations and applicable foreign laws and regulations. The FDA, state, and foreign regulatory authorities have broad
enforcement powers. Our failure to comply with applicable regulatory requirements could result in enforcement action by the FDA, state, or foreign regulatory authorities, which may include any of the following sanctions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">untitled letters or warning letters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, injunctions, consent decrees, and civil penalties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recalls, termination of distribution, administrative detention, or seizure of our device products;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">customer notifications or repair, replacement, or refunds; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">operating restrictions or partial suspension or total shutdown of production; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in or refusal to grant our requests for future clearances or approvals or foreign marketing
authorizations of new products, new intended uses, or modifications to existing products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawals or suspensions of our current 510(k) clearances, resulting in prohibitions on sales of our device
products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA refusal to issue certificates to foreign governments needed to export products for sale in other
countries; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">criminal prosecution. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any of these sanctions could result in higher than anticipated costs or lower than anticipated sales and have a material
adverse effect on our reputation, business, results of operations, and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the FDA may
change its marketing authorization policies, adopt additional regulations or revise existing regulations, or take other actions, which may prevent or delay marketing authorization of any product candidate under development or impact our ability to
modify any device products authorized for market on a timely basis. Such changes may also occur in foreign jurisdictions where we may market our device products in the future. Such policy or regulatory changes could impose additional requirements
upon us that could delay our ability to obtain marketing authorizations or certifications, increase the costs of compliance, or restrict our ability to maintain any marketing authorizations we have obtained. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our medical device products must be manufactured in accordance with applicable laws and regulations, and we could be
forced to recall our device or terminate production if we fail to comply with these regulations and other factors could affect our ability to provide our Enso device to members. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We and our third-party suppliers and manufacturers are required to comply with the FDA&#146;s current Good Manufacturing
Practice requirements for medical devices, known as the Quality System Regulation (&#147;QSR&#148;), which covers among other things, the procedures, methods and documentation for the design, testing, production, controls, quality assurance,
handling labeling, packaging, sterilization, storage, and shipping of medical devices, such as the Enso device that we provide to certain members in connection with our platform and programs. We are required to verify that our suppliers maintain
facilities, procedures, and operations that comply with our quality standards and applicable regulatory requirements. The FDA enforces the QSR through periodic announced or unannounced inspections of medical device manufacturing facilities, which
may include the facilities of third-party suppliers and subcontractors. Our device products remain subject to similar state regulations and various laws and regulations of foreign countries governing manufacturing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We or any third-party manufacturers or suppliers may not take the necessary steps to comply with applicable regulations, which
could cause delays in the delivery of our device products. In addition, failure to comply with applicable FDA requirements or later discovery of previously unknown problems with our device products or manufacturing processes could result in, among
other things: warning letters or untitled letters; fines, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
injunctions or civil penalties; suspension or withdrawal of approvals; seizures or recalls of our device products; total or partial suspension of production or distribution; administrative or
judicially imposed sanctions; the FDA&#146;s refusal to grant pending or future clearances or approvals for our device products; clinical holds; refusal to permit the import or export of our device products; and criminal prosecution of us, our
suppliers, or our employees. We rely on and expect to continue to rely on a small number of third-party suppliers and manufacturers to supply our inventory, and any disruption to their services could disrupt our ability to supply quality Enso
devices to our members, which could adversely affect our business, results of operations, and financial condition. Increases in demand could strain our suppliers&#146; and manufacturers&#146; capacity, impacting timely delivery and compliance with
quality standards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any of these actions could significantly and negatively affect supply of our products and platform. If
any of these events occurs, our reputation could be harmed, we could be exposed to product liability claims and we could lose clients, members, and contracted lives and experience reduced sales and increased costs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our medical device products may cause or contribute to adverse events or be subject to failures or malfunctions that we
may be required to report to the FDA, and if we fail to do so, we may be subject to sanctions that could harm our reputation, business, results of operations, and financial condition. The discovery of serious safety issues with our medical device
products, or a recall of our medical device products, either voluntarily or at the direction of the FDA or another governmental authority, could have a negative impact on us. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As a manufacturer of a 510(k) cleared medical device, we are subject to the FDA&#146;s medical device reporting regulations
and, to the extent applicable, similar foreign regulations, which require us to report to the FDA when we receive or become aware of information that reasonably suggests that one or more of our device products may have caused or contributed to a
death or serious injury or malfunctioned in a way that, if the malfunction were to recur, it could cause or contribute to a death or serious injury. The timing of our obligation to report is triggered by the date we become aware of the adverse event
as well as the nature of the event. We may fail to report adverse events of which we become aware within the prescribed time frame. We may also fail to recognize that we have become aware of a reportable adverse event, especially if it is not
reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of the product. If we fail to comply with our reporting obligations, the FDA could take action, including warning letters, untitled
letters, administrative actions, criminal prosecution, imposition of civil monetary penalties, revocation of our device clearance or approval, seizure of our device products, or delay in clearance or approval of future products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the FDA and foreign regulatory bodies have the authority to require the recall of commercialized products in the
event of material deficiencies or defects in design or manufacture of a product or in the event that a product poses an unacceptable risk to health. For example, the FDA&#146;s authority to require a recall must be based on a finding that there is
reasonable probability that the device could cause serious injury or death. We may also choose to voluntarily recall a device if any material deficiency is found. A government-mandated or voluntary recall by us could occur as a result of an
unacceptable risk to health, component failures, malfunctions, manufacturing defects, labeling or design deficiencies, packaging defects, or other deficiencies or failures to comply with applicable regulations. Product defects or other errors may
occur in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Depending on the corrective action we take to redress a product&#146;s deficiencies or defects, the
FDA may require, or we may decide, that we will need to obtain new clearances or approvals for the device before we may market or distribute the corrected device. Seeking such clearances or approvals may delay our ability to replace the recalled
devices in a timely manner. Moreover, if we do not adequately address problems associated with our devices, we may face additional regulatory enforcement action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Medical device manufacturers are required to maintain certain records of recalls and corrections, even if they are not
reportable to the FDA. We may initiate voluntary withdrawals or corrections for our devices in the future that we determine do not require notification of the FDA. If the FDA disagrees with our determinations, it
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
could require us to report those actions as recalls and we may be subject to enforcement action. A future recall announcement could harm our reputation with clients and members, potentially lead
to product liability claims against us and negatively affect our sales. Any corrective action, whether voluntary or involuntary, as well as defending ourselves in a lawsuit, will require the dedication of our time and capital, distract management
from operating our business, and may harm our reputation, business, results of operations, and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our platform and programs, including our medical device, may result in direct or indirect harm or injury to members, and
as a result we could be subject to claims, liabilities, and reputational harm, which may materially adversely affect our business, results of operations, and financial condition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our platform and programs are designed under the oversight of qualified healthcare professionals, and we train our care team to
comply with appropriate standards and protocol for delivery of care and the recognition and management of escalation events. Our success depends in part on the ability of our healthcare professionals to obtain and maintain all necessary licenses,
certifications, permits, and other approvals, and to provide services to members in compliance with applicable laws, including scope of practice laws, as well as our policies. Nevertheless, if future results or experience indicate that our programs
cause unexpected or serious complications or other unforeseen negative effects, we could face significant legal liability or harm to our reputation, business, results of operations, and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our success will also depend in part on the success of our current and any future medical devices we develop and provide to
members. We believe that members are and will continue to be sensitive to errors or issues resulting from the use of our medical device products. Any failure of our Enso device, or for any other medical device products we may offer, to perform as
intended or advertised, or any harm or injury resulting from the use of such products, may result in claims, liabilities, and reputational harm. For example, we have in the past received and may in the future receive complaints from members
regarding injury or potential injury related to the use of the Enso device. Any such complaints may result in legal claims against us, which would harm our reputation, business, results of operations, and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The misuse or <FONT STYLE="white-space:nowrap">off-label</FONT> use of our medical device products may harm our
reputation in the marketplace, result in injuries that lead to product liability suits or result in costly investigations, fines, or sanctions by regulatory bodies if we are deemed to have engaged in the promotion of these uses, any of which could
be costly to our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any marketing authorization we may receive for our device products will be limited to
specified indications for use. We train our marketing personnel and direct sales force to not promote our authorized medical device for uses outside of the <FONT STYLE="white-space:nowrap">FDA-authorized</FONT> indications for use, known as <FONT
STYLE="white-space:nowrap">&#147;off-label</FONT> uses.&#148; We cannot, however, prevent a physician from recommending our medical device for <FONT STYLE="white-space:nowrap">off-label</FONT> uses, when, in the physician&#146;s independent
professional medical judgment, he or she deems it appropriate. There may be increased risk of injury to patients if members or physicians attempt to use our medical device <FONT STYLE="white-space:nowrap">off-label,</FONT> which could harm our
reputation in the marketplace among current or potential clients, members, and physicians. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the FDA or any foreign
regulatory body determines that our promotional materials or training constitute promotion of an <FONT STYLE="white-space:nowrap">off-label</FONT> use of our device products, the FDA or such regulatory body could request that we modify our training
or promotional materials or subject us to regulatory or enforcement actions, including the issuance or imposition of an untitled letter, which is used for violators that do not necessitate a warning letter, injunction, seizure, civil fine, or
criminal penalties. It is also possible that other federal, state or foreign enforcement authorities might take action under other regulatory authority, such as false claims laws, if they consider our business activities to constitute promotion of
an <FONT STYLE="white-space:nowrap">off-label</FONT> use, which could result in significant penalties, including, but not limited to, criminal, civil and administrative penalties, damages, fines, disgorgement, exclusion from participation in
government healthcare programs, and the curtailment of our operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, members or physicians may misuse
medical device products or use improper techniques if they are not adequately trained, potentially leading to injury and an increased risk of product liability. If our medical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
device products are misused or used with improper technique, we may become subject to costly litigation by our clients or members. As described above, product liability claims could divert
management&#146;s attention from our core business, be expensive to defend and result in sizeable damage awards against us that may not be covered by insurance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Legislative or regulatory reforms in the United States may make it more difficult and costly for us to obtain marketing
authorizations for any medical devices or to manufacture, market or distribute any medical devices after such authorizations have been obtained. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Federal and state governments in the U.S. and foreign governments continue to propose and pass new legislation and regulations
that could significantly change the statutory provisions governing the regulation of medical devices. In addition, the FDA may change its policies, adopt additional regulations or revise existing regulations, or take other actions, which may prevent
or delay marketing authorization of our future products under development or impact our ability to modify any products for which we have already obtained marketing authorizations on a timely basis. For example, in February 2024, the FDA issued a
final rule to amend and replace the QSR, which sets forth the FDA&#146;s current good manufacturing practice requirements for medical devices, to align more closely with the International Organization for Standardization standards. Specifically,
this final rule, which the FDA expects to go into effect on February&nbsp;2, 2026, establishes the Quality Management System Regulation (&#147;QMSR&#148;), which among other things, incorporates by reference the quality management system
requirements of ISO 13485:2016. Although the FDA has stated that the standards contained in ISO 13485:2016 are substantially similar to those set forth in the QSR, it is unclear the extent to which this final rule, once effective, could impose
additional or different regulatory requirements on us that could increase the costs of compliance or otherwise negatively affect our business. If we are unable to comply with QMSR, once effective, or with any other changes in the laws or regulations
enforced by FDA or comparable regulatory authorities, we may be subject to enforcement action, which could have an adverse effect on our business, financial condition, and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we do not obtain and maintain any required international regulatory registrations and marketing authorizations for
our medical device products, we will be unable to market and sell such products outside of the United States. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As
we look towards increased international expansion, sales of our medical device products outside of the United States will be subject to foreign regulatory requirements that vary widely from country to country. In addition, the FDA regulates export
of medical devices from the United States. While the regulations of some countries may not impose significant barriers to marketing and selling our medical device or only require notification to regulators or third parties, others require that we
obtain affirmative marketing authorization from a specified regulatory body. Complying with foreign regulatory requirements, including obtaining registrations, certifications, clearances, or approvals, can be expensive and time-consuming, and we may
not receive necessary marketing authorizations in each country in which we plan to market our device products, or we may be unable to do so on a timely basis. The time required to obtain marketing authorizations and certifications, if required by
other countries, may be longer than that required for FDA marketing authorizations, and requirements for such authorizations or certifications may significantly differ from FDA requirements. If we modify our medical device products, we may need to
apply for additional marketing authorizations before we are permitted to sell the modified device or may be required to recall products we have previously modified. In addition, we may not continue to meet the quality, safety and compliance
standards required to maintain the authorizations that we have received. If we are unable to maintain our marketing authorizations in a particular country, we will no longer be able to sell the applicable device in that country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Obtaining marketing authorization from the FDA does not ensure similar marketing authorization by regulatory authorities in
other countries, and registration or marketing authorization by one or more foreign regulatory authorities does not ensure registration or marketing authorization by regulatory authorities in other foreign countries or by the FDA. However, a failure
or delay in obtaining registration or marketing authorization in one country may have a negative effect on the regulatory process in others. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Financial, Tax, and Accounting Matters </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may experience fluctuations in our tax obligations and effective tax rate, which could materially and adversely
affect our results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are subject to income taxes in both the United States and foreign
jurisdictions. Tax laws, regulations, and administrative practices in various jurisdictions may be subject to significant change, with or without advance notice, due to economic, political, and other conditions, and significant judgment is required
in evaluating and estimating our provision and accruals for these taxes. Our effective tax rates could be affected, potentially materially, by numerous factors, such as changes in tax, accounting, and other laws (including increases in tax rates),
regulations, administrative practices, principles, and interpretations, the mix and level of earnings in a given taxing jurisdiction, or our ownership or capital structures. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under Section&nbsp;382 and Section&nbsp;383 of the Internal Revenue Code of 1986, as amended (the
&#147;Code&#148;), if a corporation undergoes an &#147;ownership change,&#148; the corporation&#146;s ability to use its <FONT STYLE="white-space:nowrap">pre-change</FONT> net operating loss carryforwards (&#147;NOLs&#148;) and other tax attributes,
including research and development tax credits, to offset its post-change income or taxes may be limited. In general, an &#147;ownership change&#148; will occur if there is a cumulative change in our ownership by &#147;5% shareholders&#148; that
exceeds 50 percentage points over a rolling three-year period. Similar rules may apply under state tax laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we have
undergone previous ownership changes, or if we undergo an ownership change in the future, including as a result of this offering, our ability to use NOLs and other tax attributes to reduce future taxable income and liabilities may be limited by
Section&nbsp;382 of the Code and/or analogous provisions of applicable state tax law in states where we have incurred NOLs for state income tax purposes. Future changes in our stock ownership, some of which may be outside of our control, may result
in an ownership change under these rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Changes in accounting principles and standards related to accounting for
variable interest entities could have an adverse effect on our business, financial condition, and results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our financial statements are consolidated in accordance with applicable accounting standards and include the accounts of our
wholly-owned subsidiaries and affiliated professional medical corporations (such affiliated professional medical corporations are collectively referred to as &#147;Hinge Health Digital P.C.&#148;), which are classified as variable interest entities.
Applicable accounting standard require that, under some circumstances, the variable interest entity (&#147;VIE&#148;) consolidation model be applied when a reporting enterprise holds a variable interest, such as equity interests, debt obligations,
certain management, and service contracts, in a legal entity. Under this model, an enterprise must assess the entity in which it holds a variable interest to determine whether it meets the criteria to be consolidated as a VIE. If the entity is a
VIE, the consolidation framework next identifies the party, if one exists, that possesses a controlling financial interest in the VIE, and then requires that party to consolidate the VIE as it is the primary beneficiary. An enterprise&#146;s
determination of whether it has a controlling financial interest in a VIE requires that a qualitative determination be made, and is not solely based on voting rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The VIE consolidation model applies to our controlled, but not owned, affiliated professional medical corporations. Such
consolidation for accounting or tax purposes does not, is not intended to, and should not be deemed to, imply or provide us any control over the medical or clinical affairs of Hinge Health Digital P.C. Our determination regarding the consolidation
of Hinge Health Digital P.C. could be challenged, which could have an adverse effect on our business, financial condition, and results of operations. Further, in the event of a change in accounting standards promulgated by the Financial Accounting
Standards Board or in interpretation of its standards, or if there is an adverse determination by a regulatory agency or a court or a change in state or federal law relating to the ability to maintain our agreements or arrangements with Hinge Health
Digital P.C., we may not be permitted to continue to consolidate the revenues, expenses, assets, and liabilities of Hinge Health Digital P.C., which could have an adverse effect on our business, financial condition, and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The applicability of sales, use, and other tax laws or regulations on
our business is uncertain. Adverse tax laws or regulations could be enacted, or existing laws could be applied to us or our clients, which could subject us to additional tax liability and related interest and penalties, increase the costs of our
platform and programs, and adversely impact our business, financial condition, and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
application of federal, state, local, and international tax laws to services provided electronically is evolving. New income, sales, use, value-added, or other tax laws, statutes, rules, regulations, or ordinances could be enacted at any time
(possibly with retroactive effect) and could be applied solely or disproportionately to services provided over the internet or could otherwise materially affect our business, results of operations, and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, state, local, and foreign tax jurisdictions have differing rules and regulations governing sales, use,
value-added, and other taxes, and these rules and regulations can be complex and are subject to varying interpretations that may change over time. Existing tax laws, statutes, rules, regulations, or ordinances could be interpreted, changed,
modified, or applied adversely to us (possibly with retroactive effect). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">One or more states may seek to impose
incremental or new sales, use, value added, or other tax collection obligations that may apply to us, including to any past sales by us or our resellers and other partners. A successful assertion by a state, country, or other jurisdiction that we
should have been or should be collecting additional sales, use, value added, or other taxes on our platform and programs could, among other things, result in substantial tax liabilities for past sales, create significant administrative burdens for
us, discourage clients, members and contracted lives from utilizing our platform and programs, or otherwise harm our business, results of operations, and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Class&nbsp;A Common Stock and This Offering </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The price of our Class&nbsp;A common stock may be volatile or may decline regardless of our operating performance,
resulting in substantial losses for investors purchasing shares in this offering. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The market price of our
Class&nbsp;A common stock may fluctuate significantly in response to numerous factors, many of which are beyond our control, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or anticipated fluctuations in our results of operations, and financial condition;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the projections we may provide to the public, any changes in these projections or our failure to meet these
projections; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure of securities analysts to initiate or maintain coverage of us, changes in financial estimates or
ratings by any securities analysts who follow us or our failure to meet these estimates or the expectations of investors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements by us or our competitors of significant innovations, acquisitions, strategic partnerships, joint
ventures, results of operations, or capital commitments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">price and volume fluctuations in the overall stock market, including as a result of trends in the economy as a
whole; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in our board of directors or management; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of large blocks of our Class&nbsp;A common stock, including sales by our
<FONT STYLE="white-space:nowrap">co-founders</FONT> or our executive officers and directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lawsuits threatened or filed against us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">anticipated or actual changes in laws, regulations, insurance reimbursement, or government policies applicable
to our business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in our capital structure, such as future issuances of debt or equity securities;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">short sales, hedging, and other derivative transactions involving our capital stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expiration of <FONT STYLE="white-space:nowrap">lock-up</FONT> or market standoff agreements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic conditions in the United States, including macroeconomic factors such as interest rate
increases, inflation, and recession concerns; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other events or factors, including those resulting from war, pandemics, incidents of terrorism, or responses
to these events; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the other factors described in the sections of this prospectus titled &#147;Risk Factors&#148; and
&#147;Special Note Regarding Forward-Looking Statements.&#148; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The stock market has experienced extreme
price and volume fluctuations. The market prices of securities of companies have experienced fluctuations that often have been unrelated or disproportionate to their results of operations. Market fluctuations could result in extreme volatility in
the price of shares of our Class&nbsp;A common stock, which could cause a decline in the value of your investment. Price volatility may be greater if the public float and trading volume of shares of our Class&nbsp;A common stock is low. Furthermore,
in the past, stockholders have sometimes instituted securities class action litigation against companies following periods of volatility in the market price of their securities. Any similar litigation against us could result in substantial costs,
divert management&#146;s attention and resources, and materially adversely affect our business, results of operations, and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>There has been no prior public market for our Class&nbsp;A common stock. An active market may not develop or be
sustainable, and you may not be able to resell your shares at or above the initial public offering price or at all. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There has been no public market for our Class&nbsp;A common stock prior to this offering. The initial public offering price for
our Class&nbsp;A common stock will be determined through negotiations between us, the selling stockholders and the underwriters and may vary from the market price of our Class&nbsp;A common stock following the completion of this offering. An active
or liquid market in our Class&nbsp;A common stock may not develop upon completion of this offering or, if it does develop, it may not be sustainable. In the absence of an active trading market for our Class&nbsp;A common stock, you may not be able
to resell any shares you hold at or above the initial public offering price or at all. An inactive market may also impair our ability to raise capital to continue to fund operations by selling shares and may impair our ability to acquire other
companies or technologies by using our shares as consideration. We cannot predict the prices at which our Class&nbsp;A common stock will trade. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We do not intend to pay dividends for the foreseeable future. Consequently, any gains from an investment in our
Class&nbsp;A common stock will depend on whether the price of our Class&nbsp;A common stock increases. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have
never declared or paid cash dividends on our capital stock. We currently intend to retain any future earnings to finance the operation and expansion of our business and we do not expect to declare or pay any dividends in the foreseeable future.
Moreover, the terms of instruments relating to debt we may incur in the future may restrict our ability to pay dividends. In addition, Delaware law may impose requirements that may restrict our ability to pay dividends to holders of our Class&nbsp;A
common stock. As a result, appreciation, if any, in the market price of our Class&nbsp;A common stock will be your sole source of gain for the foreseeable future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If securities or industry analysts do not publish research, if they publish inaccurate or unfavorable research about our
business, or if our financial results differ from the guidance we provide to the public, the price of our Class&nbsp;A common stock and trading volume could decline. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The trading market for our Class&nbsp;A common stock will depend in part on the research and reports that securities or
industry analysts publish about us or our business, our market, and our competitors. We do not currently have and may never obtain research coverage by securities and industry analysts. We do not have any
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
control over these analysts. If we fail to meet the expectations of these analysts, our stock price could be adversely affected. If no or few securities analysts commence coverage of us, the
trading price for our Class&nbsp;A common stock would be negatively affected. In the event we obtain securities or industry analyst coverage, if one or more of the analysts who cover us downgrade our Class&nbsp;A common stock or publish inaccurate
or unfavorable research about our business, our Class&nbsp;A common stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, demand for our Class&nbsp;A common stock could
decrease, which may cause our Class&nbsp;A common stock price and trading volume to decline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the stock
prices of many companies in the digital health industry have declined significantly after those companies failed to meet the financial guidance publicly announced by the companies or the expectations of analysts, and stock prices have even declined
significantly after such companies exceeded, or even significantly exceeded, such guidance or expectations. If our financial results fail to meet our announced guidance or the expectations of analysts or public investors, or even if our financial
results exceed, or even significantly exceed, such guidance or expectations, or if we reduce our guidance for future periods, our stock price may decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The dual class structure of our common stock will have the effect of concentrating voting control with the holders of
our Class&nbsp;B common stock and our executive officers and directors, including our Founders, and significant stockholders, who will collectively hold in the aggregate &#8195; % of the voting power of our capital stock following the completion of
this offering. This ownership will limit or preclude your ability to influence corporate matters, including the election of directors, amendments of our organizational documents, and any merger, consolidation, sale of all or substantially all of our
assets, or other major corporate transaction requiring stockholder approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each share of our Class&nbsp;A common
stock, which is the stock we are offering by means of this prospectus, is entitled to one vote. Each share of our Class&nbsp;B common stock is entitled to 15 votes. Prior to this offering, as of &#8195;&#8195;&#8195;,&#8195;&#8195;&#8195; , our
executive officers and directors, including our Founders, and stockholders who owned more than 5% of our outstanding common stock and their respective affiliates held, in the aggregate, shares representing approximately &#8195;% of the voting power
of our outstanding capital stock. Upon the closing of this offering, that same group will, in the aggregate, hold shares representing approximately &#8195; % of the voting power of our outstanding capital stock (assuming no exercise of the
underwriters&#146; option to purchase additional shares and no exercise of outstanding options or settlement of RSUs). Our Founders will hold shares of our common stock representing, in the aggregate, approximately&#8195;% of the voting power of our
outstanding capital stock, which voting power may increase over time as our Founders exercise or vest in equity awards outstanding at the time of the completion of this offering. As directors, and as an officer in the case of Mr.&nbsp;Perez, Messrs.
Perez and Mecklenburg owe a fiduciary duty to our stockholders to act in good faith in a manner they reasonably believe to be in the best interests of our stockholders. As stockholders, Messrs. Perez and Mecklenburg are entitled to vote their
shares, and shares over which they have voting control as a result of voting agreements, in their own interests, which may not always be in the interests of our stockholders generally. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As a result of our dual class structure, Class&nbsp;B stockholders, including our Founders, will be able to significantly
influence all matters submitted to our stockholders for approval, as well as our management and affairs, particularly if they were to choose to act together. For example, these persons, if they choose to act together, would control or significantly
influence the election of directors and approval of any merger, consolidation, or sale of substantially all of our assets. This concentration of ownership control may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delay or prevent a change in control; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">entrench our management and board of directors; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">impede a merger, consolidation, takeover, or other business combination involving us that other stockholders
may desire. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, future transfers by holders of Class&nbsp;B common stock will generally result
in those shares converting to Class&nbsp;A common stock, subject to limited exceptions, such as certain transfers effected for estate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
planning purposes. The conversion of Class&nbsp;B common stock to Class&nbsp;A common stock will have the effect, over time, of increasing the relative voting power of those holders of
Class&nbsp;B common stock who retain their shares in the long term. As a result, it is possible that one or more of the persons or entities holding our Class&nbsp;B common stock could gain significant voting control as other holders of Class&nbsp;B
common stock sell or otherwise convert their shares into Class&nbsp;A common stock. See the section titled &#147;Description of Capital Stock&#148; for additional information regarding our capital stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, while we do not expect to issue any additional shares of Class&nbsp;B common stock following this offering, any
future issuances of Class&nbsp;B common stock would dilute the voting power of the holders of Class&nbsp;A common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We cannot predict the impact our dual class structure may have on the market price of our Class&nbsp;A common stock.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our dual class structure may result in a lower or more volatile market price of our Class&nbsp;A common stock, in
adverse publicity, or in other adverse consequences. Certain index providers have announced restrictions on including companies with multiple class share structures in certain of their indices. Accordingly, the dual class structure of our common
stock would make us ineligible for inclusion in indices with such restrictions. Given the sustained flow of investment funds into passive strategies that seek to track certain indices, exclusion from stock indices would likely preclude investment by
many of these funds and could make our Class&nbsp;A common stock less attractive to other investors. In addition, several stockholder advisory firms and large institutional investors have been critical of the use of multi-class structures. Such
stockholder advisory firms may publish negative commentary about our corporate governance practices or our capital structure, which may dissuade large institutional investors from purchasing shares of our Class&nbsp;A common stock. As a result, the
market price of our Class&nbsp;A common stock could be materially adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Sales, directly or
indirectly, of a substantial amount of our Class&nbsp;A common stock in the public markets by our existing security holders may cause the price of our Class&nbsp;A common stock to decline. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Sales of a substantial number of shares of our Class&nbsp;A common stock into the public market, including shares of
Class&nbsp;A common stock issued upon conversion of Class&nbsp;B common stock and in particular sales by our directors, executive officers, and principal stockholders, or the perception that these sales might occur, could cause the market price of
our Class&nbsp;A common stock to decline. Many of our existing security holders have substantial unrecognized gains on the value of the equity they hold and may take steps to sell their shares or otherwise secure or limit their risk exposure to the
value of their unrecognized gains on those shares. We are unable to predict the timing or effect of such sales on the market price of our Class&nbsp;A common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All shares of Class&nbsp;A common stock sold in this offering will be freely tradable without restrictions or further
registration under the Securities Act, except that any shares held by our affiliates, as defined in Rule 144 under the Securities Act, would only be able to be sold in compliance with Rule 144 and any applicable
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We, all of our directors and executive
officers, the selling stockholders, and certain other record holders that, based upon the number of shares outstanding as of &#8195;&#8195;&#8195;,&#8195;&#8195;&#8195;, together represent approximately&#8195;% of our outstanding Class&nbsp;A common
stock and securities directly or indirectly convertible into or exchangeable or exercisable for our Class&nbsp;A common stock are subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements or market standoff agreements that restrict our
and their ability to sell or transfer shares of our capital stock for a period of&#8195;&#8195;&#8195;&#8195;days from the date of this prospectus, subject to certain exceptions. In addition, the representatives may release certain stockholders from
the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements prior to the end of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If not otherwise released early, when the applicable market standoff agreements or
<FONT STYLE="white-space:nowrap">lock-up</FONT> periods expire, we and our stockholders subject thereto will be able to sell shares of our Class&nbsp;A common stock freely in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
public market, except that any shares held by our affiliates, as defined in Rule 144 under the Securities Act, would only be able to be sold in compliance with Rule 144. Sales of a substantial
number of such shares upon expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements and market standoff agreements, or the perception that such sales may occur, or early release of these agreements, could cause the market price
of our Class&nbsp;A common stock to fall or make it more difficult for you to sell your Class&nbsp;A common stock at a time and price that you deem appropriate. See the section titled &#147;Shares Eligible for Future Sale&#148; for additional
information regarding shares of our Class&nbsp;A common stock that will be eligible for resale after this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In
addition, as of&#8195;&#8195;&#8195;&#8195;, &#8195;&#8195;&#8195;&#8195;, we had stock options outstanding that, if fully exercised, would result in the issuance of&#8195;&#8195;&#8195;&#8195;shares of Class&nbsp;A common stock, including
&#8195;&#8195;&#8195;&#8195; such shares that are exchangeable for an equal number of shares of Class&nbsp;B common stock, as well as &#8195;&#8195;&#8195;&#8195;shares of our Class&nbsp;A common stock issuable upon vesting of outstanding RSUs. The
shares of Class&nbsp;A common stock subject to outstanding stock options and RSUs, and the shares reserved for future issuance under our equity incentive plans will be registered for public resale under the Securities Act. Accordingly, these shares
will be able to be freely sold in the public market upon issuance subject to existing <FONT STYLE="white-space:nowrap">lock-up</FONT> or market standoff agreements and applicable vesting requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Further, based on shares outstanding as of&#8195;&#8195;&#8195;&#8195;, &#8195;&#8195;&#8195;&#8195;, certain holders of
shares of our common stock will have rights after the completion of this offering, subject to certain conditions, to require us to file registration statements for the public resale of shares of our Class&nbsp;A common stock or to include such
shares in registration statements that we may file for us or other stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We will have broad discretion in
the use of the net proceeds we receive in this offering and may not use them in ways that prove to be effective. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We will have broad discretion in the use of the net proceeds we receive in this offering, including for any of the purposes
described in the section titled &#147;Use of Proceeds,&#148; and you will not have the opportunity as part of your investment decision to assess whether the net proceeds are being used appropriately. Because of the number and variability of factors
that will determine our use of the net proceeds from this offering, their ultimate use may vary substantially from their currently intended use, and it is possible that a substantial portion of the net proceeds will be invested in a way that does
not yield a favorable, or any, return for us. If we do not use the net proceeds that we receive in this offering effectively, our business, results of operations, and financial condition could be materially adversely affected, and the market price
for our Class&nbsp;A common stock could decline. Pending their use, we may invest the net proceeds from this offering in short-term, investment-grade, interest-bearing instruments, including government and investment-grade debt securities,
commercial paper, and money-market funds. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Purchasers of Class&nbsp;A common stock in this offering will experience
immediate and substantial dilution in the book value of their investment. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The initial public offering price of our
Class&nbsp;A common stock of $&#8195;&#8195;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, is substantially higher than the pro forma as adjusted net tangible book value per share of our
Class&nbsp;A common stock to be outstanding immediately after this offering. Therefore, if you purchase our Class&nbsp;A common stock in this offering, you will incur immediate dilution of $&#8195;&#8195;per share in the pro forma as adjusted net
tangible book value from the price you paid assuming a price to the public of $&#8195;&#8195;per share of Class&nbsp;A common stock, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting
underwriting discounts and commissions and estimated offering expenses payable by us. This dilution is due to the substantially lower price paid by our investors who purchased shares prior to this offering as compared to the price paid by the public
in this offering. If the underwriters exercise their option to purchase additional shares, if we issue any additional stock options or warrants or any outstanding stock options are exercised, if RSUs are settled, or if we issue any other securities
convertible to or exchangeable for our Class&nbsp;A common stock in the future, investors will experience further </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
dilution. For a further description of the dilution that investors will experience immediately after this offering, see the section titled &#147;Dilution.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Anti-takeover provisions contained in our amended and restated certificate of incorporation and amended and restated
bylaws, as well as provisions of Delaware law, could impair a takeover attempt. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated
certificate of incorporation and amended and restated bylaws, which will become effective immediately prior to the completion of this offering, contain, and Delaware law contains, provisions which could have the effect of rendering more difficult,
delaying, or preventing an acquisition deemed undesirable by our board of directors. These provisions will provide for the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a dual class common stock structure which provides our holders of Class&nbsp;B common stock with the ability
to significantly influence the outcome of matters requiring stockholder approval, even if they own significantly less than a majority of the shares of our outstanding Class&nbsp;A common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a classified board of directors with three-year staggered terms, who can only be removed for cause, which may
delay the ability of stockholders to change the membership of a majority of our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect
director candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the exclusive right of our board of directors to set the size of the board of directors and to elect a
director to fill a vacancy, however occurring, including by an expansion of the board of directors, which prevents stockholders from being able to fill vacancies on our board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine
the price and other terms of those shares, including voting or other rights or preferences, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of our board of directors to adopt, amend, or repeal our amended and restated bylaws without
obtaining stockholder approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in addition to our board of director&#146;s ability to adopt, amend, or repeal our amended and restated
bylaws, our stockholders may adopt, amend, or repeal our amended and restated bylaws only with the affirmative vote of the holders of at least 66 2/3% of the voting power of all our then-outstanding shares of capital stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the required approval of at least 66 2/3% of the voting power of the outstanding shares of capital stock
entitled to vote generally in the election of directors, voting together as a single class, to adopt, amend, or repeal certain provisions of our amended and restated certificate of incorporation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the requirement that a special meeting of stockholders may be called only by a majority of our board of
directors, the chairperson of our board of directors, or our Chief Executive Officer; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of
directors or to propose matters to be acted upon at a stockholders&#146; meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#146;s own slate of directors or otherwise
attempting to obtain control of us; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the limitation of liability of, and provision of indemnification to, our directors and officers.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or
changes in our management. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As a Delaware corporation, we are also subject to provisions of Delaware law, including
Section&nbsp;203 of the General Corporation Law of the State of Delaware (&#147;DGCL&#148;), which prevents some stockholders holding more </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
than 15% of our outstanding common stock from engaging in certain business combinations without approval of the holders of substantially all of our outstanding common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any provision of our amended and restated certificate of incorporation, amended and restated bylaws or Delaware law that has
the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common
stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Claims for indemnification by our directors and officers may reduce our available funds to satisfy
successful third-party claims against us and may reduce the amount of money available to us. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and
restated certificate of incorporation and amended and restated bylaws, which will become effective immediately prior to the completion of this offering, provide that we will indemnify our directors and officers, in each case to the fullest extent
permitted by Delaware law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, as permitted by Section&nbsp;145 of the DGCL, our amended and restated bylaws to
be effective immediately prior to the completion of this offering and our indemnification agreements that we have entered or intend to enter into with our directors and officers provide that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we will indemnify our directors and officers to the fullest extent permitted by the DGCL. The DGCL provides
that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no
reasonable cause to believe such person&#146;s conduct was unlawful; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may, in our discretion, indemnify employees and agents in those circumstances where indemnification is
permitted by applicable law; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are required to advance expenses, as incurred, to our directors and officers in connection with defending a
proceeding, except that such directors or officers will undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rights conferred in our amended and restated bylaws are not exclusive, and we are authorized to enter into
indemnification agreements with our directors, officers, employees, and agents and to obtain insurance to indemnify such persons; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not retroactively amend our amended and restated bylaw provisions to reduce our indemnification
obligations to directors, officers, employees, and agents. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While we have procured directors&#146; and
officers&#146; liability insurance policies, such insurance policies may not be available to us in the future at a reasonable rate, may not cover all potential claims for indemnification, and may not be adequate to indemnify us for all liability
that may be imposed. Additionally, given the significant increase in the costs of directors&#146; and officers&#146; insurance policies recently, we may subsequently decide to select lower overall policy limits or forgo insurance altogether that we
would otherwise rely upon to cover applicable defense costs, settlements, and damages awards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our amended and
restated certificate of incorporation and amended and restated bylaws will provide that the Court of Chancery of the State of Delaware will be the exclusive forum for certain disputes between us and our stockholders, and that the federal district
courts of the United States will be the exclusive forum for the resolution of any complaint asserting a cause of action under the Securities Act. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation and amended and restated bylaws, which will become effective immediately
prior to the completion of this offering, will provide that: (i)&nbsp;unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if such court does not
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
have subject matter jurisdiction thereof, the federal district court of the State of Delaware) will, to the fullest extent permitted by law, be the sole and exclusive forum for: (A)&nbsp;any
derivative action or proceeding brought on our behalf, (B)&nbsp;any action asserting a claim for, or based on, a breach of a fiduciary duty owed by any of our current or former directors, officers, other employees, agents, or stockholders to us or
our stockholders including, without limitation, a claim alleging the aiding and abetting of such a breach of fiduciary duty, (C)&nbsp;any action asserting a claim against us or any of our current or former directors, officers, employees, agents, or
stockholders arising pursuant to any provision of the DGCL, our amended and restated certificate of incorporation or amended and restated bylaws, or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware, or
(D)&nbsp;any action asserting a claim related to or involving us that is governed by the internal affairs doctrine; (ii)&nbsp;unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States
will, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act, and the rules and regulations promulgated thereunder, although there is
uncertainty as to whether a court would enforce this provision; (iii)&nbsp;any person or entity purchasing or otherwise acquiring or holding any interest in shares of our capital stock will be deemed to have notice of and consented to these
provisions; and (iv)&nbsp;failure to enforce the foregoing provisions would cause us irreparable harm, and we will be entitled to equitable relief, including injunctive relief and specific performance, to enforce the foregoing provisions. Nothing in
our amended and restated certificate of incorporation or amended and restated bylaws precludes stockholders that assert claims solely under the Exchange Act, from bringing such claims in federal court to the extent that the Exchange Act confers
exclusive federal jurisdiction over such claims, subject to applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The choice of forum provisions may limit a
stockholder&#146;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our current or former directors, officers, other employees, agents, or stockholders, which may discourage such claims against us
or any of our current or former directors, officers, other employees, agents, or stockholders and result in increased costs for investors to bring such a claim. We believe these provisions may benefit us by providing increased consistency in the
application of the DGCL and federal securities laws by chancellors and judges, as applicable, particularly experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative to other forums, and
protection against the burdens of multi-forum litigation. If a court were to find the choice of forum provision contained in our amended and restated certificate of incorporation or our amended and restated bylaws to be inapplicable or unenforceable
in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business, results of operations, financial condition, and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General Risk Factors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The estimates of market opportunity and forecasts of market growth as well as the calculation of certain operational
metrics included in this prospectus may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth, our business could fail to grow at similar rates, or at all. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The estimates of market opportunity and forecasts of market growth included in this prospectus may prove to be inaccurate.
Market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates that may not prove to be accurate, including as a result of any of the risks described in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The variables that go into the calculation of our market opportunity are subject to change over time, and there is no
guarantee that any particular number or percentage of addressable clients covered by our market opportunity estimates will purchase our platform and programs at all or generate any particular level of revenue for us. Even if the markets in which we
compete meet the size estimates and growth forecasted in this prospectus, our business could fail to grow at similar rates, or at all. Our growth is subject to many factors, including our success in implementing our business strategy, which is
subject to many risks and uncertainties. Accordingly, the forecasts of market growth included in this prospectus should not be taken as indicative of our future growth. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, we calculate operational metrics using internal systems and
tools that are not independently verified by any third party. These metrics may differ from estimates or similar metrics published by third parties or other companies due to differences in sources, methodologies, or the assumptions on which we rely.
Our internal systems and tools have a number of limitations, and our methodologies for tracking these metrics may change over time, which could result in unexpected changes to our metrics, including the metrics we publicly disclose on an ongoing
basis. If the internal systems and tools we use to track these metrics undercount or overcount performance or contain algorithmic or other technical errors, the data we present may not be accurate. In addition, limitations or errors with respect to
how we measure data or with respect to the data that we measure may affect our understanding of certain details of our business, which would affect our long-term strategies. If our operating metrics or our estimates are not accurate representations
of our business, or if investors do not perceive our operating metrics to be accurate, or if we discover material inaccuracies with respect to these figures, our reputation may be significantly harmed, and our results of operations, and financial
condition could be adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Uncertain or unfavorable conditions in our industry or the global economy,
including those caused by inflation, fluctuations in interest rates, ongoing conflicts around the world, natural disasters, or other catastrophic events could limit our ability to grow our business and negatively affect our results of operations.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our results of operations may vary based on the impact of changes in our industry or the global economy on us or
our clients or potential clients. Negative conditions in the general economy both in the United States and abroad, including conditions resulting from changes in gross domestic product growth, financial and credit market fluctuations, inflation and
efforts to control further inflation, fluctuations in interest rates, liquidity concerns at financial institutions, international trade relations, political turmoil, including the conflicts in Ukraine and the Middle East, natural catastrophes,
warfare and terrorist attacks in the United States, Europe, the Asia Pacific region, or elsewhere, could cause a decrease in business investments by existing or potential clients and negatively affect the growth of our business. To the extent there
is a sustained general economic downturn, our revenue, business, and results of operations may be affected by reductions in overall spending on healthcare technology and elective healthcare. Competitors, many of whom are larger and have greater
financial resources than we do, may respond to challenging market conditions by lowering prices in an attempt to attract clients for whom we compete. We cannot predict the timing, strength, or duration of any economic slowdown, instability, or
recovery, generally or within any particular industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, natural disasters or other catastrophic events may
also cause damage or disruption to our operations, international commerce and the global economy and could have an adverse effect on our business, results of operations, and financial condition. Our business operations are subject to interruption by
natural disasters, fire, power shortages, and other events beyond our control. In addition, our global operations expose us to risks associated with public health crises, such as pandemics and epidemics, which could materially adversely affect our
business, results of operations, and financial condition. Further, acts of terrorism, labor activism, or unrest and other geopolitical unrest could cause disruptions in our business or the economy as a whole. In the event of a natural disaster,
including a major earthquake, blizzard, hurricane, or a catastrophic event such as a fire, power loss or telecommunications failure, we may be unable to continue our operations and may endure system interruptions, reputational and brand harm, delays
in development, lengthy interruptions in service, breaches of data security and loss of critical data, all of which could have a material adverse effect on our business, results of operations, and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Natural catastrophic events and <FONT STYLE="white-space:nowrap">man-made</FONT> problems such as power disruptions,
computer viruses, global pandemics, data security breaches and terrorism may disrupt our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We rely heavily
on our network infrastructure and IT systems for our business operations. An online attack, damage as a result of civil unrest, earthquake, fire, terrorist attack, power loss, global pandemics, telecommunications failure or other similar
catastrophic events could cause system interruptions, delays in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
accessing our service, reputational harm and loss of critical data. Such events could prevent clients and members from accessing our platform and programs. A catastrophic event that results in
the destruction or disruption of our data centers, or our network infrastructure or IT systems, including any errors, defects, or failures in third-party hardware, could affect our ability to conduct normal business operations and adversely affect
our results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, as computer malware, viruses, computer hacking, fraudulent use attempts, and
phishing attacks have become more prevalent, we face increased risk from these activities. These activities threaten the performance, reliability, security, and availability of our platform and programs. Any computer malware, viruses, computer
hacking, fraudulent use attempts, phishing attacks, or other data security breaches to our systems could, among other things, harm our reputation and our ability to retain existing clients and attract new clients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our corporate headquarters are located in the San Francisco Bay Area, which has experienced both severe earthquakes and
wildfires. We do not carry earthquake insurance. Furthermore, integral parties in our supply chain are similarly vulnerable to natural disasters or other sudden, unforeseen, and severe adverse events. If such an event were to affect our supply
chain, it could have a material adverse effect on our business, results of operations, and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our
insurance strategy may not be adequate to protect us from all business risks. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the ordinary course of business,
we may be subject to losses resulting from general liability, consumer actions, accidents, acts of God and other claims against us, for which we may have no insurance coverage. While we currently carry commercial general liability, excess liability,
workers&#146; compensation, employment practices liability, cyber security, and directors&#146; and officers&#146; insurance policies, we may not maintain as much insurance coverage as other competitors do, and in some cases, we may not maintain any
at all. Additionally, the policies that we do have may include significant deductibles, and we cannot be certain that our insurance coverage will be sufficient to cover all future claims against us. A loss that is uninsured or exceeds policy limits
may require us to pay substantial amounts, which could adversely affect our business, results of operations, and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our management has limited experience in operating a public company. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Certain of our executive officers have limited, or no, experience in the management of a publicly traded company. Our
management team may not successfully or effectively manage our transition to a public company that will be subject to significant regulatory oversight and reporting obligations under federal securities laws. Their limited experience in dealing with
the increasingly complex laws pertaining to public companies could be a significant disadvantage in that it is likely that an increasing amount of their time may be devoted to these activities which will result in less time being devoted to the
management and growth of our business. We may not have adequate personnel with the appropriate level of knowledge, experience, and training in the accounting policies, practices or internal controls over financial reporting required of public
companies in the United States. The development and implementation of the standards and controls necessary for us to achieve the level of accounting standards required of a public company in the United States may require costs greater than expected.
It is possible that we will be required to expand our employee base and hire additional employees to support our operations as a public company, which will increase our operating costs in future periods. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We will incur significant additional costs and become subject to additional regulations and requirements as a result of
being a public company, and our management will be required to devote substantial time to compliance with our public company responsibilities and corporate governance practices. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As a public company, we will incur significant legal, accounting, and other expenses that we have not incurred as a private
company. We will be subject to the reporting requirements of the Exchange Act, the applicable requirements of the Sarbanes-Oxley Act, the Dodd-Frank Act, the rules and regulations of the SEC, and the listing rules of&#8195;&#8195;&#8195;&#8195;.
Stockholder activism and the level of government intervention and regulatory </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
reform may lead to substantial new regulations and disclosure obligations, which may lead to additional significant compliance costs and impact the manner in which we operate our business in ways
we cannot currently anticipate. The increased costs will increase our net loss or decrease our net income and may require us to reduce costs in other areas of our business. For example, we expect these rules and regulations to make it more difficult
and more expensive for us to obtain director and officer liability insurance. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, on our board
committees or as executive officers. Furthermore, if we are unable to satisfy our obligations as a public company, we could be subject to delisting of our Class&nbsp;A common stock, fines, sanctions and other regulatory action and potentially civil
litigation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We cannot predict or estimate the amount of additional costs we will incur as a public company or the timing
of such costs. In addition, our management team will need to devote substantial attention to transitioning to interacting with public company analysts and investors and complying with the increasingly complex laws pertaining to public companies,
which may divert attention away from the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> management of our business, including operational, research and development, and sales and marketing activities.
Increases in costs incurred or diversion of management&#146;s attention as a result of becoming a publicly traded company may adversely affect our business, results of operations, and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>A failure to establish and maintain an effective system of disclosure controls and procedures and internal control over
financial reporting, could adversely affect our ability to produce timely and accurate financial statements or comply with applicable regulations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As a public company, we will be required to maintain disclosure controls and procedures and internal control over financial
reporting and to report weaknesses in such internal controls. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. We are continuing to
develop and refine our disclosure controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we will file with the SEC is recorded, processed, summarized, and reported within the
time periods specified in SEC rules and forms and that information required to be disclosed in reports under the Exchange Act is accumulated and communicated to our principal executive and financial officers. We are also continuing to improve our
internal control over financial reporting. For example, as we have prepared to become a public company, we have worked to improve the controls around our key accounting processes and our quarterly close process, and we have hired additional
accounting and finance personnel to help us implement these processes and controls. The process of designing, implementing, and testing the internal control over financial reporting required to comply with this obligation is time-consuming, costly,
and complicated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In order to maintain and improve the effectiveness of our disclosure controls and procedures and
internal control over financial reporting, we have expended, and anticipate that we will continue to expend, significant resources, including accounting-related costs and investments to strengthen our accounting systems. If any of these new or
improved controls and systems do not perform as expected, we may experience material weaknesses in our controls. Further, we may not have adequate personnel with the appropriate level of knowledge, experience, and training in the accounting
policies, practices or internal controls over financial reporting required of public companies in the United States. It is possible that we will be required to expand our employee base and hire additional employees to support our operations as a
public company, which will increase our operating costs in future periods. The development and implementation of the standards and controls necessary for us to achieve the level of accounting standards required of a public company in the United
States may require costs greater than expected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, current controls and any new controls that we develop may
become inadequate because of changes in conditions in our business. Further, weaknesses in our disclosure controls and internal control over financial reporting may be discovered in the future. Any failure to develop or maintain effective controls
or any difficulties encountered in their implementation or improvement could materially adversely affect our results of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
operations or cause us to fail to meet our reporting obligations and may result in a restatement of our consolidated financial statements for prior periods. Any failure to implement and maintain
effective internal control over financial reporting also could materially adversely affect the results of periodic management evaluations and annual independent registered public accounting firm attestation reports regarding the effectiveness of our
internal control over financial reporting that we may be required to include in our periodic reports that will be filed with the SEC. Ineffective disclosure controls and procedures and internal control over financial reporting could also cause
investors to lose confidence in our reported financial and other information, which would likely have a negative effect on the trading price of our Class&nbsp;A common stock. In addition, if we are unable to continue to meet these requirements, we
may not be able to remain listed on the&#8195;&#8195;&#8195;&#8195;. We are not currently required to comply with the SEC rules that implement Section&nbsp;404 of the Sarbanes-Oxley Act and are therefore not required to make a formal assessment of
the effectiveness of our internal control over financial reporting for that purpose. As a public company, we will be required to provide an annual management report on the effectiveness of our internal control over financial reporting commencing
with our second annual report on Form <FONT STYLE="white-space:nowrap">10-K.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our independent registered public
accounting firm is not required to formally attest to the effectiveness of our internal control over financial reporting until after we are no longer an &#147;emerging growth company&#148; as defined in the JOBS Act. At such time, our independent
registered public accounting firm may issue a report that is adverse if it is not satisfied with the level at which our internal control over financial reporting is documented, designed, or operating. Any failure to maintain effective disclosure
controls and internal control over financial reporting could materially adversely affect our business, results of operations, and financial condition and could cause a decline in the trading price of our Class&nbsp;A common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We are an &#147;emerging growth company&#148; and our compliance with the reduced reporting and disclosure requirements
applicable to emerging growth companies may make our Class&nbsp;A common stock less attractive to investors. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We
are an &#147;emerging growth company,&#148; as defined in the JOBS Act, and we have elected to take advantage of certain exemptions and relief from various reporting requirements that are applicable to other public companies that are not emerging
growth companies. These provisions include, but are not limited to: being permitted to have only two years of audited financial statements and only two years of related management&#146;s discussion and analysis of financial condition and results of
operations disclosures in the registration statement of which this prospectus forms a part; being exempt from compliance with the auditor attestation requirements of Section&nbsp;404(b) of the Sarbanes-Oxley Act; being exempt from any rules that
could be adopted by the Public Company Accounting Oversight Board requiring mandatory audit firm rotations or a supplement to the auditor&#146;s report on financial statements; being subject to reduced disclosure obligations regarding executive
compensation in our periodic reports and proxy statements; and not being required to hold nonbinding advisory votes on executive compensation or on any golden parachute payments not previously approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, while we are an emerging growth company, we have elected not to be required to comply with any new financial
accounting standard until such standard is generally applicable to private companies. As a result, our financial statements may not be comparable to companies that are not emerging growth companies or elect not to avail themselves of this provision.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We will remain an emerging growth company until the earlier to occur of: (1)&nbsp;the last day of the fiscal year in
which we have more than $1.235&nbsp;billion in total annual revenue, which threshold is subject to adjustment; (2)&nbsp;the date we qualify as a &#147;large accelerated filer,&#148; with $700.0&nbsp;million or more of equity securities held by <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> as of the last business day of our most recently completed second fiscal quarter; (3)&nbsp;the date on which we have issued, in any three-year period, more than $1.0&nbsp;billion in <FONT
STYLE="white-space:nowrap">non-convertible</FONT> debt securities; and (4)&nbsp;the last day of the fiscal year ending after the fifth anniversary of the completion of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The exact implications of the JOBS Act are still subject to interpretations and guidance by the SEC and other regulatory
agencies, and we cannot assure you that we will be able to take advantage of all of the benefits </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
of the JOBS Act. In addition, investors may find our Class&nbsp;A common stock less attractive to the extent we rely on the exemptions and relief granted by the JOBS Act. If some investors find
our Class&nbsp;A common stock less attractive as a result, there may be a less active trading market for our Class&nbsp;A common stock and our stock price may decline or become more volatile. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The increasing focus on environmental, social, and governance initiatives could increase our costs, harm our reputation,
and adversely impact our business, results of operations, and financial condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There has been increasing
public focus by various stakeholders, including but not limited to investors, environmental activists, the media, and governmental and nongovernmental organizations, on a variety of environmental, social, and governance (&#147;ESG&#148;) and other
sustainability matters. Such increased scrutiny may result in increased costs, changes in demands for our platform or certain programs, enhanced compliance or disclosure obligations, or other adverse impacts on our business, results of operations,
and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From time to time, we may create and publish voluntary disclosures regarding ESG matters.
Identification, assessment, and disclosure of such matters is complex. Certain statements may be based on expectations, assumptions, or third-party information that we currently believe to be reasonable but may subsequently be determined to be
erroneous or be subject to misinterpretation. Additionally, expectations regarding companies&#146; management of ESG matters continue to evolve rapidly, in many instances due to factors that are out of our control. ESG regulation and enforcement are
also evolving rapidly, and we may be subject to investor or regulator engagement on our ESG disclosures even though we currently make them voluntarily. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Furthermore, certain market participants, including major institutional investors and capital providers, use third-party
benchmarks or scores to measure our ESG practices in making investment or voting decisions. Unfavorable ESG ratings could lead to increased negative investor sentiment towards us or our industry, which could negatively impact our share price as well
as our access to and cost of capital. To the extent ESG matters negatively impact our reputation, it may also impede our ability to compete as effectively to attract and retain employees or clients, which may adversely impact our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To the extent we do adopt certain ESG practices or policies, we may experience increased costs or be required to forego
certain business opportunities in order to execute them; however, we cannot guarantee that such efforts will have the intended results. By contrast, any failure, or perceived failure, to pursue or conform to such policies, goals, or initiatives
(including the manner in which we achieve some or any portion of our goals) within the timelines we announce, or at all, could adversely impact our reputation or business activities, including but not limited to potential enforcement actions or
private litigation. As ESG best practices, reporting standards and regulatory requirements continue to develop, we may incur increasing costs related to ESG monitoring and reporting. Such ESG matters may also impact our suppliers and clients, which
may compound or cause new impacts on our business, results of operations, and financial condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom829170_5"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This prospectus contains forward-looking statements about us and our industry that involve substantial risks and
uncertainties. All statements other than statements of historical facts contained in this prospectus, including statements regarding our strategy, future financial condition, future operations, projected costs, prospects, plans, objectives of
management, and expected market growth, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as &#147;may,&#148; &#147;will,&#148; &#147;shall,&#148; &#147;should,&#148;
&#147;expects,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;could,&#148; &#147;intends,&#148; &#147;target,&#148; &#147;projects,&#148; &#147;contemplates,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;predicts,&#148;
&#147;potential,&#148; &#147;goal,&#148; &#147;objective,&#148; &#147;seeks,&#148; or &#147;continue,&#148; or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans, or intentions.
Forward-looking statements contained in this prospectus include, but are not limited to, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain clients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract, enroll, and retain members; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain relationships with partners; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to estimate the size of our target market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the demand for MSK pain treatment and prevention solutions in general, and the demand for our platform in
particular; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to enhance our platform and programs or develop new programs, capabilities, and features;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the acceptance of remote MSK care; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to offer high-quality programs to our members; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expectations regarding the performance of our <FONT STYLE="white-space:nowrap">AI-driven</FONT> platform and
the ability of technology and AI to help deliver effective MSK care; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expectations regarding the ability of AI to provide support for our care team; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to deliver a return on investment for our clients and positive outcomes for our members;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to compete successfully in our competitive market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to contract with qualified licensed health professionals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain high ratings and reviews of our platform; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our future financial performance, including revenue, cost of revenue, and gross profit; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to achieve or maintain profitability; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to protect our brand; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding our sales and marketing efforts and investments, including our <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">go-to-market</FONT></FONT> strategy; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully execute on our growth initiatives, business strategies, or operating plans
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain key personnel and highly-qualified personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to develop, maintain, and protect our intellectual property; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to expand into new markets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to protect our client and member information in compliance with privacy and data protection laws;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to comply with changing laws and regulations; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the healthcare regulatory environment, particularly in states where new regulations regarding
telehealth are being enacted; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the increased expenses associated with being a public company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations and management of future growth; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">impact from future regulatory, judicial, and legislative changes or developments that may affect our
customers&#146; or our business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risks related to our Class&nbsp;A common stock and our dual class common stock structure; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our anticipated use of net proceeds from our initial public offering. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We caution you that the foregoing list does not contain all of the forward-looking statements made in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">You should not rely upon forward-looking statements as predictions of future events. We have based the forward-looking
statements contained in this prospectus primarily on our current expectations, estimates, forecasts, and projections about future events and trends that we believe may affect our business, results of operations, and financial condition. Although we
believe that we have a reasonable basis for each forward-looking statement contained in this prospectus, we cannot guarantee that the future results, levels of activity, performance, or events and circumstances reflected in the forward-looking
statements will be achieved or occur at all. The outcome of the events described in these forward-looking statements is subject to risks, uncertainties, and other factors described in the section titled &#147;Risk Factors&#148; and elsewhere in this
prospectus. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the
forward-looking statements contained in this prospectus. The results, events, and circumstances reflected in the forward-looking statements may not be achieved or occur, and actual results, events, or circumstances could differ materially from those
described in the forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The forward-looking statements made in this prospectus relate only to events
as of the date on which the statements are made. We undertake no obligation to update any forward-looking statements made in this prospectus to reflect events or circumstances after the date of this prospectus or to reflect new information or the
occurrence of unanticipated events, except as required by law. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements.
Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, or investments we may make. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, statements that &#147;we believe&#148; and similar statements reflect our beliefs and opinions on the relevant
subject. These statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our
statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely upon these
statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">You should read this prospectus and the documents that we reference in this prospectus and have filed as
exhibits to the registration statement, of which this prospectus is a part, completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in
this prospectus with these cautionary statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom829170_6"></A>MARKET AND INDUSTRY DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This prospectus contains estimates, projections, and other information concerning our industry and our business, as well as
data regarding market research, estimates, and forecasts prepared by our management. Information that is based on estimates, forecasts, projections, market research, or similar methodologies is inherently subject to uncertainties, and actual events
or circumstances may differ materially from events and circumstances that are assumed in this information. The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of factors, including those described in
the section titled &#147;Risk Factors.&#148; These and other factors could cause results to differ materially from those expressed in these estimates, publications and reports made by third parties or us. Unless otherwise expressly stated, we
obtained this industry, business, market, and other data from reports, research surveys, studies, and similar data prepared by market research firms and other third parties, industry and general publications, government data, and similar sources.
While we have compiled, extracted, and reproduced industry data from these sources, we have not independently verified the data. Forecasts and other forward-looking information with respect to industry, business, market, and other data are subject
to the same qualifications and additional uncertainties regarding the other forward-looking statements in this prospectus. See the section titled &#147;Special Note Regarding Forward-Looking Statements&#148; for additional information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Among others, we refer to estimates compiled by the following industry sources: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Health claims data obtained from a <FONT STYLE="white-space:nowrap">de-identified</FONT> medical claims
database representing more than 100&nbsp;million commercially insured lives from January&nbsp;1, 2017 through December&nbsp;31, 2023, across all U.S. states and territories (the &#147;Health Claims Data&#148;). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cieza, Alarcos et al. <I>Global estimates of the need for rehabilitation based on the Global Burden of Disease
study 2019: a systematic analysis for the Global Burden of Disease Study 2019</I>. The Lancet vol. 396,10267 (2021): 2006-2017. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Briggs, Andrew M. et al. <I>Reducing the global burden of musculoskeletal conditions</I>. Bull. World Health
Organ. 2018 May <FONT STYLE="white-space:nowrap">1;96(5):366-368.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Institute for Health Metrics and Evaluation (&#147;IHME&#148;). <I>WHO Rehabilitation Need Estimator</I>.
IHME, University of Washington, 2021 (the &#147;WHO Estimator&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Dieleman, Joseph L. et al. <I>US Health Care Spending by Payer and Health Condition, 1996-2016</I>. JAMA.
2020;323(9):863&#150;884. Doi:10.1001/jama.2020.0734. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Business Group on Health. <I>2025 Employer Health Care Strategy Survey</I>. August 2024. Available at:
https://www.businessgrouphealth.org/resources/2025-Employer-Health-Care-Strategy-Survey-Intro (last accessed November&nbsp;7, 2024). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Lin, Ivan et al. <I>What does best practice care for musculoskeletal pain look like? Eleven consistent
recommendations from high-quality clinical practice guidelines: systematic review</I>. British Journal of Sports Medicine <FONT STYLE="white-space:nowrap">2020;54:79-86.</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">AIS Health, a division of Managed Markets Insight&nbsp;&amp; Technology, LLC (&#147;AIS Health&#148;),
<I>Insurance Market Data (as of 2021)</I>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">World Health Organization. <I>Musculoskeletal Health Fact Sheet</I>. Available at:
https://www.who.int/news-room/fact-sheets/detail/musculoskeletal-conditions (last accessed November&nbsp;7, 2024). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. Centers for Medicare and Medicaid Services. <I>Medicare Advantage/Part D Contract and Enrollment Data,
Monthly Contract Summary Report</I>. Available at:
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">https://www.cms.gov/data-research/statistics-trends-and-reports/medicare-advantagepart-d-contract-and-enrollment-data
</FONT></FONT></FONT></FONT></FONT></FONT><I> </I>(last accessed November&nbsp;7, 2024). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Bureau of Labor Statistics, U.S. Department of Labor, <I>Occupational Outlook Handbook</I>, Physical
Therapists. Available at: https://www.bls.gov/ooh/healthcare/physical-therapists.htm (last accessed November&nbsp;1, 2024). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Bailey, Jeannie F. et al. <I>Digital Care for Chronic Musculoskeletal Pain: 10,000 Participant Longitudinal
Cohort Study</I>. J. Med. Internet Res. (2020): 11;22(5):e18250 (the &#147;2020 Longitudinal Study&#148;). This study was sponsored, funded, or supported by Hinge Health. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Study based on HIPAA-compliant, <FONT STYLE="white-space:nowrap">de-identified</FONT> members&#146; medical
claims data at the time of enrollment and 12 months post-enrollment from over 4,200 members continuously enrolled in our chronic program between January 2019 and September 2021. Our study compared the medical claims data of members enrolled in our
chronic program to a matched control group that included those of our clients&#146; employees who were not enrolled in our chronic program (the &#147;2023 Employer Claims Study&#148;). This study was sponsored, funded, or supported by Hinge Health.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Shahidi, Bahar et al. <I>Factors impacting adherence to an exercise-based physical therapy program for
individuals with low back pain</I>. PloS One vol. 17,10 (2022): e0276326. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Kenne, Kimberly et al. <I>Prevalence of pelvic floor disorders in adult women being seen in a primary care
setting and associated risk factors</I>. Scientific Reports vol. 12,1 9878 (2022). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Newman, Diane et al. <I>Continence Promotion, Education</I><I></I><I>&nbsp;&amp; Primary Prevention</I>.
International Continence Society, 2021. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Schaeffer, Katherine, <I>U.S. centenarian population is projected to quadruple over the next 30 years</I>. Pew
Research Center, January 2024. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Center for Disease Control, <I>Older Adult Fall Prevention</I>, September 2024. Available at: <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">https://www.cdc.gov/falls/pdf/CDC-DIP_At-a-Glance_Falls_508.pdf</FONT></FONT></FONT> (last accessed November&nbsp;1, 2024). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Lu, Chang-Bo et al. <I>Musculoskeletal Pain during the Menopausal Transition: A Systematic Review and
Meta-Analysis</I>. Neural plasticity vol. 2020 8842110 (2020). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Best, Matthew J. et al. <I>Economic implications of decreased elective orthopaedic and musculoskeletal surgery
volume during the coronavirus disease 2019 pandemic</I>. International Orthopaedics vol. 44,11 (2020): 2221-2228. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">University of California, Los Angeles, <I>Pelvic floor disorders frequently asked questions (2024)</I>.
Available at: https://www.uclahealth.org/medical-services/womens-pelvic-health/patient-education/pelvic-floor-disorders (last accessed November&nbsp;1, 2024). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Fullen, Brona et al. <I>Musculoskeletal Pain: Current and Future Directions of Physical Therapy Practice</I>.
Archives of Rehabilitation Research and Clinical Translation vol. 5,1 100258 (2023). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Guardado, Jos&eacute;, <I>Competition in PBM Markets and Vertical Integration of Insurers with PBMs: 2024.
</I> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Information contained on or accessible through the websites referenced above are not a part of
this prospectus, and the inclusion of the website addresses above are inactive textual references only. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom829170_7"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We estimate that we will receive net proceeds from this offering of approximately $&#8195;&#8195; (or $&#8195;&#8195; if the
underwriters exercise their option to purchase additional shares of Class&nbsp;A common stock in full), based on an assumed initial public offering price of $&#8195;&#8195; per share, which is the midpoint of the price range set forth on the cover
page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We will not receive any proceeds from the sale of Class&nbsp;A common stock by the selling stockholders.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each $1.00 increase or decrease in the assumed initial public offering price of $&#8195;&#8195;per share of Class&nbsp;A
common stock, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase or decrease, as applicable, the net proceeds to us from this offering by approximately $&#8195;&#8195;million, assuming that the
number of shares of Class&nbsp;A common stock offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.
Similarly, each increase or decrease of 1.0&nbsp;million shares in the number of shares of Class&nbsp;A common stock offered by us would increase or decrease, as applicable, the net proceeds to us from this offering by approximately
$&#8195;&#8195;million, assuming that the initial public offering price of $&#8195;&#8195; per share of Class&nbsp;A common stock, which is the midpoint of the price range set forth on the cover page of this prospectus, remains the same, and after
deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The principal
purposes of this offering are to increase our capitalization and financial flexibility, create a public market for our Class&nbsp;A common stock, enable access to the public equity markets for us and our stockholders, and facilitate an orderly
distribution of shares for the selling stockholders. We currently intend to use the net proceeds of this offering for general corporate purposes, working capital, and to fund our growth strategies discussed in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">It is possible that in the future, we will decide to &#147;net settle&#148; RSUs and PRSUs upon the applicable vesting date,
meaning that we will withhold a portion of the vested shares on the applicable vesting date and use some of the net proceeds from this offering to satisfy tax withholding and remittance obligations related to the vesting and settlement of such
awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may also use a portion of the net proceeds to us to acquire or invest in complementary businesses, products,
services, technologies, or other assets. We do not, however, have agreements or commitments to enter into any acquisitions or investments at this time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The expected use of net proceeds from this offering to us represents our intentions based upon our present plans and business
conditions. We cannot specify with certainty the particular uses of the net proceeds that we will receive from this offering. Accordingly, we will have broad discretion in the way that we use the net proceeds. Pending the use of proceeds from this
offering as described above, we may invest the net proceeds that we receive in this offering in short-term, investment grade, interest-bearing instruments, including government and investment-grade debt securities, commercial paper, and money-market
funds. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom829170_8"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have never declared or paid any cash dividends on our capital stock. We currently intend to retain any future earnings for
use in the operation of our business and do not anticipate declaring or paying any cash dividends in the foreseeable future. Any future determination to declare cash dividends will be made at the discretion of our board of directors, subject to
applicable laws and will depend on a number of factors, including our results of operations, financial condition, capital requirements, contractual restrictions, general business conditions, and other factors our board of directors may deem
relevant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom829170_9"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth our cash, cash equivalents and marketable securities and total capitalization as of
December&nbsp;31, 2024: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on an actual basis; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma basis, giving effect to (i)&nbsp;the Transactions, (ii)&nbsp;the filing and effectiveness of
our amended and restated certificate of incorporation, which will occur immediately prior to the completion of this offering, and (iii)&nbsp;stock-based compensation expense of approximately $&#8195;&#8195;that we will recognize upon the completion
of this offering related to RSUs and PRSUs subject to service-based or performance-based and liquidity-based vesting conditions for which the service-based or performance-based vesting conditions were satisfied as of December&nbsp;31, 2024 and for
which the liquidity-based vesting condition will be satisfied in connection with this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma as adjusted basis, giving effect to (i)&nbsp;the pro forma adjustments set forth above and
(ii)&nbsp;the issuance and sale by us of shares of our Class&nbsp;A common stock in this offering, based on the assumed initial public offering price of $&#8195;&#8195;per share, which is the midpoint of the estimated offering price range set forth
on the cover page of this prospectus, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The pro forma as adjusted information discussed below is illustrative only and will be adjusted based on the actual initial
public offering price and other terms of this offering determined at pricing. This table should be read in conjunction with the sections titled &#147;Summary Consolidated Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of
Financial Condition and Results of Operations&#148; and our audited consolidated financial statements and related notes included elsewhere in this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma</B><br><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma&nbsp;As<BR>Adjusted<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B><br><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except&nbsp;share&nbsp;and&nbsp;per&nbsp;share&nbsp;data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, and marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock, $0.00001 par value, &#8195;&#8195;&#8195;&#8195;shares
authorized, &#8195;&#8195;&#8195;&#8195;shares issued and outstanding, actual; no shares authorized, issued, and outstanding, pro forma or pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.00001 par value; &#8195;&#8195;&#8195;&#8195;shares authorized,
&#8195;&#8195;&#8195;&#8195;shares issued and outstanding, actual; no shares authorized, issued and outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;A common stock, $0.00001 par value, no shares authorized, issued and outstanding,
actual; &#8195;&#8195;&#8195;&#8195;shares authorized, no shares issued and outstanding, pro forma; &#8195;&#8195;&#8195;&#8195;shares authorized, &#8195;&#8195;&#8195;&#8195;shares issued and outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;B common stock, $0.00001 par value, no shares authorized or issued and outstanding,
actual; &#8195;&#8195;&#8195;&#8195;shares authorized, &#8195;&#8195;&#8195;&#8195;shares issued and outstanding, pro forma; &#8195;&#8195;&#8195;&#8195;shares authorized, &#8195;&#8195;&#8195;&#8195;&#8195;shares issued and outstanding, pro forma
as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, par value $0.00001 per share; no shares authorized, issued and outstanding,
actual; shares authorized, no shares issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The pro forma as adjusted information discussed above is illustrative only and will depend on the actual
initial offering price and other terms of this offering determined at pricing. Each $1.00 increase or decrease in the assumed initial public offering price of $&#8195;&#8195;per share of Class&nbsp;A common stock, which is the midpoint of the price
range set forth on the cover page of this prospectus, would increase or decrease, as applicable, each of our pro forma as adjusted cash, cash equivalents, and marketable securities, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital,
total stockholders&#146; deficit, and total capitalization by approximately $&#8195;&#8195;million, assuming that the number of shares of Class&nbsp;A common stock offered by us, as set forth on the cover page of this prospectus, remains the same,
and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase or decrease of 1.0&nbsp;million shares in the number of shares of Class&nbsp;A common stock offered by us
would increase or decrease, as applicable, each of pro forma as adjusted cash, cash equivalents, and marketable securities, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#146; deficit, and total
capitalization by approximately $&#8195;&#8195;million, assuming that the assumed initial public offering price of $&#8195;&#8195;per share of Class&nbsp;A common stock, which is the midpoint of the price range set forth on the cover page of this
prospectus, remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the underwriters exercise their option to purchase additional shares of our Class&nbsp;A common stock in full, our pro
forma as adjusted cash, cash equivalents, and marketable securities, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#146; deficit, total capitalization and shares of Class&nbsp;A common stock outstanding as of
December&nbsp;31, 2024 would be $&#8195;&#8195;, $&#8195;&#8195;, $&#8195;&#8195;, $&#8195;&#8195;, and &#8195;&#8195;&#8195;&#8195; shares, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The number of shares of our common stock issued and outstanding, pro forma, and pro forma as adjusted in the table above is
based on &#8195;&#8195;&#8195;&#8195; shares of our Class&nbsp;A common stock outstanding and &#8195;&#8195;&#8195;&#8195; shares of our Class&nbsp;B common stock outstanding as of December&nbsp;31, 2024, after giving effect to the Transactions.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The number of shares of our common stock to be outstanding after this offering does not include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of our Class&nbsp;A common stock issuable upon the exercise of outstanding
stock options to purchase shares of our Class&nbsp;A common stock as of December&nbsp;31, 2024, with a weighted-average exercise price of $&#8195;&#8195; per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of our Class&nbsp;B common stock issuable upon the exercise of outstanding
stock options to purchase shares of our Class&nbsp;B common stock as of December&nbsp;31, 2024, with a weighted-average exercise price of $&#8195;&#8195; per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of our Class&nbsp;A common stock issuable upon the exercise of outstanding
stock options to purchase shares of our Class&nbsp;A common stock granted after December&nbsp;31, 2024, with a weighted-average exercise price of $&#8195;&#8195; per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of our Class&nbsp;B common stock issuable upon the exercise of outstanding
stock options to purchase shares of our Class&nbsp;B common stock granted after December&nbsp;31, 2024, with a weighted-average exercise price of $&#8195;&#8195; per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of our Class&nbsp;A common stock issuable upon the vesting of RSUs for
shares of our Class&nbsp;A common stock subject to service-based and liquidity-based vesting conditions outstanding as of December&nbsp;31, 2024, for which the service-based vesting condition was not yet satisfied as of December&nbsp;31, 2024 and
for which the liquidity-based vesting condition will be satisfied in connection with this offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of our Class&nbsp;A common stock issuable upon the vesting of PRSUs for
shares of our Class&nbsp;A common stock subject to performance-based and liquidity-based vesting conditions outstanding as of December&nbsp;31, 2024, for which the performance-based vesting condition was not yet satisfied as of December&nbsp;31,
2024 and for which the liquidity-based vesting condition will be satisfied in connection with this offering; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of our Class&nbsp;B common stock issuable upon the vesting of RSUs for
shares of our Class&nbsp;B common stock subject to service-based and liquidity-based vesting conditions outstanding as of December&nbsp;31, 2024, for which the service-based vesting condition was not yet satisfied as of December&nbsp;31, 2024 and
for which the liquidity-based vesting condition will be satisfied in connection with this offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of our Class&nbsp;B common stock issuable upon the vesting of PRSUs for
shares of our Class&nbsp;B common stock subject to performance-based and liquidity-based vesting conditions outstanding as of December&nbsp;31, 2024, for which the performance-based vesting condition was not yet satisfied as of December&nbsp;31,
2024 and for which the liquidity-based vesting condition will be satisfied in connection with this offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of our Class&nbsp;A common stock reserved for future issuance under the
2025 Plan, which will become effective on the business day immediately prior to the date of effectiveness of the registration statement of which this prospectus forms a part, including &#8195;&#8195;&#8195;&#8195; new shares and the Prior Plan
Awards that expire, or are cancelled, forfeited, reacquired, or withheld; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of our Class&nbsp;A common stock reserved for future issuance under the
ESPP, which will become effective on the business day immediately prior to the date of effectiveness of the registration statement of which this prospectus forms a part. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The 2025 Plan and the ESPP also provide for automatic annual increases in the number of shares reserved thereunder. See the
section titled &#147;Executive and Director Compensation&#151;Equity Incentive Plans&#148; for additional information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom829170_10"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If you purchase shares of our Class&nbsp;A common stock in this offering, your ownership interest will be diluted to the
extent of the difference between the initial public offering price per share of our Class&nbsp;A common stock in this offering and the pro forma as adjusted net tangible book value per share of our Class&nbsp;A common stock immediately after this
offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2024, our historical net tangible book value (deficit) was $&#8195;&#8195;, or
$&#8195;&#8195; per share of our common stock. Our historical net tangible book value (deficit) per share represents our total tangible assets less total liabilities and redeemable convertible preferred stock, divided by the aggregate number of
shares of our common stock outstanding as of December&nbsp;31, 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our pro forma net tangible book value as of
December&nbsp;31, 2024 was $&#8195;&#8195;, or $&#8195;&#8195; per share. Pro forma net tangible book value per share represents tangible assets, less liabilities, divided by the aggregate number of shares of Class&nbsp;A and Class&nbsp;B common
stock outstanding, after giving effect to (i)&nbsp;the filing and effectiveness of our amended and restated certificate of incorporation and (ii)&nbsp;the Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After giving further effect to the sale by us of &#8195;&#8195;&#8195;&#8195; shares of our Class&nbsp;A common stock in this
offering at an assumed initial public offering price of $&#8195;&#8195; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and
estimated offering expenses payable by us, our pro forma as adjusted net tangible book value (deficit) as of December&nbsp;31, 2024 would have been $&#8195;&#8195;, or $&#8195;&#8195; per share. This represents an immediate increase in pro forma net
tangible book value to existing stockholders of $&#8195;&#8195; per share and an immediate dilution in pro forma net tangible book value to new investors purchasing our Class&nbsp;A common stock of $&#8195;&#8195; per share. Dilution per share
represents the difference between the price per share to be paid by new investors for the shares of our Class&nbsp;A common stock sold in this offering and the pro forma as adjusted net tangible book value per share of our Class&nbsp;A common stock
immediately after this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table illustrates this dilution on a per share basis: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book value (deficit) per share as of December&nbsp;31, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma increase in net tangible book value per share as of December&nbsp;31, 2024 attributable
to the pro forma transactions described above</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net tangible book value per share as of December&nbsp;31, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in pro forma net tangible book value per share attributable to new investors purchasing
shares of our Class&nbsp;A common stock in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma as adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The dilution information discussed above is illustrative only and may change based on the
actual initial public offering price, the number of shares we sell, and other terms of this offering that will be determined at pricing. Each $1.00 increase or decrease in the assumed initial public offering price of $&#8195;&#8195; per share of
Class&nbsp;A common stock, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase or decrease, as applicable, our pro forma as adjusted net tangible book value per share after this offering by
$&#8195;&#8195; per share and the dilution in pro forma per share to investors participating in this offering by $&#8195;&#8195; per share, assuming that the number of shares of Class&nbsp;A common stock offered by us, as set forth on the cover page
of this prospectus, remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase or decrease of 1.0&nbsp;million shares in the number of shares of
Class&nbsp;A </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
common stock offered by us would increase or decrease, as applicable, our pro forma as adjusted net tangible book value per share after this offering by $&#8195;&#8195; per share and the dilution
in pro forma as adjusted net tangible book value per share to investors participating in this offering by $&#8195;&#8195;per share, assuming the initial public offering price of $&#8195;&#8195; per share of Class&nbsp;A common stock, which is the
midpoint of the price range set forth on the cover page of this prospectus, remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the underwriters exercise their option to purchase additional shares of our Class&nbsp;A common stock in full, the pro
forma as adjusted net tangible book value (deficit) per share after this offering would be $&#8195;&#8195; per share, and the dilution in pro forma net tangible book value per share to investors participating in this offering would be
$&#8195;&#8195; per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth, on the pro forma basis described above, as of
December&nbsp;31, 2024, the number of shares of Class&nbsp;A common stock purchased from us, the total consideration paid, or to be paid, and the weighted-average price per share paid, or to be paid, by existing stockholders and by the new
investors, at an assumed initial public offering price of $&#8195;&#8195; per share of Class&nbsp;A common stock, which is the midpoint of the price range set forth on the cover page of this prospectus, before deducting estimated underwriting
discounts and commissions and estimated offering expenses payable by us: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-</B><br><B>Average&nbsp;Price</B><br><B>Per Share</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(in thousands, except share, per share and percent data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Sales by the selling stockholders in this offering will cause the number of shares held by
existing stockholders before this offering to be reduced to &#8195;&#8195;&#8195;&#8195; shares, or &#8195;% of the total number of shares of our common stock outstanding immediately after the completion of this offering, and will increase the
number of shares held by new investors to &#8195;&#8195;&#8195;&#8195;shares, or &#8195;% of the total number of shares of our common stock outstanding immediately after the completion of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each $1.00 increase or decrease in the assumed initial public offering price of $&#8195;&#8195; per share of Class&nbsp;A
common stock, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase or decrease, as applicable, the total consideration paid by new investors, total consideration paid by all stockholders, and the
weighted-average price per share paid by all stockholders by approximately $&#8195;&#8195;, $&#8195;&#8195;, and $&#8195;&#8195;, respectively, assuming that the number of shares of Class&nbsp;A common stock offered by us and the selling
stockholders, as set forth on the cover page of this prospectus, remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase or decrease of
1.0&nbsp;million shares in the number of shares of Class&nbsp;A common stock offered by us would increase or decrease, as applicable, the total consideration paid by new investors, total consideration paid by all stockholders, and the
weighted-average price per share paid by all stockholders by approximately $&#8195;&#8195;, $&#8195;&#8195;, and $&#8195;&#8195;, respectively, assuming the assumed initial public offering price of $&#8195;&#8195; per share remains the same, and
after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
foregoing discussion and tables assume no exercise of the underwriters&#146; option to purchase additional shares. If the underwriters&#146; exercise their option to purchase additional shares of Class&nbsp;A common stock in full, the number of
shares held by our existing stockholders will represent approximately&#8195;% of the total number of shares of our common stock outstanding after this offering and the number of shares held by new investors will represent approximately &#8195;% of
the total number of shares of our common stock outstanding after this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The foregoing tables and calculations (other than the historical net
tangible book value calculation) are based on&#8195;&#8195;&#8195;&#8195; shares of our Class&nbsp;A common stock outstanding and &#8195;&#8195;&#8195;&#8195; shares of our Class&nbsp;B common stock outstanding as of December&nbsp;31, 2024, after
giving effect to the Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The number of shares of our common stock to be outstanding after this offering does
not include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of our Class&nbsp;A common stock issuable upon the exercise of outstanding
stock options to purchase shares of our Class&nbsp;A common stock as of December&nbsp;31, 2024, with a weighted-average exercise price of $&#8195;&#8195; per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of our Class&nbsp;B common stock issuable upon the exercise of outstanding
stock options to purchase shares of our Class&nbsp;B common stock as of December&nbsp;31, 2024, with a weighted-average exercise price of $&#8195;&#8195; per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of our Class&nbsp;A common stock issuable upon the exercise of outstanding
stock options to purchase shares of our Class&nbsp;A common stock granted after December&nbsp;31, 2024, with a weighted-average exercise price of $&#8195;&#8195; per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of our Class&nbsp;B common stock issuable upon the exercise of outstanding
stock options to purchase shares of our Class&nbsp;B common stock granted after December&nbsp;31, 2024, with a weighted-average exercise price of $&#8195;&#8195; per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of our Class&nbsp;A common stock issuable upon the vesting of RSUs for
shares of our Class&nbsp;A common stock subject to service-based and liquidity-based vesting conditions outstanding as of December&nbsp;31, 2024, for which the service-based vesting condition was not yet satisfied as of December&nbsp;31, 2024 and
for which the liquidity-based vesting condition will be satisfied in connection with this offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of our Class&nbsp;A common stock issuable upon the vesting of PRSUs for
shares of our Class&nbsp;A common stock subject to performance-based and liquidity-based vesting conditions outstanding as of December&nbsp;31, 2024, for which the performance-based vesting condition was not yet satisfied as of December&nbsp;31,
2024 and for which the liquidity-based vesting condition will be satisfied in connection with this offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of our Class&nbsp;B common stock issuable upon the vesting of RSUs for
shares of our Class&nbsp;B common stock subject to service-based and liquidity-based vesting conditions outstanding as of December&nbsp;31, 2024, for which the service-based vesting condition was not yet satisfied as of December&nbsp;31, 2024 and
for which the liquidity-based vesting condition will be satisfied in connection with this offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of our Class&nbsp;B common stock issuable upon the vesting of PRSUs for
shares of our Class&nbsp;B common stock subject to performance-based and liquidity-based vesting conditions outstanding as of December&nbsp;31, 2024, for which the performance-based vesting condition was not yet satisfied as of December&nbsp;31,
2024 and for which the liquidity-based vesting condition will be satisfied in connection with this offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of our Class&nbsp;A common stock reserved for future issuance under the
2025 Plan, which will become effective on the business day immediately prior to the date of effectiveness of the registration statement of which this prospectus forms a part, including &#8195;&#8195;&#8195;&#8195; new shares and the Prior Plan
Awards that expire, or are cancelled, forfeited, reacquired, or withheld; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of our Class&nbsp;A common stock reserved for future issuance under the
ESPP, which will become effective on the business day immediately prior to the date of effectiveness of the registration statement of which this prospectus forms a part. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The 2025 Plan and the ESPP also provide for automatic annual increases in the number of shares reserved thereunder. See the
section titled &#147;Executive and Director Compensation&#151;Equity Incentive Plans&#148; for additional information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To the extent we issue any additional stock options, warrants, RSUs or PRSUs
or any outstanding stock options, warrants, RSUs or PRSUs are exercised or settled, or if we issue any other securities or convertible debt in the future, investors will experience further dilution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom829170_11"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>The following discussion and analysis of our financial condition and results
of operations should be read in conjunction with the section titled &#147;Summary Consolidated Financial Data,&#148; our audited consolidated financial statements and related notes, and other financial information appearing elsewhere in this
prospectus. In addition to historical consolidated financial information, the following discussion contains forward-looking statements that reflect our plans, estimates, and beliefs that involve significant risks and uncertainties. Our actual
results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to those differences include those discussed below and elsewhere in this prospectus, particularly in the sections titled
&#147;Risk Factors&#148; and &#147;Special Note Regarding Forward-Looking Statements.&#148; Data as of and for the year ended December&nbsp;31, 2023 has been derived from our audited consolidated financial statements included elsewhere in this
prospectus. Our historical results are not necessarily indicative of the results to be expected for any period in the future, and results for any interim period should not be construed as an inference of what our results would be for any full year
or future period. Our fiscal year ends on December 31. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our vision is to create a vertically integrated healthcare system powered by innovative technology &#150; and we are starting
with MSK care. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Hinge Health is a leading technology platform for individuals seeking to treat and prevent joint and
muscle pain. We leverage AI and software to deliver an outstanding member experience, improved member outcomes and cost reductions for our clients. We have designed our platform to address a broad spectrum of joint and muscle care&#151;from acute
injury, to chronic pain, to post-surgical rehabilitation. Our platform integrates <FONT STYLE="white-space:nowrap">AI-powered</FONT> motion tracking technology, a proprietary electrical nerve stimulation wearable device, and an <FONT
STYLE="white-space:nowrap">AI-supported</FONT> care team of licensed physical therapists, physicians, and board-certified health coaches to address our members&#146; MSK conditions while reducing the need for surgeries or pain medications. Our
platform is driving equity in care access by meeting our members where they are, allowing them to choose where, when, and how often they engage in their exercise therapy sessions and embrace movement as a way of life. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have developed an efficient <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">go-to-market</FONT></FONT>
model by working directly with our partners and clients. Our clients are primarily self-insured employers and include many of the nation&#146;s leading enterprises across a broad range of industries and sizes. Within this segment, we also serve many
public sector self-insured employers, such as state and local city governments. In most instances, we partner with clients&#146; health plans, TPAs, PBMs, or other ecosystem entities such as centers of excellence and healthcare navigation companies
to reduce the friction of contracting, pricing, security and IT compliance, onboarding, and billing. We are also in the early stages of expanding to serve health plans&#146; fully-insured and Medicare Advantage populations and federal insurance
plans. As of September&nbsp;30, 2024, we had approximately 18&nbsp;million contracted lives across more than 2,000 clients. We had active client agreements with 48% of the Fortune 100 companies and 42% of the Fortune 500 companies, as of
September&nbsp;30, 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that we grow efficiently because of our scalable, repeatable <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">go-to-market</FONT></FONT> model. We sell through our direct sales force and our partners. Once we contract with a client, we are typically the sole digital MSK care provider to their
contracted lives for an average contract term of three years. For the term of each contract, we are able to enroll, engage, and <FONT STYLE="white-space:nowrap">re-engage</FONT> the client&#146;s eligible lives, driving a recurring, repeatable
revenue model, which is demonstrated in our net dollar retention of &#8195;% as of December&nbsp;31, 2024. Our <FONT STYLE="white-space:nowrap">12-month</FONT> client retention rate was 98% as of September&nbsp;30, 2024, and as of October&nbsp;31,
2024, our client NPS was 87, which demonstrates our high level of client satisfaction. We also invested early in building our partner network. As of September&nbsp;30, 2024, we had over 50 partners, including four out of the five largest national
health plans by self-insured lives and the top three PBMs by market share, and we had retained 100% of our partners that we choose to work with since inception, excluding partners who were acquired. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our <FONT STYLE="white-space:nowrap">software-led,</FONT> <FONT
STYLE="white-space:nowrap">AI-powered</FONT> delivery model not only aims to provide a better experience for our members and a less expensive alternative for our clients, but also allows us to innovate and continuously improve our platform. Our <FONT
STYLE="white-space:nowrap">AI-powered</FONT> motion tracking technology, TrueMotion, allows us to deliver highly scalable care remotely and reduce the human hours associated with traditional physical therapy. As of September&nbsp;30, 2024, over 80%
of member interactions on our platform were technology-only interactions. We have also invested in building software and data integrations that connect with our partners and a growing network of <FONT STYLE="white-space:nowrap">in-person</FONT>
providers of certain members. Through HingeConnect, we integrate EHR data from over 750,000 providers across 140,000 care sites nationwide. HingeConnect gives us visibility into our members&#146; health data when they enroll in our programs, thereby
facilitating more personalized, timely care to address their needs. We also receive data that enables us to quickly identify members who are at higher risk of increased healthcare costs and to provide targeted interventions to support them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are a <FONT STYLE="white-space:nowrap">research-led</FONT> organization and we routinely expand our platform with new
programs, capabilities, and features. Over the last three years, we: launched new programs to address six new affected areas; launched Enso to deliver a <FONT STYLE="white-space:nowrap">non-addictive,</FONT>
<FONT STYLE="white-space:nowrap">non-invasive</FONT> alternative for pain relief; developed HingeConnect for real-time care interventions and external provider coordination; and integrated TrueMotion technology to replace wearable sensors for our
members. In 2022, we launched women&#146;s pelvic health, a specialized care program within our chronic program, and, in 2023, we launched a fall prevention program for eligible lives in our Medicare Advantage population. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our focus on delivering effective MSK care through technology has propelled us to achieve numerous milestones. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our History </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g829170g00u01.jpg" ALT="LOGO" STYLE="width:5.77639in;height:3.18077in;">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Business Model </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Go-to-Market</FONT></FONT> Motion&#151;Revenue
Generation Process </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The majority of our revenue is generated from clients who are self-insured employers. We are
increasingly diversifying our revenue through our partners into the fully-insured employers and Medicare Advantage markets </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
(whereby the health plan is the client and purchasing entity). We sell through our direct sales force and partners, which allows for an efficient <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">business-to-business</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">go-to-market</FONT></FONT> motion. Our typical sales cycle is five months between initial engagement and entering into a
signed contract with a client; however, our sales cycle can be more than 12 months for larger enterprise clients and fully-insured and Medicare Advantage plans. We sell an annual subscription model, whereby clients only pay for members that engage
with our programs. We primarily recognize revenue ratably over the 12 months after an eligible life becomes a member, and as such our revenue has historically been highly predictable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Depending on a client&#146;s needs, we have the ability to contract directly or through one of our many partners. Similarly,
we are able to invoice a client directly or submit via claims through a client&#146;s health plan. If a client chooses to pay via claims through a health plan, the cost typically comes directly out of their medical budget for the year and is
embedded in their medical costs, rather than a separate discretionary budget. Allocation of the spend on Hinge Health to the client&#146;s existing healthcare budget enables faster implementation as it avoids a potentially lengthy approval process.
Our agreements with partners help us simplify contracting and implementation with clients. In 2023, the vast majority of our contracts were completed via our partners, negating the need for many clients to contract directly with us since many
clients can leverage existing contracts through our partners. This is a significant strategic advantage for us as it enables implementation and launch of our platform as quickly as a few weeks after entering into a contract. As a result, most
implementations are completed in a 40&#150;100 day period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Once our platform is launched, clients only pay for the
members that engage with our programs. We typically provide various performance guarantees to our clients that may include engagement thresholds, member reported outcomes, and return on investment, where we put a portion of our fees at risk. We have
historically paid an immaterial amount related to these performance guarantees. Upon onboarding, a member&#146;s paid subscription is for one year. As of December&nbsp;31, 2024, we had&#8195;&#8195;&#8195;&#8195;members, compared to approximately
371,000 members as of December&nbsp;31, 2023. To increase awareness within our clients&#146; employee bases, we have a growth marketing team that engages with our partners and our clients&#146; human resources benefits team in targeted marketing
campaigns to encourage eligible lives who would benefit from our platform to enroll. While marketing takes place on an ongoing basis, we increase marketing during periods when we expect more enrollments from eligible lives. For example, we typically
focus marketing around new client launches, New Year resolutions, and open enrollment. In addition to direct marketing, we also actively work with our partners and our clients&#146; human resources benefits teams to assist in identifying eligible
lives that would benefit from our platform and encouraging enrollment on our platform. For example, a healthcare navigation partner can direct an individual with MSK conditions to our platform, or a client&#146;s human resources benefits team can
incorporate Hinge Health marketing into its internal benefit campaigns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are able to bill our clients once an eligible
life enrolls in our platform and performs a billable activity, in accordance with our clients&#146; billing arrangements. Some of our clients are billed for the entirety of the members&#146; annual subscriptions, and some are billed in
milestone-based payments, based on a subscription fee per member per year. We also recently introduced an alternative engagement-based pricing model in which clients are billed based on an annual upfront platform fee per member plus a fee per each
completed session. See the section titled &#147;&#151;Critical Accounting Policies and Estimates&#151;Revenue Recognition<I>&#148; </I>below for more details on our billing methodology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The majority of new clients enter into contracts with us in the second half of each calendar year, which aligns with the
typical employee benefit enrollment period. We launch our platform for most of these clients in the first half of the following calendar year. We have seen varying levels of intra-year launches since our inception. While some clients choose to sign
and launch within the same year, these are generally a much smaller percentage of our business. Due to these patterns and our annual subscription-based model, the timing of our revenue has historically been predictable. Our calculated billings,
however, show seasonality with fluctuations based on the timing of new client launches and number of intra-year launches. Historically, our calculated billings are highest in the second quarter of the year, as this is when we are able to bill the
majority of clients </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
who entered into contracts in the preceding year. Consequently, our free cash flow is typically highest in the second quarter and is usually lowest in the first quarter due to increased new
client onboarding expenses preceding cash inflows in the first quarter, and slowing billings associated with the holidays in the prior fourth quarter. We anticipate that this seasonality will continue and therefore focus on LTM calculated billings
as a result. Given the annual subscription model and ratable revenue recognition, however, our quarterly revenue stream has historically been highly predictable and has not displayed the same seasonality trends. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our <FONT STYLE="white-space:nowrap">12-month</FONT> client retention rate of 98% as of September&nbsp;30, 2024 allows for
predictable, steady revenue from our legacy client cohorts. Our NDR was&#8195;% as of December&nbsp;31, 2024. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g829170g00u02.jpg" ALT="LOGO" STYLE="width:6.06702in;height:2.29135in;">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Technology Investments Drive Effectiveness and Improved Gross Margin </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have invested and continue to invest in technology to improve the care, quality, and breadth of the programs we provide to
our members. Our ability to leverage our technology platform to deliver care at scale has strengthened our financial profile. For the year ended December&nbsp;31, 2024, we achieved a gross margin of&#8195;% compared to 66% for the year ended
December&nbsp;31, 2023. For the year ended December&nbsp;31, 2024, our <FONT STYLE="white-space:nowrap">non-GAAP</FONT> adjusted gross margin was&#8195;%, compared to 70% for the year ended December&nbsp;31, 2023. See the section titled <FONT
STYLE="white-space:nowrap">&#147;&#151;Non-GAAP</FONT> Financial <FONT STYLE="white-space:nowrap">Measures&#151;Non-GAAP</FONT> Gross Profit and Gross Margin&#148; below for a reconciliation of <FONT STYLE="white-space:nowrap">non-GAAP</FONT> gross
profit and gross margin to GAAP gross profit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our cost of revenue primarily consists of personnel-related costs, which
includes our care team, inventory costs such as our kits and Enso, and technology support costs such as hosting costs. Previously, when eligible lives became members, they were sent a tablet and wearable sensors that tracked their movements to
ensure exercises were completed correctly. In the first half of 2023, we shifted from providing members with tablets and sensors to providing members with access to our platform via our app on the members&#146; personal smartphone or tablet. In
2024, we replaced all sensors for our members with our proprietary AI motion tracking technology. By enabling members to do exercises with only the camera on their personal devices, members benefit from the convenience and accessibility of effective
motion tracking technology that provides real-time feedback. We believe that the increased convenience is beneficial to our members and makes our programs more accessible. This capability also lowers our variable cost of providing our programs
because sensors are not utilized. Some members are also provided with Enso, an <FONT STYLE="white-space:nowrap">FDA-cleared,</FONT> wearable device for <FONT STYLE="white-space:nowrap">non-addictive</FONT> and
<FONT STYLE="white-space:nowrap">non-invasive</FONT> pain relief. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have also invested in AI to increase the efficiency
of our care teams. For example, we established a staffing model that utilizes AI technology to assess risk profiles and optimizes our care team coverage to assist in making our personnel available and responsive to member needs. We are investing in
additional ways AI can improve our care team productivity while maintaining excellent care. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key Factors Affecting Our Performance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our business model delivers value for our clients by lowering MSK care costs and driving positive member outcomes. We believe
that our business performance and results of operations have been, and will continue to be, affected by many factors, including those below. While these key factors present significant opportunities, they also represent challenges that we must
successfully address in order to sustain and grow our business and improve our results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Ability to
Grow and Retain our Client Base and Contracted Lives </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have rapidly grown our client base, expanding to
approximately&#8195;&#8195;&#8195;&#8195;clients as of December&nbsp;31, 2024 from approximately 1,650 clients as of December&nbsp;31, 2023. This expansion gives us access to an increased number of contracted lives, which has grown
to&#8195;&#8195;&#8195;&#8195;million as of December&nbsp;31, 2024 from 16&nbsp;million as of December&nbsp;31, 2023. There are two ways we increase our contracted lives: through new client additions and through accessing additional contracted lives
within a current client. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Adding new clients is one of the key pillars of our growth strategy. Our partners are a key part
of this effort as they assist in the self-insured employer sales process with Hinge Health as their preferred partner. This partnership model allows for simplicity and speed in the contracting and implementation of new clients, including security
and IT compliance, billing, and payments. In addition to self-insured employers, which currently make up the majority of our business, we are in the early stages of entering the fully-insured and Medicare Advantage markets, and federal insurance
plans. Our growth and financial results will depend on our ability to efficiently expand access to or acquire more contracted lives in the market segments where we plan to focus our growth efforts. We closely monitor our client acquisition costs and
believe we have an efficient sales process. Our sales efficiency has been improving as a greater portion of our business has moved through our partners and we have found ways to optimize marketing costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Retaining our existing clients is also integral to our success. Our <FONT STYLE="white-space:nowrap">software-led,</FONT> <FONT
STYLE="white-space:nowrap">AI-powered</FONT> delivery model aims to provide a better experience for our members and a less expensive alternative for our clients. Once we contract with a client, we are typically the sole digital MSK care provider to
their contracted lives for an average contract term of three years. Our <FONT STYLE="white-space:nowrap">12-month</FONT> client retention rate was 98% as of September&nbsp;30, 2024, and as of October&nbsp;31, 2024, our client NPS was 87, which
demonstrates our high level of client satisfaction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Expansion of Members within Existing Clients </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We also intend to grow by expanding the number of enrollments of eligible lives within our launched clients. The long-term
value of our platform to our clients increases as our clients&#146; eligible lives increase adoption and usage of our platform. There are four main focus areas that we believe drive adoption and engagement with our platform within our clients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>New product adoption: </I>We increase member enrollments and drive growth by fostering adoption of our recently launched
programs, including women&#146;s pelvic health and a fall prevention program. These new programs, as well as the availability of Enso, allow us to reach contracted lives who may not have otherwise engaged in one of our programs, thereby expanding
our reach and diversifying our member base. This approach not only fuels our growth, but also positions us to engage with previously <FONT STYLE="white-space:nowrap">non-targeted</FONT> populations or stigmatized affected areas, thereby
strengthening our presence and impact in the industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Targeted interventions: </I>Based on our analysis of Health
Claims Data, approximately 6% of the population of individuals covered by the health plan drove 85% of <FONT STYLE="white-space:nowrap">MSK-related</FONT> medical costs in 2023. To optimize our client&#146;s ROI, we identify and engage such
high-risk eligible lives through targeted interventions enabled by HingeConnect, our proprietary <FONT STYLE="white-space:nowrap">AI-driven</FONT> database. As of September&nbsp;30, 2024, HingeConnect integrated EHR
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
data from over 750,000 providers across over 140,000 care sites nationwide and combined with our internal proprietary data. By applying advanced algorithms and AI to this comprehensive dataset,
we proactively identify high-risk eligible lives before they become high-cost claimants to the client. We then educate and engage those high-risk eligible lives to encourage enrollment in our platform. Our objective is to provide more conservative
options such as personalized exercise therapy and Enso for pain relief. Additionally, we leverage data integrations to proactively identify high-risk members before they progress further down the care path towards surgery. Our targeted interventions
assist us in our objective to improve patient outcomes and reduce the need for surgical interventions in high-risk cases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Brand awareness and marketing:</I> We focus on creating and retaining demand for our platform by increasing brand
awareness. Our team is continually developing new and better ways of enrolling eligible lives given the pervasive nature of MSK conditions. We employ a holistic communication strategy that incorporates multiple channels to meet our clients&#146;
eligible lives at their point of need. We are also dedicated to improving the effectiveness of our marketing through the use of data analytics and A/B testing. We implemented a number of different marketing formats, which helped us to increase
membership applications per impression from our legacy clients by 36% in a <FONT STYLE="white-space:nowrap">six-month</FONT> period between the first quarter and the third quarter of 2024, and by 62% in a
<FONT STYLE="white-space:nowrap">12-month</FONT> period between the third quarter of 2023 and the third quarter of 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Partnerships and referrals</I>: Our partners also assist us in identifying and encouraging member enrollment into our
platform. For example, a healthcare navigation partner can see if an eligible life with MSK conditions has access to Hinge Health and can direct them to our platform and programs if they are not currently enrolled. Additionally, we encourage members
to refer <FONT STYLE="white-space:nowrap">co-workers</FONT> and family to try Hinge Health, increasing enrollment by referral. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We track our performance in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">land-and-expand</FONT></FONT> by
our NDR, which was&#8195;%&nbsp;as of December&nbsp;31, 2024. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Innovation and Client Product Adoption </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are committed to continuous innovation at Hinge Health. We believe the market for digital MSK care is still in its early
stages and intend to continue investing for long-term growth. We enable positive member outcomes and proven cost reductions by pairing AI motion tracking technology and wearable pain relief and have continually driven innovations in MSK care since
2014. We have increased the number of affected areas addressed by our programs, from two at our inception (knee and back), to sixteen as of September&nbsp;30, 2024 (neck, upper back, shoulders, elbows, forearms, wrists, hands, lower back, hips,
pelvic region, thighs, knees, shins, calves, ankles, and feet). This increase allows us to reach more members and drive increased utilization within the eligible life populations of our clients. In 2023, we unveiled our proprietary AI motion
tracking technology, TrueMotion, to replace sensors for our members, which enables us to provide effective motion guidance and enables members to engage with their exercises using only the camera on their preferred device. This not only increases
accessibility and enables our members to engage anywhere but has also lowered our cost of providing care by reducing hardware costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have also introduced Enso, an <FONT STYLE="white-space:nowrap">FDA-cleared,</FONT> wearable device for lasting pain relief,
and developed HingeConnect, our proprietary <FONT STYLE="white-space:nowrap">AI-driven</FONT> database for real-time care interventions and external provider coordination. More recently, we launched specialized care for women&#146;s pelvic health
and a fall prevention program to help adults aged 65 and older improve their physical abilities. Clients representing over 75% of eligible lives have adopted our women&#146;s pelvic health program as of September&nbsp;30, 2024. In addition, a fall
prevention program has recently launched within Medicare Advantage where almost 70% of those clients&#146; eligible lives now have access to Hinge Health. We believe we have a significant runway ahead within our current and future partner and client
populations to expand adoption of our newly launched programs, and we plan to continue to innovate and identify ways to further integrate our platform and programs into the member journey for MSK care. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Expansion of Client Base in New Markets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We see opportunities to expand beyond our current markets of self-insured and fully-insured employers, Medicare Advantage
plans, and federal insurance plans. We currently cover eligible lives within the United States and Canada, and expect to expand to more international markets through 2024 and 2025. We first plan to introduce our global platform to our clients that
are United States based multinational corporations, and look to expand to new client opportunities thereafter. We are also looking to expand into additional government agencies and government healthcare programs such as Medicare and Medicaid. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Sales Cycle and Intra-Year Launches </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Given our typical sales cycle, we experience seasonality in our business that has historically resulted in higher calculated
billings and related costs during certain periods. A majority of clients enter contracts with us in the second half of each calendar year, in line with the typical employee benefit enrollment period. Most of these clients are launched in the first
half of the following calendar year. We have seen varying levels of intra-year launches since our inception. While some clients choose to sign and launch within the same year, these clients represent a much smaller percentage of our clients. We
believe that any improvements in the speed at which we can sign and launch new clients can increase our revenue in a given year. Through strategic partnerships with health plans, PBMs, TPAs, and other ecosystem entities, we have streamlined our
implementation process to enable activation in a 40&#150;100 day period compared to what we believe is a typically much longer implementation period in healthcare. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Successful Management of Changes to Macroeconomic Conditions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe our business is resilient even in difficult macroeconomic conditions given our focus on delivering positive outcomes
for our members and ROI for our clients. In tougher economic periods, our business continued to see substantial growth as cost management became an even higher priority for clients. Our cost base is mostly variable, and we maintain strong
operational focus with efficiency improvement targets for every function within the company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key Metrics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We monitor the following key metrics to help us evaluate our business, identify trends affecting our business, formulate
business plans and make strategic decisions. We believe the following metrics are useful in evaluating our business: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of clients</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Members</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">370,526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LTM average eligible lives (in thousands)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LTM calculated billings (in thousands)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">328,827</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Number of Clients: </I>We view this number as an important metric to assess the performance
of our business as an increased number of clients drives growth, increases brand awareness, and helps provide scale to our business. Clients are defined as businesses or organizations, which we call entities, that have at least one active agreement
with us at the end of a particular period. Entities that procure our platform through our partners are counted as individual clients. We do not count our partners as clients, unless they also separately have at least one active client agreement with
us. When a partner has an agreement with us for their fully-insured population, that partner is deemed to be one client, despite there being multiple fully-insured employers within that entity that have access to our platform. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Members: </I>Growth in the number of members is an indicator of penetration of our platform and programs within clients and
expansion of our client base.&nbsp;This metric is a key driver of our calculated billings and provides </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
an indication of our future revenue performance. We calculate the number of members at the end of a particular period based on the total number of eligible lives who have engaged with our
platform in the last 12 months and whose engagements have been billed or are contractually eligible to be billed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>LTM
Average Eligible Lives: </I>This represents the population to whom we can begin meaningful marketing and promotion. As eligible lives can fluctuate throughout the year given changes in our clients&#146; populations, we take the average of the
clients who are live in the first quarter to those who are live at the end of the last quarter in a given <FONT STYLE="white-space:nowrap">12-month</FONT> period to best determine the number of lives we had access to convert into members. Our
management uses LTM average eligible lives to model the business and measure the enrollment we are able to achieve within our client base. LTM average eligible lives are defined as the average number of eligible lives calculated as the sum of
eligible lives as of the first quarter to the end of the last quarter in a given annual period, divided by two. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>LTM
Calculated Billings: </I>We believe calculated billings on a last <FONT STYLE="white-space:nowrap">12-month</FONT> basis helps investors better understand our performance for a particular period given the seasonality in our model, with quarterly
fluctuations based on the timing of new client launches and number of intra-year launches. We anticipate that this seasonality will continue and therefore focus on LTM calculated billings as a result. Our revenue generally does not reflect this
seasonality given that we recognize revenue ratably over the term that members have access to our platform. LTM calculated billings are defined as total revenue, plus the change in deferred revenue, less the change in contract assets for a given <FONT
STYLE="white-space:nowrap">12-month</FONT> period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Components of Results of Operations </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Revenue is the income generated from member subscription fees paid to access our technology platform to treat and prevent MSK
pain. Revenue recognition begins once a billable activity is completed and is typically ratable over the <FONT STYLE="white-space:nowrap">12-month</FONT> member subscription period. For more information on how we recognize our revenue, see the
section titled &#147;Critical Accounting Policies and Estimates&#151;Revenue Recognition.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Cost of Revenue
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cost of revenue consists of costs that are related to the delivery of our platform. These costs primarily include
personnel-related costs, including employee salaries, stock-based compensation, and other related expenses for our care team, support operations personnel, and site reliability engineering personnel. Cost of revenue also includes inventory costs,
which are amortized over the member&#146;s subscription period, provisions for excess and obsolete inventory, and technology support costs, which include hosting and information technology costs and amortization of
<FONT STYLE="white-space:nowrap">internal-use</FONT> software. In order to support the growth of our business and serve our members and clients, we expect our cost of revenue to increase on an absolute dollar basis as our revenue increases. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Gross Profit and Gross Margin </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Gross profit represents revenue less cost of revenue. Gross margin is gross profit expressed as a percentage of revenue and is
affected by several factors, including the timing of the acquisition of new clients and launch of our programs, our introduction of new programs, and the extent to which we can increase the efficiency of our technology through ongoing improvements,
cost reduction, and operational efficiency. We expect our gross profit to increase on an absolute dollar basis over time primarily due to an increase in revenue and gross margin to fluctuate quarter to quarter. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Research and Development </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Research and development expenses consist primarily of personnel-related costs, including employee salaries, stock-based
compensation, and other related expenses for our engineering and product teams that are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
responsible for enhancing our platform and developing new or enhanced programs. Research and development expenses also include costs for third-party services and contractors and software-related
costs. We capitalize <FONT STYLE="white-space:nowrap">internal-use</FONT> software development costs that qualify for capitalization and appropriately reduce research and development expenses. We expect research and development expenses will
increase on an absolute dollar basis as we continue to enhance our platform and develop new and enhanced programs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Sales and Marketing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Sales and marketing expenses consist primarily of personnel-related costs, including employee salaries, stock-based
compensation, and other related expenses, internal and third-party sales commissions, and marketing and promotional expenses. We amortize third-party sales commissions and amortize a portion of internal sales commissions over the respective benefit
periods. We expect sales and marketing expenses will increase on an absolute dollar basis as we continue to grow our business and expand into new markets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>General and Administrative </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">General and administrative expenses consist primarily of personnel-related costs, including employee salaries, stock-based
compensation, and other related expenses for finance, legal, human resources, and other administrative related teams. General and administrative expenses also include third-party professional services for outside legal and accounting services,
information technology and software related costs, and other corporate related expenses. We expect general and administrative expenses will increase as we continue to grow our business and incur compliance costs associated with being a
publicly-traded company, including legal, audit, insurance, and consulting fees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Other Income, Net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other income, net consists primarily of income earned from our cash deposits held in interest-bearing accounts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Provision For (Benefit From) Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Provision for (benefit from) income taxes consists primarily of income taxes in U.S. federal, state, and local jurisdictions
and certain foreign jurisdictions in which we conduct business. We maintain a full valuation allowance on our U.S. federal and state net deferred tax assets as we have concluded that it is not more likely than not that the deferred tax assets will
be realized. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following tables set forth selected consolidated statements of operations data and such data as a percentage of revenue for
each of the years indicated. The <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-year</FONT></FONT> comparisons of our historical results are not necessarily indicative of the results that may be expected in the future.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">292,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">194,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">324,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(130,514</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(108,546</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Benefit from) income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(405</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(108,141</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(as&nbsp;a&nbsp;percentage&nbsp;of&nbsp;revenue)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Benefit from) income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Comparison of the Years Ended December&nbsp;31, 2023 and 2024 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Revenue </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8194;&#8195;2023&#8195;&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8194;&#8195;2024&#8195;&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$&#8195;&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;&#8195;%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">292,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Revenue was $292.7&nbsp;million for the year ended December&nbsp;31, 2023,
which consisted of revenue from new and existing clients, including expansion within existing clients. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Cost of
Revenue </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8194;2023&#8195;&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8194;2024&#8195;&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$&#8195;&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;&#8195;%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except&nbsp;percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">98,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cost of revenue was $98.6&nbsp;million for the year ended December&nbsp;31, 2023, which
primarily consisted of personnel-related costs, inventory costs, and technology support costs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Gross Profit and
Gross Margin </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8194;2023&#8195;&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8194;2024&#8195;&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$&#8195;&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;&#8195;%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except&nbsp;percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">194,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross margin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Gross profit was $194.2&nbsp;million for the year ended December&nbsp;31, 2023, which
primarily consisted of revenue from new and existing clients, including expansion of existing clients, less personnel-related costs, inventory costs and technology support costs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Operating Expenses </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Research and Development </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8194;2023&#8195;&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8194;2024&#8195;&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$&#8195;&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;&#8195;%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except&nbsp;percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">110,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Research and development expenses were $110.1&nbsp;million for the year ended
December&nbsp;31, 2023, which primarily consisted of personnel-related costs and costs for third-party services and contractors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Sales and Marketing </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8194;2023&#8195;&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8194;2024&#8195;&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$&#8195;&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;&#8195;%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except&nbsp;percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">147,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Sales and marketing expenses were $147.6&nbsp;million for the year ended December&nbsp;31,
2023, which primarily consisted of personnel-related costs, internal and third-party sales commissions, and marketing and promotion costs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>General and Administrative </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8194;2023&#8195;&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8194;2024&#8195;&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$&#8195;&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;&#8195;%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except&nbsp;percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">67,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">General and administrative expenses were $67.0&nbsp;million for the year
ended December&nbsp;31, 2023, which primarily consisted of personnel-related costs and third-party professional service expenses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Other income, net </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8194;2023&#8195;&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8194;2024&#8195;&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$&#8195;&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;&#8195;%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except&nbsp;percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other income, net was $22.0&nbsp;million for the year ended December&nbsp;31, 2023, which
primarily consisted of interest earned from our cash, cash equivalents, and marketable securities held in interest-bearing accounts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Benefit from Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Benefit from income taxes was $0.4&nbsp;million for the year ended December&nbsp;31, 2023, which primarily consisted of a
foreign valuation allowance release partially offset by foreign withholding taxes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-GAAP</FONT> Financial Measures
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to our results prepared in accordance with GAAP, we believe the following
<FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures, including <FONT STYLE="white-space:nowrap">non-GAAP</FONT> gross profit and gross margin, <FONT STYLE="white-space:nowrap">non-GAAP</FONT> income (loss) from operations and
operating margin, and free cash flow included in this prospectus, provide users of our financial information with additional useful information in evaluating our performance and liquidity and allows them to more readily compare our results across
periods without the effect of <FONT STYLE="white-space:nowrap">non-cash</FONT> and other items as detailed below. Additionally, our management and board of directors use our <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures to
evaluate our performance and liquidity, identify trends and make strategic decisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There are limitations to the use of
the <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures presented in this prospectus. For example, our <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures may not be comparable to similarly titled measures of other
companies. Other companies, including companies in our industry, may calculate <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures differently than we do, limiting the usefulness of those measures for comparative purposes. Our <FONT
STYLE="white-space:nowrap">non-GAAP</FONT> financial measures should not be considered in isolation or as alternatives to gross profit, gross margin, income (loss) from operations, net cash provided by (used in) operating activities or any other
measure of financial performance calculated and presented in accordance with GAAP. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I><FONT STYLE="white-space:nowrap">Non-GAAP</FONT> Gross Profit and Gross Margin </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We define <FONT STYLE="white-space:nowrap">non-GAAP</FONT> gross profit as gross profit presented in accordance with GAAP,
adjusted to exclude <FONT STYLE="white-space:nowrap">non-cash,</FONT> <FONT STYLE="white-space:nowrap">non-operational</FONT> and <FONT STYLE="white-space:nowrap">non-recurring</FONT> items, including excess and obsolete inventory charges related to
our <FONT STYLE="white-space:nowrap">AI-powered</FONT> motion tracking technology transition, stock-based compensation expenses and amortization of intangible assets. We define <FONT STYLE="white-space:nowrap">non-GAAP</FONT> gross margin as <FONT
STYLE="white-space:nowrap">non-GAAP</FONT> gross profit divided by revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The principal limitation of <FONT
STYLE="white-space:nowrap">non-GAAP</FONT> gross profit and <FONT STYLE="white-space:nowrap">non-GAAP</FONT> gross margin is that it excludes significant expenses that are required by GAAP to be recorded in our consolidated financial statements,
including <FONT STYLE="white-space:nowrap">non-cash</FONT> expenses, and the impact of <FONT STYLE="white-space:nowrap">non-recurring</FONT> charges that we do not consider to be indicative of our ongoing core operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table provides a reconciliation of <FONT
STYLE="white-space:nowrap">non-GAAP</FONT> gross profit and <FONT STYLE="white-space:nowrap">non-GAAP</FONT> gross margin to gross profit and gross margin, which are the most directly comparable financial measures presented in accordance with GAAP:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8194;2023&#8195;&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8194;2024&#8195;&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands, except<BR>percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-GAAP</FONT> gross profit and gross margin
reconciliation:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GAAP gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">194,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GAAP gross margin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Excess and obsolete inventory charge</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-GAAP</FONT> gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">204,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-GAAP</FONT> gross margin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">For further stock-based compensation expense details, see the section titled
<FONT STYLE="white-space:nowrap">&#147;&#151;Non-GAAP</FONT> Loss From Operations and Operating Margin&#148; below. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I><FONT STYLE="white-space:nowrap">Non-GAAP</FONT> Loss From Operations and Operating Margin </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We define <FONT STYLE="white-space:nowrap">non-GAAP</FONT> loss from operations as loss from operations presented in accordance
with GAAP, adjusted to exclude <FONT STYLE="white-space:nowrap">non-cash,</FONT> <FONT STYLE="white-space:nowrap">non-operational</FONT> and <FONT STYLE="white-space:nowrap">non-recurring</FONT> items, including excess and obsolete inventory charges
related to our computer vision technology transition, stock-based compensation expenses and amortization of intangible assets. We define <FONT STYLE="white-space:nowrap">non-GAAP</FONT> operating margin as
<FONT STYLE="white-space:nowrap">non-GAAP</FONT> loss from operations divided by revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The principal limitation of <FONT
STYLE="white-space:nowrap">non-GAAP</FONT> loss from operations and <FONT STYLE="white-space:nowrap">non-GAAP</FONT> operating margin is that it excludes significant expenses that are required by GAAP to be recorded in our consolidated financial
statements, including <FONT STYLE="white-space:nowrap">non-cash</FONT> expenses, and the impact of <FONT STYLE="white-space:nowrap">non-recurring</FONT> charges that we do not consider to be indicative of our ongoing core operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table provides a reconciliation of <FONT STYLE="white-space:nowrap">non-GAAP</FONT> loss from operations and
operating margin to loss from operations and operating margin, the most directly comparable financial measures presented in accordance with GAAP: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8194;2023&#8195;&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8194;2024&#8195;&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands, except<BR>percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-GAAP</FONT> loss from operations and operating margin
reconciliation:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GAAP loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(130,514</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating margin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Excess and obsolete inventory charge</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-GAAP</FONT> loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(118,227</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-GAAP</FONT> operating margin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Stock-based compensation expense: </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8194;2023&#8195;&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8194;2024&#8195;&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Free Cash Flow </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We define free cash flow as net cash provided by (used in) operating activities less cash used for purchases of property and
equipment and capitalized <FONT STYLE="white-space:nowrap">internal-use</FONT> software. We believe that free cash flow is a helpful indicator of liquidity that provides information to management and investors about the amount of cash generated or
used by our operations that, after the investments in property and equipment and capitalized <FONT STYLE="white-space:nowrap">internal-use</FONT> software, can be used for strategic initiatives, including investing in our business and strengthening
our financial position. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The principal limitation of free cash flow is that it does not represent the total increase or
decrease in our cash balance for a given period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table provides a reconciliation of free cash flow to net
cash used in operating activities, the most directly comparable financial measures presented in accordance with GAAP: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Free cash flow reconciliation:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(63,909</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: cash purchases of equipment and software (including capitalized <FONT
STYLE="white-space:nowrap">internal-use</FONT> software)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,615</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Free cash flow</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(68,524</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have historically financed our operations primarily through net proceeds from the sale of our redeemable convertible
preferred stock and payments received from our clients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2023, our principal sources of liquidity
were cash and cash equivalents of $235.0&nbsp;million, and marketable securities of $188.4&nbsp;million. Our cash and cash equivalents consist of cash in bank accounts, money market accounts, and other highly liquid investments with original
maturities of 90 days or less from the date of purchase. Our marketable securities consist of U.S. treasury securities, investment-grade corporate and government agency securities, and commercial paper. Our primary uses of cash are
personnel-related, inventory and selling, marketing and related costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe our existing cash, cash equivalents,
and marketable securities will be sufficient to meet our working capital and capital expenditure needs for at least the next 12 months, though we may require additional capital resources in the future. Our future capital requirements will depend on
many factors, including our growth rate, headcount, sales and marketing activities, research and development activities, the introduction of new features and programs, and acquisitions. If we require additional capital, we may not be able to raise
such capital on reasonable terms, or at all. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Cash Flows </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes our cash flows for the years indicated: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(63,909</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Operating Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cash used in operating activities was $63.9&nbsp;million for the year ended December&nbsp;31, 2023, resulting from a net loss
of $108.1&nbsp;million, which was partially offset by <FONT STYLE="white-space:nowrap">non-cash</FONT> activity of $34.8&nbsp;million and net cash inflows from changes in operating assets and liabilities of $9.4&nbsp;million. <FONT
STYLE="white-space:nowrap">Non-cash</FONT> items consisted primarily of amortization of deferred contract costs of $20.3&nbsp;million, excess and obsolete inventory transition charges of $10.3&nbsp;million, depreciation and amortization costs of
$5.6&nbsp;million, allowance for credit losses of $4.9&nbsp;million, <FONT STYLE="white-space:nowrap">non-cash</FONT> operating lease expense of $3.3&nbsp;million, and stock-based compensation expense of $1.6&nbsp;million, partially offset by
$10.8&nbsp;million of accretion of discounts and amortization of premiums on marketable securities. The change in operating assets and liabilities were driven by an increase in deferred revenue of $36.0&nbsp;million, increase in accounts payable and
accrued liabilities of $11.6&nbsp;million and a decrease in inventory of $10.6&nbsp;million, partially offset by an increase in deferred contract costs of $27.8&nbsp;million and an increase in accounts receivable of $23.1&nbsp;million due to
billings growth. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Investing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cash provided by investing activities was $1.5&nbsp;million for the year ended December&nbsp;31, 2023, driven by proceeds from
marketable securities maturities of $459.5&nbsp;million, offset in part by purchases of marketable securities of $453.3&nbsp;million and $4.6&nbsp;million used for purchases of property, equipment and capitalized
<FONT STYLE="white-space:nowrap">internal-use</FONT> software. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Financing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cash used in financing activities was $3.0&nbsp;million for the year ended December&nbsp;31, 2023, consisting of
$2.9&nbsp;million cash paid for the settlement of acquisition related holdbacks and $0.6&nbsp;million for deferred offering costs, partially offset by $0.5&nbsp;million of proceeds from the exercise of employee stock options. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Cash Management </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We manage our operating cash activities through banking relationships with our domestic and international subsidiaries. We
diversify our cash deposits across well-established financial institutions to reduce our exposure to counterparty and concentration risk. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect a continued increase in our cash balances as our business continues to grow and as a result of the proceeds
generated from our initial public offering. We expect to maintain a diversified cash management strategy to primarily include money market funds, highly-liquid debt instruments such as U.S. treasury securities, investment-grade corporate and
government agency securities and commercial paper to reduce our exposure on banking deposits. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Lease Obligations
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We enter into various <FONT STYLE="white-space:nowrap">non-cancellable</FONT> lease agreements for certain office
space in the normal course of business. Our <FONT STYLE="white-space:nowrap">non-cancellable</FONT> lease obligations as of December&nbsp;31, 2023 were $15.7&nbsp;million, of which $4.6&nbsp;million is payable within 12 months. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Other Contractual Obligations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We enter into various <FONT STYLE="white-space:nowrap">non-cancellable</FONT> agreements with marketing vendors and various
service providers. Our noncancellable obligations as of December&nbsp;31, 2023 were not material for disclosure purposes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Vesting of RSUs and PRSUs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have granted RSUs and PRSUs to our employees and certain <FONT STYLE="white-space:nowrap">non-employees.</FONT> All the RSUs
vest upon the satisfaction of both a time and a service-based vesting condition and a liquidity event vesting condition. All the PRSUs vest upon the satisfaction of both the performance condition and a service-based vesting condition, and a
liquidity event. During the quarter in which this offering is completed, we will be recording stock-based compensation expenses for the RSUs and PRSUs that have previously achieved the service-based vesting condition or the performance-based
condition and begin recording stock-based compensation expense for these RSUs and PRSUs with a liquidity-based vesting condition as the service-based vesting condition or performance-based condition is achieved. If this offering had occurred on
December&nbsp;31, 2023, we would have recognized cumulative stock-based compensation expense related to RSUs and PRSUs of $269.6&nbsp;million and $111.3&nbsp;million, respectively, for which the service-based vesting condition was satisfied or
partially satisfied, and the remaining unrecognized stock-based compensation expense relating to these RSUs and PRSUs would have been $87.5&nbsp;million and $118.1&nbsp;million, respectively. At the time of the offering, we expect to recognize
stock-based compensation expense of approximately $&#8195;&#8195; million for which the service-based vesting condition was satisfied or partially satisfied as of and for which we expect the liquidity-based vesting condition to be satisfied in
connection with this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Off Balance Sheet Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We did not have during the periods presented, and we do not currently have, any
<FONT STYLE="white-space:nowrap">off-balance</FONT> sheet financing arrangements or any relationships with unconsolidated entities or financial partnerships, including entities sometimes referred to as structured finance or special purpose entities,
that were established for the purpose of facilitating <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements or other contractually narrow or limited purposes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have prepared our consolidated financial statements in accordance with GAAP. The preparation of these consolidated financial
statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, costs, and expenses, and related disclosures. On an ongoing basis, we evaluate our estimates and assumptions. Our actual
results may differ from these estimates under different assumptions or conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that of our significant
accounting policies, which are described in Note 2 of the notes to our consolidated financial statements, the following accounting policies involve a greater degree of judgment and complexity. Accordingly, these are the policies we believe are the
most critical to aid in fully understanding and evaluating our consolidated financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Revenue Recognition </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We earn revenue from subscription fees by providing access to our platform and programs to treat and prevent MSK pain. We
currently sell subscriptions to our clients in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We determine revenue recognition through the following
five steps: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Identification of the contract, or contracts, with a client; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Identification of the performance obligations in the contract; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Determination of the transaction price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Allocation of the transaction price to the performance obligations in the contract; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Recognition of revenue, when, or as, we satisfy a performance obligation. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We determine that we have a contract with a client (1)&nbsp;when the contract has been approved by both parties, (2)&nbsp;we
can identify each party&#146;s rights regarding the services to be transferred and the payment terms for the services, and (3)&nbsp;we have determined that the client has the ability and intent to pay. We apply judgment in determining the
client&#146;s ability and intent to pay, which is based on a variety of factors, including the client&#146;s payment history or new client reputation and relationship with a health plan partner, as applicable. Our typical contracts are three years.
After the initial term, our contracts renew automatically for additional <FONT STYLE="white-space:nowrap">one-year</FONT> terms unless notice of termination is given by the client or us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The contracts contain a number of promised goods and services, including access to our platform, technical support, as well as
peripheral products, which includes the Enso device. We have determined our contracts contain three performance obligations which are provided to members: (1)&nbsp;access to the platform that is delivered over time; (2)&nbsp;technical support which
is delivered in the same pattern using the output method; and (3)&nbsp;the peripheral products, when and if sent as a part of our platform. As the platform and technical support are provided to the client concurrently over the contract term and have
the same pattern of transfer, we have concluded that these performance obligations represent one performance obligation consisting of a series of distinct services over the contract term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may provide the Enso device as part of our platform, which remains our legal property during the contract term. We
determine whether or not the Enso device is sent to members based on criteria that we control. If the Enso device is sent to a member as part of the platform, it constitutes a lease component as this device remains our property and the member has
the right to direct the use of the device during the contract term. Delivery of the device causes a change to the scope of the contract, as both our and client&#146;s rights have changed. We account for this change as a contract modification
resulting in the termination of the old contract and the start of a new contract. Our Enso device qualifies to be accounted for as an operating lease and the pattern of delivery from contract modification date to contract termination is consistent
with the timing for <FONT STYLE="white-space:nowrap">non-lease</FONT> components in the contract. For these client arrangements where the Enso device is leased in combination with services, we consider the arrangement to be predominately a service
and thus a combined single performance obligation for purposes of revenue recognition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The transaction price is a fixed
annual fee during a service period. The majority of our contracts are billed after a member&#146;s first completed billing activity, either the full annual fee at that time or upon the achievement of cohort milestones which are primarily achieved
once contractual exercise thresholds are met at a cohort level. When the billable volume varies based upon the achievement of cohort milestones, the consideration is variable at contract outset, and we estimate the volume of members based on
historical experience and adjust revenue as members complete cohort milestones. If the actual amounts of consideration received differ from our estimates, we adjust reported revenue in the period such variances become known. For the year ended
December&nbsp;31, 2023, changes to estimated variable consideration were not material. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Members have access to our
platform for a <FONT STYLE="white-space:nowrap">12-month</FONT> subscription term, which begins after the individual has completed their first billable activity on the platform&#151;we do not earn any fees until this point. We recognize revenue for
each member ratably over the <FONT STYLE="white-space:nowrap">12-month</FONT> member subscription period in order to match the pattern of revenue recognition to the pattern of costs incurred in delivering our platform. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Timing of revenue recognition may differ from the timing of billing. A majority of our clients are billed upfront or
throughout the first quarter of the member&#146;s subscription period. Our performance obligations are satisfied within 12 months of the member&#146;s first billable activity. Our contracts do not contain significant financing components. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, certain performance guarantees are included in most contracts
and are estimated at each reporting period based on our historical performance or other available information. We recognize any estimated adjustments to the contract price for not achieving the performance guarantees as an adjustment to revenue.
Payouts on these performance guarantees have been immaterial to date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We measure stock-based compensation awards, including stock options and RSUs, PRSUs and restricted stock awards
(&#147;RSAs&#148;) based on the estimated fair value of the awards on the date of grant. We record stock-based compensation expenses for awards issued to employees and <FONT STYLE="white-space:nowrap">non-employees</FONT> at fair value with a
corresponding increase in additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital. For awards that contain service conditions only, we recognize compensation expenses on a straight-line basis over the requisite service period of the
award. We recognize forfeitures when they occur. We have not granted stock options since March 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The RSUs vest upon
the occurrence of both a service-based condition and a liquidity event. We have not recognized any compensation cost related to awards with liquidity-based vesting conditions through December&nbsp;31, 2023, as we have determined the occurrence of a
liquidity event is not probable. We will record the expense for these awards using the accelerated attribution method over the remaining service period when the liquidity-based vesting condition is determined to be probable. We calculate the fair
value of each RSU grant based on the estimated fair value of our common stock on the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The PRSUs granted are
subject to not only a service-based, but also a performance-based vesting condition. The performance condition includes various milestones based on market capitalization thresholds or revenue targets as well as the occurrence of a liquidity event.
We have not recognized any compensation cost through December&nbsp;31, 2023, as we have determined the occurrence of a liquidity event is not probable. We will record the expense for these awards using the accelerated attribution method over the
remaining service period when we determine satisfaction of the liquidity-based vesting conditions, and the milestones are probable. The fair value of market condition PRSU grants are based on the Monte Carlo simulation model which incorporates
multiple valuation assumptions, including the probability of achieving the market condition, the term of the awards, and the expected common share volatilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The RSAs are considered issued because they are legally issued and have voting and dividends rights. The shares are included
in the outstanding common stock on the statement of redeemable convertible preferred stock and stockholders&#146; deficit in the consolidated balance sheets but are excluded in the calculation of basic net loss per share attributable to common
stockholders in the consolidated statement of operations and comprehensive loss because the shares are considered to be contingently returnable shares for accounting purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Given the absence of an active market for our common stock, management is required to estimate the fair value of our common
stock at the time of each grant of a stock-based compensation award. We utilize various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants&#146; Technical Practice Aid, Valuation of
Privately Held Company Equity Securities Issued as Compensation to estimate the fair value of our common stock. Each valuation methodology includes estimates and assumptions that require our judgment. These estimates and assumptions include a number
of objective and subjective factors in determining the value of our common stock at each grant date, including the following factors: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Prices paid for our capital stock, which we have sold to outside investors in
<FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> transactions, considering the rights and privileges of the securities sold relative to the common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Prices paid for shares of our common stock sold in secondary market transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Valuations performed by an independent valuation specialist; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our stage of development and revenue growth; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The market performance of comparable publicly traded companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Adjustments necessary to recognize a lack of marketability for the common stock underlying the granted RSUs,
PRSUs and RSAs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The likelihood of achieving a liquidity event for the common stock underlying the stock-based awards, such as
an IPO or sale of us, given prevailing market conditions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The U.S. and global economic and capital market conditions and outlook.<B><I> </I></B> </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Common Stock Valuation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Because our common stock is not publicly traded, our management exercises significant judgment in determining the fair value of
our common stock on the date of each grant. In determining the fair market value of our common stock, our management considers several objective and subjective factors, as noted above, with input from management and assistance from an independent
third-party valuation firm. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In valuing our common stock, we first determine the equity value using both the income and
market approach valuation methods. In addition, we also consider values implied by sales of preferred and common stock, if applicable. We then allocate the equity value to our classes of stock using an option pricing method. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The income approach estimates equity value based on the expectation of future cash flows that we will generate. These future
cash flows, and an assumed terminal value, are discounted to their present values using a discount rate based on a weighted-average cost of capital that reflects the risks inherent in the cash flows. The market approach estimates equity value based
on a comparison of the subject company to comparable public companies in a similar line of business as us. From the comparable companies, a representative market value multiple is determined and then applied to our financial forecasts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Once we determine an equity value, we use a combination of approaches to allocate the equity value to each of our classes of
stock. We have used an option pricing model, which allocates values to each equity class by creating a series of call options on our equity value, with exercise prices based on the liquidation preferences, participation rights, and strike prices of
the equity instruments. In determining the estimated fair value of our common stock, we consider the fact that our stockholders could not freely trade our common stock in the public markets. Accordingly, we also applied a lack of marketability
discount to the equity value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Following this offering, it will not be necessary to determine the fair value of our common
stock, as our shares will be traded in the public market. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">See Note 2 to our audited financial statements included elsewhere in this prospectus for more information about recent
accounting pronouncements, the timing of their adoption, and our assessment, to the extent we have made one yet, of their potential impact on our financial condition of results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>JOBS Act Accounting Election</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are an emerging growth company, as defined in the JOBS Act, and, for so long as we continue to be an emerging growth
company, we may take advantage of certain exemptions from various reporting requirements that would have been applicable were we a public company that was not an emerging growth company. Such exemptions include, but are not limited to, the exemption
to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, the exemption from holding a <FONT
STYLE="white-space:nowrap">non-binding</FONT> advisory vote on executive compensation, and the exemption from stockholder approval of any golden parachute payments not previously </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
approved. In addition, pursuant to Section&nbsp;107 of the JOBS Act, as an emerging growth company, we have elected to take advantage of the extended transition period for complying with new or
revised accounting standards until those standards would otherwise apply to private companies. If we cease to be an emerging growth company, we will no longer be able to take advantage of these exemptions or the extended transition period for
complying with new or revised accounting standards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and Qualitative Disclosures about Market Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Market risk represents the risk of loss that may impact our financial position because of adverse changes in financial market
prices and rates. Our market risk exposure is primarily a result of exposure resulting from potential changes in interest rates or exchange rates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Interest Rate Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2023, we had $235.0&nbsp;million in cash and cash equivalents and marketable securities of
$188.4&nbsp;million. Our cash, cash equivalents, and marketable securities consist of cash held in readily available checking, money market accounts, U.S. treasury securities, investment-grade corporate and government agency securities, and
commercial paper. As of December&nbsp;31, 2023, we did not hold any financial instruments for trading purposes. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest
rates. The effect of a hypothetical 10% change in interest rates would have a $0.7&nbsp;million impact on our consolidated statement of operations for the year ended December&nbsp;31, 2023. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Foreign Currency </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have employees and contract with vendors in foreign countries, primarily in India and Canada. We are therefore subject to
fluctuations in foreign currency rates in connection with these agreements. Given our exposure to these fluctuations is only applicable to a small portion of our expenses, we do not hedge our foreign currency exchange rate risk. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We report gains and losses from foreign currency transactions in other income in the statement of operations. The impact of
foreign currency costs on our operations has been immaterial for all periods presented, but we may experience material foreign exchange gains or losses in the future. As of December&nbsp;31, 2023, a 10% increase or decrease in current exchange rates
would not have a material impact on our consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom829170_12"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our vision is
to create a vertically integrated healthcare system powered by innovative technology&#151;and we are starting with MSK care. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Hinge Health is a leading technology platform for individuals seeking to treat and prevent joint and muscle pain. We leverage
AI and software to deliver an outstanding member experience, improved member outcomes, and cost reductions for our clients. We have designed our platform to address a broad spectrum of joint and muscle care&#151;from acute injury, to chronic pain,
to post-surgical rehabilitation. Our platform integrates <FONT STYLE="white-space:nowrap">AI-powered</FONT> motion tracking technology, a proprietary electrical nerve stimulation wearable device, and an
<FONT STYLE="white-space:nowrap">AI-supported</FONT> care team of licensed physical therapists, physicians, and board-certified health coaches to address our members&#146; MSK conditions while reducing the need for surgeries or pain medications. Our
platform is driving equity in care access by meeting our members where they are, allowing them to choose where, when, and how often they engage in their exercise therapy sessions and embrace movement as a way of life. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There is no shortage of new technologies in the healthcare industry, yet the cost of care continues to rise. In other
industries, the launch of new technologies has generally improved user experiences and lowered costs. In healthcare, however, new technologies have not always been successful in lowering the cost of care or improving clinical outcomes. We believe
the key reasons healthcare&#146;s response to technology has been idiosyncratic are because: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Previous technologies often delivered care digitally, but without significantly differentiating the member
experience, outcomes, or cost savings as compared to offline providers; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The current framework for healthcare reimbursement has specific pathways to pay for care, which means new
technologies are constrained to deliver within this framework. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At Hinge Health, we have taken a
different approach to solving these problems. Our platform uses AI and software to deliver effective MSK care with an <FONT STYLE="white-space:nowrap">AI-supported</FONT> care team. We developed novel billing methods for our innovative technology by
partnering with health plans, PBMs, TPAs and other ecosystem entities such as centers of excellence and healthcare navigation companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">MSK pain is pervasive&#151;it affects people around the world, across all ages, genders, and socioeconomic backgrounds. MSK
conditions impact an estimated 1.7&nbsp;billion people worldwide and are a leading contributor to disability. MSK conditions include more than 150 ailments and are characterized by impairments in the muscles, bones, joints, and connective tissues,
leading to temporary or long-term limitations in physical function. Within the United States alone, our current core market, approximately 40% of the United States adult population suffered from an MSK disorder in 2021, according to the WHO
Estimator. Medical literature indicates that conservative, less invasive care, including physical therapy and pain education, can be an effective route for addressing many MSK conditions. However, only about 9% of adults in the United States pursued
physical therapy in 2023, according to our analysis of Health Claims Data. Further, according to our analysis of Health Claims Data from 2023, the majority of the estimated $381&nbsp;billion spent annually on MSK conditions in the United States is
driven by <FONT STYLE="white-space:nowrap">non-conservative</FONT> care, including surgical intervention, imaging, and other related costs. A review of high-quality clinical practice guidelines demonstrated that patients should address education,
physical activity, and exercise as a first line of treatment for the most common MSK pain. While physical therapy is typically the ideal course of treatment, adherence to traditional physical therapy remains a significant challenge. According to a
2022 study on physical therapy adherence published in PloS One, 57% of participants did not adhere to their physical therapy program, with 32% discontinuing treatment prior to completion due to logistical and accessibility issues. Additionally,
physical therapy is often expensive, time-consuming, inconvenient, and difficult to access, which we believe leads many to eventually opt instead for surgery or pain medications. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While the MSK market is massive, the existing solutions have fallen short as
they are often expensive and ineffective. Effective MSK care should be engaging, easy to use, and accessible anytime, anywhere. We developed Hinge Health to address the inefficiencies in the legacy system that treats MSK conditions today. We
designed our platform to be simple, accessible, complete, and personalized. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Simple and accessible</B>: Traditional MSK care can be difficult to access. While digital physical therapy
that provides basic teleconferencing capabilities may address certain barriers to access, such as reducing the distance to care, effective accessible care must provide the right type of care at the right time with the right people. Members can
access our broad spectrum of MSK care through a single <FONT STYLE="white-space:nowrap">on-demand</FONT> app, designed to provide an engaging, seamless, and convenient digital experience whenever and wherever the member chooses.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Complete</B>: Our platform offers a wide range of support with multiple programs across many affected areas
to provide a continuum of care from prevention to treatment of acute injury and chronic pain, as well as surgery decision support and post-surgical recovery. We also offer <FONT STYLE="white-space:nowrap">non-addictive</FONT> and <FONT
STYLE="white-space:nowrap">non-invasive</FONT> pain relief via electrostimulation through our proprietary <FONT STYLE="white-space:nowrap">FDA-cleared</FONT> wearable device, Enso, that is seamlessly integrated into our platform.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Personalized</B>: Our platform delivers smarter care through AI and machine learning. Our AI model is
trained on a large, proprietary MSK data set, and our technology is continuously learning and improving as each new member enrolls and engages with our programs, which creates a positive feedback loop. As of September&nbsp;30, 2024, we have treated
over one million members and our programs have tracked over 59&nbsp;million activity sessions and 27&nbsp;million member-reported outcome logs. We focus on personalization to keep members moving: from customized care plans to real-time <FONT
STYLE="white-space:nowrap">in-app</FONT> exercise adjustments based on the member&#146;s feedback and our proprietary motion tracking technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have developed an efficient <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">go-to-market</FONT></FONT>
model by working directly with our partners and clients. Our clients are primarily self-insured employers and include many of the nation&#146;s leading enterprises across a broad range of industries and sizes. Within this segment, we also serve many
public sector self-insured employers, such as state and local city governments. In most instances, we partner with clients&#146; health plans, TPAs, PBMs, or other ecosystem entities to reduce the friction of contracting, pricing, security and IT
compliance, onboarding, and billing. We are also in the early stages of expanding to serve health plans&#146; fully-insured and Medicare Advantage populations and federal insurance plans. As of September&nbsp;30, 2024, we had approximately
18&nbsp;million contracted lives across more than 2,000 clients. We had active client agreements with 48% of the Fortune 100&nbsp;companies and 42% of the Fortune 500 companies, as of September&nbsp;30, 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that we grow efficiently because of our scalable, repeatable <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">go-to-market</FONT></FONT> model. We sell through our direct sales force and our partners. Once we contract with a client, we are typically the sole digital MSK care provider to their contracted lives for an average
contract term of three years. For the term of each contract, we are able to enroll, engage, and <FONT STYLE="white-space:nowrap">re-engage</FONT> the client&#146;s eligible lives, driving a recurring, repeatable revenue model, which is demonstrated
in our net dollar retention of &#8195;% as of December&nbsp;31, 2024. Our <FONT STYLE="white-space:nowrap">12-month</FONT> client retention rate was 98% as of September&nbsp;30, 2024, and as of October&nbsp;31, 2024, our client NPS was 87, which
demonstrates our high level of client satisfaction. We also invested early in building our partner network. As of September&nbsp;30, 2024, we had over 50 partners, including four out of the five largest national health plans by self-insured lives
and the top three PBMs by market share. Accordingly, we benefit from flywheel effects in our partnership sales motion. We start with selling into self-insured businesses within a health plan. When the plan witnesses the benefits we bring to its
self-insured customer base, they often designate us as a preferred partner within their network. Our results position us favorably to then contract with our health plan partners for both their fully-insured and Medicare Advantage businesses &#150;
as of September&nbsp;30, 2024, we have 26 fully-insured or Medicare Advantage contracts with health plans, almost all of which started with a self-insured employer relationship. Given the conservative nature of our industry, this market success in
turn encourages other plans and employers to partner with us as a market leader. As of September&nbsp;30, 2024, we had retained 100% of our partners that we choose to work with since inception, excluding partners who were acquired. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our <FONT STYLE="white-space:nowrap">software-led,</FONT> <FONT
STYLE="white-space:nowrap">AI-powered</FONT> delivery model not only aims to provide a better experience for our members and a less expensive alternative for our clients, but also allows us to innovate and continuously improve our platform. Our <FONT
STYLE="white-space:nowrap">AI-powered</FONT> motion tracking technology, TrueMotion, allows us to deliver highly scalable care remotely and reduce the human hours associated with traditional physical therapy. As of September&nbsp;30, 2024, over 80%
of member interactions on our platform were technology-only interactions. While members receive a dedicated care team, our technology automates key aspects of the care delivery while allowing our members to progress through their exercise therapy
sessions on their own time. Our members can be confident in their movements as our technology provides exercise form guidance and correction through our <FONT STYLE="white-space:nowrap">AI-powered</FONT> motion tracking. TrueMotion uses the camera
on a smartphone or tablet to measure three-dimensional human motion across more than 100 unique points on a member&#146;s body. This allows our care team to spend time with members where our care team can be most impactful and enables us to train
our AI technology to improve delivery of care. We have also invested in building software and data integrations that connect with our partners and a growing network of <FONT STYLE="white-space:nowrap">in-person</FONT> providers of certain members.
Through HingeConnect, we integrate EHR data from over 750,000 providers across 140,000 care sites nationwide. This data includes daily and weekly insurance claims feeds, prior authorization records, and health plan partner referrals. Through
real-time data feeds, we have visibility into our members&#146; health data when they enroll in our programs, thereby facilitating more personalized, timely care to address their needs. We also receive data that enables us to quickly identify
members who are at higher risk of increased healthcare costs and to provide targeted interventions to support them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We
are a <FONT STYLE="white-space:nowrap">research-led</FONT> organization and we routinely expand our platform with new programs, capabilities, and features. Over the last three years, we: launched new programs to address six new affected areas;
launched Enso to deliver a <FONT STYLE="white-space:nowrap">non-addictive,</FONT> <FONT STYLE="white-space:nowrap">non-invasive</FONT> alternative for pain relief; developed HingeConnect for real-time care interventions and external provider
coordination; and integrated TrueMotion technology to replace wearable sensors for our members. In 2022, we launched women&#146;s pelvic health, a specialized care program within our chronic program, and, in 2023, we launched a fall prevention
program for eligible lives in our Medicare Advantage population. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have experienced significant growth since our
inception, with a recurring revenue business model and an efficient <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">go-to-market</FONT></FONT> motion. As of December&nbsp;31, 2024, we had approximately &#8195; members and
approximately&#8195;&#8195;&#8195;&#8195; clients, compared to approximately 371,000 members and approximately 1,650 clients as of December&nbsp;31, 2023. Our revenue was $&#8195;&#8195;million and $293&nbsp;million for the years ended
December&nbsp;31, 2024 and 2023, respectively, representing a year-over-year growth rate of &#8195;%. Gross profit was $&nbsp;&#8195;&#8195;million and $194&nbsp;million for the years ended December&nbsp;31, 2024 and 2023, respectively. For the year
ended December&nbsp;31, 2024, we achieved a gross margin of&#8195;% compared to 66% for the year ended December&nbsp;31, 2023. For the year ended December&nbsp;31, 2024, our <FONT STYLE="white-space:nowrap">non-GAAP</FONT> adjusted gross margin
was&#8195;%, compared to 70% for the year ended December&nbsp;31, 2023. Net cash used in operating activities was $&#8195; million and $63.9&nbsp;million for the years ended December&nbsp;31, 2024 and 2023, respectively, and free cash flow was an
outflow of $&#8195;&#8195;&nbsp;million and $68.5&nbsp;million for the years ended December&nbsp;31, 2024 and 2023, respectively. See the section titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations&#151;Non-GAAP Financial Measures&#148; for a reconciliation of non-GAAP gross profit and gross margin to GAAP gross profit and free cash flow to net cash used in operating activities. We incurred net losses of $&#8195;&#8195; million and
$108.1&nbsp;million for the years ended December&nbsp;31, 2024 and 2023, respectively. As of December&nbsp;31, 2023, we had an accumulated deficit of $510.8&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Industry Background </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>MSK conditions are widespread and significantly impact quality of life. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">MSK conditions include more than 150 ailments and are characterized by impairments in the muscles, bones, joints, and
connective tissues that lead to temporary or long-term limitations in physical function. The pain caused by MSK conditions can have debilitating effects on one&#146;s quality of life, comorbidities, mental well-being, and ability to work. Findings
from the State of MSK Care 2024 Survey indicate that pain, especially </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
chronic pain, can create a vicious cycle of fear, depression, sleep issues, activity avoidance, and more. Among the takeaways from the State of MSK Care 2024 Survey: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I></I><B><I>Barriers to traditional physical therapy include cost and access</I></B><I></I>: 50% of
respondents indicated that traditional physical therapy was too expensive for them to pursue. Of those who initiated physical therapy but later stopped, 54% indicated that their insurance did not cover sufficient physical therapy sessions;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I></I><B><I>People in pain want to avoid costly, risky interventions</I></B><I></I>: 77% of respondents said
that <FONT STYLE="white-space:nowrap">non-surgical</FONT> options to treat their MSK pain are preferred; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I></I><B><I>Pain is a mental health issue</I></B><I></I>: 38% of respondents reported that their MSK pain
made them feel more depressed and 44% reported that their MSK pain made them feel more anxious. Furthermore, respondents reported that their pain increased and amplified symptoms of these mental health conditions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I></I><B><I>Pain rarely exists in isolation</I></B><I></I>: 53% of respondents said that MSK pain affected
their sleep, 22% reported being obese, and 17% reported having type 2 diabetes; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I></I><B><I>Pain negatively impacts everyday life and work</I></B><I></I>: 27% of respondents reported that
MSK pain had decreased their productivity at work, and 22% reported that pain had caused them to consider leaving their jobs because they were unable to manage their pain at work. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Furthermore, MSK pain is often an overlooked symptom associated with pelvic floor disorders. Pelvic floor disorders can happen
at any age and include a variety of symptoms depending on the kind of pelvic floor disorder. According to a study published in Scientific Reports in 2022, 32% of women attending primary care clinics have at least one pelvic floor disorder. However,
most do not receive treatment due to a lack of awareness, stigma, and inadequate access to pelvic floor physical therapists. According to the International Continence Society, the average time it takes for impacted women to seek out a diagnosis for
certain pelvic disorder conditions is more than six years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">MSK conditions are also a key driver of injuries related to
falls among senior citizens. In 2024, there are roughly 62&nbsp;million adults aged 65 and older in the United States, which account for approximately 18% of the population. As we age, our balance, strength, and reactions tend to worsen, increasing
our risk of falls. According to the Centers for Disease Control and Prevention Centers, more than one in four older adults fall each year, which leads to an estimated 3.6&nbsp;million emergency department visits with estimated costs of over
$80&nbsp;billion in medical treatments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Rising costs related to MSK conditions are too big to ignore. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Within the United States alone, our current core market, approximately 40% of adults suffered from an MSK disorder in 2021,
according to the WHO Estimator. The U.S. economy suffers from the weight of MSK medical costs, which rose to an estimated $381&nbsp;billion in 2016. MSK conditions are one of the top drivers of healthcare spending in the United States and accounted
for nearly one in seven dollars spent on healthcare expenses in 2016. Because of population growth and aging, the number of people living globally with MSK conditions and associated functional limitations is increasing. Employers notice the costs:
for example, approximately 74% of employers reported that MSK conditions were a top driver of their healthcare spending in 2024, according to a survey conducted by Business Group on Health. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The high cost of treating MSK conditions is largely due to expensive and invasive surgeries. According to a study published in
International Orthopaedics, the total cost of elective orthopedic and MSK surgery in the United States was approximately $205&nbsp;billion in 2017, or an average of approximately $42,800 per procedure given the more than 4.8&nbsp;million elective
orthopedic and MSK surgical procedures conducted that year. According to our analysis of Health Claims Data, approximately 62% of spending on the treatment of MSK conditions in 2022 was attributed to surgery intervention and related costs. The
remainder of spending on the treatment of MSK conditions is spread across physical therapy, imaging, office visits, and other ancillary services. A review </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
of high-quality clinical practice guidelines demonstrated that patients should address education, physical activity, and exercise as a first line of treatment for the most common MSK pain. Given
the considerable spending on MSK conditions, employers understand the clear cost benefits that utilizing our platform can enable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The existing approach to MSK pain is inadequate and leaves individuals seeking more effective alternatives. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Medical literature indicates that conservative care management through physical therapy can be an effective route for
addressing many chronic MSK conditions. However, there is often a disconnect between the MSK care that is needed and the care that is received. According to the Hinge Health People in Pain Survey of individuals that suffered from chronic and acute
MSK pain, almost half of respondents reported that they wouldn&#146;t be able to manage pain without professional help. However, our analysis of Health Claims Data indicates that only 9% of adults in the United States pursued <FONT
STYLE="white-space:nowrap">in-person</FONT> physical therapy in 2023. While the Hinge Health People in Pain Survey found that 70% of respondents reported that they understood the health benefits available to them, 64% of respondents reported that
they were not currently using a care plan created by a professional. According to the survey, the disparities were further emphasized when taking demographic differences into account. At the time of the survey: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">13% of lower income individuals used <FONT STYLE="white-space:nowrap">in-person</FONT> physical therapy
compared to 29% of higher income individuals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">12% of women used <FONT STYLE="white-space:nowrap">in-person</FONT> physical therapy compared to 26% of men;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">7% of individuals age 57 and older used <FONT STYLE="white-space:nowrap">in-person</FONT> physical therapy
compared to 29% of people age&nbsp;26&#150;40. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe the reason for the disparities and disconnect
between the MSK care needed and the MSK care received is that the legacy system for treating MSK conditions is often difficult to access, incomplete, and can drive people to potentially avoidable surgeries, injections, and pain medications. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Difficult to access</B>: <FONT STYLE="white-space:nowrap">In-person</FONT> physical therapy can be
difficult to access due to barriers such as the limited supply of providers and their availability, the location of providers, and an individual&#146;s ability to commit time to the process. For instance, physical therapy appointments may take time
to schedule, depending on the availability of the provider, and the experience can be highly dependent on the expertise of the particular provider. In order to make care more accessible, there is a need to reduce potential points of friction.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Incomplete</B>: According to the Hinge Health 2022 AQ Survey, four in five respondents needed more than
physical therapy to improve their recovery. Whether there is too much pain to begin a physical therapy program or a <FONT STYLE="white-space:nowrap">co-existing</FONT> health condition, providing physical care alone often leaves a gap in the care
needed and mental health or other supportive care is also required. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Avoidable surgery</B>: Whether <FONT STYLE="white-space:nowrap">in-person</FONT> or digital, siloed care
within the legacy treatment system means that a physician visit could quickly escalate to a nearly $100,000 surgery because divisional units within the system can result in disjointed care. According to our analysis of Health Claims Data,
approximately 62% of spending on the treatment of MSK conditions in 2022 was attributed to surgery intervention and related costs. A review of high-quality clinical practice guidelines demonstrated that patients should address education, physical
activity, and exercise as a first line of treatment for the most common MSK pain.<I> </I> </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Market Opportunity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe there is a substantial opportunity to use technology and AI to transform how individuals approach physical therapy,
treatment of chronic and acute pain, and care management for MSK conditions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Within the United States alone, our current core market, approximately 40% of the U.S. adult population suffered from an MSK disorder in 2021, according to the WHO Estimator, leading to an
estimated $381&nbsp;billion spent in that year on MSK treatments. Based on our analysis of Health Claims Data, we believe that approximately $42&nbsp;billion is spent annually on physical therapy, which is a subset of MSK treatment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our initial focus has been on self-insured employers, who bear the healthcare costs of their employees and employees&#146;
dependents. According to AIS Health, approximately 120&nbsp;million individuals received healthcare coverage from self-insured U.S. employers as of 2021. Based on our analysis of Health Claims Data and our finding that approximately 9% of adults in
the United States pursued <FONT STYLE="white-space:nowrap">in-person</FONT> physical therapy in 2023, combined with our pricing methodology, we believe that the addressable market opportunity for our platform and programs is approximately
$10&nbsp;billion based on our current platform and programs. We recently expanded our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">go-to-market</FONT></FONT> motion to include fully-insured employers, Medicare Advantage, and
federal insurance plans. We believe that by further expanding into these segments, an additional 96&nbsp;million lives can be addressed by our platform and programs, which, combined with our pricing methodology, represent an additional addressable
market opportunity of $8&nbsp;billion. As a result, we believe that the immediate addressable market opportunity for our platforms and programs is approximately $18&nbsp;billion across the self-insured and fully-insured, Medicare Advantage, and
federal insurance market segments. We developed a fall prevention program to help us better address the needs of the Medicare Advantage population. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We further believe that government agencies and government healthcare programs, such as Medicare and Medicaid, can provide an
additional 112&nbsp;million lives that can be addressed by our platform and programs, which, combined with our pricing methodology, represent an additional addressable market opportunity of $9&nbsp;billion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are strategically expanding into international markets. Initially, we are expanding through the global footprint of our
current clients&#146; employee base with the objective of supporting our clients&#146; employees in geographies that are key to them. We also plan to expand to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> based employers in other countries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have a history of product innovation, and we plan to continue to expand our programs. We recently launched a program that
delivers specialized care for women&#146;s pelvic health, a segment that is historically underserved even though, according to a 2022 study published in Scientific Reports, 32% of women attending primary care clinics have at least one pelvic floor
disorder and, according to UCLA Health, one in three women will suffer from a pelvic floor disorder in their lifetime. Another segment that we have identified as being underserved is specialized MSK care for women in their perimenopause, menopause,
and postmenopausal phases. An estimated 71% of perimenopausal women experience MSK pain, according to a 2020 study on MSK pain during the menopausal transition published in the Neural Plasticity journal. As we introduce new programs, we further
expand our addressable market opportunity by increasing the eligible lives that can benefit from our technology platform. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">According to the U.S. Bureau of Labor Statistics, the demand for physical therapy is expected to increase due to an aging
population and increased prevalence of chronic conditions such as diabetes and obesity. We believe that these trends will continue, and that our technology platform enables more accessible and affordable MSK care, driving the expansion of the
broader physical therapy market as utilization and adherence increase. We believe we are well positioned to address the large and durable market opportunity for our platform and products and continue to grow our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Platform </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are a
leading technology platform for individuals seeking to treat and prevent joint and muscle pain. We leverage technology and AI to automate the key aspects of care while delivering improved member outcomes, personalized member experiences, and cost
reductions for our clients. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Adherence is one of the largest challenges with physical therapy. We have
designed our platform to meet our members where they are, allowing them to choose where, when, and how often they engage in their exercise therapy sessions and embrace movement as a way of life. We address both the physical problems and the mental
health challenges of coping with and moving past pain. In doing so, we believe we reduce the need for surgeries and medications. To achieve this, we built a platform that pairs <FONT STYLE="white-space:nowrap">AI-powered</FONT> motion tracking
technology and a wearable device with an <FONT STYLE="white-space:nowrap">AI-supported</FONT> care team of licensed physical therapists, physicians, and board-certified health coaches. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We designed our platform to treat and prevent a broad spectrum of joint and muscle pain through scalable and personalized
care. We offer a wide range of support with multiple programs, including for those suffering from chronic pain to those considering surgical interventions or undergoing post-surgery rehabilitation. Our platform and programs aim to treat and prevent
MSK pain and injuries across the body, including the neck, upper back, shoulders, elbows, forearms, wrists, hands, lower back, hips, pelvic region, thighs, knees, shins, calves, ankles, and feet. Our
<FONT STYLE="white-space:nowrap">AI-powered</FONT> motion tracking technology allows us to provide exercise adjustments in real-time remotely, which reduces the human hours associated with traditional physical therapy and results in a more scalable
model of care. We also use AI and machine learning to provide personalized care through our programs, which are customized based on a member&#146;s affected areas and movement threshold. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We routinely expand our platform with new programs, capabilities, and features. Over the last three years, we have launched
new programs to address six additional affected areas, including specialized programs to address women&#146;s pelvic health and fall prevention. We also launched Enso to deliver a <FONT STYLE="white-space:nowrap">non-addictive,</FONT> <FONT
STYLE="white-space:nowrap">non-invasive</FONT> alternative for pain relief, developed HingeConnect for real-time care interventions and external provider coordination, and integrated TrueMotion technology to replace wearable sensors. As of
September&nbsp;30, 2024, we had approximately 18&nbsp;million contracted lives across more than 2,000 clients. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Value Proposition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Value to Our Members: </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At Hinge Health, we put our members first. Pain is personal. When a member reports a reduction in pain, they often share their
experience with others. As of September&nbsp;30, 2024, approximately nine out of ten members surveyed by us have reported being satisfied with our programs. We believe that our platform can address needs across demographics, occupations, and
lifestyles. Our members have ranged in age from 18 to over 90 and have represented all 50 states and several U.S. territories. As of September&nbsp;30, 2024, the average age of our members was 47. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Substantial outcomes</B>: We are encouraged by the positive outcomes our members report after using our
platform and programs. The research related to our programs spans 18 peer-reviewed research articles and studies and outcomes analyses, including the 2020 Longitudinal Study that evaluated the efficacy of our platform in a large population of
participants with chronic knee and back pain, where participants reported a 68% average improvement in reported pain and a 58% reduction in reported depression and anxiety after 12 weeks. We believe that what makes these results possible is the
high-quality care that our programs are designed to enable, coupled with the convenience and simplicity of our technology platform. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Accessible</B>: Traditional MSK care is often inconvenient, expensive, and hard to find. We have designed
our platform to allow members to access MSK care resources directly from their phone or tablet at their convenience. We allow members to reclaim their time while still accessing the care that they need. Because we provide care that is facilitated by
software and AI, members can engage with our platform and programs on demand. Our platform is typically offered at no direct cost to our members and is fully paid for by their employers or health plans. By comparison, the cost of <FONT
STYLE="white-space:nowrap">in-person</FONT> physical therapy copays for even 10&#150;12 sessions can be burdensome. We have redesigned the exercise therapy experience to encourage adherence through increased accessibility and affordability, and we
continually look for ways to further health equity. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Comprehensive care</B>: We continue to delve deeper into MSK care gaps and create tailored programs for
additional affected areas, needs, and members. Our platform allows us to track over 100 unique points on the body to address an individual&#146;s range of motion. In order to address physical and behavioral needs, we combat care gaps by pairing
technology with a care team. We believe that access to a physical therapist alone may not be enough to improve outcomes. We provide physical therapists, physicians, and health coaches, which are recognized for their value by the American Medical
Association, to address member needs and enable favorable member outcomes. A significant challenge with traditional physical therapy is adherence, so we designed our platform to not only address physical problems, but also the mental challenge of
moving past pain. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Personalized</B>: Our AI personalization engine estimates a member&#146;s risk profile and develops a
tailored care program for each member, which is overseen by our care team. We deliver members a specific care plan designed to align with their focus areas, meet their goals, and improve their overall quality of life. Our platform incorporates
member&#146;s real-time progression and feedback and adjusts their care plan to include exercises that align with the member&#146;s needs as they evolve over time. We also integrate a robust data set with EHRs from more than 750,000 <FONT
STYLE="white-space:nowrap">in-person</FONT> providers to get a comprehensive view of our members. This data set allows us to quickly identify member needs and flag those that are at risk of becoming high-cost claimants for additional intervention.
Examples of intervention include providing surgery decision support, adding our Enso device to a member&#146;s care plan, or addressing additional affected areas in their care plan, or providing additional care team support. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Educational</B>: According to an article published in the Archives of Rehabilitation Research and Clinical
Translation in 2023, an evidence-based, best practices approach for optimal management of chronic pain should include the three pillars of effective MSK pain care: exercise therapy; pain neuroscience education (&#147;PNE&#148;); and lifestyle and
behavioral adjustments. Two of the largest gaps in traditional treatment for MSK pain that are addressed by our platform are PNE and lifestyle and behavioral adjustments. Most people know that exercise therapy is directly linked to feeling better,
but for those with chronic pain, lasting behavioral change is critical in order for people to recover from their pain and achieve improved long-term outcomes The educational content and information delivered as part of the Hinge Health app is an
integral component of our platform. Our education helps members understand the causes of their chronic pain, the benefits of exercise therapy, and the lifestyle and behavioral health factors that influence their pain, as well as how to address and
improve them. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Seamless and simple</B>: We are dedicated to creating seamless healthcare experiences that are designed to
be easy to use and even fun, regardless of a member&#146;s background. We design our member experience to be streamlined with access to a single app where our platform is accessible on a device of a member&#146;s choosing. Hinge Health was the top
rated digital MSK care app in the Apple App store as of September&nbsp;30, 2024 with a 4.9 rating based on over 63,000 reviews. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Value to Our Clients: </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our clients are the businesses and organizations that pay for our platform for their covered employees and adult dependents,
either by contracting with us directly or by contracting for access to our platform through one of our partners. Our clients are primarily self-insured employers and include many of the nation&#146;s leading enterprises across a broad range of
industries and sizes. Much of the value to our members is aligned with the value to our client. Below are the added benefits that our clients receive through our platform. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Measurable outcomes and cost savings</B>: MSK costs are a top area of medical spend in the United States,
and with healthcare costs rising each year, employers and health plans look for ways to optimize costs. We believe our platform and programs provide our clients with financial benefits and our members with care that makes a difference in their
lives. We demonstrate medical claims-backed cost savings to our clients coupled with measurable outcomes for our members. Our platform is supported by the results from 18 studies, including our 2023 Employer Claims Study that estimated an ROI of
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
2.4x for clients included in the study, based on the estimated $2,387 average cost savings per member over a <FONT STYLE="white-space:nowrap">12-month</FONT> period divided by the cost of our
chronic program, as well as the 2020 Longitudinal Study that evaluated the efficacy of our platform in a large population of participants with chronic knee and back pain, where participants reported a 68% average improvement in reported pain and a
58% reduction in reported depression and anxiety after 12 weeks. Our clinical studies have been performed by third-party researchers at leading institutions such as Stanford University, University of California, San Francisco (&#147;UCSF&#148;), and
Vanderbilt University, and our medical claims ROI study was externally reviewed by a global leader in actuarial science. We can provide clients with estimated medical claims-based average ROI, specific outcomes as reported by their members on
several metrics, including pain, depression, and anxiety reduction, and NPS. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Employee wellbeing and productivity</B>: MSK pain is personal, and it can open the door to depression,
missed days at work, loss of productivity, and other adverse effects. Care that focuses only on physical injury is often not enough to overcome the debilitating physical, emotional, and financial costs of MSK pain. We think bigger about MSK pain by
addressing both the physical and mental strain of MSK pain in a way that is designed to lead to happier, healthier, and more productive employees. We provide outcomes information to our clients such as reported pain-related work absenteeism or
impaired work productivity in order to quantify the impact of our program on our members. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Ability to attract and retain talent</B>: Healthcare benefits have gained greater significance in the
recruitment and retention of employees, particularly in tight labor markets. Employees adopt technology in many other aspects of their lives and expect the same in their healthcare. Through technology, we aim to equip our members with the ability to
lead more enriching lives with improved health outcomes, which in turn may serve as a draw for our clients when recruiting talent. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Simplicity of implementation</B>: We are dedicated to streamlining processes for our clients and focus on
eliminating the time-related impairments associated with implementation. Through our strategic partnerships with health plans, PBMs, TPAs, and other ecosystem partners, we have streamlined the contracting and implementation process to enable launch
in as little as weeks compared to typically much longer implementation periods that are common within healthcare. This can substantially reduce the burden on our clients and expedite the cost savings our platform brings for them.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Value to Our Ecosystem Partners: </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have a vast ecosystem partner network that includes: health plans, PBMs, TPAs, digital health providers, centers of
excellence, healthcare navigation partners, brokers, and consultants. Similar to our approach with members and clients, we strive to create value for ecosystem partners. Examples of the value we help create with our partners include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Source of innovation</B>: In addition to the core medical and pharmacy products that clients purchase,
clients have grown to expect their health plans and PBMs to survey, vet, and select leading solutions that address their highest medical cost categories, such as MSK conditions. We designed our platform to create superior member experiences that
result in positive outcomes across a wide range of clients and demographics, allowing us to validate outcomes at scale. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Cost savings</B>: In addition to removing the administrative burden of selecting, contracting, and
integrating with healthcare solutions, ecosystem partners have selected our platform and programs for their fully-insured and Medicare Advantage plan populations to potentially increase their cost savings and optimize their star ratings.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Ease of client implementation</B>: With the proliferation of digital health providers, ecosystem partners
have become increasingly flexible at implementing <FONT STYLE="white-space:nowrap">one-off</FONT> solutions at the request of their clients. By taking a more proactive approach in selecting preferred providers, ecosystem partners can better
streamline integrations for their clients as opposed to a series of <FONT STYLE="white-space:nowrap">one-off</FONT> solutions that are disconnected and siloed. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>High-risk member engagement</B>: Given growing data that indicates that a small percentage of individuals
drive the majority of the healthcare costs, the imperative to identify, intervene, and treat high-risk members has become a top priority across our partners. Together with our data and interventions, our partners&#146; claims and prior authorization
data help us serve high-risk members more immediately. In addition, since most high-risk members have one or more comorbidities, we have designed our platform to seamlessly integrate with our partners&#146; care management arm to offer comprehensive
and tailored member care. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Competitive Strengths </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We seek to be the best solution on the market, the most validated solution on the market, and the easiest to buy. We believe
the following strengths differentiate our platform and programs, which will drive our continued success with new and existing clients and members. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Scale and Market Leadership </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are a leading digital MSK platform in the United States, with over 2,000 clients and approximately 18&nbsp;million
contracted lives as of September&nbsp;30, 2024. As of September&nbsp;30, 2024, we had over 50 partners, consisting of health plans (including four out of the five largest national health plans based on self-insured lives), PBMs (including the top
three PBMs by market share), TPAs, and other ecosystem partners (entities such as centers of excellence and healthcare navigation companies). We believe that our leadership and market differentiation make us a recognized and trusted brand within the
industry, as evidenced by our 98% client retention as of September&nbsp;30, 2024 for the last 12 months and client NPS of 87 as of October&nbsp;31, 2024. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Member-first, <FONT STYLE="white-space:nowrap">Software-led</FONT> Digital Care Delivery </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At Hinge Health, we begin with the member experience. We are invested in a platform that is designed to provide a seamless
member experience accessible <FONT STYLE="white-space:nowrap">on-demand</FONT> via a single app, which offers members the ability to access care from a member&#146;s personal smartphone or tablet. Our
<FONT STYLE="white-space:nowrap">software-led,</FONT> <FONT STYLE="white-space:nowrap">AI-powered</FONT> delivery model also enables us to deliver care at scale&#151;where members have the potential to benefit from the technology and expertise of
our entire platform instead of the individualized knowledge of an individual care provider, and where we can consistently innovate on our platform and member experience. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>AI Technology and Data Advantage </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have invested heavily in our AI algorithms to deliver smarter and scalable care. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Our <FONT STYLE="white-space:nowrap">AI-powered</FONT> application</B>: Traditional physical therapy, which
is typically conducted without the aid of <FONT STYLE="white-space:nowrap">AI-powered</FONT> motion tracking technology, is generally delivered in person through a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-to-one,</FONT></FONT> or up to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-to-four,</FONT></FONT> provider to member setting. Provider time is often
expensive and not scalable. We designed our app to offer members personalized exercise therapy treatment plans, provide support to our care team in evaluating members and making recommendations, and allow members to chat with their care team. We
leverage <FONT STYLE="white-space:nowrap">AI-powered</FONT> motion tracking technology to provide members with real-time audio and visual feedback during their exercise sessions to help correct their form. AI is also streamlining our care
team&#146;s interactions with members by providing summarized aggregate medical information and automating suggested message content when engaging with our members. We believe this increases our care team&#146;s efficiency and helps standardize the
quality of the interaction. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Proprietary data advantage</B>: We actively deploy large language models across our databases and implement
new uses of AI on our platform. Our proprietary exercise personalization engine leverages machine-learning from more than one million lifetime members that have used our platform and has tracked over 59&nbsp;million activity sessions and
27&nbsp;million member-reported outcome logs as of September&nbsp;30, 2024. AI is only as good as the data that are fed into the algorithm, and we believe we have the broadest data repository of any digital MSK solution, much of which is proprietary
and consistently refreshed through continued use of our platform. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>HingeConnect</B>: With surgeries accounting for the majority of MSK medical spending on average, based on
our analysis of Health Claims Data, it is important to identify high-risk eligible lives that are considering surgery, in order to consult with and further educate them on a range of MSK pain treatment options. According to our analysis of Health
Claims Data, approximately 6% of individuals drive 85% of MSK costs in 2023. HingeConnect is our proprietary <FONT STYLE="white-space:nowrap">AI-driven</FONT> database that helps us identify and target the cost-driving individuals by leveraging a
vast array of data, including demographics, comorbidities, exercise forms, and pain scores, as well as EHR data with daily claims feeds across over 750,000 providers. With our rich data set, combined with machine learning-based algorithms, we
designed our surgery decision support and high-risk program to proactively identify high-risk members in real-time before they become high-cost claimants to the client. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Scalable and Efficient <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Go-to-Market</FONT></FONT>
Strategy </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our partner relationships provide us with an important competitive advantage. We are the preferred MSK
partner for over 50 health plans, PBMs, TPAs, and other ecosystem partners (entities such as centers of excellence and healthcare navigation companies), including four of the five largest national health plans by self-insured lives and the top three
PBMs by market share. Our partners collaborate with our sales force to win new clients. When we enter into an agreement with a partner, we typically win a large majority of the employers using that partner who go on to select a digital MSK solution.
Many employer clients prefer purchasing their benefits through their health plan because contracting and implementation are established and less onerous. Our partners also assist us in identifying and encouraging enrollment on our platform. For
example, a healthcare navigation partner can see if a contracted life with MSK conditions has access to Hinge Health and can direct them to our platform. Additionally, we enable members to refer <FONT STYLE="white-space:nowrap">co-workers</FONT> and
their dependent family members to try Hinge Health, which activates personal networks to increase enrollment in our programs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Outcomes for Members and ROI to Clients </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have tools designed to identify and appropriately intervene in order to provide improved outcomes for our members and cost
savings to our clients. We provide comprehensive care that includes providing surgery decision support with physicians, adding Enso to care plans to relieve pain, and addressing multiple affected areas at once. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We seek to change the lives of our members through improved physical and mental health. MSK pain can impact every facet of
life and can have a significant negative impact on mental health. Throughout our platform we track a number of member-reported outcomes including pain, depression, and anxiety to refine our holistic care approach. We believe that our focus on mind,
body, and behavioral support has led to members reporting improvements after the use of our programs, including the 2020 Longitudinal Study that evaluated the efficacy of our platform in a large population of participants with chronic knee and back
pain where participants reported a 68% average improvement in reported pain and a 58% reduction in reported depression and anxiety after 12&nbsp;weeks. Our research partnerships have included collaborations with institutions such as Stanford
University, UCSF, Vanderbilt University, University of Rhode Island, University of Washington, and University of Texas Austin. Our team of researchers have conducted or collaborated on numerous studies, including randomized controlled trials
(&#147;RCTs&#148;), observational clinical studies, and medical claims-based outcomes research studies. Since 2017, we have published 14 peer-reviewed research articles in established journals on program engagement, clinical outcomes, medical care,
and prescription drug utilization, in addition to four reviewed medical claims-based studies, in an effort to demonstrate the benefits of our programs in improving member outcomes and cost savings in medical cost. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Some of our published studies examine how member outcomes can lead to cost savings for our clients. Our 2023 Employer Claims
Study estimated a 2.4x ROI for clients, based on the estimated $2,387 average cost savings per member over a <FONT STYLE="white-space:nowrap">12-month</FONT> period divided by the cost of our chronic program. This study and its methodology were
externally reviewed by a leading actuarial and benefit consulting firm. For additional </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
information regarding our member and ROI studies, see the section titled &#147;&#151;Our ROI Studies&nbsp;and Clinical Outcomes.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Platform Extensibility and Proven Record of Innovation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are committed to continuous innovation. We have increased the number of affected areas addressed by our programs, from two
at our inception (knee and back), to sixteen (neck, upper back, shoulders, elbows, forearms, wrists, hands, lower back, hips, pelvic region, thighs, knees, shins, calves, ankles, and feet) as of September&nbsp;30, 2024. This breadth allows us to
reach more clients and increase utilization among our contracted lives and members. We have also introduced Enso, an <FONT STYLE="white-space:nowrap">FDA-cleared,</FONT> wearable device, developed HingeConnect, our proprietary <FONT
STYLE="white-space:nowrap">AI-driven</FONT> database for real-time care interventions and external provider coordination, and integrated our proprietary <FONT STYLE="white-space:nowrap">AI-powered</FONT> motion tracking technology to replace
wearable sensors and provide motion guidance during exercise therapy. We recently launched a program that delivers specialized care for women&#146;s pelvic health and a fall prevention program for eligible lives in our Medicare Advantage population.
We believe we have the ability to further increase access to our newly launched programs, and we plan to continue to innovate and identify ways to further integrate our platform into the member journey for MSK care. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Growth Strategy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We
have experienced significant growth since inception, which we attribute to expanding our client base, increasing adoption across our existing client base, launching new programs, and expanding into new markets. We believe we are well positioned for
continued growth, as we believe our current total contracted lives only represent approximately 5% of our target addressable market. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Expand Our Client Base in Our Core Markets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our core client base is self-insured employers. We believe the addressable market for self-insured employers in the United
States is approximately 120&nbsp;million lives, according to our analysis of data from AIS Health, of which approximately 17&nbsp;million were contracted in our existing client base as of September&nbsp;30, 2024. This provides a sizable growth
opportunity, which we can address by leveraging our experienced sales force and strong relationships with health plans, benefits consultants, and other ecosystem partners. Our sales force has a client-specific strategy, which is customized by
segment and client size. Our ecosystem partners play an important role by often offering us as their preferred MSK solution and providing a faster implementation route than contracting and implementation directly with clients. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Expand into New Markets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have expanded beyond our core self-insured employer market and will continue to evaluate opportunities to do so in the
future. In addition to self-insured employers, we also offer our platform to fully-insured health plan populations and Medicare Advantage populations. In many cases, after we have delivered positive outcomes for our partners&#146; self-insured
employers, they decide to contract with us for their fully-insured and Medicare Advantage lines of business. These two populations, combined with the federal insurance populations we are also expanding into, represent an estimated 96&nbsp;million
additional lives in the United States. We also developed a fall prevention program for eligible lives in our Medicare Advantage population and have seen compelling early interest in this program. We also expect to expand into additional government
agencies and government healthcare programs, such as Medicare and Medicaid, which represent an additional 112&nbsp;million lives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Regarding international expansion, we expanded into Canada in 2024 and expect to offer a global program to individuals in
several additional countries outside of the United States that are employees of U.S.-based multinational corporations by the end of 2024 and grow that program in 2025. We believe this could increase our number of contracted lives. We also plan to
expand to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> based employers in other countries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Increase Adoption Across Existing Client Base </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We also plan to drive growth by increasing adoption by eligible lives within our existing client base. First, we expect to
leverage our partner integrations, our proprietary HingeConnect <FONT STYLE="white-space:nowrap">AI-driven</FONT> database, and our growth team&#146;s capabilities to reach out to eligible lives when we believe they are most likely to benefit from
our platform. Through data integrations with EHRs and health plans, we receive information about when eligible lives have seen a provider about pain or requested imaging or surgery. When we offer our platform to eligible lives in a timely way, it
often increases adoption. We implemented a number of different marketing formats, which helped us to increase membership applications per impression from our legacy clients by 36% in a <FONT STYLE="white-space:nowrap">six-month</FONT> period between
the first quarter and the third quarter of 2024, and by 62% in a <FONT STYLE="white-space:nowrap">12-month</FONT> period between the third quarter of 2023 and the third quarter of 2024. We are continuing to refine this approach and believe we have
significant runway ahead to optimize how we convert and engage new members. Second, we have dedicated research and development resources to continuously optimize our targeting to maximize the number of eligible lives that enroll in our programs.
Third, many members cycle in and out of pain over the course of their lives and will likely need our platform for multiple years. We have continued to focus on making our programs relevant for members so that they continue to use them throughout
their lives, including by adopting our programs across multiple years. Additionally, we have increased the number of affected areas addressed by our platform, from two at our inception (knee and back) to sixteen (neck, upper back, shoulders, elbows,
forearms, wrists, hands, lower back, hips, pelvic region, thighs, knees, shins, calves, ankles, and feet) as of September&nbsp;30, 2024. We have also created programs for many different types of care by expanding from chronic care to include acute, <FONT
STYLE="white-space:nowrap">pre-</FONT> and post-surgery, and preventative care. These developments allow us to reach and engage more members. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Launch New Programs and Capabilities Driven by Investment in Our Platform </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have a history of innovation and expect to continue to develop and invest in our platform to provide more value to our
members, clients, and partners over time. We launched our platform for individuals with two affected areas and required physical sensors to deliver care, and we have since added fourteen affected areas and replaced all sensors with <FONT
STYLE="white-space:nowrap">AI-powered</FONT> motion tracking technology, while also broadening our programs. We believe we have a promising product roadmap ahead of us, including an expansion of our women&#146;s pelvic health and fall prevention
programs and further AI use cases. Given the broad potential of our platform, we believe that we have a truly significant opportunity to launch new programs and capabilities to attract new clients and increase adoption by eligible lives within our
existing clients, as well as to improve programs and optimize engagement with our care team given our proprietary data and AI advantage. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Programs
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since we first launched Hinge Health in 2014, we have been committed to continuous innovation, delivering accessible
and personalized MSK care, and providing a platform and programs that benefit our members and clients. We offer broad MSK care with multiple programs. From those suffering from chronic pain to those considering surgical interventions or undergoing
post-surgery rehabilitation, we created our platform and programs to treat and prevent MSK pain. By combining technology and AI with the expertise of a highly scalable care team, we can align members with the right program, provide them with a
personalized care plan designed to address their individual goals, and enable them to improve their overall quality of life. Our programs are described below: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Chronic</I></B>: Our chronic program focuses on both the physical and behavioral aspects of care for members suffering
from chronic musculoskeletal conditions. This program is available for a range of affected areas: upper and lower back, hip, pelvic floor, shoulders, knee, thigh, calf, shin, neck, elbow, forearm, hand, wrist, ankle, and foot. The vast majority of
our members are enrolled in our chronic program. Each member receives tailored exercise therapy through our <FONT STYLE="white-space:nowrap">AI-powered</FONT> technology, robust educational content, and the support of a care team composed of
licensed physical therapists, physicians, and board-certified coaches that support care escalations. If </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
more than one area of the body needs focus, our chronic program is available for multiple affected areas at the same time. 60% of new members enrolled in our chronic program in 2024 have used the
program to address more than one affected area. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Women&#146;s pelvic health</I></B>: In 2022, we launched our
women&#146;s pelvic health program as part of our chronic program in order to support women across stages of life when pelvic disorders are most common, including pregnancy, postpartum, and menopause. Our women&#146;s pelvic health program is
designed to address pelvic pain and other symptoms through our chronic program with the support of a care team composed of pelvic health physical therapists, board-certified women&#146;s health coaches, and urogynecologists that support care
escalations. We personalize member care around five women&#146;s pelvic health needs: pregnancy, postpartum, bladder control, pelvic pain, and pelvic strength. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Acute</I></B>: Our acute program is for members with short-term pain or a
<FONT STYLE="white-space:nowrap">one-time</FONT> injury, such as a sprained ankle. Similar to our other programs, members receive tailored exercise therapy and access to a care team. The acute program is more short-term oriented; however, if pain
persists beyond 12 weeks, a member can transition to our chronic program for ongoing care. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Surgery decision support
and high-risk member program</I></B>: Since surgeries accounted for the majority of MSK medical spending based on our analysis of Health Claims Data from 2023, it is important to identify high-risk eligible lives that are considering surgery in
order to consult with and educate them on a range of MSK treatment options. HingeConnect allows us to provide an enhanced care approach to support members by offering increased support and targeted interventions to help members reduce surgeries or
invasive treatments as appropriate. With our rich data set, combined with machine learning-based algorithms, HingeConnect is designed to proactively identify high-risk eligible lives before they become high-cost claimants to the client. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I><FONT STYLE="white-space:nowrap">Pre-</FONT> and post-surgery</I></B>: For members for whom MSK surgery is the treatment
recommended by medical professionals caring for them, we offer programs designed to improve the quality of their <FONT STYLE="white-space:nowrap">pre-</FONT> and post-surgical experience. Our <FONT STYLE="white-space:nowrap">pre-</FONT> and
post-surgery program is designed to expedite functional improvement and increase member satisfaction while reducing postoperative costs for the member and client. Through our platform, members receive guidance on exercise therapy for before and
after surgery, tailored education about the surgery and recovery, progress tracking, and tools to aid with surgical preparation, pain management, and recovery. A member&#146;s care plan can be shared with their surgeon in an effort to coordinate
care. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Fall prevention</I></B>: We launched a fall prevention program in 2023 to help adults aged 65 and older
improve their physical abilities and reduce their risk of falling. This program includes a combination of exercise therapy, education, and care team support. We currently offer the fall prevention program to our Medicare Advantage clients and expect
to make this program available to our self-insured employer populations in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Prevention</I></B>: Our
prevention program is a way for our members to maintain and improve their health and wellness and incorporate movement into their lives. Eligible lives who do not have MSK pain that are best addressed with our other programs are directed to our
prevention program. Members may also move to our prevention program after completing one of our other programs. We provide our prevention program at no charge to our clients. Our prevention program offers access to exercise routines and education
about sleep, stress management, nutrition, and movement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Technology </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe the thoughtful development of technology can radically improve the Triple Aim in healthcare (experience, outcomes,
and costs) while ensuring consistent care regardless of income level or geography. We firmly believe that in order to truly lower costs and ensure consistent care, technology must automate key aspects of care delivery. To that end, we have built our
platform to incorporate a number of features, including our: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Intelligently personalized exercise engine</I></B>:
Once an eligible life completes our screening process, our proprietary algorithm automatically analyzes the inputs and enrolls the eligible life onto our platform. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
algorithm takes the newly enrolled member&#146;s profile and health history into consideration and ingests various attributes, such as demographics, comorbidities, exercise outcomes, and pain
scores. We utilize data integration and machine learning to identify risk levels and specialized needs, and then place members into a program based on their profile. Our technology combines the member risk profile with any member-specific functional
goals and develops personalized exercise treatment plans for the member based on their focus areas, all overseen by our care team. Treatment plans are sets of curated stretching and strengthening exercises targeting the individual member&#146;s
focus areas. Members receive personalized, <FONT STYLE="white-space:nowrap">AI-generated</FONT> audio and visual feedback as they progress through their program, and their treatment plans evolve using near real-time feedback based on exercise form
tracked via our <FONT STYLE="white-space:nowrap">AI-powered</FONT> motion tracking technology, self-reported pain scores, and other member input. Our proprietary AI model is continuously learning and improving as each member enters our platform.
From inception through September&nbsp;30, 2024, we have had over 1&nbsp;million members, over 59&nbsp;million activity sessions tracked, and over 27&nbsp;million member reported outcome logs generated. The continuous improvement of our AI model and
growth of our dataset enables better and more effective recommendations that are personalized to each member. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Patented <FONT STYLE="white-space:nowrap">AI-powered</FONT> motion tracking technology (TrueMotion)</I></B>: Our
patented TrueMotion <FONT STYLE="white-space:nowrap">AI-powered</FONT> motion tracking technology is the foundation of our programs, intended to enable remote delivery at a fraction of the cost of traditional
<FONT STYLE="white-space:nowrap">in-person</FONT> care, which involves additional fees and costs such as overhead from rent and often requires a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-to-one</FONT></FONT> ratio between
the provider and care recipient. Our <FONT STYLE="white-space:nowrap">AI-powered</FONT> motion tracking technology gives members access to leading exercise form guidance and correction using the measurement of human motion in 3D, which are available
through the camera on their mobile device or personal tablet. Computer vision captures movement across the member&#146;s body through over 100 reference points in order to guide complex exercises and allows us to track smaller areas of the body like
the head, wrist or hand. Our <FONT STYLE="white-space:nowrap">AI-powered</FONT> motion tracking technology guides the member with feedback on pace, alignment, and depth of an exercise, like a squat, to increase confidence in movement. This
technology enables near real-time feedback for a wide range of movements and provides our data model and our physical therapists with more insights to personalize the member&#146;s continuing care plan. The TrueMotion technology is supported by U.S.
and foreign issued patents as well as pending patent applications as of September&nbsp;30, 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Proprietary
high-risk identification engine (HingeConnect)</I></B>: According to our analysis of Health Claims Data, approximately 6% of health plan individuals drove 85% of <FONT STYLE="white-space:nowrap">MSK-related</FONT> medical costs in 2023. To optimize
ROI for our clients, it is important to identify and engage high-risk individuals. Utilizing HingeConnect, our proprietary engine, we integrate EHR data from over 750,000 providers across over 140,000 care sites nationwide as of September&nbsp;30,
2024. This data includes daily and weekly insurance claims feeds, prior authorization records, and health plan partner referrals. Applying advanced algorithms and AI to this broad dataset, we can identify likely high-cost individuals efficiently
before they become high-cost claimants to the client. We then either engage the eligible life through targeted marketing to enroll in our programs, or, for members, offer additional conservative care options. Additionally, with the members&#146;
approval, we foster collaboration by sharing member progress and engagement with national health information exchanges and partners, which can enable continuity of care for our members across the broader healthcare ecosystem. We believe that by
using HingeConnect we are revolutionizing healthcare delivery in a way that is designed to provide the right care at the right time to our members and in the most cost-effective manner for our clients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I><FONT STYLE="white-space:nowrap">AI-supported</FONT> care team assistant</I></B>: We empower our care team with <FONT
STYLE="white-space:nowrap">AI-supported</FONT> technology to improve member interactions and the member experience as a whole. We believe our AI approach is a differentiator, allowing our care team more time to connect with members in the most high
impact way. We have developed a Care Team Assistant, which is a generative AI tool that automates repetitive and straightforward tasks such as message generation, data aggregation, and profile reviews. By summarizing information and prompting our
care team with suggested action plans and draft responses, this AI tool helps reduce time spent on administrative tasks and allows our care team to focus more on meaningful interactions with members. We believe our use of the Care Team Assistant
enhances member retention and engagement while also enabling our care team to be more cost-effective as compared to traditional methods that do not utilize AI. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Advanced electrical stimulation technology (Enso)</I></B>: Enso, our
proprietary electrical stimulation technology, is supported by issued patents as well as pending patent applications in the United States and the European Patent Office, as of September&nbsp;30, 2024. We believe Enso is a valuable part of our
platform because many people are in too much pain to move or have frequent flare ups. Enso is a small, lightweight, wearable device that delivers electrical nerve stimulation designed to provide <FONT STYLE="white-space:nowrap">non-addictive</FONT>
and <FONT STYLE="white-space:nowrap">non-invasive</FONT> pain relief. Enso is an <FONT STYLE="white-space:nowrap">FDA-cleared</FONT> device indicated for the symptomatic relief and management of chronic intractable pain, and for temporary relief of
pain associated with sore and aching muscles in the shoulder, waist, back, neck, upper extremities (arm) and lower extremities (leg) due to strain from exercise or normal household work activities. We believe that Enso can provide an easier way to
manage pain, without drugs or surgery, and help members focus on enjoying life through reduced pain. Enso works by delivering electric pulses in a unique waveform that includes high frequency components. The Journal of Pain Research published
results in 2024 from two RCTs that we conducted on our Enso device, the most recent of which demonstrated that Enso increased the likelihood of pain reduction versus exercise therapy alone and other transcutaneous electronic nerve stimulation. We
have integrated Enso into our core programs for high-risk members and are the sole digital MSK platform with this solution. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Care Team </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to our technology, what makes us different from traditional physical therapy is that we provide simple, robust, and
intelligently personalized care with a multidisciplinary care team of licensed physical therapists, physicians, and board-certified health coaches. Empowered by our AI algorithms, our physical therapists work with members to personalize their
exercise therapy plan, and our health coaches provide education and behavioral support to help members overcome barriers that typically prevent engagement and recovery in traditional MSK care. Our physicians help oversee our programs, guide our
clinical studies, and provide surgery decision support for members. Because our technology automates many of the processes, we believe our care team is able to be more efficient with their time and focus on providing members with tailored care. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Physical Therapists</I></B>: All of our physical therapists are licensed Doctors of Physical Therapy and possess an
average of over seven years of clinical experience as of September&nbsp;30, 2024. Many have additional specialized training in areas such as orthopedics, pelvic health, and pain neuroscience and additional board certifications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Physicians</I></B>: Our physicians are board certified musculoskeletal medicine specialists. They are responsible for
managing and designing our programs and offering surgery decision support to members when facing the possibility of surgery. Our physicians review <FONT STYLE="white-space:nowrap">in-person</FONT> provider recommendations, provide advice on
alternative options, and answer questions throughout the care process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Health Coaches</I></B>: Our health coaches
are typically Nationally Board-Certified Health and Wellness Coaches <FONT STYLE="white-space:nowrap">(NBC-HWC)</FONT> who have completed a credentialed coach training program, which requires over 50 coaching sessions, 4,000 hours of work
experience, practical skills assessments, written examinations, and a series of case studies. Health coaches can often be a catalyst for behavior change, using positive psychology, ability building, and motivational interviewing to help break down
barriers that members may face over the course of their program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Hinge Health Digital P.C., our affiliated professional
medical corporations, contracts with or otherwise employs physicians, physical therapists, and other licensed health professionals in order to provide services to our clients and members, and under certain management services agreements, we serve as
the exclusive manager and administrator of Hinge Health Digital P.C.&#146;s <FONT STYLE="white-space:nowrap">non-clinical</FONT> functions and services. For more information regarding our arrangements and relationships with licensed health
professionals, see the section titled &#147;Business&#151;Regulatory Environment&#151;State Corporate Practice of Licensed Professions and <FONT STYLE="white-space:nowrap">Fee-Splitting</FONT> Laws.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Member Journey </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To encourage <FONT STYLE="white-space:nowrap">non-invasive</FONT> care management, we streamline and simplify the member
journey. A member&#146;s journey starts with the discovery of Hinge Health. After we contract with a client, we receive an eligibility file that lists the client&#146;s population of eligible lives, including contact details for eligible lives,
which are updated frequently. Through a combination of these contact details, our health plan integrations, and client claims data, we send both targeted and broad marketing campaigns to the eligible life populations of our clients. Our marketing
campaigns educate and increase awareness of our platform in order to enroll eligible lives in our platform and programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We employ a holistic communication strategy that incorporates multiple channels and is designed to reach eligible lives. We
are dedicated to improving the performance of our channels through data analytics. All of our marketing channels are regularly subject to A/B testing to optimize their results. We implemented a number of different marketing formats, which helped us
to increase membership applications per impression from our legacy clients by 36% in a <FONT STYLE="white-space:nowrap">six-month</FONT> period between the first quarter and the third quarter of 2024, and by 62% in a
<FONT STYLE="white-space:nowrap">12-month</FONT> period between the third quarter of 2023 and the third quarter of 2024. We are exploring additional marketing channels and plan to diversify our touchpoints as we grow. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Eligible lives can access our screening tool on our website, either directly or through the QR code on a printed mailer, an
email, or any other of our marketing channels. There, they answer a series of text-based questions that allows our algorithm to generate a risk profile, check eligibility, and place eligible lives into a program. That individual can then immediately
download our mobile application and complete their first exercise therapy session to start moving in minutes. A member will be introduced to their care team, which is available at their convenience as needed. Members can then access education
articles, do their <FONT STYLE="white-space:nowrap">on-demand</FONT> exercise therapy and video visits, and communicate with their care team&#151;all from one
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">easy-to-use</FONT></FONT> application on their own mobile device or tablet, allowing them to access our platform wherever and whenever is most convenient. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Throughout the member journey, our physical therapists are available to help members with advice and our health coaches use
positive psychology, ability-building, and motivational interviewing to encourage adherence to our programs. The program evolves with the member&#146;s progress, while the member receives messages that are personalized to their experience and
behavior to drive engagement. Many members will cycle in and out of pain and may use our programs for multiple years as they progress through life. Some choose to use our platform for shorter, episodic cycles to get through <FONT
STYLE="white-space:nowrap">flare-up</FONT> pain while others choose to engage with our platform as a lifestyle of movement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Members receive a <FONT STYLE="white-space:nowrap">one-year</FONT> subscription to our platform after they have completed
their first billable activity on our platform. If they engage after the end of their <FONT STYLE="white-space:nowrap">one-year</FONT> subscription, they continue to be members for the subsequent year, and clients are billed for another full year. In
2023, members completed an average of 34 treatment sessions in their first year. As of December&nbsp;31, 2024, we had approximately&#8195;&#8195;&#8195;&#8195;members, compared to approximately 371,000 members as of December&nbsp;31, 2023, which
represents an increase of &#8195;%. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Clients </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our clients are the businesses and organizations that pay for our platform for their covered employees and adult dependents,
either by contracting with us directly or by contracting for access to our platform through one of our partners. Our clients are primarily self-insured employers and include many of the nation&#146;s leading enterprises across a broad range of
industries and sizes. Within the self-insured segment, we also serve many public sector self-insured employers, such as state and local city governments. In most instances, we partner with clients&#146; health plans, TPAs, PBMs, or other ecosystem
partners (entities such as centers of excellence and healthcare navigation companies) to reduce the friction of contracting, pricing, security and IT compliance, onboarding, and billing. We are also in the early stages of expanding to serve health
plans&#146; fully-insured and Medicare Advantage populations and federal insurance plans. We foster impactful, long-term relationships with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
our clients by delivering exceptional experiences for their members and dollar savings for our clients. As a result, our <FONT STYLE="white-space:nowrap">12-month</FONT> client retention rate was
98% as of September&nbsp;30, 2024. Our contracts covered approximately 18&nbsp;million contracted lives across more than 2,000 clients as of September&nbsp;30, 2024. We define a client as a business or organization, which we call an entity, that
have at least one active agreement with us at the end of a particular period. Entities that procure our platform through our partners are counted as individual clients. We do not count our partners as clients, unless they also separately have at
least one active client agreement with us. For example, our HCSC (Health Care Service Corporation) fully-insured population is counted as one client, even though there are thousands of employers within that client whose employees and adult
dependents are eligible for our programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We serve a wide range of clients from small- and
<FONT STYLE="white-space:nowrap">medium-sized</FONT> businesses to large enterprises. As of September&nbsp;30, 2024, our smallest client had a population of 52 eligible lives and our largest client had a population of over 370,000 eligible lives. We
had active client agreements with 48% of the Fortune 100&nbsp;companies and 42% of the Fortune 500 companies, as of September&nbsp;30, 2024. Our clients also represent over 25 broad industries, including construction, education, energy, financial
services, healthcare, hospitality, information technology, labor unions, manufacturing, nonprofit, and retail.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Case Studies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe
the following case studies are representative examples of how our clients can benefit from our platform. We highlight clients of varying types across the different segments of our client base. Because these clients cover varied member populations,
we believe the following case studies provide a helpful representation of the potential results that may be achieved by our broader client base. However, the individual client experiences highlighted in the following case studies are illustrative
only and the results stated herein may not be representative of the results experienced by our other clients, including future results. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g829170g47a83.jpg" ALT="LOGO" STYLE="width:8.5in;height:11in;">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P ALIGN="center" STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">Client A Case Study ~33,000 eligible lives as of
September 30, 2024 CLIENT SINCE 2019 INDUSTRY: RETAIL SUBSTANTIAL OUTCOMES REPORTED BY CLIENT As MEMBERS IN A SURVEY CONDUCTED ONE YEAR POST-ENROLLMENT 1 65% Reduction in their expectations of having surgery in the next year 63% Reduction in pain
levels 50% Reduction in pain-related work absenteeism or impaired productivity 50% Reduction in depression My positive attitude is just one of the tools in my backpack! I can honestly say that Hinge Health has really helped me improve my overall
mental, physical and emotional wellbeing. I am happier, healthier and able to do more things that I enjoy. CLIENT A MEMBER ENROLLED IN HINGE HEALTH Workforce overview Client A is a Fortune 300 company and leader in the automotive retail sector. MSK
challenges Client As employees often engage in repetitive lifting as part of their jobs, making MSK issues prevalent. Since many employees often proceed directly to surgery to address their pain, MSK conditions were one of Client As top categories
of claims spending. Client A believed that a preferable approach would be to reduce the incidence of MSK injuries through non-surgical treatment, prevention, and education. 1Outcomes are averages based on survey data reported by 986 of Client As
members between May 2019 and September 2024. Members responded to a survey at screening and one year post-enrollment and reported on their: (1) pain level in the preceding 24 hours, (2) depression based on responses to a questionnaire, in which
members were considered depressed based on a score of 10 or greater on the Personal Health Questionnaire depression scale (PHQ8), (3) work absenteeism based on a work productivity and impairment score accounting for hours generally worked per week,
hours missed during the preceding seven days due to members MSK condition, and the impact of MSK pain on their productivity, and (4) members expectations of having surgery on the affected area in the next year. </FONT></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g829170g90e80.jpg" ALT="LOGO" STYLE="width:8.50001in;height:11in;">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P ALIGN="center" STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">CASE STUDY CONTINUED Why Hinge Health? Client A has
embraced a value-based model and shifted to an integrated approach to care driven by outcomes. Our platform was aligned with Client As healthcare priorities. Personalization and integration are top priorities for Client A, as is removing roadblocks
to care for Client As eligible lives. We believe that our programs, combined with our technology and robust care team, drive member engagement by helping to reduce barriers to care, setting personal goals and enabling members to be accountable and
motivated. Outcomes As Client As eligible lives enrolled and became members, many reported that they gradually began to experience reductions in their MSK pain levels. On average, members reported reductions in pain, depression, pain-related work
absenteeism or impaired productivity, and their expectations of having surgery on the affected area in the next year. Client As members did not pay to enroll in Hinge Health and Client A lowered its average MSK claims costs. Furthermore, Client A
believes that when their employees are feeling healthy and in less pain, they are more focused and able to deliver better service to their customers. Our employees have been satisfied in many ways from the great service. We hear from employees about
how Hinge Health has changed their lives in a positive way, by improving the quality of their lives and getting them back to work sooner. Many have commented that they thought they were going to have to have surgery, but didnt. CLIENT AS DIRECTOR,
BENEFITS </FONT></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sales and Marketing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Sales </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We sell our platform to employers, health plans, and government entities through direct and indirect sales by leveraging our
relationships with health plans, PBMs, TPAs, and other ecosystem entities such as centers of excellence and healthcare navigation partners. Our sales organization leverages our network of partners to execute an efficient <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">go-to-market</FONT></FONT> strategy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our sales coverage model
takes into consideration both client size and industry. Our employer sales team sells primarily to self-insured employers. Our partnership sales team sells primarily to partners who service multiple lines of business such as fully-insured employers
and Medicare Advantage. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Employer Sales </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our employer sales team is focused on selling into enterprise, large market,
<FONT STYLE="white-space:nowrap">mid-market,</FONT> public sector, and health systems clients. The employer sales team identifies and closes opportunities primarily within self-insured employers. The employer sales team is supported by business
development representatives, who support prospecting and pipeline generation activities, and collaborates with our partnership sales team and our partners to pursue opportunities within their employer population. Our employer sales team consisted of
44 sales professionals as of September&nbsp;30, 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The sales cycle for employer sales varies greatly depending on the
size and complexity of the employer, partnerships, and existing contracting vehicles. On average, the sales cycle for employer sales lasts roughly five months between engagement and signing, and for large complex deals it may last more than 12
months. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Partnerships Sales </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our partnerships sales team pursues opportunities with health plan providers, PBMs, TPAs, and other potential partnerships. As
of September&nbsp;30, 2024, we had over 50 partners, consisting of health plans (including four out of the five largest national health plans by self-insured lives), PBMs (including the top three PBMs by market share), TPAs, and other ecosystem
partners, including Accolade, Inc., Carrum Health, Inc., Castlight Health, Inc., Employer Direct Healthcare, LLC doing business as Lantern Specialty Care, Personify Health, Inc., Quantum Health, Inc., Teladoc Health, Inc., and Vera Whole Health,
Inc. Our partnerships sales team supports the employer sales team by educating key partners on the benefits of Hinge Health and sets an overall strategy for engagement with partners that is used by the employer sales team to prospect and close new
clients in collaboration with partners. Our partnerships provide us with access to our partners&#146; self-insured employer populations, enabling our employer sales team to then pursue opportunities with those self-insured employers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our partnerships act as a force multiplier as our partners often assist in sales efforts, contracting, implementation, and
billing. Our partner network streamlines and simplifies contracting for employers even in cases in which our direct sales force leads the client sales and engagement process. As of September&nbsp;30, 2024, a majority of our clients were contracted
through our partnerships, which facilitates an easier contracting process by allowing clients to leverage existing contracts through our partners. This channel is a significant strategic advantage for us. Contracting through our partners shortens
onboarding and implementation time. Most implementations are completed within a 40&#150;100 day period from entering into a contract with a client. Typically, we enter into contracts with clients in the second half of the year and launch them on our
platform in the first half of the following calendar year. Pursuant to our agreements, our partners often receive an administrative or a marketing fee for their services when we contract with a client through a partner. Although we utilize our
partners to facilitate certain interactions with our clients, we engage directly with our clients to provide our platform. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our partnership agreements are generally three years in duration. From inception through September&nbsp;30, 2024, we have
maintained 100% retention of the partners that we choose to work with, excluding partners who were acquired. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to partnering with health plans and PBMs to access their
self-insured populations, this team also sells directly to these partners&#146; fully insured and Medicare Advantage lines of business. Our partnership sales team consisted of 34 sales professionals as of September&nbsp;30, 2024. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Marketing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There are three main components to our marketing: enterprise marketing, product marketing, and growth marketing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our enterprise marketing team is responsible for brand awareness, sales enablement, demand generation, event management, and
our trial experience program. Business to business marketing generated by our enterprise marketing team is meant to support our sales teams in acquiring new clients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our product marketing team is responsible for managing the life cycle of our platform and programs. They are organized to
align with our development teams and are responsible for market intelligence, market readiness, product definition, packaging, pricing, and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">go-to-market</FONT></FONT> readiness across
our operational teams. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our growth marketing team focuses on business to consumer marketing and is responsible for
reaching the eligible lives of our clients to encourage those who could benefit from our platform to enroll. This team is key to growing our member engagement throughout the lifetime of the client. To increase awareness within our clients&#146;
employee bases, our growth marketing team engages with our partners and our clients&#146; human resources benefits team in targeted marketing campaigns to encourage eligible lives who would benefit from our platform to enroll. While marketing takes
place on an ongoing basis, we increase marketing during periods when we expect more enrollments from eligible lives. For example, we typically focus marketing around new client launches, New Year resolutions, and open enrollment. In addition to
direct marketing, we also actively work with our partners and our clients&#146; human resources benefits teams to assist in identifying eligible lives that would benefit from our platform and encouraging enrollment on our platform. For example, a
healthcare navigation partner can direct an individual with MSK conditions to our platform, or a client&#146;s human resources benefits team can incorporate Hinge Health marketing into its internal benefit campaigns. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Client Success and Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our client success and client operations teams are responsible for delivering exceptional service and supporting the long-term
success of our clients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our client operations team is responsible for implementing our client contracts and launching our
platform with our clients. They are also responsible for the ongoing technical elements of our client relationships, including eligibility file set up, member-level data sharing, and billing configurations. Implementation managers are assigned to
clients based on the client&#146;s size and partner relationship. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After a client is launched, our client success team is
responsible for managing the client relationship. The team focuses on managing the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> needs of the client, securing eligible life marketing approvals to drive
awareness and enrollment, delivering client reports with metrics that demonstrate the performance of our platform and programs, gaining new populations where applicable, and acting as the voice of the client within Hinge Health. Our client success
team is assigned based on the client&#146;s size, line of business, industry, and partner relationship. We engage with our clients through various service models that scale with the complexity of the client, including a pooled model for our small
business segment, a <FONT STYLE="white-space:nowrap">right-sized</FONT> version for our <FONT STYLE="white-space:nowrap">mid-market</FONT> segment, and a white glove model for our largest clients that includes ongoing executive support. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and Development </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our research and development organization is responsible for the design, architecture, operation, and quality of our platform.
In addition to improving our existing features, functionality, and reliability, the engineering and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
product teams are also responsible for developing capabilities beyond what is available through our current platform and programs. Since 2022, these development efforts have included our launch
of Enso and the addition of our women&#146;s pelvic health program, a fall prevention program, five new MSK affected areas for our chronic and acute programs, and our AI motion tracking technology. These teams are also responsible for furthering our
<FONT STYLE="white-space:nowrap">AI-powered</FONT> capabilities and data integrations. In 2023, we opened our Bangalore, India office and, as of September&nbsp;30, 2024, around 7% of our employees were based there. We plan to continue expanding our
geographic footprint to further dedicate resources to research and development while diversifying talent and reducing costs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our ROI Studies and
Clinical Outcomes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are committed to conducting rigorous research to support the performance of our programs. Since
2017, we have published 14 peer-reviewed research articles in leading medical journals on topics including program engagement, member outcomes, medical care, and prescription drug utilization, in addition to four externally reviewed claims-based
studies, in an effort to demonstrate improvements in member outcomes and cost savings. In partnership with leading universities and research institutions, our team of researchers, many of which hold doctorate-level degrees, have also sponsored four
RCTs, seven observational clinical studies, and seven claims-based outcomes research studies. Findings in our published clinical studies have been consistent with results from the claims-based cost and utilization studies. We believe that the
results from these studies collectively suggest that our programs can provide both clinically meaningful improvements in pain and functional status as well as meaningful cost savings due to lower utilization of medical care by our members. We also
believe these studies highlight our programs&#146; strong potential to drive member outcomes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our ROI Studies
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have conducted four large-scale claims-based cost studies and three health service research studies across
various health systems, among both commercial insurance and Medicare populations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In 2022, we conducted the 2023 Employer
Claims Study to estimate the cost savings to our clients as a result of their employees using our chronic program. This is our most comprehensive ROI study to date, given the scope of clients it covered. Our study was based on members&#146; medical
claims data at the time of enrollment and 12 months post-enrollment from over 4,200 members that were continuously enrolled in our chronic program between January 2019 and September 2021. Over 130 clients across 46
<FONT STYLE="white-space:nowrap">sub-industries</FONT> were represented in the study&#146;s member population. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
internal financial savings study compared the medical claims data of members enrolled in our chronic program to a matched control group that included those of our clients&#146; employees who were not enrolled in our chronic program. We matched
members enrolled in our chronic program and control group individuals by their specific pain region and by the approximate time that the member enrolled or when the control group individual visited a healthcare professional. Members enrolled in our
chronic program had an average of $2,387 less in medical claim costs related to MSK treatment compared to the control group over a <FONT STYLE="white-space:nowrap">12-month</FONT> period. The average cost savings observed in the study represents an
estimated 2.4x ROI for clients, based on the estimated $2,387 average cost savings divided by the cost of our chronic program. This study and its methodology were externally reviewed by a leading actuarial and benefit consulting firm. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In 2024, we engaged an external research firm to conduct a financial savings study to estimate medical care use and medical
claims spending by Medicare Fee for Service (FFS) beneficiaries that were enrolled in Medicare Part A and Part B plans. The study was based on medical spending and claims data from over 1,200 members aged 65 and older that were continuously enrolled
in our chronic program between February 2019 and January&nbsp;2022. The financial savings study compared the medical spending and claims data of members enrolled in our chronic program to a number of matched control groups that included Medicare
beneficiaries who were not enrolled in our chronic program. The study matched members enrolled in our chronic program and control </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
group individuals by their specific pain region and by the approximate time that the member enrolled or when the control group individual initiated physical therapy. Researchers from a leading
health plan conducting the study estimated that members enrolled in our chronic program had an average of $274 less in overall chronic MSK costs compared to the control group over a <FONT STYLE="white-space:nowrap">12-month</FONT> period. The
average cost savings observed in the study represents an estimated 3.3x ROI for our clients, based on the annualized savings calculated using the estimated $274 average cost savings per member per month, divided by the cost of our chronic program.
The study estimated that 83% of estimated cost savings were generated by avoided spending on hospital inpatient and outpatient services and over 15% of estimated cost savings were generated by avoided professional services. Estimated savings were
largely identified in the osteoarthritis diagnostic category. This is our largest study of the Medicare population, in terms of individuals evaluated, which demonstrated potential financial benefits of digital MSK care. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our Clinical Outcomes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Journal of Medical Internet Research published results in 2018 from a RCT conducted by us that compared the outcomes of
members enrolled in our chronic program whose affected area was the knee (n=101) against a control group (n=61). Participants in the treatment group were enrolled in our digital care program for chronic knee pain. The control group received three
education articles regarding self-care for chronic knee pain. Both groups had access to customary treatment during the study. The primary endpoint was assessed using the Knee Injury and Osteoarthritis Outcome Score (&#147;KOOS&#148;) Pain subscale
and KOOS Physical Function Shortform <FONT STYLE="white-space:nowrap">(KOOS-PS)</FONT> questionnaires. Results from the study showed a significantly greater reduction in pain compared to the control group at the end of the program (p=0.002), as well
as a significantly greater improvement in measures of physical function (p=0.001).<SUP STYLE="font-size:75%; vertical-align:top">2</SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">NPJ Digital Medicine published results in 2019 from a RCT conducted by us that examined the outcomes of members enrolled in
our chronic program whose affected area was the lower back (n=128) against a control group (n=49). The treatment group received <FONT STYLE="white-space:nowrap">12-weeks</FONT> in our chronic program, focusing on their lower back pain, including a
tablet computer with the Hinge Health app installed and two Bluetooth wearable motion sensors with straps to be placed along the lower back and torso during the <FONT STYLE="white-space:nowrap">in-app</FONT> exercise therapy. Participants in the
treatment group were also assigned a personal coach that provided unlimited support and accountability throughout the trial period, and were placed in a team to provide peer support through a discussion feed within the app. The control group
received only three digital education articles from the Hinge Health library and maintained access to their usual treatment. An analysis of the results at 12 weeks showed that participants in the treatment group had significantly improved pain
scores compared to participants in the control group, including on each primary outcome measure: Oswestry Disability Index (p&#8201;&lt;&#8201;0.001), Korff Pain Scale (p&#8201;&lt;&#8201;0.001) and Korff Disability Scale (p&#8201;&lt;&#8201;0.001).
Participants in the treatment group also reported improvements in secondary outcome measures, including a 62% reduction in pain as measured on a visual analogue scale, compared to an 8% reduction in the control group.<SUP
STYLE="font-size:75%; vertical-align:top">3</SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Journal of Pain Research<I> </I>published results in 2024 from<I>
</I>two RCTs that we conducted on our Enso device. Although clinical data were not required in connection with the FDA&#146;s clearance of our Enso device, which is designed to deliver electrical nerve stimulation to provide <FONT
STYLE="white-space:nowrap">non-addictive</FONT> and <FONT STYLE="white-space:nowrap">non-invasive</FONT> pain relief, we conducted two RCTs to evaluate the performance of our Enso device among our members. The more recent of the two RCTs was a <FONT
STYLE="white-space:nowrap">three-arm</FONT> study that compared Hinge Health participants (n=109) who received Enso to participants who received other transcutaneous electronic nerve stimulation (&#147;TENS&#148;) treatment (n=108) and to
participants who engaged in exercise therapy alone (n=108). In this study, pain was primarily evaluated using a </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Mecklenburg, Gabriel et al. <I>Effects of a <FONT STYLE="white-space:nowrap">12-Week</FONT> Digital Care
Program for Chronic Knee Pain on Pain, Mobility, and Surgery Risk: Randomized Controlled Trial</I>. J. Med. Internet Res 2018;20(4):e156. This study was sponsored, funded, or supported by Hinge Health. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Shebib, Raad et al. <I>Randomized controlled trial of a <FONT STYLE="white-space:nowrap">12-week</FONT>
digital care program in improving low back pain</I>. npj Digital Medicine 2, 1 (2019). This study was sponsored, funded, or supported by Hinge Health. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
validated patient-reported outcome measure in which subjects scored their MSK pain within the prior 24 hours on a scale of 0 to 100. Among participants who completed the study according to
protocol, Enso participants were on average 2.3 times and 2.8 times more likely to achieve a clinically meaningful improvement or minimal clinically important difference (&#147;MCID&#148;) compared to participants using other TENS treatment and
participants engaged in exercise therapy alone, respectively. The study defined MCID as a 34% improvement from baseline in reported pain scores after four weeks of use. The percentage of participants achieving the MCID in pain scores was 14.1%
higher for the Hinge Health participants that received Enso compared to participants using other TENS treatment and 12.9% higher than participants engaged in exercise therapy alone, as reported at week four of treatment, although these improvements
were not statistically significant.<SUP STYLE="font-size:75%; vertical-align:top">4</SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">BMC Musculoskeletal Disorders
published an observational study in 2022 showing that our members achieved an MCID in pain improvement to a higher degree than individuals in a <FONT STYLE="white-space:nowrap">non-participant</FONT> control group. A pain improvement MCID was
defined as a 30% improvement from baseline in reported pain scores over the prior 24 hours, measured at three and 12 months. A greater percentage of our members also showed functional improvements at three and six months when compared to the <FONT
STYLE="white-space:nowrap">non-participant</FONT> control group. We believe this study was among the first to evaluate a digital MSK platform over one year after participation. At 12 months, 72.2% of participants reported a pain improvement MCID
(n=706) compared to 56.2% of the <FONT STYLE="white-space:nowrap">non-participant</FONT> control group (n=153).<SUP STYLE="font-size:75%; vertical-align:top">5</SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have also evaluated our acute and surgery programs in three studies and observed similar improvement in measures of pain,
functional status and mental health. In one of these observational, longitudinal studies published in the Journal of Medical Internet Research in 2022<SUP STYLE="font-size:75%; vertical-align:top">6</SUP> comparing Hinge Health participants to
nonparticipants, we analyzed data from nonparticipants (n=116) and Hinge Health participants (n=105) for pain improvement at three, six, and 12 weeks. We observed a decrease of pain scores of 73% at 12 weeks in the Hinge Health participants with
acute and subacute pain based on a participant-reported pain score between zero to 100 over a preceding 24 hours. The percentage of participants reporting that pain was better or much better at <FONT STYLE="white-space:nowrap">follow-up</FONT> was
significantly higher by 31% at 12 weeks for Hinge Health participants versus nonparticipants, and the Hinge Health participants saw significantly higher functional improvement at <FONT STYLE="white-space:nowrap">follow-up</FONT> of 25% at 12 weeks.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Journal of Pain Research published a study in 2023 showing Hinge Health participants had lower use of opioids in the
12 months after starting Hinge Health compared to <FONT STYLE="white-space:nowrap">non-participants</FONT> that only received physical therapy. Using commercial medical and pharmacy claims data, this study of 4,195 Hinge Health participants and
4,195 propensity-score matched control <FONT STYLE="white-space:nowrap">non-participants</FONT> found that approximately 8% of Hinge Health participants had opioid prescriptions within 12 months after starting the Hinge Health program versus
approximately 14% of matched <FONT STYLE="white-space:nowrap">non-participants</FONT> (p &lt; 0.001). Hinge Health participants had significantly fewer opioid prescriptions (approximately 17 per 100 participants) versus matched <FONT
STYLE="white-space:nowrap">non-participants</FONT> (approximately 22 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">4</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Hong, Mindy et al. <I>Effectiveness of Hybrid Form Impulse Therapy (HFIT) Compared to Traditional
Transcutaneous Electronic Nerve Stimulation (TENS) in Patients with Chronic Low Back and Knee Pain: A Randomized Controlled Trial</I>. Journal of Pain Research, 2024;17:2417-2430. Originally published by, adapted and used with permission from Dove
Medical Press Ltd. This study was sponsored, funded, or supported by Hinge Health. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">5</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Wang, G., Yang, M., Hong, M. et al. <I>Clinical outcomes one year after a digital musculoskeletal (MSK)
program: an observational, longitudinal study with nonparticipant comparison group</I>. BMC Musculoskeletal Disorders 23, 237 (2022). This study was sponsored, funded, or supported by Hinge Health. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">6</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Wang, Grace et al. <I>Clinical Outcomes After a Digital Musculoskeletal Program for Acute and Subacute Pain:
Observational, Longitudinal Study With Comparison Group</I>. BMC Musculoskeletal Disorders 2022;9(2):e38214. This study was sponsored, funded, or supported by Hinge Health. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
per 100 participants). Hinge Health participants also had lower odds of initiating opioids and significantly fewer prescriptions compared to matched
<FONT STYLE="white-space:nowrap">non-participants</FONT> after controlling for available confounding factors.<SUP STYLE="font-size:75%; vertical-align:top">7</SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The American Journal of Managed Care published a study in 2023 of 1,760 participants examining the effect of Hinge Health
program participation among participants with osteoarthritis and showed that Hinge Health participants had fewer knee or hip replacement surgeries in the 12 months after participating in the program, compared to patients who received traditional
care. Results of this retrospective, longitudinal claims study found that approximately 4% of Hinge Health participants and approximately 14% of comparison group <FONT STYLE="white-space:nowrap">non-participants</FONT> had a total knee replacement
surgery (p&lt;0.001) at 12 months after initiating the program or traditional care and approximately 16% of Hinge Health participants and approximately 33% of comparison group <FONT STYLE="white-space:nowrap">non-participants</FONT> had a total hip
replacement surgery at 12 months after initiating the program or traditional care. These findings suggested that participants who used the Hinge Health program to manage osteoarthritis had lower rates of total joint replacement surgery in the 12
months after initiating the program or traditional care.<SUP STYLE="font-size:75%; vertical-align:top">8</SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">BMC
Musculoskeletal Disorders published a study in 2024 of 6,848 participants showing that Hinge Health program participants with lower back pain had lower rates of spinal fusion surgery compared to lower back pain
<FONT STYLE="white-space:nowrap">non-participants</FONT> who received traditional care. Specifically, 56% fewer Hinge Health program participants underwent spinal fusion surgery in the 12 months after participating in Hinge Health&#146;s chronic
program, compared to matched <FONT STYLE="white-space:nowrap">non-participants.</FONT><SUP STYLE="font-size:75%; vertical-align:top">9</SUP> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our
Culture and Employees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Mission and Culture </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our employees are integral to the long-term success of Hinge Health and we are proud of our talented and mission-driven team.
People join Hinge Health because they believe in our vision of creating a vertically integrated healthcare system powered by innovative technology. We seek people who are ready to unpack their bags for the long term and do the best work of their
careers at Hinge Health. We emphasize written communication, with a focus on driving greater efficiency and deeply understanding the problems that we are solving. To support our distinctive culture, we have intentionally built a work environment
that balances accountability with empathy and that is based on mutual trust, transparency, intellectual honesty, opportunities for growth and recognition, and the spirit of belonging and inclusion. </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">7</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Wang, Grace et al. <I>Opioid Initiation Within One Year After Starting a Digital Musculoskeletal (MSK)
Program: An Observational, Longitudinal Study with Comparison Group</I>. Journal of Pain Research, 2023;16:2609&#150;2618. Originally published by, adapted and used with permission from Dove Medical Press Ltd. This study was sponsored, funded, or
supported by Hinge Health. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">8</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Lu, Louie et al. <I>Digital Musculoskeletal Program Is Associated with Decreased Joint Replacement
Rates</I>. American Journal of Managed Care. 2024;30(4):e103-e108. This study was sponsored, funded, or supported by Hinge Health. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">9</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Yadav, Sandhya et al. <I>Spinal fusion surgery use among adults with low back pain enrolled in a digital
musculoskeletal program: an observational study</I>. BMC Musculoskeletal Disorders 25, 520 (2024). This study was sponsored, funded, or supported by Hinge Health. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Leadership Principles </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At Hinge Health we believe that everyone is a leader. This can mean a <FONT STYLE="white-space:nowrap">C-suite</FONT> member
championing a major strategic initiative, an engineering manager building a <FONT STYLE="white-space:nowrap">top-performing</FONT> team, a coach sharing best practices with their peers, or a sales leader going beyond the sales playbook to sign an
important client. We define our culture through a set of leadership principles that describe the behaviors a Hinge Health employee exhibits. Our leadership principles guide the kind of leader that helps us build a company ready to face the
challenges that will present themselves as we grow. Some key aspects of our leadership principles include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Put members first: </I>We focus first and foremost on creating a seamless experience for our members that
enables them to increase mobility, decrease pain, and live their best lives. We are motivated and humbled by the opportunity to help people, at scale. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Create trust</I>: We check our ego at the door and collaborate to help our teams and the entire company to
be successful. We are intellectually honest, transparent, and honor our commitments. We demonstrate curiosity and communicate in ways that convey clarity of thought and rigor, while being concise. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Are <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">learn-it-alls</FONT></FONT></I>: Our
people are not <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">know-it-alls.</FONT></FONT> We prioritize truth over being right, welcome contrary opinions, and continue to challenge ourselves to get better every day. We invest
significant time and resources to uplevel our people so they are continuously growing and having an impact while fulfilling their long term career goals at Hinge Health. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Make results happen</I>: We measure ourselves by results and impact, not actions or good intentions. We are
prepared to say no to a lot of important opportunities, in order to put maximum resources behind the few initiatives that we believe will improve outcomes for our members, clients, and business. We understand that great trees start from small seeds
nurtured over many years. As such we think big, challenge the status quo, and do not sacrifice long-term value for short-term results. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Act like owners</I>: We prize having strong judgment in allocating resources (people, money, time) in a way
that is best for the company and not just one team. Our people have high standards and understand that their name is on the door. We seek to excel at high-level strategy but also value the insight and intuition that comes from spending time in the
details. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Human Capital </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of September&nbsp;30, 2024, we had 1,459 full-time employees, including 1,312 employees based in the United States. We also
have employees based in other countries, including India, Canada, and the United Kingdom. 465 of our employees are care team members. We maintain a full-time workforce and supplement our workforce with contractors and consultants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To our knowledge, none of our employees are represented by a labor union or party to a collective bargaining agreement. We
consider our relationships with our employees to be good. Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing, and integrating our existing and new employees. The principal purposes of our
equity incentive plans are to attract, retain, and reward personnel through the granting of stock-based compensation awards in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best
of their abilities and achieve our objectives. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competitive Landscape </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are a leading technology platform for individuals seeking to treat and prevent joint and muscle pain. We built our platform
to address the inefficiencies in the legacy system that treats MSK conditions today. The markets in which we operate are competitive and characterized by rapid change. We believe the success of our platform is contingent on our ability to provide an
outstanding member experience, improved member outcomes, and cost reductions for our clients. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our competitors fall into the following categories: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Digital platforms that provide broad MSK care or programs that address a segment of MSK care, including Kaia
Health Software, Inc., Omada Health, Inc., Sword Health Technologies, Inc., and Vori Health, Inc.; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Health plans and health systems which may offer or develop products or services with features or benefits that
overlap with our platform and programs. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe we compete favorably based on multiple factors,
including the strength of our market leadership, our ability to deliver comprehensive care, our software, data and AI advantage, our demonstrable member outcomes and ROI, our scalable
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">go-to-market</FONT></FONT> strategy, and the extensibility of our platform. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We
rely on a combination of trademarks, copyrights, patents, trade secrets, license agreements, confidentiality procedures, <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreements, employee disclosure and invention assignment agreements, as
well as other legal and contractual rights, to establish and protect our intellectual and proprietary rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of
September&nbsp;30, 2024, we owned 11 issued patents and 37 pending patent applications in the United States as well as 11 pending PCT applications, 13 foreign issued patents and 61 pending foreign patent applications. Our issued patents and pending
patent applications generally relate to our TrueMotion AI motion tracking technology and Enso, a wearable device that utilizes our proprietary electrical stimulation technology accessed through the Hinge Health app, as well as our platforms and
programs generally. Due to the nature of our technology and the rapid technological changes that characterize the markets we operate in, we also rely on trade secrets, other unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> and copyrights
relied upon in connection with the development of new products and services and the enhancement of existing products and services, which are also important in establishing and maintaining a competitive advantage. Nevertheless, we continually review
our development efforts to assess the existence and patentability of new intellectual property. Notwithstanding these efforts, we cannot be sure that patents will be granted with respect to any patent applications we have filed or may license or
file in the future, and we cannot be sure that any patents that are licensed or granted to us will not be challenged, invalidated, or circumvented or that such patents will provide us with any competitive advantage. Moreover, trade secrets can be
difficult to protect. While we have confidence in the measures we take to protect and preserve our trade secrets, such measures can be breached, and we may not have adequate remedies for any such breach. In addition, our trade secrets may otherwise
become known or be independently discovered by competitors. See the section titled &#147;Risk Factors&#151;Risks Related to Our Intellectual Property, Data Privacy, Information Technology, Cybersecurity.&#148; We have a policy in place regarding the
use of third-party and open-source AI tools to protect our proprietary, confidential, or otherwise protected information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of September&nbsp;30, 2024, we owned six registered trademarks and two pending trademark applications in the United States
and also held 23 registered trademarks and 14 pending trademark applications in foreign jurisdictions. In addition, we have registered domain names for websites that we use in our business, such as hingehealth.com. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have a policy of requiring employees and consultants that contribute to the development of material intellectual property
to execute confidentiality agreements upon the commencement of an employment or consulting relationship with us. Our employee and independent contractor agreements also require relevant employees and independent contractors to assign to us all
rights in and to any potentially-patentable inventions and other intellectual property made or conceived during their employment or engagement with us. Employees, independent contractors, or other third parties may breach or violate the terms of
these agreements, and we may not have adequate remedies for any such breach or violation, or we may not have executed, or may in the future fail to execute, such agreements with employees, contractors, consultants, or other third parties who may be
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
involved in the development of our intellectual property. See the section titled &#147;Risk Factors&#151;Risks Related to Our Intellectual Property, Data Privacy, Information Technology,
Cybersecurity.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the aggregate, our intellectual property assets are of material importance to our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Regulatory Environment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Government Regulation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our business is subject to rigorous laws, rules, and regulations in the jurisdictions in which we operate. These laws, rules,
and regulations include, without limitation, federal and state laws, and country specific laws, governing health information privacy, scope of practice, licensure, the corporate practice of medicine and physical therapy, remote healthcare, fraud and
abuse, exclusion and debarment, anti-kickback obligations, false claims, patient referrals, fee splitting, regulation of devices, and other aspects of healthcare delivery. These laws, rules, and regulations and interpretations thereof continue to
evolve. Accordingly, we continuously monitor our compliance with laws in every jurisdiction in which we operate. As the applicable laws, rules, and regulations change, we may adjust our business model and delivery of our platform and programs from
time to time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>United States Regulation of Medical Devices </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our operations are subject to extensive regulation by the FDA and other federal and state authorities in the United States, as
well as comparable authorities in foreign jurisdictions. Certain of our products, including our Enso device, are subject to regulation as medical devices in the United States under the FDCA as implemented and enforced by the FDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA regulates the development, design, <FONT STYLE="white-space:nowrap">non-clinical</FONT> and clinical research,
manufacturing, safety, efficacy, labeling, packaging, storage, installation, servicing, recordkeeping, premarket clearance or approval, adverse event reporting, advertising, promotion, marketing and distribution, and import and export of medical
devices to ensure that medical devices distributed domestically are safe and effective for their intended uses and otherwise meet the requirements of the FDCA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unless an exemption applies, each medical device commercially distributed in the United States requires either FDA clearance
of a 510(k) premarket notification, or approval of a premarket approval PMA application. Under the FDCA, medical devices are classified into one of three classes&#151;Class&nbsp;I, Class&nbsp;II, or Class&nbsp;III&#151;depending on the degree of
risk associated with each medical device and the extent of manufacturer and regulatory control needed to ensure its safety and effectiveness. Class&nbsp;I includes devices with the lowest risk to the patient and are those for which safety and
effectiveness can be assured by adherence to the FDA&#146;s General Controls for medical devices (&#147;General Controls&#148;), which include compliance with the applicable portions of the current QSR, facility registration and product listing,
reporting of adverse medical events, labeling, advertising, and promotional materials. Class&nbsp;II devices are subject to the General Controls, as well as certain special controls deemed necessary by the FDA to ensure the safety and effectiveness
of the device. These special controls can include, among other things, performance standards, post-market surveillance, patient registries, and FDA guidance documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While most Class&nbsp;I devices are exempt from the 510(k) premarket notification requirement, manufacturers of most
Class&nbsp;II devices are required to submit to the FDA a premarket notification under Section&nbsp;510(k) of the FDCA requesting permission to commercially distribute the device. The FDA&#146;s permission to commercially distribute a device subject
to a 510(k) premarket notification is generally known as 510(k) clearance. Devices deemed by the FDA to pose the greatest risks, such as life-sustaining, life-supporting, or some implantable devices, or devices that have a new intended use, or use
advanced technology that is not substantially equivalent to that of a legally marketed device, are placed in Class&nbsp;III, requiring approval of a PMA. Some devices are unclassified but remain subject to FDA&#146;s premarket notification and
clearance process in order to be commercially distributed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>510(k) Clearance Marketing Pathway and &#147;de novo&#148; Classification </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Certain of our products, including the Enso device, have received 510(k) clearance from the FDA. To obtain 510(k) clearance, a
manufacturer must submit to the FDA a premarket notification demonstrating that the proposed device is &#147;substantially equivalent&#148; to a predicate device already on the market. A predicate device is a legally marketed device that is not
subject to premarket approval, i.e., a device that was legally marketed prior to May&nbsp;28, 1976 <FONT STYLE="white-space:nowrap">(pre-amendments</FONT> device) and for which a PMA is not required, a device that has been reclassified from
Class&nbsp;III to Class&nbsp;II or I, or a device that was found substantially equivalent through the 510(k) process. If the FDA agrees that the device is substantially equivalent to a predicate device, it will grant 510(k) clearance to commercially
market the device. If the FDA determines that the device is &#147;not substantially equivalent&#148; to a previously cleared device, the device is automatically designated as a Class&nbsp;III device. The device sponsor must then fulfill more
rigorous PMA requirements or can request a risk-based classification determination for the device in accordance with the &#147;de novo&#148; process, which is a route to market for novel medical devices that are low to moderate risk and are not
substantially equivalent to a predicate device. This procedure allows a manufacturer whose novel device is automatically classified into Class&nbsp;III to request down-classification of its medical device into Class&nbsp;I or Class&nbsp;II on the
basis that the device presents low or moderate risk, rather than requiring the submission and approval of a PMA application. We do not currently market any of our products pursuant to an approved PMA, nor have we sought de novo classification for
our products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>PMA Approval Pathway </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Class&nbsp;III devices require PMA approval before they can be marketed, although some
<FONT STYLE="white-space:nowrap">pre-amendment</FONT> Class&nbsp;III devices for which FDA has not yet required approval of a PMA are cleared through the 510(k) process. The PMA process is more demanding than the 510(k) premarket notification
process. In a PMA, the manufacturer must demonstrate that the device is safe and effective, and the PMA must be supported by extensive data, including data from preclinical studies and human clinical trials. If FDA accepts a PMA application for
review, it has 180 days under the FDCA to complete its review of a PMA, although in practice, the FDA&#146;s review often takes significantly longer, and can take up to several years. The FDA will approve the device for commercial distribution if it
determines that the data and information in the PMA constitute valid scientific evidence and that there is reasonable assurance that the device is safe and effective for its intended use(s). The FDA may approve a PMA with post-approval conditions
intended to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling, promotion, sale and distribution, and collection of long-term <FONT STYLE="white-space:nowrap">follow-up</FONT> data from
patients in the clinical study that supported PMA approval or requirements to conduct additional clinical studies post-approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Clinical Studies </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Clinical studies are almost always required to support a PMA or a de novo request, and are sometimes required to support 510(k)
submissions. All clinical investigations of devices to determine safety and effectiveness must be conducted in accordance with the FDA&#146;s investigational device exemption (&#147;IDE&#148;) regulations which, among other things, govern
investigational device labeling, prohibit promotion of the investigational device, and specify an array of recordkeeping, reporting, and monitoring responsibilities of study sponsors and study investigators. If the device presents a
&#147;significant risk&#148; to human health, the FDA requires the device sponsor to submit an IDE application to the FDA, which must become effective prior to commencing human clinical studies. The FDA defines a significant risk device as one that
presents a potential for serious risk to the health, safety, or welfare of a patient and either is implanted, used in supporting or sustaining human life, substantially important in diagnosing, curing, mitigating or treating disease or otherwise
preventing impairment of human health, or otherwise presents a potential for serious risk to a subject. If the device under evaluation does not present a &#147;significant risk&#148; to human health, then the device sponsor is not required to submit
an IDE application to the FDA before initiating human clinical studies, but must still comply with abbreviated IDE requirements when conducting such studies, such as monitoring the investigation, ensuring that the investigators obtain informed
consent, and labeling and record-keeping requirements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Regardless of the degree of risk presented by the medical device, clinical
studies also must be approved by, and conducted under the oversight of, an Institutional Review Board (&#147;IRB&#148;) for each institution where the study will be conducted, or under a centralized IRB. The IRB is also responsible for study
oversight, and may pose additional requirements for the conduct of the study. If an IDE application is approved by the FDA and the study is approved by one or more IRBs, the study may begin at a specific number of investigational sites with a
specific number of patients, as approved by the FDA. If the device presents a <FONT STYLE="white-space:nowrap">non-significant</FONT> risk to the patient, a sponsor may begin the clinical study after obtaining approval for the trial by one or more
IRBs, without separate approval from the FDA. During a clinical study, the sponsor is required to comply with the applicable FDA requirements, including, for example, monitoring, selecting clinical investigators and providing them with the
investigational plan, ensuring IRB review, adverse event reporting, record keeping, and prohibitions on the promotion of investigational devices or on making safety or effectiveness claims for them. Additionally, after a study begins, the sponsor,
the FDA, or the IRB could suspend or terminate the study at any time for various reasons, including a belief that the risks to study subjects outweigh the anticipated benefits. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Post-Market Regulation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After a device is cleared or approved for marketing, numerous and pervasive regulatory requirements continue to apply. These
include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishment registration and device listing with the FDA; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">QSR requirements, which currently require manufacturers, including third-party manufacturers, to follow
stringent design, testing, control, documentation, and other quality assurance procedures during all aspects of the design and manufacturing process; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">labeling regulations and FDA prohibitions against the promotion of investigational products or the promotion
of <FONT STYLE="white-space:nowrap">&#147;off-label&#148;</FONT> uses of cleared or approved products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requirements related to promotional activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clearance or approval of certain product modifications; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">medical device reporting regulations, which require that a manufacturer report to the FDA if a device it
markets may have caused or contributed to a death or serious injury, or has malfunctioned and the device or a similar device that it markets would be likely to cause or contribute to a death or serious injury if the malfunction were to recur;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">correction, removal, and recall reporting regulations, which require that manufacturers report to the FDA
field corrections and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk to health; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">complying with laws and regulations requiring Unique Device Identifiers on medical devices and also requiring
the submission of certain information about each device to the FDA&#146;s Global Unique Device Identification Database; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA&#146;s recall authority, whereby the agency can order device manufacturers to recall from the market a
product that is in violation of governing laws and regulations; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">post-market surveillance activities and regulations, which apply when the FDA deems necessary to protect the
public health or to provide additional safety and effectiveness data for the device. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Manufacturing
processes for medical devices are required to comply with the applicable portions of the QSR, which currently cover the methods and the facilities and controls for the design, manufacture, testing, production, processes, controls, quality assurance,
labeling, packaging, distribution, installation, and servicing of finished devices intended for human use. The QSR also requires, among other things, maintenance of a device master file, device history file, and complaint files. Manufacturers of
medical devices are subject to periodic scheduled or unscheduled inspections by the FDA. Failure to maintain compliance with the QSR requirements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
could result in, among other things, the shutdown of, or restrictions on, manufacturing operations and the recall or seizure of marketed products. The discovery of previously unknown problems
with marketed medical devices, including unanticipated adverse events or adverse events of increasing severity or frequency, whether resulting from the use of the device within the scope of its clearance or
<FONT STYLE="white-space:nowrap">off-label</FONT> by a physician in the practice of medicine, could result in restrictions on the device, including the removal of the product from the market or voluntary or mandatory device recalls. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA has broad regulatory compliance and enforcement powers. If the FDA determines that a manufacturer has failed to comply
with applicable regulatory requirements, it can take a variety of compliance or enforcement actions, which may result in any of the following sanctions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">warning letters, untitled letters, &#147;it has come to our attention&#148; letters, fines, injunctions,
consent decrees, and civil penalties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recalls, withdrawals, or administrative detention or product seizures; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">operating restrictions or partial suspension or total shutdown of production; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusing or delaying requests for clearance, approval, or reclassification of new products or modified
products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawing clearances or approvals that have already been granted; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal to grant export approvals for devices being shipped to foreign markets; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">criminal prosecution. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Healthcare Fraud and Abuse Laws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We and our affiliated professional entities are subject to a number of federal and state healthcare regulatory laws that
restrict certain business practices in the healthcare industry. These laws include, but are not limited to, federal and state anti-kickback, false claims, self-referral, and other healthcare fraud and abuse laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The federal Anti-Kickback Statute (the &#147;AKS&#148;) prohibits, among other things, knowingly and willfully offering,
paying, soliciting, or receiving remuneration, directly or indirectly, in cash or kind, to induce or reward either the referral of an individual for, or the purchase, order, or recommendation of, any good or service, for which payment may be made
under federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. The AKS includes statutory
exceptions and regulatory safe harbors that protect certain arrangements. Failure to meet the requirements of a safe harbor, however, does not render an arrangement illegal. Rather, the government may evaluate such arrangements on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis, taking into account all facts and circumstances, including the parties&#146; intent and the arrangement&#146;s potential for abuse, and arrangements may be
subject to greater scrutiny by enforcement agencies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Stark Law prohibits a physician who has a financial
relationship, or who has an immediate family member who has a financial relationship, with entities providing DHS from referring Medicare and Medicaid patients to such entities for the furnishing of DHS, unless an exception applies. The Stark Law
also prohibits the entity from billing for any such prohibited referral. Unlike the AKS, the Stark Law is violated if the financial arrangement does not meet an applicable exception, regardless of any intent by the parties to induce or reward
referrals or the reasons for the financial relationship and the referral. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Federal False Claims Act (the
&#147;FCA&#148;) prohibits a person from knowingly presenting, or causing to be presented, a false or fraudulent request for payment from the federal government or from making a false statement or using a false record to have a claim approved. The
FCA further provides that a lawsuit thereunder may be initiated in the name of the United States by an individual (a &#147;whistleblower&#148;) who is an original source </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
of the allegations. Moreover, the government may assert that a claim including items and services resulting from a violation of the AKS or the Stark Law constitutes a false or fraudulent claim
for purposes of the civil FCA. Penalties for a violation of the FCA include fines for each false claim, plus up to three times the amount of damages caused by each false claim. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Further, the Civil Monetary Penalties Statute authorizes the imposition of civil monetary penalties, assessments, and
exclusion against an individual or entity based on a variety of prohibited conduct, including, but not limited to, offering remuneration to a federal healthcare program beneficiary that the individual or entity knows or should know is likely to
influence the beneficiary to order or receive healthcare items or services from a particular provider. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Health
Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and regulations implemented thereunder HIPAA, also established federal criminal statutes that
prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payers, and knowingly and willfully falsifying, concealing, or covering up a
material fact or making any materially false, fictitious, or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items, or services. Similar to the AKS, a person or entity does not need to have actual
knowledge of the statute or specific intent to violate it in order to have committed a violation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Several states in which
we operate also have adopted similar fraud and abuse laws as described above. The scope of these laws and the interpretations of them vary from state to state and are enforced by state courts and regulatory authorities, each with broad discretion.
Some state fraud and abuse laws apply to items or services reimbursed by any payer, including patients and commercial insurers, not just those reimbursed by a federally funded healthcare program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics, and medical supplies
for which payment is available under Medicare, Medicaid, or the Children&#146;s Health Insurance Program, with certain exceptions, to report annually to the CMS information related to &#147;payments or other transfers of value&#148; made to
physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors), certain <FONT STYLE="white-space:nowrap">non-physician</FONT> practitioners (physician assistants, nurse practitioners, clinical nurse specialists,
anesthesiologist assistants, certified registered nurse anesthetists, anesthesiology assistants, and certified nurse midwives), and teaching hospitals, and to report annually to CMS certain ownership and investment interests held by physicians and
their immediate family members. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Violation of any of these laws or any other governmental regulations that apply may
result in significant penalties, including, without limitation, administrative civil and criminal penalties, damages, disgorgement, fines, additional reporting requirements and compliance oversight obligations, contractual damages, the curtailment
or restructuring of operations, exclusion from participation in government healthcare programs, and/or imprisonment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Healthcare Reform </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the United States, there have been, and we expect there will continue to be, a number of legislative and regulatory changes
to the healthcare system, many of which are intended to contain or reduce healthcare costs. By way of example, the ACA substantially changed the way healthcare is financed by both governmental and private insurers. Since its enactment, there have
been judicial, executive, and congressional challenges to certain aspects of the ACA. On June&nbsp;17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA without specifically ruling on the constitutionality of the
ACA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the ACA requires (with limited exceptions) that private health plans cover certain recommended
preventive services without imposing member cost-sharing. For individuals covered by HDHPs, receiving </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
preventive care coverage without cost-sharing will not affect their eligibility to make HSA contributions. Furthermore, HDHP participants retain their
<FONT STYLE="white-space:nowrap">HSA-eligibility</FONT> if they receive (i)&nbsp;telehealth and other remote services (under a temporary exception included in the CARES Act) and (ii)&nbsp;disease management or wellness programs that do not provide
significant benefits in the nature of medical care or treatment, even if these are provided before the high deductible is met. The CARES Act provision regarding telehealth coverage on a &#147;first-dollar&#148; basis is set to expire at the end of
2024 unless additional congressional action is taken. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other legislative changes have been proposed and adopted since the
ACA was enacted, and we expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments and other third-party payers will pay for healthcare
products and services. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>State Corporate Practice of Licensed Professions and
<FONT STYLE="white-space:nowrap">Fee-Splitting</FONT> Laws </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our arrangements with our affiliated professional
entities are subject to various state laws in California and other jurisdictions, commonly referred to as corporate practice of medicine and physical therapy, respectively, and <FONT STYLE="white-space:nowrap">fee-splitting</FONT> laws, which are
intended to prevent unlicensed persons from interfering with or influencing the provider&#146;s professional judgment and prohibit the sharing of professional service fees with <FONT STYLE="white-space:nowrap">non-professional</FONT> or business
interests. These laws vary from state to state and are subject to broad interpretation and enforcement by state regulators. A determination of <FONT STYLE="white-space:nowrap">non-compliance</FONT> against us and/or our affiliated professional
entities could lead to adverse judicial or administrative action, civil or criminal penalties, receipt of cease and desist orders from state regulators, loss of provider licenses, and/or restructuring of these arrangements. In order to comply with
the corporate practice of medicine doctrine in states in which we operate, we have entered into a management or administrative services agreement (an &#147;MSA&#148;) with each of our affiliated professional entities. Under the MSAs, we provide
various administrative and operations support services in exchange for scheduled fees for our services. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Telehealth
Provider Licensing, Scope of Practice and Related Laws and Guidelines </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The practice of medicine and physical
therapy is subject to various federal, state, and local certification and licensing laws, regulations, and approvals relating to, among other things, the adequacy of medical care, the provision of telehealth, and operating policies and procedures.
Physicians, physical therapists and other licensed health professionals who provide professional services to an individual via telehealth must, in most instances, hold a valid license to practice in the state in which the individual is located. In
addition, certain jurisdictions in which we operate may prohibit or otherwise restrict our affiliated providers&#146; ability to provide such professional services via telehealth. Failure to comply with these laws could result in professional
discipline for the affiliated professional entities&#146; providers or civil or criminal penalties, limit our ability to offer our platform and programs to individuals, and/or increase our costs of doing business. We continue to monitor and assess
the development of new interpretations of existing laws or implementation of new laws to ensure that our affiliated providers are appropriately licensed under applicable state law and that their provision of telehealth to our members occurs in each
instance in compliance with applicable rules governing telehealth. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Data Privacy and Security Laws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Numerous state, federal and foreign laws, regulations and standards govern the collection, use, access to, confidentiality and
security of health-related and other personal information, and could apply now or in the future to our operations or the operations of our partners. In the United States, numerous federal and state laws and regulations, including data breach
notification laws, health information privacy and security laws and consumer protection laws and regulations govern the collection, use, disclosure, and protection of health-related and other personal information. For example, HIPAA, as amended by
the Health Information Technology for Economic and Clinical Health Act of 2009, and regulations implemented thereunder, or collectively HIPAA, imposes privacy, security and breach notification obligations on certain healthcare providers, health
plans, and healthcare </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
clearinghouses, known as covered entities, as well as their business associates that perform certain services that involve creating, receiving, maintaining or transmitting individually
identifiable health information for or on behalf of such covered entities, and their covered subcontractors. HIPAA requires covered entities and business associates to develop and maintain policies with respect to the protection of, use and
disclosure of PHI, including the adoption of administrative, physical and technical safeguards to protect such information, and certain notification requirements in the event of a breach of unsecured protected health information. Privacy and
security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal
penalties and restrictions on data processing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our corporate headquarters is located in San Francisco, California, where we lease approximately 53,000&nbsp;square feet for
office space, pursuant to a lease agreement that expires in September 2027, subject to the terms thereof. We <FONT STYLE="white-space:nowrap">sub-lease</FONT> an additional approximately 12,000 square feet of office space in Montreal, which <FONT
STYLE="white-space:nowrap">sub-lease</FONT> expires in March 2025, and we lease <FONT STYLE="white-space:nowrap">co-working</FONT> office spaces in Bangalore and Minneapolis, as well as <FONT STYLE="white-space:nowrap">on-demand</FONT> <FONT
STYLE="white-space:nowrap">co-working</FONT> office spaces in Seattle, New York City, Denver, Austin and Chicago, which are used as needed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that our facilities are suitable to meet our current needs. We intend to expand our facilities or add new
facilities as we grow, and we believe that suitable additional or alternative spaces will be available on commercially reasonable terms, if required. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From
time to time, we may be involved in various legal proceedings or subject to claims and investigations in the ordinary course of business. We are not presently a party to any litigation to which the outcome, we believe, if determined adversely to us,
would individually or taken together have a material adverse effect on our business, results of operations, or financial condition. Future litigation may be necessary to defend ourselves and our customers by determining the scope, enforceability,
and validity of third-party proprietary rights, to establish our proprietary rights, or for other matters. Involvement in such proceedings is costly and can impose a significant burden on management and employees. We cannot predict the results of
any such proceedings, claims, or investigations, and despite the potential outcomes, the existence thereof may have a material adverse impact on us due to diversion of management time and attention as well as the financial costs related to resolving
such matters. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom829170_13"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers and Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth information regarding our executive officers and directors as of September&nbsp;30, 2024: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="59%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Age</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Position(s)</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers and Employee Director:</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel Perez</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">39</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer, <FONT STYLE="white-space:nowrap">Co-Founder,</FONT> and
Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James Budge</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">57</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jim Pursley</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">45</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Founder Director:</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gabriel Mecklenburg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">36</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Chairman, <FONT STYLE="white-space:nowrap">Co-Founder,</FONT> and Director</P></TD></TR>

<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors:</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ben Blume</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">34</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kristina Leslie<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">60</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elliott Robinson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">39</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Teddie Wardi<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">40</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Member of the audit committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Member of the compensation committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Member of the nominating and corporate governance committee. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Executive Officers and Employee Director </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Daniel Perez </I></B>is our <FONT STYLE="white-space:nowrap">co-founder</FONT> and has served as our Chief Executive
Officer and a member of our board of directors since January 2012. Prior to joining Hinge Health, Mr.&nbsp;Perez was the <FONT STYLE="white-space:nowrap">co-founder</FONT> and Chief Executive Officer at Oxbridge Biotech Roundtable Ltd., a global
biotechnology research platform, from June 2011 to May&nbsp;2016. Mr.&nbsp;Perez holds a B.S. in Biology from Westminster University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe Mr.&nbsp;Perez is qualified to serve as a member of our board of directors because of the insight and experience he
brings as our <FONT STYLE="white-space:nowrap">co-founder</FONT> and Chief Executive Officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>James Budge
</I></B>has served as our Chief Financial Officer since March 2023. Prior to joining Hinge Health, Mr.&nbsp;Budge was the Chief Financial Officer of Automation Anywhere, Inc., a private robotic process automation company, from May 2021 to April
2023. Previously, he served as the Chief Financial Officer of Pluralsight, Inc., an online education company that was public from May 2018 through April 2021, from April 2017 to May 2021 and Anaplan, Inc., a financial planning and performance
management company, from January 2016 to February&nbsp;2017. Prior to Anaplan, Inc., he served as Chief Financial Officer and Chief Operating Officer at Genesys Cloud Services, Inc., a private contact center solutions company, from May 2012 to
January 2016 and Rovi Corporation, a digital entertainment technology company that was public from May 2008 until September&nbsp;2016, from September 2005 to May 2012. Mr.&nbsp;Budge began his career at PricewaterhouseCoopers LLP, an accounting
firm. Mr.&nbsp;Budge holds a B.S. in Accounting from Brigham Young University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Jim Pursley </I></B>has served as
our President since March 2021. Prior to joining Hinge Health, Mr.&nbsp;Pursley served as the Chief Commercial Officer of Livongo Health, Inc., a publicly held digital health company, from April 2014 to November 2020. Previously, he served in
various executive roles at Care Innovations, LLC, a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
private digital health company, from January 2011 to April 2014, most recently as Vice President, Sales and Marketing from August 2012 to April 2014. Earlier in his career, Mr.&nbsp;Pursley held
roles of increasing responsibility at GE HealthCare Technologies Inc. from 2003 to 2010. Mr.&nbsp;Pursley holds an M.B.A. from Kellogg School of Management at Northwestern University and a B.S. in Management Science and Information Systems from
Pennsylvania State University. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Founder Director </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Gabriel Mecklenburg </I></B>is our <FONT STYLE="white-space:nowrap">co-founder</FONT> and has served as the Executive
Chairman of our company since February 2021 and a member of our board of directors since March 2016. He also served as our Chief Operating Officer from October 2014 to February 2021. From December 2011 to May 2014, Mr.&nbsp;Mecklenburg was the Chief
Operating Officer at Oxbridge Biotech Roundtable Ltd., a global biotechnology research platform. He has served on the board of directors of Digital Therapeutics, Inc., doing business as Pelago Health, a privately held virtual care company focused on
substance use management, since January 2022. Mr.&nbsp;Mecklenburg holds an M.Sc. in Materials Science from the University of Cambridge and an M.Phil. in Bioengineering from Imperial College London. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe Mr.&nbsp;Mecklenburg is qualified to serve as a member of our board of directors because of the insight and
experience he brings as our <FONT STYLE="white-space:nowrap">co-founder</FONT> and former Chief Operating Officer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I><FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Directors </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Ben Blume </I></B>has served as a member of our
board of directors since January 2019. Mr.&nbsp;Blume has served in several roles at Atomico (UK) Partners LLP (&#147;Atomico&#148;), an international investment firm, since August 2013, including most recently as partner since January 2021. Prior
to joining Atomico, Mr.&nbsp;Blume served as an Associate Consultant at Bain&nbsp;&amp; Company Inc., an international consulting firm, from October 2011 to July 2013. He currently serves on the boards of directors of several privately held
enterprise software and SaaS companies, including Bitmovin, Inc., Katana Technologies O&Uuml;, Pactum AI, Inc., Digital Therapeutics, Inc., doing business as Pelago Health, Pocket Solutions AB, Dexory Ltd. and Harbor Lab S.A. Mr.&nbsp;Blume holds a
B.A. in Computer Science from University of Cambridge. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe Mr.&nbsp;Blume is qualified to serve as a member of our
board of directors because of his experience in the venture capital industry and with AI technology companies as well as his experience as a member of the boards of directors of other technology companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Kristina Leslie </I></B>has served as a member of our board of directors since April 2024. Ms.&nbsp;Leslie previously
served as Chief Financial Officer of DreamWorks Animation SKG Inc., a multimedia animation company, from 2004 to 2007. Over the past 15 years, Ms.&nbsp;Leslie has served on a number of public and private boards. Currently, Ms.&nbsp;Leslie serves as
a member of the board of directors of Sunstone Hotel Investors, Inc., a publicly held lodging real estate investment trust, and Justworks, Inc., a private human resource technology company, and is the chair of the board of directors of Blue Shield
of California, a health plan company. Previously, Ms.&nbsp;Leslie served on the boards of several other publicly held companies, including Rover Group, Inc. from July 2021 to February&nbsp;2024, a pet care company that was public during
Ms.&nbsp;Leslie&#146;s tenure as director, CVB Financial Corp. from 2015 to 2022, a bank holding company, Pico Holdings Inc., a water resources and storage company, from 2009 to 2016, Orbitz Worldwide, Inc., a travel search and fare aggregator
company, from 2011 to 2015, Obagi Medical Products, a skin care company, from 2012 to 2013, and Bare Escentuals Inc., a cosmetics company, from 2007 to 2010. Additionally, Ms.&nbsp;Leslie has previously served on the boards of several private
companies, including Glassdoor Inc. from 2015 to 2018 and Methodist Hospital of Southern California from 2007 to 2013. Ms.&nbsp;Leslie holds an M.B.A. from Columbia Business School and a B.A. in Economics from Bucknell University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that Ms.&nbsp;Leslie is qualified to serve as a member of our board of directors because of her extensive
experience serving on public company boards, as well as her professional experience as Chief Financial Officer of a large public company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Elliott Robinson </I></B>has served as a member of our board of
directors since February 2020. Mr.&nbsp;Robinson has served as a Partner at Bessemer Venture Partners (&#147;Bessemer&#148;), a venture capital firm, since March 2019. Prior to joining Bessemer, Mr.&nbsp;Robinson served as a partner at M12, a
venture capital subsidiary of Microsoft Corporation, from November 2016 to March 2019, and as a Vice President at Georgian Partners, an investment firm, from March 2014 to October 2016. From 2006 to 2013, Mr.&nbsp;Robinson held roles of increasing
responsibility at Syncom Venture Partners, a venture capital firm. He currently serves on the board of directors of several privately held technology, software, and artificial intelligence companies, including Coactive Systems Inc., Databook Labs,
Inc., Hyper Labs, Inc., Imply Data, Inc., Netlify, Inc. and Render Services, Inc. Mr.&nbsp;Robinson holds an M.B.A. from Columbia Business School and a B.S. in Mathematics from Morehouse College. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that Mr.&nbsp;Robinson is qualified to serve as a member of our board of directors because of his extensive
experience as a venture capital investor and a member of the boards of directors of other technology companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Teddie Wardi </I></B>has served as a member of our board of directors since November 2018. Mr.&nbsp;Wardi has served as
a Managing Director at Insight Venture Management, LLC (&#147;Insight&#148;), a private investment firm, since October 2017. Mr.&nbsp;Wardi is also a <FONT STYLE="white-space:nowrap">co-founder</FONT> and has served as an advisor to Icebreaker.vc, a
venture capital firm, since December 2013. Prior to joining Insight, Mr.&nbsp;Wardi served as a partner at Atomico (UK) Partners LLP, an international investment firm, from March 2016 to October 2017. Previously, Mr.&nbsp;Wardi served as
Vice&nbsp;President at Dawn Capital LLP, a private investment firm, from March 2014 to March 2016. He <FONT STYLE="white-space:nowrap">co-founded</FONT> Nervogrid Oy, a software company acquired by ALSO Holding AG, and served as Nervogrid&#146;s
Chief Technology Officer from March 2006 to August 2012. Currently, Mr.&nbsp;Wardi is a member of the board of directors of SentinelOne, Inc., a publicly held cybersecurity company. Mr.&nbsp;Wardi holds an M.B.A. from Harvard Business School and a
B.Sc. in Business Technology and Finance from Aalto University in Finland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that Mr.&nbsp;Wardi is qualified to
serve as a member of our board of directors because of his experience in the venture capital industry, including his experience with investments in healthcare and technology companies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Family Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There are no family relationships among any of our executive officers or directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Structure and Composition </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Director Independence </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors currently consists of six members. Our board of directors has determined that all of our directors,
other than Mr.&nbsp;Perez and Mr.&nbsp;Mecklenburg, qualify as independent directors in accordance with the listing rules of the&#8195;&#8195;&#8195;&#8195; (the &#147;Listing Rules&#148;). Mr.&nbsp;Perez is not considered independent by virtue of
his position as an executive officer of the company. Mr.&nbsp;Mecklenburg is not considered independent by virtue of his position as executive chairman, an employee, of the company. Under the Listing Rules, the definition of independence includes a
series of objective tests, such as that the director is not, and has not been for at least three years, one of our employees and that neither the director nor any of his or her family members has engaged in various types of business dealings with
us. In addition, as required by the Listing Rules, our board of directors has made a subjective determination as to each independent director that no relationships exists that, in the opinion of our board of directors, would interfere with the
exercise of independent judgment in carrying out the responsibilities of a director. In making these determinations, our board of directors reviewed and discussed information provided by the directors and us with regard to each director&#146;s
relationships as they may relate to us and our management. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Classified Board of Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In accordance with our amended and restated certificate of incorporation, which will be effective immediately prior to the
completion of this offering, our board of directors will be divided into three classes with staggered three-year terms. At each annual general meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from
the time of election and qualification until the third annual meeting following election. Our directors will be divided among the three classes as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Class&nbsp;I directors will be &#8195;&#8195;&#8195;&#8195; and &#8195;&#8195;&#8195;&#8195;, and their
terms will expire at the annual meeting of stockholders to be held in 2026; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Class&nbsp;II directors will be &#8195;&#8195;&#8195;&#8195; and &#8195;&#8195;&#8195;&#8195;, and their
terms will expire at the annual meeting of stockholders to be held in 2027; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Class&nbsp;III directors will be &#8195;&#8195;&#8195;&#8195; and &#8195;&#8195;&#8195;&#8195;, and their
terms will expire at the annual meeting of stockholders to be held in 2028. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect that any
additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist <FONT STYLE="white-space:nowrap">of&nbsp;one-third&nbsp;of</FONT> the
directors. The division of our board of directors into three classes with staggered three-year terms may delay or prevent a change of our management or a change in control. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Voting Arrangements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The election of the members of our board of directors is currently governed by our Fourth Amended and Restated Voting Agreement
that we entered into with certain holders of our capital stock and the related provisions of our Seventh Amended and Restated Certificate of Incorporation. Pursuant to our Fourth Amended and Restated Voting Agreement and Seventh Amended and Restated
Certificate of Incorporation, Messrs. Mecklenburg and Perez were elected by our Founders; Ms.&nbsp;Leslie was elected by the independent directors of the our board of directors; Mr.&nbsp;Blume was elected by the holders of our Series&nbsp;A
redeemable convertible preferred stock; Mr.&nbsp;Wardi was elected by the holders of our Series B redeemable convertible preferred stock; and Mr.&nbsp;Robinson was elected by the holders of our Series&nbsp;C redeemable convertible preferred stock.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our Fourth Amended and Restated Voting Agreement will terminate and the provisions of our Seventh Amended and Restated
Certificate of Incorporation by which our directors were elected will be amended and restated in connection with this offering. After this offering, the number of directors will be fixed by our board of directors, subject to the terms of our amended
and restated certificate of incorporation and amended and restated bylaws that will become effective immediately prior to the completion of this offering. Each of our current directors will continue to serve as a director until the election and
qualification of his or her successor, or until his or her earlier death, resignation, or removal. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Role of Board in Risk Oversight Process </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Risk assessment and oversight are an integral part of our governance and management processes. Our board of directors
encourages management to promote a culture that incorporates risk management into our corporate strategy <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">and&nbsp;day-to-day&nbsp;business</FONT></FONT> operations. Management
discusses strategic and operational risks at regular management meetings, and conducts specific strategic planning and review sessions during the year that include a focused discussion and analysis of the risks facing us. Throughout the year, senior
management reviews these risks with the board of directors at regular board meetings as part of management presentations that focus on particular business functions, operations or strategies, and presents the steps taken by management to mitigate or
eliminate such risks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors does not have a standing risk management committee, but rather administers
this oversight function directly through our board of directors as a whole, as well as through various standing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
committees of our board of directors that address risks inherent in their respective areas of oversight. While our board of directors is responsible for monitoring and assessing strategic risk
exposure, our audit committee is responsible for overseeing our major financial risk exposures and the steps our management has taken to monitor and control these exposures. The audit committee also approves or disapproves any related person
transactions. Our nominating and corporate governance committee monitors the effectiveness of our corporate governance guidelines. Our compensation committee assesses and monitors whether any of our compensation policies and programs has the
potential to encourage excessive risk-taking. The risk oversight process also includes receiving regular reports from our committees and members of senior management to enable our board of directors to understand our risk identification, risk
management, and risk mitigation strategies with respect to areas of potential material risk, including operations, finance, legal, regulatory, cybersecurity, strategic and reputational risk. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Committees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Effective as of the date the registration statement of which this prospectus forms a part is declared effective by the SEC, our
board of directors will have three standing committees: an audit committee; a compensation committee; and a nominating and corporate governance committee. Each committee is governed by a charter that will be available on our website following
completion of this offering. Members serve on these committees until their resignation or until otherwise determined by our board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Audit Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Effective as of the date the registration statement of which this prospectus forms a part is declared effective by the SEC, the
members of our audit committee will consist of Kristina Leslie, Teddie Wardi, and &#8195;&#8195;&#8195;&#8195; . Kristina Leslie will be the chairperson of our audit committee. The composition of our audit committee meets the requirements for
independence under the Listing Rules&nbsp;and Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> of the Exchange Act. Each member of our audit committee is financially literate. In addition, our board of directors has determined
that&#8195;&#8195;&#8195;&#8195;is an &#147;audit committee financial expert&#148; within the meaning of the SEC rules. This designation does not impose on such directors any duties, obligations, or liabilities that are greater than are generally
imposed on members of our audit committee and our board of directors. Our audit committee is directly responsible for, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appointing, retaining, compensating, and overseeing the work of our independent registered public accounting
firm; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assessing the independence and performance of the independent registered public accounting firm;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing with our independent registered public accounting firm the scope and results of the firm&#146;s
annual audit of our financial statements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing the financial reporting process and discussing with management and our independent registered
public accounting firm the financial statements that we will file with the SEC; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">pre-approving</FONT> all audit and permissible
<FONT STYLE="white-space:nowrap">non-audit</FONT> services to be performed by our independent registered public accounting firm; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing policies and practices related to risk assessment and management; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing our accounting and financial reporting policies and practices and accounting controls, as well as
compliance with legal and regulatory requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing, overseeing, approving, or disapproving any related-person transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing with our management the scope and results of management&#146;s evaluation of our disclosure controls
and procedures and management&#146;s assessment of our internal control over financial reporting, including the related certifications to be included in the periodic reports we will file with the SEC; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing procedures for the confidential anonymous submission of concerns regarding questionable
accounting, internal controls, or auditing matters, or other ethics or compliance issues. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Compensation Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Effective as of the date the registration statement of which this prospectus forms a part is declared effective by the SEC, the
members of our compensation committee will consist of&#8195;&#8195;&#8195;&#8195;,&#8195;&#8195;&#8195;&#8195;, and&#8195;&#8195;&#8195;&#8195;. &#8195;&#8195;&#8195;&#8195;will be the chairperson of our compensation committee. Each
of&#8195;&#8195;&#8195;&#8195;,&#8195;&#8195;&#8195;&#8195;, and&#8195;&#8195;&#8195;&#8195;is a <FONT STYLE="white-space:nowrap">non-employee</FONT> director, as defined by Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the
Exchange Act and meets the requirements for independence under the Listing Rules. Our compensation committee is responsible for, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving the compensation of our executive officers, including reviewing and approving
corporate goals and objectives with respect to compensation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authority to act as an administrator of our equity incentive plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving, or making recommendations to our board of directors with respect to, incentive
compensation and equity plans; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and recommending that our board of directors approve the compensation for our <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing and reviewing general policies relating to compensation and benefits of our employees.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Nominating and Corporate Governance Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Effective as of the date the registration statement of which this prospectus forms a part is declared effective by the SEC, the
members of our nominating and corporate governance committee will consist of&#8195;&#8195;&#8195;&#8195;,&#8195;&#8195;&#8195;&#8195;, and &#8195;&#8195;&#8195;&#8195;. &#8195;&#8195;&#8195;&#8195;will be the chairperson of our nominating and
corporate governance committee.&#8195;&#8195;&#8195;&#8195;,&#8195;&#8195;&#8195;&#8195;, and&#8195;&#8195;&#8195;&#8195; meet the requirements for independence under the Listing Rules. Our nominating and corporate governance committee is
responsible for, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying and recommending candidates for membership on our board of directors, including the consideration
of nominees submitted by stockholders, and on each of the board&#146;s committees; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and recommending our corporate governance guidelines and policies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing proposed waivers of the code of business conduct and ethics for directors and executive officers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing the process of evaluating the performance of our board of directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assisting our board of directors on corporate governance matters. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Business Conduct and Ethics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with this offering, our board of directors will adopt a code of business conduct and ethics that applies to all
of our employees, officers, and directors, including our Chief Executive Officer, Chief Financial Officer, and other executive and senior financial officers. Upon completion of this offering, the full text of our code of business conduct and ethics
will be posted on the investor relations section of our website. We intend to disclose future amendments to our code of business conduct and ethics, or any waivers of such code, on our website or in public filings. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification and Insurance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We maintain directors&#146; and officers&#146; liability insurance. Our amended and restated certificate of incorporation and
amended and restated bylaws will include provisions limiting the liability of directors and officers and indemnifying them under certain circumstances. We have entered or will enter into indemnification agreements with each of our directors and
officers to provide our directors and officers with additional indemnification and related rights. See the section titled &#147;Description of Capital Stock&#151;Limitations on Liability and Indemnification Matters&#148; for additional information.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">None of the members of our board of directors who will serve on our compensation committee upon the effectiveness of the
registration statement of which this prospectus forms a part is or has been an officer or employee of our company. None of our executive officers currently serves, or in the past fiscal year has served, as a member of a compensation committee (or if
no committee performs that function, the board of directors) of any other entity that has an executive officer serving as a member of our board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom829170_14"></A>EXECUTIVE AND DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This section discusses the material components of the executive compensation program for our executive officers who are named
in the &#147;2023 Summary Compensation Table&#148; below. In 2023, our &#147;named executive officers&#148; and their positions were as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Daniel Perez, Chief Executive Officer and Founder; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">James Budge, Chief Financial Officer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Jim Pursley, President; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Ron Will, Former Chief Financial Officer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Mr.&nbsp;Will ceased providing services to us as our Chief Financial Officer on February&nbsp;1, 2023. Following which
Mr.&nbsp;Budge commenced services as our Chief Financial Officer on March&nbsp;20, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This discussion may contain
forward-looking statements that are based on our current plans, considerations, expectations, and determinations regarding future compensation programs. Actual compensation programs that we adopt following the completion of this offering may differ
materially from the currently planned programs summarized in this discussion. As an &#147;emerging growth company&#148; as defined in the JOBS Act, we are not required to include a Compensation Discussion and Analysis section and have elected to
comply with the scaled disclosure requirements applicable to emerging growth companies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2023 Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth information concerning the compensation of our named executive officers for the year ended
December&nbsp;31, 2023. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards($)<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation&nbsp;($)<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel Perez</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,438,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,945,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer and <FONT STYLE="white-space:nowrap">Co-Founder</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James Budge<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">392,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,493,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,892,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jim Pursley</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">375,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,226,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,606,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ron Will<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">290,828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">338,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Former Chief Financial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Amounts reflect the full grant-date fair value of stock awards granted during 2023 computed in accordance
with ASC Topic 718, rather than the amounts paid to or realized by the named individual. See Note 2 to the audited financial statements included in this prospectus for a discussion of valuation assumptions made in determining the grant date fair
value and compensation expense of our RSUs and PRSUs. The value in the table above for the PRSUs reflects both the probable outcome of the performance conditions and the highest level of achievement of the performance conditions.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Unless otherwise stated, the amounts in the &#147;All Other Compensation&#148; column reflect the
company&#146;s contributions to the applicable named executive officer&#146;s 401(k) plan (except for Mr.&nbsp;Will). For Mr.&nbsp;Perez, the amount represents company contributions to a 401(k) plan, totaling $6,600. For Mr.&nbsp;Budge, the amount
represents contributions to a 401(k) plan, totaling $6,600. For Mr.&nbsp;Pursley, the amount represents contributions to a 401(k) plan, totaling $4,688. For Mr.&nbsp;Will, the amount represents company contributions to a 401(k) plan, totaling $958,
cash severance payments, totaling $275,000, and COBRA reimbursements, totaling $14,870. For a more detailed description of the severance provided to Mr.&nbsp;Will, see the section below titled &#147;&#151;Executive Compensation Arrangements.&#148;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Mr.&nbsp;Budge commenced services with us on March&nbsp;20, 2023, and his base salary was <FONT
STYLE="white-space:nowrap">pro-rated</FONT> for his partial year employment. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Mr.&nbsp;Will&#146;s salary reflects payments made for his part-year service with us, ending on
February&nbsp;1, 2023. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Narrative To Summary Compensation Table<SUP
STYLE="font-size:75%; vertical-align:top"> </SUP> </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>2023 Salaries </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In 2023, the named executive officers received an annual base salary to compensate them for services rendered to our company.
The base salary payable to each named executive officer is intended to provide a fixed component of compensation reflecting the executive&#146;s skill set, experience, role and responsibilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For fiscal year 2023, Mr.&nbsp;Perez&#146;s annual base salary was $500,000; Mr.&nbsp;Budge&#146;s annual base salary was
$500,000, for which he was actually compensated $392,361 due to his part-year employment with us commencing on March&nbsp;20, 2023; Mr.&nbsp;Pursley&#146;s annual base salary was $375,000; and Mr.&nbsp;Will&#146;s base salary was $550,000 for which
he was actually compensated $47,917 due to his part-year employment with us ending on February&nbsp;1, 2023. No salary or bonus was foregone in exchange for equity awards or other compensation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The actual salary provided to each named executive officer for 2023 services rendered is set forth above in the Summary
Compensation Table in the column entitled &#147;<I>Salary</I>.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>2023 Bonuses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">No cash bonuses or similar incentive arrangements were awarded to the named executive officers in 2023. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Equity Compensation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each of our named executive officers currently holds stock and stock option awards pursuant to the 2017 Plan. For additional
information about the 2017 Plan, including the amendments thereto, see the section titled &#147;&#151;2017 Equity Incentive Plan&#148; below. Mr.&nbsp;Will did not receive any equity awards in 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Daniel Perez</I>. In May 2023, we granted to Mr.&nbsp;Perez 5,193,377 PRSUs. The PRSUs vest upon the occurrence of
(i)&nbsp;a liquidity event, which will be satisfied in connection with this offering, that (ii)&nbsp;satisfies a milestone-vesting event based on one or more performance conditions, including the liquidity event itself and subsequent public market
valuations of our common stock in connection with the liquidity event, subject to the named executive officer&#146;s continued service through the applicable vesting date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>James Budge</I>. In April 2023, we granted to Mr.&nbsp;Budge 505,000 RSUs which vest subject to both service-based and
liquidity event-based conditions. The RSUs will satisfy the service prong as to 25% of the total RSUs on the first anniversary of March&nbsp;20, 2023 and 1/48th of the total number of RSUs on each subsequent 36&nbsp;monthly anniversaries thereafter,
subject to Mr.&nbsp;Budge&#146;s continuous service through the applicable date. The liquidity event requirement will be satisfied in connection with this offering, so long as the offering occurs before the seventh anniversary of the March&nbsp;20,
2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Jim Pursley</I>. In April 2023, we granted to Mr.&nbsp;Pursley 90,000 RSUs, which vest subject to both
service-based and liquidity event-based conditions. The RSUs will satisfy the service prong as to 1/48th of the total number of stock units on each subsequent monthly anniversary of March&nbsp;1, 2023, subject to Mr.&nbsp;Pursley&#146;s continuous
service through the applicable date. The liquidity event requirement will be satisfied in connection with this offering, so long as the offering occurs before the seventh anniversary of March&nbsp;1, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We intend to adopt the 2025 Plan, in order to facilitate the grant of cash and equity incentives to directors, employees
(including our named executive officers) and consultants of our company and certain of its affiliates </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
and to enable our company and certain of its affiliates to obtain and retain services of these individuals, which is essential to our long-term success. We expect that the 2025 Plan will be
effective on the date on which it is adopted by our board of directors, subject to approval of such plan by our stockholders. For additional information about the 2025 Plan, see the section titled &#147;&#151;2025 Incentive Award Plan&#148; below.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Other Elements of Compensation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Retirement Plans </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We currently maintain a 401(k) retirement savings plan for our employees, including our named executive officers, who satisfy
certain eligibility requirements. We expect that our named executive officers will be eligible to participate in the 401(k) plan on the same terms as other full-time employees. The Internal Revenue Code allows eligible employees to defer a portion
of their compensation, within prescribed limits, on a <FONT STYLE="white-space:nowrap">pre-tax</FONT> basis through contributions to the 401(k) plan. Currently, we match contributions made by participants in the 401(k) plan up to a specified
percentage of the employee contributions, and these matching contributions are fully vested as of the date on which the contribution is made. We believe that providing a vehicle for <FONT STYLE="white-space:nowrap">tax-deferred</FONT> retirement
savings though our 401(k) plan, and making fully vested matching contributions, adds to the overall desirability of our executive compensation package and further incentivizes our employees, including our named executive officers, in accordance with
our compensation policies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Employee Benefits and Perquisites </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Health/Welfare Plans</I>. All of our full-time employees, including our named executive officers, are eligible to
participate in our health and welfare plans, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">medical, dental, and vision benefits; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">medical and dependent care flexible spending accounts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">short-term and long-term disability insurance; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">life insurance. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We did not make any perquisites to our named executive officers in 2023, although we continue to evaluate the need for any
perquisites in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>No Tax <FONT STYLE="white-space:nowrap">Gross-Ups</FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We do not make <FONT STYLE="white-space:nowrap">gross-up</FONT> payments to cover our named executive officers&#146; personal
income taxes that may pertain to any of the compensation or perquisites paid or provided by our company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at Fiscal <FONT STYLE="white-space:nowrap">Year-End</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes the number of shares of common stock underlying outstanding equity incentive plan awards for
each named executive officer as of December&nbsp;31, 2023. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Vesting<BR>Commencement<BR>Date</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares<BR>or Units of Stock<BR>That Have Not<BR>Vested&nbsp;(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Market&nbsp;Value<BR>of Shares or<BR>Units&nbsp;of&nbsp;Stock<BR>That
Have<BR>Not&nbsp;Vested&nbsp;($)<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity&nbsp;Incentive<BR>Plan Awards:<BR>Number of<BR>Unearned<BR>Shares, Units or<BR>Other Rights<BR>That Have<BR>Not&nbsp;Vested&nbsp;(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity&nbsp;Incentive<BR>Plan Awards:<BR>Market or<BR>Payout Value of<BR>Unearned<BR>Shares, Units or<BR>Other Rights<BR>That Have Not<BR>Vested ($)<SUP
STYLE="font-size:75%; vertical-align:top">(6)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel Perez</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/21/20</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">848,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,718,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/1/22</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/17/23</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,193,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145,102,953</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James Budge</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/20/23</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">505,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,109,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jim Pursley</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/15/21</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">884,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,706,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/1/22</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/16/22</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,816,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/1/23</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,514,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ron Will<SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/21</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">558,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/1/22<SUP STYLE="font-size:75%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(</SUP><SUP STYLE="font-size:75%; vertical-align:top">2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/16/22</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">378,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The RSUs vest subject to service-based and liquidity event-based conditions. The RSUs will satisfy the
service prong as to 1/48th of the total number of stock units on each subsequent monthly anniversary of the Vesting Commencement Date, subject to the applicable named executive officer&#146;s continued service through the applicable date. The
liquidity event requirement will be satisfied in connection with this offering, so long as the offering occurs prior to the seventh anniversary of the grant date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The RSUs vest subject to service-based and liquidity event-based conditions. The RSUs will satisfy the
service prong as to 1/12th of the total number of stock units on each subsequent monthly anniversary of the Vesting Commencement Date, subject to the applicable named executive officer&#146;s continued service through the applicable date. The
liquidity event requirement will be satisfied in connection with this offering, so long as the offering occurs prior to the seventh anniversary of the grant date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The PRSUs vest upon the occurrence of (i)&nbsp;a liquidity event, which will be satisfied in connection with
this offering, that (ii)&nbsp;satisfies a milestone-vesting event based on one or more performance conditions, including the liquidity event itself and subsequent public market valuations of our common stock in connection with the liquidity event,
subject to the named executive officer&#146;s continued service through the applicable date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The RSUs vest subject to time-based and liquidity event-based conditions. The RSUs will satisfy the service
prong as to 25% of the total RSUs on the first anniversary of the Vesting Commencement Date and 1/48th of the total number of RSUs on each monthly anniversary thereafter, subject to the applicable named executive officer&#146;s continued service
through the applicable date. The liquidity event requirement will be satisfied in connection with this offering, so long as the offering occurs prior to the seventh anniversary of the grant date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The PRSUs vest in three tranches subject to (1)&nbsp;liquidity event-based and (2)&nbsp;either (a)
service-based or (b)&nbsp;performance-based conditions, as applicable. The liquidity event requirement for all three tranches will be satisfied in connection with this offering, so long as the offering occurs prior to the seventh anniversary of the
grant date. The first tranche of PRSUs, equaling 60% of the total PRSUs, is also subject to service-based conditions, subject to the applicable named executive officer&#146;s continued service through the applicable date. The first tranche of PRSUs
will satisfy the service prong as to 12.5% of the first tranche of PRSUs on the first anniversary of the Vesting Commencement date, then 1/96th of the first tranche of </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
PRSUs on each monthly anniversary for 12 months, and then 1/32th of the first tranche of PRSUs on each monthly anniversary for 24 months thereafter. The second (30% of the PRSUs) and third
tranches (10% of the PRSUs) of PRSUs are subject to performance-based conditions tied to achieving specified levels of deployment revenue, meaning billable users multiplied by revenue per user collected, over four consecutive quarters. Each of the
deployment revenue targets must be achieved separately to satisfy the performance-based conditions. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The market value of shares that have not vested is calculated based on the fair market value of our common
stock as of December&nbsp;31, 2023, which our board of directors determined to be $27.94. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Mr.&nbsp;Will&#146;s employment with us terminated on February&nbsp;1, 2023. As a result, all of the RSUs
that had not satisfied the service prong terminated as of such date. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Compensation Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are party to an employment agreement or offer letter with each of our named executive officers. These agreements set forth
the terms and conditions of employment of each named executive officer, including initial base salary, standard employee benefits eligibility, and certain severance provisions described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Daniel Perez</I>. We entered an employment agreement with Mr.&nbsp;Perez, effective as of June&nbsp;5, 2017, to serve as
our Chief Executive Officer. The agreement provides for Mr.&nbsp;Perez&#146;s annual base salary, expense reimbursement, benefits plans, and time off. The agreement also contains a requirement that he enter a confidentiality agreement and
proprietary information and inventions assignment agreement. The agreement provides that in the event Mr.&nbsp;Perez&#146;s employment is terminated other than for cause (as the terms are defined in the employment agreement) by the company,
conditioned upon signing a company release effective within sixty&nbsp;days of the date of termination, Mr.&nbsp;Perez will be entitled to severance equaling four months of pay at the rate of base salary and upon the normal payroll schedule in
effect at the date of termination. In the event Mr.&nbsp;Perez wishes to voluntarily terminate his employment (as the terms are defined in the employment agreement), then Mr.&nbsp;Perez must give the company 120 days of written notice, and, during
the notice period, Mr.&nbsp;Perez will continue to receive regular pay based on his base salary and benefits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>James
Budge</I>. We entered an employment agreement with Mr.&nbsp;Budge, effective as of March&nbsp;20, 2023, to serve as our Chief Financial Officer. The agreement provides for Mr.&nbsp;Budge&#146;s annual base salary, expense reimbursement, benefits
plans, time off, and a grant of RSUs. The agreement also contains a requirement that he enter our standard employee proprietary information and inventions assignment agreement. The employment agreement further provides that in the event
Mr.&nbsp;Budge&#146;s employment is terminated other than for cause or by him for good reason (as the terms are defined in the employment agreement) within three months prior to and ending 12 months following a corporate transaction (as defined in
the employment agreement, and such period, a &#147;corporate transaction period&#148;), the service-based prong of his RSUs will accelerate in full (since we are more than one year after his start date with us), conditioned upon his executing a
separation agreement, releasing any and all claims against us, complying with ongoing obligations to us, and resigning from all positions with the company. The employment agreement also provides that in the event Mr.&nbsp;Budge&#146;s employment is
terminated other than for cause or by him for good reason, he will be entitled to severance equaling six months of his base salary and continued healthcare coverage under COBRA for six months. Severance is contingent upon executing a separation
agreement and releasing any and all claims against us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Jim Pursley</I>. We entered an employment agreement with
Mr.&nbsp;Pursley, effective as of January&nbsp;21, 2021, to serve as our President. The agreement provides for Mr.&nbsp;Pursley&#146;s base salary, expense reimbursement, benefits plans, vacation, and a grant of RSUs grant. The agreement also
contains a requirement that he enter our standard employee proprietary information and inventions assignment agreement. The employment agreement further provides that in the event Mr.&nbsp;Pursley&#146;s employment is terminated other than for cause
or by him for good reason outside of a corporate transaction period, the service-based prong of his RSUs will accelerate with respect to 50% of the unvested RSUs, conditioned upon his executing a separation agreement, releasing any and all claims
against us, complying with ongoing obligations to us, and resigning from all positions with the company. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
employment agreement further provides that in the event Mr.&nbsp;Pursley&#146;s employment is terminated other than for cause or by him for good reason within a corporate transaction period, the
service-based prong of his RSUs will accelerate in full (since we are more than one year after his start date with us), conditioned upon his executing a separation agreement, releasing any and all claims against us, complying with ongoing
obligations to us, and resigning from all positions with the company. The employment agreement also provides that in the event Mr.&nbsp;Pursley&#146;s employment is terminated other than for cause or by him for good reason, he will be entitled to
severance equaling six months of his base salary and reimbursements for healthcare coverage under COBRA for six months. Severance is contingent upon executing a separation agreement, releasing any and all claims against us, complying with ongoing
obligations to us, and resigning from all positions with the company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Ron Will</I>. We entered an employment agreement
with Mr.&nbsp;Will, effective as of September&nbsp;8, 2020, to serve as our Chief Financial Officer. The employment agreement provided for Mr.&nbsp;Will&#146;s base salary, expense reimbursement, benefits plans, vacation, and a stock option grant.
The agreement further provided that in the event of an involuntary termination of Mr.&nbsp;Will&#146;s employment (as the term is defined in the employment agreement), conditioned upon his executing a separation agreement and release of all claims
against the company, he is entitled to severance, including six months of his annual salary and reimbursements equal to the premium costs for healthcare coverage under COBRA for six months. On February&nbsp;1, 2023, we entered a separation agreement
with Mr.&nbsp;Will, terminating his employment with us and providing for severance and a general release of all claims against the company. Consistent with the employment agreement, Mr.&nbsp;Will received severance pay totaling $275,000,
representing six months of his base salary, and reimbursements for continued healthcare coverage under COBRA for six months, totaling $14,870. In addition to severance, in connection with the separation agreement, we entered a revised agreement with
respect to a loan we made to Mr.&nbsp;Will in 2020. The amendment did not result in a change in the amount owed on the loan or result in any form of additional compensation or severance. However, we did amend the repayment timing to provide that
Mr.&nbsp;Will&#146;s termination of service would not constitute a repayment of the loan. The loan will be repaid prior to the public filing of this Form <FONT STYLE="white-space:nowrap">S-1.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We
do not have a formal policy with respect to compensation payable to our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors for service as directors, or otherwise. No <FONT STYLE="white-space:nowrap">non-employee</FONT> director was
compensated with cash for service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have granted equity and options awards to one employee director, Gabriel
Mecklenburg. We did not grant any equity awards or other payments or benefits in 2023 to any <FONT STYLE="white-space:nowrap">non-employee</FONT> director. In 2023, we granted to Mr.&nbsp;Mecklenburg 5,193,377 PRSUs, which vest upon the occurrence
of (i)&nbsp;a liquidity event, which will be satisfied in connection with this offering, that (ii)&nbsp;satisfies a milestone-vesting event based on one or more performance conditions, including the liquidity event itself and subsequent public
market valuations of our common stock in connection with the liquidity event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We intend to approve and implement a
compensation policy for our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors to be effective on the consummation of this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth information concerning the compensation
earned by our directors during the year ended December&nbsp;31, 2023, except for Mr.&nbsp;Perez, our Chief Executive Officer, who did not receive any additional compensation for his service as a director and his compensation as the CEO is set forth
in the executive compensation discussion above. Note that only stock awards were made in 2023, so the other columns have been omitted from the table. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2023 Director Compensation Table </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards&nbsp;($)<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Other&nbsp;($)<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ben Blume</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kristina Leslie</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gabriel Mecklenburg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,438,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,938,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elliott Robinson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Teddie Wardi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Amounts reflect the full grant-date fair value of stock awards and stock options granted during 2023
computed in accordance with ASC Topic 718, rather than the amounts paid to or realized by the named individual. See Note 2 to the audited financial statements included in this prospectus for a discussion of valuation assumptions made in determining
the grant date fair value and compensation expense of our RSUs and PRSUs. The value in the table above for the PRSUs reflects both the probable outcome of the performance conditions and the highest level of achievement of the performance conditions.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Amounts in the &#147;Other&#148; column reflect our payment of base salary compensation to
Mr.&nbsp;Mecklenburg for his services to the company as an employee as our Executive Chairman and Chief Commercial Officer. Under an employment agreement, effective as of June&nbsp;5, 2017, Mr.&nbsp;Mecklenburg serves as our Chief Commercial
Officer, and the payments above represent certain base salary payments made for his services. Mr.&nbsp;Mecklenburg did not receive any other payments in connection with his employment. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The table below shows the aggregate numbers of option awards (exercisable and unexercisable) and unvested stock awards held as
of December&nbsp;31, 2023 by each director who was serving as of December&nbsp;31, 2023 (note none of our other directors currently held any unvested stock awards or outstanding stock options as of December&nbsp;31, 2023, besides our Chief Executive
Officer, which is disclosed in the Summary Compensation Table above). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Options&nbsp;Outstanding&nbsp;at<BR>Fiscal Year End (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unvested&nbsp;Restricted&nbsp;Shares<BR>Outstanding at Fiscal Year<BR>End (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gabriel Mecklenburg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">873,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,466,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Incentive Plans </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>2017 Equity Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The 2017 Plan was adopted by our board of directors, effective as of July&nbsp;6, 2017, and was amended as of each of
July&nbsp;3, 2018, January&nbsp;10, 2020, December&nbsp;20, 2020, October&nbsp;22, 2021, February&nbsp;16, 2022, December&nbsp;22, 2022, and April&nbsp;20, 2023, and will terminate on July&nbsp;6, 2027 unless sooner terminated. As of
December&nbsp;31, 2023, options to purchase 3,358,132 shares of our common stock at a weighted average exercise price per share of $1.31, and 24,939,494 RSUs remained outstanding under the plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Administration</I>. The 2017 Plan is administered by our board of directors, or a committee thereof appointed by the board
of directors and composed of members of the board of directors, or the board of directors or committee thereof may delegate to one or more officers of the company or its subsidiaries the power to grant awards, subject to limitations on the terms and
maximum number of the awards granted by such officers where </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
no officer may grant an award to himself or herself. The board of directors and any committee or officer that it delegates its powers or authority under the 2017 Plan to are collectively referred
to as the plan administrator below. The plan administrator has the authority to make all determinations and interpretations under, prescribe all forms for use with, and adopt rules for the administration of, the 2017 Plan, subject to its express
terms and conditions. The plan administrator also sets the terms and conditions of all awards under the 2017 Plan, including any vesting and vesting acceleration conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Eligibility</I>. Our employees and consultants, directors, employees, and
<FONT STYLE="white-space:nowrap">non-employee</FONT> members of our board of directors are eligible to receive awards under the 2017 Plan, provided that only employees may be granted awards intended as incentive stock options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Shares Available</I>. As of December&nbsp;31, 2023, a total of 35,841,864 shares of our common stock had been authorized
for issuance under the 2017 Plan. As of December&nbsp;31, 2023, options to purchase a total of 3,358,132 shares of our common stock and 24,939,494 RSUs were issued and outstanding and a total of 5,559,893 shares of common stock had been issued upon
the exercise of options or pursuant to other awards granted under the 2017 Plan and were outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Awards</I>. The
2017 Plan provides that the plan administrator may grant (i)&nbsp;stock options, including incentive stock options, or ISOs, and nonqualified stock options, or NSOs, (ii)&nbsp;stock appreciation rights, or SARs, (iii)&nbsp;restricted stock,
(iv)&nbsp;RSUs, and (v)&nbsp;unrestricted stock. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Stock Options</I></B>: Stock options provide for the purchase of shares of our common stock in the
future at an exercise price set on the grant date. ISOs, by contrast to NSOs, may provide tax deferral beyond exercise and favorable capital gains tax treatment to their holders if certain holding period and other requirements of the Code are
satisfied. The exercise price of a stock option may not be less than 100% of the fair market value of the underlying share on the date of grant (or 110% in the case of ISOs granted to certain significant stockholders), except with respect to certain
substitute options granted in connection with a corporate transaction (as defined in the 2017 Plan). The term of a stock option may not be longer than ten years (or five years in the case of ISOs granted to certain significant stockholders). Vesting
conditions determined by the plan administrator may apply to stock options and may include continued service, performance, and/or other conditions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>SARs</I></B>: SARs entitle their holder, upon exercise, to receive from us an amount equal to the
appreciation of the shares subject to the award between the grant date and the exercise date. The exercise price of a SAR may not be less than 100% of the fair market value of the underlying share on the date of grant (except with respect to certain
substitute SARs granted in connection with a corporate transaction) and the term of a SAR may not be longer than ten years. Vesting conditions determined by the plan administrator may apply to SARs and may include continued service, performance
and/or other conditions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Restricted Stock and RSUs</I></B>; Restricted stock is an award of nontransferable shares of our common
stock that remain forfeitable unless and until specified conditions are met, and which may be subject to a purchase price. RSUs are contractual promises to deliver shares of our common stock in the future, which may also remain forfeitable unless
and until specified conditions are met, that may be accompanied by the right to receive the equivalent value of dividends paid on shares of our common stock prior to the delivery of the underlying shares. Delivery of the shares underlying RSUs may
be deferred under the terms of the award or at the election of the participant, if the plan administrator permits such a deferral. Conditions applicable to restricted stock and RSUs may be based on continuing service, the attainment of performance
goals, and/or such other conditions as the plan administrator may determine. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Other Stock Awards</I></B>: Other stock awards of fully vested shares of our common stock and other
awards valued wholly or partially by referring to, or otherwise based on, shares of our common stock. Other stock awards may be granted to participants and may also be available as a payment form in the
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
settlement of other awards, as standalone payments and as payment in lieu of base salary, bonus, fees or other cash compensation otherwise payable to any individual who is eligible to receive
awards. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Corporate Transactions.</I> The plan administrator has broad discretion to take action under
the 2017 Plan, as well as make adjustments to the terms and conditions of existing and future awards, to prevent the dilution or enlargement of intended benefits and facilitate necessary or desirable changes in the event of certain transactions and
events affecting our common stock, such as stock dividends, stock splits, mergers, acquisitions, consolidations and other corporate transactions. In the event of a corporate transaction, the plan administrator has discretion to (1)&nbsp;accelerate
vesting of options and SARs, (2)&nbsp;cause any restricted stock or RSU to become <FONT STYLE="white-space:nowrap">non-forfeitable,</FONT> (3)&nbsp;permit option substitutions, (4)&nbsp;cancel options, SARs, restricted stock, and RSUs for no
consideration, (5)&nbsp;cancel any option in exchange for cash or other consideration equal to the difference between the fair market value per shares on the date of the corporate transaction and the exercise price of that option, (6)&nbsp;exchange
restricted stock or RSUs for restricted stock of or restricted stock units in respect of the capital stock of a successor, or (7)&nbsp;redeem or cancel restricted stock or RSUs for cash or other consideration at fair value. In taking the foregoing
actions, the plan administrator is not obligated to treat grantees, awards, awards held by grantees, or awards of the same type identically. Individual award agreements may provide for additional accelerated vesting and payment provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Plan Amendment and Termination</I>. Our board of directors may amend or terminate the 2017 Plan at any time; however,
except in connection with certain changes in our capital structure, stockholder approval will be required for any amendment that increases the number of shares available under the 2017 Plan. No award may be granted pursuant to the 2017 Plan after
the tenth anniversary of the earlier of the date on which our stockholders approved the 2017 Plan or the date on which our board of directors adopted the 2017 Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>2025 Incentive Award Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We intend to adopt the 2025 Plan subject to approval by our stockholders, under which we may grant cash and equity incentive
awards to eligible service providers in order to attract, motivate, and retain the talent for which we compete. The material terms of the 2025 Plan, as it is currently contemplated, are summarized below. Our board of directors is still in the
process of developing, approving and implementing the 2025 Plan and, accordingly, this summary is subject to change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Eligibility and Administration</I>. Our employees, consultants, and directors and the employees, consultants, and directors
of our subsidiaries will be eligible to receive awards under 2025 the Plan. Following our initial public offering, the 2025 Plan will be administered by our board of directors with respect to awards to
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors and by our compensation committee with respect to other participants, each of which may delegate its duties and responsibilities to committees of our directors and/or officers (referred
to collectively as the plan administrator below), subject to certain limitations that may be imposed under Section&nbsp;16 of Exchange Act and/or stock exchange rules, as applicable. The plan administrator will have the authority to make all
determinations and interpretations under, prescribe all forms for use with, and adopt rules for the administration of, the 2025 Plan, subject to its express terms and conditions. The plan administrator will also set the terms and conditions of all
awards under the 2025 Plan, including any vesting and vesting acceleration conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Limitation on Awards and Shares
Available</I>. An aggregate of&#8195;&#8195;&#8195;&#8195;shares of our common stock will be available for issuance under awards granted pursuant to the 2025 Plan, which shares may be authorized but unissued shares, or shares purchased in the open
market. The number of shares available for issuance will be increased by (i)&nbsp;the number of shares available under the prior plan and the number of shares represented by awards outstanding under our prior plan that expire, lapse, or are
terminated, exchanged for or settled in cash, surrendered, repurchased, cancelled without having been fully experienced, or forfeited following the effective date of the 2025 Plan, with the maximum number of shares to be added to the 2025 Plan equal
to&#8195;&#8195;&#8195;&#8195;shares, and (ii)&nbsp;an annual increase on the first day of each calendar year beginning January&nbsp;1, 20&#8195; and ending on and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
including January&nbsp;1, 20&#8195;, equal to the lesser of (A)&#8195;% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year
and (B)&nbsp;such smaller number of shares as is determined by our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If an award under the 2025 Plan
expires, lapses, or is terminated, exchanged for or settled for cash, surrendered, repurchased, or cancelled without having been fully exercised or forfeited, any shares subject to such award may, to the extent of such forfeiture, expiration or cash
settlement, be used again for new grants under the 2025 Plan. Further, shares delivered to us to satisfy the applicable exercise or purchase price of an award under the 2025 Plan or the prior plan and/or to satisfy any applicable tax withholding
obligations (including shares retained by us from the award under the 2025 Plan or the prior plan being exercised or purchased and/or creating the tax obligation) will become or again be available for award grants under the 2025 Plan. The payment of
dividend equivalents in cash in conjunction with any awards under the 2025 Plan will not reduce the shares available for grant under the 2025 Plan. However, the following shares may not be used again for grant under the 2025 Plan: (i)&nbsp;shares
subject to SARs that are not issued in connection with the stock settlement of the SAR on exercise, and (ii)&nbsp;shares purchased on the open market with the cash proceeds from the exercise of options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Awards granted under the 2025 Plan upon the assumption of, or in substitution for, awards authorized or outstanding under a
qualifying equity plan maintained by an entity with which we enter into a merger or similar corporate transaction will not reduce the shares available for grant under the 2025 Plan. The 2025 Plan provides that, commencing with the calendar year
following the calendar year in which the effective date of the 2025 Plan occurs, the sum of any cash compensation and the aggregate grant date fair value (determined as of the date of the grant under ASC Topic 718, or any successor thereto) of all
awards granted to a <FONT STYLE="white-space:nowrap">non-employee</FONT> director as compensation for services as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director during any calendar year may not exceed the amount equal to
$&#8195;&#8195;&#8195;&#8195;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Awards</I>. The 2025 Plan provides for the grant of stock options, including ISOs and
NSOs, dividend equivalents, RSUs, performance shares, other incentive awards, SARs, and cash awards. No determination has been made as to the types or amounts of awards that will be granted to specific individuals pursuant to the 2025 Plan. Certain
awards under the 2025 Plan may constitute or provide for a deferral of compensation, subject to Section&nbsp;409A of the Code, which may impose additional requirements on the terms and conditions of such awards. All awards under the 2025 Plan will
be set forth in award agreements, which will detail all terms and conditions of the awards, including any applicable vesting and payment terms and post-termination exercise limitations. Awards other than cash awards generally will be settled in
shares of our common stock, but the plan administrator may provide for cash settlement of any award. A brief description of each award type follows. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Stock Options</I></B>: Stock options provide for the purchase of shares of our common stock in the
future at an exercise price set on the grant date. ISOs, by contrast to NSOs, may provide tax deferral beyond exercise and favorable capital gains tax treatment to their holders if certain holding period and other requirements of the Code are
satisfied. The exercise price of a stock option may not be less than 100% of the fair market value of the underlying share on the date of grant (or 110% in the case of ISOs granted to certain significant stockholders), except with respect to certain
substitute options granted in connection with a corporate transaction. The term of a stock option may not be longer than ten years (or five years in the case of ISOs granted to certain significant stockholders). Vesting conditions determined by the
plan administrator may apply to stock options and may include continued service, performance, and/or other conditions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>SARs</I></B>: SARs entitle their holder, upon exercise, to receive from us an amount equal to the
appreciation of the shares subject to the award between the grant date and the exercise date. The exercise price of a SAR may not be less than 100% of the fair market value of the underlying share on the date of grant (except with respect to certain
substitute SARs granted in connection with a corporate transaction) and the term of a SAR may not be longer than ten years. Vesting conditions determined by the plan administrator may apply to SARs and may include continued service, performance,
and/or other conditions. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Restricted Stock and RSUs</I></B>: Restricted stock is an award of nontransferable shares of our common
stock that remain forfeitable unless and until specified conditions are met, and which may be subject to a purchase price. RSUs are contractual promises to deliver shares of our common stock in the future, which may also remain forfeitable unless
and until specified conditions are met, that may be accompanied by the right to receive the equivalent value of dividends paid on shares of our common stock prior to the delivery of the underlying shares. Delivery of the shares underlying RSUs may
be deferred under the terms of the award or at the election of the participant, if the plan administrator permits such a deferral. Conditions applicable to restricted stock and RSUs may be based on continuing service, the attainment of performance
goals, and/or such other conditions as the plan administrator may determine. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Other Stock or Cash Based Awards</I></B>: Other stock or cash based awards of cash, fully vested shares
of our common stock, and other awards valued wholly or partially by referring to, or otherwise based on, shares of our common stock. Other stock or cash based awards may be granted to participants and may also be available as a payment form in the
settlement of other awards, as standalone payments and as payment in lieu of base salary, bonus, fees, or other cash compensation otherwise payable to any individual who is eligible to receive awards. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Dividend Equivalents</I></B>: Dividend equivalents represent the right to receive the equivalent value
of dividends paid on shares of our common stock and may be granted alone or in tandem with awards other than stock options or SARs. Dividend equivalents are credited as of dividend record dates during the period between the date an award is granted
and the date such award vests, is exercised, is distributed, or expires, as determined by the plan administrator. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Performance Awards</I>. Performance awards include any of the foregoing awards that are granted subject to vesting and/or
payment based on the attainment of specified performance goals or other criteria the plan administrator may determine, which may or may not be objectively determinable. Performance criteria upon which performance goals are established by the plan
administrator may include but are not limited to: (1)&nbsp;net earnings (either before or after one or more of the following: (a)&nbsp;interest, (b) taxes, (c)&nbsp;depreciation, (d) amortization, and
<FONT STYLE="white-space:nowrap">(e)&nbsp;non-cash</FONT> equity-based compensation expense); (2) gross or net sales or revenue; (3)&nbsp;net income (either before or after taxes); (4) adjusted net income; (5)&nbsp;operating earnings or profit;
(6)&nbsp;cash flow (including, but not limited to, operating cash flow and free cash flow); (7) return on assets; (8)&nbsp;return on capital; (9)&nbsp;return on stockholders&#146; equity; (10)&nbsp;total stockholder return; (11)&nbsp;return on
sales; (12)&nbsp;gross or net profit or operating margin; (13)&nbsp;costs; (14) funds from operations; (15)&nbsp;expenses; (16) working capital; (17)&nbsp;earnings per share; (18)&nbsp;adjusted earnings per share; (19)&nbsp;price per share of common
stock; (20)&nbsp;regulatory achievements or compliance; (21)&nbsp;implementation or completion of critical projects; (22)&nbsp;market share; (23)&nbsp;economic value; (24)&nbsp;debt levels or reduction; (25)&nbsp;sales-related goals;
(26)&nbsp;comparisons with other stock market indices; (27)&nbsp;operating efficiency; (28)&nbsp;employee satisfaction; (29)&nbsp;financing and other capital raising transactions; (30)&nbsp;recruiting and maintaining personnel; and <FONT
STYLE="white-space:nowrap">(31)&nbsp;year-end</FONT> cash, any of which may be measured either in absolute terms for us or any operating unit of our company or as compared to any incremental increase or decrease or as compared to results of a peer
group or to market performance indicators or indices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Certain Transactions</I>. The plan administrator has broad
discretion to take action under the 2025 Plan, as well as make adjustments to the terms and conditions of existing and future awards, to prevent the dilution or enlargement of intended benefits and facilitate necessary or desirable changes in the
event of certain transactions and events affecting our common stock, such as stock dividends, stock splits, mergers, acquisitions, consolidations and other corporate transactions. In addition, in the event of certain
<FONT STYLE="white-space:nowrap">non-reciprocal</FONT> transactions with our stockholders known as &#147;equity restructurings,&#148; the plan administrator will make equitable adjustments to the 2025 Plan and outstanding awards. In the event of a
change in control of our company (as defined in the 2025 Plan), to the extent that the surviving entity declines to continue, convert, assume or replace outstanding awards, then all such awards will become fully vested and exercisable in connection
with the transaction. Upon or in anticipation of a change of control, the plan administrator may cause any outstanding awards to terminate at a specified time in the future and give the participant the right to exercise such awards during a period
of time </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
determined by the plan administrator in its sole discretion. Individual award agreements may provide for additional accelerated vesting and payment provisions.<I> </I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Foreign Participants, Claw-Back Provisions, Transferability, and Participant Payments</I>. The plan administrator may
modify award terms, establish subplans, and/or adjust other terms and conditions of awards, subject to the share limits described above, in order to facilitate grants of awards subject to the laws and/or stock exchange rules of countries outside of
the United States. All awards will be subject to the provisions of any claw-back policy implemented by our company to the extent set forth in such claw-back policy and/or in the applicable award agreement. With limited exceptions for estate
planning, domestic relations orders, certain beneficiary designations, and the laws of descent and distribution, awards under the 2025 Plan are generally <FONT STYLE="white-space:nowrap">non-transferable</FONT> prior to vesting, and are exercisable
only by the participant. With regard to tax withholding, exercise price and purchase price obligations arising in connection with awards under the 2025 Plan, the plan administrator may, in its discretion, accept cash or check, shares of our common
stock that meet specified conditions, a &#147;market sell order&#148; or such other consideration as it deems suitable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Plan Amendment and Termination. </I>Our board of directors may amend or terminate the 2025 Plan at any time; however,
except in connection with certain changes in our capital structure, stockholder approval will be required for any amendment that increases the number of shares available under the 2025 Plan. Stockholder approval is not required for any amendment
that &#147;reprices&#148; any stock option or SAR, or cancels any stock option or SAR in exchange for cash or another award when the option or SAR price per share exceeds the fair market value of the underlying shares. No award may be granted
pursuant to the 2025 Plan after the tenth anniversary of the earlier of the date on which our stockholders approved the 2025 Plan or the date on which our board of directors adopted the 2025 Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>2025 Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with the offering, we intend to adopt the ESPP, which will become effective on the day the ESPP is adopted by our
board of directors. The material terms of the ESPP, as it is currently contemplated, are summarized below. Our board of directors is still in the process of developing, approving, and implementing the ESPP and, accordingly, this summary is subject
to change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Shares Available; Administration</I>. We expect a total of&#8195;&#8195;&#8195;&#8195;shares of our common
stock to be initially reserved for issuance under our ESPP. In addition, we expect that the number of shares available for issuance under the ESPP will be annually increased on January&nbsp;1 of each calendar year beginning in 20&#8195; and ending
in 20&#8195;, by an amount equal to the lesser of: (i)&#8195;% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (ii)&nbsp;such smaller number of shares as is determined by
our board of directors. In no event will more than&#8195;&#8195;&#8195;&#8195;shares of our common stock be available for issuance under the ESPP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors or a committee designated by our board of directors will have authority to interpret the terms of the
ESPP and determine eligibility of participants. We expect that the compensation committee will be the administrator of the ESPP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Eligibility</I>. The plan administrator may designate certain of our subsidiaries as participating &#147;designated
subsidiaries&#148; in the ESPP and may change these designations from time to time. Employees of our company and our designated subsidiaries are eligible to participate in the ESPP if they meet the eligibility requirements under the ESPP established
from time to time by the plan administrator. However, an employee may not be granted rights to purchase stock under the ESPP if such employee, immediately after the grant, would own (directly or through attribution) stock possessing 5% or more of
the total combined voting power or value of all classes of our common or other class of stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the grant of a purchase
right under the ESPP to any eligible employee who is a citizen or resident of a foreign jurisdiction would be prohibited under the laws of such foreign jurisdiction or the grant of a purchase </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
right to such employee in compliance with the laws of such foreign jurisdiction would cause the ESPP to violate the requirements of Section&nbsp;423 of the Code, as determined by the plan
administrator in its sole discretion, such employee will not be permitted to participate in the ESPP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Eligible employees
become participants in the ESPP by enrolling and authorizing payroll deductions by the deadline established by the plan administrator prior to the relevant offering date. Directors who are not employees, as well as consultants, are not eligible to
participate. Employees who choose not to participate, or are not eligible to participate at the start of an offering period but who become eligible thereafter, may enroll in any subsequent offering period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Participation in an Offering</I>. We intend for the ESPP to qualify under Section&nbsp;423 of the Code and stock will be
offered under the ESPP during offering periods. The length of offering periods under the ESPP will be determined by the plan administrator and may be up to 27 months long. Employee payroll deductions will be used to purchase shares on each purchase
date during an offering period. The number of purchase periods within, and purchase dates during, each offering period will be established by the plan administrator. Offering periods under the ESPP will commence when determined by the plan
administrator. The plan administrator may, in its discretion, modify the terms of future offering periods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect that
the ESPP will permit participants to purchase our common stock through payroll deductions of up to 20% of their eligible compensation, which will include a participant&#146;s gross base compensation for services to us, including overtime payments
and excluding sales commissions, incentive compensation, bonuses, expense reimbursements, fringe benefits, and other special payments. The plan administrator will establish a maximum number of shares that may be purchased by a participant during any
offering period or purchase period, which, in the absence of a contrary designation, will be&#8195;&#8195;&#8195;&#8195;shares for an offering period and/or a purchase period. In addition, no employee will be permitted to accrue the right to
purchase stock under the ESPP at a rate in excess of $25,000 worth of shares during any calendar year during which such a purchase right is outstanding (based on the fair market value per share of our common stock as of the first day of the offering
period). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On the first trading day of each offering period, each participant automatically will be granted an option to
purchase shares of our common stock. The option will be exercised on the applicable purchase date(s) during the offering period, to the extent of the payroll deductions accumulated during the applicable purchase period. We expect that the purchase
price of the shares, in the absence of a contrary determination by the plan administrator, will be 85% of the lower of the fair market value of our common stock on the first trading day of the offering period or on the applicable purchase date,
which will be the final trading day of the applicable purchase period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Participants may voluntarily end their
participation in the ESPP at any time at least one week prior to the end of the applicable offering period (or such longer or shorter period specified by the plan administrator) and will be paid their accrued payroll deductions that have not yet
been used to purchase shares of common stock. Participation ends automatically upon a participant&#146;s termination of employment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Transferability</I>. A participant may not transfer rights granted under the ESPP other than by will, the laws of descent
and distribution, or as otherwise provided in the ESPP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Certain Transactions</I>. In the event of certain transactions
or events affecting our common stock, such as any stock dividend or other distribution, change in control, reorganization, merger, consolidation or other corporate transaction, the plan administrator will make equitable adjustments to the ESPP and
outstanding rights. In addition, in the event of the foregoing transactions or events or certain significant transactions, including a change in control, the plan administrator may provide for (i)&nbsp;either the replacement of outstanding rights
with other rights or property or termination of outstanding rights in exchange for cash, (ii)&nbsp;the assumption or substitution of outstanding rights by the successor or survivor corporation or parent or subsidiary thereof, (iii)&nbsp;the
adjustment in the number and type of shares of stock subject to outstanding rights, (iv)&nbsp;the use of the participants&#146; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
accumulated payroll deductions to purchase stock on a new purchase date prior to the next scheduled purchase date and termination of any rights under ongoing offering periods, or (v)&nbsp;the
termination of all outstanding rights. Under the ESPP, a change in control has the same definition as given to such term in the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Plan Amendment; Termination</I>. The plan administrator may amend, suspend or terminate the ESPP at any time. However,
stockholder approval of any amendment to the ESPP must be obtained for any amendment which increases the aggregate number or changes the type of shares that may be sold pursuant to rights under the ESPP, changes the corporations or classes of
corporations whose employees are eligible to participate in the ESPP, or changes the ESPP in any manner that would cause the ESPP to no longer be an employee stock purchase plan within the meaning of Section&nbsp;423(b) of the Code. The ESPP will
terminate on the tenth anniversary of the date it is initially approved by our board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom829170_15"></A>CERTAIN RELATIONSHIPS AND RELATED-PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following includes a summary of transactions since January&nbsp;1, 2021 and any currently proposed transactions, to which
we were or are to be a participant, in which (i)&nbsp;the amount involved exceeded or will exceed $120,000; and (ii)&nbsp;any of our directors, executive officers, or holders of more than 5% of our capital stock, or any affiliate or member of the
immediate family of the foregoing persons or entities, had or will have a direct or indirect material interest, other than compensation and other arrangements that are described under the section titled &#147;Executive and Director
Compensation.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe the terms obtained or consideration that we paid or received, as applicable, in connection
with the transactions described below were comparable to terms available or the amounts that we would pay or receive, as applicable, in <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> transactions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Redeemable Convertible Preferred Stock Financing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In October 2021, we entered into a Series&nbsp;E redeemable convertible preferred stock purchase agreement with various
investors, pursuant to which we issued and sold an aggregate of 5,163,674 shares of our Series&nbsp;E redeemable convertible preferred stock at a purchase price of $77.4642 per share, for gross proceeds of approximately $400&nbsp;million in multiple
closings through December&nbsp;2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The table below sets forth the number of shares of our Series&nbsp;E redeemable
convertible preferred stock and purchased by holders of more than 5% of our capital stock and their affiliated entities. None of our directors or executive officers purchased shares of Series E redeemable convertible preferred stock. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares of<BR>Series&nbsp;E<BR>Redeemable<BR>Convertible<BR>Preferred&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Purchase&nbsp;Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Tiger Global PIP <FONT STYLE="white-space:nowrap">15-35</FONT> LLC<SUP
STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,581,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">199,999,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Coatue US 70
LLC<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,581,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">199,999,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">See the section titled &#147;Principal and Selling Stockholders&#148; for additional information regarding
these stockholders and their equity holdings. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Entities affiliated with Tiger Global PIP <FONT STYLE="white-space:nowrap">15-35</FONT> LLC (&#147;Tiger
Global&#148;) collectively beneficially own more than 5% of our outstanding capital stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Entities affiliated with Coatue US 70 LLC (&#147;Coatue&#148;) collectively beneficially own more than 5% of
our outstanding capital stock. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investors&#146; Rights Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are party to our amended and restated investors&#146; rights agreement which provides, among other things, that certain
holders of our capital stock, including entities affiliated with Insight Venture Partners, Atomico, Coatue, Tiger Global, 11.2 Capital, (&#147;11.2 Capital&#148;), and Bessemer, each of which hold more than 5% of our outstanding capital stock, have
the right to demand that we file a registration statement or request that their shares of our capital stock be included on a registration statement that we are otherwise filing. See the section titled &#147;Description of Capital
Stock&#151;Registration Rights&#148; for additional information regarding these registration rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Right of First Refusal </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to our equity compensation plans and certain agreements with our stockholders, including an amended and restated right
of first refusal and <FONT STYLE="white-space:nowrap">co-sale</FONT> agreement with certain holders of our capital stock, including entities affiliated with Insight Venture Partners, Atomico, Coatue, Tiger Global, 11.2 Capital, and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Bessemer, each of which hold more than 5% of our outstanding capital stock, Daniel Perez, our Chief Executive Officer and Director, and Gabriel Mecklenburg, our Executive Chairman and Director,
we or our assignees have a right to purchase shares of our capital stock which certain stockholders propose to sell to other parties. This right under the right of first refusal and <FONT STYLE="white-space:nowrap">co-sale</FONT> agreement will
terminate upon the consummation of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since January&nbsp;1, 2021, we have waived our right of first refusal
in connection with secondary sales of shares of our capital stock, including sales or purchases by certain of our executive officers or holders of more than 5% of our capital stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tender Offer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In December
2021, Tiger Global and Coatue, each of which hold more than 5% of our outstanding capital stock, conducted a tender offer for shares of our outstanding common stock from certain of our employees, advisors, and directors and purchased an aggregate of
1,104,016 shares of our outstanding common stock at a purchase price of $77.4642 per share, for an aggregate purchase price of $85.5&nbsp;million (the &#147;2021 Tender Offer&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The table below summarizes purchases of common stock from our executive officers and directors in the 2021 Tender Offer. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of<BR>Common<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Purchase<BR>Price</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel Perez</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer and Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">81,632<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$6,323,558</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gabriel Mecklenburg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Chairman and Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">64,549</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$5,000,237</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jim Pursley</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">29,642</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$2,296,194</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ron Will</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Former Chief Financial Officer<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">68,262</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$5,287,861</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Includes 17,083 shares of common stock sold by Mr.&nbsp;Perez&#146;s spouse in the 2021 Tender Offer.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Ron Will was our Chief Financial Officer at the time of his participation in the 2021 Tender Offer.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The 2021 Tender Offer&nbsp;was&nbsp;conducted to reward and incentivize our employees, advisors, and
directors and to provide liquidity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Founder Secondary Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In October 2021, we helped facilitate sales of shares of common stock held by Daniel Perez, our Chief Executive Officer and
Director, and Gabriel Mecklenburg, our Executive Chairman and Director. Each of Mr.&nbsp;Perez and Mr.&nbsp;Mecklenburg sold 193,637 shares of common stock to nine institutional investors at a purchase price of $77.4642 per share, for an aggregate
purchase price for each of Mr.&nbsp;Perez&#146;s and Mr.&nbsp;Mecklenburg&#146;s shares of $15.0&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Loans to Certain Officers and Directors
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In August 2020, each of Daniel Perez, our Chief Executive Officer and Director, Gabriel Mecklenburg, our then Chief
Operating Officer and Director, and our former Chief Financial Officer purchased shares of common stock pursuant to restricted stock awards in exchange for partial recourse promissory notes. Mr.&nbsp;Perez purchased a total of 1,162,012 shares of
common stock at a purchase price of $1.90 per share in exchange for a partial recourse promissory note of $2,207,822.80, Mr.&nbsp;Mecklenburg purchased a total of 1,162,012 shares of common stock at a purchase price of $1.90 per share in exchange
for a partial recourse promissory note of $2,207,822.80, and our former Chief Financial Officer purchased a total of 585,107 shares of common stock at a purchase price of $1.90 per share in exchange for a partial recourse promissory note of
$1,111,703.30. The notes bear interest at </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
a rate of 0.41% compounded annually. The outstanding principal and interest under Mr.&nbsp;Perez&#146;s and Mr.&nbsp;Mecklenburg&#146;s partial recourse promissory notes is due upon the earlier
of: (i)&nbsp;the eighth anniversary of such note&#146;s issuance, (ii)&nbsp;within ninety days of termination of employment of the borrower, whether voluntary or involuntary, (iii)&nbsp;the date (a)&nbsp;that any person (within the meaning of
Section&nbsp;13(d)(3) or 14(d)(2) of the Exchange Act), other than any person who currently owns more than a majority of the company&#146;s common stock, becomes the beneficial owner (within the meaning of Rule
<FONT STYLE="white-space:nowrap">13d-3</FONT> promulgated under the Exchange Act) of more than 50% of the combined voting power of the then outstanding voting securities of the company, except for any change in the ownership of the stock of the
company as a result of a private financing of the company that is approved by our board of directors, (b)&nbsp;of a consolidation or merger of the company with or into another entity, unless the stockholders of the company immediately before such
consolidation or merger own, directly or indirectly, a majority of the combined voting power of the outstanding voting securities of the corporation or other entity resulting from such consolidation or merger, (c)&nbsp;the sale of all or
substantially all of the assets of the company, or (d)&nbsp;the liquidation, dissolution or winding up of the company, (iv)&nbsp;upon insolvency of the borrower, or (v)&nbsp;upon the sale, transfer, or disposition of the pledged shares. In February
2023, following our former Chief Financial Officer&#146;s departure from the company, his promissory note was amended to extend the maturity date, and provides that outstanding principal and interest is due upon the earlier of: (i)&nbsp;the date of
a Corporate Transaction, as defined in the 2017 Plan, (ii)&nbsp;one month following email or written notice from the company to the borrower that the company has submitted a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT>
in response to comments from the SEC to the company&#146;s initial filing of a registration statement on Form <FONT STYLE="white-space:nowrap">S-1,</FONT> (iii) upon insolvency of the borrower, (iv)&nbsp;upon the sale, transfer, or disposition of
the pledged shares, or (v)&nbsp;upon (a) the company becoming subject to the restrictions of the Sarbanes-Oxley Act or (b)&nbsp;the borrower becoming an officer or director of a parent entity subject to the restrictions of the Sarbanes-Oxley Act.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of September&nbsp;30, 2024, $2,245,168.03 aggregate principal and interest amount was outstanding pursuant to
Mr.&nbsp;Perez&#146;s partial recourse promissory note, $2,245,168.03 aggregate principal and interest amount was outstanding pursuant to Mr.&nbsp;Mecklenburg&#146;s partial recourse promissory note, and $531,539.36 aggregate principal and interest
amount was outstanding pursuant to our former Chief Financial Officer&#146;s partial recourse promissory note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each of
the outstanding partial recourse promissory notes described herein will be fully paid and terminated prior to the consummation of this offering. Refer to Note 9, Equity Incentive Plans, Common and Stock-Based Compensation in our audited consolidated
financial statements included elsewhere in this prospectus for additional information regarding the partial recourse promissory notes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Services
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From time to time, we engage the law firm of Perkins Coie LLP for various legal services. Fees paid for services
provided by Perkins Coie LLP for each year since January&nbsp;1, 2021 did not exceed $3.0&nbsp;million for any of the years in question. A sibling of Daniel Perez, our Chief Executive Officer and Director, is a partner with Perkins Coie LLP. Our
board of directors believes that the terms of Perkins Coie LLP&#146;s representation are no less favorable to us than those that could be obtained from an unrelated third party. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting Agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are
party to an amended and restated voting agreement under which certain holders of our capital stock, including entities affiliated with Insight Venture Partners, Atomico, Coatue, Tiger Global, 11.2 Capital, and Bessemer, each of which hold more than
5% of our outstanding capital stock, and our Founders have agreed as to the manner in which they will vote their shares of our capital stock on certain matters, including with respect to the election of directors. Upon the effectiveness of the
registration statement of which this prospectus forms a part, the voting agreement will terminate and none of our stockholders will have any special rights regarding the election or designation of members of our board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On March&nbsp;22, 2023, Daniel Perez, our Chief Executive Officer and Director, transferred 493,063 shares of common stock to
his spouse for no consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have entered into employment agreements with certain of our executive officers that,
among other things, provide for certain compensatory and change in control benefits. For a description of these agreements with our named executive officers, see the section titled &#147;Executive and Director Compensation&#151;Executive
Compensation Arrangements.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have also granted stock options, RSUs, PRSUs, and restricted stock to our executive
officers. For a description of these equity awards, see the section titled &#147;Executive and Director Compensation&#151;Outstanding Equity Awards at Fiscal Year-End.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director and Officer Indemnification </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have entered into indemnification agreements with certain of our current executive officers and directors, and we intend to
enter into new indemnification agreements with each of our current executive officers and directors before the completion of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation also provides that, and our amended and restated certificate of
incorporation, which will be in effect immediately prior to the completion of this offering, will also provide that, to the fullest extent permitted by law, we will indemnify any officer or director of our company against all damages, claims, and
liabilities arising out of the fact that the person is or was our officer or director, or served any other enterprise at our request as an officer or director. Amending this provision will not reduce our indemnification obligations relating to
actions taken before an amendment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Policies and Procedures for Related Person Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors will adopt a written related person transaction policy, to be effective upon the completion of this
offering, that applies to our executive officers, directors, director nominees, holders of more than 5% of any class of our voting securities and any member of the immediate family of, and any entity affiliated with, any of the foregoing persons.
Such persons will not be permitted to enter into a related person transaction with us without the prior consent of our audit committee, or other independent members of our board of directors in the event it is inappropriate for our audit committee
to review such transaction due to a conflict of interest. Any request for us to enter into a transaction with an executive officer, director, director nominee, principal stockholder, or any of their immediate family members or affiliates, in which
the amount involved exceeds $120,000 must first be presented to our audit committee for review, consideration, and approval. In approving or rejecting any such proposal, our audit committee will consider the relevant facts and circumstances
available and deemed relevant to our audit committee, including, but not limited to, the commercial reasonableness of the terms of the transaction, whether the transaction is on terms comparable to those that could be obtained in an <FONT
STYLE="white-space:nowrap">arm&#146;s-length</FONT> transaction with an unrelated third party and the extent of the related person&#146;s interest in the transaction and the materiality, and the character of the related person&#146;s direct or
indirect interest in the transaction. All of the transactions described in this section occurred prior to the adoption of this policy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom829170_16"></A>PRINCIPAL AND SELLING STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table contains information about the beneficial ownership of our common stock as of September&nbsp;30, 2024,
(i)&nbsp;immediately prior to the consummation of this offering and (ii)&nbsp;as adjusted to reflect the sale of shares of our Class&nbsp;A common stock offered by this prospectus by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person, or group of persons, known to us who beneficially owns more than 5% of our capital stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our named executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all directors and executive officers as a group; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of the selling stockholders. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have based percentage ownership of our common stock before this offering on 64,409,887 shares of our common stock
outstanding, as of September&nbsp;30, 2024. The following table assumes the occurrence of each of the filing and effectiveness of our amended and restated certificate of incorporation, which will be in effect immediately prior to the completion of
this offering and the Transactions, in each case as if it had occurred as of September&nbsp;30, 2024. Percentage ownership of our common stock after this offering assumes our sale of &#8195;&#8195;&#8195;&#8195; shares of Class&nbsp;A common stock
in this offering, assuming no exercise by the underwriters of their option to purchase additional shares of Class&nbsp;A common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In accordance with the rules of the SEC, beneficial ownership includes voting or investment power with respect to securities
and includes the shares issuable pursuant to stock options that are exercisable within 60 days of September&nbsp;30, 2024 or issuable pursuant to RSUs and PRSUs that are subject to vesting and settlement conditions expected to occur within 60 days
of September&nbsp;30, 2024 (including those for which the liquidity-based vesting condition will be satisfied in connection with this offering). Shares issuable pursuant to stock options are deemed outstanding for computing the percentage of the
person holding such options but are not outstanding for computing the percentage of any other person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For further
information regarding material transactions between us and certain of our stockholders, see the section titled &#147;Certain Relationships and Related-Party Transactions.&#148; Unless otherwise indicated, the address for each listed stockholder is:
c/o Hinge Health, Inc., 455 Market Street, Suite 700, San Francisco, California 94105. Except as indicated in the footnotes to the following table or pursuant to applicable community property laws, we believe, based on information furnished to us,
that each stockholder named in the table has sole voting and investment power with respect to the shares set forth opposite such stockholder&#146;s name. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" ROWSPAN="3" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; "><B>Name&nbsp;of&nbsp;Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Beneficially</B><br><B>Owned<BR>Before this</B><br><B>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>% of Total<BR>Outstanding</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>% Total<BR>Voting<BR>Power<BR>Before&nbsp;this<BR>Offering</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of<BR>Class&nbsp;A<BR>Common<BR>Stock<BR>Being<BR>Offered</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Beneficially</B><br><B>Owned<BR>After this</B><br><B>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>% of Total<BR>Outstanding</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>% Total<BR>Voting<BR>Power<BR>After&nbsp;this<BR>Offering</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>Named Executive Officers, and Directors:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8195;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8195;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Daniel Perez<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,322,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Ben Blume<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Kristina Leslie<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Gabriel Mecklenburg<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,012,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Elliott Robinson<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Teddie Wardi<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">James Budge<SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">227,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Jim Pursley<SUP STYLE="font-size:75%; vertical-align:top">(8)</SUP><SUP
STYLE="font-size:75%; vertical-align:top"> </SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">898,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Ron Will<SUP STYLE="font-size:75%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">306,656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" ROWSPAN="3" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; "><B>Name&nbsp;of&nbsp;Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Beneficially</B><br><B>Owned<BR>Before this</B><br><B>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>% of Total<BR>Outstanding</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>% Total<BR>Voting<BR>Power<BR>Before&nbsp;this<BR>Offering</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of<BR>Class&nbsp;A<BR>Common<BR>Stock<BR>Being<BR>Offered</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Beneficially</B><br><B>Owned<BR>After this</B><br><B>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>% of Total<BR>Outstanding</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>% Total<BR>Voting<BR>Power<BR>After&nbsp;this<BR>Offering</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">All current executive officers and directors as a group (8&nbsp;persons)<SUP
STYLE="font-size:75%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,130,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,334,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>Other 5% or Greater Stockholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Entities affiliated with Insight Venture
Partners<SUP STYLE="font-size:75%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,279,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Entities affiliated with
Atomico<SUP STYLE="font-size:75%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,364,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Entities affiliated with
11.2&nbsp;Capital<SUP STYLE="font-size:75%; vertical-align:top">(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,100,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Entities affiliated with Coatue<SUP STYLE="font-size:75%; vertical-align:top">(14)</SUP></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">552,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,983,533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Entities affiliated with Tiger
Global<SUP STYLE="font-size:75%; vertical-align:top">(15)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">552,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,979,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Entities affiliated with Bessemer Venture
Partners<SUP STYLE="font-size:75%; vertical-align:top">(16)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,833,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman; " ALIGN="justify">Represents beneficial ownership of less than 1%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman; " ALIGN="justify">Consists of (i) 8,519,291 shares of Class&nbsp;B common stock held by Daniel Perez, (ii) 512,384 shares of
Class&nbsp;B common stock held by Mr.&nbsp;Perez&#146;s spouse, (iii) 831,340 shares of Class&nbsp;B common stock issuable upon the vesting and settlement of RSUs held by Mr.&nbsp;Perez for which the service-based vesting condition was satisfied as
of September&nbsp;30, 2024 and for which we expect the liquidity-based vesting condition to be satisfied or settlement to occur in connection with this offering, (iv) 1,416,374 shares of Class&nbsp;B common stock issuable upon the vesting and
settlement of PRSUs held by Mr.&nbsp;Perez for which the performance-based vesting condition was satisfied as of September&nbsp;30, 2024 and for which we expect the liquidity-based vesting condition to be satisfied or settlement to occur in
connection with this offering, (v) 35,470 shares of Class&nbsp;B common stock subject to stock options held by Mr.&nbsp;Perez&#146;s spouse that are exercisable within 60 days of September&nbsp;30, 2024, and (vi) 7,860 shares of Class&nbsp;B common
stock issuable upon the vesting and settlement of RSUs held by Mr.&nbsp;Perez&#146;s spouse for which the service-based vesting condition was satisfied as of September&nbsp;30, 2024 and for which we expect the liquidity-based vesting condition to be
satisfied or settlement to occur in connection with this offering. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman; " ALIGN="justify">Ben Blume, a member of our board of directors, is a partner at Atomico (UK) Partners, LLP. Mr.&nbsp;Blume
disclaims beneficial ownership of the shares of the company held by the Atomico Entities (as defined in footnote 12 below) except to the extent of his pecuniary interest, if any, in such securities through an indirect interest in the Atomico
Entities. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman; " ALIGN="justify">Consists of 4,375 shares of Class&nbsp;A common stock issuable upon the vesting and settlement of RSUs held
by Kristina Leslie for which the service-based vesting condition was satisfied as of September&nbsp;30, 2024 and for which we expect the liquidity-based vesting condition to be satisfied or settlement to occur in connection with this offering.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman; " ALIGN="justify">Consists of (i) 1,475,711 shares of Class&nbsp;B common stock held by Gabriel Mecklenburg, (ii) 873,138
shares of Class&nbsp;B stock subject to stock options held by Mr.&nbsp;Mecklenburg that are exercisable within 60 days of September&nbsp;30, 2024, (iii) 1,246,951 shares of Class&nbsp;B common stock issuable upon the vesting and settlement of RSUs
held by Mr.&nbsp;Mecklenburg for which the service-based vesting condition was satisfied as of September&nbsp;30, 2024 and for which we expect the liquidity-based vesting condition to be satisfied or settlement to occur in connection with this
offering, and (iv) 1,416,374 shares of Class&nbsp;B common stock issuable upon the vesting and settlement of PRSUs held by Mr.&nbsp;Mecklenburg for which the performance-based vesting condition was satisfied as of September&nbsp;30, 2024 and for
which we expect the liquidity-based vesting condition to be satisfied or settlement to occur in connection with this offering. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman; " ALIGN="justify">Elliott Robinson, a member of our board of directors, is a partner at Bessemer Venture Partners.
Mr.&nbsp;Robinson disclaims beneficial ownership of the shares of the company held by the Bessemer Entities (as defined in footnote 16 below) except to the extent of his pecuniary interest, if any, in such securities through an indirect interest in
the Bessemer Entities. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman; " ALIGN="justify">Mr.&nbsp;Wardi is a Managing Director at Insight Venture Management, LLC, the investment manager of Insight
Venture Partners X, L.P., Insight Venture Partners (Cayman) X, L.P., Insight Venture Partners (Delaware) X, L.P., and Insight Venture Partners X <FONT STYLE="white-space:nowrap">(Co-Investors),</FONT> L.P. (collectively, the &#147;Insight
Entities&#148;), and does not have voting or investment power over the shares held by the Insight Entities. Mr.&nbsp;Wardi disclaims beneficial ownership of the shares held by the Insight Entities except to the extent of his pecuniary interest. See
footnote 11 below for more information regarding the Insight Entities. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman; " ALIGN="justify">Consists of 227,345 shares of Class&nbsp;A common stock issuable upon the vesting and settlement of RSUs
held by James Budge for which the service-based vesting condition was satisfied as of September&nbsp;30, 2024 and for which we expect the liquidity-based vesting condition to be satisfied or settlement to occur in connection with this offering.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman; " ALIGN="justify">Consists of (i) 44,463 shares of Class&nbsp;A common stock held by Jim Pursley, (ii) 91,577 shares of
Class&nbsp;A common stock issuable upon the vesting and settlement of RSUs held by Mr.&nbsp;Pursley for which the service-based vesting condition was satisfied as of September&nbsp;30, 2024 and for which we expect the liquidity-based vesting
condition to be satisfied or settlement to occur in connection with this offering, and (iii) 762,687 shares of Class&nbsp;A common stock issuable upon the vesting and settlement of PRSUs held by Mr.&nbsp;Pursley for which the performance-based
vesting condition was satisfied as of September&nbsp;30, 2024 and for which we expect the liquidity-based vesting condition to be satisfied or settlement to occur in connection with this offering. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman; " ALIGN="justify">Consists of (i) 273,050 shares of Class&nbsp;A common stock and (ii) 33,606 shares of Class&nbsp;A common
stock issuable upon the vesting and settlement of RSUs held by Ron Will for which the service-based vesting condition was satisfied as of September&nbsp;30, 2024 and for which we expect the liquidity-based vesting condition to be satisfied or
settlement to occur in connection with this offering. Ron Will stepped down from his position as Chief Financial Officer effective February&nbsp;1, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman; " ALIGN="justify">Consists of (i) 44,463 shares of Class&nbsp;A common stock, (ii) 36,984,929 shares of Class&nbsp;B common
stock, (iii) 323,297 shares of Class&nbsp;A common stock issuable upon the vesting and settlement of RSUs for which the service-based vesting condition was satisfied as of September&nbsp;30, 2024 and for which we expect the liquidity-based vesting
condition to be satisfied or settlement to occur in connection with this offering, (iv) 762,687 shares of Class&nbsp;A common stock issuable upon the vesting and settlement of PRSUs for which the performance-based vesting condition was satisfied as
of September&nbsp;30, 2024 and for which we expect the liquidity-based vesting condition to be satisfied or settlement to occur in connection with this offering, (v) 908,608 shares of Class&nbsp;B stock subject to stock options that are exercisable
within 60 days of September&nbsp;30, 2024, (vi) 2,086,151 shares of Class&nbsp;B common stock issuable upon the vesting and settlement of RSUs for which the service-based vesting condition was satisfied as of September&nbsp;30, 2024 and for which we
expect the liquidity-based vesting condition to be satisfied or settlement to occur in connection with this offering, and (vii) 2,832,748 shares of Class&nbsp;B common stock issuable upon the vesting and settlement of PRSUs for which the
performance-based vesting condition was satisfied as of September&nbsp;30, 2024 and for which we expect the liquidity-based vesting condition to be satisfied or settlement to occur in connection with this offering. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman; " ALIGN="justify">Consists of (i) 5,955,502 shares of Class&nbsp;B common stock held by Insight Venture Partners X, L.P.,
(ii) 5,082,591 shares of Class&nbsp;B common stock held by Insight Venture Partners (Cayman) X, L.P., (iii) 1,083,817 shares of Class&nbsp;B common stock held by Insight Venture Partners (Delaware) X, L.P., and (iv) 157,694 shares of Class&nbsp;B
common stock held by Insight Venture Partners X <FONT STYLE="white-space:nowrap">(Co-Investors),</FONT> L.P. Each of Jeffrey L. Horing, Deven Parekh, Jeffrey Lieberman and Michael Triplett is a member of the board of managers of Insight Holdings
Group, LLC and may be deemed to have shared voting and dispositive power over the shares held by each of the Funds. The foregoing is not an admission by any of Jeffrey L. Horing, Deven Parekh, Jeffrey Lieberman or Michael Triplett that he is the
beneficial owner of the shares held by the Insight Entities. The principal business office address for each of the foregoing persons is 1114 Avenue of the Americas, 36th Floor, New York, New York 10036. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman; " ALIGN="justify">Consists of 7,639,858 shares of Class&nbsp;B common stock held by Atomico IV, L.P. and 1,724,308 shares of
Class&nbsp;B common stock held by Atomico IV (Guernsey), L.P. (together with Atomico IV, L.P., the &#147;Atomico Entities&#148;). Atomico Advisors IV, Ltd. (&#147;Atomico Advisors IV&#148;) is the general partner of the Atomico Entities. Niklas
Zennstr&ouml;m, Mark Dyne, Nicole Ramroop and Claris Ruwende, the members of the board of directors of Atomico Advisors IV, may be deemed to have shared voting and dispositive power over the shares held by the Atomico Entities. The business address
of Atomico IV L.P. and Atomico Advisors IV is One Capital Place, Grand Cayman, <FONT STYLE="white-space:nowrap">KY1-1103</FONT> Cayman Islands. The principal business address of Atomico IV (Guernsey), L.P. is Old Bank Chambers, La Grande Rue St.
Martin&#146;s, Guernsey, GY4 6RT, Channel Islands. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman; " ALIGN="justify">Consists of (i) 3,823,954 shares of Class&nbsp;B common stock held by 11.2 Capital I, L.P., (ii) 171,550
shares of Class&nbsp;B common stock held by 11.2 Capital HH, LLC, and (iii) 1,105,360 shares of Class&nbsp;B common stock held by 11.2 Capital IVY, LLC. The principal business address for these entities is c/o 11.2 Capital, 1611 Spring Gate Ln, Unit
371763, Las Vegas, Nevada 89134. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman; " ALIGN="justify">Consists of (i) 552,008 shares of Class&nbsp;A common stock held by Coatue US 70 LLC, (ii) 2,581,837 shares
of Class&nbsp;B common stock held by Coatue US 70 LLC, and (iii) 2,401,696 shares of Class&nbsp;B common stock held by Coatue Growth Fund IV LP. The principal business address for these entities is 9 West 57th Street, 25th Floor, New York, NY 10019.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman; " ALIGN="justify">Consists of (i) 552,008 shares Class&nbsp;A common stock and (ii) 4,979,816 shares of Class&nbsp;B common
stock held by affiliates of Tiger Global Management, LLC. Tiger Global Management, LLC is controlled by Chase Coleman, and as such Mr.&nbsp;Coleman may be deemed to beneficially own such shares. The principal business address for these entities and
individuals is c/o Tiger Global Management, LLC, 9 West 57th Street, 35th Floor, New York, New York 10019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(16)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman; " ALIGN="justify">Consists of (i) 2,493,260 shares of Class&nbsp;B common stock held by Bessemer Venture Partners X L.P.
(&#147;Bessemer X&#148;) and (ii) 2,340,513 shares of Class&nbsp;B common stock held by Bessemer Venture Partners X Institutional L.P. (&#147;Bessemer X International,&#148; and together with Bessemer X, the &#147;Bessemer Entities&#148;). Deer
X&nbsp;&amp; Co. L.P. (&#147;Deer X L.P.&#148;) is the general partner of the Bessemer Entities. Deer X&nbsp;&amp; Co. Ltd. (&#147;Deer X Ltd.&#148;), is the general partner of Deer X L.P. Robert P. Goodman, David Cowan, Jeremy Levine, Byron Deeter,
Adam Fisher, Brian Feinstein, Alex Ferrara, Scott Ring, Sandra Grippo and Stephen Kraus are the directors of Deer X Ltd. and hold the voting and dispositive power for the Bessemer Entities. Investment and voting decisions with respect to the
securities held by the Bessemer Entities are made by the directors of Deer X Ltd. acting as an investment committee. The principal address for the Bessemer Entities is c/o Bessemer Venture Partners, 1865 Palmer Avenue, Suite 104, Larchmont, New York
10538. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom829170_17"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>The following summary describes our capital stock and certain provisions of our amended and restated certificate of
incorporation and our amended and restated bylaws, which will become effective immediately prior to the completion of this offering, the amended and restated investors&#146; rights agreement to which we and certain of our stockholders are parties,
and of the Delaware General Corporation Law. Because the following is only a summary, it does not contain all of the information that may be important to you. For a complete description, you should refer to our amended and restated certificate of
incorporation, amended and restated bylaws, and amended and restated investors&#146; rights agreement, copies of which are filed as exhibits to the registration statement of which this prospectus is part. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Immediately
following the completion of this offering, our authorized capital stock will consist of &#8195;&#8195;&#8195;&#8195;&nbsp;shares of Class&nbsp;A common stock, par value $0.00001 per share,&#8195; shares of Class&nbsp;B common stock, par value
$0.00001 per share, and &#8195;&#8195;&#8195;&#8195; shares of undesignated preferred stock, par value $0.00001 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to the completion of this offering, we intend to (i)&nbsp;reclassify all outstanding shares of our common stock (other
than those held by our Founders) into an equal number of shares of our Class&nbsp;A common stock (ii)&nbsp;reclassify all shares of common stock underlying outstanding equity awards under our Prior Plans (other than those held by our Founders) into
shares of Class&nbsp;A common stock pursuant to an amendment to our Prior Plans, (iii)&nbsp;reclassify all outstanding common stock held by our Founders into an equal number of shares of Class&nbsp;B common stock, (iv)&nbsp;amend the terms of
outstanding stock options to purchase shares of common stock, RSUs, and PSRUs under our 2017 Plan held by our Founders to provide that such awards are exercisable for or settle into shares of Class&nbsp;B common stock (referred to collectively as
the Common Stock and Preferred Stock Reclassification), and (v)&nbsp;amend the terms of our outstanding convertible preferred stock to provide that such shares are initially convertible into shares of Class&nbsp;B common stock (collectively referred
to as the Common Stock and Preferred Stock Reclassifications). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, prior to the completion of this offering, all
outstanding shares of our redeemable convertible preferred stock shall automatically convert into shares of our Class&nbsp;B common stock (referred to as the Preferred Stock Conversion). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We refer to the Common Stock and Preferred Stock Reclassification, the Preferred Stock Conversion, and the Class&nbsp;B
Conversion collectively as the Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of &#8195;&#8195;&#8195;&#8195; , 2024, after giving effect to
(i)&nbsp;the Transactions and (ii)&nbsp;the filing and effectiveness of our amended and restated certificate of incorporation, there were &#8195;&#8195;&#8195;&#8195; shares of our Class&nbsp;A common stock outstanding
and&#8195;&#8195;&#8195;&#8195; shares of our Class&nbsp;B common stock outstanding, held by &#8195;&#8195;&#8195;&#8195; stockholders of record, and no shares of our preferred stock outstanding. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Class&nbsp;A Common Stock and Class&nbsp;B Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We will have two classes of authorized common stock: Class&nbsp;A common stock and Class&nbsp;B common stock. All outstanding
shares of our redeemable convertible preferred stock will be converted into shares of our Class&nbsp;B common stock immediately prior to the completion of this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Voting Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders.
Each holder of our Class&nbsp;A common stock is entitled to one vote per share and each holder of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
our Class&nbsp;B common stock is entitled to 15 votes per share on all matters submitted to a vote of the stockholders. The holders of our Class&nbsp;A common stock and Class&nbsp;B common stock
will generally vote together as a single class on all matters submitted to a vote of our stockholders, unless otherwise required by Delaware law or our amended and restated certificate of incorporation. Delaware law could require either holders of
our Class&nbsp;A common stock or Class&nbsp;B common stock to vote separately as a single class in the following circumstances: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we were to seek to amend our amended and restated certificate of incorporation to increase or decrease the
par value of a class of our capital stock, then that class would be required to vote separately to approve the proposed amendment; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we were to seek to amend our amended and restated certificate of incorporation in a manner that alters or
changes the powers, preferences, or special rights of a class of our capital stock in a manner that affected its holders adversely, then that class would be required to vote separately to approve the proposed amendment. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation will not provide for cumulative voting for the election of directors.
Our amended and restated certificate of incorporation will establish a classified board of directors, to be divided into three classes with staggered three-year terms. Only one class of directors will be elected at each annual meeting of our
stockholders, with the other classes continuing for the remainder of their respective <FONT STYLE="white-space:nowrap">three-year</FONT> terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Dividends </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subject to preferences that may be applicable to any then outstanding preferred stock, holders of our Class&nbsp;A common stock
and Class&nbsp;B common stock are entitled to receive dividends as may be declared from time to time by our board of directors out of legally available funds. See the section titled &#147;Dividend Policy&#148; for additional information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Conversion </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each outstanding share of Class&nbsp;B common stock is convertible at any time at the option of the holder into one share of
Class&nbsp;A common stock. In addition, each share of Class&nbsp;B common stock will convert automatically into one share of Class&nbsp;A common stock upon any transfer, whether or not for value, which occurs after the completion of this offering,
except for certain permitted transfers further described in our amended and restated certificate of incorporation, including estate planning or charitable transfers where exclusive voting control with respect to the shares of Class&nbsp;B common
stock is retained by the transferring holder, transfers from one Founder to the other Founder, and transfers to affiliates or certain other related entities of the transferring holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each share of Class&nbsp;B common stock not held of record or beneficially owned by a Founder or an affiliate of a Founder
will automatically convert into one share of our Class&nbsp;A common stock upon the earlier of (i)&nbsp;5:00&nbsp;p.m. New York City time on the seven-year anniversary of the effectiveness of the registration statement of which this prospectus forms
a part (the &#147;Effective Time&#148;), or (ii) 5:00 p.m. New York City time on the date when such holder and its affiliates cease to beneficially own in the aggregate a number of shares of capital stock equal to at least 50% of the capital stock
that such holder and its affiliates beneficially owned in the aggregate as of the Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, each share
of Class&nbsp;B common stock held by our Founders or an affiliate of a Founder will automatically convert into one share of Class&nbsp;A common stock upon the earlier of (i) 5:00 p.m. New York City time on the date when such Founder and such
Founder&#146;s affiliates cease to beneficially own in the aggregate a number of shares of capital stock equal to at least 50% of the capital stock that such Founder and such Founder&#146;s affiliates beneficially owned in the aggregate as of the
Effective Time (which initial and subsequent beneficial ownership calculations shall include only the net issuance share amount upon vesting and settlement of RSUs, after giving effect to the withholding of shares by the company to cover all federal
and state tax liabilities of such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Founder relating to such settlement at the maximum applicable rates) or (b) 5:00 p.m. New York City time on the date that such Founder is no longer an employee or a director of the company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Once converted into Class&nbsp;A common stock, the Class&nbsp;B common stock may not be reissued. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Right to Receive Liquidation Distributions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event of our liquidation, dissolution, or winding up, holders of our Class&nbsp;A common stock and Class&nbsp;B common
stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities, subject to the satisfaction of any liquidation preference granted to the
holders of any then outstanding shares of preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>No Preemptive or Similar Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our Class&nbsp;A common stock and Class&nbsp;B common stock are not entitled to preemptive rights and are not subject to
redemption or sinking fund provisions. The rights, preferences, and privileges of the holders of our Class&nbsp;A common stock and Class&nbsp;B common stock will be subject to, and may be adversely affected by, the rights of the holders of shares of
any series of our preferred stock that we may designate in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Fully Paid and <FONT
STYLE="white-space:nowrap">Non-Assessable</FONT> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All of the outstanding shares of our Class&nbsp;A common stock
and Class&nbsp;B common stock are fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the provisions of our amended and restated certificate of incorporation, each currently outstanding share of
redeemable convertible preferred stock will automatically be converted into one share of Class&nbsp;B common stock effective upon the completion of this offering. Following this offering, no shares of redeemable convertible preferred stock will be
outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Following the completion of this offering, our board of directors will be authorized, subject to limitations
prescribed by Delaware law, to issue preferred stock in one or more series, to establish from time to time the number of shares to be included in each series, and to fix the designation, powers, preferences, and rights of the shares of each series
and any of its qualifications, limitations, or restrictions, in each case without further vote or action by our stockholders. Our board of directors can also increase or decrease the number of shares of any series of preferred stock, but not below
the number of shares of that series then outstanding, without any further vote or action by our stockholders. Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the
voting power or other rights of the holders of our common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of
delaying, deferring, or preventing a change in control of our company and might adversely affect the price of our common stock and the voting and other rights of the holders of our common stock. We have no current plans to issue any shares of
preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock Options </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of &#8195;&#8195;&#8195;&#8195; , 2024, and after giving effect to the Transactions, we had outstanding options to purchase
an aggregate of &#8195;&#8195;&#8195;&#8195; shares of our Class&nbsp;A common stock, with a weighted-average exercise price of $&#8195;&#8195;&#8195;&#8195; per share, and &#8195;&#8195;&#8195;&#8195; shares of our Class&nbsp;B common stock, with a
weighted-average exercise price of $&#8195;&#8195;&#8195;&#8195; per share, in each case issued pursuant to the Prior Plans. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Restricted Stock Units </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of &#8195;&#8195;&#8195;&#8195; , 2024, and after giving effect to the Transactions, we had outstanding RSUs and PRSUs
representing the right to receive upon vesting&#8195;&#8195;&#8195;&#8195; shares of our Class&nbsp;A common stock and&#8195;&#8195;&#8195;&#8195; shares of our Class&nbsp;B common stock, in each case issuable upon satisfaction of service-based or
performance-based and liquidity-based vesting conditions and issued pursuant to the 2017 Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Following the completion of this offering, and subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements
entered into in connection with this offering, the holders of an aggregate of &#8195;&#8195;&#8195;&#8195; shares of our common stock or their permitted transferees will be entitled to rights with respect to the registration of these shares under
the Securities Act. These rights are provided under the terms of an amended and restated investors&#146; rights agreement between us and the holders of these shares, which was entered into in connection with our redeemable convertible preferred
stock financings, and include Form <FONT STYLE="white-space:nowrap">S-1</FONT> and Form <FONT STYLE="white-space:nowrap">S-3</FONT> demand registration rights and piggyback registration rights. In any registration made pursuant to such amended and
restated investors&#146; rights agreement, all fees, costs, and expenses of underwritten registrations will be borne by us and all selling expenses, including all underwriting discounts and commissions, will be borne by the holders of the shares
being registered. We will not be required to bear the expenses in connection with the exercise of the demand registration rights of a registration if the request is subsequently withdrawn at the request of the selling stockholders holding a majority
of securities to be registered. In an underwritten public offering, the underwriters have the right, subject to specified conditions, to limit the number of shares such holders may include. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The registration rights terminate after the earlier of (i)&nbsp;two years following a Qualified IPO, as defined in the amended
and restated investors&#146; rights agreement, (ii)&nbsp;at such time as Rule 144 or another similar exemption under the Securities Act is available for the sale of all of such holder&#146;s shares during a three-month period without registration,
and (iii)&nbsp;upon a liquidation transaction, as defined in the amended and restated investors&#146; rights agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Form <FONT STYLE="white-space:nowrap">S-1</FONT> Demand Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The holders of an aggregate of &#8195;&#8195;&#8195;&#8195; shares of our common stock, or their permitted transferees, are
entitled to Form <FONT STYLE="white-space:nowrap">S-1</FONT> demand registration rights. Under the terms of the amended and restated investors&#146; rights agreement, at any time beginning 180 days after the effective date of the registration
statement of which this prospectus forms a part, the holders representing a majority of the then-outstanding shares that are entitled to registration rights can request that we file a registration statement on Form
<FONT STYLE="white-space:nowrap">S-1</FONT> covering all or some of their shares as soon as practicable, and in any event within 90 days after the date of such request, if the aggregate price to the public of the shares offered is at least
$10.0&nbsp;million (net of underwriting discounts and commissions). We may be required to effect up to two registrations pursuant to this provision of the amended and restated investors&#146; rights agreement. We may postpone the filing of a
registration statement once for up to 120 days in a <FONT STYLE="white-space:nowrap">12-month</FONT> period if our board of directors determines that the filing would be materially detrimental to us. We are not required to effect a Form <FONT
STYLE="white-space:nowrap">S-1</FONT> demand registration under certain additional circumstances specified in the amended and restated investors&#146; rights agreement, including during the period beginning 90 days prior to our good faith estimate
of the date of filing and ending on a date 90 days after the effective date of a registration statement filed by our initiation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Form <FONT STYLE="white-space:nowrap">S-3</FONT> Demand Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The holders of an aggregate of &#8195;&#8195;&#8195;&#8195; shares of our common stock, or their permitted transferees, are
also entitled to Form <FONT STYLE="white-space:nowrap">S-3</FONT> demand registration rights. Under the terms of the amended and restated investors&#146; rights agreement, at any time once we are eligible to file a registration statement on Form <FONT
STYLE="white-space:nowrap">S-3,</FONT> the holders </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
representing a majority of the then-outstanding shares that are entitled to registration rights can request that we file a registration statement on Form
<FONT STYLE="white-space:nowrap">S-3</FONT> covering all or some of their shares, as soon as practicable, if the aggregate price to the public of the shares offered is at least $5.0&nbsp;million (net of underwriting discounts and commissions). The
holders may only require us to effect at most two registration statements on Form <FONT STYLE="white-space:nowrap">S-3</FONT> in any <FONT STYLE="white-space:nowrap">12-month</FONT> period. We may postpone the filing of a registration statement once
for up to 120 days in a <FONT STYLE="white-space:nowrap">12-month</FONT> period if our board of directors determines that the filing would be materially detrimental to us. We are not required to effect a Form
<FONT STYLE="white-space:nowrap">S-3</FONT> registration under certain additional circumstances specified in the amended and restated investors&#146; rights agreement, including during the period ending on a date 180 days after the effective date of
a registration statement filed by our initiation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Piggyback Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we register any of our securities for public sale, holders of an aggregate of &#8195;&#8195;&#8195;&#8195; shares of our
common stock entitled to registration rights, or their permitted transferees, will have the right to include their shares in the registration statement. However, this right does not apply to a registration relating to the sale of securities pursuant
to any company stock plan, a registration relating to an SEC Rule 145 transaction, a registration in which the only common stock being registered is common stock issuable upon conversion of debt securities that are also being registered, or a
registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the common stock. The underwriters of any underwritten offering will have the
right to limit the number of shares registered by these holders if they determine that marketing factors require limitation, in which case the number of shares to be registered will be apportioned pro rata among these holders, according to the total
amount of securities entitled to be included by each holder, or in such other proportions as shall mutually be agreed to by such holders. However, in no event shall (a)&nbsp;the amount of securities of the holders included in the offering be reduced
below 20% of the total amount of securities included in such offering, unless such offering is this initial public offering, in which case, the holders may be excluded if the underwriters make the determination that such offering will jeopardize the
success of the offering and no other holder&#146;s securities are included or (b)&nbsp;any securities held by a Founder be included if any securities held by any holder are excluded unless all other securities of such holders are first entirely
excluded from the underwriting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Provisions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Certain provisions of Delaware law, our amended and restated certificate of incorporation, and our amended and restated bylaws,
which will become effective immediately prior to the completion of this offering, which are summarized below, may have the effect of delaying, deferring, or discouraging another person from acquiring control of us. They are also designed, in part,
to encourage persons seeking to acquire control of us to negotiate first with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the
disadvantages of discouraging a proposal to acquire us because negotiation of these proposals could result in an improvement of their terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Delaware Law </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are subject to Section&nbsp;203 of the Delaware General Corporation Law, which prohibits a Delaware corporation from
engaging in any business combination with any interested stockholder for a period of three&nbsp;years after the date that such stockholder became an interested stockholder, with the following exceptions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the business combination or transaction which resulted in the stockholder becoming an interested stockholder
was approved by the board of directors prior to the time that the stockholder became an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the
interested stockholder owned at least 85% of the voting stock of the corporation </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
outstanding at the time the transaction commenced, excluding shares owned by directors who are also officers of the corporation and shares owned by employee stock plans in which employee
participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at or subsequent to the time the stockholder became an interested stockholder, the business combination was
approved by the board of directors and authorized at an annual or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock which is not owned by the interested
stockholder. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In general, Section&nbsp;203 defines a &#147;business combination&#148; to include
mergers, asset sales and other transactions resulting in financial benefit to a stockholder and an &#147;interested stockholder&#148; as a person who, together with affiliates and associates, owns, or within three years did own, 15% or more of the
corporation&#146;s outstanding voting stock. These provisions may have the effect of delaying, deferring, or preventing changes in control of our company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Dual Class&nbsp;Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As described above in the section titled &#147;&#151;Class&nbsp;A Common Stock and Class&nbsp;B Common Stock&#151;Voting
Rights,&#148; our amended and restated certificate of incorporation will provide for a dual class common stock structure, which will provide our Founders and current investors with significant influence over all matters requiring stockholder
approval, including the election of directors and significant corporate transactions, such as a merger or other sale of our company or its assets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation and our amended and restated bylaws, which will become effective
immediately prior to the completion of this offering, will include a number of provisions that could deter hostile takeovers or delay or prevent changes in control of our board of directors or management team, including the following: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Classified Board </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation will further provide that our board of directors is divided into three
classes, Class&nbsp;I, Class&nbsp;II, and Class&nbsp;III, with each class serving staggered three-year terms. In addition, directors may only be removed from the board of directors for cause. The existence of a classified board could delay a
potential acquirer from obtaining majority control of our board of directors, and the prospect of that delay might deter a potential acquirer. See the section titled &#147;Management&#151;Board Structure and Composition&#148; for additional
information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Board of Directors Vacancies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation and our amended and restated bylaws will authorize only our board of
directors to fill vacant directorships, including newly created seats. In addition, the number of directors constituting our board of directors will be permitted to be set only by a resolution adopted by a majority vote of our entire board of
directors. These provisions would prevent a stockholder from increasing the size of our board of directors and then gaining control of our board of directors by filling the resulting vacancies with its own nominees. This will make it more difficult
to change the composition of our board of directors and will promote continuity of management. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Stockholder Action; Special Meeting of Stockholders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation will provide that our stockholders may not take action by written
consent, but may only take action at annual or special meetings of our stockholders. As a result, a holder controlling a majority of our capital stock would not be able to amend our amended and restated bylaws or remove directors without holding a
meeting of our stockholders called in accordance with our amended and restated bylaws. Our amended and restated bylaws will further provide that special meetings of our stockholders may be called only by a majority of our board of directors, the
chairperson of our board of directors, or our Chief Executive Officer, thus prohibiting a stockholder from calling a special meeting. These provisions might delay the ability of our stockholders to force consideration of a proposal or for
stockholders controlling a majority of our capital stock to take any action, including the removal of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Advance Notice Requirements for Stockholder Proposals and Director Nominations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated bylaws will provide advance notice procedures for stockholders seeking to bring business before our
annual meeting of stockholders or to nominate candidates for election as directors at our annual meeting of stockholders. Our amended and restated bylaws will also specify certain requirements regarding the form and content of a stockholder&#146;s
notice. These provisions might preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting of stockholders if the proper procedures are not followed. We
expect that these provisions may also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#146;s own slate of directors or otherwise attempting to obtain control of our company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>No Cumulative Voting </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Delaware General Corporation Law provides that stockholders are not entitled to cumulate votes in the election of directors
unless a corporation&#146;s certificate of incorporation provides otherwise. Our amended and restated certificate of incorporation will not provide for cumulative voting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Amendment of Charter and Bylaws Provisions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Amendments to our amended and restated certificate of incorporation will require the approval of 66&nbsp;2/3% of the
outstanding voting power of our common stock. Our amended and restated bylaws will provide that approval of stockholders holding 66 2/3% of our outstanding voting power voting as a single class is required for stockholders to amend or adopt any
provision of our bylaws. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Issuance of Undesignated Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors will have the authority, without further action by our stockholders, to issue up
to&#8195;&#8195;&#8195;&#8195;shares of undesignated preferred stock with rights and preferences, including voting rights, designated from time to time by our board of directors. The existence of authorized but unissued shares of preferred stock
would enable our board of directors to render more difficult or to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest, or other means. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Choice of Forum </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation and amended and restated bylaws will provide that, unless we consent in
writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: any derivative action or
proceeding brought on our behalf; any action asserting a claim of breach of fiduciary duty owed by any of our directors, officers, or stockholders to us or to our stockholders; any action asserting a claim against us arising pursuant to the Delaware
General Corporation Law, our amended and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
restated certificate of incorporation, or our amended and restated bylaws (as either may be amended from time to time); or any action asserting a claim against us that is governed by the internal
affairs doctrine. As a result, any action brought by any of our stockholders with regard to any of these matters will need to be filed in the Court of Chancery of the State of Delaware and cannot be filed in any other jurisdiction; provided that,
the exclusive forum provision will not apply to suits brought to enforce any liability or duty created solely by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction; and provided further that, if and only if
the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware. Our amended and restated certificate of
incorporation and amended and restated bylaws will also provide that the federal district courts of the United States of America will be the exclusive forum for the resolution of any complaint asserting a cause or causes of action against us or any
defendant arising under the Securities Act. Such provision is intended to benefit and may be enforced by us, our officers and directors, employees, and agents, including the underwriters and any other professional or entity who has prepared or
certified any part of this prospectus. Nothing in our amended and restated certificate of incorporation and amended and restated bylaws precludes stockholders that assert claims under the Exchange Act from bringing such claims in state or federal
court, subject to applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If any action the subject matter of which is within the scope described above is filed
in a court other than a court located within the State of Delaware (a &#147;Foreign Action&#148;), in the name of any stockholder, such stockholder shall be deemed to have consented to the personal jurisdiction of the state and federal courts
located within the State of Delaware in connection with any action brought in any such court to enforce the applicable provisions of our amended and restated certificate of incorporation and amended and restated bylaws and having service of process
made upon such stockholder in any such action by service upon such stockholder&#146;s counsel in the Foreign Action as agent for such stockholder. Although our amended and restated certificate of incorporation and amended and restated bylaws will
contain the choice of forum provision described above, it is possible that a court could find that such a provision is inapplicable for a particular claim or action or that such provision is unenforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This choice of forum provision may limit a stockholder&#146;s ability to bring a claim in a judicial forum that it finds
favorable for disputes with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims or make such lawsuits more costly for stockholders, although our stockholders will not be
deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations on Liability and
Indemnification Matters </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation will limit the liability of our
directors and officers to the fullest extent permitted by the Delaware General Corporation Law, and our amended and restated bylaws will provide that we will indemnify them to the fullest extent permitted by such law. We expect to enter into
indemnification agreements with our current directors and executive officers prior to the completion of this offering and expect to enter into a similar agreement with any new directors or executive officers. Further, pursuant to our indemnification
agreements and directors&#146; and officers&#146; liability insurance, our directors and executive officers will be indemnified and insured against the cost of defense, settlement, or payment of a judgment under certain circumstances. In addition,
as permitted by Delaware law, our amended and restated certificate of incorporation will include provisions that eliminate the personal liability of our directors and executive officers for monetary damages resulting from breaches of certain
fiduciary duties as a director or officer. The effect of this provision is to restrict our rights and the rights of our stockholders in derivative suits to recover monetary damages against a director or officer for breach of fiduciary duties as a
director or officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These provisions may be held not to be enforceable for violations of the federal securities laws of
the United&nbsp;States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We intend to apply to list our Class&nbsp;A common stock on the &#8195;&#8195;&#8195;&#8195; under the symbol
&#147;&#8195;&#8195;&#8195;&#8195;.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The transfer agent and registrar for our common stock will be&#8195;&#8195;&#8195;&#8195;. The transfer agent and
registrar&#146;s address is &#8195;&#8195;&#8195;&#8195;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">185 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom829170_18"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to this offering, there has been no public market for our Class&nbsp;A common stock. Future sales of substantial amounts
of our Class&nbsp;A common stock in the public market could adversely affect market prices prevailing from time to time. Furthermore, because only a limited number of shares will be available for sale shortly after this offering due to existing
contractual and legal restrictions on resale as described below, there may be sales of substantial amounts of our Class&nbsp;A common stock in the public market after the restrictions lapse. This may adversely affect the prevailing market price and
our ability to raise equity capital in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the completion of this offering, based on the number of shares of
our capital stock outstanding as of &#8195; , 2024, we will have an aggregate of &#8195;&#8195;&#8195;&#8195;shares of Class&nbsp;A common stock outstanding and &#8195;&#8195;&#8195;&#8195;&nbsp;shares of Class&nbsp;B common stock outstanding,
assuming no exercise of the underwriters&#146; option to purchase additional shares of Class&nbsp;A common stock and no additional exercise of any stock options or settlement of RSUs and PRSUs after such date, and after giving effect to the
Transactions. All of the shares of Class&nbsp;A common stock sold in this offering by us or the selling stockholders, plus any shares sold by us upon exercise, if any, of the underwriters&#146; option to purchase additional shares will be freely
tradable without restrictions or further registration under the Securities Act, except for any shares purchased by our &#147;affiliates,&#148; as that term is defined in Rule 144 under the Securities Act, whose sales would be subject to the Rule 144
resale restrictions described below, other than the holding period requirement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The remaining shares of common stock and
shares of common stock subject to stock options or underlying outstanding RSUs and PRSUs will be on issuance deemed &#147;restricted securities,&#148; as that term is defined in Rule&nbsp;144 under the Securities Act. These restricted securities are
eligible for public sale only if they are registered under the Securities Act or if they qualify for an exemption from registration under Rules 144 or 701 under the Securities Act, which are summarized below. We expect that substantially all of
these shares will be subject to the &#8195;&#8195;&#8195;&#8195; <FONT STYLE="white-space:nowrap">-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> period under the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described
below. Upon expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, we estimate that approximately &#8195;&#8195;&#8195;&#8195;shares will be available for sale in the public market, subject in some cases to applicable volume
limitations under Rule&nbsp;144. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 144 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In general, a person who has beneficially owned restricted shares of our common stock for at least six months would be entitled
to sell such securities, provided that (i)&nbsp;such person is not deemed to have been one of our affiliates at the time of, or at any time during the 90 days preceding, a sale; and (ii)&nbsp;we are subject to the Exchange Act periodic reporting
requirements for at least 90 days before the sale. Persons who have beneficially owned restricted shares of our common stock for at least six months but who are our affiliates at the time of, or any time during the 90 days preceding, a sale, would
be subject to additional restrictions, by which such person would be entitled to sell within any&nbsp;three-month&nbsp;period only a number of securities that does not exceed the greater of either of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1% of the number of shares of our Class&nbsp;A common stock then outstanding, which will equal
approximately&#8195;&#8195;&#8195;&#8195; shares immediately after this offering, assuming no exercise of the underwriters&#146; option to purchase additional shares; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average weekly trading volume of shares of our Class&nbsp;A common stock on the
&#8195;&#8195;&#8195;&#8195; during the four calendar weeks preceding the filing of a notice on Form 144 with respect to that sale; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">provided, in each case, that we are subject to the Exchange Act periodic reporting requirements for at least 90&nbsp;days before the sale.
Such sales both by affiliates and by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> must also comply with the manner of sale, current public information, and notice provisions of Rule 144 to the extent applicable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 701 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In general,
under Rule 701 as currently in effect, any of our employees, directors, officers, consultants, or advisors who acquired common stock from us in connection with a written compensatory stock or option plan or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">186 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
other written agreement in compliance with Rule 701 before the effective date of the registration statement of which this prospectus is a part (to the extent such common stock is not subject <FONT
STYLE="white-space:nowrap">to&nbsp;a&nbsp;lock-up&nbsp;agreement)&nbsp;and</FONT> who are not our &#147;affiliates&#148; as defined in Rule 144 during the immediately preceding 90 days, is entitled to rely on Rule 701 to resell such shares beginning
90 days after the date of this prospectus in reliance on Rule 144, but without complying with the notice, manner of sale, public information requirements or volume limitation provisions of Rule 144. Persons who are our &#147;affiliates&#148; may
resell those shares beginning 90 days after the date of this prospectus without compliance with minimum holding period requirements under Rule 144 (subject to the terms
<FONT STYLE="white-space:nowrap">of&nbsp;the&nbsp;lock-up&nbsp;agreement&nbsp;referred</FONT> to below, if applicable). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> and Market Standoff Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with this offering, we, our directors, officers, the selling stockholders, and the holders of substantially all
of our common stock, stock options, RSUs, PRSUs, and other securities convertible into, exercisable, or exchangeable for our common stock have entered into or will enter into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the
underwriters pursuant to which we and they have agreed not to, among other things and subject to certain exceptions more fully described under the section titled &#147;Underwriters,&#148; offer, sell, contract to sell, pledge, or otherwise dispose
of or enter into any transaction which is designed to, or might reasonably be expected to, result in the disposition (whether by actual disposition or effective economic disposition due to cash settlement or otherwise) any shares of Class&nbsp;A
common stock or securities convertible into or exchangeable for shares of our Class&nbsp;A common stock during the period ending on the &#8195;&#8195;&#8195;&#8195; day after the date of this prospectus, except with the prior consent of Morgan
Stanley&nbsp;&amp; Co. LLC, Barclays Capital Inc. and BofA Securities, Inc., in their sole discretion, may release any of the securities subject to these <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements at any time. See the section titled
&#147;Underwriters&#148; for additional information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to the restrictions contained in the <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements described above, we have entered into agreements with certain security holders, including in connection with our amended and restated investors&#146; rights agreement and the equity awards issued
under our equity incentive plans, that contain market standoff provisions imposing restrictions on the ability of such security holders to offer, sell, or transfer our equity securities for a period of &#8195;&#8195;&#8195;&#8195; days following the
date of this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have granted Form <FONT STYLE="white-space:nowrap">S-1</FONT> and Form <FONT STYLE="white-space:nowrap">S-3</FONT> demand
and piggyback registration rights to certain of our stockholders. Registration of the sale of these shares under the Securities Act would result in these shares becoming freely tradable without restriction under the Securities Act immediately upon
the effectiveness of the registration, except for shares purchased by affiliates. See the section titled &#147;Description of Capital Stock&#151;Registration Rights&#148; for additional information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Incentive Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We intend to file with the SEC one or more registration statements on Form <FONT STYLE="white-space:nowrap">S-8</FONT> under
the Securities Act to register all of the shares of our common stock issuable or issuable and reserved for issuance under the 2017 Plan, the 2025 Plan, and the ESPP. Shares covered by such registration statement will be eligible for sale in the
public market, subject to the Rule 144 limitations, vesting restrictions, and the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above, if applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">187 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom829170_19"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO <FONT
STYLE="white-space:nowrap">NON-U.S.&nbsp;HOLDERS</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following discussion is a summary of the material U.S.
federal income tax consequences to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders (as defined below) of the purchase, ownership, and disposition of our Class&nbsp;A common stock issued pursuant to this offering, but does not purport to be
a complete analysis of all potential tax effects. The effects of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local, or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws are not discussed. This
discussion is based on the Code, Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the U.S. Internal Revenue Service (the &#147;IRS&#148;), in each case in effect as of the
date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
Holder. We have not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary position to that discussed below regarding the tax consequences of the
purchase, ownership, and disposition of our Class&nbsp;A common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This discussion is limited to <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders that hold our Class&nbsp;A common stock as a &#147;capital asset&#148; within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). This discussion does not address
all U.S. federal income tax consequences relevant to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s particular circumstances, including the impact of the Medicare contribution tax on net investment income and the alternative
minimum tax. In addition, it does not address consequences relevant to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders subject to special rules, including, without limitation: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. expatriates and former citizens or long-term residents of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons holding our Class&nbsp;A common stock as part of a hedge, straddle, or other risk reduction strategy
or as part of a conversion transaction or other integrated investment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">banks, insurance companies, and other financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">brokers, dealers, or traders in securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies,&#148; and
corporations that accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes
(and investors therein); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations or governmental organizations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons deemed to sell our Class&nbsp;A common stock under the constructive sale provisions of the Code;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who hold or receive our Class&nbsp;A common stock pursuant to the exercise of any employee stock
option or otherwise as compensation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;qualified foreign pension funds&#148; as defined in Section&nbsp;897(l)(2) of the Code and entities all
of the interests of which are held by qualified foreign pension funds. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If an entity treated as a
partnership for U.S. federal income tax purposes holds our Class&nbsp;A common stock, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership, and certain determinations made at
the partner level. Accordingly, partnerships holding our Class&nbsp;A common stock and the partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences to them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT TAX ADVICE. INVESTORS SHOULD CONSULT THEIR TAX ADVISORS WITH
RESPECT TO THE </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">188 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>
APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP, AND DISPOSITION OF OUR CLASS A COMMON STOCK ARISING
UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL, OR <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Definition of a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For purposes of this discussion, a <FONT STYLE="white-space:nowrap">&#147;Non-U.S.</FONT> Holder&#148; is any beneficial owner
of our Class&nbsp;A common stock that is neither a &#147;U.S. person&#148; nor an entity treated as a partnership for U.S. federal income tax purposes. A U.S. person is any person that, for U.S. federal income tax purposes, is or is treated as any
of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation created or organized under the laws of the United States, any state thereof, or the District of
Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust that (1)&nbsp;is subject to the primary supervision of a U.S. court and all substantial decisions of
which are subject to the control of one or more &#147;United States persons&#148; (within the meaning of Section&nbsp;7701(a)(30) of the Code), or (2)&nbsp;has a valid election in effect to be treated as a United States person for U.S. federal
income tax purposes. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As described in the section titled &#147;Dividend Policy,&#148; we do not anticipate declaring or paying any cash dividends in
the foreseeable future. However, if we do make distributions of cash or property on our Class&nbsp;A common stock, such distributions will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated
earnings and profits, as determined under U.S. federal income tax principles. Amounts not treated as dividends for U.S. federal income tax purposes will constitute a return of capital and first be applied against and reduce a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s adjusted tax basis in its Class&nbsp;A common stock, but not below zero. Any excess will be treated as capital gain and will be treated as described under the section titled &#147;&#151;Sale
or Other Taxable Disposition&#148; below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subject to the discussion below regarding effectively connected income,
dividends paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends (or such lower rate specified by an applicable income tax treaty,
provided the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder furnishes a valid IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or other
applicable documentation) certifying qualification for the lower treaty rate). A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that does not timely furnish the required documentation, but that qualifies for a reduced treaty rate, may
obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding their entitlement to benefits under
any applicable tax treaties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If dividends paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder are
effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains a permanent establishment in the United States to which such dividends are attributable), the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be exempt from the U.S.
federal withholding tax described above. To claim the exemption, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder must furnish to the applicable withholding agent a valid IRS Form <FONT STYLE="white-space:nowrap">W-8ECI,</FONT> certifying
that the dividends are effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any such effectively connected dividends will be subject to U.S. federal income tax on a net income basis at the regular rates
applicable to U.S. persons. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation also may be subject to a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">189 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on such effectively connected dividends, as adjusted for certain items. <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding any applicable tax treaties that may provide for different rules. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sale or Other Taxable Disposition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will not be subject to U.S. federal income tax on any gain realized
upon the sale or other taxable disposition of our Class&nbsp;A common stock unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s
conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains a permanent establishment in the United States to which such gain is
attributable); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is a nonresident alien individual present in the
United States for 183 days or more during the taxable year of the disposition and certain other requirements are met; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Class&nbsp;A common stock constitutes a U.S. real property interest (&#147;USRPI&#148;) by reason of our
status as a U.S. real property holding corporation (&#147;USRPHC&#148;) for U.S. federal income tax purposes. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Gain described in the first bullet point above generally will be subject to U.S. federal income tax on a net income basis at
the regular rates applicable to U.S. persons. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax
treaty) on such effectively connected gain, as adjusted for certain items. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder described in the second bullet point above will be subject to U.S. federal income tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on gain realized upon
the sale or other taxable disposition of our Class&nbsp;A common stock, which gain may be offset by certain U.S. source capital losses of the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder (even though the individual is not considered a
resident of the United States), provided the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder has timely filed U.S. federal income tax returns with respect to such losses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">With respect to the third bullet point above, we believe we currently are not, and do not anticipate becoming, a USRPHC.
Because the determination of whether we are a USRPHC depends, however, on the fair market value of our USRPIs relative to the fair market value of our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> real property interests and our other business
assets, there can be no assurance we currently are not a USRPHC or will not become one in the future. Even if we are or were to become a USRPHC, gain arising from the sale or other taxable disposition of our Class&nbsp;A common stock by a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will not be subject to U.S. federal income tax if our Class&nbsp;A common stock is &#147;regularly traded,&#148; as defined by applicable Treasury Regulations, on an established securities market,
and such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder owned, actually and constructively, 5% or less of our Class&nbsp;A common stock throughout the shorter of the five-year period ending on the date of the sale or other taxable
disposition or the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s holding period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding any applicable tax treaties that may provide for different rules. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Reporting and Backup Withholding </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Payments of dividends on our Class&nbsp;A common stock will not be subject to backup withholding, provided the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder certifies its <FONT STYLE="white-space:nowrap">non-U.S.</FONT> status, such as by furnishing a valid IRS Form <FONT STYLE="white-space:nowrap">W-8BEN,</FONT> <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or <FONT STYLE="white-space:nowrap">W-8ECI,</FONT> or otherwise establishes an exemption. However, information returns are required to be filed with the IRS in connection with any distributions on
our Class&nbsp;A common stock paid to the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder, regardless of whether such distributions constitute dividends or whether any tax was actually withheld. In addition, proceeds of the sale or other
taxable disposition of our Class&nbsp;A common stock within the United States or conducted through certain U.S.-related brokers generally will not be subject to backup withholding or information reporting
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">190 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
if the applicable withholding agent receives the certification described above or the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder otherwise establishes an exemption. Proceeds of a
disposition of our Class&nbsp;A common stock conducted through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> broker that does not have certain enumerated relationships with the United
States generally will not be subject to backup withholding or information reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Copies of information returns that
are filed with the IRS may also be made available under the provisions of an applicable treaty or agreement to the tax authorities of the country in which the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder resides or is established. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a
refund or a credit against a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s U.S. federal income tax liability, provided the required information is timely furnished to the IRS. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Withholding Tax on Payments Made to Foreign Accounts </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Withholding taxes may be imposed under Sections 1471 to 1474 of the Code (such Sections commonly referred to as the Foreign
Account Tax Compliance Act (&#147;FATCA&#148;)) on certain types of payments made to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> financial institutions and certain other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entities. Specifically, a
30% withholding tax may be imposed on dividends on, and (subject to the proposed Treasury Regulations discussed below) gross proceeds from the sale or other disposition of, our Class&nbsp;A common stock paid to a &#147;foreign financial
institution&#148; or a <FONT STYLE="white-space:nowrap">&#147;non-financial</FONT> foreign entity&#148; (each as defined in the Code), unless (i)&nbsp;the foreign financial institution undertakes certain diligence and reporting obligations,
(ii)&nbsp;the <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity either certifies it does not have any &#147;substantial United States owners&#148; (as defined in the Code) or furnishes identifying information regarding each
substantial United States owner, or (iii)&nbsp;the foreign financial institution or <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity otherwise qualifies for an exemption from these rules. If the payee is a foreign financial
institution and is subject to the diligence and reporting requirements in (1)&nbsp;above, it must enter into an agreement with the U.S. Department of the Treasury requiring, among other things, that it undertake to identify accounts held by certain
&#147;specified United States persons&#148; or &#147;United States owned foreign entities&#148; (each as defined in the Code), annually report certain information about such accounts, and withhold 30% on certain payments to <FONT
STYLE="white-space:nowrap">non-compliant</FONT> foreign financial institutions and certain other account holders. Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the United States governing FATCA
may be subject to different rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under applicable Treasury Regulations and administrative guidance, withholding under
FATCA generally applies to payments of dividends on our Class&nbsp;A common stock. While withholding under FATCA would have applied also to payments of gross proceeds from the sale or other disposition of our Class&nbsp;A common stock beginning on
January&nbsp;1, 2019, proposed Treasury Regulations eliminate FATCA withholding on payments of gross proceeds entirely. Taxpayers generally may rely on these proposed Treasury Regulations until final Treasury Regulations are issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prospective investors should consult their tax advisors regarding the potential application of withholding under FATCA to
their investment in our Class&nbsp;A common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">191 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom829170_20"></A>UNDERWRITERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the terms and subject to the conditions in an underwriting agreement dated the date of this prospectus, the underwriters
named below, for whom Morgan Stanley&nbsp;&amp; Co. LLC, Barclays Capital Inc. and BofA Securities, Inc. are acting as representatives, will severally agree to purchase, and we and the selling stockholders will agree to sell to them, severally, the
number of shares of our Class&nbsp;A common stock indicated below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number
of<BR>Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Morgan Stanley&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Barclays Capital Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BofA Securities, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The underwriters and the representatives are collectively referred to as the
&#147;underwriters&#148; and the &#147;representatives,&#148; respectively. The underwriters are offering the shares of Class&nbsp;A common stock subject to their acceptance of the shares from us and the selling stockholders and subject to prior
sale. The underwriting agreement will provide that the obligations of the several underwriters to pay for and accept delivery of the shares of Class&nbsp;A common stock offered by this prospectus are subject to the approval of certain legal matters
by their counsel and to certain other conditions. The underwriters will be obligated to take and pay for all of the shares of Class&nbsp;A common stock offered by this prospectus if any such shares are taken. However, the underwriters will not be
required to take or pay for the shares covered by the underwriters&#146; over-allotment option described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
underwriters initially propose to offer part of the shares of Class&nbsp;A common stock directly to the public at the offering price listed on the cover page of this prospectus and part to certain dealers at a price that represents a concession not
in excess of $&#8195;&#8195;&#8195;&#8195; per share under the public offering price. After the initial offering of the shares of Class&nbsp;A common stock, the offering price and other selling terms may from time to time be varied by the
representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We will grant to the underwriters an option, exercisable for 30 days from the date of this prospectus,
to purchase up to &#8195;&#8195;&#8195;&#8195; additional shares of Class&nbsp;A common stock from us at the public offering price listed on the cover page of this prospectus, less underwriting discounts and commissions. The underwriters may
exercise this option solely for the purpose of covering over-allotments, if any, made in connection with the offering of the shares of Class&nbsp;A common stock offered by this prospectus. To the extent the option is exercised, each underwriter will
become obligated, subject to certain conditions, to purchase about the same percentage of the additional shares of Class&nbsp;A common stock as the number listed next to the underwriter&#146;s name in the preceding table bears to the total number of
shares of Class&nbsp;A common stock listed next to the names of all underwriters in the preceding table. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following
table shows the per share and total public offering price, underwriting discounts and commissions, and proceeds before expenses to us and the selling stockholders. These amounts are shown </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">192 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
assuming both no exercise and full exercise of the underwriters&#146; option to purchase up to an additional &#8195;&#8195;&#8195;&#8195; shares of Class&nbsp;A common stock from us. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per<BR>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Full Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions to be paid by us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions to be paid by the selling stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to the selling stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The estimated offering expenses payable by us, exclusive of underwriting discounts and
commissions, are approximately $&#8195;&#8195;&#8195;&#8195; . We will agree to reimburse the underwriters for expense relating to clearance of this offering with the Financial Industry Regulatory Authority in an amount up to $&#8195;&#8195;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The underwriters have informed us that they do not intend sales to discretionary accounts to exceed 5% of the total number of
shares of Class&nbsp;A common stock offered by them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We intend to apply to list our shares of Class&nbsp;A common stock
on the&#8195;&#8195;&#8195;&#8195;under the trading symbol&nbsp;&#147;&#8195;&#8195;&#8195;&#8195;.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection
with this offering, we, our directors, our executive officers, the selling stockholders and the holders of substantially all of our outstanding common stock, stock options and other securities convertible into or exercisable or exchangeable for our
common stock, will agree that, without the prior written consent of the representatives on behalf of the underwriters, we and they will not take certain actions during the period ending days after the date of this prospectus (the &#147;restricted
period&#148;), including to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(1)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or
contract to sell, grant any option, right or warrant to purchase, lend, make any short sale or otherwise transfer or dispose of, directly or indirectly, any shares of common stock or any securities convertible into or exercisable or exchangeable
(directly or indirectly) for, or that represent the right to receive, shares of common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(2)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">file any registration statement with the Securities and Exchange Commission relating to the offering of any
shares of common stock or any securities convertible into or exercisable or exchangeable for common stock; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(3)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any swap, hedging transaction or other arrangement that transfers to another, in whole or in part,
any of the economic consequences of ownership of the common stock or any other securities convertible into or exercisable or exchangeable for common stock; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">whether any such transaction described above is to be settled by delivery of common stock or such other securities, in cash or otherwise. In
addition, we and each such person will agree that, without the prior written consent of the representatives on behalf of the underwriters, we or such other person will not, during the restricted period, make any demand for, or exercise any right
with respect to, the registration of any shares of common stock or any security convertible into or exercisable or exchangeable for common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The restrictions described in the immediately preceding paragraph will not apply in certain circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The representatives, in their sole discretion, may release the common stock and other securities subject to the <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements described above in whole or in part at any time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">193 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In order to facilitate the offering of our Class&nbsp;A common stock, the
underwriters may engage in transactions that stabilize, maintain or otherwise affect the price of our Class&nbsp;A common stock. Specifically, the underwriters may sell more shares than they are obligated to purchase under the underwriting
agreement, creating a short position. A short sale is covered if the short position is no greater than the number of shares available for purchase by the underwriters under the over-allotment option. The underwriters can close out a covered short
sale by exercising the over-allotment option or purchasing shares in the open market. In determining the source of shares to close out a covered short sale, the underwriters will consider, among other things, the open market price of shares compared
to the price available under the over-allotment option. The underwriters may also sell shares in excess of the over-allotment option, creating a naked short position. The underwriters must close out any naked short position by purchasing shares in
the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of our Class&nbsp;A common stock in the open market after pricing that could adversely affect
investors who purchase in this offering. As an additional means of facilitating this offering, the underwriters may bid for, and purchase, shares of our Class&nbsp;A common stock in the open market to stabilize the price of our Class&nbsp;A common
stock. These activities may raise or maintain the market price of our Class&nbsp;A common stock above independent market levels or prevent or retard a decline in the market price of our Class&nbsp;A common stock. The underwriters are not required to
engage in these activities and may end any of these activities at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We, the selling stockholders, and the
underwriters will agree to indemnify each other against certain liabilities, including liabilities under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A prospectus in electronic format may be made available on websites maintained by one or more underwriters, or selling group
members, if any, participating in this offering. The representatives may agree to allocate a number of shares of Class&nbsp;A common stock to underwriters for sale to their online brokerage account holders. Internet distributions will be allocated
by the representatives to underwriters that may make internet distributions on the same basis as other allocations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The underwriters and their respective affiliates are full-service financial institutions engaged in various activities, which
may include securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing, and brokerage activities. Certain of the underwriters and their respective
affiliates have, from time to time, performed, and may in the future perform, various financial advisory and investment banking services for us, for which they received or will receive customary fees and expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, in the ordinary course of their various business activities, the underwriters and their respective affiliates may
make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers and may at any
time hold long and short positions in such securities and instruments. Such investment and securities activities may involve our securities and instruments. The underwriters and their respective affiliates may also make investment recommendations or
publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long or short positions in such securities and instruments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pricing of the Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to this offering, there has been no public market for our Class&nbsp;A common stock. The initial public offering price
will be determined by negotiations between us, the selling stockholders, and the representatives. Among the factors considered in determining the initial public offering price will be our future prospects and those of our industry in general, our
sales, earnings and certain other financial and operating information in recent periods, and the price-earnings ratios, price-sales ratios, market prices of securities and certain financial and operating information of companies engaged in
activities similar to ours. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">194 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selling Restrictions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Notice to Prospective Investors in the European Economic Area </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In relation to each Member State of the European Economic Area (each, a &#147;Member State&#148;), no shares of our
Class&nbsp;A common stock have been offered or will be offered pursuant to the offering to the public in that Member State prior to the publication of a prospectus in relation to the shares of common stock which has been approved by the competent
authority in that Member State or, where appropriate, approved in another Member State and notified to the competent authority in that Member State, all in accordance with the Prospectus Regulation, except that offers of our Class&nbsp;A common
stock may be made to the public in that Member State at any time under the following exemptions under the Prospectus Regulation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(a)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to any legal entity which is a qualified investor as defined under the Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(b)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus
Regulation), subject to obtaining the prior consent of the representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(c)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in any other circumstances falling within Article 1(4) of the Prospectus Regulation; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">provided that no such offer of shares shall require us or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus
Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation and each person who initially acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged, and agreed to and with each of
the underwriters and us that it is a &#147;qualified investor&#148; within the meaning of Article 2(e) of the Prospectus Regulation. In the case of any shares being offered to a financial intermediary as that term is used in the Prospectus
Regulation, each such financial intermediary will be deemed to have represented, acknowledged, and agreed that the shares acquired by it in the offer have not been acquired on a <FONT STYLE="white-space:nowrap">non-discretionary</FONT> basis on
behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer of any shares to the public other than their offer or resale in a Member State to qualified investors as so
defined or in circumstances in which the prior consent of the underwriters have been obtained to each such proposed offer or resale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to any shares in any Member
State means the communication in any form and by any means of sufficient information on the terms of the offer and the shares of our Class&nbsp;A common stock to be offered so as to enable an investor to decide to purchase or subscribe for any
shares of our Class&nbsp;A common stock, and the expression &#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Notice to Prospective Investors in the United Kingdom </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">No shares of common stock have been offered or will be offered pursuant to the offering to the public in the United Kingdom
prior to the publication of a prospectus in relation to the shares our Class&nbsp;A common stock which has been approved by the Financial Conduct Authority, except that our Class&nbsp;A common stock may be offered to the public in the United Kingdom
at any time: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(a)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to any legal entity which is a qualified investor as defined under Article 2 of the U.K. Prospectus
Regulation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(b)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the
U.K. Prospectus Regulation), subject to obtaining the prior consent of the representatives of the underwriters for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(c)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in any other circumstances falling within Section&nbsp;87 of the Financial Services and Markets Act 2000 (the
&#147;FSMA&#148;); </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">195 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">provided that no such offer of our Class&nbsp;A common stock shall require our company or
any underwriter to publish a prospectus pursuant to Section&nbsp;85 of the FSMA or supplement a prospectus pursuant to Article 23 of the U.K. Prospectus Regulation. For the purposes of this provision, the expression an &#147;offer to the
public&#148; in relation to the shares of our Class&nbsp;A common stock in the United Kingdom means the communication in any form and by any means of sufficient information on the terms of the offer and any shares of our Class&nbsp;A common stock to
be offered so as to enable an investor to decide to purchase or subscribe for any shares of our Class&nbsp;A common stock and the expression &#147;U.K. Prospectus Regulation&#148; means Regulation (EU) 2017/1129 as it forms part of domestic law by
virtue of the European Union (Withdrawal) Act 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, in the United Kingdom, this document is being
distributed only to, and is directed only at, and any offer subsequently made may only be directed at persons who are &#147;qualified investors&#148; (as defined in the Prospectus Regulation)&nbsp;(i) who have professional experience in matters
relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the &#147;Order&#148;), and/or (ii)&nbsp;who are high net worth companies (or persons to whom it may
otherwise be lawfully communicated) falling within Article 49(2)(a) to (d)&nbsp;of the Order, or, all such persons together being referred to as relevant persons, or otherwise in circumstances which have not resulted and will not result in an offer
to the public of shares of our Class&nbsp;A common stock in the United Kingdom within the meaning of the FMSA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any person
in the United Kingdom that is not a relevant person should not act or rely on the information included in this document or use it as basis for taking any action. In the United Kingdom, any investment or investment activity that this document relates
to may be made or taken exclusively by relevant persons. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Notice to Prospective Investors in Canada </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The shares of our Class&nbsp;A common stock may be sold only to purchasers purchasing, or deemed to be purchasing, as principal
that are accredited investors, as defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument
<FONT STYLE="white-space:nowrap">31-103</FONT> Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of our Class&nbsp;A common stock must be made in accordance with an exemption from, or in a transaction not subject
to, the prospectus requirements of applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Securities legislation in certain provinces or territories
of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within
the time limit prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for
particulars of these rights or consult with a legal advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to section 3A.3 of National Instrument <FONT
STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts (NI <FONT STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT>
regarding underwriter conflicts of interest in connection with this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Notice to Prospective Investors in
Switzerland </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our Class&nbsp;A common stock may not be publicly offered in Switzerland and will not be listed on the
SIX Swiss Exchange (&#147;SIX&#148;), or on any other stock exchange or regulated trading facility in Switzerland. This document does not constitute a prospectus within the meaning of, and has been prepared without regard to the disclosure standards
for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated
trading facility in Switzerland. Neither this document nor any other offering or marketing material relating to our Class&nbsp;A common stock or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">196 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Neither this document nor any other offering or marketing material relating
to the offering, us or our Class&nbsp;A common stock have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of our Class&nbsp;A common stock will not be
supervised by, the Swiss Financial Market Supervisory Authority (&#147;FINMA&#148;), and the offer of our Class&nbsp;A common stock has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes (the
&#147;CISA&#148;). The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of our Class&nbsp;A common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Notice to Prospective Investors in the Dubai International Financial Centre (the &#147;DIFC&#148;) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This document relates to an Exempt Offer in accordance with the Markets Rules 2012 of the Dubai Financial Services Authority
(the &#147;DFSA&#148;). This document is intended for distribution only to persons of a type specified in the Markets Rules 2012 of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for
reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth herein and has no responsibility for this document. The securities to which this
document relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the securities offered should conduct their own due diligence on the securities. If you do not understand the contents of this document you
should consult an authorized financial advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In relation to its use in the DIFC, this document is strictly private and
confidential and is being distributed to a limited number of investors and must not be provided to any person other than the original recipient, and may not be reproduced or used for any other purpose. The interests in the securities may not be
offered or sold directly or indirectly to the public in the DIFC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Notice to Prospective Investors in the United
Arab Emirates </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Shares of our Class&nbsp;A common stock have not been, and are not being, publicly offered, sold,
promoted, or advertised in the United Arab Emirates (including the DIFC) other than in compliance with the laws of the United Arab Emirates (and the DIFC) governing the issue, offering, and sale of securities. Further, this prospectus does not
constitute a public offer of securities in the United Arab Emirates (including the DIFC) and is not intended to be a public offer. This prospectus has not been approved by or filed with the Central Bank of the United Arab Emirates, the Securities
and Commodities Authority, or the DFSA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Notice to Prospective Investors in Australia </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This prospectus: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">does not constitute a disclosure document or a prospectus under Chapter 6D.2 of the Corporations Act 2001
(Cth) (the &#147;Corporations Act&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">has not been, and will not be, lodged with the Australian Securities and Investments Commission (the
&#147;ASIC&#148;), as a disclosure document for the purposes of the Corporations Act and does not purport to include the information required of a disclosure document for the purposes of the Corporations Act; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">may only be provided in Australia to select investors who are able to demonstrate that they fall within one
or more of the categories of investors, available under section 708 of the Corporations Act, Exempt Investors. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our Class&nbsp;A common stock may not be directly or indirectly offered for subscription or purchased or sold, and no
invitations to subscribe for or buy our Class&nbsp;A common stock may be issued, and no draft or definitive offering memorandum, advertisement, or other offering material relating to any shares may be distributed in Australia, except where
disclosure to investors is not required under Chapter 6D of the Corporations Act or is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">197 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
otherwise in compliance with all applicable Australian laws and regulations. By submitting an application for our Class&nbsp;A common stock, you represent and warrant to us that you are an Exempt
Investor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As any offer of our Class&nbsp;A common stock under this document will be made without disclosure in Australia
under Chapter 6D.2 of the Corporations Act, the offer of those securities for resale in Australia within 12 months may, under section 707 of the Corporations Act, require disclosure to investors under Chapter 6D.2 if none of the exemptions in
section 708 applies to that resale. By applying for our Class&nbsp;A common stock you undertake to us that you will not, for a period of 12 months from the date of issue of our Class&nbsp;A common stock, offer, transfer, assign, or otherwise
alienate those shares of our Class&nbsp;A common stock to investors in Australia except in circumstances where disclosure to investors is not required under Chapter 6D.2 of the Corporations Act or where a compliant disclosure document is prepared
and lodged with ASIC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Notice to Prospective Investors in Japan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our Class&nbsp;A shares of common stock have not been and will not be registered pursuant to Article 4, Paragraph 1 of the
Financial Instruments and Exchange Act. Accordingly, none of our Class&nbsp;A common stock nor any interest therein may be offered or sold, directly or indirectly, in Japan or to, or for the benefit of, any &#147;resident&#148; of Japan (which term
as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or to
or for the benefit of a resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the Financial Instruments and Exchange Act and any other applicable laws, regulations and ministerial
guidelines of Japan in effect at the relevant time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Notice to Prospective Investors in Hong Kong </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our shares of Class&nbsp;A common stock have not been offered or sold and will not be offered or sold in Hong&nbsp;Kong, by
means of any document, other than (i)&nbsp;to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (the &#147;SFO&#148;) of Hong Kong and any rules made thereunder; or (ii)&nbsp;in
other circumstances which do not result in the document being a &#147;prospectus&#148; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong (the &#147;CO&#148;), or which do not constitute an offer
to the public within the meaning of the CO. No advertisement, invitation, or document relating to our Class&nbsp;A common stock has been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in
Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares of our
Class&nbsp;A common stock which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; as defined in the SFO and any rules made thereunder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Notice to Prospective Investors in Singapore </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Singapore SFA Product Classification&#151;In connection with Section&nbsp;309B of the SFA and the CMP Regulations 2018, unless
otherwise specified before an offer of shares of our Class&nbsp;A common stock, we have determined, and hereby notify all relevant persons (as defined in Section&nbsp;309A(1) of the SFA), that the shares of our Class&nbsp;A common stock are
&#147;prescribed capital markets products&#148; (as defined in the CMP Regulations 2018) and Excluded Investment Products (as defined in MAS Notice SFA <FONT STYLE="white-space:nowrap">04-N12:</FONT> Notice on the Sale of Investment Products and MAS
Notice <FONT STYLE="white-space:nowrap">FAA-N16:</FONT> Notice on Recommendations on Investment Products). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each
underwriter has acknowledged that this prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, each underwriter has represented and agreed that it has not offered or sold any shares of our
Class&nbsp;A common stock or caused our Class&nbsp;A common stock to be made the subject of an invitation for subscription or purchase and will not offer or sell any shares of our Class&nbsp;A common stock or cause our Class&nbsp;A common stock to
be made the subject of an invitation for subscription or purchase, and has not circulated or distributed, nor will it circulate or distribute, this prospectus or any other document or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">198 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
material in connection with the offer or sale, or invitation for subscription or purchase, of our Class&nbsp;A common stock, whether directly or indirectly, to any person in Singapore other than:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">to an institutional investor (as defined in Section&nbsp;4A of the Securities and Futures Act (Chapter 289)
of Singapore, as modified or amended from time to time (the &#147;SFA&#148;)) pursuant to Section&nbsp;274 of the SFA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">to a relevant person (as defined in Section&nbsp;275(2) of the SFA) pursuant to Section&nbsp;275(1) of the
SFA and in accordance with the conditions specified in Section&nbsp;275 of the SFA; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Where the shares of our Class&nbsp;A common stock are subscribed or purchased under Section&nbsp;275 of
the SFA by a relevant person which is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole
business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each
beneficiary of the trust is an individual who is an accredited investor, securities or securities-based derivatives contracts (each term as defined in Section&nbsp;2(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest
(howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the shares pursuant to an offer made under Section&nbsp;275 of the SFA except: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">to an institutional investor or to a relevant person, or to any person arising from an offer referred to in
Section&nbsp;276(4)(i)(B) of the SFA, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">where no consideration is or will be given for the transfer, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">where the transfer is by operation of law, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">as specified in Section&nbsp;276(7) of the SFA, or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">as specified in Regulation 37A of the Securities and Futures (Offers of Investments) (Securities and
Securities-based Derivatives Contracts) Regulations 2018. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Notice to Prospective Investors in
Bermuda </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Shares of our Class&nbsp;A common stock may be offered or sold in Bermuda only in compliance with the
provisions of the Investment Business Act of 2003 of Bermuda which regulates the sale of securities in Bermuda. Additionally, <FONT STYLE="white-space:nowrap">non-Bermudian</FONT> persons (including companies) may not carry on or engage in any trade
or business in Bermuda unless such persons are permitted to do so under applicable Bermuda legislation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Notice to
Prospective Investors in Saudi Arabia </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This document may not be distributed in the Kingdom of Saudi Arabia except
to such persons as are permitted under the Offers of Securities Regulations as issued by the board of the Saudi Arabian Capital Market Authority (the &#147;CMA&#148;), pursuant to resolution number <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">2-11-2004</FONT></FONT> dated October&nbsp;4, 2004, as amended by resolution number <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-28-2008,</FONT></FONT> as amended (the &#147;CMA Regulations&#148;).
The CMA does not make any representation as to the accuracy or completeness of this document and expressly disclaims any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this document. Prospective purchasers
of the securities offered hereby should conduct their own due diligence on the accuracy of the information relating to the securities. If you do not understand the contents of this document, you should consult an authorized financial adviser. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">199 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Notice to Prospective Investors in the British Virgin Islands
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The shares of our Class&nbsp;A common stock are not being and may not be offered to the public or to any person in
the British Virgin Islands for purchase or subscription by or on behalf of us. Our Class&nbsp;A common stock may be offered to companies incorporated under the BVI Business Companies Act, 2004 (British Virgin Islands) (&#147;BVI Companies&#148;),
but only where the offer will be made to, and received by, the relevant BVI Company entirely outside of the British Virgin Islands. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Notice to Prospective Investors in China </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This prospectus will not be circulated or distributed in the PRC and our Class&nbsp;A common stock will not be offered or sold,
and will not be offered or sold to any person for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, to any residents of the PRC except pursuant to any applicable laws and regulations of the PRC. Neither this
prospectus nor any advertisement or other offering material may be distributed or published in the PRC, except under circumstances that will result in compliance with applicable laws and regulations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Notice to Prospective Investors in Korea </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our shares of Class&nbsp;A common stock have not been and will not be registered under the Financial Investments Services and
Capital Markets Act of Korea (the &#147;FSCMA&#148;), and the decrees and regulations thereunder and the shares have been and will be offered in Korea as a private placement under the FSCMA. None of our shares of Class&nbsp;A common stock may be
offered, sold, or delivered, directly or indirectly, or offered or sold to any person for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Korea or to any resident of Korea except pursuant to the applicable
laws and regulations of Korea, including the FSCMA and the Foreign Exchange Transaction Law of Korea (the &#147;FETL&#148;), and the decrees and regulations thereunder. Our Class&nbsp;A common stock has not been listed on any of securities exchanges
in the world including, without limitation, the Korea Exchange in Korea. Furthermore, the purchaser of our Class&nbsp;A common stock shall comply with all applicable regulatory requirements (including but not limited to requirements under the FETL)
in connection with the purchase of our Class&nbsp;A common stock. By the purchase of our Class&nbsp;A common stock, the relevant holder thereof will be deemed to represent and warrant that if it is in Korea or is a resident of Korea, it purchased
our Class&nbsp;A common stock pursuant to the applicable laws and regulations of Korea. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Notice to Prospective
Investors in Taiwan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our Class&nbsp;A common stock has not been and will not be registered with the Financial
Supervisory Commission of Taiwan pursuant to relevant securities laws and regulations and may not be sold, issued or offered within Taiwan through a public offering or in circumstances which constitutes an offer within the meaning of the Securities
and Exchange Act of Taiwan that requires a registration or approval of the Financial Supervisory Commission of Taiwan. No person or entity in Taiwan has been authorized to offer, sell, give advice regarding or otherwise intermediate the offering and
sale of our Class&nbsp;A common stock in Taiwan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Notice to Prospective Investors in South Africa </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Due to restrictions under the securities laws of South Africa, no &#147;offer to the public&#148; (as such term is defined in
the South African Companies Act, No.&nbsp;71 of 2008, as amended or <FONT STYLE="white-space:nowrap">re-enacted)</FONT> (the &#147;South African Companies Act&#148;), is being made in connection with the issue of our Class&nbsp;A common stock in
South Africa. Accordingly, this document does not, nor is it intended to, constitute a &#147;registered prospectus&#148; (as that term is defined in the South African Companies Act) prepared and registered under the South African Companies Act and
has not been approved by, and/or filed with, the South African Companies and Intellectual Property Commission or any other regulatory authority in South Africa. Shares of our Class&nbsp;A common stock are not
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">200 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
offered, and the offer shall not be transferred, sold, renounced, or delivered, in South Africa or to a person with an address in South Africa, unless one or other of the following exemptions
stipulated in section 96 (1) applies: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Section&nbsp;96 (1)(a)&#8195;the offer, transfer, sale, renunciation, or delivery
is to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">persons whose ordinary business, or part of whose ordinary business, is to deal in securities, as principal
or agent; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the South African Public Investment Corporation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">persons or entities regulated by the Reserve Bank of South Africa; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">authorized financial service providers under South African law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">financial institutions recognized as such under South African law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">a wholly-owned subsidiary of any person or entity contemplated in (iii), (iv), or (v), acting as agent in
the capacity of an authorized portfolio manager for a pension fund, or as manager for a collective investment scheme (in each case duly registered as such under South African law); or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">any combination of the person in (i)&nbsp;to (vi), or </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Section&nbsp;96 (1)(b)&#8195;the total contemplated acquisition cost of the securities, for any single addressee acting as
principal is equal to or greater than ZAR1,000,000 or such higher amount as may be promulgated by notice in the Government Gazette of South Africa pursuant to section 96(2)(a) of the South African Companies Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Information made available in this prospectus should not be considered as &#147;advice&#148; as defined in the
South&nbsp;African Financial Advisory and Intermediary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">201 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom829170_21"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The validity of the shares of Class&nbsp;A common stock offered hereby will be passed upon for us by Latham&nbsp;&amp; Watkins
LLP, Menlo Park, California. Davis Polk&nbsp;&amp; Wardwell LLP, Redwood City, California, is acting as counsel for the underwriters in connection with certain legal matters related to this offering. &#8195; is acting as counsel for the selling
stockholders in connection with certain legal matters related to this offering. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom829170_22"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The financial statements of Hinge Health, Inc. as of December&nbsp;31, 2023, and for the year in the period ended
December&nbsp;31, 2023 included in this prospectus, have been audited by Deloitte&nbsp;&amp; Touche LLP, an independent registered public accounting firm, as stated in their report. Such financial statements are included in reliance upon the report
of such firm given their authority as experts in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom829170_23"></A>WHERE YOU CAN FIND ADDITIONAL
INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-1,</FONT>
including exhibits and schedules, under the Securities Act, with respect to the shares of Class&nbsp;A common stock being offered by this prospectus. This prospectus, which constitutes part of the registration statement, does not contain all of the
information in the registration statement and its exhibits. For further information with respect to us and our Class&nbsp;A common stock, we refer you to the registration statement and its exhibits. Statements contained in this prospectus as to the
contents of any contract or any other document referred to are not necessarily complete, and in each instance, we refer you to the copy of the contract or other document filed as an exhibit to the registration statement. Each of these statements is
qualified in all respects by this reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">You may read our SEC filings, including this registration statement, over
the Internet at the SEC&#146;s website at <I>www.sec.gov</I>. Upon the completion of this offering, we will be subject to the information reporting requirements of the Exchange Act and we will file reports, proxy statements, and other information
with the SEC. These reports, proxy statements, and other information will be available for review at the SEC&#146;s website referred to above. We also maintain a website at <I>www.hingehealth.com</I>, at which, following the completion of this
offering, you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. Information contained on, or that can be accessed through, our website does not constitute
part of this prospectus or the registration statement of which it forms a part, and the inclusion of our website address in this prospectus is an inactive textual reference only. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">202 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HINGE HEALTH, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom829170_24"></A>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin829170_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consolidated Financial Statements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin829170_2">Consolidated Balance Sheet</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin829170_3">Consolidated Statement of Operations and Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin829170_4">Consolidated Statement of Redeemable Convertible Preferred Stock and Stockholders&#146;
 Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin829170_5">Consolidated Statement of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin829170_6">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin829170_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To the stockholders and the Board of Directors of Hinge Health, Inc. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion on the Financial Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have audited the accompanying consolidated balance sheet of Hinge Health, Inc. and subsidiaries (the &#147;Company&#148;) as
of December&nbsp;31, 2023, the related consolidated statements of operations and comprehensive loss, redeemable convertible preferred stock and stockholders&#146; deficit, and cash flows, for the year then ended, and the related notes (collectively
referred to as the &#147;financial statements&#148;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&nbsp;31, 2023, and the results of its operations and its
cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis for Opinion
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express
an opinion on the Company&#146;s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the
Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We conducted our audit in accordance with the&nbsp;standards&nbsp;of the PCAOB and in accordance with auditing standards
generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.
The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for
the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due
to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the
accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Deloitte&nbsp;&amp; Touche LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">San Francisco, California </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">November&nbsp;14, 2024 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have served as the Company&#146;s auditor since 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HINGE HEALTH, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin829170_2"></A>CONSOLIDATED BALANCE SHEET </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and par value data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">234,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">188,404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable, net of allowance for credit losses of $3,439</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred contract assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,564</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">529,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property, equipment and software, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease right-of-use assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">622,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, redeemable convertible preferred stock and stockholders&#146; deficit</B></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities, non-current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">195,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Redeemable convertible preferred stock:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock, $0.00001 par value; 48,190,771 shares authorized;
48,150,146 shares issued and outstanding; aggregate liquidation preference of $845,478</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">851,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Stockholders&#146; deficit:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.00001 par value: 96,408,866 shares authorized; 15,956,516 shares issued and
outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive gain</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(510,802</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(423,994</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, redeemable convertible preferred stock and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">622,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HINGE HEALTH, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin829170_3"></A>CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,&nbsp;2023</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">292,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">194,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">324,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(130,514</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(108,546</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Benefit from) income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(405</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(108,141</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8.31</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive gain (loss):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized gain on marketable securities, net of taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(108,006</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HINGE HEALTH, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin829170_4"></A>CONSOLIDATED STATEMENT OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#146; DEFICIT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Redeemable&nbsp;Convertible</B><br><B>Preferred&nbsp;Stock</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-in&nbsp;Capital</FONT></B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Other<BR>Comprehensive<BR>Loss</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balances as of December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,150,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">851,272</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,505,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">84,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(75</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(402,661</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(318,125</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of common stock upon exercise of options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">694,673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Restricted stock award forfeiture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(243,795</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Unrealized gain on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(108,141</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(108,141</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balances as of December&nbsp;31, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,150,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">851,272</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,956,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">86,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(510,802</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(423,994</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HINGE HEALTH, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin829170_5"></A>CONSOLIDATED STATEMENT OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(108,141</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of deferred contract assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of discounts and amortization of premiums on marketable securities, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,759</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Excess and obsolete inventory transition charge</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-cash operating lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for credit losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(473</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,126</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred contract assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,773</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,111</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(63,909</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,976</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalized internal-use software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,639</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(453,335</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Maturities of marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">459,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for settlement of wrnch acquisition related holdback</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,847</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments for deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(645</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net decrease in cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(65,408</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash, beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">302,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash, end of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">237,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance
sheet:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">234,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">237,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosures of noncash investing and financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment purchased and unpaid at year end</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Right-of-use assets obtained in exchange for new operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unpaid deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HINGE HEALTH, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin829170_6"></A>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Organization and Business Description </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Hinge Health, Inc. (&#147;Hinge Health&#148; or the &#147;Company&#148;) is a leading technology platform for individuals
seeking to treat and prevent joint and muscle pain. Through a combination of AI-powered motion tracking technology, a proprietary electrical nerve stimulation wearable device and an AI-supported care team of licensed physical therapists, physicians,
and board certified health coaches, the Company&#146;s platform helps members address musculoskeletal (&#147;MSK&#148;) conditions, enables improved member outcomes and supports cost reductions for its clients. The Company&#146;s clients are
primarily self-insured employers. The Company&#146;s members represent an eligible life (employees and adult dependents of the Company&#146;s clients) who has engaged with the Company&#146;s platform at any point and whose engagement has been billed
or is contractually eligible to be billed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company was incorporated in Delaware in March 2016 and is headquartered in
San Francisco, California. The Company has wholly-owned subsidiaries in Canada, India and the United Kingdom. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Summary of Significant Accounting
Policies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The accompanying consolidated financial statements reflect the application of certain significant accounting
policies as described below and elsewhere in these notes to the consolidated financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Basis of
Presentation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The accompanying consolidated financial statements have been prepared in conformity with accounting
principles generally accepted in the United States (&#147;GAAP&#148;). The Company&#146;s consolidated financial statements include the accounts of the Company, its wholly-owned subsidiaries and its affiliated professional medical corporations. The
Company&#146;s affiliated professional medical corporations are collectively referred to as Hinge Health Digital P.C. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Hinge Health Digital P.C. contracts with or otherwise employs physicians, physical therapists and other licensed health
professionals in order to provide services to the Company&#146;s clients, and under certain management services agreements, the Company serves as the exclusive manager and administrator of Hinge Health Digital P.C.&#146;s non-clinical functions and
services. Hinge Health Digital P.C. is considered a variable interest entity (&#147;VIE&#148;) for which the Company is the primary beneficiary. The Company has the rights and power to control the activities of Hinge Health Digital P.C. and as a
result the Company consolidates the activities of Hinge Health Digital P.C. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2023 total assets of
the consolidated VIE, all of which are current, were $3.1 million, and total liabilities, all of which are current, were $3.2 million after the elimination of intercompany transaction balances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All intercompany transactions and balances have been eliminated in consolidation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any reference in these notes to applicable guidance is meant to refer to authoritative GAAP as found in the Accounting
Standards Codification (&#147;ASC&#148;) and Accounting Standards Update (&#147;ASUs&#148;) of the Financial Accounting Standards Board (&#147;FASB&#148;). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The preparation of consolidated financial statements in accordance with GAAP requires management to make estimates and
assumptions that affect the amounts reported in the Company&#146;s consolidated financial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HINGE HEALTH, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
statements. Significant items that require estimates include, but are not limited to, inventory valuation, capitalized internal-use software development costs, the period of benefit for deferred
contract assets for commissions, and the valuation of the Company&#146;s common stock and stock-based compensation. Despite the Company&#146;s intention to establish accurate estimates and use reasonable assumptions, actual results may vary from the
Company&#146;s estimates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Emerging Growth Company Status </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company is an emerging growth company, as defined by the Jumpstart Our Business Startups Act of 2012 (the &#147;JOBS
Act&#148;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards that have effective dates that apply differently to public and private companies until the earlier of the date that (i)&nbsp;the company
is no longer an emerging growth company or (ii)&nbsp;the company affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these consolidated financial statements may not be comparable to
companies that comply with the new or revised accounting pronouncements as of public company effective dates. The Company expects to use the extended transition period for any other new or revised accounting standards during the period in which it
remains an emerging growth company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Segment Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Operating segments are defined as components of an enterprise where separate financial information is evaluated regularly by
the chief operating decision maker, which the Company has identified as being the Chief Executive Officer (&#147;CEO&#148;), in deciding how to allocate resources and assessing performance. The Company operates in one operating segment. The
Company&#146;s chief operating decision maker allocates resources and assesses performance at the consolidated level. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Concentration of Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and
cash equivalents, marketable securities and trade accounts receivable. The primary focus of the Company&#146;s investment strategy is to preserve capital and meet liquidity requirements. The Company&#146;s investment policy addresses the level of
credit exposure by limiting the concentration in any one corporate issuer and establishing a minimum allowable credit rating. To manage risk exposure, the Company invests cash equivalents and marketable securities in a variety of fixed income
securities, including government and investment-grade debt securities and money market funds. The Company places its cash primarily in checking and money market accounts with reputable financial institutions. Deposits held with these financial
institutions may exceed the amount of insurance provided on such deposits, if any. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company monitors accounts
receivable for uncollectible accounts on an ongoing basis. No client represented greater than 10% of the Company&#146;s accounts receivable as of December&nbsp;31, 2023. Additionally, no client represented greater than 10% of the Company&#146;s
revenue for the year ended December&nbsp;31, 2023. For the purpose of assessing the concentration of credit risk for significant clients, the Company defines a client as a business or organization that purchases access to the Company&#146;s platform
directly from the Company or indirectly through one of the Company&#146;s partners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company is subject to supplier
concentration risk from third party suppliers that supply its inventory. The Company relies and expects to continue to rely on a small number of third-party suppliers to supply its inventory requirements. The Company&#146;s inventory and ability to
provide its peripheral Enso device product to members could be adversely affected by a significant interruption from these third-party suppliers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HINGE HEALTH, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Foreign Currency Transactions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has subsidiaries in Canada, India and the United Kingdom that provide research and development support. The
functional currency of the Company&#146;s foreign subsidiaries is the U.S. dollar. Accordingly, assets and liabilities of the Company&#146;s foreign subsidiaries are remeasured into U.S. dollars at the exchange rates in effect at the reporting date
with differences recorded as transaction gains and losses within other income, net. Foreign currency transaction gains and losses were immaterial for the period presented. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Fair Value of Financial Instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Certain assets and liabilities are carried at fair value in accordance with ASC 820, <I>Fair Value Measurement</I>. The
accounting guidance for fair value provides a framework for measuring fair value, clarifies the definition of fair value, and expands disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an
asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. A financial instrument&#146;s categorization within the valuation hierarchy is based upon the lowest level of input
that is significant to the fair value measurement. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Level 1 inputs: quoted prices in active markets for identical assets or liabilities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Level 2 inputs: observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar
assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Level 3
inputs: unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the
determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Cash and Cash Equivalents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company considers all highly liquid marketable securities with an original maturity of three months or less when purchased
to be cash equivalents. Cash equivalents are recorded at cost, which approximates fair value. The Company does not hold or issue financial instruments for trading purposes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Restricted Cash </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2023, restricted cash consisted of cash used as collateral to a letter of credit issued by a bank in
favor of the Company in connection with a lease agreement, which totaled $2.5 million as of December&nbsp;31, 2023. The restricted cash is included in other assets in the accompanying consolidated balance sheet. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Marketable Securities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Marketable securities consist of U.S. treasury securities, investment-grade corporate and government agency securities and
commercial paper. The Company has designated all marketable securities as available-for-sale and, therefore, marketable securities are subject to periodic impairment under the available-for-sale debt security
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HINGE HEALTH, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
impairment model. Available-for-sale debt securities in an unrealized loss position are written down to fair value through a charge to interest income if the Company intends to sell the security
or it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. The Company evaluates the remaining securities to determine what amount of the excess, if any, is caused by expected
credit losses. A decline in fair value attributable to expected credit losses is recorded to other income, net, while any portion of the loss related to non-credit factors is recorded in unrealized gain (loss) on marketable securities. For
securities sold prior to maturity, the cost of the securities sold is based on the specific identification method. Realized gains and losses on the sale of marketable securities, are recorded in interest income in the accompanying consolidated
statement of operations and comprehensive loss. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Accounts Receivable and Allowance for Credit Losses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accounts receivable are stated at the amount management expects to collect from outstanding balances, net of allowances for
credit losses. The Company records accounts receivable when it has the unconditional right to bill and receive payment regardless of whether revenue has been recognized. Unbilled receivables include contractually billable invoices that are not yet
billed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Allowances for credit losses are provided for those outstanding balances considered to be uncollectible based on
the age of each outstanding invoice, historical collection history and the client&#146;s expected ability to pay. Balances that are still outstanding after management has made reasonable collection efforts are written off through a charge to the
allowance for credit losses. Allowance for credit losses during the year ended December&nbsp;31, 2023 included a provision for credit losses of $4.9 million partially offset by write-offs of $2.4&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accounts receivable, net as of December&nbsp;31, 2023 was composed of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Billed accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,752</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unbilled accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Allowance for credit losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,439</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total accounts receivable, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46,563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Inventory </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Inventory consists of peripheral products, which primarily include the Company&#146;s kits and Enso device product. Inventory
is stated at the lower-of-cost or net realizable value. The cost of inventory is based on a standard cost method, which approximates the actual cost on a first-in first-out basis. Inventory that is obsolete or in excess of forecasted demand is
written down to its estimated net realizable value. Inherent in the estimates of market value in determining inventory valuation are estimates related to market and economic conditions, technology changes, new product introductions and changes in
strategic direction. Inventory write-downs are recognized as cost of revenue in the accompanying consolidated statement of operations and comprehensive loss. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Deferred Inventory Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Deferred inventory costs are primarily composed of the Company&#146;s kits and Enso device product, which are sent to members.
These costs are amortized on a straight-line basis over the 12-month member subscription period and are included in cost of revenue in the accompanying consolidated statement of operations and comprehensive loss. Deferred inventory costs were $14.4
million as of December&nbsp;31, 2023, which were recorded to prepaid expenses and other current assets in the consolidated balance sheet. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HINGE HEALTH, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Deferred Offering Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company capitalizes deferred offering costs related to this initial public offering (&#147;IPO&#148;), which consist of
direct incremental legal, professional, accounting, and other third-party fees. The deferred offering costs will be offset against IPO proceeds upon the consummation of this offering. Should this anticipated IPO be abandoned, the deferred issuance
costs will be expensed immediately as a charge to operating expenses in the consolidated statement of operations. Deferred offering costs were $1.0 million as of December&nbsp;31, 2023, which were recorded to prepaid expenses and other current
assets in the accompanying consolidated balance sheet. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Deferred Contract Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has determined that certain sales incentives provided to the Company&#146;s sales team and payments related to
partnerships agreements are required to be capitalized when the Company expects to generate future economic benefits from the related revenue-generating contracts subsequent to the initial sales transaction. When determining the economic life of the
contract acquisition assets recognized, the Company considers historical renewal rates, expectations of future client renewals of contracts, and other factors that could impact the economic benefits that the Company expects to generate from the
relationship with its clients. Deferred contract assets are amortized over the 12-month member subscription period for partner commissions and estimated five-year client period of benefit for sales commissions and are included in sales and marketing
expense in the accompanying consolidated statement of operations and comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A summary of the activity of the
Company&#146;s contract asset balances during the year ended December&nbsp;31, 2023 are as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended<BR>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalized costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortized costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,328</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at end of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Classified as:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred contract assets - current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,564</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets - non current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Property, Equipment and Software, Net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Property, equipment and software are recorded at cost and depreciated over the estimated useful lives of the related assets
using the straight-line basis. Expenditures for maintenance and repairs are charged to expense as incurred, whereas major improvements are capitalized as additions to property and equipment. The estimated useful lives for machinery and equipment and
furniture and fixtures span over five years and computer software and equipment over three years. The estimated useful lives for leasehold improvements span over the lesser of the lease term or useful life. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company classifies internal-use software in property, equipment and software. Internal-use software is capitalized during
the application development stage and includes eligible employee salaries and compensation-related costs as well as costs incurred in developing new features and enhancements when the costs will result in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HINGE HEALTH, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
additional functionality. Capitalized internal-use software development costs are amortized on a straight-line basis over their estimated useful life of three years and are included in cost of
revenue in the accompanying consolidated statement of operations and comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Capitalization begins when
(1)&nbsp;the preliminary project stage is complete, (2)&nbsp;management, with appropriate authority, authorizes and commits to the funding of the software project, (3)&nbsp;it is probable the project will be completed, (4)&nbsp;the software will be
used to perform the functions intended, and (5)&nbsp;certain functional and quality standards have been met. Costs related to planning and post implementation activities are expensed as incurred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Goodwill and Long-Lived Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Goodwill represents the excess of the purchase price of an acquired business over the fair value of the underlying net tangible
and intangible assets. Goodwill amounts are not amortized, but rather tested for impairment at least annually, and more frequently when changes in circumstances indicate that the carrying value may not be recoverable. The Company has determined that
it operates its business as one reporting unit and the Company completes its annual impairment test in the fourth quarter. In the event that the Company determines that the fair value of the reporting unit is less than the reporting unit&#146;s
carrying value, a goodwill impairment charge will be incurred for the amount of the difference during the period in which the determination is made. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company evaluates long-lived assets for possible impairment in the fourth quarter of each year or whenever events or
changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of these assets is measured by comparison of the carrying amount of each asset to the future undiscounted cash flows the asset is
expected to generate. In the event that the Company determines that the fair value of a long-lived asset is less than the carrying value, the Company will incur an impairment charge. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company did not record any goodwill or long-lived asset impairments during the year ended December&nbsp;31, 2023. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Leases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Leases are accounted for under ASC 842. The Company determines if an arrangement is a lease at inception. The Company&#146;s
lease agreements generally contain lease and non-lease components. Payments under its lease arrangements are primarily fixed. Non-lease components primarily include payments for maintenance and utilities. The Company combines fixed payments for
non-lease components with lease payments and accounts for them together as a single lease component, which increases the amount of the Company&#146;s right-of-use (&#147;ROU&#148;) assets and lease liabilities. Certain lease agreements contain
variable payments, which are expensed as incurred, and are immaterial and not included in the Company&#146;s ROU assets and lease liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">ROU assets and lease liabilities are recognized at the present value of the future lease payments at the lease commencement
date. The interest rate used to determine the present value of the future lease payments is the Company&#146;s incremental borrowing rate, because the interest rate implicit in its leases is not readily determinable. The Company&#146;s incremental
borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments, and in economic environments where the leased asset is located. The Company&#146;s lease terms include a period with options to
extend or terminate the lease when it is reasonably certain that it will either exercise the option to extend the lease or not exercise the option to terminate the lease. The Company generally uses the base, non-cancelable, lease term when
determining the ROU assets and lease liabilities. ROU assets are adjusted for any prepaid lease payments and lease incentives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Lease expense is recognized on a straight-line basis over the lease term. The Company has elected not to record leases with an
original term of 12 months or less on its consolidated balance sheet and recognizes those lease payments in operating expenses in the consolidated statement of operations and comprehensive loss.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HINGE HEALTH, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The ROU assets are assessed for impairment in accordance with the
Company&#146;s accounting policy for long-lived assets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Deferred Revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Deferred revenue primarily consists of amounts that the Company has billed or can contractually bill from subscriptions and is
recognized as the revenue recognition criteria is met. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes the changes in the balances of
deferred revenue during the year ended December&nbsp;31, 2023 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">104,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Add: billings during the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">328,699</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: revenue recognized</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(292,730</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at end of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">140,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s performance obligations are satisfied within&nbsp;12 months&nbsp;of the
initial contract date. As of December&nbsp;31, 2023, the deferred revenue balance was comprised entirely of noncancellable performance obligations that will be satisfied within 12 months. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Redeemable Convertible Preferred Stock</I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company records shares of redeemable convertible preferred stock at their respective fair values on the dates of issuance,
net of issuance costs. The redeemable convertible preferred stock is recorded outside of permanent equity because while it is not mandatorily redeemable, redemption is contingent upon the occurrence of certain events considered not solely within the
Company&#146;s control. The Company has not adjusted the carrying values of the redeemable convertible preferred stock to the liquidation preferences of such shares because it is uncertain whether or when a deemed liquidation event would occur that
would obligate the Company to pay the liquidation preferences to holders of shares of redeemable convertible preferred stock. Subsequent adjustments to the carrying values to the liquidation preferences will be made only when it becomes probable
that such a deemed liquidation event will occur. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Revenue Recognition </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company earns revenue from subscription fees by providing access to its platform and programs to treat and prevent MSK
pain. The Company currently sells its subscriptions to its clients in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company determines revenue
recognition through the following five steps: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Identification of the contract, or contracts, with a client; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Identification of the performance obligations in the contract; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Determination of the transaction price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Allocation of the transaction price to the performance obligations in the contract; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Recognition of revenue, when, or as, the Company satisfies a performance obligation.</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HINGE HEALTH, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company determines it has a contract with a client: (1)&nbsp;when the
contract has been approved by both parties; (2)&nbsp;it can identify each party&#146;s rights regarding the services to be transferred and the payment terms for the services; and (3)&nbsp;it has determined that the client has the ability and intent
to pay. The Company applies judgment in determining the client&#146;s ability and intent to pay, which is based on a variety of factors, including the client&#146;s payment history or, new client reputation and relationship with a health plan
partner, as applicable. The Company&#146;s typical contracts are three years. After the initial term, the Company&#146;s contracts renew automatically for additional one-year terms unless notice of termination is given by the client or the
Company.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The contracts contain a number of promised goods and services, including access to the Company&#146;s platform,
technical support, as well as the Company&#146;s peripheral products, which includes the Enso device. The Company has determined its contracts contain three performance obligations which are provided to members; (1)&nbsp;access to the platform that
is delivered over time; (2)&nbsp;technical support which is delivered in the same pattern using the output method; and (3)&nbsp;the peripheral products, when and if sent as a part of its platform. As the platform and technical support are provided
to the client concurrently over the contract term and have the same pattern of transfer, the Company has concluded that these performance obligations represent one performance obligation consisting of a series of distinct services over the contract
term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company may provide the Enso device as part of its platform, which remains the legal property of the Company
during the contract term. The Company determines whether or not the Enso device is sent to members based on criteria that it controls. If the Enso device is sent to a member as part of the Company&#146;s platform, it constitutes a lease component as
this device remains the property of the Company and the member has the right to direct the use of the device during the contract term. Delivery of the device causes a change to the scope of the contract, as both the Company&#146;s and clients&#146;
rights have changed. The Company accounts for this change as a contract modification resulting in the termination of the old contract and the start of a new contract. The Company&#146;s Enso device qualifies to be accounted for as an operating lease
and the pattern of delivery from contract modification date to contract termination is consistent with the timing for non-lease components in the contract. For these client arrangements where the Enso device is leased in combination with services,
the Company considers the arrangement to be predominately a service and thus a combined single performance obligation for purposes of revenue recognition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The transaction price is a fixed annual fee during a service period. The majority of the Company&#146;s contracts are billed
after a member&#146;s first completed billing activity, either the full annual fee at that time or upon the achievement of cohort milestones, which are primarily achieved once contractual exercise thresholds are met at a cohort level. When the
billable volume varies based upon the achievement of cohort milestones, the consideration is variable at contract outset, and the Company estimates the volume of members based on historical experience and adjusts revenue as members complete cohort
milestones. If the actual amounts of consideration received differ from its estimates, the Company adjusts reported revenue in the period such variances become known. For the year ended December&nbsp;31, 2023 changes to estimated variable
consideration were not material. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Members have access to the Company&#146;s platform for a 12-month subscription term that
begins after the individual has completed their first billable activity on the platform. The Company does not earn any fees until this point. The Company recognizes revenue for each member ratably over the 12-month member subscription period in
order to match the pattern of revenue recognition to the pattern of costs incurred in delivering its platform. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Timing of
revenue recognition may differ from the timing of billing. A majority of the Company&#146;s clients are billed upfront or throughout the first quarter of the member&#146;s subscription period. The Company&#146;s performance obligations are satisfied
within 12 months of the member&#146;s first billable activity. The Company&#146;s contracts do not contain significant financing components. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HINGE HEALTH, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, certain performance guarantees&nbsp;are included in most
contracts and are estimated at each reporting period based on the Company&#146;s historical performance or other available information. The Company recognizes any estimated adjustments to the contract price for not achieving the performance
guarantees as an adjustment to revenue. Payouts on these performance guarantees have been immaterial to date.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Cost
of Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cost of revenue consists of costs that are related to the delivery of the Company&#146;s platform.
These costs primarily include personnel-related costs, including employee salaries, stock-based compensation and other related expenses for the Company&#146;s care team, support operations personnel, and site reliability engineering personnel. Cost
of revenue also includes inventory costs, which are amortized over the member&#146;s subscription period, provisions for excess and obsolete inventory, and technology support costs, which include hosting and information technology costs, and
amortization of internal-use software. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Research and Development </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Research and development expenses consist primarily of personnel-related costs, including employee salaries, stock-based
compensation and other related expenses for the Company&#146;s engineering and product teams that are responsible for enhancing its platform and developing new or enhanced programs. Research and development expenses also include costs for
third-party services and contractors and software-related costs. The Company capitalizes internal-use software development costs that qualify for capitalization and appropriately reduces research and development expenses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Sales and Marketing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Sales and marketing expenses consist primarily of personnel-related costs, including employee salaries, stock-based
compensation and other related expenses, internal and third-party sales commissions, and marketing and promotional expenses. The Company amortizes third-party sales commissions and a portion of internal sales commissions over the respective benefit
periods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Advertising costs, which are expensed and included in sales and marketing expenses, for the year ended
December&nbsp;31, 2023 were $23.8 million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>General and Administrative </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">General and administrative expenses consist primarily of personnel-related costs, including employee salaries, stock-based
compensation and other related expenses for finance, legal, human resources, and other administrative related teams. General and administrative expenses also include third-party professional services for outside legal and accounting services,
information technology and software related costs, and other corporate related expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Stock-Based Compensation
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company measures stock-based compensation awards, including stock options and restricted stock units
(&#147;RSUs&#148;), performance-based restricted stock units (&#147;PRSUs&#148;) and restricted stock awards (&#147;RSAs&#148;) based on the estimated fair value of the awards on the date of grant. Stock-based compensation expense is recorded for
awards issued to employees and non-employees at fair value with a corresponding increase in additional paid-in capital. For awards that contain service conditions only, the Company recognizes compensation expense on a straight-line basis over the
requisite service period of the award. Forfeitures are recognized when they occur. The Company has not granted stock options since March 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HINGE HEALTH, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">RSUs vest upon the occurrence of both a service-based condition and a
liquidity event. No compensation cost related to awards with liquidity-based vesting conditions have been recognized through December&nbsp;31, 2023 as the Company has determined the occurrence of a liquidity event is not probable. The Company will
record the expense for these awards using the accelerated attribution method over the remaining service period when the Company has determined the liquidity-based vesting condition is probable. The fair value of each RSU grant is calculated based on
the estimated fair value of the Company&#146;s common stock on the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">PRSUs granted are subject to not only a
service-based, but also a performance-based vesting condition. The performance condition includes various milestones based on market capitalization thresholds or revenue targets as well as the occurrence of a liquidity event. No compensation cost
has been recognized through December&nbsp;31, 2023 as the Company has determined the occurrence of a liquidity event is not probable. The Company will record the expense for these awards using the accelerated attribution method over the remaining
service period when it determines that satisfaction of the liquidity-based vesting condition and the milestones are probable. The fair market value of market condition PRSU grants are based on the Monte Carlo simulation model, which incorporates
multiple valuation assumptions, including the probability of achieving the market condition, the term of the awards, and the expected common share volatilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">RSAs are considered issued because they are legally issued and have voting and dividend rights. The underlying shares are
included in the Company&#146;s outstanding common stock on the statement of redeemable convertible preferred stock and stockholders&#146; deficit in the consolidated balance sheet but are excluded in the calculation of basic net loss per share
attributable to common stockholders in the consolidated statement of operations and comprehensive loss because the shares are considered to be contingently returnable shares for accounting purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Given the absence of an active market for the Company&#146;s common stock, management and the Board are required to estimate
the fair value of the Company&#146;s common stock at the time of each grant of a stock-based compensation award. The Company and the Board utilize various valuation methodologies in accordance with the framework of the American Institute of
Certified Public Accountants&#146; Technical Practice Aid, Valuation of Privately Held Company Equity Securities Issued as Compensation to estimate the fair value of its common stock. Each valuation methodology includes estimates and assumptions
that require the Company&#146;s judgment. These estimates and assumptions include a number of objective and subjective factors in determining the value of the Company&#146;s common stock at each grant date, including the following factors: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prices paid for the Company&#146;s capital stock, which the Company has sold to outside investors in
arm&#146;s-length transactions, considering the rights and privileges of the securities sold relative to the common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prices paid for shares of its common stock sold in secondary market transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">valuations performed by an independent valuation specialist; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s stage of development and revenue growth; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the market performance of comparable publicly traded companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adjustments necessary to recognize a lack of marketability for the common stock underlying the granted RSUs,
PRSUs and RSAs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the likelihood of achieving a liquidity event for the common stock underlying the stock-based awards, such as
an IPO or sale of the Company, given prevailing market conditions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. and global economic and capital market conditions and outlook. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HINGE HEALTH, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and
liabilities are determined based on temporary differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect on deferred
tax assets and liabilities of a change in tax laws is recognized in the consolidated statement of operations and comprehensive loss in the period that includes the enactment date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Valuation allowances are established when necessary to reduce deferred tax assets to the amounts that are more likely than not
expected to be realized based on the weighting of positive and negative evidence. Future realization of deferred tax assets ultimately depends on the existence of sufficient taxable income of the appropriate character (for example, ordinary income
or capital gain) within the carryback or carryforward periods available under the applicable tax law. The Company regularly reviews its deferred tax assets for recoverability based on historical taxable income, projected future taxable income, the
expected timing of the reversals of existing temporary differences and tax planning strategies. The Company&#146;s judgments regarding future profitability may change due to many factors, including future market conditions and the ability to
successfully execute its business plans. If there is a change in the ability to recover deferred tax assets, the tax provision is increased or decreased in the period in which the assessment is changed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s tax positions are subject to income tax audits in the United States and certain foreign jurisdictions. The
Company recognizes the tax benefit of an uncertain tax position only if it is more likely than not that the position is sustainable upon examination by the taxing authority, solely based on its technical merits. The tax benefit recognized is
measured as the largest amount of benefit, which has a greater than 50 percent likelihood of being realized upon settlement with the taxing authority. The Company recognizes interest accrued and penalties related to unrecognized tax benefits in the
income tax provision. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Contingencies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From time to time, the Company has become involved in claims and other legal matters arising in the ordinary course of
business. The Company investigates these claims as they arise. The Company records a loss contingency when it is probable that an asset has been impaired or a liability has been incurred and the amount of the loss can be reasonably estimated. The
Company also discloses material contingencies when it is believed a loss is not probable but reasonably possible. Accounting for contingencies requires the Company to use judgment related to both the likelihood of a loss and the estimate of the
amount or range of loss. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Net Loss Per Share Attributable to Common Stockholders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Basic and diluted net loss per share attributable to common stockholders is presented in conformity with the two-class method
required for participating securities. The Company considers all series of redeemable convertible preferred stock to be participating securities as the holders of such stock are entitled to receive non-cumulative dividends on an as-converted basis,
in the event that a dividend is paid on common stock. Under the two-class method, the net loss attributable to common stockholders is not allocated to the redeemable convertible preferred stock as the holders of the Company&#146;s redeemable
convertible preferred stock do not have a contractual obligation to share in the losses of the Company. Under the two-class method, net income is attributed to common stockholders and participating securities based on their participation rights.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common
stockholders by the weighted-average number of shares of common stock outstanding during the period. Net loss attributable to common stockholders is calculated by adjusting net loss with current </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HINGE HEALTH, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
period accretion of redeemable convertible preferred stock. As the Company has reported net losses for the period presented, all potentially dilutive securities are antidilutive and, accordingly,
basic net loss per share equals diluted net loss per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Accounting Pronouncements Recently Adopted </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In June 2016, the FASB issued ASU 2016-13, <I>Financial Instruments&#151;Credit Losses (Topic 326) Measurement of Credit Losses
on Financial Instruments</I>. The FASB issued further updates to this guidance in November 2018 through ASU 2018-19, <I>Codification Improvements to Topic 326, Financial Instruments&#151;Credit Losses</I>, in April 2019 through ASU 2019-04,
<I>Codification Improvements to Topic 326, Financial Instruments&#151;Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments</I>, in May 2019 through ASU 2019-05<I>, Financial Instruments&#151;Credit Losses (Topic
326): Targeted Transition Relief</I>, and in November 2019 through both ASU No.&nbsp;2019-10, <I>Financial Instruments&#151;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates</I> and ASU 2019-11,
<I>Codification Improvements to Topic 326, Financial Instruments&#151;Credit Losses</I>. The pronouncement requires an entity to utilize a new impairment model known as the current expected credit loss (&#147;CECL&#148;) model to estimate its
lifetime &#147;expected credit loss&#148; and record an allowance that, when deducted from the amortized cost basis of the financial asset, presents the net amount expected to be collected on the financial asset. The CECL model is expected to result
in more timely recognition of credit losses. The Company adopted this standard as of January&nbsp;1, 2023. The adoption of this standard did not have a material impact on the consolidated financial statements or related disclosures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In October 2021, the FASB issued ASU 2021-08, <I>Business Combinations (Topic 805), Accounting for Contract Assets and
Contract Liabilities from Contract with Customers</I>. The ASU requires that an acquirer recognize and measure contract assets and contract liabilities in a business combination in accordance with Topic&nbsp;606. The ASU is effective for fiscal
years beginning after December&nbsp;15, 2023, including interim periods within those fiscal years, with early adoption permitted. The Company adopted this standard as of January&nbsp;1, 2023. The adoption of this standard did not have a material
impact on the consolidated financial statements or related disclosures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Recently Issued Accounting Pronouncements
Not Yet Adopted </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In November 2023, the FASB issued ASU 2023-07,&nbsp;<I>Segment Reporting (Topic 280): Improvements
to Reportable Segment Disclosures</I>. The ASU expands public entities&#146; segment disclosures by requiring disclosure of significant segment expenses that are regularly reviewed by the CODM and included within each reported measure of segment
profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#146;s profit or loss and assets. The ASU also allows, in addition to the measure that is most consistent with
GAAP, the disclosure of additional measures of segment profit or loss that are used by the CODM in assessing segment performance and deciding how to allocate resources. All disclosure requirements under ASU 2023-07 are also required for public
entities with a single reportable segment. The ASU is effective for fiscal years beginning after December&nbsp;15, 2023, and interim periods within fiscal years beginning after December&nbsp;15, 2024, on a retrospective basis, with early adoption
permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements and disclosures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In December 2023, the FASB issued ASU 2023-09,&nbsp;<I>Improvements to Income Tax Disclosures</I>. The ASU requires greater
disaggregation of information about a reporting entity&#146;s effective tax rate reconciliation as well as information on income taxes paid. The ASU applies to all entities subject to income taxes and is intended to help investors better understand
an entity&#146;s exposure to potential changes in jurisdictional tax legislation and assess income tax information that affects cash flow forecasts and capital allocation decisions. The ASU is effective for annual periods beginning after
December&nbsp;15, 2024, with early adoption permitted. The ASU should </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HINGE HEALTH, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
be applied on a prospective basis although retrospective application is permitted. The Company is currently evaluating the impact of this standard on its consolidated financial disclosures. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Cash, Cash Equivalents and Marketable Securities and Fair Value Measurements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2023, cash, cash equivalents and marketable securities consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortized<BR>cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross<BR>unrealized<BR>gains</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross<BR>unrealized<BR>losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total fair<BR>value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">196,763</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">196,763</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commercial paper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202,904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202,901</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable securities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commercial paper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. treasury securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Government agency securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">188,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">188,404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">391,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">391,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2023, the contractual maturities of the marketable securities held by
the Company were 12 months or less. The Company does not intend to sell the marketable securities, and it is not more likely than not that the Company will be required to sell the marketable securities before recovery of their amortized cost basis,
which may be at maturity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the year ended December&nbsp;31, 2023, interest income earned from cash and cash
equivalents and marketable securities included in other income, net included in the consolidated statement of operations and comprehensive loss, was comprised as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended<BR>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s cash equivalents and marketable securities classified as Level 1 financial
instruments are composed of money market funds and U.S. treasury securities. Level 1 financial instruments are in active markets using unadjusted quoted market prices for identical instruments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s marketable securities classified as Level 2 financial instruments are composed of investment-grade
corporate and government agency securities and commercial paper. Level 2 financial instruments are not in active markets but are from a primary professional pricing source that uses quoted market prices for identical or comparable instruments,
rather than direct observations of quoted prices in active markets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HINGE HEALTH, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Fair values obtained from this professional pricing source can also be based on pricing models whereby all significant observable inputs, including maturity dates, issue dates, settlement dates,
benchmark yields, reported trades, broker-dealer quotes, issue spreads, benchmark securities, bids, offers or other market related data, are observable or can be derived from, or corroborated by, observable market data for substantially the full
term of the asset. The Company validates the quoted market prices provided by its primary pricing service by comparing the fair values of its Level 2 marketable securities portfolio balance provided by its primary pricing service against the fair
values provided by the Company&#146;s marketable security managers. The Company had no Level 3 securities as of December&nbsp;31, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The fair value measurements of assets and liabilities that are measured at fair value on a recurring basis (in thousands):
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">196,763</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">196,763</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commercial paper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">196,763</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202,901</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable securities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commercial paper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. treasury securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Government agency securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">188,404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">264,564</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">126,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">391,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There were no transfers into or out of Level 3 securities during the year ended
December&nbsp;31, 2023. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Balance Sheet Details </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Prepaid Expenses and Other Current Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prepaid expenses and other current assets as of December&nbsp;31, 2023 was composed of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred inventory costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Deferred inventory costs for members are amortized ratably over a 12-month period. The
amortization costs for the year ended December&nbsp;31, 2023 were $40.7 million. These amortization costs are included in cost of revenue in the consolidated statement of operations and comprehensive loss. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HINGE HEALTH, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Inventory </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Inventory as of December&nbsp;31, 2023 was composed of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Raw materials</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Work in process</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finished goods</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">During the year ended December&nbsp;31, 2023, excess and obsolete inventory transition charges
were $10.3&nbsp;million. These excess inventory transition charges represent the write-down of inventory costs due to the Company&#146;s transition from physical sensors to utilizing computer vision technology to replace the physical kits containing
tablets and sensors that were previously provided to members. As part of the transition, the Company shifted to a model that encourages members to use their own devices to access the platform. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Property, Equipment and Software, Net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Property, equipment and software as of December&nbsp;31, 2023 was composed of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalized internal-use software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computers and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Machinery and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,772</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total property, equipment and software, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">During the year ended December&nbsp;31, 2023 depreciation expense was $1.8 million. During the
year ended December&nbsp;31, 2023, the Company capitalized internal-use software costs of $2.6 million and amortization expense was $3.5 million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Accounts Payable and Accrued Liabilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accounts payable and accrued liabilities as of December&nbsp;31, 2023 was composed of the following (in&nbsp;thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued employee related costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued commissions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued taxes payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued inventory costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued client refunds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HINGE HEALTH, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Intangible Assets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The changes in intangible assets, net for the year ended December&nbsp;31, 2023 were as follows (in thousands, except years):
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross<BR>Carrying<BR>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Amortization</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Net&nbsp;Carrying<BR>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Remaining<BR>Term<BR>(years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Developed technology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(793</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade names</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(176</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(969</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The useful life of developed technology and trade names is eight years and ten years,
respectively. Amortization expense for the year ended December&nbsp;31, 2023 was $0.4 million and included in cost of revenue in the consolidated statement of operations and comprehensive loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Future amortization expense related to intangible assets is as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="93%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Years Ending December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2028</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Commitments and Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations and Commitments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Legal Matters </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From time to time, the Company may become involved in legal proceedings or be subject to claims arising in the ordinary course
of its business. As of December&nbsp;31, 2023, the Company was not subject to any pending or threatened litigation the outcome of which, the Company believes, if determined adversely to the Company, would individually, or in the aggregate, have a
material effect on its consolidated financial position or results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Indemnification Obligations
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the normal course of business, the Company includes in its agreements indemnification provisions of varying
scope and terms pursuant to which it may agree to indemnify third parties with whom it enters into contractual relationships, including clients, lessors, and parties to other transactions with the Company, with respect to certain matters. The
Company has agreed, under certain conditions, to hold these third parties harmless against specified losses, such as those arising from a breach of representations or covenants, other third-party claims that the Company&#146;s platform, programs or
device, when used for their intended purposes, infringe the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HINGE HEALTH, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
intellectual property rights of such other third parties, or other claims made against certain parties. It is not possible to determine the maximum potential amount of liability under these
indemnification obligations due to the Company&#146;s limited history of prior indemnification claims and the unique facts and circumstances that are likely to be involved in each particular claim. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Leases </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company
leases office spaces under non-cancelable operating lease agreements. These leases have remaining lease terms of approximately one to four years, which represent the non-cancellable periods of the leases. Lease payments consist primarily of fixed
rental payments for the right to use the underlying leased assets over the lease terms as well as variable payments for common area maintenance and administrative services. Variable lease costs were immaterial for the year ended December&nbsp;31,
2023. The Company has also received certain incentives from landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases. The Company&#146;s leases are
classified as operating leases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the year ended December&nbsp;31, 2023, the Company&#146;s operating lease costs
consisted of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended<BR>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term lease costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less sublease income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(132</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The cash payments made for operating leases, the weighted-average remaining operating lease
term and weighted-average discount rate used in the calculation for the Company&#146;s lease assets and lease liabilities as of December&nbsp;31, 2023 were as follows (in thousands, except years and percentages): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended<BR>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for amounts included in the measurement of lease liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating cash flows from operating leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended<BR>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average remaining lease term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average discount rate (as a percentage)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.55</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HINGE HEALTH, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2023, remaining maturities of operating lease
liabilities was as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Year ended December&nbsp;31:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2028</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: imputed interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,356</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Classified as:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities - current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities - non-current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Redeemable Convertible Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Redeemable convertible preferred stock outstanding as of December&nbsp;31, 2023 consisted of the following (in thousands,
except share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Redeemable convertible preferred Stock</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Authorized<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Issued and<BR>Outstanding<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Net<BR>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series Seed - 1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,078,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,078,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series Seed - 2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">493,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">493,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A-1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">975,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">975,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A-2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,112,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,112,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,500,586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,500,586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,253,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,253,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C-1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,258,620</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,258,620</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,354,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,314,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">326,457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">319,763</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series E</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,163,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,163,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">399,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,190,771</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,150,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">851,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">845,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company recorded its redeemable convertible preferred stock at the value of proceeds
received on the dates of issuance, net of issuance costs. The Company classified its redeemable convertible preferred stock outside of stockholders&#146; deficit because in the event of certain liquidation events that are not solely within its
control (including merger, acquisition, or sale of all or substantially all of its assets), the shares would become redeemable at the option of the holders. The Company did not adjust the carrying values of its redeemable convertible preferred stock
to the deemed liquidation values of such shares since a liquidation event was not probable at the consolidated balance sheet date. Subsequent adjustments to increase or decrease the carrying values to the ultimate liquidation values will be made
only if and when it becomes probable that such a liquidation event will occur. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HINGE HEALTH, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The holders of the Company&#146;s redeemable convertible preferred stock have
the following rights, preferences and privileges as of December&nbsp;31, 2023: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Conversion</I>&#151;Each share of
redeemable convertible preferred stock is convertible, at the option of the holder, into shares of common stock determined by dividing the applicable original issue price by the applicable conversion price in effect at the time of conversion. The
original issue prices and initial conversion prices of Series Seed-1, Series Seed-2, Series A-1, Series A-2, Series B, Series C, Series C-1, Series D, and Series&nbsp;E redeemable convertible preferred stock are $0.3435, $0.4174, $0.8280, $1.0350,
$2.26072, $7.3149, $6.76629, $43.7191, and $77.4642 per share, respectively. Each share of Series Seed-1, Series Seed-2, <FONT STYLE="white-space:nowrap">Series&nbsp;A-1,</FONT> Series&nbsp;A-2, Series B, Series C, Series C-1, Series D and Series E
redeemable convertible preferred stock is convertible into common stock on a one-for-one basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Shares of redeemable
convertible preferred stock will be automatically converted into shares of common stock upon the earlier of: (a)&nbsp;the sale of the Company&#146;s common stock in a firm commitment underwritten public offering pursuant to a registration statement
under the Securities Act of 1933, as amended, of which the price per share is not less than $77.46420 and with aggregate proceeds to the Company of $100 million or more; or (b)&nbsp;the date specified by written consent or agreement of the holders
of a majority of the then outstanding shares of redeemable convertible preferred stock, voting together as a single class. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Dividend Rights</I>&#151;The holders of Series Seed-1, Series Seed-2, Series A-1, Series A-2, Series B, Series&nbsp;C,
Series C-1, Series D, and Series E redeemable convertible preferred stock are entitled to receive non-cumulative dividends, on a <I>pari passu</I> basis, when and if declared by the board of directors. Such dividends shall be in an amount at least
equal to the dividend payable on each share of each series of redeemable convertible preferred stock determined as if all shares of such series had been converted into common stock calculated on the record date for determination of holders entitled
to receive such dividends. As of December&nbsp;31, 2023, no dividends have been declared or paid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Voting
Rights</I>&#151;The holders of redeemable convertible preferred stock have the right to one vote for each share of common stock into which such redeemable convertible preferred stock could then be converted and, with respect to such vote, holders of
redeemable convertible preferred stock are entitled to vote together with the holders of common stock as a single class. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The holders of Series A-2 redeemable convertible preferred stock, voting separately and as a single class, are entitled to
elect one member of the board of directors. The holders of Series B redeemable convertible preferred stock, voting separately and as a separate class, are entitled to elect one member of the board of directors. The holders of Series C redeemable
convertible preferred stock, voting separately and as a separate class, are entitled to elect one member of the board of directors. The holders of Series D and Series E redeemable convertible preferred stock do not have rights to elect member(s) to
the board of directors. The holders of common stock, voting separately and as a separate class, are entitled to elect three members of the board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Liquidation Preference</I>&#151;In the event of any liquidation, dissolution or winding up of the Company, whether
voluntary or involuntary, the holders of the Company&#146;s outstanding convertible Series C, Series C-1, Series D, and Series E redeemable convertible preferred stock are entitled to receive out of the proceeds of such liquidation, on a<I> pari
passu</I> basis, prior and in preference to holders of each other series of redeemable convertible preferred stock and common stock, an amount per share equal to $7.3149 per share (as adjusted for stock dividends, stock splits, combinations, or
other similar recapitalizations) for Series C, an amount per share equal to $6.76629 per share (as adjusted for stock dividends, stock splits, combinations, or other similar recapitalizations) for Series C-1, an amount per share equal to $43.7191
per share (as adjusted for stock dividends, stock splits, combinations, or other similar recapitalizations) for Series D, and an amount per share </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HINGE HEALTH, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
equal to $77.46420 per share (as adjusted for stock dividends, stock splits, combinations, or other similar recapitalizations) for Series E. After payment to holders of Series C, Series C-1
Series D, and Series E redeemable convertible preferred stock, the holders of Series B are entitled to receive out of the proceeds of such liquidation, on a <I>pari passu</I> basis, prior and in preference to holders of each other series of
Preferred Stock and common stock, an amount per share equal to $2.26072 per share (as adjusted for stock dividends, stock splits, combinations, or other similar recapitalizations). After payment to holders of Series B, Series C, <FONT
STYLE="white-space:nowrap">Series&nbsp;C-1</FONT> Series D, and Series E, the holders of all other series of redeemable convertible preferred stock are entitled to receive out of the proceeds of such liquidation, on a <I>pari passu</I> basis, prior
and in preference to holders of each other series of redeemable convertible preferred stock and common stock, an amount per share equal to $0.3435&nbsp;per share (as adjusted for stock dividends, stock splits, combinations, or other similar
recapitalizations) for Series Seed-1, an amount per share equal to $0.4174 per share (as adjusted for stock dividends, stock splits, combinations, or other similar recapitalizations) for Series Seed-2, an amount per share equal to $0.8280 per share
(as adjusted for stock dividends, stock splits, combinations, or other similar recapitalizations) for <FONT STYLE="white-space:nowrap">Series&nbsp;A-1,</FONT> and an amount per share equal to $1.0350 per share (as adjusted for stock dividends, stock
splits, combinations, or other similar recapitalizations) for Series A-2 redeemable convertible preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After
payment of the foregoing liquidation preferences in full, any remaining assets would be distributed among the holders of common stock on a pro rata basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Redemption</I>&#151;The holders of redeemable convertible preferred stock have no voluntary rights to redeem shares. If a
deemed liquidation event occurs and the Company does not effect a dissolution of the Company, the holders of redeemable convertible preferred stock have the right to require the Company to redeem the Company&#146;s redeemable convertible preferred
stock at the same amount as the liquidation amount. Although the redeemable convertible preferred stock is not mandatorily or currently redeemable, a deemed liquidation would constitute an event outside the Company&#146;s control in which the
Company would be obligated to redeem shares of redeemable convertible preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Equity Incentive Plans, Common Stock and Stock-Based
Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>2017 Equity Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In 2017, the Board adopted the 2017 Equity Incentive Plan (&#147;2017 Plan&#148;). The Board, at its sole discretion, is
responsible for the administration of the 2017 Plan. As of December&nbsp;31, 2023, there were 35,841,864 common shares authorized under the 2017 Plan, with 2,004,678 common shares available to be issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The 2017 Plan provides for the grant of various types of stock-based compensation awards, including, but not limited to RSUs,
PRSUs, incentive stock options, non-qualified stock options, stock appreciate right (&#147;SARs&#148;), and RSAs to qualified employees and non-employees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s amended and restated certificate of incorporation currently in effect authorizes the Company to issue up to
96,408,866 shares of common stock, par value $0.00001 per share, and 48,190,771 shares of preferred stock, par value $0.00001 per share. The holders of common stock are entitled to receive dividends whenever funds and assets are legally available
and when declared by the Board, subject to the prior rights of holders of all series of convertible preferred stock outstanding. No dividends were declared in the year ended December&nbsp;31, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each share of common stock is entitled to one vote. The holders of common stock are also entitled to receive dividends
whenever funds are legally available and when declared by the board of directors, subject to the priority rights of holders of all classes of redeemable convertible preferred stock outstanding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HINGE HEALTH, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Stock-Based Compensation Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Stock-based compensation expense for the year ended December&nbsp;31, 2023 was as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended<BR>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2023, there was approximately $586.5 million of unrecognized
stock-based compensation related to 24,939,494 of unvested RSUs and PRSUs subject to both a service-based vesting condition, or a performance-based vesting condition, or both, and a liquidity event. A liquidity event is satisfied on the earlier of:
(1)&nbsp;a change in control or (2)&nbsp;the effective date of an initial public offering of the Company&#146;s securities or (3)&nbsp;the acquisition of the Company by a special purpose acquisition company (hereinafter referred to as
&#147;liquidity event&#148;). As of December&nbsp;31, 2023, the liquidity event was not probable of occurring and no compensation expense was recorded related to these RSUs and PRSUs. The Company will record the stock-based compensation expense over
the remaining service period when the liquidity event is probable of occurring. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Units and Performance-Based
Restricted Stock Units </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">RSUs granted under the 2017 Plan vest upon the&nbsp;satisfaction of both a service condition
and a liquidity event. In general, RSUs vest 25% after one year, with the remainder vesting monthly over the following three years. The fair value of each RSU is based on the estimated fair value of the Company&#146;s common stock on the date of
grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Performance-based awards from prior years included service-based components and revenue targets that are generally
satisfied over seven years, subject to continued employment and a liquidity event.&nbsp;The fair value of each PRSU is based on the estimated fair value of the Company&#146;s common stock on the date of grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">During the year ended December&nbsp;31, 2023, the Company granted performance-based awards to each of the Chief Executive
Officer (&#147;CEO&#148;) and Executive Chairman (&#147;EC&#148;) with vesting milestones. Each of the aforementioned individuals will receive the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Milestone</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;PRSUs&nbsp;to<BR>Vest&nbsp;Upon&nbsp;Achievement<BR>of Each Milestone</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Execution of employment agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,416,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IPO event</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">944,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in control or IPO and a specified public market valuation of the Company&#146;s outstanding
common shares is attained</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,832,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The grant date fair value of the PRSUs granted in 2023 include a market condition and the
grant date fair value is based on a Monte Carlo simulation model. The assumptions for the Monte Carlo simulation model include an expected term of seven years, a risk-free rate of 4.51%, a discount for lack of marketability of 50%, volatility of
80%, and expected dividend yield of 0%. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HINGE HEALTH, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following is a summary of the Company&#146;s RSU and PRSU activity during
the year ended December&nbsp;31, 2023: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Restricted<BR>Stock Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR><FONT STYLE="white-space:nowrap">Grant-Date</FONT><BR>Fair Value<BR>(per share)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Performance-<BR>Based&nbsp;Restricted<BR>Stock Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average&nbsp;Grant-<BR>Date&nbsp;Fair&nbsp;Value<BR>(per&nbsp;share)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December 31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,315,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,040,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,287,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,386,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,088,387</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,287</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December 31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,514,658</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,424,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2023, the Company had $357.1 million of unrecognized stock-based
compensation expense related to RSUs. Because the RSUs vest upon the satisfaction of both the service-based and liquidity event, no stock-based compensation will be recognized until the liquidity event is probable of being satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The intrinsic value of the RSUs is $377.6 million as of December&nbsp;31, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2023, the Company had $229.4 million of unrecognized stock-based compensation expense related to
PRSUs. As the PRSUs vest upon the satisfaction of both the service-based and performance-based vesting condition, and a liquidity event, no stock-based compensation will be recognized until the liquidity event is probable of being satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The intrinsic value of the PRSUs is $319.2 million as of December&nbsp;31, 2023. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Options </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Stock options granted under the 2017 Plan generally expire within ten years from the date of grant, generally vest over four
years and are exercisable for shares of the Company&#146;s common stock. The Company has not issued stock options since March&nbsp;31, 2021. A summary of the stock options and changes during the year ended December&nbsp;31, 2023 are presented below
(in thousands, except shares, per share amounts and years): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Exercise<BR>Price Per<BR>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Remaining<BR>Contractual<BR>Life (years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balances at December&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,122,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">79,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(694,673</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options forfeited and expired<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53,871</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balances at December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,374,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">89,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercisable at December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,267,948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">87,177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options vested and expected to vest at December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,374,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">89,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Options expired consisted of 8,476 common shares at a weighted average price of $6.02 per share.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HINGE HEALTH, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The fair value of the options were expensed over the vesting period, on a
straight line-basis, as the services are being provided. The intrinsic value is calculated as the difference between the exercise price of the underlying stock option award and the estimated fair value of the Company&#146;s common stock. The total
intrinsic values of options exercised during the year ended December&nbsp;31, 2023 was $16.9 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">During the year
ended December&nbsp;31, 2023, the total grant date fair value of options vested was $1.5 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31,
2023, the Company had $0.7 million of unrecognized compensation expense related to unvested options which is expected to be recognized over a weighted-average period of 0.3 years. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Awards and Partial Recourse Promissory Notes </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In August 2020, the Company&#146;s CEO, EC and a former executive officer, each of which were related parties, purchased RSAs
for 2.9&nbsp;million shares of common stock in exchange for a partial recourse promissory note receivable with the principal amount of $5.5 million. The notes bear interest at a rate of 0.41% compounded annually. For accounting purposes, each
promissory note was determined to be non-recourse and, as such, the issuance of the promissory notes are considered non-substantive and will not be recorded in the consolidated financial statements until the promissory notes are repaid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since the RSAs have a purchase price, the Company accounted for the RSAs as stock options and applied a Black-Scholes
valuation model to estimate the grant date fair value of $1.39 per share with compensation expense being recognized over the term over which the shares vest. No RSAs were granted during the year ended December&nbsp;31, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The RSAs are considered issued because they are legally issued and have voting and dividend rights. The shares are included in
the outstanding common stock on the statement of redeemable convertible preferred stock and stockholders&#146; deficit as of December&nbsp;31, 2023 but are excluded in the calculation of basic net loss per share attributable to common stockholders
for the year ended December&nbsp;31, 2023 because the shares are considered to be contingently returnable shares for accounting purposes<I>.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">During the year ended December&nbsp;31, 2023, 0.3&nbsp;million RSAs were forfeited and returned to the Company for no
consideration by a former executive. The promissory note agreement was amended to reduce the remaining balance of the promissory note owed by the former executive to the amount outstanding related to the RSAs that had vested prior to the former
executive&#146;s departure. The agreement was also amended to extend the maturity date for the former executive from termination date to one month following email or written notice from the Company to the former executive that the Company has
submitted a revised draft registration statement on Form S-1 under the Securities Act of 1933, as amended, in response to comments from the U.S. Securities and Exchange Commission (&#147;SEC&#148;) to the Company&#146;s initial submission of the
Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2023, 2.6&nbsp;million RSAs were outstanding in exchange for $5.0 million
of principal outstanding on the promissory notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HINGE HEALTH, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Income Taxes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The components of loss before income taxes for the year ended December&nbsp;31, 2023 was as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended<BR>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">United States</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(99,847</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">International</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,698</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(108,545</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The federal and state income tax provision (benefit) is summarized as follows (in thousands):
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended<BR>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">International</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>Deferred</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">International</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(473</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(473</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s effective tax rate for the year ended December&nbsp;31, 2023 is less than
the U.S. federal statutory income tax rate of 21.0% primarily due to the valuation allowance on United States and foreign deferred tax assets and permanent differences, offset by state taxes as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended<BR>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">United States federal taxes at statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20.2</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Permanent differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign rate differential</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5.1</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.1</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Deferred income taxes reflect the net tax effects of (1)&nbsp;temporary differences between
the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, (2)&nbsp;operating losses and tax credit carryforwards and (3)&nbsp;foreign withholding taxes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HINGE HEALTH, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The tax effects of significant items comprising the Company&#146;s deferred
tax assets as of December&nbsp;31, 2023 are as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">77,590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalized research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accruals and reserves</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment and intangibles</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(130,327</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Right-of-use deferred tax liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,092</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign withholding tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(550</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,642</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Classified as:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2023, the Company has not provided foreign withholding taxes on the
undistributed earnings of its foreign operations because it intends to permanently reinvest such earnings outside of the United States. However, due to a one-time transaction, the Company accrued foreign withholding taxes of $0.5 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Based on the cumulative operating losses to date, the Company believes that it is more likely than not that the deferred tax
assets will not be realized, such that a full valuation allowance has been recorded against its United States federal and state net deferred tax assets as of December&nbsp;31, 2023. Furthermore, the Company believes the portion of the deferred tax
assets in a foreign jurisdiction that it operates in, is more likely than not to be realized in the future, and has released a $1.0 million valuation allowance against this foreign deferred tax assets. This foreign valuation allowance release is
offset by foreign withholding taxes of $0.5 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The valuation allowance increased $27.4 million during the year
ended December&nbsp;31, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net operating losses and tax credit carryforwards as of December&nbsp;31, 2023 are as
follows (in thousands, except for years): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Expiration&nbsp;Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating losses, federal (post December&nbsp;31, 2017)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">295,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">indefinitely</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating losses, federal (pre January&nbsp;1, 2018)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2033-2038</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating losses, foreign</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2036-2042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating losses, state</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">219,698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2025-2041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax credits, federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax credits, state</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HINGE HEALTH, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under Section&nbsp;382 of the Internal Revenue Code of 1986, as amended, the
Company&#146;s ability to utilize net operating loss carryforwards or other tax attributes, such as research and development tax credits (under IRC Section&nbsp;383), in any taxable year may be limited if it experiences an ownership change. During
the year ended December&nbsp;31, 2023, the Company completed a Section&nbsp;382 study and concluded that all tax operating losses and credits are available for use and not subject to a Section&nbsp;382 limitation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company files federal, state and foreign tax returns in jurisdictions with varying statutes of limitations. Due to the
Company&#146;s net operating loss carryforwards, income tax returns generally remain subject to examination by federal and most state tax authorities. All tax years since inception remain subject to examination by the tax jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s policy is to recognize interest and penalties associated with uncertain tax benefits as part of the income
tax provision and include accrued interest and penalties with the related income tax liability on the Company&#146;s consolidated balance sheet. To date, the Company does not have any liability for uncertain tax positions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Net Loss Per Share </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table presents the reconciliation of the numerator and denominator for calculating basic and diluted net loss per
share (in thousands, except per share data): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended<BR>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Numerator:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(108,141</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Denominator:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares used in computing net loss per share attributable to common
stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8.31</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Certain potentially issuable shares have been excluded from the calculation of diluted net
income per share during the year ended December&nbsp;31, 2023 because their inclusion would have been anti-dilutive. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended<BR>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilutive effect of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilutive effect of restricted stock units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilutive effect of performance restricted stock units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilutive effect on restricted stock awards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79,061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The RSAs are excluded from the calculation of net loss per share attributable to common
stockholders for the year ended December&nbsp;31, 2023 because they were issued in exchange for a promissory note as discussed in Note 9<I>, Equity Incentive Plans, Common Stock and Stock-Based Compensation</I> and will not be recorded in the
consolidated financial statements until the promissory notes are repaid. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HINGE HEALTH, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Related Party </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In August 2020, the Company&#146;s CEO, EC and a former executive officer, each of which were related parties, purchased RSAs
for 2.9&nbsp;million shares of Common Stock in exchange for a partial recourse promissory note receivable with the principal amount of $5.5 million. The notes bear interest at a rate of 0.41% compounded annually. Refer to Note 9, <I>Equity Incentive
Plans, Common and Stock-Based Compensation </I>for further details. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">During the year ended December&nbsp;31, 2023, the
promissory note agreement was amended to reduce the remaining balance of the promissory note owed by the former executive to the amount outstanding related to the RSAs that had vested prior to the former executive&#146;s departure. The agreement was
also amended to extend the maturity date for the former executive from termination date to one month following email or written notice from the Company to the former executive that the Company has submitted a revised draft registration statement on
Form S-1 under the Securities Act of 1933, as amended, in response to comments from the SEC to the Company&#146;s initial submission of the Registration Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2023, 2.6&nbsp;million RSAs were outstanding in exchange for $5.0 million of principal outstanding on
the promissory notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the Company&#146;s CEO and EC, principal plus interest is due upon the earlier of: (i)&nbsp;the
eighth anniversary of the note&#146;s issuance, (ii)&nbsp;within ninety days of the employee&#146;s termination, whether voluntary or involuntary, (iii)&nbsp;the date of a Corporate Transaction as defined in the 2017 Plan, (iv)&nbsp;upon insolvency
of the borrower, (v)&nbsp;upon the sale, transfer or disposition of the pledged shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company engages the law firm
of Perkins Coie LLP, a related party, for various legal services. Fees incurred for services provided by Perkins Coie LLP for the year ended December&nbsp;31, 2023 were $2.3 million, of which $1.0 million were included in accounts payable and
accrued liabilities included in the consolidated balance sheet. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Employee Benefit Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company sponsors a qualified 401(k) defined contribution plan covering eligible employees. Participants may contribute a
portion of their annual compensation limited to a maximum annual amount set by the Internal Revenue Service. Employer contributions to the plan are discretionary. During the year ended December&nbsp;31, 2023 the Company contributed $3.1 million to
this plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Subsequent Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On April&nbsp;1, 2024, the Company&#146;s Board approved the seventh amended and restated certificate of incorporation
(&#147;certificate of incorporation&#148;) to include provisions which immediately upon the effectiveness of the IPO, the authorized shares of the Company shall be reclassified into authorized shares of Class&nbsp;A common stock, $0.00001 par value
per share (&#147;Class A common stock&#148;), and authorized shares of Class B common stock, $0.00001 par value per share (&#147;Class B common stock&#148;), with (i)&nbsp;the authorized number of shares of Class B common Stock being equal to the
number of shares held by the Company&#146;s CEO and EC&nbsp;or their affiliates (together, the &#147;founders&#148;) shares and preferred shares converted into common shares as described in Note 8. <I>Redeemable Convertible Preferred Stock</I>, and
(ii)&nbsp;the authorized number of shares of Class&nbsp;A common stock being equal to all then authorized shares of common stock, minus the number of founder shares described in (i)&nbsp;above.&nbsp;The Class&nbsp;A common stock and the Class B
common stock will each be a separate series within the class of common stock, and not separate classes of stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HINGE HEALTH, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Except as required by law, each share of Class&nbsp;A common stock will
entitle the holder to one vote for each share of Class&nbsp;A common stock held and each share of Class B Common Stock will entitle the holder to 15 votes for each share of Class B common stock held, in each case, on any matter submitted to the
stockholders of the Company for a vote or approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any share of Class B common stock will automatically convert into
Class&nbsp;A Common Stock upon certain transfers of such share. In addition, Class B common stock held by non-founders will automatically convert into Class&nbsp;A common stock on the seven-year anniversary of the effective date of the registration
statement of which this prospectus forms a part. Further, Class B common stock held by founders will automatically convert into Class&nbsp;A common stock at the time the founder is no longer an employee or director of the Company, or upon the
founder&#146;s death or disability. With respect to all holders, Class B Common Stock shall convert to Class&nbsp;A Common Stock when such holder ceases to hold at least 50% of the capital stock of the Company that such holder beneficially owned as
of the effective date of the registration of which this prospectus forms a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On April&nbsp;11, 2024, the Company
announced a plan to reduce its current workforce by approximately 160 individuals to simplify its operations and better align its resources with its priorities. Restructuring charges were $7.5 million, the majority of which were incurred in the
second quarter of fiscal year 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On April&nbsp;25, 2024, the Company amended its charter to increase the authorized
number of shares of common stock from 96,408,866 to 98,109,595. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><I>&#8195;&#8195;&#8195;Shares </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g829170g70a04.jpg" ALT="LOGO" STYLE="width:2.52941in;height:1.00572in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><I>Class&nbsp;A Common Stock </I></P>
<P STYLE="font-size:150pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Preliminary Prospectus </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:150pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:14pt">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="36%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:14pt">
<TD VALIGN="top"><I>MORGAN&nbsp;STANLEY</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><I>BARCLAYS</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><I>BOFA&nbsp;SECURITIES</I></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&#8195;&#8195;&#8195;&#8195;, 2025 </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&#8201;13. Other Expenses of Issuance and Distribution </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth the costs and expenses, other than underwriting discounts and commissions, payable by the
registrant in connection with the sale of the Class&nbsp;A common stock being registered. All amounts are estimates except for the U.S. Securities and Exchange Commission (the &#147;SEC&#148;) registration fee, the Financial Industry Regulatory
Authority (&#147;FINRA&#148;) filing fee and the &#8195;&#8195;&#8195;&#8195; listing fee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount&nbsp;to&nbsp;Be<BR>Paid</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer agent&#146;s fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Blue Sky fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">To be completed by amendment. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&#8201;14. Indemnification of Directors and Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Section&nbsp;145 of the Delaware General Corporation Law provides that a corporation may indemnify directors and officers as
well as other employees and individuals against expenses (including attorneys&#146; fees), judgments, fines, and amounts paid in settlement actually and reasonably incurred by such person in connection with any threatened, pending, or completed
actions, suits, or proceedings in which such person is made a party by reason of such person being or having been a director, officer, employee, or agent to the registrant. The Delaware General Corporation Law provides that Section&nbsp;145 is not
exclusive of other rights to which those seeking indemnification may be entitled under any bylaw, agreement, vote of stockholders or disinterested directors or otherwise. Article 9 of the registrant&#146;s amended and restated certificate of
incorporation, to be in effect immediately prior to the completion of this offering, provides for indemnification by the registrant of its directors, officers and employees to the fullest extent permitted by the Delaware General Corporation Law. The
registrant has entered or will enter into indemnification agreements with each of its current directors, executive officers, and certain other officers to provide these directors and officers additional contractual assurances regarding the scope of
the indemnification set forth in the registrant&#146;s amended and restated certificate of incorporation and amended and restated bylaws, each to be in effect immediately prior to the completion of this offering, and to provide additional procedural
protections. There is no pending litigation or proceeding involving a director or executive officer of the registrant for which indemnification is sought. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Section&nbsp;102(b)(7) of the Delaware General Corporation Law permits a corporation to provide in its certificate of
incorporation that a director or officer of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or officer, except for liability (i)&nbsp;for any
breach of the director&#146;s or officer&#146;s duty of loyalty to the corporation or its stockholders, (ii)&nbsp;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii)&nbsp;for unlawful
payments of dividends or unlawful stock repurchases, redemptions or other distributions, or (iv)&nbsp;for any transaction from which the director or officer derived an improper personal benefit. The registrant&#146;s amended and restated certificate
of incorporation, to be in effect immediately prior to the completion of this offering, provides for such limitation of liability. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The registrant maintains standard policies of insurance under which coverage
is provided (a)&nbsp;to its directors and officers against loss rising from claims made by reason of breach of duty or other wrongful act and (b)&nbsp;to the registrant with respect to payments that may be made by the registrant to such officers and
directors pursuant to the above indemnification provision or otherwise as a matter of law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The proposed form of
underwriting agreement to be filed as Exhibit 1.1 to this registration statement provides for indemnification of directors and officers of the registrant by the underwriters against certain liabilities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&#8201;15. Recent Sales of Unregistered Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since January&nbsp;1, 2021, the registrant made sales of the following unregistered securities: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Option and Common Stock Issuances </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since January&nbsp;1, 2021, the registrant granted to its employees, consultants, and other service providers options to
purchase an aggregate of 32,401 shares of its common stock under its 2017 Equity Incentive Plan (as amended, the &#147;2017 Plan&#148;), at an exercise price of $15.89 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since January&nbsp;1, 2021, the registrant granted to its employees, consultants, and other service providers restricted stock
units covering an aggregate of 18,389,218 shares of its common stock under its 2017 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since January&nbsp;1, 2021, the
registrant granted to its employees performance-based restricted stock units covering an aggregate of 11,427,123 shares of its common stock under its 2017 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since January&nbsp;1, 2021, the registrant issued and sold to its employees, consultants, and other service providers an
aggregate of 2,560,765 shares of its common stock upon the exercise of stock options under its 2017 Plan, at exercise prices ranging from $0.30 to $15.89 per share, for a weighted-average exercise price of $1.01. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since January&nbsp;1, 2021, the registrant issued 603,074 shares of common stock in connection with certain acquisitions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Redeemable Convertible Preferred Stock Issuances </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In January 2021, the registrant sold an aggregate of 69,533 shares of its Series D redeemable convertible preferred stock to
two accredited investors at a purchase price of $43.7191 per share, for an aggregate purchase price of approximately $3.0&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In October 2021, the registrant issued an aggregate of 245,806 shares of its Series D redeemable convertible preferred stock
to seven accredited investors in connection with an acquisition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Between October and December 2021, the registrant sold
an aggregate of 5,163,674 shares of its Series E redeemable convertible preferred stock to two accredited investors at a purchase price of $77.4642 per share, for an aggregate purchase price of $400.0&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The registrant believes these offers, sales, and issuances were exempt from registration under the Securities Act in reliance
upon Section&nbsp;4(a)(2) of the Securities Act or Regulation D promulgated thereunder, or Rule 701 promulgated under the Securities Act as transactions by an issuer not involving a public offering or pursuant to benefit plans and contracts relating
to compensation as provided under Rule 701. The recipients of the securities in each of these transactions represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any
distribution thereof, and appropriate legends were placed upon the stock certificates issued in these transactions. All recipients had adequate access, through their relationships with the registrant, to information about the registrant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&#8201;16. Exhibits and Financial Statement Schedules </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">See the Exhibit Index attached to this registration statement, which Exhibit Index is incorporated herein by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Schedules not listed above have been omitted because the information required to be set forth therein is not applicable or is
shown in the financial statements or notes thereto. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&#8201;17. Undertakings </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(a)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors,
officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act
and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer, or controlling person of the registrant in the
successful defense of any action, suit, or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered hereunder, the registrant will, unless in the opinion of its counsel the matter has
been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of
such issue. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(b)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The undersigned registrant hereby undertakes that: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">For purposes of determining any liability under the Securities Act, the information omitted from the form of
prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of
this registration statement as of the time it was declared effective. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">For the purpose of determining any liability under the Securities Act, each post-effective amendment that
contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="91%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit<BR></B><br><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit Description</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;1.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Underwriting Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;3.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Seventh Amended and Restated Certificate of Incorporation, as currently in effect</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;3.2*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Amended and Restated Certificate of Incorporation, to be in effect immediately prior to the completion of this offering</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;3.3*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Bylaws, as currently in effect</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;3.4*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Amended and Restated Bylaws, to be in effect immediately prior to the completion of this offering</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;4.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Reference is made to Exhibits&nbsp;3.1 through 3.4</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;4.2*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Common Stock Certificate</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;4.3*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Fourth Amended and Restated Investors&#146; Rights Agreement, dated October&nbsp;22, 2021, by and among the Registrant and the investors listed therein</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;5.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Opinion of Latham&nbsp;&amp; Watkins&nbsp;LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;10.1*#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">2017 Equity Incentive Plan, as amended, and forms of agreements thereunder</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;10.2*#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">2025 Incentive Award Plan, and forms of agreements thereunder</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;10.3*#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Employee Stock Purchase Plan</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;10.4*#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Program</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;10.5*#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Indemnification Agreement between the Registrant and each of its Directors and Executive Officers</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;21.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">List of subsidiaries</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;23.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Consent of Deloitte&nbsp;&amp; Touche LLP, independent registered public accounting firm</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;23.2*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Consent of Latham&nbsp;&amp; Watkins&nbsp;LLP (included in Exhibit&nbsp;5.1)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;24.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Power of Attorney (reference is made to the signature page to the Registration Statement)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>107.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Filing Fee Table</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">To be filed by amendment. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">#</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Indicates management contract or compensatory plan. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration
statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Francisco, State of California, on the &#8195;&#8195;&#8195;&#8195; day of &#8195;&#8195;&#8195;&#8195;, 2025. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>HINGE HEALTH, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel Perez</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Daniel Perez and
James Budge, and each of them, his or her true and lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, with full power of substitution and resubstitution, for him or her and in his or
her name, place, and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement and any and all additional registration statements pursuant to Rule&nbsp;462(b) of the
Securities Act of 1933, as amended, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto each said <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and agents full power and authority to do and perform each and every act in person, hereby ratifying and confirming all that said <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents or either of them or their or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the
following persons in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Daniel Perez</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Chief Executive Officer and Director (Principal Executive Officer)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="right">, 2025</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">James Budge</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Chief Financial Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Principal Financial and Accounting Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="right">, 2025</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Ben Blume</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="right">, 2025</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Kristina Leslie</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="right">, 2025</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Gabriel Mecklenburg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="right">, 2025</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Elliott Robinson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="right">, 2025</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Teddie Wardi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="right">, 2025</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g829170g00u01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g829170g00u01.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_X8&?:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^87!P;&EC
M871I;VXO<&]S='-C<FEP=#PO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET
M;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F
M.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/F<P,'4P,3PO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @
M(" @(#QD8SID97-C<FEP=&EO;CX*(" @(" @(" @(" @/')D9CI!;'0^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M<F5P86ER(CY&:6QE
M($YA;64Z(" @(" @(" @(" @(" @56YT:71L960M,28C>$$[57-E<FYA;64Z
M(" @(" @(" @(" @("!R<C,S,C@S-"8C>$$[3&]C86P@5&EM93H@(" @(" @
M(" @(" @,30M3F]V+3(P,C0@,#,Z-3DZ,# F(WA!.T535"!4:6UE.B @(" @
M(" @(" @(" @,3,M3F]V+3(P,C0@,3@Z,CDZ,# F(WA!.U-C<FEP="!697)S
M:6]N.B @(" @(" @(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @
M,38N,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($%R='=O<FLF(WA!
M.R8C>$$[XH"B(#<Y-"!B;&%C:R!T97AT(&-H87)A8W1E<G,@8VAA;F=E9"!T
M;R!O=F5R<')I;G0N)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E
M('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @(%!O<'!I
M;G,M0F]L9"8C>$$[(" @(" @(" @($%R:6%L350F(WA!.R8C>$$[5&AE(&9O
M;&QO=VEN9R!C;VQO<G,@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C
M>$$[(" @(" @(" @($--64LF(WA!.R @(" @(" @("!";&%C:R8C>$$[)B-X
M03LM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TF(WA!.SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @
M(" @(" @(#PO9&,Z9&5S8W)I<'1I;VX^"B @(" @(#PO<F1F.D1E<V-R:7!T
M:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @
M(" @(" @("!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"\B"B @(" @(" @(" @('AM;&YS.GAM<$=);6<](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]G+VEM9R\B/@H@(" @(" @(" \>&UP.DUE=&%D871A
M1&%T93XR,#(T+3$Q+3$U5# Q.C4V.C0V*S U.C,P/"]X;7 Z365T861A=&%$
M871E/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C R-"TQ,2TQ-50P,3HU
M-CHT-BLP-3HS,#PO>&UP.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z0W)E
M871E1&%T93XR,#(T+3$Q+3$U5# Q.C4V.C0U*S U.C,P/"]X;7 Z0W)E871E
M1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!);&QU<W1R
M871O<B!#4S8@*%=I;F1O=W,I/"]X;7 Z0W)E871O<E1O;VP^"B @(" @(" @
M(#QX;7 Z5&AU;6)N86EL<SX*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \>&UP1TEM9SIW:61T:#XR-38\+WAM<$=);6<Z
M=VED=&@^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.FAE:6=H=#XQ-#0\
M+WAM<$=);6<Z:&5I9VAT/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIF
M;W)M870^2E!%1SPO>&UP1TEM9SIF;W)M870^"B @(" @(" @(" @(" @(" @
M(#QX;7!'26UG.FEM86=E/B\Y:B\T04%14VM:2E)G04)!9T5!4T%"24%!1"\W
M44%S54=H=F1'.7IA1SEW241-=4U!0311:VQ.02LP04%!04%!0D%!4T%!04%!
M14$F(WA!.T%10DE!04%!05%!0B\K-$%$:T9K8C)*;$%'5$%!04%!068O8D%)
M44%"9U%%0D%514)G549"9VM'0E%92D-W9T="9V=,1$%O2T-W;TLF(WA!.T1"
M04U$07=-1$%W441!-%!%03A/1$)-5$9"451%>'=B1WAS8TAX.&9(>#AF2'@X
M9DAW14A"=V-.1$$P645"05E':%521E)O9DAX.&8F(WA!.TAX.&9(>#AF2'@X
M9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF
M2'@X9B\X04%%46=!:T%%04%W15(F(WA!.T%!25)!44U2068O14%A24%!04%(
M05%%0D%114%!04%!04%!04%!449!=TE'05%!2$-!:TM#=T5!06=)1$%114)!
M445!04%!04%!04$F(WA!.T%104-!=U%&0F=C24-1;TQ%04%#05%-1$%G44-"
M9V-$0D%)1T%N34)!9TU20D%!1DE227A15D5'13)%:6-9155-<$=H0GA7>%%I
M4$(F(WA!.U5T2&A->%II.$-2>6=V16Q1>E)4:W%+>5DS4$-.55%N:S9/>DYH
M9%5:2%1$,'5)24IO34I#:&=::$I21E)Q4S!6=$Y62T)R>30O4$4F(WA!.S%/
M5#!:6%=&;&%7,7AD6&PY5UHR:'!A;71S8E<U=EDS4C%D;F0T95AP-V9(,2MF
M,T]%:%EA2&E);4MI-'E.:F\K0VLU4U9L<&59;5HF(WA!.W%B;DHR96XU2VIP
M2U=M<#9I<'%Q=7-R839V;U)!04E#05%)1$)1545"45E%0T%-1&)114%!:$5$
M0D-%4TU514954DYH26=:>&=:17DF(WA!.V]B2'=&34A2-%-.0T962FEC=D5Z
M2D121&=H85-5>5=I63=,0T(S4%-.94I%9WAD56MW9TI#:&=:2FI:1D=I9&MD
M1E4S.'%/>G=Y9W F(WA!.S K4'IH2E-K=$U453504FQD65=6<&)81C%E6#%2
M;%IM9&]A5W!R8D<Q=6(R4C%D;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.
M:F\F(WA!.RM$;$I75VPU:5IM<'5C;EHV9FMQ3VMP86%N<4MM<7$V>71R<2MV
M+V%!07=$05%!0T5135)!1#A!.54T<3=&6%EQ-T9867$W1EA9<3<F(WA!.T98
M67$W1EA9<3=&6%EQ-T9867%W>C@U1D1F;&YR;TQ"9C-56G%F85I$5#9C<GDO
M4S0K<2]U<&4U:78X07IJ:3%W=FM'+TU#2DI**VPF(WA!.U@K1U)I:3A41&(X
M:GE#=G5&<5%+8FYB8G)G=SAN2#=.+W5Z-R]W0D%:3C5I.'DO;5AP970S>39B
M-5146$Y#4TM*-U,T:74T<E=934DF(WA!.S5';D1)>&UE5#1G9U5,1W S+V%Y
M,3)#1F9Z<"MB459Y;C5C1GE);S-19G!M>DA+4FA'6&HS6&)H>68T=2](,WA6
M1V8T;B]-=&)E5U4F(WA!.RM3;&58-GA+:TYU3E1T;&(P131I3U)M24LQ:W%X
M;T]L2TAX35I%:FM'=DI+42MK8UAX<$172&UB.#(Q3"]8+TIS36\R15IG=C=E
M2VPF(WA!.T=!66YK.'1A9S%!,G!4=EAA06Q0=6%H:WDY62]A:%8X,F9N5W%2
M0B]),79*23!P.5ER<4YS:7)#<D-N1W-J17,V:S<O04Q.3VAR45<F(WA!.W53
M:68X6F9M>6)4,4(K6%%&>49"83-B5V)-0W!A445+-%)G84)53S1(,G8X;F16
M;RMC4'IA3C9S82]L.'$R9G)C5VY/<C)J3UEE9D@F(WA!.VYW0VII94HU,#5(
M<%1Q831Q>41Y<')8;3=5:F-F-&<X=69O1# P:6%$+U198C,Q2&9N-G%(,&=V
M2# K2S<O=&-V8D9745EQ-T9867$F(WA!.S=&6%EQ-T9867$W1EA9<3=&6%EQ
M-T9867$W1EA9<3=&6%EQ-T9867$W1E5,<6UQ5T=L,DUL.7%%=V=T26EO:VU9
M16AE8FA&<GA"4#(F(WA!.VU'2W!0<% U:"M43E=U24Q7=S%33U<U=5-O9V=:
M6DDU2$Q#66EI4TMJ9$Q743E0,F9C5E93<C@V-494.'-.8UIU:%-"9G!A-6I5
M9G(F(WA!.WEV3#E,:F%W,6EK>&HO;DAT64EV>39U;G5,;C9T1RMQ<S-Q.'A(
M4G5.=7%P>5 X04]W0S W,7!K8U!*<#=/1EDO:6\K9&15+TQ:4'HF(WA!.T(Q
M2TA5=DU7=&57=&1A1WET2FTP-E(T66)K2WEY>$5E:$A->DUV,6A9,F%7;7I5
M6&)L;'IN<V5K,4@X;4QV54E:-&9Z1#AZ9E=R:5DF(WA!.TQB5')C6&9/0E=5
M0DDQ:VQT>DE)+W="*W%J:U-F:4Y4.6\T<3!M=2]K-4-44&0O;5 U<65/-71P
M+U%G=34W-E9&:FY2-V8Q-"]W1%(F(WA!.VU03#=42E9T:C%(55EQ;6QV-7 O
M2S8Y45=T;"M96&U3-VQS-U)B:5I9-VDU4U$R,71%6EIP,UHT27=X5T9J2DE!
M951C84MP8C1407<F(WA!.W9Q5W%E2&E.,TEE-'%-;78O;&I!-&AU=GI$.'E8
M37E45%)+,%5L-E=I6D915C1R07I&;%=25C5,5W!9-U5R465(-6QR+TQF,'!F
M3G$F(WA!.S8X,69K+V-2:35U+T\O;4-"4'%H5U53>3-,9V]33&%E36=W4S%9
M>6-4248K16UH1E%.:S1V37-J<#<V>2MA*S,X-69L8DY95&HO2&XF(WA!.VUE
M,V=S-%)D4UAK:S$Q>6MI95@P0DEP.4)Y4GIN455#:G-A5D1(1#1F;55F;#EQ
M-'!F3D18=79F:SEC,F1V;W0W*UE/=DE,1G!B-'@F(WA!.U%T9GAC-$I%:FUI
M4V-.0DE'14UC4W-G6&I2:7A!0DY-35DP1S-(1&A&8S!4.6$O2C5:2&AG.#1E
M64Q3.&Q7,W10,&=J,W-D>6EH4TDF(WA!.UE233EV-FYP>DYE*W-Q-WAK,$LP
M5E%-;7I383)(-4Q4-FYD,W<X*RM:<F953E-,;2]D-35B9&M-,$QN9WII,E%-
M0TE65E96;41-:4LF(WA!.TMI;4)75V524$]F-5<V3WDS;' U,#%J54QA5F9Q
M149N<6I817-#2&U*:UI)>$%G43A*1D-T5V=39S9J84UP06,R=DIL:D-U23@R
M6%(F(WA!.R]N4"M7<VY$:')&9E5B9VXK:EA1<3-W:G9&+VQR:V9&:C-T63%E
M33EF=F-V-7HO;&]7:E5A>'9-=U=/='1D0W!)56IR1C1/369&:78F(WA!.S5V
M2'1V>CDW:R]/9CAT6&M33F19<3AH54E0<3$P2VPK4$AR1C,U:DAX63DV:E8T
M>C$K.4\O3&YN3'DO-6I-,S9(=4=U16AJ:6UA4F\F(WA!.W!9;$M43DEQ1F96
M5D,R.$Q!,'E56D$X;7I(;&I0:VY74V)(67$W1EA9<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T960RLP*W<Q0S).<F8F(WA!.S(P5C-B37ES,$4V3$EH84YG-D5Q
M-$EQ<DM'2&=C5E-V5"]),VMN5' P=4Y0.'8V8EHS16)I4T]A,W,T26Y6,4)5
M37))9TE)1'-+*S4F(WA!.WA6:#,O3U$Y-39(-6101E=N,74W9V@K9$]5=FHO
M=T%66E9M3WIH9&]'<U)69GE-=&)I,"],0W=L:6I%:W0Q3DY.-F).=RM%>FU)
M;70F(WA!.T0P5D]1.&-/265L;&]25TE,4$TS-6AE6F1-.#)85VMJ47)$5TY,
M4S4P*T<Q9CE),G1V8U)46%12*VXV<T5J>7E&;6Q,3D8K-U0W1F0F(WA!.S8Q
M1FIL<C0O4&XU<7DS06=J+TPK35-W;$1E=T17<DHS4DI&6&IS04-U-6-I;S-#
M8F1D;%9A,#@R9FTS4&%--RM3;TEP6DEZ3&)U3E0F(WA!.W0U14AX2GAI64PY
M;VQ78S@Q8FIS4$A"2S8R67I*03(S2TMU9DTS-6YM,$%T+TIK85A5:TI:6&)5
M8F5227!A4%)85#DQ>C-69G-V,&(F(WA!.W)S8VAX4S=M:S5-;&94.7%4,EAM
M3#@V8D)W8G9Y9EI45W!:;6MJ<W!O-%AA4U-2:%5F=G V8VU:6%II=3-X5CA2
M2&EN,TY9>5IH>FDF(WA!.T4W;3@P9FU7<%9O+TI+>4E42W)2:E9,65 X1E!3
M97!53'AF9F)C:G94=DQI;#-.:'E:4#5V9C$O2$YQ+SAX9FU#,6<W<#5&4S=U
M574F(WA!.S0Q:'1*3E1T5E5X04Y)3&YM>4U&36-I24].3U94561-;$5K.'<R
M=VQ),UEP2W),6'9Z3&)6;C%A*R],4T-/-TE3>E<U9S%'>&4X1FTF(WA!.T]5
M:FHQ;31C,#E107)'4V=Q86YX>51.15 U>"].-6)L1B\U5C5',$AO3DDW2G).
M<50V<&HU<$=/4THP66-(4$=L5%5%<4ML5E9(;6(F(WA!.S@R6#1,+V<K2T0Q
M;W!'37!V8F5B-G9):S=Q<71'2EEV5SE304EW;S9!3G-72#=);&1B35IK,71Z
M5C5F3E U;'@X,%1Y44IY:$MP34XF(WA!.U1T67A)0GE!9F=E6E1L44AJ>4Y+
M.61S:'A3-VUK-4UN.'HW47!P-6DO37%3-# O-C$U1VE:03@S,6E986QB1F]7
M4TYF5&U24T0O93@F(WA!.S-4:4159'I4<DM.;FU'>D=:165O56=O+U!0-790
M8W<R.&XU8V96>DMY;'!Z<3ER3D=S64DY56YI:2]%06%"83<Y4E5!-4IS43=E
M8V8F(WA!.WI5;&U7-4@U5TI.3VQ"-G@Q93!6,%I/83AA>E%X=#A03F='5W%K
M365*24].3%%::#5F,5AZ9&9A;&5*<2MH<'!';G=Q9W1:9G)59'DF(WA!.S@W
M<T%73DDV8T949&%-3BMU2W O:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER
M<U93+U9D4W9B2U,Q5S(P>30Q1EHS6EI48G1#=G F(WA!.T)53$)M.6%3269%
M4E1R+T-O2G!J2U)(4S%$.4]A;B\Q3#)O9CAJ3$0O<W%W8U(W:V-2-VHY;C8S
M9G!Z52]W1'%8=%$O-4=72"]:5FHF(WA!.WA(=5AI4&-F<R]7.%HO-7E..'<S
M1GIA-DYP8W1J8U=,8S5B<#!U1W0R-4)123!).4-78BM:=71-<'EY9&(R;%!9
M0VYP4&M38E5D23@F(WA!.VTV3G T,$<K8W=7:UA.,65X0W,W<GIC:FQC<3%#
M>DAQ0FQK0U%/5&Y98FI!0W5N;"MT4C%,>79O97!A<%!Q=#$U4C%)-FAD4&%Y
M>GHF(WA!.W@S:T5*85-X8FQB4%-+*U)E55(V1VQC;'A(=2LU<S1J,T@W4#%P
M3E K5D@U9E1Q-GIE47(V4EI::F-Y2S$U15$P<#5%<U(K:TMF-W,F(WA!.V)B
M<&IX2'4K-65).7@K>CEB2F9,96XR6&QM,&US.40X<#,Y;F)4>6EE4TI:-TXQ
M-6E.25%2-FPT+T@Y,T5I,$<R,E!%935E23EX*WHF(WA!.SEA8B]!2V,Q4"]Q
M6'11+S5'5T@O04=663A2-VPT:C-(-U Q=2]4;7 O=T15=F%H+WE-<U K>7)(
M:5!C=D5E-"]:*W0S-F,Q4"]Q6'0F(WA!.U$O-4=72"]:5FIX2'58:5!C9G,O
M5S<Y3V%N+S%,,F]F.&I,1"]S<7@T:C-,>$AU4#)F<F0K;DY4+W=#<&4Q1"]!
M2D=72"]:5FIX2'4F(WA!.UAI4&-F<R]7-SE/86XO,4PR;V8X:DQ$+T%,2W-E
M23EY.%(W:CEN-C-F<'I5+W=$<5AT42\U1U=(+UI6:GA(=5AI4&-F<R]7-SE/
M86XF(WA!.R]W0E,Y<4@O04--<U K>7)(:5!C=D5E-"]:*W0S-F,Q4"]Q6'11
M+S5'5T@O04=663A2-VPT:C-(-U Q=2]4;7 O=T15=F%H+WE-<U F(WA!.RMY
M<DAI4&-V164T+UHK=#,V8S%0+W%8=%$O-4=72"]:5FIX2'58:5!C9G,O5S<Y
M3V%N+S%,,F]F.&I,1"]S<7@T:C-,>$AU4#)F<E0F(WA!.V9*33-9<3=&6%EQ
M-T9867$W1EA9<3=&6%EQ-T9867$W1E5U6'I*-61A;DA68DTQ;T)3-&E.83AA
M9G1D+U58-W@T-'%M3TMV;3,X,$@F(WA!.U!M>C@V3%11-#(U=U%35S)N:VIO
M05<Y4V,O-T@Q1W(X<WAC;3AQ9%!Q9C-M8U(W;G1V;F=A0R]L8GI(1'%K.'=S
M9C!B24Y3:G1N6#$F(WA!.UDW6F\U05=I5U-S87561%5*,DY..'EN8U!)1C%F
M.'%O1W5,2B]W03 O3D-G1C)H4DIR>$1(2$%K>7E+1T9Q5DY'1&M5<#EL44]M
M-G$F(WA!.W1:*UI0>6MM9451*V1V36PO3&11,VPP;6UT3$YS<&EV4%=99W=2
M<7)R-FMN2#0V,59$,$9C0DY#,%-.06LY17AS=%<O3&4U=6MG9S@F(WA!.S<K
M6D)C14QB4EA0<EA":W5E8WHS2T-Q=T8R-&5Q63$U0558665/56U54V5:8T]7
M5$A-,DI%93<U;V$Y;"]*,F538E5"-78Q=TYF>' F(WA!.T1C4E%T8T$S5%<X
M4U)Q6D$Q=%=2>CA*<7AO5RMN26YG-WDQ131R-'5+5R]V,RMX9&0S=C56>F%B
M3DYQ6&YZ>D=B4T=&2G(R,G5*-VDF(WA!.U91:VI2;T))9W0S5FE';E%F1%@X
M0V-K0D=7,6QS:$-%>E%L3#4O:G95<G)64'EA5TIR9'90978R.7!*-G,T<VQE
M.#E.87AP8W5E3%<F(WA!.W)';U=66"M+<'%4,6%U5#A,>DQA9$M0-3!V;717
M-R]**WEU6DQY4'IJ<CA&>$9(1D9D6'DK=$9-<UE%26A$<V)62EA2=SA94V=:
M84<F(WA!.V\R<6-(9VIV2VI41'9K9W(W>C4K5T57<S9L66%X-3(X,5=J,DE7
M1#9S-WIP2$M):SE&:TMO:VI&,SE,,4A,:$%E63<X<44T+TUR*U8F(WA!.W,S
M>%,K86$R=FY8.'!7:FYU9CA!2'9M3E!39VEK=5EP2G(U+U$T>E)X1C))9V1A
M=$PK-V5J1F9I4$AA:$(X4'I,26%F*VQ,-7-U;"\F(WA!.S5Y02],0S-V.5%S
M8G952G)A8E1,:6$R=6EB5V5603A,;$-W84)*87%X5G5*.70V8E9M,W%K;C4K
M9FQ42&-,0DYR1'A02DA(3D@V;&XF(WA!.V5P>5-9,%)G1$-$4G%G9VM524E)
M,GA69F-F;GHK5D9T0CE9;3$P3$131G51=&)X=')L1VMI,D5*4'A,1W@Y=2M+
M<E K5C@O;&TP<V,F(WA!.V-7;U13=$Q0.5A4:F$S03-6:U(S4$I&;W%.249.
M9#8Y06-66E U53@U*U=V3FQJ3&8K6#=Z-C=A=WE#1U-4,#59<4]9,6Q!-'ER
M1S,F(WA!.S)*1E!41E4V>%9#>6%T<%57;WAA6DIE=TIQ539M4T=Y859"3S9$
M:U-Y>&LX,DAW3G5",D]#,D)Y4D5U1WAX9'I7<C9V<'5J-F10<5<F(WA!.W!4
M<F)73G-V2V%:<6M!16=$64%K:VMG04%62GA*<&-M4TU);55J44-8*U<O3C)L
M-BLQ,41B4C-.<F4R4$0V-UE8<T0R.#A);#5E:U<F(WA!.U9H5#DT<6-H46YA
M;&%927ET<G<V:4]3=TQ"2$U%56YE4V(S67$W1EA9<3=&6%EQ-T9867$W1E=M
M54UP53%O4E$P2D(S.7AV:7)#5B\F(WA!.TI4.'-L2DDP8SAM6DAD:F186DQ.
M2#9F07-43CA22&]R,3DO-6UQ<7DS5F13='1-,'DW,4<U4$<S<S18;FQ0.$%K
M>'%74#9S0DY"17 F(WA!.T%#>2MF=GE&,"LU,2]W1$U(52].1C1/5%=O;&Y:
M*S,Q;3A::'18+TDY5$UF14QL8G%.0DAJ>4=:+T9V9&9-;7!A;' R:6%T9E=K
M540F(WA!.U,R5G!*8U=R5'ER2$<P:V%->$5P:TU+4F]/27%X:T$X4TM::W4T
M95EF.41!-FLP,'=J,$141&)X8W@Y669Z2'!S4VQQ>D-&875&1EHF(WA!.V92
M1$-H4'=S1S9B;%9F2BME4&U3,6M70R]W1$PK;#(X.79B,U4Q+T=034=N4$E*
M8E)*>C9+47%Z4R]%.$MG=%$X2VUO*T5N1E9'-B\F(WA!.U!(6$@Q4DQ7,#AT
M-E!,9$U*23=3.5!M3%185E%Z4F=B1&DQ6%HT+S-F249U,VIJ4S V-"\U>40Q
M2T<O97I':#9B33=.2C90<&$W85,F(WA!.V9#:F-12#E#3V8T,D%:>4%0:$9/
M6&II5DIP3E8O32]7<FXY27IR<#)K86YP<TYY<#!P9C!N85<P:E%*2CA%.'9Q
M>5,X2$1.1#A$26HF(WA!.TMZ1&]D<W!'475(*UIL=E%",S(S2#0W:T,O-70S
M<V0W2G$P,F=A2S@P8TAP4E1P<F5N=&-X>$4X-4EV55AM-W$W27)"15AQ3S4V
M1'@F(WA!.U0S9F%X+TYN=6HO<&=J3&XX-7154T8O4C!Z5$AL:TPO049.;C%Q
M>FHU27A$44Y*1DE59$]C4C559FHP<'-30F@X52]G<&QQ>4]G+S F(WA!.W<K
M0S)0.#8Y44TU=&XP>E0Q:VQ3-V4Q=78P=&$K9V91<C918VIK13E2-E)H;5I1
M>#-',U%E2U8O3C<X:#$O:4@T.&MZ,&8X04U8>G F(WA!.W$Y=U19959R5S=T
M5CE.6C-T9%IS<'I%6&]3>FU0;'1X3W=P,CDY<$-:4%0W5V--.#5C;R\W24]N
M."LO;51A5#)L=F,K47!':W9'8TPF(WA!.TI$97),2$A2-D%3=D1&3T4K17(X
M5%5",W P3DAJ:T]I4$AY5T)W8R]0.6ER<2MU9FU$95AC=6UZ9FPW1&4V44QT
M5D9Z8V%J6GE2>5$F(WA!.U)437E4+U8S1E$Q26MD060Q66HK6$Q83%,U9D]0
M-7%Y,U1W4V9L56Q(84=A-&Q/<U=257158TA*35%$=D@V439';V]0.&Y&57AH
M.#(F(WA!.R]M,4ID5W-C;FM*65E,:65*8FUC-G!A=CE79UI9:DLU555-<%5T
M24%&<#EK9&$T<6@O.$%(6#5V2F%Z,TTO-6$X0D-+:49.6G1:6E@F(WA!.RM"
M,G%I>'A.54)K0VYF;#A1;T1V4E9'5V9M,S@Q2F1B9W1B:GE#='9P8W-Q>'DV
M:"ML<E8O4VHY57$P>&I696(O=39/14%R,G(T2V\F(WA!.T@X=U!*9'<Q+W%'
M=6%F<&DV:DIF,FEP2DQ%4TY1<V)Y,%9N=')Y,&-S1TLQ0W)*1D92:GA59TY6
M:&Q5-#E1-C-6-EDX4FU"9&HO3VDF(WA!.U)Y22]30CEQ5#9L*UI0;'982#AI
M>F%L95=Q,G%35&%P<E%6;58W83AS3%EM2F5!675&85HR-$M14SE!0EAU1$U'
M;6EE=&A0=WI):78F(WA!.W%L-45$.69Z6G U971,;E903C)O96)*-U-A>70O
M<7%A5G!59'=':6UL:&IM95=A95-"=T=J1'E%0U!L4G5)<59&4FMW3$YU8FAI
M6EHF(WA!.T1K26]6=VHY2G(W;4IE5C1D8R\U5B]P16XQ=3(O4E@V6G1V.48K
M<E-F5U K3S9O+S-O.69H.79F*S4V8F4K46AF0U!X,6-814HK14XF(WA!.WAW
M.&9D=CA!,VYF9C9%>2]X5#5L834Q4WHP:CE(,D5/;5<Y.68X1W1:2$5R=V%L
M95%C5'=M:D-E;TQC33=C4V5436-423E'=UIS:$HF(WA!.T5E16-.;FPO4VM/
M+WE8:CAW=%1K=F)A4U,U<SE05S=V3D]G<V1$;FE,,U9X8E@T='DY=VMO;5=V
M17EY0E=%9D5C4T=Q,U%I6E-D6$LF(WA!.RM91FU.1'%183,U*UHV9$9V-60O
M;4(U:SAW95E*8DQ667)+,FA.=F-40WII66TW9VQT-30T5$A.1U<U4F-E931K
M449M<58K2%E-2FLF(WA!.VYD9$IQ-35*,4QH1W@R-FEJ,3=N;RM7=7AD:7)S
M5F1I<5AA<S-M25,R=S!I3S!E23@O<EIU,VM59U5(<"MN-F%T,W)7=5)..4=*
M=F\F(WA!.VAE9FY8+V9/;2\X04DR9B]!2W T4%8U3#9N8R]/=CA!=FY49BM2
M<R\O5E!(,653*W U:"MF4&UZ>D)995A).4-U+W%K8C9S,5A&<S@F(WA!.VIV
M-DU,0FI8;7$P1%!X2'9V;%=74G%I-$=V>6U-3T@K8VTO-4\K5W9.1V<K5$QD
M-V4S<V<K<&XV-TEB:#56;'!);T5A<T919U5103 F(WA!.W(S>5=-14)T,&5)
M=WAJ>C-:83$U-6=V<&)Z4S)':EA5<U-+="]9;6534FQJ;E9U26UI.4UK3$EO
M86Y)9D5+-5 Q951L97!,9CA#>&,F(WA!.VUB+T,S;&YK>D(R8C9U2VQG0V]9
M;C!/;U9I2S0K<GE8,4]0:RM/95<U62M84$Q5<W-R34QT:D-'6FUE<G-*4#-&
M4U<Y56LQ-CAJ-#0F(WA!.RMR>5@Q24,X+TPS4TEB>4Q78G9Y-S5B=#5,4D]#
M4W5:26]&2'<P3%(K;7-*6F946&EZ3%9A0VA'2DUV2D)*.&M9,VMA,BMT0U)V
M2R\F(WA!.VQJ-C!X955/64(V:%II4%5E=F]6<5-W-4A(,653;2]*9F,K6#1R
M5TUI-3!8>7I"2$EV16E246ES=DY.=FEH1E(V9VHK;FHS<&ME1W4F(WA!.V=9
M2$=/;VDQ1C5-:65%1TQY,35:84=4:DEP5T5&5S)01FA30V@R8EDT.$HW9V=9
M62]W03)+.2]*6$UK=C5:.'1S5%-V2T-T94EO3W,F(WA!.TA963A*-V=P=V<O
M=WAA5'EI0C9L=6YL,WDP4#-A<$Q#<U@K-GDO3E%Y:4@W2F1/47(S1F-E13EW
M6'=O.'5'2U P>E(Y8S!P6D8P>E,F(WA!.W1%<T9L;UI28D-314YX1D8U8TEL
M<E%D34E"2&-Z:D1H-4%"1S@O3W8K*V1.+W=#4G,O.$$Q5'<K<GE:97 S4'IR
M+W9N5&8X06MB4"\F(WA!.T%.53AF5C5,-FYC+T]V.$%V;E1F*U)S+R]64$@Q
M95,K<#-0>G(O=FY49CA!:V)0+T%.53AF5C5,-FYC+T]V.$%V;E1F*U)S+R]6
M4$@F(WA!.S%E4RMP,U!Z<B]V;E1F.$%K8E O04Y5.&96-4PV;5!E8U!Z1'9,
M0W<Q4S<P8U=Q5W5J4W9B6&PO9F-P235B<%EG>3)T=$1!-&MD+U4F(WA!.V15
M9#-+<6TO,G%'9VQ0=6-,56%S>&I)>'%O.'EE+W5&9690=5ET2#5+,41Y-TPK
M6&=U3E=U8D=/2C=I,&PO,VMD<E,Y,4,S6B]3:"\F(WA!.V-Y0GA*34A1;5%V
M,C1K9&-J=S%4:413>7@K1F-I3UDV8D=1-F)D+V9B33<S>DHU:CAQ;C9X-6]7
M0R\P2#DQ2"MM3$-*;UI)2D=:67DF(WA!.S$S8G9*2CA$1B]T4DUA52MZ=4M3
M36E/9DIZ<%IP-'0X;$=(94YQ.31V-W9K;DAN2%9B=E-T1"MV5VEY4U1*9#)+
M1TM&5F534DIB>4<F(WA!.TM33D9E:3AN4C)58FIR,4A82E-.0G0Q17I'3FIV
M:CDT67$O-6LS3G8U;'9N,4-Z=DY0,&DP,#(S;"MO6&%7,%5P;FYV9G$T;$1M
M5&DF(WA!.T503E9Q.&]554I.3W51.%1D>'9Z6D5Z>$%I26E.:EA5,3,O<&%G
M,69Y+S5I,4]$5TY09E8Y4FY%>F5P-61H=5E$86E85&U1*W51.'<F(WA!.W1I
M16%E1F@V5356:59B:5=$14YG-S=O1U-'4UA%3TM8.4=X6' V.#8V:FMF=%)T
M-34V=G<T=CA!5')75S=S<G4Q,$ME,G1#259D1C$F(WA!.U,W;FIK6FDP:V9X
M=$=Q26\U:T(V2#=023143#E$2U=Q4$])<T51-W8T:690.$@T;VE0>EAQ2#%Z
M5G)A.',W,D,R3C=A,E9V9E(O56HF(WA!.SE493ET8E%*1S1-:G-Z<F-83E-2
M2$EU+U5Q3FIX36AN3GE"0D%S0R]4=%EJ*VLY>$1+8E-#-6A%:7HS2G515U@P
M;5I&5FQ54G%P1&,F(WA!.T%Q<U=D5V5O02LQ4VQ":V<U8U%2>DMV:%I/>%9:
M3DY$0D,X,'IR1D1%<&534GE&5E955DQ-5'-!0C%/2V]+,#AX95@W>6%/1S Q
M3S F(WA!.W5*<%-W:6II;FID;4MC9W=52WA*-"MM,69K9D1&564W;VE--W-&
M4E%76FU.04%.>5-4:7(U;&M-;C5P+VY#1D):=$=I96=/.49S8EDF(WA!.S<K
M4$@Q5R]&.'AF<FLV6"LO=T$O.45F9"LQ.4HS6719-U1J2T=70E1'04EG-$E)
M9%%L4%,K2VQA93%/=3):5'5N:S,U:G8X06M.2C4F(WA!.VEV>C5Z1#(R='%%
M=#)U2S-J35970D-J>'!B;5)!<7)E:%)Z459A=7@T-'%X,&HO;D4K63A(4BM-
M,&$R<G4S-EEJ<4E$8F]K6E5L5W(F(WA!.R]D9G,Y<6LY8U943%0W<B]!2GAO
M:#!E,W1R9%=T-T%L-VU#3FPQ4W)",T$U;'9I67%X:$)!2C)P,$<K5E1-3#-C
M6%!K>%A5*V9X4DXF(WA!.W5N+T]/='='=#=+23-,>%)03SA33G%+;%E%:E8U
M<$MY36=P2$9&>DE"-555:%%7,DU+>'1-5' K;F0U.'1L3S9G+S5X<T%3,V4S
M-4LF(WA!.T),870V4S9L54M6+V5C*TY'979Q:&57-3-(66)'-$)).$-*0DA-
M93E4,#9Y+W=#8V)D2VA7-V=T1S Y3"MX0EHK5V\Q94)B:TLP8D(F(WA!.TAE
M<DQ004]8:E1Q5GE2;D5J9'1N<6-::G5D=FHS;VDS,4@O;D@V-5=C4$9.2$)(
M2$-/8W Q1&DP6D,V9D55;WI..6U:539D-CEI4D<F(WA!.TEH23=-36-C33EH
M,V5F9%@S26953F0O-7AK=DQL3%<X;$Q81G1#.'EO63E75FMI8U!E<U-6568W
M.5HV2'AP-UI:-%57,E=L>'DU:% F(WA!.V9++VMR.&IF36I8-C9(64=D<E@P
M:W9O,V)58F-H6E%*;W9H;F%0:W)H47=+:6A(>G=E1D9(-5!&,U!2=$@P8E1D
M1S K4%0Y3F@Y0WHF(WA!.VE:,FII-4\Y1$LU:V8T;DQ.=3=K.6-M0E1F1TEI
M2T-.=W-N67$W1EA9<3=&6%EQ>#)(>4(U6E179C!V2D1*8S--8S!L,6%26$4P
M:S F(WA!.T9T3DTO<5-Y5SA,<U5J6C50:DIP<S-3;5(T0F1U34Y*:C1U2W)0
M4#-E-5@X-"M8:G(R9WI78TQI2%5):71Z<&0P84%W,VM"-7=30FDF(WA!.W-H
M56-H4FE"6&E335I#=WDQ1TAX255/9DUE4DA*:D=P96(Y479F2W0W;VUQ-D9E
M=RMA8C(Q;'-X<'-6=DI*0E!,3$=),FMI=55,46DF(WA!.T%'549Y,'151F5P
M<%=";'185GA:-F=Y>&U-;VYJ27%Q,E!X-58X9&U4-D1O46HX<&%,<%=P>$%Y
M,DYT66E734UA3&-766ID4T=1:78F(WA!.T=724AW4'EY64=W8W)&:7)(1TUU
M9TAZ2#=68E5F2S)H-FID>5AL,V)S,3%,1$AB3DUK<W-B0T]#8C9X1GA-8G)X
M6DIF:D1,4G$Y.%0F(WA!.T5&;%!$1U)S:F8X059V.$%E<V9Y;G!$,CA53$YE
M17=L>DAC9EAR>C9Y0DIX-7 Y63EB,75$8T9*5&YX<4%A5D%X-%%G-$DQ5R]W
M07HF(WA!.V9Z=3%Y959D0E,Q*W%P8F-99G$Q=%I+0DI)1U='>5IN=&=R.'53
M=$5Z;&QC2&Q8971135!#1D=#1E98440U8W9L,S@Q5E!,=6M*0DHF(WA!.T(V
M5$]K<SEV9'EM4U=74C-N=$)#25I'9#):>58K<E(Q<69I<#A686UR4U)H:E9E
M65!Y<79U0UDT5S$R2W5X5D0V:G Y<G%.:&,V9F0F(WA!.W%Z,G0S1SA--DDW
M>'-5:T)69TAJ2W5T465Q:TA&5TYA3BM64&M,4G13=&14,#-41$)E,DI,5W-P
M=4QM44E41SA2;W-K<DPO9'ES=30F(WA!.S952#=+,%99=BMF,VYO84PU94=G
M,F-L3E(Q:%-S=$]Q5W92>B]W03E0<T0R-5I4;&Q1<'=D9&XT23!/6E9V>4<X
M:B]O3'EX*VQR=5 F(WA!.VIQ97-"6DYX.%-7=S-I5&9P>2LR9FU01$1I:E%T
M3VAW8T5,4$UV5$IJ34DO,TE5>59&035)1DMJ;#!"-V1-=&,Q:79M0S O3398
M>DPF(WA!.V)3-DAE-F)"-616669R549W<VXQ;&E*,&%B:5%J<G9!2%9456)N
M<"LQ:7)(8FTT+S5Y4&=U<D<Q=#=B>7AD>%1#55A..&9R:7!$-F4F(WA!.S9'
M6#DT:FMY:F(Y,T5W1&1A1$95-#%74#@V+W)-.&5M5"M81W1#:4,S=4HT-S)/
M8FM6:CE2;6I$5$E+3C9V16-M+UIR,WA665(K95@F(WA!.V]7>$1E5U)/:T$K
M=4IX=C)74S0K<TU#26TU2C9A9E9U2D):5U!Q5D@R5%5+;T-X6#@K;VU!34AL
M;4M+-&AA8WAH8G-#2S=E349K:TLF(WA!.T]0:&%D:3%61&LO1E9H<V-64FUO
M<BME-'553VY.-5EE,SE!0U)B:C8K:"MS3E%S9F=$,5)E:3=G;G%A9$%Q<%)7
M+S4S5%=';G)D+S0F(WA!.V1K=6],;&UV,6Q3-45C:V-::3E&;W5*;"M,:TI8
M1$5,=C9F=VHT:&EQ2&HP,S@W=G)F-E1K<R]*,S9:.40V<6(U578O049$1E=2
M>$8F(WA!.S9H6#%05#E4,#(T5G Y;SEA67%Q<D8O>FM+<VHX<"]+<GAR-FI2
M2&AQ0VQM2EE2<31Q,49!24IP=G13<#9L5D97<2]N:VXQ4#9Y,VPF(WA!.W%1
M144V:G@K=D%H:DQ+44E0:"MY2793035I=&58=&EQ1$U0+T%$:TU:4%=&>#56
M56A#=C%B:&9T15=O<#5L='!+.'51-C!#.6EE:7$F(WA!.TQI:2]013-S6')Z
M*UA&<T1C<3@T:5<Y37=T:$ML631Y,W=C>D-'2EIG9FE.3FAU1E8V5VXU>&U-
M=W9E84]&83%D1&-J,6I/='IW:TTF(WA!.V-I+W521E0Q1VI$5E$O0T-A5C)Y
M=7 K5&IK6F8V4$PW54)A-E@K9E9T875X,6I2<C(X17%'3T\V4U0P5$9W:T1Q
M>'0W93-C2&MY34LF(WA!.V5(:'-405,V<W--8V<K<S,K4&-%8F5X9FYJ-C1E
M>6XX=6-&9U)"2$MT-D5A9&QG37)S1D)E:75S-&I!8V9#5C564%-B8VY8;$IF
M>D$F(WA!.U9::#5U9E,U1S12;3-B4WAC3"LX3%-'5EA%+S=#<5EW:$<U;WA0
M8D97431Q-T9867$W1EA9<3=&6%EQ-T9867%L,G$V=RMN>E<X4S8F(WA!.V9D
M,W8Q9T]E9')'<G)(=S0O=T(T5UI/4$QL.%!J435%>7!I6E5H9CA45&8Y5U15
M=BM255@O5EA">"M26&DX;F8T;6TO-G-M<&8X:6\F(WA!.W8K<7502#5&94QY
M465S969B6%(Y3FXQ3%5.2S%#,W1,9&55:VIX>$%B;6=(.3<Q2DY"9T]3=6I'
M95521FYK.$,X=#)U<"]M3"M912\F(WA!.VU$5F)+-'9.36AL5U<W9W0Q1&A9
M>%@P8EE&;5%54$=H,W)3<#8U45!58F12:&EC*UAI23E)+T909#EB+T%$1S!N
M44Q71S0Q9E0W-G<F(WA!.W1:6E9T-#5P631L:D1S<%E";3E3:4%+:$I:<4%!
M8FY-:FDX:3=N:3AK=&PO3UAY1E!&>&$Y2$0W9DM/.',P3D5*879*3&M';C=S
M,3DF(WA!.V=A-U9X-"])<GAE5$1.9#@P9FPQ<E=Q6$8W1#5U,7)36DQT=E=N
M:#!V57)',6I$2D9%:$UL2%IL26IT4G1),C-X539N1'AE4EAI.&PF(WA!.T=.
M4$IG;EE,-3 X,DQ00DEY3C9M<C)H8V-N:DIJ-5--5S1L;U(S-VM:1'A1,2M0
M1D-(4W9Y.'-L;G5)9DXO;6DR;FY733-.,6)A<EHF(WA!.W)0355!2W9)63(U
M>6UJ:C=6858R<%AD3UE,*UEH,V\R-'902D%H6D8X-BM:-#-A2DEP2&<Q93!A
M5FU4,&=*4T$W2#%#<T%$3E1O5S@F(WA!.V-F1T-0>DU/+W=#-417,'9K-C!J
M4U,U."ME83=S8S5H2%173&-J-#%O;DE2>6QI66=&8G)X3&1243AC9D=#+VU9
M9"\S27$Q8GEB1$,F(WA!.TQ75'ID-6EM9T12>G="=%-S>5)X4$E027AK2VQM
M;69M1V].-E4S1F-H2U%05715<%)K8C1J.'=J<GI5+TM31EI*=DYN;4]#<TU3
M040F(WA!.U9B46-G:V-B2S18,4XR:U%+>$DK,7ER,WA-:#-L:65$*V9,+T%%
M,W4O2'A53&4W,$<T,4=/1S(X-2M92F]P15="8E).4W1(=4=U0S@F(WA!.UE1
M<31N<#A81&IW.4]P3$AF=&=S9#513T5N85HK63AV>#A5.5AY<3E99E5V+T]K
M>7=L5T-36%5*1$9'3'%8;U)Y;W@O065'4W(K<S(F(WA!.T1$5F)Z*V%H3#5/
M=35*;&(Y3"MD;&<T8UAJ1C-(57-!;T1C=59/9U!)8V1Y96\W=&8Q;4HP.2]X
M5"MA2%@X=#E-5U):=E8X,VUD3U F(WA!.T-9>C(O36-!06Q'-V-E2SAF1&E0
M1$)W1'I585ED."]M>F923E%M,&Y427)!5T=U6#1I3&M85CDV53@W8S-,,&51
M>4%T>#556#)P;&<F(WA!.VQ847521#!I='HW,&0O:6%B+W%Y86PO>4MI+S9Q
M-&50>4Q0:3AN9C1M;2\V<VUP9CAI;W8K<7502#5&94QY9"]I86(O04MS;7!F
M.$$F(WA!.TEQ3"]!2W$T.&9K5C1V2G1F37-X24@V1C%)5C)Q66]Q9CAN8V5,
M>4LX6&MN5U1:3WA6,DMU>%8R2W5X5C)+=7A6,DMU>%9H;FY$>CDF(WA!.W$K
M9S9X2%E76&QJ54Y::&%$,35B>3%I;F%.1RM0.3-625I66G9G0G!Y-D@K8FER
M2W-G.'4V=F1A<&]S1V\S=&A,<%4X;G%E<%I81E$F(WA!.SAF<'E-9TQC;%$P
M64QY1S-1-'$X02].5'IP9BMF+TY&=#55.'0Q=4Y0:6TY3TAG9FAU2BMJ4VLY
M4%115F]F0W)::7IL>$=G-F)66FHF(WA!.VUN=U$U4&,O279K*W@X<&583&)3
M3%=J=6XW>3=U2U5-<S=!8S-0,U58=T%'6D5),$AA66-1>'A%46<O3TTK;%<K
M:4EB-WET2G)L9S$F(WA!.S%-6CE/:G1%=35!5FIN:SED3&-,27)'5C$T<51X
M+W9+<U)V:VTQ-2\K;E!Y-G193%<Q5#AP9%-5>7EW,E9U;#%O=')'1V%6,VI!
M33 F(WA!.WHX82]A,UIT*U<U,TIX5F10-6XX<'1/3$Q49GEM=7!*<$EM33!&
M-7!-1F]F43E6;$I60DA-6%AM4W@R2#)H,T]2;DEG8W)A.&MZ16(F(WA!.T,P
M>75F32]K-F57-&AS+WDX=4QJ5D5A15A-1GAP8V%C1FQD=4UL=UE5=5I65VM2
M9&8S8E8R<#=6;5%04GAP6EEK+U)V-W8W935%2%8F(WA!.R]*85-S;B]+=&12
M<7%U3V$V2D-625%%555J*V(P=T8K:D=X+TXK>%!(069W2"]3+VIU*S52:S%R
M>6I&9G=13BM6*V]M2U-2-#0W<5 F(WA!.U)91U9/3$EV3G=.,%9I>D=V9TLO
M2U511#!B65%H3"M'<3AK3&8K8B]!0S!04W5V*U93-GI08UAN3U5S*VDR>&8T
M<7%7;$M.2WES>D0F(WA!.V-04G50>&1+5FQW1'5B4$-H9#!%3G$S;64Q:G9D
M4VYS4'EI=F130FDK<WE4,TYK<U1Y>G!/65-G4F]:=FA)45-+62M42&QY2T0T
M;40F(WA!.W=$=5AW;SEW4E X06EF>71B1C5R+W=$2S=5-'I#0DI03W5L4GIX
M4C T=W V5'EC2TES55%,8U965D$W,7)J=T1U4C153S1/5'HW-54F(WA!.VQI
M<V16,#,X<V18=6A.2&(S1G1E4C900G1!1DQX3D9*1UI+<VEX1#!X<U!S,$E"
M0G<X23=K*T9'*U%:2&,O;7)/:V%08BM4=DU6=S<F(WA!.U!.1SA(,45P26I2
M<W%X=3-.:$@V579X55I83$-N,F0X3$YY+VUW4W)V+V=Z>E%%5%E%-F-+<V96
M159&6#%E6#=83W1+8V9U>%93=&8F(WA!.WIB=5I!:&XX:RM:;U),2GAI07-#
M-45:.4U"-69J6&@O93=G5F]&3RLQ359D3BMB<VEO9E,X:RMA6&M+27E+,FUL
M5DIC4FM+>D(R-#@F(WA!.V96;S(R,T9V1$955"]W07)4+S!K=V8T43AZ541H
M1$PK:G9G,VU-4$MV<6)Q3U!0669924]+<S1X5C)+=7A6,DMU>%8R2W5X5C)+
M=7@F(WA!.U9#87)*<7-D<'DP=4='93<U>&=2,T5J4E(X0S1%:#5+<VAQ17)4
M8D%B-DEL9&))4#8Q-74O=T-R8G O+T%%;GIF.6ME0S5F:BMX:F,F(WA!.W4T
M9E Y:G9R6&TW+T%+='5N+SA!4V9.+S)2-#-,.&8R3&-U-&90.$%9-S8Q-74O
M-G1U;B]!4%-F3B\R4C0S3#AF,DQC=31F4#EJ=G(F(WA!.UAM-R]!2W1U;B\X
M05-F3B\R4C0S3#AF,DQC=31F4#A!63A5+TYJ.#,Y5G924#53,&U/1DI*2#E#
M*W5R2V0W:U-6,DYV1WI244AC-TTF(WA!.U%$6' T-5)0251S-C-6-G,O4DAN
M*TYM42]L6BM8*W1E5%EN=F)N5#=+-#%U.&=-;%IB<5=.-$E&-#AO=T9T<&M$
M8VU(3#0Y+V]Y94\F(WA!.T)'-V1P3DUC67-G8U)5-V8O;DIJ>79*<#!D.4E,
M83-6+U1$4E!.97,V4$E/4FI9>%=-:V9+3F0S-'-F1&,W6EHV=G@O635V<3=H
M."\F(WA!.S))4%AF>F(O04,K.#1714=H*UE,87IK=')O<&-*87DS96]X2&MS
M-&AH2F5#>4)Q>G151&PP*S%42#%F:BMX1GDW:#@O,DUB<W!F>40F(WA!.W5)
M631O9$5S5#E:;FA33T@V-W)R=DI*34I59T9&<S)*-7%(-'(W-V=(1S5F:BMX
M3GDW:#@O=T)I:%HV:"]W030X3F)Y>%)A4%E)<S F(WA!.UIU6C17=3EE0CE.
M94UX<E=Y<'A":4A1.&5W-C=T>3=V>#AL=5AC4&XK>&YV;'8X04\S>7)&63(R
M;&%:1&%7='9A2D9B5V1O.'5P8V<F(WA!.V=H6FM24BMJ,V(T5FAD9#DV<C-"
M56PY6&0K4&MI-61W*V8W1CEJ+WIK4F].+V13,CEP2&)Z96Y#.7=K;VMV=VIP
M16AK8FE4<#1+-TDF(WA!.R]W0G-,.6LK,5%344PO2#-);$UX0DI!;V9J=5(T
M+U!$4F9232]/>#E)57$S<6%L,%!)02\X8S-P5TYT+V))94PK4'=':C@U1W(O
M6"\F(WA!.T%-4V]X+VYZ;VI#478Y5&E#2#13.#$K96%50D5I.$Y086EM=C=6
M1#=94$<O2#1#4'IK9GAF-FM*<5@O3U%D=%EY5VY,4U9N=#=Y4#$F(WA!.V]B
M<4LU:SE0,"]6:VDU15!B2DE.-%=0,F5M2GIE5$=7=4%R8FUY-WEP-3,Q6'I4
M<%DQ2%-R0WEA145*3$A*97IO.&-H:E=89W<K<&LF(WA!.T5H6D8S56ME*U1J
M36YL*U!S8CA78FI&:CAF66Y0,7)Z9"\Q8F10.$$K:RMB+W-J>59Y+T@Y:EIC
M=31F4#EJ=G)8;3<O04MT=6XO.$$F(WA!.U-F3B\R4C0S3#AF,DQC=31F4#A!
M63<V,35U+S9T=6XO05!39DXO,E(T,TPX9C),8W4T9E Y:G9R6&TW+T%+='5N
M+SA!4V9.+S)2-#,F(WA!.TPX9C),8W4T9E X05DW-C$U=2\V='5N+T%04V9.
M+S)2-#-,.&8R3&-U-&90.6IV<EAM-R]!2W1U;B\X05-F3B\R4C0S3#AF,DQC
M=30F(WA!.V90.$%9-S8Q-74O-G1U;B]!4%-F3B\R4C0S3#AF,DQC=31F4#EJ
M=G)8;3<O04MT=6XO.$%39DXO,E(T,TPX9C),8W4T9E X05DT6%@F(WA!.VTR
M;W)P=&=",TEV-6HO,DHT,F9X+UET>3=H."\R2G9K;6)S5F1I<G-69&ER<U9D
M:7)43495<V$P07%A06LW97<S>%8U<VXU="M9,G F(WA!.U1Y1G)2<3AA<E-'
M46-H2C9.5TA/2DM"4%=.969(-THX1S1Q=E-I44)5-T%D5&ER=VHX,G9Z;F4W
M851Y>#52:V%5>6XP8G9564MK=50F(WA!.W-98F9J=6$Y0S0V+W,K3UDK5$IE
M=V18<3E:+T)$;BM/4V4O:S<K5'-E9U)X83ER,%%F5S-(2S)T;6]6=%9)-FYX
M;% O04%U4W@T-C,F(WA!.TQB;SE(=V5Q6#%F8SE6;"MT1GES65%2;4YV,VA9
M.&A*='A(2&E2>#8Q3F9O>35Z,VYE;7@O=T1/47-%2S)T,THU875P26]O+SE0
M:RLF(WA!.W1G>75755!Y5TI99T=#:'HX36%R=710,G-64CEP1BMD>&YH*W5Y
M*UAL=#)L:&$U.40V-7I734=$,6QI-7)4-&=*-F-Q.58V8C1Q,4(F(WA!.V%F
M;DY#:75*4$Q:=4AL8C8P=VIV1D5Q0T]&56QB:G5:87!)0U!S:&506'1'6$8P
M87-N2%DT82M+,C9K+T\V,FEM;FEI,$<Y<$AY5S$F(WA!.VHK<VE1>3A!3T5:
M:V%&3TA09C0R<E0V36HV+TIR4&I$*V)Y."MA274W9CA!3G,Q:W-L.'926$US
M6E-E9&AD.#9Q.'9P,$E'-%9(5#<F(WA!.U@W6%!S8U1X*U-:94PP-&9T."\R
M9F%P0TPX-V92.45Z95AI46]8-GI3.#E8645C>4]0<#AI84@W3E!B0C8O2F8S
M,SE(-U<U8F8X-GHF(WA!.T=)63=V44M54W0Q=W5L;')3<B]$.&-:*TQA=$)5
M9&@R9E@U3%=B*VHY<3)64'IT1%)1=WEA0R]P4F\X;'I+=#!Q>7E%14UN1E-X
M2$@F(WA!.W)5058R<%1D42MV>5%F1S9C4#)O:#,O3TDX230P,$%/<V%M85IX
M9"MM>G,P=%)';UEV.$%#;VDK,3-*;V9!*W9Y5"LY+V\O8C4O<U<F(WA!.TMV
M-3!R1T4U95A89&51.59V<F],555C0U9504%L<3AQ9E)J-B]*9C,S.4@W5V)#
M=$XK=F9,2$ED:7)S5F1I<G-69&ER<U9D:7)S5F0F(WA!.VER<U9D:7)S5E%C
M97,V4$MN3TLK=#-3<$A*6E5)<7!+:U9"-T55=V-14EE8+W!45% K5W5(+VM9
M;CEC8D,R-SE+85HO>3%W+SAJ12\F(WA!.W)J65<S9G!45% X06QR:"\U1THO
M6$=W=&]B55!-=FPO5')/5SAV9%)T-$QA16-P2D=K6%EE=T)*2CA!3GIG36=%
M4VU!3$IF4"]W0UDF(WA!.T@U=#8U-3%V9CA/*U8T<%E.36U9>&UN=WI824]X
M36AR4T]+;F%V5#=89TUE95%Y,D1Q32MR;&Q00D1K>C<X<E!Y=SAU*U99-#E4
M,5,F(WA!.S=T<G9Z07=Q2$5I1T\R<4XQ:7%D,F]D,RLW,W-X=T$S4$YZ3DQP
M630Y>G9*-E@K;$Y-+S5A-&8K4FEF,7DR=S5L;V4U=DY,8W1,.6,F(WA!.U%S
M26YJ16%Z9TMW96@K>EAJ>2M(63 R,W@T9W1H-$I984PU-7,W3S)M,"MY,31H
M-$EW=')*-71S-%)$1D55;FIH0T<S1E!I6C1E2E@F(WA!.UI"5&)L:GA"3FA#
M<#5E+TUW>'A12D8U:G1,3T-.*T5-6&Y#>#E6;CE-0E%:0DAX0R]U4CA02%EU
M5%=G<&IX0F)#<F8O04IE6%-X8TPF(WA!.V)19%,Q065N151*9&593DM347E#
M3UE3<E5W4R]T;G)8-"MF26AA15I58V-4,6-396MH26MK;F8X9G!4;34P+WIT
M2F%83GDQ;'%I6'DF(WA!.S-+1TQ48E1Z3%EX,FI+=V4T865(;$1X:C14;W-F
M<&QD9S%14T)H-$(S<WIG0DXX579M9V)Z5&9Z3F4R8S)S3W)P9E9K4S)U2F9-
M,6LF(WA!.R]P>$5X4G)Z0W)'6#5!3DI13W4T.&-4060W139F8F%5=FUP5VQX
M*UE/<3)-6G4W4%=,9$Y+:D9R8GHO<#17,&QZ8R]81U(U>6HR.#@F(WA!.RLV
M5%96>6Y%4G%F:7!J=V5A5&=S06-5=FTY3&DO3"]165E(9W0O3C)S5S9-;D5E
M;'%3<%)V534X+VA55F5N=U9.9F@K+T512&5P=T0F(WA!.RMD3#5Q1W0O;#=B
M86UY3U!Z0C$V>F1"16@K<F%L1D5P:FE*<E99,%0T,E)Q1BLU04Q6-S)!:'E!
M85%B+T%*4C9$3#90,6IZ.35L=5 F(WA!.U%F,49%=7-Q-#5J-TPW<#A,2BMY
M5F]2:GA"3G)R5#AS:U=Y;'1,,SAX=&5L074W:64Q;G0Y4TU-<7=496PV8T5R
M=5IZ2C98;S=-3TDF(WA!.RM*=FA&8V5)3%E29#<K6&5L5'1.3$0U-#%Y,VUL
M4C!5<G%L5E5.4#E94E-11FM+;U1W2'AH=4)+.'4K4$5%5T9/1#AS.4AJ=7)7
M-&LF(WA!.S@Y95E,:C9T4$AC9E8U=%@Y4T-1>$](16-K8G$S2D]3.7I8,W@T
M9VTQ,$@U86%(0EIF5EEF4$AM0D,Q4SEX*VU#6D=::$M'63%"448F(WA!.W98
M0DY&1S9+979,:SA15W<Q2"M7*VU26$5B4F5E.613,D5S:SAT=4Y45F5C:V='
M,55684I8:WI#;%-Z5G%/-WA"1F]3>2]+-4DT3'4F(WA!.S)U+WI).'=4>%-Z
M<DQ:>E(V;5DW:4=-4G-H:651;5):3U)B;%AG=E%5-S%E24IT2'EF;'IO8VYO
M*W U,#%X,FET;S=6;6)5,%EY1T<F(WA!.V-Z>'IV5DXU;%DP1&IT,G)V:GA"
M1FA#6$@U5F%.3VMI3C4O.'AQ2F\P:6Y),6%+<G!'9U%":5EI9#EY9D5S9DA(
M:4-B1$Y03&-';6$F(WA!.TAO='9P9C9B;3%-5S--0SDQ1S53939F;35F.$%E
M4T%*>30X=4LW9$%":EE2651-87!P<$Y"9'<Q+W=#36EF,7AS3&%*=W!D:7)S
M5F0F(WA!.VEQ0V@P5%)O27A&0EE7,%5A,4E225DQ559.5'-",TIW8TE126AI
M,G)F;48K5E=K-FI.<'5O6#%N0F97-U-,4$%91UIK34U1;69N>&HF(WA!.V%G
M-$5%13=(;TXY<V5%3%1+3%<Q,%,W=%EB<3)G=#5R83126EE*55)#<F\T1$MY
M;6Y19S%X-%%T0FAN;C,X>"])=FQ&2&=E,V=V.$$F(WA!.U8V9D)P.$-X,54Y
M=E=E:$59+T@R>75C-&AX<RMP:&HU."LU-#-:85 U.2].:E=0<DAP<&%A5$<U
M2')+;G!78T$W<6EJ95(V9DTK2D$F(WA!.WEK07E,<E)(2G%$9DM,,W)Y6BM7
M9FQB>7)99E8W4S)7-75802MS,S%W<79,269P2'=R-$M0>$\K6D5C641T8T]N
M:FI&0E!*9%!T4DDF(WA!.U5J,#9":SE.;45P5DMC=U)X5&I3=2]J:W%$9%1Z
M=E1F35@U;BMI<T=O9FQL8G9F>'A2=E!,1&8R8U5$<S=+<F5M1T5V1VYX;FHV
M:D4F(WA!.V-2+TU-945*;TEL3F$O36PU-V%-+VQT87A2>GI23%!-,F\R5$,S
M:$MX1U(R0VIL25%Z4T0T45!S.4181V=I9W8P+U90>DAN4T=7-R\F(WA!.T%#
M+W,W4VMI2F,R,S$R,6MD:UI'3'EP279W<GAB:CA*0DHX931H2S<R1%A->4(R
M1G0S1W)F;4PY66E.=BM89'(Y5U9A>F\Y.5IL,UHF(WA!.VQ(=V\T;T4T3E=T
M5F)L-UE.*S5P3U1,+T%$4'1#*U!69GI!96159CAV3&%+2FY1;5@V+UIV>&IO
M3UE)04),9&%%9F-E-W8S2D=42F4F(WA!.SA0=$-S,G%E9%)!:FHX=DE';%IA
M=$5.4G,O:$Y82$5S67=++T%P,G%0:3EJ:G8X07I5.&53=F\K,&9J*S%#,W5S
M9FU';#!)-U X=7(F(WA!.V4T='!0<7IP4$IF5U52:E=33E=U235%*TUS,%0X
M;#5,<V5W3E!I<V]/44%H3#-Z5"M99&TY.6139FQG<C9:06AA,E=/.'1*8G K
M2WDF(WA!.TY5>%<V,T1%=3-P<'=25'A.5%9H,&5%2F].:GI**UHS1#%%+TMU
M0UI'3EEZ*VQ,2T8K1$1K=DM/4T]Q:U8T=%4Q<C)X-%%T0D9N5R\F(WA!.U Y
M6%I0>3%I9%!44F\P9E5,0TYX25E'85--,#E114Q/9U)8,G%R0G%#:$=00T55
M14YC83DK6E5.<$)C:CAU3&%6,4EJ=7)28C(Q.5(F(WA!.VY:<$96;U=54TPV
M6B]D1FUB9$MK54E"9%AH0S!%6&9A,34Y:79O;W)0.'198FUY:U=&;75M,4MY
M:F%->4EJ4W$X4E$W>$UZ3#A,2&PF(WA!.W@R-C0X25=G<'HV-2M9<V1T6DY"
M*U=D=F-Z>3)V<3-Y;E4W2T526$EK9$=H6#1*96165EA6<3!O,41U1&I15%%7
M6$=T9FUB0V]E3#@F(WA!.W1B3SA!:71U56$V;F%1=5IP6695=4]02DA8:$1*
M*S8S87 K,'119FAA0S!&6%-T6"]-4V$W=%4Q1#AU<E<Q=#4U66MU2E)Q1FTO
M,64F(WA!.THU2D)*265+<UI04VI733A6035%;6U00T551V4O;W944"M74T@O
M:U=N.4UA0S W.48V6B]Y>5$O.&DP+W!J45=N9F]V5% X06QK:"\F(WA!.S5&
M<"]41V=T3R]296UF.$%,2D0O04UI,"]P:E%7;F9O=E10*U=32"]!2D9P+U1'
M9W1/1VPV84155VM.9BM-868P>&],4T<Q2%@W2%0F(WA!.S=Y1S!N:G5N:VYJ
M959$8C)T>&-+1FI+<652:%-3:"M-9C4P=T=624UW0W!F-' P>B]F3V]F.7<R
M+W=$*W%'4$=0=T5C63@O:UAF-' F(WA!.S!Z+V9/;V8Y=S(O+T%/<4=01U!W
M1C1X-2])=2]X5'!N*RMD42]W0S1B9CA!+U9$2&I(-$,X63@O:UAF-' P>B]!
M2'IQ2"]C3G8O.$$F(WA!.W%H:GAJ.$)E365F>4Q%9&8Q8CAM9$HY5S0Q;E-,
M5S-M=6I.2W=U9$AK4U-D-78W-"]V8F1E8E,P2$UK-SDX0GE!34HV:45"8VI8
M>F4F(WA!.V)E85!Z<S@P95DU4F]8:W%X;7-B5F@V8U,R>48W>#!8<V=J0CE*
M46\V2G50-7-P;&Q*-4]T>38V8WIW-'@K=%4X:69L2'!V<4IQ6&XF(WA!.TID
M46QK63@O,%A&66%G9FER6#DO37-0>&9*1"]!3$Q"1TAE>7=A26,U,E0S55AT
M,7!R*VA79'1(83)L;F4R.71#;U=+1TQ3-S5%5E(F(WA!.S)64D%!379%:"M!
M-TU3035F8U98+T9/;68W-3%$+W5',R\X03%1=SA9+T%8:DAN.&EO>2M9=$]K
M:TI),4U21TYO,F=';3-V06QI4&HF(WA!.W%B8FYY049".%9..7@P>#1X*T%V
M1U!0-49G9'8U1S!A,RMQ:41Z5#4S:6AT4%1%5G5G=FMH-%),1W%O63%S=W9'
M:U<T04A5-#A9+T$F(WA!.UAJ2&XX:7-T4$E':#)T>&)3<C5Q.#A3>#(P<V,U
M=%IJ9GE14W9(2C9V-S)-,FYX0FTK,$)3=5!'4'=%*TE0=T-U5'E2<&I1271X
M-7,F(WA!.S@W>3-#4G%N<G(K:U4T=4EL:6%21BMR3GA:<44W:S=K*T]01U!W
M16-9."]K5S=Z>4IO5C58-GHU;3@V>6=V3DIW65@O04%R4'-Y.&8F(WA!.W%L
M3T%7<6A/;$-2,W@T>"M!5C1X-2])<DIV25=I6&1P<'-';RM:9D]6,C)N=VU)
M<U4Q04Q.23!K:VAM:U4R<E9C97-553$K=T95,7 F(WA!.VIX:CA7=D=0=T-I
M>#50.$%,;SE1:E=V3F]E94='0S9K158K2&U70D9J1%-S3%0T,EI5*TEN>$Y+
M5GES9UAE-U1+04I*=5%V,W%..34F(WA!.U)T6E!4*V]E869.,6MP=5!6=44Y
M2%575F]M<5I%:D-14D)'6FI536563B]H3F-(1#5L<FYH=FQ+63,X,%)D955T
M0W5O1F=N,2]W030F(WA!.U-28U%S<4]M;T]S=$<U5FM6<E9L-T%B040R<E4T
M5$5D.&U2>$$Y6B]B*W!U-3AQ849C=WA1>C8Y-79K:E)A3W)P<41I43%Q1V-.
M87,F(WA!.TMI9W!39SEQ,4I":40Q:W9H1'9N.78V;$MF>6)O1GIX1C%R+T%*
M=W5);$-H65I)-S5K0E)1;V)J.54K,51Q9F,T;4E056\X15@Y52\F(WA!.W0O
M575F>7)P<W1Y,#AN;51Z97)+:5%W96Q&9F]6:E-*27I5+U97<7IS;DYI2U9B
M=&AO9#58=U(O3VXY=C9M85=F;4A43&$P9W1Q87 F(WA!.U V16%X*W9.<#DK
M,'(X1D,X,V(P0E9M<%5N>'E9:U!.>5)-1'8K4E9V.%4V6B]V;E50.$%U1S,O
M05 Q47<X62]!6&I(;CAI-R]&3VTF(WA!.V8W-3%$+W5',R\X03%1>#1X*T%V
M1U!0-48S*TMD32\S>G%(+T%(1&(O=T0V;UDX62]!6&I(;CAI-R]&3VUF-S4Q
M1"]U1S,O+T%&47@F(WA!.S1X*T%V1U!0-48S*TMD32\S>G%(+V-.=B]W1'%H
M:GAJ.$)E365F>4QV.%4V6B]V;E50.$%U1S,O05 Q47@T>"M!=D=04#5&,RM+
M9$TF(WA!.R]W0C@V:"\S1&(O+T%+;UDX62]!6&I(;CAI-R]!0E1P;BLK9%$O
M-VAT+SA!.55-94UF9TQX:GHK4F-03D=M16=E:F8W*T]N6#0O-6LF(WA!.UDX
M42]!6&I(;CAI;2M36G90<C-4=GIV3W S<SEL<6UJ<%E-2GA95VMY>4U63&UB
M,$=K:U="5#A!84MO1F5H1R]6;%5D-6XP+S@Q<FTF(WA!.T]Y6%%.5# V,&-0
M23$Y239-=G=-53E*158T-W)M54%B:SE5-61!<3$U2W%G9% X04]6.351,&4U
M2#5L835P."MR1S1D-T],5'=X8S(F(WA!.WA29E15>&-),C5C9WA*<'@S-C5'
M57='<DIM:$0V:3@X.#!F.#5"*UED6&U/;2M4-T(W6#%356IU1U@Q-W0V+WE2
M2T=61"]W5U53>6LF(WA!.SAN5S5/,$I3,GAH4CAS+VM4-74X>#-F-E8X-#-K
M='!(365C:7E0-G0W25!F;'E74"]:5DDO;'AJ:4HU<FHP335N:7E(.6(R+WET
M-4TF(WA!.SAT*U8W4#9T;S%M;'9Y045S-2M+85-N9#5$.%(K6%%D:&PX66=C
M;EHT.%590V]H3C-367EX36MN1TYA*W!(>$(U,49"=C)O9#AK,E F(WA!.T]9
M9DLO=T-99#ED6#!U:2]M8V@P,S8U3T9T-'1.=$QX<EDK<7I.8D=E4U=2:3!F
M3&E1-#)P44)2=&ER5CDU3"]!1%%H33EX3BM:-70F(WA!.V)+5U5T27(V5EIQ
M<4DW0E5J4U5Y0FLW2T-$,3,V-'%J-"]+;FYI-'5*2C104'IY>$ID5%0R<4I:
M5S=#3T,T06%/0BM,.%IE0TY65V0F(WA!.V4T24$R>45G5'E.3F,T:SAJ5&\O
M25!N3#E),FPW9"MD<G%C5WI24$Y#<TIG:FPY3V-43T=32UI9*TQR5DM&5#A0
M='1K94$S9'1F9WHF(WA!.S)U4VQ"-58X.'19=DMN-6AL-V0R:VMU3'!B1S)9
M145!2&<W4T]);%1I9&MO0FIW;G91354V*W8W079B>5 K66@U=D@U+VU$*W)*
M3F(F(WA!.T4V9D%Y4FE72UIE2EAM4%954$UJ9U!51&=!;T$V5VAY47E0>7!O
M=74V5&%835=S-C-*<G1Z4% V>5A-:TM7-5)04FIJ35E336Q+8S0F(WA!.S)F
M-%%0=&1-5E134R]S67E22F-225)+:T(U3V]P3$IX2U(W;C=B8S%O=E4Q1TMQ
M=VMJ36AJ1$%Y2T%Z2EAC0G%G16IW4$4T<3-I<G,F(WA!.U9D:7)S5F1I<G-6
M9&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5E5,,3<Q3&1M<V]O<#=G9EEJ;6MA
M1D0X,U=/66HO9V-"46(V4$YV32LF(WA!.V=F;G)R465+,C%B4V1)=$<R.4MZ
M;'56:TDY-6I!6'(O04MV2$LU4FU81'EW>GDU1TE(>"]5>&)19BMC8DPK5SAA
M-#@P875J<5<U4$@F(WA!.UI&-4AK2C-*86%:530O.$%!2$E$1#-U4&HW3TI.
M>DPQ-WEZ-4LX<BM765!3,&)4-')::4M04%1L32\X07)Y=%9Z.'$P>39-04]4
M<V,F(WA!.V5+34)54E-D-4IS9&EQ;3EV8GE3>'I016IY=S%-36I+0WEC:%)U
M2D\T<4YJ5$98;C)T9FM"*U=7<C9H.65N<TIO<%IB:#=Q.5-+-6TF(WA!.T-8
M3'E'4FU744UZ;%8U5$TS-V]O9"MT3G-64D9Z*U)0-50S36--575G2G=T,&%/
M1E5N=55O<G%%8C=%<3%*0S%*3SEA=#%*2E96;V8F(WA!.WE4+TLK1T(T271#
M:E=*,31&4%=U3F='-2]$5U0T5%AU=$0R-DA)2$=#8F%:-F5%:5-2>E8W=CA!
M2U X04PR-TU2=4Y+3&U"2&EI4#$F(WA!.VDV1D5K:VML8V)3:718;F,W*U!Y
M>#A/3$4V6$=E62LO.&162B]W06UF>3%C0E<P96]6:31(,6DV*S!1;THO=F8K
M2S%W949(=54V6$@F(WA!.S-/4#5.+VPK6&UK*V]/2G!5:6IJ;#EE8FQ%:T-)
M:U-P5G%F0C93=#A13E0Q<4YS9D-I;S!U4'4O05<R9C5-9FPQ8E=S54(P<WIT
M2$@F(WA!.TA'6C5:<&I)>&IB;4AQ<G%Q=5<S2E%,,4DK>G1J-%554C!M34-Q
M6%)F:W@K5VM5<&Q44E9%<%=*1$HV.7E7-'=32DQ'2VU7=$9E2E0F(WA!.SE(
M>GE91DXX66E);V-K,#AR9FPO-5(X<4TU,$-W*W!C-%5T,T%M;FM":FID-49&
M2EAC5D1Y=6$Y9#A,2FM/2W5X5C)+=7A6,DMU>%8F(WA!.S)+=7A6,DMU>%8R
M2W5X5C)+=7A6,DMV+S)1/3T\+WAM<$=);6<Z:6UA9V4^"B @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @
M(#PO>&UP.E1H=6UB;F%I;',^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@
M(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @
M("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM
M+R(*(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B"B @(" @(" @(" @('AM
M;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O
M4F5S;W5R8V5%=F5N=",B/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX
M;7 N:6ED.C5#,SDU-$8T0D)!,D5&,3$X.#0X13,U-#9$,#5#14%#/"]X;7!-
M33I);G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N
M9&ED.C5#,SDU-$8T0D)!,D5&,3$X.#0X13,U-#9$,#5#14%#/"]X;7!-33I$
M;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$
M/G5U:60Z-40R,#@Y,C0Y,T)&1$(Q,3DQ-$$X-3DP1#,Q-3 X0S@\+WAM<$U-
M.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.E)E;F1I=&EO
M;D-L87-S/F1E9F%U;'0\+WAM<$U-.E)E;F1I=&EO;D-L87-S/@H@(" @(" @
M(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YU=6ED.CAF-&5D9C@P
M+3AE.#0M-# V8BTY96,X+3=E93)A9&0V.#DR.#PO<W12968Z:6YS=&%N8V5)
M1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^>&UP+F1I9#HU0C,Y
M-31&-$)"03)%1C$Q.#@T.$4S-30V1# U0T5!0SPO<W12968Z9&]C=6UE;G1)
M1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED
M.C5$,C X.3(T.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X/"]S=%)E9CIO<FEG
M:6YA;$1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIR96YD:71I;VY#
M;&%S<SYD969A=6QT/"]S=%)E9CIR96YD:71I;VY#;&%S<SX*(" @(" @(" @
M/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^
M"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C)%,#(U-C=&,$%!
M,D5&,3$Y-CE#.# Q.3$T,S5#-S0P/"]S=$5V=#II;G-T86YC94E$/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(T+3$Q+3$T5# S.C4Y.C(X
M*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I
M/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^
M<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.FEN<W1A;F-E240^>&UP+FEI9#HU0S,Y-31&-$)"03)%1C$Q.#@T.$4S-30V
M1# U0T5!0SPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @
M/'-T179T.G=H96X^,C R-"TQ,2TQ-50P,3HU-CHT-BLP-3HS,#PO<W1%=G0Z
M=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^
M061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A
M<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO
M<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@
M(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z:6QL=7-T<F%T;W(]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO:6QL=7-T<F%T;W(O,2XP+R(^"B @(" @
M(" @(#QI;&QU<W1R871O<CI3=&%R='5P4')O9FEL93Y0<FEN=#PO:6QL=7-T
M<F%T;W(Z4W1A<G1U<%!R;V9I;&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N
M/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @
M(" @("!X;6QN<SIX;7!44&<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]T+W!G+R(*(" @(" @(" @(" @>&UL;G,Z<W1$:6T](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]S5'EP92]$:6UE;G-I;VYS(R(*(" @(" @(" @
M(" @>&UL;G,Z<W1&;G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S
M5'EP92]&;VYT(R(*(" @(" @(" @(" @>&UL;G,Z>&UP1STB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+V<O(CX*(" @(" @(" @/'AM<%109SI(87-6
M:7-I8FQE3W9E<G!R:6YT/E1R=64\+WAM<%109SI(87-6:7-I8FQE3W9E<G!R
M:6YT/@H@(" @(" @(" \>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD^
M1F%L<V4\+WAM<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/@H@(" @(" @
M(" \>&UP5%!G.DY086=E<SXQ/"]X;7!44&<Z3E!A9V5S/@H@(" @(" @(" \
M>&UP5%!G.DUA>%!A9V53:7IE(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @/'-T1&EM.G<^.38P+C P,# P,#PO<W1$:6TZ=SX*(" @
M(" @(" @(" @/'-T1&EM.F@^-30P+C P,# P,#PO<W1$:6TZ:#X*(" @(" @
M(" @(" @/'-T1&EM.G5N:70^4&]I;G1S/"]S=$1I;3IU;FET/@H@(" @(" @
M(" \+WAM<%109SI-87A086=E4VEZ93X*(" @(" @(" @/'AM<%109SI&;VYT
M<SX*(" @(" @(" @(" @/')D9CI"86<^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" \<W1&;G0Z9F]N=$YA;64^4&]P<&EN<RU";VQD/"]S=$9N=#IF;VYT3F%M
M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86UI;'D^4&]P<&EN
M<SPO<W1&;G0Z9F]N=$9A;6EL>3X*(" @(" @(" @(" @(" @(" @/'-T1FYT
M.F9O;G1&86-E/D)O;&0\+W-T1FYT.F9O;G1&86-E/@H@(" @(" @(" @(" @
M(" @(" \<W1&;G0Z9F]N=%1Y<&4^3W!E;B!4>7!E/"]S=$9N=#IF;VYT5'EP
M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.G9E<G-I;VY3=')I;F<^-"XP
M,#0\+W-T1FYT.G9E<G-I;VY3=')I;F<^"B @(" @(" @(" @(" @(" @(#QS
M=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T1FYT.F-O;7!O<VET93X*(" @(" @
M(" @(" @(" @(" @/'-T1FYT.F9O;G1&:6QE3F%M93Y0;W!P:6YS+4)O;&0N
M;W1F/"]S=$9N=#IF;VYT1FEL94YA;64^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" \+W)D9CI"86<^"B @(" @(" @(#PO>&UP5%!G
M.D9O;G1S/@H@(" @(" @(" \>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @
M(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI/D-Y86X\+W)D
M9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y-86=E;G1A/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D^665L;&]W/"]R9&8Z;&D^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D^0FQA8VL\+W)D9CIL:3X*(" @(" @(" @(" @
M/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<%109SI0;&%T94YA;65S/@H@(" @
M(" @(" \>&UP5%!G.E-W871C:$=R;W5P<SX*(" @(" @(" @(" @/')D9CI3
M97$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U<$YA;64^1&5F
M875L="!3=V%T8V@@1W)O=7 \+WAM<$<Z9W)O=7!.86UE/@H@(" @(" @(" @
M(" @(" @(" \>&UP1SIG<F]U<%1Y<&4^,#PO>&UP1SIG<F]U<%1Y<&4^"B @
M(" @(" @(" @(" @(" @(#QX;7!'.D-O;&]R86YT<SX*(" @(" @(" @(" @
M(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/E=H:71E/"]X;7!'.G-W
M871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO
M9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N
M,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X
M;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.G-W871C:$YA;64^0FQA8VL\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T53
M4SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT
M83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N
M,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8FQA8VL^,3 P+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @
M(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @
M(" @(#PO<F1F.E-E<3X*(" @(" @(" @(" @(" @(" @/"]X;7!'.D-O;&]R
M86YT<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" \>&UP1SIG<F]U<$YA;64^1W)A>7,\+WAM<$<Z9W)O=7!.86UE
M/@H@(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U<%1Y<&4^,3PO>&UP1SIG
M<F]U<%1Y<&4^"B @(" @(" @(" @(" @(" @(#QX;7!'.D-O;&]R86YT<SX*
M(" @(" @(" @(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]
M,"!-/3 @63TP($L],3 P/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\
M+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P
M,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F)L86-K/C$P,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @
M(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @
M(" \+W)D9CI397$^"B @(" @(" @(" @(" @(" @(#PO>&UP1SI#;VQO<F%N
M=',^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D
M9CI397$^"B @(" @(" @(#PO>&UP5%!G.E-W871C:$=R;W5P<SX*(" @(" @
M/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F
M.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]P9&8O,2XS+R(^"B @(" @(" @(#QP9&8Z4')O9'5C97(^061O
M8F4@4$1&(&QI8G)A<GD@,3 N,#$\+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R
M9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M!@0%!@4$!@8%!@<'!@@*$ H*"0D*% X/#! 7%!@8%Q06%AH=)1\:&R,<%A8@
M+" C)B<I*BD9'RTP+2@P)2@I*/_; $,!!P<'"@@*$PH*$R@:%AHH*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*/_
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M*\<S6!XVX>L#U(G+V1>7E,'E'D_;Q=OK?9\XYM?=WK]?/"R5L3Y8VR.^BPN
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MP+>4..CT)T==XW_#N02A%CTE=25A?Y'505'(=.[*0.Y?OT>B_75M*U\C'5,
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MF.N=''4TSI.;T7/Y3OV$=1ON(VL;#<1H,MXAYG3W:2H\FAJI']G#)R!SC*\
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M[.VTQP<.O+R]X_LJ0XW9Z?'[#06BB?*^FHH6P1NE(+RUHT-D #?X!!2'$O\
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M+&;_ -UN_P#Z2N9==K^F'O[%&+-/^^HM=D-[MV.VB>YWJJ924, !?*\$ZV=
M #9))\ MBM'FF+V[,,>J;->&R&EF+3S1.Y7L<#L.:>O7\%HZF5CE^MF26F&Y
MV2K95T,N^61H(Z@Z(((!!]A"V2T.#XI;<,Q^&SV82^31N<\NE=S/>XGJXG0&
M^[N'@M\@+EVXWF^WCBYE5HFXAS8S;Z25[H733:C.G- 8T%S1W$G\%U$N1;O^
MR;;QGR^KRW%[C>K=+-(V%D$+CI_,TAV]CIH$=_BB86_<LSJ^&F"62JN#YLPH
M99'-FO$,X!])Y+21Z6QKH#S:]'7386SL_%:BR'/(,=QB@?<Z<P-J)[BR;ECA
M:1OJ-$DC;1KIZ1UTT5#L\RRCDX*4-MQC'*R-UY:^BI;?- 7.IV->6E[AUT=@
M<O7O(/@M7P*I[CPVSBOQ/([;RFY-CDAN$49<PN .F%^OHGTA['#VH-U_Z0+)
MJFYT=OQ*Y5M?1RE@BIY.<.8TN#GN(:2T#0\#W^&E*<5XQ8_?,+NF0SB:A;:P
M/*Z9^G/:7=&<I_K<QZ#NZ]^E1_"C-YL&R#-:PV"LNE%-5!DDM*-F!X?*6!WJ
M:[;NO^SXKWQOA_D>2X%GEX_9TM'/=IHZBDHBTM,H9*Z1P:#X:=IOK(03IORB
MHFVV:X5&(72*B)Y:6H+_ .CG=O1:7\NFG6STYN[7M6ZO_'"CLMEQ2YU%EG?#
M?8W2\K)P70-:X _U?2/7?AW*J+OFMSN_!?YF0XC<655#%#%55!B/)$V.1NG:
MUL/<0 1[2O>]VVL?;."K?(JAW8G^E'9./)_3Q_2Z=.GK06EC/&VFN68TV/WG
M';E8YJPAM*^KZ%Y/T>9I +=]P(V-KZS+C72V7+9<>LEAK[]74_2I\E/T".\-
M :XN(\>X ]%H>.=%43\7>'$U/32R,CJ8^TD9&2&@3L/4CN\5'(:^Y<)N,63U
M]QL%=<J"\R2/IYZ9FR>>3G :>X]3REO?T!]6PSN#&8"\<7LTNLU95Q6<44M4
M(JIY @:)(R=MV0"!ON]JWLOR@82)J^CQ&\5&.0R]D^YCHT'>N[6AX="X=X[E
M!^'=GN^3YQQ)956R:TU-XM=4&1RL+6QODD86M)UW]>OX]%%+;3R6NPR8S=['
MFTU[[8Q_L^FJW14DK2[>^7E=_($'OV@Z'SCC)8L<L5HKZ**6[37:/M:.GA/*
M7,[MN)WR]>FM$[V/ JJ,CXAUF4<5L"8VCNMBGBK((JN@G<YG-S3-(.NG,"/6
M OG-,1NN#5& 9-1V2IJ*.U0M;4T7:]NZG=VSY=.>&C^\(YM:!;]V_/(\@N&<
M\7L$O46.7"W6Z.JIXXY)XCS2 3@N<2!H-&]#\?P"_.*.9G!,9%Y-M?<(A.R&
M1C)>S+ [>G;T?$ ?BHIGG&RVXG/86.MTM8VZ4<=;S,F#>RC>?1)&COQ]7<IC
MQ0L?SCX?WZUM9SRS4KG1#UR-])G_ ,S0N7\5Q>Z9IC64UMTHJALUGL<-)0MD
MC<"3&[G'+L=3RQN'_.A#HVJXBTT7$J+$HZ(R-\C-9/7=L&L@9REW5NO4&]=_
MUE!Z[Y0U(*FJFM&+W2XV2E?R37%IY6M]NN4@;\.8@_<H_P $;!=,L@S6ZW>*
M6EK:RU,LL$DK"W_[ &.=U'^Q&?Q*C^.91>,(P&^X#<<1N,EVJC-'"YD1+']H
MWE).AZ6N\%NP>G<@N++^,MJLF&6;);=1R7.BN<IB:T2")T9 .P[H>H((TM$S
MY0EMI[O!#><=NULM=0.:"MG;U>WP?R:ZM[NH)[U66;X9>,?X)8M05M).ZNEN
M<M5) QA>80YF@TZ[CH GVG2GWRJ*">KL^)-I:268LJ7@B.,NY1RM]0Z#H@V]
MIX\T51D]%;+MCMTM%+7O:VEJZKISAQTUQ:0--)UU!.EN<\XM4^.Y(W';+9*[
M(+X&!\M-2=.S!&]$@.).M'H.XCJHE\J*BJ*FLPAU)32S&.KDYC%&7<HW%WZ[
MNY13B78JG%^+]TOMWI\B?8KFSF95V24QRM<0WT'.[NA:?1)&QH^&D%IV3C+;
M+KB%_NS+=4P7&R,YZNVSN#7CKKH[7=O8[M@CJ.Y1EWRB(OV53W*/#[L^@+N2
MHJ0_^BB?LCE#^73CK1Z\O?I1''L<DFP#/<@AL5ZHG5E$Z"%]PJS/+5[>'%W+
MV;3OT1Z6SO9TI+;Z"H'R2)*4TLOE)@D/8F,\^_*R?HZW[4$IXBW2^Y99,.=P
M_GN$%-=JELL]=3 M["#6CSD=WTCT];5EYQQ1;C&1T^,V:Q7#(+UV(E=#"_1:
MW1/4Z)<=#9Z>/>MAP&AE@X2X[%/&^*5L3P6/:6D?TK^\%5IQVIZ*/.H*R]X[
M>Z:G$($-_LLVY=@=&N86\NP=CZ0.M=? !;7#3.J+.[--64E-/1U%/)V-12SC
MTHW=_?X@^OIW'HHQG?&2EQ#-?F]466LK)#"V1DE,\.<]S@>5@9KJ20!W^*\O
MDXUF45N,5[\H=724S9P*":N:1-)'KKO?4CNT3OQZ]%7O$NZU-D^4O0W.CMDM
MTEI:1LAI8AM[V]D\.+?:&DN'W(+)X=\8J3*<DEQ^Z6>KL5W +HX*EV^?0V1U
M#2':ZZ([@>JU-TX\P"NN'S>Q>Z7JU6]Q%5<(26QL [W#33TZ'J2%#[ +EQ3X
MV4^1T]GJ[3:*"G,3YIFZ<=,>!L]Q<2_N&] *#V^V5&%17BP9';<O-P=*131V
MJJ,--5 CE]+T3L'7> =@Z(&D%E\>\UAR'A#8[[C-;4P15%Q:QW(\QR,(CDYF
M.T>\$#V=Q4[LO$EC,^H<*K[;)#/+2,E@K73!S9OZ(/\ HZV.YP[^\*GN(&)U
M-HX#V>FI[-744]3>/*WT4DIJ)(@8GM',0QNNC0=:Z;Z]5+>.EIKK:S!LTLU+
M+-76MT44T<;27.;H/:#KKK8>T_[Z"3W?B-17V]YEB(M$]116VW5+JRK94AG,
MUL>G, Y>AYB6[WX$^Q:#A7F6+85P9FO,-/7T]":^2-L$\S9IIYB&] 0UK1T'
MJ&@"5B<'<=K(>%6;Y!<X)1=;Y%5.T]A#RUK'^!Z]7N?_ "4$IL+O5[^3W2_L
M^AJ)*NWW>6H?2]F1(^,L ):WO)'3IZMH+8QCCM2W"_6^VW_';A8FW$M%'43N
MYF2<QTTG;6]"=#8V.OXJ5\<9YJ7A3D<U-+)#,R!I:^-Q:YO](WN(4$L'%&\9
M=?+-:[+@[M,#6UM17QGDIN[F+3KH !TWHDZ&E.N.D,D_"?(XH(WR2.@:&L8T
MDG^D;W (*EP?C:_&L!LD59CUYN--"#%4W-SB&<Y>X\K7$$.(!'>0K4S+BO8\
M<QFTW>-D]P?=V!]!2P#4DH(!Z_V=; />=G6BJ_GH*@_)'%**67RGL&GL>S//
MORL'Z.M^U0_+,3N\O#WAQ?Z:BN$\%L@[.LAI-LJ(F]KS!S>A+3W^EKH=%!<&
M$<7H;YD[,=O]AK\=N\S>>"*KV1*-$ZV0T@D ZZ:.CUVM-6<?J#]OUE+9\=N=
MUME$XBIKZ;J&-!T7AH!]'H>I(VH3P_L]+F/$*BK*"T9:^BH0'_M2\7#9B(!(
M:&\AWZ1^B'>)/18_#*_WKA147W%KAB=?<:^JGYJ9T##RS.URCKKJP]#L;ULH
M);?N* SK@[FM;;:2HMC[?V+&O$^W.YI&]00 1T'\U#,LSS(['P@P:.U5%QIY
MJB-TLMR:\D/].0=D20=GH'=_<%@X);+A'P4XE0S4-1'4224W+%V3@3J3KRC7
M7\%O,TQR[7+Y-F'MH:"IGFHINUGA9&3(UA[4<W+WZ!(_B@^N-69W6Y8=A]UE
MI+G8975DS)8'R.8][6AGI'HW8/4CHIW;..M'-E5#:;MCEUM%-7O:VEJZL<O.
M''37%A TTDCJ"=;4!XQWB?-L.PJOI+/7T_)6RPR02Q$N;RA@V=#N*E'RGJ*H
MJ;M@;J6FEF[.KEYC'&7<HYH>_7=W(+AS"]MQO&+G>7P&H;10.F,0=RE^O#?@
MJ=_](J)]LBN%-B%TFHVGEJYQ)_10'>@WGY=$D:/77?I6/QF_U5Y1_P #)_DN
M=\8SZMM?!5^*MQ:MJ9+C'/#25<<?-%*V1S@YW0;+VG8T/4.Y"%T9=QGM5CQ*
MPY#0T4MQHKL]S&@2"-T1;](.&CU!V->Q?-'QNL4N+7;(*BDJZ>@I*H4M,UVN
MTJW%NQRM[AT![SW#\%3.<8==K)P?PFWUM'4.K'UT]1- UA<80_6FNUW'6M^T
ME6Q\I;#[CD&$T#K!2NG?;)^T-+"W9=&6EOHM'?KIT'AM!XV#CW25-XH:/(L=
MN%BIJ\CR6KG)=&\$Z#CMK?1ZCJ-@;]75;//N,M+C>4C';39*V^W5@!FBICKD
MV-\HT'%QUU/30WW]ZJS-[[=N,TF.V"SXQ6T$E++S551,PAD!(#3UUT:.IZ]3
MT&EL;I/<N%7&^[W^LLM9=+5=8G,BF@9LCF+':![N8%FM$CH=H+"P3C+1Y?EE
M59*6S55*8*9]0Z2>0!P+>7F86:Z$$D=_@M3B?R@+?D5UMMMAL57'6UM8RFY>
MU#FQL<0.T+M>LGIKP[PH5PMN%5=_E Y'7UMMDME156^:7R20>G&"V/EYO]HC
M1/M*E/R3;9)38A?C54LE/42UG)S21EKBT1MUW^ )/\2@S[AQ\H6Y#645FQVY
MW>WT+B*FMINH8T'1>&@';>AZDC:S<?XUTMZQ#)[_  V:9D-D[/\ HC."9P\D
M @\OH]WM59\-+[>>$EQOV-7#%;A<JRJG#J5].PZF(!:.NNK#T.QO6ST6MX?V
MVX1\(N*$5103PU$II^6+LB-D/=L-'CKV(+!=\HN 4-+7_-&[&W/=R357/_1Q
MOW]%KN73CK7>6_\ FLN[?*$MM)-'44>.7>KL+GB,W,M[-A=XAH(T2.O0N'<M
M9+03_P#HCBE\DE\I[!I['LSS[\KW]'6]^*7R@G=\DVFI6TDIJ1!">R$9YP?*
M 3TUO?>@O&DNL%=88KM;MU-/-3BIAY1UD:6\P ]I7/?"7BADUQXE76CN-!=J
MVCJZOLVT[B2+4TRN^GZ/0-'H]=?15R<'HY(>&&,QS,?'(VBC#FO&B#ZB%4&$
M2W##..64T=SLUP=#D%<YE/51QGLVM?*YS7EW<1IW71Z$()-?^/5)37BOH\=Q
MVXWVGH"155<!+8V '1<--=Z/0]3H=/5U5C8!F-LSC'X[M9W/$?,8Y8I!I\3Q
MK;7?@0=CP*YXP:_7;@S)D5@O&,5U?+52\U+/"PEDY +1UUU:>AZ;(V1I63\F
M3$KIC.'5LUZ@DI9[C4"9E-(-.8P- !</ GKT]0"#6T$]@I?E&9!)%;[A^V8*
M)TSYG58,+OZ%A.F<NP2"!U<1XZ]7A3?*)966F>MH<.NE3Y,[_M!CDYHH8]#3
MG/#>F^O0CP[UB1T55_Z2F65'DT_8/MCVMD[,\I/81C0/<O3Y.U!40<&\LAJJ
M66*626HTR2,M+AY.T=Q'7Q06!'Q:QYW#@9C(9V4?-V/D^@9>V_NP-Z)\=[UK
MJHOCW'JDK+U;Z._8Y<+)37$@4E7,[F9("=!QVUOH]1U&P-^KJJKL^&7J^_)Y
MGBH**I=6T5\?5FE,9#Y(^Q8T\K3U)&]Z]A5@V#BA><FK;%9++@SGS1,9%62U
M\9[.FUH%S3KH  3UT3T&D'A:+]5T'RB,XDFGJ9Z.AMDM0VE,IY/0CB=H#N![
M^NO%6+A7$>+*.'MTRJ.VR4T=")R:=TP<7]FP/^EH:WO7<JUMUFK*_P"4+GL0
M@ECBK+5-!',YA#"YT<31UUI17!LEO6*8!DV#5&)W::ZS"H+7LC/)&U\?*YSO
M8 TD$;!06_0<9K5)PUDS"X44U+%Y2ZDBI&R"1\L@&P = =VS[ "JEXN\7:O)
M\*HX([/=\>JGU;*B"8O<&5$(8\'E> W?5S>G4>U:^+#KS>/D\4IH:&I?56^[
M2U$E+V9YW1E@:7!O>==/PVO7BSF]QS_!;51T>)7"ECH:AAJ*@Q$M$G9N:(V:
M&]'TC^ 07+DO%*DQ"@Q^UP6^LO=_K:.*2.CIOI$%O>XZ)V2#T )Z%;#AMQ1H
M\QNE99ZNV5=EOM(WGDHJKO+>FR#H'8V-@@=X[U3W%''*^U9CCN55%+>IK));
MH(JB6TO,=13N;%RD!VO1[P>N@>HZ*0<"[-'=<[JLE@LV04]+!&YD5PN]=VCZ
MC8#0WE+!OT?$.(&@$%J<2,XBPFDHIYJ%]6*F0QZ;)R<NAO?<=J,,XTT,-S9%
M=K)<K?0R@NAJ96]7M\'<FNX^PE8WRCJ6>JM=B;3P23:J7<P8PNT.4=^E^?*$
MHY:EV+^3T[Y>2H?S<C"[0]#OUX+*JJJ)G'HX+UR[357-,\(QZ=6RM/%ZEJ<A
MI;;<K)7VR.L<&T\]1TYN8Z:2W0T"?$$K89=Q)BL]^-DM%IK+U=6-YY8:;H(Q
MK?> 23H@]WCWJ/<>J6:>]8:^G@DDY*E_,YC">4<T7?KN49S2TSXYQ*NETND-
M\-IKP7QU-IE,;P3H\KCW=""-$CP*B:JHS"M=Z[1FG/*8XXZPL2W<4;?7XI=[
MM'13QU=K \HH97<KQLZZ'7=O?AX=RT3N-D0H:>N&-7(T+CR2U'-_1L=OZ+7:
MTXZ]H49M=BD?@687>.T7.D?5P-CC-94&:2H_I XNY>1I\!UZ[V5OW4<W_HV^
M3^3R=OV0_H^0\V_*=]W>FJJ?A$7;U4<\<,\O=,\GXC6>Q8[;[L>UJA<&!])!
M&-/D&@3O?<!L ^TK5XKQ3I[K?HK/>+1666NG_P! VHV0_?<.H!!/ATT?6J^N
M]BNT6(8%D%'035@M3=STP:>8:EYP2W6]'1!.NG19\M77\3.(>/UMOL]70V^V
M/:^:HG;KN>'$;[O#0'?U)375DF_<U1^W#'//-):[B_'!?+K::;'ZZLK:.9\,
M;*=_.9>5Q!=H-VT=-^/>MSB'$VTW^TW.KJ8Y+=+;6&2IAE/,6M];3X]1K6M[
M^\*KL>R27%^)^9UXM51<*8U,\<QIQM\6YB0?N)&C^"]<<QF\Y='F][%"^A;=
M(',I87CE[1QE;)H;UOZ &^[;OO4174BC:+DSPG,\>&$HCXVPN@J:LXW<1;6;
M;'5<VVN?X-<=::3]Y6RJN+$$&/6"ZFTR.;=I9(FQ]N-Q\CPW9/+UWM5[291<
M6<,JK#AC-<:Z&)[))#&0QC.8O+G#6PX=WWZ^Y?%SL5TFX0XG6TE%/*^W5,[Y
M8@P\S6ND)#B._7HC^*:ZNJL;1=Q.)SPSR]<PN+/LWCQ"JL\,E"^J-QD=&"V0
M,Y-%HWW'?T_Y+7Y5Q(%IR.6QVBR5EYN$$8EG9 >41MT#ZB3T(\/$*M.(.25N
M:7#%JFGL-QI*6GG/])+&3SO+H^;6O :'7VK;<4XJ6'-9JJYV:\T!,8["[VF7
MF,I   <T@ $=0?2!Z#P4S7/'#2O:*IU31/#,?V_WFGU'Q*LTV%2Y),V>"&)_
M8OIW#<G:^#!X'>][]7JT5I+;Q>B=744=\L%?::*M(%/5S';'@]Q.VCIU'4$]
MZB-39\MRK@Z?VE%53UE+7"HIV3-/;30AA!Z'J3MQ(WU.O'HM+24D.45%LM5/
M:,JK)FZ%0*VN+8:=W<2-L.@.O?H^"B:ZE:MHN\,=(].;HV^72FLMHJ[E7%PI
MJ:,R/Y1LD#P ]9[E75JXNLJ*N@-QQZOH+77R=G3USG<S''>MD:'3??HG2G&6
MP/?BMP@AMS;HXP%ODCW\G;#Q'-Z];U[=+GZQU%RH[M:X,*I\CHJXSZJ[=5;?
M3,&_7H=._9<!KUJ]=4Q+;:+M=%41$\%V46;QU7$2MQ04+VR4T7:&I[0$.]%K
MM<NO]KU^"\8L^BDS:[8[^SWA]OIW5!G[4:?IK7:UKI]+U^"@>4S5V&<9I\BF
MM=766VMA:QKH&[/^C:TCU<P+.X^!6%BDU=<>*>2W2MME50-J+;,X1S,(+1R,
MY03Z] '2C7/+W4F_7$Z<\=7TWD'&YE5;Y*BBQFOJ'PDF8,?MD3-#3G/#>F^O
M37AWJ05?%*W-P1F345)+41]N*:2F+PQ\;R-D$Z(]1]NU57"_-9\5Q"Y0_L&I
MKHJF=W93QMVPR<C06/Z=VM'\2O.JQ^OLG!&IEN<+Z>2MN44K(7C3FL#2 2/
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MI<L<R"Z9-EESBN60W!IC<Z$'D8TD$]2!LGE:.@  &@K51$!$1 1$0$1$!$1
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M+R.9S:<6GHX ]X/@H3\H>VR7'A7=G15LU**0"I<(S_IF@$=F[K]$\V_P"JO
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MS7#F.V]VMGQ/XMY[+>*Q'+.,9_=?5VN-+:+957&XR]C1TL;I9I.4NY6@;)T
M2?P6-C-_MF36B*Z6.J%502ES62ACF;+3H]' 'O'J44X\6V2Y<+KX(JV:D\G@
M=4N,1_TK6-),9Z_1/BJ@X6R5^$\#[OFM+<ZFH>^)T%/02;,-.\SB,2 ;UO9V
M>BU=CIY%RC/:<RI.&47$D9S<G5Q+9W4ID<6<CI.0#Z7*>I!Y>77@K[QS,):_
MA-%EE1 WRAMMDJY(F] Y\;7%P'J!+3_%!,T7&-'?\BR.UUU_GR/+?V[VKC20
M6^FD=2C7]7F:=-\1H#IX[VI/Q,S'*:SAEA%;45%?:KS+4S05!87TYE+=!KG-
M&N\:/=K9*)PZG1<L\1:3-^&5^L=;39M6W*IN[GQ/%1OLVR#E!] DM+?3Z=!K
M2S,CAROA9Q!Q6:7+J^]T]WG$=1%4.<&N]-C7CE+B.YXT1HC2&'32\*^J914-
M153!QB@C=*X-&SIH).OX+FRLAR7*>/F3X[;LJN%IHN0N>8Y7.Y(PV/;8V\P
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M%_/%AGVC-[K)\$\\6&?:,WNLGP4H^:F/?8-I]SC^"?-3'OL&T^YQ_!/,8O\
M6/B?Y1?SQ89]HS>ZR?!//%AGVC-[K)\%*/FICWV#:?<X_@GS4Q[[!M/N<?P3
MS&+_ %CXG^47\\6&?:,WNLGP3SQ89]HS>ZR?!2CYJ8]]@VGW./X)\U,>^P;3
M[G'\$\QB_P!8^)_E%_/%AGVC-[K)\$\\6&?:,WNLGP4H^:F/?8-I]SC^"?-3
M'OL&T^YQ_!/,8O\ 6/B?Y1?SQ89]HS>ZR?!<UY;<Q><GNMQ828ZFIDD9L:]
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M ^2I934,_8,<6C7](6<H(<T=Y[M#U+QS;A/?+OQ%GRS'\F9:*E\3(V:@+G-
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M2*:L.>+-V*>,=?7USS0[,17W/@QC-WK;I53N;4RQ212O<_M7%\G*]Q)[VAA
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M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!5[QWNO[,X=UD;7:DK9&4K?N)YG?\
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M,>5T.5WDQXY11.%-!V#2>TW'H-Y6\SCHN[S_ )*T\)S['<SH:JJL=<'MI?\
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M>I/]*'$_>KR^9V,_NY9O<8OTK96VUT%K@?#;*&EHX7NYG,IXFQM)UK9  ZZ
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MP9+-;);K'<Y+=1/N48Y65;H&F9HT1H/UL#1/CXE'6:V.NS;HZW41N;1RMJS
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MS)VC3L;!#M#\1KH@GJ(B##_:EO\ VE^S_+J7R_7-Y-VS>UUK>^3>^[KW+,5
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MS:]770Z#^-J\YX-]HFY%7ESC'#'7W;?(^)M[MF%XI=X8J-]1<NU-0TQG7HN
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M 0T!QYB!U/K7ZMWJ"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M(S,8=@_.JP_;%#^<U/G58?MBA_.:N4/FK?OLBM_**?-6_?9%;^45.^GHV_\
ME;W_ .O^[J_YU6'[8H?SFKFKC%5T];Q!N=11S1S0.$7*]AV#J-H[UI?FK?OL
MBM_**U=;25%%4OIZR%\,[-<S'C1&QON5:ZYJC$PY-LVVYM%$4UTXXNEN /\
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MOR?^$]1KKBJ(E2-JVJB_3:NSCC'[\75RB6=9[:<0A#:QSIZUXW'31?2/M)\
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M6]%H!'KT3KVJ)JB.:M=ZBW.*I6^B@_$/B%3XE/1T5/0RW.Z58YHZ:)W+Z.]
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MFU2U@CEJ Y^]C9!=_6'3J-]%.[SP\LEXQFVV2M\I=!;V!E/,UX$K0!KOUH[
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M1RTK'3"!_(Y[6T[3R[]1.MJ;TWR=\0@92D55X,\$O:]MV[.9^M::1R:Y1KP
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M'XZ'X+*B-53SMEMQ?VF(ICAG/[+M1$78^M<V_*'I3#F\-1KT9Z5G7UEI(/\
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MQ4]C9-MHVF.'">C8HB*[L$1$!<K\;_\ 65=ONB_\-JZH7*_&_P#UE7;[HO\
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MF#?.RWS^1OUK[E6S.(ER_B:M-NY5T_Y<JWZZ5.17^IKJIX,]5+OJ=!H[@/8
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MP=7._  E=FVZC@MU!345(P1T]/&V*-H\&@:"VLTYG+T?Q]G55O)]&0B(NE[
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M-?%#-[CG?#VV6VDQ*X4S:":,U-08B6-D#'-#&:&]'9/LT%T_BD6\0L\4S/\
M\!A:YKA_^C ((1$\N"'5/%>C@P.DR3]GR.-14FE%*)AMKAS'?-KU 'N\0LBM
MXF4\-EQFMIK=)42WR3LXH!* 6.!#3LZZZ<0.Y55C&-5M1G%-B==2S&ST%QJ*
MESW,/*]O* .O=UY&_P"(K)X76:YU&>6JUW*GE%'C[ZF1KGL(:3S>!/3Z>BL(
MKJEYE.T7IF(Z\/WX96+E'%2GM=]GM%FL]9>JRFWVXI]@1Z[QT!)UX]-!9-!Q
M/MMPPNYWZDII3+;PWMZ-[@U[22 .O4:/7K["H'1UM?PQSW(JBXV:KKJ*YO=)
M!40-WO;RX#?=_6T1W["P;58+L<%SN^5M!+2&Z\KH*7D/,1VO,3R]^NNA^*G7
M4MO[F9X]>&.6.24GC="*2GK/FU<?(7'EEJ.;T&.W]%IUIQU[0LFX\::&FE9-
M36.Y5%G<X,\O+>1I/B&@C1(^\=RP*BCF_P#1M%/Y/)V_9-/9<AYM^4@]W>EZ
MHYG?)SIJ=M/(9Q%">S##S ]L-].],U=?0WE[']7_ *YY?27Y;Q'MEBH;9+30
MS7*JN;&R4E- /2>T]Q/JWO7<3OP7GA?$6"_WJ2RW&V55GN[6\[:>H_K@#9T2
M =ZZZ([E5628_<(+9A-_-+<9:&GM\5/4BB)9/#REQV#K;=AW?[-'6UO>&=MA
MO6=1WBEME^%+1M)97W.LYG./*6AO+R=?I'H'=!_!(KJF4TW[LW(C].'LVL'&
MIM3#5FCQFX5,U,[TVPOYFM8-[<YP;Z/=ZO6MQ4YI-E7#*Y7+%*>L%S&J<01#
MFECD);LC7?Z)WM:/Y/5)-3TF3>4T\D1?4,UVC"WF&G>OO7I\F^FGIK'>6U$$
ML)-4T@/86['+[4IFJ<9]2U7<KTQ5/]43^S>5^4/P#$+)#>A67:]U8Y!'S[?)
M(=%P+CX N#1W^"S<)SUN0W:JM%PM55:+K3L[0P3]>9O3N.AUZ@ZUW%:GC?3L
MGM= ZJL%1=*..0F2>DE+)J7NZ@!IV"-]_38&_!:+@U67B;*JZ&DFO%3BS8?Z
M.2Z-]-K^F@#UZ_2Z#IKP4YF*L+S<JHNQ;SP_W_<IMQ'SN'"6VUU11/JF5CWM
MVV3EY WEV>X[^DH]0\8J1][IJ.Z62OME'5D"GJJCIS G0<6Z&F]W4$Z6H^4I
MS<N,=FP/?V\O*T]SCZ&@M)G5VN?$JXV>QT./5M#44\I-0^=I_HB= ]==&COV
M>_IT455S$S$*7;]=-RJ*9Y8Q&.:PLHXFQVR_RV6R6:MO=P@'-.RFWJ/UCH"2
M1L;Z:&^]:R_9S2Y5PJR&LM?E%'6TK&LFA<[EDB<7C1!'@>O7V%0?(K3-BO$"
M]55XAOYMU>]\T%3:93&7%SN;E<>[ILC7?T!ZK.MEAECX99=<F6BXT4E='&UC
M*J<S23 2 E^N1I'?WG>^OXQJJG,*S>N5353/OP;[',_.,85APN=)-50W$/8^
ML=-UC(E(/,"#O0(/?X*89/G,=FRZT8]!0/K*NX<IVV4-$32[6ST.^YQ^X*"U
M6.2W?Y/E!$('^74+'54;"TAWHR/YAKOZM)Z?<O'@Y2W'(\WJLCOE/+&ZAI(J
M:+M&D;?R!G,-^QKB?:]3$U<(6IN7(FFW'KC_ );+AU78_;<LSBKA@JZ0T;GN
MJIIZ@2,Y1([?*T-!'4;ZDGP^_P"QQMIN=M2_';DVRND[(5V^F_NUK?LYE&[!
MC]?=[CQ/H889(Y:ISNP+VEH>1,YP )Z==:_%?>+YO=+)B]#BT6(U55=Z>1S#
M'-$>1P+B[9&M[Z_=X[415,1T4INU4Q$9Q''T]<\E[TM5#6T,552R"2":,21O
M;W.:1L'^"YXX8<0JNP6:ZB2W7.]S]L)7%KG.;!&!WN=HZZ[\/!=!VX3BUTXJ
MXHH:CLF]I'#]!CM=0WV JI?D^4<T&-9$VIIY(W/FZ"1A!<.3V]ZO5F9C#HO1
M5-RC3..:6T?$RR3X1)DLG;101R=@^G(!D[7^P/ [!!WZEIK9Q>B?<***^6"O
MM%'7$"FJYCMC]]Q.VCIU'4;[U65CQ6ZW?A)<HJ2DG-52W05/8%A#I&B+E/*#
MWGKO\%ZTE'#E-5;+73VC*JR5NA4>6UQ;%3'H"1MAT!U[]'PTJ:ZN#F\3=G'Z
M?*ULSXGT]AR 62W6JJN]R !DC@.N38WH:!).NO=XKXQ3B?3Y/D4]FI[94TSF
M0.D,DSP'-<T#F:6ZZ$$D=_@H;=9*[A]Q:N%[J+557"VW",LCDB;LCFY3H'NY
M@6ZT? K\P&2ON/&6Z72LM51;Q4TLCQ%(PCE!:SEV==Y&B?:2IU3E??W->,^N
M,8]/U:+&<JO%LX5WVIII:Z:J?7LB;5"0N-,.4'F).] ZY?#JY2&7+;M>."=V
MDK(*ZGJJ5E.&U[W%OE/-,-N:=#NUHZ)[UK,$LEQK>#V84,-)/Y7+.Q\<3F$.
M?R\CCH'O.FE9D5RGN7 JZV;]F5L%7;601N[2,_TI,^_1'?T ZJL9Q^S&B:HI
MXS_ZS_EEXWQ:_8F+6:.KLETJJ1D8BFN#CIKG]=AI(TXCVD=RNJWU<-PH:>LI
M'\]/41MEC=ZVN&P?X%5!D%',[Y.U' VGD,XB@_HPP\P/:C?3O]:L/APQ\>!V
M!DC7,>VCC!:X:(/*%I1,YQ+LV>JN*M%4YC$2JV+Y0C*HUT%NQ&YUM;2O(,4$
MG..0$ASW$-/*.@\#W]X4BMW&>U7+AQ=LJHZ&9TMK,;:F@?(&O:7O#1IVB"#L
MD'7@52O!W.IL%JLMJG8_672CJ*AK734HZQ2 OY6N.N@=L]?9XK)L>,7IO"#B
M-?*ZW34IO,E.ZFI!&0X@5 <7!NM\OIZ'L!6CL6UA?'"SY+4U+74-10TM';WU
MU752OVR(M+06#0VXZ=W].O0 K1_^D32\_EGS3N_S?[7LOVCL:W]VN7?LYUL;
M%BU5>ODT0V.AA["OJ*'F;&X<A=().?1WW%Q&NOK57?.R[GA/YM1A]S_;>^PW
MV)Y>7M>?FY=;YO#U>._!!=N?<7[)BUFM-92QR7:>[1B6C@@/+SL.O2<2/1ZG
M6M$[V-="H];N/,51D5ELE7BUQH+C7U$=/+'4OY##SN#6N +=N'7?AW?BH!EV
M&W[ V\.\@=;Y+FRRT[(ZR&(%_9/$SY=$C>A_2%H=W M'L6-EF63YEQAP"Z.L
ME5:J/RNGB@-4W4DX$X+G?[H)T/Q_ ++R?CU;L>RB]62JLM5+-0$LB=%*#V[_
M $>FM>B-$G?7N[NJR\QXUTECNM#:+98ZR\WB>&.:6FIW:[+G:'!G1I+G:.]
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M^&F>.LWJ<?4WV>/W*7X'P@M]EDCK+X]EQK6Z<V/EU%&?N_K?C_!6FT!H :
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MZM^3\2+Y25\MMT:6"E;TY@26[]!H !.^@))TKL1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MX>B9O35TA(T1%TOI!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!J:K&;%5U$D
M]79+9//(=ODDI(W.<?621LKVMMDM5KE=+;+90T<CV\KGT].R,D>HD =%L$0:
MNJQVRU=<*VKL]NGK 01/+3,=(-?[1&UE7&W45R@$%QHZ:KA:X.$<\39&@]1O
M1!&^I_BLI$&D^:.-_N]9_<H_TKUJ\:L=9.Z>KLMLGF< #)+2QN<0!H=2-]
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M0-L[Q]'DUH]Z#I1%SWQ,R'+[[Q QS!+9<Q8ZJHI62UL])(X#M2USG\KAIQ:
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M%?)L%%WR6YUU=4W*0RPBJF<_LXAT;H$]-GF/3P+40M)1>GSJS3YW48C&Z?\
M;$$?:O!C]#EY6N^E]S@J@RJZ95GW&>OQ&PY#46"W6N,O=)3N<USN4-YG'E(+
MCS/  V  -_?H,'-TQ_Y0=\=DM8+G7V^W2NEJ&#E,S&0,+21X$L#=^WU]Z)=3
M(N-X\YR+):6YWRJS2\VZY,>XT=MH:65U.[0V&ES#RCOUU!/B5O\ .N(F55_#
M;#:^.MK;9=Y*R>EJ70N=!VY9R<KB!KH01T[M[0PZI1<O9]+Q$X:9!9:EV92W
M>6\%\?93M/8QR>B".S)(UZ8(( [NY9E[J,VX8\0L7-TRZIOM'>)Q'/#+S!@]
M-K7@,)(&N<$%NN[N]8PZ51<\WJZ97Q(XMWG%K'D4^/6NT-=S/I]A[RTAI)Y2
MTG;G=VP !Z^_#QC-<GHK=Q&Q*^726LN%DM]1/2W%KB)6\GHGTN\_2:03U'7K
MZB,.DD7*%J@SZ[<(I<Q&=7&)E!VCXZ42/YI&-?Z1?)S;)WO0((T %)\HS7,K
MMP,QR]6=U4RIJ)'1W.JHH]RM8QSF\P ^CLMV2-:/3H"B<.B%I<>RJRY%45T%
MEN$57-0N#*AK 1V;B2-'8];3_!4KP?N5=>;I=[9:N(4USH*FBD:V*XB1M=2R
M%NA(S?0\I/\ 5?ZNXJ._)MQZY3YW?ZF*_P!5##:ZIHJH&@\M?LRM!?Z7@03U
MWWH.ID7+?!:;B#FEQE?'E%0VT6ZX0RU7E-0]TDP#M]DT]3R\K3L; .^N_#+Q
M&HSCBSDU_N=LRZIL-%;I0VFIXN8LZEW(US 0#T;U<[??W>H8=)UM5#0T515U
M<@BIX(W2RO/<UK1LG\ "L''+_:\DMWE]CK(ZRCYS'VK 0.8=XZCVKFO"*_)\
MJP[BE1W?(ZX5-%"V3G[5TC6AAE=)&P;&FO#.7ITT>X]RR.!\EQQ3A7?LS9=9
MYZ2"&:*&TO![%LW,S4OTM=_0]-ZWU0PZ@1<9Q9EDT]E&0PYQ?9,@=+SBVLI)
M33%O-K6_]'W==<NO#O4URG/,JS:\X9C-DK9;!472C9/5RQET;A(>?FT1Z0:!
M&2 "-[T4,+OO>=6:S9?:\:K73BYW%K70!D>V$%SFC;O#JTJ4+E6OL]]L/'_"
MK=D=[=>Y(NR--5R-Y9#$7OZ/V2=AW-U)/377U7!\H',*_#< =5VA_9UU74,I
M(YM ]ES-<XN /CIA ^]!92+E3-K=Q"PWAW1WZ7.J^JCN#HC/!VSP^!SVES>2
M0N)(Z:(&A["MAF%^RNHRSAK;+)D-;1372RT;I'F5SF.D?S!TCV[T\ZZ]>_00
MPZ;1<[X]7Y7@O&^V8O>,EJK_ &ZZ1<Y=4DDC8?H@.)Y2',/<=$'^$Z^4)FE?
MA>#MGLSA'7UE0VFCF(![(%KG%P!Z;TW0^_?@B%G(N0Z3-<AQBXVBXVK*[[D?
M:.!N%#64DPC Z;#"_8]8!&B-#PZ+?\5\BR&'B-<:>_9!?<:L+8@;9/0Q/[%[
MM#1>6$$]>;?>1W:1.'1F0WRVX[;'W&]5;*2B8X-=*\$@$G0[O:HUGO$*DQ?#
M*7(Z2CGN])5/C$7DYY06O!(>21T&AZN\@*FN)XN]YX!V^YUV44UT;25/+))1
M<W)6-<YH9VFPTA[#OO;_ #7E?&9!AWR>[7<*;*+C)+7STDL')(Z,TL3H7'L6
MGF/H]!ZAT[D'2MHK1<K515PAE@%3"R812C3V<S0>5P\"-]5EKFOB)?<J?E_#
MJV6&_P!90SW.V4O.[M7%CI'D@R/;W./CU[]+"N+^(6'\2J3#X<TGN#KW"SLZ
MNK:7]B'.<"YK7%W*X<CM:.CL?@,.H47/&*7'+,'XVT&)7S(ZF_V^Y0F3GJ"X
MD;:\@@.)+2',(T#H@_PUN)5&;\6<HO\ <K9EU38:*VRAM-3Q<Q9U+N1KF @'
MHWJYV^_N]1#I&Y5U-;;?4UU=*V&DIHW2RR.[F,:-DG\ L;'KY;<BMC+C9:ME
M71/<6ME8" 2#H]_M7+N-U^3Y1A/%"GO.1UQFM\;9G RND80WMC)$T; #7<NN
MG36NA6VX1U%TPS@O>,SCNTU33B%\--;) >R@E,P8)/I:/4[(T/O1.'3J+C2/
M,<G;9X,@I,WOM3?WR![K::24TW+S=P/^C/3KKEUX#VSO-\XR?,<@PW&+!6RV
M"6[445552QES'M>X.+AL>ERM##H C>^J&%T7O.K-9LNM>-5KIQ<[BUKH R/;
M""XM&SX=6E;ZZ7"EM=!/6W"=D%+ WGDD?W-'_P!_@N7KA9[[8>/V%6[([VZ]
MOC[(TU7(WED,1>_H_9)V'<W4D]-=?5TKE%AH<DM$ENNG:&D>YKW"-_(3RG8Z
M^I)]E:LX\O-'+!Q4Q>^7:.W4E5-'42NY(C-$6-D=X 'UGVZ4Y5!W.DH<KX@X
M]9L0IV?LVP<OE%;&!RZ:X'Z0[_HZ!\23X=5>ERK8+=;ZFMK']G34\;I9'>IH
M&RJ453.<L+%RJJ*M7IZM7E65V;%H();W5BG$[BV,!CGN=KOZ $Z'K]H6TMU9
M!<:"FK:1Y?3U$;98W$$;:X;!T?8N7\NNL.8T=]R2Y5\,<\;HZ>V6[M1VC6<X
MYG%N]]Q/WDGU!6;7QU=TX.6JNQF]RTM9:Z*-TAIZDL:[DC'/&_1UL:WU\>GB
MJQ<S,LJ-JFJJK$<(C,=5MK77^]V['Z#RV\5+::EYPSM"TN](]PZ GP52<-+[
M?^(.5,KZNOFH[9:X(Q-34TQ8VHEZ]7-![B02?#0 6^^43_J]_P#VN+_)RMKS
M3-4-/$:K4W*8Y)+:N(6*W6LCI*&]4SZB0\K&.#F<Q]0+@ 3[%N;Y>[;8J/RJ
M\5L-)!O0=([Z1]0'>3[ N:[AY'ED-@Q[&L:\@OD38W3U+FMB+QV8VXZZD'8?
ML]==W>I?>J)F2<=*:RY"]TU!14[1'$XD"4B(//\ %Q)/K TJQ<EC3M5<QRB9
MS$1TX_PM+'LWQS(:DT]HNL,]0!L1$.C<?N#@"?P68_)+2S(F6)U8T79[>=M/
MRNV1REV]ZUW GO50\=,=M.,T%HO./T\5MN+*L,;Y..3F :YW-H=-@M'7_:ZK
M(BF?4?*%LTTS>222@#W-]1-.\D)KF)Q*_B*Z:M%41G,?:ULNR*WXIC]7>;O(
MYE'3 %W(-N<2=!K1XDD@+6\-\S@SJP/NU'0U5% )W0L;4@<SP T\PUTUZ6OP
M*K[Y5]#43\/(:N*MDA@IJEHEIV[Y9^8Z'-U_JD;'0]Z@U=?<EPSACA=CL][F
MFK\EY)HJF4$&CA<R)K8&$DZ +N\:T-Z 6KM=1HN;:ZLS'A'G&-P77*:G(K5>
M).SFCJ2XEOI-:[EYG.((YP001ON(6')59]D_%_,,=QK):BBIXWR$F>=_)!$'
MM&HP-\IV0.FNF^H0PZ>10SB7D55A?#2X76'EFKJ6".-CG]09'.:P./KT7;]J
MJ/%<8XH7;'[3EMIS>2>NK3VSJ"KD<(!&2==.K3W?1#1K?0]$0N>Y9U9K=FU!
MBM2Z<7:MC$D(;'MFCS=[O#Z!6OX=<08\TN5\I&6>NMYM<HB+Z@=)-EP]7HN]
M'NZ]ZK'+73N^4[A#JQC(ZDT$9E8QW,UK]3; /B-[ZK58?Q#OEHLG%.Z55?55
M\MNJ(HZ)E5*Z1D+GS2,! )Z >B=>/*$2Z;1<:Q9CD]/:J2_T.;7VMOKY ^6V
MOI)33<I/<"?0/AT#0.O3NZS3,,GRJ_\ $W#:.PWFLLAO%J@F?#SN,<3WB0O)
MCWIQ '3?B AATLM+:LJLMVO5?:+=<(I[C0DBI@:#S1Z/*=[&N_HJ2Q"X95A_
M&R+#;SDE5?*&XT[GMEJ"XN83&YS7 .)+2"PC0.B#]VHOP@Q>[2\:K_3,R:LC
MFM529*N<!W-<&LF <U_I]SO'9=^*#J]%R9E62Y,W,K]'E.67O%ZJ*H(MC&12
M>1N8''7-R=2.7EZAKM[.UTQA%555F)VNHN%=1W"JD@!?549W%-_MMZ#O&MC0
MT=HANT1$!$1 1$0$1$!$1 1$0$1$!$1 55<7N&PO['W>R1AMT:/Z2$: J!Z_
M8[_-6JBBJF*HQ+&_8HOT317R<03PR03/BG8Z.5A+7-<-$'U%2?"L[O&)2ZH9
M1+2..WTTQ)8?61UZ'VKH+/\ AU:LMC=,1Y)<@--J8VCTO]\?UA_-4#E/#S(<
M=<]]51.FI >E1!Z;3]X'4?BN6:*J)S#YR]L=_9*M='+K'^5RV#C/CU=$/VH)
MK;-XAS3(W^+1_P"2D+N).(MCYS?*;7J <3_#6UR6BF+U32G\O?B,3$2Z%ROC
M7;*6!\>.0NK:@C3996ED;3Z]'J?Y*A;O<JN[W">NN$SIJF9W,Y[C_(>SV+%8
MUSW!K&ESCT  V2K'P;A/>+Y-%/=8WV^VG3BY^NTD'J:WO'WG^:K,U5RPKN[1
MMU6GG^G)Y<&</DR+(8ZVIBW:Z)W/(X]SW][6C\>I73ZP;+:J.RVV&@ML+8::
M(::T#O\ :?63ZUG+IHHTP^AV/98V:WI]9YB(BNZQ$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!85[N=-9K35W&N?R4U-&9'GQZ> ]I[A
M[2LU<^_*'S'RJM9C5!)N"G(DJRT_2D_JL_ =3[2/4JUU:8RQOWHLT34JK*;Y
M4Y%?JRZ5I_I:A_,&[Z,;W-:/8!H+5(BXGSLS,SF1$4^X,XC\Z,J8^ICYK;0Z
MFGV.CSOT6?B1U]@*F(S.(6MT3<JBF/5=' [$OF[BS:RJCY;C<0V638ZLC_J-
M_@=GVGV*QD1=M,8C#Z.W1%NF*8]!$12N(B("(B B(@(B("(B"#<8\)J,]Q-E
MHI:R*CD;4LG[21I<--#AK0_WEH<TX2OOUBQ84-W-NO\ C]/%#!6,82U_(UOA
MO8])NP?#9Z%6NB"J>''"VOL>7U.597?3>;W+%V3'-9RM8- ;WXG0T!H #?>H
M]=.!]Y@JKO2XKETELQ^ZR%]10NC)Y0[O:-'J-=/#IH':O=$&AP7&*/#L7H;)
M;W/DAIFG<C_I2.))<X_>2>G@H38.%'DF6YK<KK60U5NR-DL3J=C"U\;7OYN_
MU@?S5J(@Y]IN!.1TMMK[%3YO*S')N=S:5L;@7N(]$.&] ;UO7?KN6RK>"E?4
M<)K?B N]*VHIK@ZM-08G<K@0\<NN_?I?R5X(AE6_&*TV5_"F2CRBHG@HZ9L+
M15P0F0PRCT6OY1X;.C['>"YPS6G;'P\H1-Q"COT+'L;;[7"3N)NCMTC2=MY1
MT (Z;Z%=HUE+!6TLM-60QST\K2R2*1H<U[3W@@]X4+MO"3!K;=&7"DQZF;4L
M=SLYWO>UKO6&.<6_R1**77A949%C&%W*VW&2R91:+;30LGY.8>C&/1<.\$'F
MZ^T@@K><.L O=EOM1?,LRFKO-PD:6,A:YS((]@ NY=Z)T-#H .O?X62B(%7W
M$G![QD%SH+OC&2U5FN=(.7D)+X)1LD<S-ZWU/>#L="%8*(*CPC@ZVW4^2R95
M<FW.MO\ &8JDT\0A8QI/,2T#^MS:.] #7<HW!P,R6.GBLGSYF;B\4W:M@CC<
MV0=2= ;T.\^.MG>ET B"H^(G![]M5-EN.+75]GN]I@9313.V[G8SZ)+AU#AL
M]>N]]5K+)P:O=+Q LV4WC*/VI5TQ#ZDS1GF>1S -9UZ- (_FKO1!4N*<(&T#
M\WAO=;%5T.2.WR0M+71#G>X'9\07 CVA:*AX,Y;!#368Y_4Q8U32<\<5.QT<
MP;LGE!!Z=Y\2!WZ5[H@QZ>CA@M\=$ Z2G9$(=2.+RYH&O2)ZGIWDJD'<%<CM
M#Z^WX=FDMLQZNE[22F<P]I']S@>O0 ;!:2 -J]T05)GG"*>_X'9,=H;S(9*"
M<SR5=<72OF):X$GKTZNZ#P'1;'C%PYJL]L]GHJ6OAHW4,O:.=(PN#O1UH:5E
M(@KCC'P[J<]98Q2U\-'^SIW2N[1A=S@\O0:_W55.<V2JO_RFY*&VW.:U5WDK
M98*N(;,;VP;'3Q![C["NG5HOFC8_G8,F\@;^W SL_*NT?OEY>77+OE[NG<@K
MS .$5=:LHJ\FRR^F\WN2)T4+^4\K.9O+S$GJ3R]    "?P\L4X)Q47#J\8K?
M;@RI%;5"JBJ*=A:87AK0T@'O[C]X)"N5$% 0<"K_ ' 6^V91F4M=CE X&&DC
M8X.+1T ZG3>G3?I:'0+8_*HAM--PQHZ>5@CJ8JJ-EO8S^KH$.'^[R;_'E5W*
M/Y-AMAR>KH:F_6]M;+1.+J?GD>&L)()]$$ ]P[P>Y!'.#V$P8_PNIK/<( 9;
MA"Z:N8X?2=*W1:?N;IOX*$Q<%<IMD4]GQ[.IZ+&IINU,/9D2LZ]P((]0[BT'
MU*^405/F7"::\OPMM#=G-BQ]Y>]]872RU&WL<27>LEA_BK81$%19CPSR:KO]
MSK\6RZ2DI;FQS*FAKF&>)H=]+D#M@ _<"/ K[AX+T;.$TF&NN<AFDG\L-9V?
M03=.YF_HZ&M;]JMI$%21\)[A<N&%1B>49 :Z9D[9:&K;&?\ LS6,#6-Y3WCZ
M7CW.44NO K*;SCU';KMFHJFT3PVEA?$XQ1QAI'WEWT0/4-A=#(@I[/.$%9=K
MW:\@QB^?LB_4D$<$DO*>63E;RAP(Z@ZZ$=01K\?##^#UVLO$F@RRZ9)^U9XV
M/-298R'R/=&YG0[T&C8T/4/P5T(@Y@X^8_295QML%EM6Q<JN&-E<YO<QFR0X
M_P"T(P3]P:NF*"D@H*&GHZ2,1T]/&V*-@[FM:- ?P"TU'AMAH\HJ<CI[>UMZ
MJ 6R53I'N<00 = D@= !T'=T4@05!G_"2X7/-1E>'7\V2[2-#9]M)#CKEY@1
MZP """#K:\<%X.UN/9]/D-TOHN[*BG?%.)HSVDKWM <2=D:WOIZM*Y404.>"
MN26@UUNQ#-9;;CM;+VKZ<L/:1_<X'J= #8+=@#:W><<()[[CF,VJAO+]VB5\
MLE17%TLDY=HDD[Z=0>G@-!6ZB"N.+O#NISJLQR>EKX:06J=\KQ(PN[0.+#H:
M[OH?S3BIP[J<TON+U]-7PTK+1.97LD87&0%S':&N[Z!_BK'1!4&;<)+C59E-
ME.$9 ZQW6I;RU#2TEC^@!(([MZ&P0>HWT7UB_!L67%\G@J;L:_(;]32035\K
M#RLY@>X;).W'9)/70[E;J(*TL/#>JMG!RLPM]P@DJ9XYHQ4AA#!SN)'3OZ;6
MMCX27"/AM9K!1Y+46^[6N262.LI"]L<G.\NY7M!&QU'W:]JMU$%38#PNNUMS
MJ3+LMOL-SNW9&)@IJ<1-ZMY>9V@-G6QW>W:^<9X4W/%^(M5?+)D1CLM;4.GJ
MK>Z,@O!YB&[WH@%QT>BMM$%<<%^'=3P^H[O#5U\-8:V=LK3$PMY0 1H[^]16
MKX*WFW93<:_"<MELEON3BZHA:P\S 220W1T=;.MZ(WWJ\405-PMX1NPZGRFC
MK[BVNH[S&( &-+7M9J0'F)[R0]>'#_A%78Y37BS72_FY8O74\D(HA&8RU[RW
M^D[SIV@>[QZJX$04-2<%\LHZ>.R4>?5%/C,<ID9%%&YDS0220"#[3XZWUTM_
MQ&X0?M^2R7#';O-;+U:860154KG/=(QO5I<[>^8$D\W7>RK:1!1UIX,WV+.[
M)E%YRD72LI7MDJ3-&=N+2=-9ZF@:_':LGB1AM'G6*U%FKI'0\SA+#.T;,4C=
MZ=KQ[R"/42I0B#GBNX%95=,?BM=WS8U--1EHHJ=S'&)@'39V=[ Z >&^_P %
M+JGA562Y?@]Y%SIQ'CU#3TDD?9G<QCYMN:? '?BK91!7&2<.ZF[\6[%F$=?#
M'3VZ%L3J=S"7/T9.H/=_7'\%ON)6%46>8Q+9Z^1T!YQ+!.P;,4@V [7B-$@C
MU%2E$%,6'A5EANUM?E.<U=9:[=H14U*7Q&5HUIKR".G0;WLZZ;67F/#/)JN_
MW*X8METE'2W-CF5-#6L,\30[Z7('; WW]P(\"K<1!5=OX.T=-PEJ\+DN,CWU
M,OE+ZP1_1FVT@AF_H^@!K?7KZUHZO@]D-=PV.*W')H:KLJN*6EE?$[EAB8QS
M>S [_%7@B"JKMPNJZ[,,)O+;E R.P4T$$D9C.Y3&220?#?M6=E7#NIO7%?'\
MNCKX8J>V1-C?3N82Y^G2'8/</IC^"L=$%<7_ (=U-SXOV7,F5\,=/00B)U,6
M$O>1VG4'N_KC^"BM9P5O-NRJXU^$Y9+9+?<G%U1"UAYF DDANCHZ).MZ(WWJ
M\405#PVX.G%J'+;?<+DVLHKY#Y."QI;(QFI!LD]"[3_XA?."\(JZR6:\X]?+
M^;GC=; Z**E;&8S$XN![0;) /3?WJX$04/1<&<MIX*:RC/ZF+&:>7GCBIV.C
MF V3R@@].\^)'CI2+B9PD.25%FN6/7:6U7JU1,@AJ'ESR]C>K>9V^;F!)]+K
MO9VK61!1UJX,WV/.[)D]ZRD72LI'MDJ#-&=NY2=-9UZ-UK\=JT,\L-5DF-SV
MNBN#J!\SF\TH:3MGBT@$="I"BB8SP153%48E4..\+<BL#6Q6S,#3TW:"22**
MFY>?U[/-ZNBE%LQ"X_M[()K[>I;E9KDU\;*!Y<&L:X[UW]-#T?1[]J;(HBB(
M94[/13PC^\JRRK@]8:^T/@L-)#;JXN:6SN?(\  ]1HN\5Z73AU5.P.BQFRUU
M/00DM?7R<KG&=P WKKT!(V1[![59*)HI1X>WQQ'-6MGX:R8UE]+=<8KV4]#V
M+8:JDF!=VH TX['B=!WL/LZ+?\3,6FR_&OV93U,=,_MF2\[VEPT-].GWJ5HF
MF,86BS1%,T1'"5:7OAO535V-W2S7"&CNUJ@C@DE=&2V8,: .@_Y@?6#KP6PX
M@\/8LIJ*6Y4=:^V7NF #*F+9! Z@'1!Z'N(Z_>IVB:(1N*,3&.:I[5PJKZV\
M4U?FU_EO#:4[BI_2+3X]2?#U@#KZU()\)GDXIT^6"LB$$4)C-/RGF/\ 1N9O
M?=X[4X1(HB"-GHB.7KE#>+>'SYQALUEI:N.DDDECD$LC2X#E.]:"T&6<)(,D
MX?X]8ZBO-/=++3QQ4]=$S8YFL:UVV[WRGE![]C0_&T45FRE<=X.7>?*K??,^
MR=]\?;B#2P!IY=M.VEQ/AO1T!U/>5(\-X=U-@XGY)E4M?#-!=6O:R!K"'1\S
MVNZGN/T58Z(-5E=AH\GQVOLUS#C2U<?(XM.G-/>'#V@@$?<J5I>!N2]C26:L
MSB=V,4LO:1T\+'-DUL]!UT.\^) V>BO]$%973AE+4<4L=RBDK88:&TTK*84K
MFN<]P:'@:=]SQW^I8&)<'66^ES6COE;'6461/:X-A:6NATY[@=GQ!<"/:%;B
M(*(H.#66PQ4EGFS^J9C5))S1Q4S71S<O7T=@].\]Y('J4KNW#2:JXJ8]E5/7
MQLH[53,I_)Y YTCPT/&^;?\ MCO]2LQ$%<77AW4UO&2V9JVOA;34D'9.IBP\
M[CR/;L'N_K_R6K?PIN=!Q0FRO'<B-%35M0V:NI'1DF1O.'/9S ]0X@^'3:MM
M$%(9%P@R>IENM%9\S?\ L"YNW-27",U#HAO>F.=ONWWCE/=O?>K3P;'(,2Q2
MW6.EF?/%1QEO:/&B\EQ<XZ\.I/3P6\1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 0C8ZHB#177#\>NTADN%GHII3WR=F&N/XC16G;PNQ%LG/\ LEA_V2]VO\U-
M44:8Z,JK%JJ<S3'PT]HQBR6=W-;+51TS^[G9$.;_ !=ZW"(IB,+TTQ3&*8P(
MB(L(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MJB73S0P-8^4D[VYP&W=23U6&,0QP77]IBPVH7#FY_*/)6=IS?VMZWOV]Z&5
M<1J&@K.*G"RC_9LD%LDI:9HH:OTG,C[4ZC>"3W#0()/J6QSRW4=I^4SA7[+I
M8:,3P1OD$# P.<7RM)('CR@#\%?5;8[577&FN%;;**HKZ;785,L#7R1:.QRN
M(V.O7HE58[55W2GN57;**>XTX#8:J2!KI8P"2 UY&QU)[CXE#+CS&)GV*Y9A
M29!?:&SW#M'-J(ZZTBL?5=7<P83W;)WX;V#OITR;O8*FFX >4VFKK:VSNO0J
M'&6E,&F]D6<P',[;>;0WZUUC><5L%ZJ65%XLEMKJAG1LE13,D<!ZMD=WL6S-
M)3&C\D-/":3D[/L>0<G+K7+R]VM>"&7(G%_(\"NW#['Z3$J.&.ZP.89.SI3&
MZ%G(0YKW:',2[7B>XG?KZ?LO^KNA_P#A4?\ X(2/!L4CI9*9F-684\CQ(^+R
M*/E<X;T2-=XV=>K96^93PQTS:=D4;:=K.S$8: T-UKEUW:UTTB'%W".FPZ2T
M3S93E]TLE8RJW'3TLA:R1@:T\Q 8[KO8[_!65GE-17CY3N)1U44551344<G)
M(W;7@"9S=@]_4 ]5<OF_P[]T[!__ &^+]*VC[!9WW.GN+[50.N%.P1PU)IV&
M6-H! :UVM@:)Z#UE$Y4/74-+:?E7VIEMI8Z:*6D=))% P,#B8)-]!H;.A^*K
MFHK[98+;?CC-YHZFVNJFNGL%^MX$[W!W3E(WOE\2"T]#^/8$ECM4EXCNTELH
MG72-O*RL= TS-&B-!^M@:)'?XE8=?A^.7"X^7UUAM=16[WV\M*QSR?621U0R
MYNXC5-/^W>%U_O=I-+B;J&#GHPPOBA(>7/;KQ'*6'7B LUM;9LG^45CE7PZA
M:*2GC:ZLFIX##&0.;G)&A_4+6[(ZDZ72UQMU%<Z)U'<J.GJZ1WTH9XP]A_ C
M2QK'C]GL,;X[):Z*WL>=O%- V/F^_0ZH*Z^4]1BHX45TS8!))3S0O#^798TO
M )!\/#:J3/ZNBO? '''8SRR0VR2".[MAA+.27L>4%_0<W4ZYNH](+K">&.HA
M?#/&R6)X+7L>T.:X'O!![PM?;<?L]KI:BFMEIH*2FJ#N:*"G9&R0ZUZ0 T>G
MK0<L<5[OB.44.(6[AQ1,_;8D:T-IJ8Q/C!  8XZ',[FT=]=:)WUZWUQPHKC6
M<(;]3T ?)6=@QSQ'WN:U[3)K_E#E)K/BF/V:K?56BQVVBJ7;!EIZ9C':]6P-
MZ6Z0<2"JM5;PZM=LK,HHV-,@_P"P4UC#ZF)^SU,NP7;]>^NP->JP.-]-"[&,
M!Q:EBJ*_,V10B![1V<S&<@&GC9T2X#IOIRD[]=_T^(8Y3W3]I4]AM<5PYN;R
MAE*P/#O7O6]^U97[!M'[9_:_[+H?VKK7EGD[.VUKE^GKF[NG?W(9<^\*JVT'
M@%FEMI833WRFI*HW%DO^D>2QP:[UZ '+KP(/KZQ+ \CP&@X-WNVWVCA?D,PF
M[,/IB^25Q&HW,DUIH:?:-:)\>O1V;XG;Y,7RB6RV6B;>Z^@J(NU@IV-FF<]I
MZ%P&SLZ[RHMP8X?TL7#NVTN9XY1ON5--,YK:VG9(]@+R1U(/3QT@H*\6RZ4W
M!?#:RXP3OLS;I4R.9U']&_L^3[M\DVC_ +7M6UX[Y#@]\@Q\8130,F@V)WP4
MI@#&'7*QVP-G8/KUUZ]5UY54%)5T+J*JI8)J-S>1T$D8=&6^HM/32TK,'Q5M
M&VD&-6;R9K^T$1HHRT.[N;6N_7BAE2^24%)<OE86BFN%/%4TYI \QRM#FDM@
MD<W8/?H@'\%AUMM%#\IFY45@ACHWU%LFY&0@,;VCJ4D'0Z#TM'[^JZ&=8[4^
M\,NSK91.NK&\K:PP-,S1HC0?K8&B1W^*?L.U?MC]K_LRB_:O+R^6=@WMM:UK
MGUO6NG?W(9<H\)K[@UCP;);9F= PWU\DC1'-2&261O(&MC:[1Y'!X=WD:)!^
MZQ?D?_\ N3>O_B/_ -K8K@FQ6P3W;]J362VR7+>_*G4S#)OU\VM[]JRK-9;7
M9('PV:VT=OAD=SO92P-B:YVM;(:!LZ 047F]9::#CVVIR*)LEMCCC,@='SM:
M>RTUQ;X@'17Q;9*2_<9WU.#1]G2,I9.>2*,QL+NR<WFUH:!<6CN[^JF%5C%?
M5<<3<ZFVF:ROIC&^61H=&[^A+=$'OZ].Y6/:;-;;/&]EJM]+1->=N$$36<Q]
MNAU6,43,S^KSJ+%5=4YX1JS[N>.&MVQ*SXU?J#+*-ANSI'M#):<O>]O* &-.
MCRN#@[U=X]73%QK_ %&9;_QL'_5&NC9L>L\UR%PFM5#)7 [%0Z!I?OU\VM[7
MY%CEEBH)J&*T6]E%,X.E@;3,$;R.XENM$]!_!-W*8V2J(QF.$3'RH&^T\55Y
MJ*>H8V2&6*)CV.&PYID8"#^"DG$6@I+=QBPIUOIH:4RR1!_8L# [^EUU ]AU
M]RMQU@M#S1EUJH'&CT*8FG9_0:.QR=/1Z@=R]:NTVZLK(*NKH*6>KIR##-+"
MUSX]'8Y7$;'7KT4[M;PLXGCT^D8XS_ZL[[_W;/\ Q&JMZZR6QOR=8JUM!3"M
M#62]N(QVG,9PTGF[^XZ^Y7K6TE-7TLE-74\5332='Q2L#VNZ[Z@]#U7@ZT6U
MUK%M=;Z0VX #R4PM[+0._H:UW]>Y6JHS.6ERQKJFKK&%(WZR6R/Y/E%6QT-,
MVL#(I>W$8#RYT@!)=WG8*TV5EL#>&MQO<3Y[&RA@;*".8'E=MP(\?1Y>GB N
MAY+1;9;8VW26^D?;V@ 4SH6F( '8]'6N])[1;9[:VW3T%))0, :VG=$TQM [
M@&ZT-*LVV=6R9Y3Z1].?<KNN.7;BEBLV*QQ"%M1 V:2*$Q,>[M1H:('4#QUZ
MO4I%C-!25_R@<D;6TT50V*%TC&RL#@'?T8WH^.B?XJUXL8L47DW96:VM\F=S
M0$4S-Q.WO;>G0[ .QZEE06FW07&6X04%+'73#EDJ&0M$CQTZ%VMGN'\$BB<Y
MDIV:K5JJF.>5 4EOE9F'$RW66+L]T$_9PQ#0UVC"6@#V%P ]JPK+>\.BX15E
MMJZ:)V0N$@ -.3(Z0N)8\/UT &O$=QZ=>O1E-:;=2U\U=34%+#6S@B6HCA:V
M20;WZ3@-GN'?ZEB_-BQ>535/[&MW;SM<V63R9FW@C1!.NN_'UINY1X2J.4QZ
M_;F^ZT]0_@QCD[6/?10W"?MPWN!)]$G_ .8;]JS.+M[Q"[6JS,Q2GB9/%_I'
M14YBY&:Z,=T&SO[^X^M77FMDN,.)/H\)I[?3/:_F=1FGC[*9AWS-Y2.4'>C^
M"JJIQC)LM-NM#\4H\=H(9A+53PQB,/.M%VO'IO0&^_OTJ54S'!SW;-5$31''
M,1Z=.DO//1-0<7H*NOK8;?32TL9I:NII?*(F 1@$<O\ O<WW;!7M@E+3U-XR
MZYT%T=6C]G5#*AT5!Y/ XEO0CTO'E)UH>*O6XVBW7.E937*AIJN!GT63QAX'
MM&U]4=JM]%0NHJ.AIH*-P(=#'$UK' ]#L :.U?=\<NGPLZYJSPSGU4?PRLEL
MJ^#.255504TU3JI(F?&"]O)$"W1[QH]>B8%9+94\#;]5U%#3257)4O$SHP7@
ML9MNG=XT0KNI+1;:*@EH:.WTD%%+S=I!%"UL;]C1VT#1V.A2FM%MI;?)04UO
MI(:&0$/IXX6MC<#W[:!H[\5,6TT[+C'M&',5UAJY.%6)5.WFWT];4MF/+SM8
M7/:6DCQ[G_QUXK?4C*6^9_C_ )+D45=6P21OC=;[2(6AK7<Q#B'#N /@= _@
MN@*>T6ZGMSJ"GM])%0NWNG9"T1G??Z.M+RM-AM-G<]UJME%1N?T<Z"%K"[V$
M@*-VI&QS$QQZ=?147#VW4=?QGS,UU+#4=DZ4L$K X-)E ) /CI8_#.AB&8<1
MK;3P,-,.U9'!R[;TD>&@#V>"NJEM-NI*V>LI*"E@JY]]K/'"UKY-G9YG ;/7
MUI1VFW457455'04M/4U!)FEBA:U\AWO;B!L]>O53%#2G9L8]IF?E3_R;[A:V
M4%7;9#&+T9WRM:8CS]ERL!]+7=L'IM..K6TV:8G<+M$Z6Q1O#9AR\S=AX+P1
M[6ZZ>.BK>I[+:Z:X/KZ>VT<5<\$/J&0-;([??MP&RLBNHZ:OIGT]=3PU-._Z
M4<S ]I^\'HFB=.DC9YW.[F52T]TPV^Y5518C:9I;X:27LKA3,,4+#V1&R.8>
ML#?+WD*$\.[QB-KPV^V_)J-AO#WO:&24Y?(\<H#6M=KT2' ^K1ZKHBTV:V6>
M-[+5;Z6C:_JX01-9S??H=5Y2X[9I;C^T);30/KN_MW0-+]^O>M[31/-$[/7,
MQ5F,\?3AQ<YV/_4+D?\ \3B_^UKWNU\PZ3A#2VREIHAD(;&"!3D2-D#@7O+]
M=01OQ\1ZNEK\3\6:_AY<+9B]I@CEFFBD["DB;'S$/&SH:&]#^2V>'XI;H\>L
M4MULU'^UJ:DB8^26!CI&.:T#OUWA4T3G'LPC9J]6B.W&<>ZE;Y3OL]TX?566
MT\DEJCH8FR,>TN T]Q+2WV-<S8]0TLN\7/'[KQDQFHQ:.-M,)X&2R10F)DCP
M_O#2!W @;TNA+G;:*Z4QI[E205<!.^SGC#V[]>CXK#AQJQPOI7Q6>W,?2]8'
M-IF Q==^B==.O7HK;N6L[)5G$3PX3[\%#8U=<=M/%G*YLJCB,#JFH;#)+"96
M,=VIWT /4C?77K]:\L3$=7+Q*N%E@=#876ZH;&WEY6[)VP >'0.Z> *OV;&;
M%,:HRV:W/=5.YIR:9A,IWO;CKJ=]=E9-/:+;36U]OIZ"EBH'@M=3LB:(W ]X
M+=:.TBW)&R5>LQCC]N;;U_J$Q_\ ^*2?_;%,G@'Y0-B! (- T$'_ +AZME^.
M622WQT#[/;G4,;R]E.:9AC:X[V0W6@>IZ^U>_P"Q[;^T8[A^SZ3RZ-O(RH[%
MO:-;K6@[6P-$A(M_X33LLQCCT^E)8!4VJS<8LGI+JR*"2HJW1T3'0D^F926A
MNAZ/0C1Z+30TU75S<5X;>U[IR\NY6=Y:*DEX_P (<NA:FRVNJKXJZIMM'-6Q
M$%E1) UTC2.XAQ&QI?5%:;=0U514T5!2T]14'<TL4+6.D.][<0-GJ2>J;OT/
M"SC3GAQ^W+K*BW56#T%!57^E8TO_ /J.&TAU1&_9ZF38WOU[Z[TIGFM'16^X
M8B*B\U5KOM+011Q5=52!T#V@'7/U/*X$D'H[O'WJYH<9L<-P\NBL]O96;YNW
M;3L#]^O>N_VK*NEJH+M (;I14U9$#L,GC#P#ZQON2+?!6G9)BF8F>/#KZ?NK
M#@7=Q<:_(8GT-O%1#(WM*^AC+&5.W.ZD=WK(T!T/<K;6+;+;16NF%/;:2GI(
M-[[.",,;OUZ"RE>F,1AUV:)MT13,Y$1%9H(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B BI/CMG]TLUSALEDG=2.,0FGG9],[)TUI\.[>QUZC\8CPWXKW2
MTW>.'(Z^>MM,NQ(Z;<DD1UT<#WGKWA9S=B)PY*MMMTW-W+II%7OGCPW[0G]V
MD^">>/#?M"?W:3X*VNGJU\1:[H^5A(J]\\>&_:$_NTGP3SQX;]H3^[2?!-=/
M4\1:[H^5A(J]\\>&_:$_NTGP3SQX;]H3^[2?!-=/4\1:[H^5A(J]\\>&_:$_
MNTGP3SQX;]H3^[2?!-=/4\1:[H^5A(J]\\>&_:$_NTGP3SQX;]H3^[2?!-=/
M4\1:[H^5A(J]\\>&_:$_NTGP3SQX;]H3^[2?!-=/4\1:[H^5A(J]\\>&_:$_
MNTGP3SQX;]H3^[2?!-=/4\1:[H^5A(J]\\>&_:$_NTGP3SQX;]H3^[2?!-=/
M4\1:[H^5A(J]\\>&_:$_NTGP3SQX;]H3^[2?!-=/4\1:[H^5A(J]\\>&_:$_
MNTGP3SQX;]H3^[2?!-=/4\1:[H^5A(J]\\>&_:$_NTGP47XC<8+7/C<])BU1
M+)75/]$Z4Q.9V3#WD;\3W#U;WX*)KIB.:M6TVJ8F=4(7QRS7YQ7W]F4$N[70
M.+06GI++W.=]P[A^)\56*(N29S.9>#<N3<JFJH1$4*)YP=PTY7DS7549-KHB
M):@GN?\ V6?B>_V KK!H#0 T  = !X*FL SO!<2QJFML-PE=-_I*B44LG])(
M>\]W=W >P!2/SQX;]H3^[2?!=5O33'-[6RS:LT8FJ,SSXK"15[YX\-^T)_=I
M/@GGCPW[0G]VD^"OKIZNGQ%KNCY6$BKWSQX;]H3^[2?!//'AOVA/[M)\$UT]
M3Q%KNCY6$BKWSQX;]H3^[2?!//'AOVA/[M)\$UT]3Q%KNCY6$BKWSQX;]H3^
M[2?!//'AOVA/[M)\$UT]3Q%KNCY6$BKWSQX;]H3^[2?!//'AOVA/[M)\$UT]
M3Q%KNCY6$BKWSQX;]H3^[2?!//'AOVA/[M)\$UT]3Q%KNCY6$BKWSQX;]H3^
M[2?!//'AOVA/[M)\$UT]3Q%KNCY6$BKWSQX;]H3^[2?!//'AOVA/[M)\$UT]
M3Q%KNCY6$BKWSQX;]H3^[2?!//'AOVA/[M)\$UT]3Q%KNCY6$BKWSQX;]H3^
M[2?!//'AOVA/[M)\$UT]3Q%KNCY6$BKWSQX;]H3^[2?!//'AOVA/[M)\$UT]
M3Q%KNCY6$BKWSQX;]H3^[2?!//'AOVA/[M)\$UT]3Q%KNCY6$BKWSQX;]H3^
M[2?!//'AOVA/[M)\$UT]3Q%KNCY6$BKWSQX;]H3^[2?!//'AOVA/[M)\$UT]
M3Q%KNCY6$BKWSQX;]H3^[2?!//'AOVA/[M)\$UT]3Q%KNCY6$BKWSQX;]H3^
M[2?!//'AOVA/[M)\$UT]3Q%KNCY6$BKWSQX;]H3^[2?!//'AOVA/[M)\$UT]
M3Q%KNCY6$BKWSQX;]H3^[2?!//'AOVA/[M)\$UT]3Q%KNCY6$BKWSQX;]H3^
M[2?!//'AOVA/[M)\$UT]3Q%KNCY6$BKWSQX;]H3^[2?!//'AOVA/[M)\$UT]
M3Q%KNCY6$BKWSQX;]H3^[2?!//'AOVA/[M)\$UT]3Q%KNCY6$BKWSQX;]H3^
M[2?!//'AOVA/[M)\$UT]3Q%KNCY6$BKWSQX;]H3^[2?!//'AOVA/[M)\$UT]
M3Q%KNCY6$BKWSQX;]H3^[2?!//'AOVA/[M)\$UT]3Q%KNCY6$BKWSQX;]H3^
M[2?!//'AOVA/[M)\$UT]3Q%KNCY6$BKWSQX;]H3^[2?!//'AOVA/[M)\$UT]
M3Q%KNCY6$BKWSQX;]H3^[2?!//'AOVA/[M)\$UT]3Q%KNCY6$BKWSQX;]H3^
M[2?!//'AOVA/[M)\$UT]3Q%KNCY6$BKWSQX;]H3^[2?!//'AOVA/[M)\$UT]
M3Q%KNCY6$BKWSQX;]H3^[2?!//'AOVA/[M)\$UT]3Q%KNCY6$BKWSQX;]H3^
M[2?!//'AOVA/[M)\$UT]3Q%KNCY6$BKWSQX;]H3^[2?!//'AOVA/[M)\$UT]
M3Q%KNCY6$BKWSQX;]H3^[2?!//'AOVA/[M)\$UT]3Q%KNCY6$BKWSQX;]H3^
M[2?!//'AOVA/[M)\$UT]3Q%KNCY6$BKWSQX;]H3^[2?!//'AOVA/[M)\$UT]
M3Q%KNCY6$BKWSQX;]H3^[2?!//'AOVA/[M)\$UT]3Q%KNCY6$BKWSQX;]H3^
M[2?!//'AOVA/[M)\$UT]3Q%KNCY6$BKWSQX;]H3^[2?!//'AOVA/[M)\$UT]
M3Q%KNCY6$BKWSQX;]H3^[2?!//'AOVA/[M)\$UT]3Q%KNCY6$BKWSQX;]H3^
M[2?!//'AOVA/[M)\$UT]3Q%KNCY6$BKWSQX;]H3^[2?!//'AOVA/[M)\$UT]
M3Q%KNCY6$BKWSQX;]H3^[2?!//'AOVA/[M)\$UT]3Q%KNCY6$BKWSQX;]H3^
M[2?!//'AOVA/[M)\$UT]3Q%KNCY6$BKWSQX;]H3^[2?!//'AOVA/[M)\$UT]
M3Q%KNCY6$BKWSQX;]H3^[2?!//'AOVA/[M)\$UT]3Q%KNCY6$BKWSQX;]H3^
M[2?!//'AOVA/[M)\$UT]3Q%KNCY6$BKWSQX;]H3^[2?!//'AOVA/[M)\$UT]
M3Q%KNCY6$BKWSQX;]H3^[2?!//'AOVA/[M)\$UT]3Q%KNCY6$BKWSQX;]H3^
M[2?!//'AOVA/[M)\$UT]3Q%KNCY6$BKWSQX;]H3^[2?!//'AOVA/[M)\$UT]
M3Q%KNCY6$BKWSQX;]H3^[2?!//'AOVA/[M)\$UT]3Q%KNCY6$BKWSQX;]H3^
M[2?!//'AOVA/[M)\$UT]3Q%KNCY6$BKWSQX;]H3^[2?!//'AOVA/[M)\$UT]
M3Q%KNCY6$BKWSQX;]H3^[2?!//'AOVA/[M)\$UT]3Q%KNCY6$BKWSQX;]H3^
M[2?!//'AOVA/[M)\$UT]3Q%KNCY6$BKWSQX;]H3^[2?!//'AOVA/[M)\$UT]
M3Q%KNCY6$BKWSQX;]H3^[2?!//'AOVA/[M)\$UT]3Q%KNCY6$BKWSQX;]H3^
M[2?!//'AOVA/[M)\$UT]3Q%KNCY6$BKWSQX;]H3^[2?!//'AOVA/[M)\$UT]
M3Q%KNCY6$BKWSQX;]H3^[2?!//'AOVA/[M)\$UT]3Q%KNCY6$BKWSQX;]H3^
M[2?!//'AOVA/[M)\$UT]3Q%KNCY6$BT^+9);<HMSZZS3.FIF2F$N<PL/, "1
MH^QP16B<M8F*HS#<(B(D1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$05AQ=X:29?-!<;5/%#<HH^R<R;89*P$D=0#HC9\.N_8M!PXX-3VV[LN.4N
MI)F0[,=(S^D:]W=M^QK0]77P_&[D5)MTS.7/.RVZJ]Y,<6H^:]@^P[7[I'\$
M^:]@^P[7[I'\%MT5L0VT4]&H^:]@^P[7[I'\$^:]@^P[7[I'\%MT3$&BGHU'
MS7L'V':_=(_@GS7L'V':_=(_@MNB8@T4]&H^:]@^P[7[I'\$^:]@^P[7[I'\
M%MT3$&BGHU'S7L'V':_=(_@GS7L'V':_=(_@MNB8@T4]&H^:]@^P[7[I'\$^
M:]@^P[7[I'\%MT3$&BGHU'S7L'V':_=(_@GS7L'V':_=(_@MNB8@T4]&H^:]
M@^P[7[I'\$^:]@^P[7[I'\%MT3$&BGHU'S7L'V':_=(_@GS7L'V':_=(_@MN
MB8@T4]&H^:]@^P[7[I'\$^:]@^P[7[I'\%MT/0;*8@T4]$3RBCQ7'+'5W2OL
MMK$,#=AHI8]O=X-'3O)7)=XKW7.Z5-:Z&& S/+Q%"P,8P>#0!X *?<:\X^<]
M[\@M\N[10N(80>DTG<7_ '> ]FSXJM5RW*LSB'B;9>BY5IIY0(B+-QBOC@-@
M$$M ^_WVDBG;."RDAG8'-Y=]9"#Z^X>S9\0JXX6X?)F&21T[PX6ZGU+5R#P;
MOHT'UN[OXGP77%/#'3P1PP,;'%&T,8QHT&@#0 6UJC/FEZ.P;/JG>5<FK^:]
M@^P[7[I'\$^:]@^P[7[I'\%MT71B'K:*>C4?->P?8=K]TC^"?->P?8=K]TC^
M"VZQ[E74UMM]375TK8:2FC=++([N:UHV3_ )B#13T8'S7L'V':_=(_@GS7L'
MV':_=(_@L'!LWL6;T=14X]5.G93O$<K7QECF$]VP? ^!^]25,0:*>C4?->P?
M8=K]TC^"?->P?8=K]TC^"VZYIXPW6N?QOI[/+E]?CMGEI&.DGBJ',CC/(\[Y
M0X#J0!^*8@T4]%__ #7L'V':_=(_@GS7L'V':_=(_@JTLUTJ\)X;W*]V2\S9
M_!'4F2666I+711AH#N4^GOEZ$CIT)/@ORCXWP7RXXW;<4M!N5RNC.>HB?/V8
MHM'1#CRG>M./AT /BF(-%/19GS7L'V':_=(_@GS7L'V':_=(_@JOR'C74VS.
MKKB]%BM3<ZRE]"G%-,7.F?IKNK0WT0 2=]>[V]-EPZXQ4F23W:AOUNEL-TMD
M+ZB>&9Q<.S9],]0""WQ!'_GIB#13T3[YKV#[#M?ND?P3YKV#[#M?ND?P5.0?
M*!JJIM?<*+"[C/CM*7-=7->3RG73GTWE;X;'-T!\5L_/:_S6?/#]A-YOVAY#
MY+Y5_L[YN;D_EI,0:*>BT/FO8/L.U^Z1_!/FO8/L.U^Z1_!4_/Q_J*)]MK+I
MAEQH[!6\O)72/(YMCJ6#ETX=^NO4=5(N)/%Z+&;W0V.PVB:_7BJC;*(87D -
M=U;K0))(&]:[NJ8@T4]$^^:]@^P[7[I'\$^:]@^P[7[I'\%SSCV55.3_ "E+
M'4U-!6VF9M.^&HH:@D&.1L,N_5L=002 IE=.-]7/<KFS#\2K+Y;;82*JM9(6
MMT-[( :>G0D$]X&])B#13T6I\U[!]AVOW2/X)\U[!]AVOW2/X*#5/&BP1<-F
M9='%-())?)6T6P).WULL)[@ /2WZM=-G2IKC+Q+NV483;Z:YXU<+#)+5LJJ:
M=SG=G41!CP=$M;U])I\=CU>+$&BGHZ>^:]@^P[7[I'\$^:]@^P[7[I'\%BR5
M]5;<$CKJ"ADN-9!0LDCI6$ATS@P>B#H]3]RI'Y-F=Y)<*FLH[U'<;I;G/=)+
M=JFH<]E)RQD\AV#WZ]8[TQ!HIZ+X^:]@^P[7[I'\$^:]@^P[7[I'\%3U9Q^J
M9YJZJQW#J^YV"A=J>OYW- ']K080T:Z]3W=^E;.%Y509AC%/>[/SN@E!!C>-
M/8\=['>W?_D4Q!HIZ,CYKV#[#M?ND?P3YKV#[#M?ND?P5-8!FV35/$>XPU%!
M<:J&HG[.2C?,YS;>TR %VM=S>[N"QL>R:OL?$K-/(+56WFJDJ9FQT\).F@2G
M;CT.AW#N\5GKIZ.2-IMS$3I]<+N^:]@^P[7[I'\$^:]@^P[7[I'\%#K!Q2AN
M^)WRY_LY\%?:6<\U&^3H[OUIVO81W=-+RPOBM'DE;%"ZTRTE.R"6:JJG/+HX
M>39T#R]>@!ZZ[_%6U4M(NV9Q'7V3;YKV#[#M?ND?P3YKV#[#M?ND?P5<2<8:
MN6*HN-NQ6LJ;!3R<CZTR<OXZY2!WCIOQ\%OLAXH6VWV2T5ELIIKE574;I*5G
MHN/7E/-WZ(=Z.AO93521>LS$ST]DI^:]@^P[7[I'\$^:]@^P[7[I'\%%,2XC
M27+(Q8,ALL]ENDC>>%DCN9L@T3KJ!HZ!UW@Z*V/$[-3A-KI*QM"*SMYNQY#+
MV?+Z).]Z/J3-.,K:[6F:_2/9NOFO8/L.U^Z1_!/FO8/L.U^Z1_!5\.+\E-=Z
M&*\8U6VZUUI @JIG$$M.O2Y2W6NH)T>@/BMCF?$UUGR5MAL=FGO%R: 961N(
MY=C>@ "2==3X#::J5=]9QG_"8?->P?8=K]TC^"?->P?8=K]TC^"@N/\ %6>]
M7ZMM<./SQ5%/2R3=E)*1(9&-V8^7EZ;=TW_+P4;X-YAD5=E-PI*VFKZ^FGG
MDDEF<]M /3.M$'O[O#N4:Z5=_:F8B(SGV6G0VC$Z\S"AM]BJ3"[DE$,,3^1W
MJ=H=#["LOYKV#[#M?ND?P56<,<@QVPV_,;G%;IK?!1S1B7=09C+MSPUK00-=
M?O[^IZ+)AXS5$?D];=,6K:6QU#^2.L#R[?M&V@'N/0'P/>D54XXE-^UIB:L<
M5E?->P?8=K]TC^"?->P?8=K]TC^"B6;\3(\:O%II(+:^XP7"%L[)(9/2(<2
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MH !X%:FW\6JJ;);58Z[&ZB@K*J5D4S9Y2TQ\QT' %OI#77P353R)O68G3/\
M98'S7L'V':_=(_@GS7L'V':_=(_@J9M5TKK=Q XC5-##/5SPPR]G"QY!ZRM&
MQWZT"3^"R.$^4WVZ8S>Z2Y0UU;3B"HD%SFE<\,<(QJ+J/Q[_ !58KCEAG3M%
M$SIFGK]+>^:]@^P[7[I'\$^:]@^P[7[I'\%17#3/KCCF%U3:6PUMUCAJ7S5%
M3SD1Q-+6@ NT>O0GPTKQPS(Z7*L?I[K1,=&R7;71OZEC@=$'_P"_NTK4U4U-
M+-VW=Y1Q>GS7L'V':_=(_@GS7L'V':_=(_@H+?.*L]NR^XX_2X]/7U,'HPB"
M0ETKM ]6\O0:)Z]>Y>N,\1F9/37NU5]NEM5WIJ65Y@>XG8#2#W@$$;'0A-5/
M(WUF9TQS_1-?FO8/L.U^Z1_!/FO8/L.U^Z1_!5)PFRNGQ?A3<KK<S+-RW%T<
M<8=Z4CS''IH)[O$_<"LNHXT5]':XZRX8E54[*@@TTCY2(Y6^.G%G?K1Z;VHU
MTXS*D;19TQ-7#/%:'S7L'V':_=(_@GS7L'V':_=(_@H1D?%1UFN=DI!99:LW
M*BBJP(9=O#I-Z8UO+Z74 ;]J]\0XF27;*CC][LD]GN#VET39'EW-H<VB"T:Z
M D'Q4ZJ<X7WMG5I]?T3#YKV#[#M?ND?P3YKV#[#M?ND?P6NXC96<.QX7-M(*
ML]LV+LS)R=X/7>CZE!I>,U13MHZVKQ6NALM1IHJW.(YCKKR[;H^.NO77@DU4
MQPE-=VS;G35_997S7L'V':_=(_@GS7L'V':_=(_@HGF_$ZFL4UMI+/0R7>OK
MXFSPQ1.('([Z)Z DD^ TL"R\5IZ_+K=8*O'IZ"JG/).)Y2'1.T3T;R]1H [Z
M=_\ %JISA$W;,5:?7]$[^:]@^P[7[I'\$^:]@^P[7[I'\%7%9QE=!>KI:X[!
M-455+4.@B$4I=VG*XM+CZ/HCH/7WJ/U.;Y-3\7:UD-ON-3'&71MM(F?REH:
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M#"Y[V:IW@[:!L:)TM%D]NR#!^)5CS>BL=5=J"6WP1310L<71.$ B<TZ!+3H
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MJ'$^G&UKFZV>FP[1 [R% [;)?<GLM;?Y)\\K,C=*XTL]NI7/I&D?U2YIV/\
MEUR].A725JX:4]%Q)OF635YJ6W6G=3R43X &M:X,!]+?7HSU>*AU3\G]C7U-
M':LNNU#CU3+VLEM:"YI/W\P![AHEI/0=Z"#9AEF89!:\"Q:Z3UECKKH[LJZ6
M1CH'R'MNR8YPZ'6AS$= 2?N6'Q Q"IPOB)@5NDOU7=J)U9%) VJ.WP'MF!X'
M7Z)T"/N/WFZ<SX-V+(<7M-HI)9K=):6EM)5,]-P!ZNYP=<VSU[QU4=I^ ?\
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M#3-K8C$90SF+.O?K8W_%5GB_!B[X]/;VT?$&[BWTDS911,C<R)[0_F<S0DT
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M]BSR>-S@&@CKOITUWGJIQ:. [&7&WNR#*[G>;7;R/):"4%K&@:TW?,?1Z#8
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M1$0(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M/_?Q?XPAE5V+\)&4%US>2\5D5909(7[AC86.B#GO=WGQ',-'UA1/S#9 *(V
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MJI_[^+_&$,O5%Y>54_\ ?Q?XPGE5/_?Q?XPAEZHO+RJG_OXO\83RJG_OXO\
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MY>54_P#?Q?XPGE5/_?Q?XPAEZHO+RJG_ +^+_&$\JI_[^+_&$,O5%Y>54_\
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MP^TR6ZV25$D+YC.3.X%W,0!X =/1"+?HK1&.$-Z:8IC$<A$12D1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M7LF<YL<S0"-.+03T)!'0CHI1@]HJK#B5JM=PK#6U=) V*2<[/,1ZM]=#N&_
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M1PRT#Q+3O8""QX(/-O?4[ ZG?<LGB733UG#W)*:DADGJ);?.R.*)I<][BP@
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M"V0N'E%3KN_V6^MQ_EWGVS$3,XA:BB:YTT\WUPQP.KS.Z://!:H'#RBHU_\
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MO))()W[>GK6RS+&[M7\7<:O%)1NDMM+$QLTP>T!A#Y">A.^YP[AXJWFYM?\
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M8;>Z2.FIXY W36OY1K8/374Z[R4BN<HC::M4Q$9S,8^,K^!#@"""#W$+R%3
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M37SR.#'RN#8V\A/J.R>I/4=5A6C'[QBG$3':K&;#76$.DCCJJ>MNL$AJ8R\
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MGR9_]3UG_P"\G_\ &<JNM-@I^*W&/,J?,*ZK;%;'214E/%*&<C&R%@(V#H
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M3EFB/9_3T\>C]_J7*_#O%J/BQFF7W#,;G6,K*27^AABE#'1M+GC8V#IK.4
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M#FD;!!'=WK]) &R>BC3"FXMXQA#L.X>6?%GU4U(^IJ:VI88Y*FI>'/Y3W@:
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M<^(.YXY(W<LD3N[F:?Q]H4A12NK+"."^.XK>X[NV>X7.X0C4$E=(UPAZ:!:
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M'/<TN)<=@:;KD:-^/K085*VJXBY#DMQR"VY'=I8)"R!EMD8UE$-NT"'^ T-
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MV0_NS=?Y?!6ZB::NIN[O?]*B\]D/[LW7^7P3SV0_NS=?Y?!6ZB::NIN[O?\
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M7$35;''G:T=>8C6ATZ\OJ\0M-9\?R;B?Q1DR*_6*IQZV4]')2M;.QS7G<;V
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M'45U54NJ2XL+=-#W 'O)WRZ Z=Z#:UO'2[UU5<ZC$,1FNMBMKM3UA>X%P_M
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M -0?Q4X1!7UMX8TE#F>2Y$VXSOFO=-+320E@Y8@\M)(/CKE_FJGXQX-3\/\
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MGQ3Y[XO^\-J]Z9\5I_--A7V*/>9OUIYIL*^Q1[S-^M//[&;_ $C[;CY[XO\
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MGQ3Y[XO^\-J]Z9\5I_--A7V*/>9OUIYIL*^Q1[S-^M//[&;_ $C[;CY[XO\
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M]AVUP/<01WA!]HB("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@*N>.%YRJUXW3P8/;Z
MNIN-7*6/GIX#*:>,#J=:(!)( )]OBK&41XF9[;,!L7E]S#Y9Y264U,SZ4SP.
M[?@!TV3_ #/1!2 O.><->(V-VV_Y&^]T]V,0F@>]T@:'OY"!S=00>H(UO2V_
M$#)\PS'BO/A6#W/]E04+"9IVO+"YP +G.< 7:!<&@#Q[_9'N&=TM&4Y]\]N(
M.06^*O$H;;[;S_0(.F;'@&[Z#O)ZGVY=+>:/AY\I;(*O))'4U!<(G\E06%P
MDY'M=H G6VEO3Q1+=\*\LRVWYW>.'^77 5M>V!YI*ISN8MD#.8>GK9:6GFZC
M8TM3PTO^;4/'*#%,JO\ +7-A;)VT;7\T3CV!>W1+0>FQX=Z8-7P9O\IVLO\
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MWZX4N(W"QP137&SL8'TTDC6[<.0CJ2 0"T@]?N28JQ,)N47)IJIXSRG^5EV
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MT8Y3V4C?H\W-WN'AXH*?K+G9[OGN>U646"[9%5BIDAI8J,NU2PL<]I>2.[E
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M2<<T3&S-)D'7JT;ZCH>[U+GV]S/RC-L,H,NJ9(;?+;H)'ES^0/<YA)._ N<
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MBDG<X;+P-C?-KP/]7Q37/1;Q-49\O'A/RO>CJJ>M@;/1SQ5$+NZ2)X<T_B%
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M&CMI[][Z[4N^35BCJJRY977BU"&SWR1L<-)*T@.B'.3H?V?3 !]GL5_O8QX
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6$1 1$0$1$!$1 1$0$1$!$1 1$0?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g829170g00u02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g829170g00u02.jpg
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MZ2LLMSO,XBA;P8P<7RNZFM'63_\ 4\%J%M&V@WK:%=F1O$D="),4MOARX9/
M$X\)Y[?'PPN;6P\^MVBNE&/-/=I^WBJKW36[1A?24G%KJ]PQ+)_D'Z \?/R*
M :%V=:DUY5.J*6)S*1SR9;A5$[A.>.#S>?)YR%:FRC82UK8;KK=F\_@^.V@\
M!V&4CG_E'GZPM@Z>&*F@CAIXV10QM#6,8T-:T#D !R"YBLVXRPIH7UIV]6?H
MKC0FQK3.EVQS3P"ZW%N#W15M!:T_X6<AY\GQJR@ !@< $1=Q&.3VTI6D8K B
M(JZ$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M^<L^S]GQ_P#34YB(B[>P1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MY[C@<?$OE7W*AMS&ON%;34K'< Z>5K ?C*K;+U(OA15M+70]-0U,-3%RWX9
M]OQA<U%53TVYW3/%%OG#>D>&[Q\64,OLB\=PNE!;@PW"NI:0/\'IYFQ[WDR5
MZ898YHFR0O9)&X9:]AR".T%#+NB+6;T1NJK_ &O7\%%:KS7T-,*.-PCIIW1
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M4B:Q@1$7381$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MGC)ST396. \0)83\>5<R),1);2I?Q0B6@=GUBT-'4"R1SF:H#1+-/)ON<!G
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MI:'+3\9!^A#M;?[Q]8?P\_S4VH9[ZG5:**K/5:D]Y&L/X>?YKCU69?>1J_\
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M;,F6=[XX1SE]8Z_5VT]Q=:)9M,:2<<-JB/\ BZMO:WVH\8^,\E+M+;,]+:<
M?26R*IJ^;JNL'32N/;D\ ?( IBQK6,:QC0UK1@ #  7*1"5THCC;C(  , 8
M1$5:B(B B(@(B("(B B(@(B("(B B(@(B("B>J-GFE]2L?Z9VBG%0[E4P-Z*
M4'MWF\_/D*6(B36+1B84]/#K#9CF>">HU3I-GY2*7C5TC.T'](#XO$WFK*TO
MJ&VZFM$-RLU2VHI9.&1P+'=;7#J([%EU3NL;3/LUOSM8:9A<;'4/#;Q;8_!
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M/)2VPS\T;=Y'_;<KQHOR05';#/S1MWD?]MRO&B_)!(Y0XT?!7Y0]"(B-!$1
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M%VJB\34IK&-CIMTXRZ3D<\QA>/0^N*C4==?K/=[2;5>+6!TT(F$S7-<#@AP
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M,;/Q;7 9.Z">.!X3B?$/%*M3U,]1Z%B%]53MIW]ST\;6-;N@L;.T,=C_ !-
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M47BHIHJ;?:(XXF<=UC>63UGQJ- $D #)/(!9R\5[9MSRW1V EYV2V#?SG=E
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ML+BZW>W6B)LEUN%)11O.&NJ9FQAQ[ 7$96N^N[W;*K8WL\H*:NIY:UE12.=
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M,9<WK%ZS67Y\/:YCW->TM<TX((P05*MFFJ[MI34]-465[2Z=[89:>0D1S G
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MWXNI:/!'8\=1\?(_0LKUQQA\OM.A-9VZ\D[U-LHVD:EU'N7FXPU]. "VNEJ
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MJ(WLD8U['#!!&01Y%GEU<P.'%!0NJ=CMDN$CY:2.2WS'C_PY[PG_ "GA\6%
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MR#=EIF1M(=N"-IQU NSD8R"%,[U+JFQ:-I!>=866@KS4.%1<YX!CHSDM;&S
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M.AZ*MCW'G&.^ [./Q@J0*NXF)C,"(OC6U4%#15%75R"*F@C=++(>36M&23Y
M"BOLB\5ENE%>K9!<+74-J:*<$QRM! < 2#SX\P5[4(G/&!$1 P%QNCL7*BFB
M-9Q:JN.H:2*C?3&T59I'.<\.Z4@N&\.'#P>2)-HB8CJE>$1$41%'M6:NMNEI
M;7'<Q.77&H%-#T3-[OSCGQ&!Q1)F(C,I"BCVKM76W2IMOIH)_P#CZ@4T/1,W
MN_/;Q& EJU,+AJRZV,6RX0&@8U_=<L>(9<XX-/7S^@J93;C.$A1$5="(B B(
M@\-]]9+C^SR?9*J385^8-J\DGWCE;=]]9+C^SR?9*J385^8-J\DGWCE/-E/[
MD?*?Z6_1^ %Z@O+1^ %Z@JU$1$!$1!U?R57;*_9*VE?M5-]EZM%_)5=LK]DK
M:5^U4WV7J3S97\5?G_4K31$5:B(B B(@(B("(B B(@+C [%RB!@=B(B B(@(
MB("(B B(@(B("J3;OZ[Z#^%A_LK;52;=_7?0?PL/]E)Y,M;P?Q]TYLW@!2"/
MP5'[-X 4@C\%5I#LB(BB(B 5 =LGL=:A_9'*?%0';)['6H?V1RD\G&IX)^20
MZ"_,;3OP;3?=-6=6"T%^8VG?@VF^Z:LZD<EIX8$1%70B(@(B("(B B(@)@(B
M#C='8N<(B B(@(B("(B B(@(B("(B"C]&>R3K[X0;]3E;]N\$*H-&>R3K[X0
M;]3E;]N\$*5Y,M'P_P _=D0B!%6HB(@+@\ERN#R05?LW]EO:3^LI/NW*T55V
MS?V6]I/ZRD^[<K14JRT?#]9^\B(BK41$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MROV2MI7[53?9>K1?R57;*_9*VE?M5-]EZD\V5_%7Y_U*TT1%6HB(@(B("(B
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MN]]EOMMNU.^2.2HB:V2%[0X\QU=[]/B5?5VN]0U]JGKX-75-/J62XFDCL-/
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M"KK7^NKO8]8V?3M@L]/<:RXPNE9TT_1>#O9&>7)I*L545M>@%5MJTA";K):
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M$<8Z>J^&ZALSK?)7-N]N-#$[<?4"I88VN["[. ?$O3;;C172E%3;*RGK*<G
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M"4GLW,Y2HO\ 9Z:XLM]1=:"*O?@-IGU#&R'/+#2<JCMBU!HVMT8RY:A-!+J
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MGGM<E:)&9+,.#F\\-+OC 4FV[4%7<]EMZI+=2SU=4\PED,$9>]V)F$X:.)X
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M$Z.9C9(W##FN&01XPJWU)LGM\E4;KHZI?IR]MXMDI>$,GB?'RP?%YP4XP?\
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M*>)DU6^^N@@;)X&^X'B['4 "5(]+[1KG#K:R6FOU#:-14EU!8]U#%T;J27'
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MOM/4--5/CI*C=Z6, 8?EY!SYE6J>(O)1W.AK97Q4=;33R,\)L4K7%OE *]:
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MG=2SS550^20Q$8+ XG@/)Q7TTSLXT_IZ[MNE)'53U[&&.*:KJ'3&)IYAN>7
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M])+(<DG^7BZEQ:^.#R=H[3N_TUYK2U3MZU/=)'LL[8+33'P=QHEDQXW.X?$
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M;!4:JL6L-1WJPOJ:N4NA@I>DCK8WC&\#N.)R/&!@CKRMI T D@#)YE"T$@D
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M_;K\A$15J(B("(B B+AQPTH*']%%JQ]%::33M)(6R5WXZIP>/1-/>M\A</\
MM\:UF5@[>[B^X[4+OO.RRFW*=@[ UHS_ -Q=\:KY86G,OB]HOMZDBG6QC1C-
M:ZSBHJO>%OIV&HJMTX+F @!H/5DD#R94%5S>A9N]/0ZXK*&H<UCZ^E+(2>M[
M7!V[YQO'S*5YN=&(MJ1%N2]=::@9HNV6NSZ<M GN5>7TUNHX=V.-I:W)<2>
M R#X_I7.@[Y=;W355FUE8I*.Z4\3>Z-]C7T]2UV>+2,M\K<GZ\>/;/2Q36:B
MGKM/RWBW4TKI:E]+,8ZFE:&_E(\$9Z\C/9YL/L-96RU5VK:&*ZT^D:B.,V^*
MYS=)(7_IN;Q.&GR\>"VSQ?4VIC4V?)2NWW0M/HW5$4MK9N6NXM=+#'_\)X/?
ML'BX@CRXZE75LK9[;<*>MHWEE1 \2,<.H@J]O19W>GFN-BM,3FNJ*9DD\H'Z
M(?NAH_[2?B5 +*W">#YFO$5U)BK=+0U_CO-FHJ^(X941A^/:GK'F.0IU3/WV
M+7?T/EQ=)IJ2G<[^SU+FM\32 [ZR5?EKDWHPMHG,9?7TK[=(LR2(BK01$0$1
M$!$1!1NLO9\_\E;]ZK7L/Y%JJC67L^?^2M^]5KV'\BU2K+2_]?.6;')$')%6
MHB(@+J_D5V75_(H*GVQ^N>AO]14OUE6TJEVQ^N>AO]14OUE6TI'.65/';Z"(
MBK41876MTELFD;S<Z9H=/24DLT8(R-X-)&?%E5SLCTI4W&TV35]9J:]37.I)
MGGC=4;T$C27#HRSLY=? ]2F>.&=KXM%8A<"BFTO63-#V"*Z243JT25+*?HVR
M;F-X..<X/M>2KFSV^JVF:WUDV[7NZT5)9ZGN.DI:&HZ(,P7C?(ZSWF?.>P*#
MWV^W*\[#S%=ZI]9-;]0MI&5+SETC!&XC)ZSQ/'LPN9LQOKSLS,1UQ]%^T.LV
M56T>NTF*)S7TM&VK-3TF0[.[WN[CAX?//4I8J:H9HZ?T0^IYIYN@BCL0>^7V
M@ B)=YN:KS4=W;;;;0:@TK<-:SS"L:TW2X/(I:D9.\T#/+(Y8Y @J[6#?[,3
M,\>,K\O6LF6S7UBTP:)TC[I%)(*@28$>Z''&[CCG=[0I8J/VM6Z6[;:=&4$%
M?46]\]+*TU-.<2,;W^\&GJ)&1GJRO)8;I<=":PUW8Z>XUETH+=:7W*F%9(97
M1R-8UP!/9W_'&,X";2QK36TQ;EG^E]HM;I+1<CLC]4 ZJO7X0'_B<BJ(AQTN
MYN;G9CJY9X8PLA?:J\:PU]HNWLO-=:H;Q8(YZL4LA;S#WOW1R!.Z!GL[>2;2
M]X]W3U; KR7>Y4EHMM1<+E.V"CIV[\LC@2&CMP.*J_:%#:K9#IK3U==]4U4[
M('1Q4-J?F>L  &_(1C.-T]8ZSU%5K&:RZZ#VB6VLK[Y'262HBJ*2"KF_'-!Z
M1IBEYY;R);VC*38OK[,XQ_L9;.6RNIKG;Z>NH)1-25$8EBD (#FD9!X\5Z51
MEM-1H7T/\U\M5PN$];64=,]@J91(RF<\M9^*&.] W\XX\@L/IJ'4=-<M*W&P
M46L9)I98O326XR;]-4Q/QO. WC@<20>S'6FT;_&(F.+8M%0VU+TPH->5=PU4
M-1'2)AC;25%HJ"QM*_ #G/ Z][/$]HY\A<,44-XT@V*@KII(*RAW(:P/(D<'
M,P),\#O<0<]JL3EI74VIF,<F81:L5.K+]<-F5LTU25M8-14]?5,G>V9PF,<#
M#(079S^D!_T*;Z:U+6:XV@Z,;2UD[:2AM'=U>R*0M:^8]X6N /'#MWGVE2+9
M95[3%IQ$=/\ ?18MMUK3S#44MSM]=:J*S2ECZFKB(9,T$C?9CB1WN>'41VKT
MWW5=);]$5.IZ)O=]''3]TQACMSI6GEQ(X<^Q4;<655]TWM9;772Y;EMN3IH6
M-J#NX!E;T9!SWG$=Z,>".Q9RWV)EJ]#E=*ME?<*DW"VQRNBJ9M^.''Z,8P-T
M<>7'D%-J7,:UIS\I7+I:["_:<MMV;"8&UM.R<1%V]N;PSC/6LFM8JJVW+2>B
M=":JHM1762KJ9Z:!U,^7%.V)S"X,#!U -P<YSG/!;.KJ)RVTM2;\)CCP$1%6
MKPWWUDN/[/)]DJI-A7Y@VKR2?>.5MWWUDN/[/)]DJI-A7Y@VKR2?>.4\V4_N
M1\I_I;]'X 7J"\M'X 7J"K41$0$1$'5_)5=LK]DK:5^U4WV7JT7\E5VROV2M
MI7[53?9>I/-E?Q5^?]2M-$15J+X5\3IZ&HA9C?DC<P9Y9((7W1!3-%LWOL.P
MNMTF_N3TVEFZ1N)3T>.E:[PL=C3U+,:JT1=KFW9V*8TW_L*:%]7O2$<&B/.[
MPX^ >SJ5G(ILPRW-<8_W!4.JM WBGV@5VI;%;+)>J>X1-9/17-H_%O: -YA(
M(Y-'QG@LK<M*7JY[*[S9I+=8[==*TYC@MS3' !O,(WCCB[#3DX[%9*)LFYKQ
M]ZJ=2:"O%PTQH"@IS3=/9)J9]7O2$##&M#MTXX\EWUQH6[WK7U1>*,TW<<EB
MGMXWY"'=*]L@'#'+OQQ5IHFS!.C6?3T4#ZGFT&31-%HJ6>S-LCG-?+4ASNEB
M&_ON9C]+#N((''AQ"FFTW9[/?+/IT6%U(:RPO:8(:UN]%,P!H+'\#SW&^+GY
M592*;,)&A6(F%2QZ5U'<K-?J6JTUI2S&JMTM- :%N)72N  RX# 9SSU\E*M(
MV6\6#9G16F T?IU2TA8SI270])DD!Q''''J4P17#JNE%9RJ#1^A;VW:33ZGN
M-LM%AA@@?%)36V0N%4]P(WG#  ''/;EH\JD.UG1UPU-#9Z^PU$$-YL]4*JFZ
M?/1OX@EI(Y<6M/FQUY4^1,>21HUBLUZJLL^E-4W[7UMU+K5MNHX[5$YE+24;
MW/WGN!RYQ/+GGGU#S]M&:&NUHL>O*2K--TMZGJ'TNY(2,/:X-WN'#F%:*)@C
M1K'%$]E5@K-,:"M=HN?1=UTX?O\ 1.WF]](YPP?(0L!KS2-__#FVZPT>ZBEK
MZ>G-+/25;BULK.."".OOO%R'D5EHF.&%G3B:Q7HJBP[/KS<:W5=ZU=/20W:^
M43J!D5)ES*>,M#>9YGO6_%SX\(C6;.=H=PT!%I2HDLD5OH'[T!8]Q?4'?)&7
M8PT#><>0)X!;"HILPXGL]9C"O:S2%REVP674K#!Z6TEN-+)E_?[^)!P&.7?C
MK5A(BL1AK6L5SCS$1%70JDV[^N^@_A8?[*VU4FW?UWT'\+#_ &4GDRUO!_'W
M3FS> %((_!4?LW@!2"/P56D.R(B*(B(!4!VR>QUJ']D<I\5 =LGL=:A_9'*3
MR<:G@GY)#H+\QM._!M-]TU9U8+07YC:=^#:;[IJSJ1R6GA@15QMPI=0U-BMY
MT\RNFI8ZH/N%/02]'/+#V-(X]O 9YCAP5<WK65/0;,>AT7<;ZR2KNS:2H972
M%]51Y9ET;">6=WAQYEW+JDVPROK129B8;&HJ0T)37ZV;0[<VU6_5<&G:B%[*
MYMZ>'@/#7%KVG>."2&CSKRZ6M%RU=M-UC#5ZBNM-;K3<Q-'303$!SR]VZ#G.
M&@,(P.WJ3:(UIG'#BMBSZD?<=47>SFTU],V@#2*N:/$4^?:'K4A5"5VJ;K9M
M4[6*JGJYY#0T\/<L<CRYD+G8;O-:> QO9\RPEB;J5L&FKQI^DUE47662*6NG
MK)-^DJHGC+L#>/>\1CARX\\)M.8U\<,9_P#W#99%1&U7TPH->5-PU0W4+M(=
M QM+/:*@L%*_ WG/ Z][>XGM'/D+?I+C!'I"*XT,\E=3LH1/%*\Y=,T,R"?&
M<<?&58EK74VIF.C,*);1]:1:,MM'-W#+<*RMJ&TU-2QN#"]Y[2<X'F/$A4[:
M[7<=1[+[IKRMU1>([XP3U$+8*HLAB$9/>;@Y9P>1',>?S:^CGU39-F=\N-?7
MQUERFAHYFQ2[K&D/P9F-QWLASG/DX<%S-N#&VO,UX0V)L%957"T4U5<;>^W5
M<C29*5[P\QG)&-X<#RSYU[UB(Z'TGTLZCAJJJ?N6E<QL]1)ORNPT]\YW#)\:
MULIJ2\S[&#K*355[[OH)PRFB;4$1M;TH:<];G$N)R3R ')69PTOJSIXC&>'V
M;5*/4VI'S:UJ]/FTU[&04XG[O='^(?G=[T.[>^^@]BIVK@N^FM2[/+V=1W2N
MJK_.QM='/)^)(?N=ZU@X  /(QQY C"E]EKZQ_HB+_1/JZAU&RU,>R R$QM=^
M*XAN< \3\93:<[Z9X8QQ2C0VLF:JKM0TS*)U*;16NHRXR;_2X)&]R&.7+BI8
MM9(=0UVFM,[4JRU2&*LDOO0,E;SCWGORX>/ (!\:SNE:;4%NU;INHL5!K 4D
MSA'=G79X?#*UV/Q@[XX(RX^8>/,BSFFO/")C,_\ 5_+%R:@M<>HH[$^L8+M)
M#T[*?=.2SCQSC'4>OJ5)[036VS7MTK=;/U+%IZ0QMMU=::@MBI.&.^:.O/;Q
MX<CD+RWG2U-=]O='317R\BGN%N[N;5056[(T'?(:QV[P9P'#'65=I;:\YQ$>
M>&Q2*FM1BLUEMDFTE4W6OM]EMUO%2Z.CFZ)]0\[G-W7X8^2>W*P=KNEUM%NV
MI:;-VK:RFM%*Z2CJ9I29HLM=WN_S[/.#C&4VG4Z^)Y</PV!1:P7B"]679QI?
M7+=47B>ZR30Q]%).>A$6'8;N]?@#)).]DY4DUS=JV^;6KG8ZJ+453:;92L+*
M2R2!CW/<UCND?Q&0-_'Q>/+:<]XX<8Z>J^T5,Z;BUY-LEU#0!MQAO44SF6V2
ML<&U#X,M."[/A;N^ <\SSX+Z;$:ZVMNU5;GR:CH]0QTH-7;[M.Y['$$9E9GK
MR?%P=RZTR[C6S,1CFN)$1=-E'Z,]DG7WP@WZG*W[=X(50:,]DG7WP@WZG*W[
M=X(4KR9:/A_G[LB$0(JU$1$!<'DN5P>2"K]F_LM[2?UE)]VY6BJNV;^RWM)_
M64GW;E:*E66CX?K/WD1$5:HSM)TO^&&C;A9FS-AFF#712.&0U[7!PSXN&#Y5
MA- T^O89:.CU0RSQ6JCI^A+J=SGRU) #6DYX 8&3R\BL%%,>;B=.)MM*0MVB
M=>Z6M%XTSILV>ILM?)(8:NHD<V6!KQNG('7@#J/'CXE[ZG9=74=/LYI+7+!-
M#8*PU-9)(XL+]Z1CW%HP<\6NP/(K@139AQ&A7D@-+I.XQ;9ZS5#N@]+);:*5
MN']_OY9U8Y=Z>M11^D[CIC9_M/DN?0;MQ=4U4'1/WN\(=C/#@>*NE?&LI8*V
MDFI:R&.>FF:6212-#FO:>8(/,*[*SI1Y>_U:[:?TIK;6.SC3UC=/:H],2;DY
MJAO"=L8<>\+>1(.<8Y\,GFK$K]!5=3M1BN_XD6,6=UN<-_\ &9(<W &.QW-6
M)04=-;Z.*DH8(J>EB;NQQ1-#6M'8 %]U(JYKH5B./N]%%:?T!JK3="ZST^GM
M'7>%DCC!<:Z/OPTG/?C=R<=G5RR5*MJ>C[U=YM)W/3;:$U]BG,HIY261O!W#
M@8Y &,<.' JRT39\EC0K%=E2]XT)J4:M&JH;7IZ[5=?21QW"WU@S''*UK1O1
M%P/#O1Q/'GSSPS=PT/<=0[,[K9;C16.SW&JE$T$=MC+86%I:6[_#BXX() Y$
M=BLU%=F"-&O'WJ-K]&;0M0Q:99?76:*"RU4#A'"]V_,UN-Z1SN(S@# &,Y/+
M@K7UO:*B_:2NUJHJGN:IJZ=T3)22 ">W''!Y'Q%9M$B,.JZ45B8ZM?Z39?J:
M5FEHY+1IVW-LU7"^::G>3-5!K@7/<[=[!R/,GJ5@W'25RJ-L]JU1&8/2RFM[
MJ9^7]_OGI.0QR[\=:GZ*16'-="M?]T5))LTN%?<-HS:V6"*EU (NY)&N+BUS
M"7 N&. SN_2H[=M![1;]I&U6&YOLL5):7Q=$(Y'%]1N#=:7.Q@ -)ZAGL5^H
MFS"3V>LO'>J9]99Z^EAW>DG@DB;O' RYI S\:JNQ:0U38=G%IL3;38;P&/G-
M;25DA+3O/WHRQV,9 )SD=8PK@168:6TXM.4!V-:/K]':=JZ:YR0=-55;JD4]
M.YSHZ=I  8TGB>7_ .?F9\B)$86E8I&S B(JZ5/MY_MFA?AN)3JS_DPH+MY_
MMFA?AN)3JS_DPI'FRIX[?1G6<ERN&<ERJU$1$!$1!3_HIO8WI_A&+[$BU-6V
M7HIO8WI_A&+[$BU-6-^;Y/;/W$HV6>R1ICX1@^V%O4M%=EGLD:8^$8/MA;U+
MK3Y/1V'PR(B+1[A$1 56[:?7G9[_ *BIOM*TE5NVGUYV>_ZBIOM*3R9:W@G_
M 'FM)$15J(B("(B B(@*OMNL3IMF%_:SF(6N\S7M)^@*P5A=5VUEVL5?;Y>#
M*J!\)/9O-(S]*D\G-XVJS#4O8WI>BNEUFONI)&4^FK.625,LH[Q[R0&1^/)(
MSXN'6M@MJ]YJKE-0:(TW+BYWEN:B9G$4M)^F\^49 \6>T+6G2>L;[H"Y5M'
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MOU-<&15]'32EK+:UW?3EN-X..1@X/ 'F<9P%LQ"Z.YZ8;^#-7%1,EAW:6=D
M<V'J_)G X8QNG&#P75:9XR]&AV7;C:LJ"FUEM>HZ-D-=HV"M<QNZZ4QG>D\9
M#7XSY OA1[9M37NU-H]+:+F==&@QOD8'/AA(X<&@#'D<1CQJP#H_5E2"VX;0
MJXQGFVDM\$!\S@"5#-4;1]/[+[)^#>DAZ9W.(NWWR2;[62.)+G2O'A/S^B/H
MY+OC'F]%MJD9M:8CWX:\ZTIKY3:CK!JMD[;O(X23=,07.R,@Y'#&.6.'4L(L
MCJ*^7#45VGN5XJ75-9,>^>[A@#D !P '8%CEB^9;$S.%X>A\8YMKN$GZ+J@
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M.KCH=$%US#V"BOM/7,BPT8XR-X'(XCCXL*XK'3U-+9;?3W"?NBLBIXXYYO\
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MKA<&^F-3(V-L$33(YI<0!O8\'F.:R&K=46G2=K%??:KN>G<\1LPPN<]Q!(:
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M$) !). %TAECF;O0R,D;RRUP(5=NZ(B"C=9>SY_Y*W[U6O8?R+55&LO9\_\
M)6_>JU[#^1:I5EI?^OG+-CDB#DBK41$0%U?R*[+J_D4%3[8_7/0W^HJ7ZRK:
M52[8_7/0W^HJ7ZRK:4CG+*GCM]!$15J(B("(B BZ3S1T\,DT\C(HHVESWO<
MUH',DGD%@;1K;3-XN'<%LOE!55ASB*.8$NQSW>WS(DVB.$I"B\%->;=4W:IM
ME/6T\EQIFATU.UX+XP<8)'5S'QKXTFI+-66VKN%+=*.:AI"YM1.R4%D1:,G>
M/5@(;4,JBP5?K#3MOMM-7UMZH8:.J;O02.F&)1VMZSYEVCU98)+(^\1WBA=:
MV.#'5(F&XUQ(&">HY(X'M3*;5>KZ:=TW:M.1U;++2"F;5SFHF D<_?D/,]\3
MCER'!9=8NW:AM%RDKV4%RI:AU 0*KHY 1#S\(\AX)^(KRV;66G+U7NHK3>J"
MKJVY/113 N(',CM\RG B:QPAGD4:J=>:5I8V23Z@MK&/D=$"9V^$TX(\RS[J
MJG;2&K=/$*4,Z3IB\;FYC.]O<L8XY56+1/*7V18*QZOT]?:N2EL]YH:RI8"3
M'%*"[ ZP.L>,+K1ZRTY6W@VJDO=!-<<EO0,F!<2.8':1@\ F4VZ]6?18*^:O
MT]8:N.EO%YH:.H> 1'+* [':1U#QE9N-[9(VOC<U[' .:YIR"#R(18F)X0[(
MB(HB(@(B(/#??62X_L\GV2JDV%?F#:O))]XY6W??62X_L\GV2JDV%?F#:O))
M]XY3S93^Y'RG^EOT?@!>H+RT?@!>H*M1$1 1$0=7\E5VROV2MI7[53?9>K1?
MR57;*_9*VE?M5-]EZD\V5_%7Y_U*TT1%6HB(@(B("(B B(@(B("(B B(@(B(
M"(B B(@(B("(B JDV[^N^@_A8?[*VU4FW?UWT'\+#_92>3+6\'\?=.;-X 4@
MC\%1^S> %((_!5:0[(B(HB(@%0';)['6H?V1RGQ4!VR>QUJ']D<I/)QJ>"?D
MD.@OS&T[\&TWW35G5@M!?F-IWX-IONFK.I'):>&!$15T(B("(B#$ZGT[:]3V
MT6^^4IJJ,2-EZ/I'L!<,XR6D$\^7)92*-D43(XFAL; &M:!P '(+LB)B,Y$1
M$41$0$1$!$1 1$0$1$!$1 1$0$1$%'Z,]DG7WP@WZG*W[=X(50:,]DG7WP@W
MZG*W[=X(4KR9:/A_G[LB$0(JU$1$!<'DN5P>2"K]F_LM[2?UE)]VY6BJNV;^
MRWM)_64GW;E:*E66CX?K/WD43VJZBJ-*Z!NUWH0TU<+&MB+AD-<]X8'$>+>S
MYE+%C=266CU%8ZRTW-A?253-QX:<$=8(/:" 1XPK+N\3-9B.:C-1C4^BM'V+
M63-772X551) ZKHZF3>IWMD:7;K6]6.7TC"S\.L*W2>T;6-)?*V>HMTEO-VM
M[)WDAN!DQL[.)<,#VBR%%L?WC;:6^:GN5ULEN>U]-;I6-8P;O@AQ!.\ .'5P
MX<%E=J&S"BU[54%3/7S4,]*QT1?$P.Z1A.=TY[./QE<8EY8T]2(S7W<,_P H
MC1ZEU#IO8!+J&MKIZJ]5S^EAEJ#O]"V1X:W /4&C> Y9*Q6G+KJ2BU%IF6V3
MZTN457(R*ZMNM&_N<-?N@R1DC#0,D^0#CC*NB_:6MEZTG)IVKC<VW.A;"T1G
M#HPW&Z6GM&!\2CFF]"7JTU5"*G6UTK+;1X$=&86,#F@8#7O&2X>),2ZG2O$Q
MCEP0S85%J74\<.H+MJFODHZ&JE@91%Q<)^&29#GC@O&.>-U2#T25#+4[,:ZI
MCK9X(Z5\;I(&'O*@.E8T!_B!.\/&%*=G&CH=$6&6UT]7)5L?4/J.D>P-(+@!
MC _RK(:QT_3:ITU7V6M>^."K8&E[/":0X.:1Y" 58CAAU72G=36><PJJ]VBH
MM7H<KCW3=:NX]TT=-.SN@YZ!IZ+$;?\ "%'O_P!9='VC9]?&ZGK:J&X24U,^
MWN[V!D+FC=:&\N#>!.,YXJSZ;9W-ZGM?I6Y:AJZZ.H#61U$D0!@C;N[K&MSR
M&[V]:]%^V>4]WT_IBU/KY8F6.6&1D@C!,O1MW<$9X94PXG2M/&(\H\_>KG4V
MI[C?=HNH+9+7:II+;:@V&"+3\#GN,F.+Y2WCC(. >?BP<V-L:N5]N>BHGZJ@
MJHKC#,^'>JH3%)*P8+7EI [<9Z\+SW[9S+/JFJU!IO4-98;A6,#*KHHFRQS8
MX [KN1X#_P!94LTS:ZBSVF.DK+G572H#G.?4U.-YQ)SC X #J"L1.>+O3I>+
MS-E2[=;/;K?=-)U=%1P0U59?(Y*B9K>_E/#F>?FY*W;_ #VNAM[[C>^YV4M#
MF?I9V@B(X(R,]?$CAQXXZU ]:;+:G55X[MJM67**&.<5%-3"-KF4[AC!;Q\2
M]6JMFTFIM'V^Q734=?*ZEF,SZIS 73GOL!PSCAO</(G'B1%JS:8KS1?8_:Y]
M0;0+]M =2FAMM8'04,1;NF5O>@R$>1GG)/8II9MH5->KM+:X+)J"DE#)"*BJ
MH^CA&Z"?"WCSQPX+XZ0T'<]/W2EJ)M8W:X4<#"P44P B(W< 8SPQP(\BG<K!
M)&]A. X$)$+I4M%>G5J_;ZS5]=LBJ=8/UC<V2VV?<AIVN.)!TC03([.7'O\
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M+' .!(ZN!43M.TW3-VO4=MM]343/EE,$<XIG]"]XSWH?C'5Y%<K-ZQSE-44
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M5M*_:J;[+U)YLK^*OS_J5IHB*M1$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M"(B B(@(B("(B B(@(B("(B B(@(B("J3;OZ[Z#^%A_LK;52;=_7?0?PL/\
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M35!,8GS2U89/,T$;SV,QRXCM^O&:UQM.;I^U:8N-MMK[E3WOC&P.W9,%K2T
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M$1 1$0$1$!$1 1$0$1$!5)MW]=]!_"P_V5MJG]KDHK]IFA[4SB:?IJZ4=@P
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MZYE7#9KI1WFV4]PME0RHHYVA\<C#P(_V/:.I2.C/2MC]$\X>Q$15J(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B J5]$+>!7RV?1U*_,E7**JL#3X,+2<
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MSS[KJ/=$ORRG==1[HE^64WAW_P"'U?H8B_//NNH]T2_+*=UU'NB7Y93>'?\
MX?5^AB+\\^ZZCW1+\LIW74>Z)?EE-X=_^'U?H8B_//NNH]T2_+*=UU'NB7Y9
M3>'?_A]7Z&(OSS[KJ/=$ORRG==1[HE^64WAW_P"'U?H8B_//NNH]T2_+*=UU
M'NB7Y93>'?\ X?5^AB+\\^ZZCW1+\LIW74>Z)?EE-X=_^'U?H8B_//NNH]T2
M_+*=UU'NB7Y93>'?_A]7Z&(OSS[KJ/=$ORRG==1[HE^64WAW_P"'U?H8B_//
MNNH]T2_+*=UU'NB7Y93>'?\ X?5^AB+\\^ZZCW1+\LIW74>Z)?EE-X=_^'U?
MH8B_//NNH]T2_+*=UU'NB7Y93>'?_A]7Z&(OSS[KJ/=$ORRG==1[HE^64WAW
M_P"'U?H8B_//NNH]T2_+*=UU'NB7Y93>'?\ X?5^AB+\\^ZZCW1+\LIW74>Z
M)?EE-X=_^'U?H8B_//NNH]T2_+*=UU'NB7Y93>'?_A]7Z&(OSS[KJ/=$ORRG
M==1[HE^64WAW_P"'U?H8B_//NNH]T2_+*=UU'NB7Y93>'?\ X?5^AB+\\^ZZ
MCW1+\LIW74>Z)?EE-X=_^'U?H8B_//NNH]T2_+*=UU'NB7Y93>'?_A]7Z&(O
MSS[KJ/=$ORRG==1[HE^64WAW_P"'U?H8B_//NNH]T2_+*=UU'NB7Y93>'?\
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MSS[KJ/=$ORRG==1[HE^64WAW_P"'U?H8B_//NNH]T2_+*=UU'NB7Y93>'?\
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MSS[KJ/=$ORRG==1[HE^64WAW_P"'U?H8B_//NNH]T2_+*=UU'NB7Y93>'?\
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MSS[KJ/=$ORRG==1[HE^64WAW_P"'U?H8B_//NNH]T2_+*=UU'NB7Y93>'?\
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E?\,?+X\^96FBZBD0VT^RTIQYR  # X (B+IZ1$1 1$0$1$'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g829170g47a83.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g829170g47a83.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" SD"?8# 2(  A$! Q$!_\0
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MF;/8Y;#<9Z&2:>1LCHB 7 -& 5B/DVZXU+J/7E31WR\55;2MH))!'*00'![
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M:)_/35439HW>+7#(^E1:!5HB*HLNL]1T>D],U]ZN!^T4L?,& X,CCLU@]9)
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M5]/%4TLS>62*5H<UX\""M67+R?M#UE2Z6*"OHP3GLZ>I]'_O!Q_6IB?=(LG
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MQ7T\+?)/#8*:YPQ4K02T3'M6\SW>).1MW CQ.>N$F- B(H!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MFH)8J.Y5 CJFF9[^9O:1MZDDC9QZ+HW1VE+1H^UOMU@IW4](^4S%CI'/](@
MG+B3T:$GP+ZB(J@B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B H'Q1R.#I(V.+>A+0<*-$!>/:U
M[2U[0YIZ@C(*]1!#&QD;>6-K6M\&C 6$\1-$RZRN^FO.*B%MGMU4:JJIW ET
M[@!R =V/A ^IQ6<(I!0211R@"5C7@=SAE1HH # P.B(B" 11B0R"-@>>K@-S
M[U&B(/'-:]I:\!S3U!&05Y&QL;0V-K6M'<T8"B1 1$00.AC=('NC87CHXM&1
M[U&B("(B#36J.+EQT=JZX4.LM,SLL+G8HJND^V=HWQ)<0UV>N,@MZ;]5A.KM
M03<<+M9M/:4M593V.EJ!/5U<[ T,VQGT20,-+L#.23T"Z9>QLC"V1K7-/4.&
M05Y%&R)@9$QK&#HUHP IV(FM#6AK1@ 8 7J(H$$D4<H D8UX&XYAG"C1$!$1
M!!'%'%GLHV,SUY6@94:(@(B("(B H)(HY0!+&QX'3F&5&B !@8'10211RC$K
M&O'@X94:(   P-@$1$'CVM>TM>T.:>H(R"C&M8T-8T-:.@ P%ZB H(XHXR3'
M&QA/7E&,J-$!$1! (HQ)V@C9VGXW*,_*HT1 1$0% R*-CW/9&QKG=2&@$J-$
M!0/BC>X.?&QSF]"6@D*-$!:'\G!A^NWB2'M]%U>W8C8_;)UOA%(ACC9&WEC8
MUC?!HP%$B*! (V"0O#&AYV+@-S[U$X!P(< 0>H*]1!#'&R)O+&QK&^#1@*)$
M0$1$!$1! (HQ(9 QO:';FQO\JC1$$$D4<HQ*QKQX.&5&    , (B B(@* Q1
MF3M#&SM/QN49^51H@+QP#FD. (/4'O7J((8XV1MY8V-8WP:,!83Q&T3+K.Y:
M;9/41,L]OJS5U=.X$NG( Y&CNQ\('/<Y9PBD$1% (B("@9%&QSG,C8USNI P
M2HT0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1%9:[55AH
M*N2EKKQ04]1&</CDG:US=L[@E$6M6O>TZ7I%CWU[:8_+]L^<M_BGU[:8_+]L
M^<M_BFX4]MC^U']V0HL>^O;3'Y?MGSEO\4^O;3'Y?MGSEO\ %-P>VQ_:C^[(
M46/?7MIC\OVSYRW^*?7MIC\OVSYRW^*;@]MC^U']V0HL>^O;3'Y?MGSEO\4^
MO;3'Y?MGSEO\4W![;']J/[LA18]]>VF/R_;/G+?XI]>VF/R_;/G+?XIN#VV/
M[4?W9"BQ[Z]M,?E^V?.6_P 4^O;3'Y?MGSEO\4W![;']J/[LA18]]>VF/R_;
M/G+?XI]>VF/R_;/G+?XIN#VV/[4?W9"BQ[Z]M,?E^V?.6_Q3Z]M,?E^V?.6_
MQ3<'ML?VH_NR%%CWU[:8_+]L^<M_BGU[:8_+]L^<M_BFX/;8_M1_=D*+'OKV
MTQ^7[9\Y;_%/KVTQ^7[9\Y;_ !3<'ML?VH_NR%%CWU[:8_+]L^<M_BGU[:8_
M+]L^<M_BFX/;8_M1_=D*+'OKVTQ^7[9\Y;_%/KVTQ^7[9\Y;_%-P>VQ_:C^[
M(46/?7MIC\OVSYRW^*?7MIC\OVSYRW^*;@]MC^U']V0HL>^O;3'Y?MGSEO\
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M.^9_XT^P-'_2)WS/_&MV(G1!\F<7['ZS_+2?V!H_Z1.^9_XT^P-'_2)WS/\
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MN* BIJ>OI*F>6&GJH)9HMI(XY YS-\;@';=5* BIJVX4=#R>>U=/3<^>7MI
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MAD$'((4CU%X2 "20 -R2K;]<%F_*]O\ G+/XJ!<T5L^N"S?E>W_.6?Q5R!!
M(((.X(0>HB("*BNEVMUIB;)=;A244;M@ZIF;&#[W$**VW.AND!FME;2UD(..
MTIY6R-S[6DJ15HB* 16=^J+ RL\T??+6VKSR]B:N,/SX<N<J\*01%3UM=24+
M6NK:J"G:XX:9I P'V9*@5"+QK@YH<T@M(R".]"0 23@#O0>HK,S56GWU?FK+
M]:G5.<=B*R,OSX<N<J\J01$4 B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(J2LN=!12-96UU+3O<.8-EE:PD>."4%6B*FFKZ
M2&JCIIJJGCJ),<D3I 'NSL,#.2@J412ZB>&FA=-4RQQ1-^$^1P:T>TE!,14]
M'6TM;&Z2BJ8:AC3RET4@> ?#(4=340TL+IJF:.&%OPGR.#6CVDH)J*V?7!9O
MRO;_ )RS^*K*2LIJQA?1U,,[!U=$\.'ZD$]$7A(:"20 -R2@]14E'<J&N>YE
M%6TU0YHRX12M>0/$X*JT!%1U%SH*:H%/45U+%.<8C?*UKCGIL3E5B BEU$\-
M-"^:IECAA8,N?(X-:T>LGHK;;]26.Y5'86Z]6RKG_P"K@JHY'?("2I%V1%;Y
MKW:H)7Q3W.ACE8<.8^=@+3X$$J!<$5L^N"S?E>W_ #EG\5.I+M;JR;LJ2X4D
M\N,\D4S7''L!05J*555,%)"Z:JFCAB;U?(X-:/>50_7!9ORO;_G+/XH+FBDT
MM53U<7:4D\4\?3GC>'#Y0IDLC(HWR2O:R-@+G.<<  =22@B14E'<J&N>YE%6
MTU0YHRX12M>0/$X*JT!%1.NUN;5>;.N%(*GFY.R,S>?F\,9SE5J B(@(BIZR
MMI:%C7UM3!3L<<!TL@8"?#=!4(K9]<%F_*UO^<L_BKA#+'/$V2&1DD;MPYAR
M#[P@C1%155VMU),8JNX4D$H&2R69K78]A*"M16SZX+-^5[?\Y9_%5E'64U;$
M9*.HAJ(P>4NB>'@'PR$$]%0U-XMM+,Z&JN-'#,W&623M:X=^X)4KZX+-^5[?
M\Y9_%!<T5!3WFV5,S8::XT4TKO@LCG:YQ]@!5>@(J>LKJ2A:UU;504[7'#3+
M(& GU9*G@@@$'(/>@]1%2UMQHJ$M%;64U.7[M$TK69]F2@JD7C'->QKF.#FN
M&00<@A4M;<J&A<UM;6TU.YPRT32M82/5DH*M%XUP<T.:06D9!'>O4!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%B/%+6M/H3
M2<]UF8)JASA#2P$X[24@X!]0 )/J"RY<R^6%5RFX::I,D0-BFEQW%Q+1^H#]
M:F(V,:TKHK6'&FNEO=\NCH+:'EC:B9I<W/>V&,$# \<@>TY65WGR9Y(J,R6/
M47:5C!EL=3!R-<?SFDEOR%;WT'04]KT78Z.C:&P14<0&.\EH)/M))/O5]4[&
ML^!-OUK;=/U-/KB;F;')R4D<SNTF:T9!+G@[M/X.<GW85O\ *D^]3/\ &X?I
M*VXM1^5)]ZF?XW#])41Y$[R8OO2T'QB?]LK:RU3Y,7WI:#XQ/^V5M9)\C%.+
M'WLM5?ZMG_8<M1^1W_FG4WZ>#]EZVYQ8^]EJK_5L_P"PY:C\CO\ S3J;]/!^
MR]3'@;5XQ_>MU1\1D^A<O\'N$PXBVZXU7U8^I_FDK8N7S;M>;(SG/,,+J#C'
M]ZW5'Q&3Z%RIPKU!KZST%='H2@J:JFDE:Z<Q47;@.QMDX.-E,>!MJP^3@+5?
M+=<?KG,OFE3'4=GYCR\W(X.QGM-LX70:U!P3U!Q O%XN,6NJ"II:2. .@=+0
M]@"_F&0#@9V[EM]5D<,U^J+AH_C%?;O:9.6:&ZU0<P_!E89G<S'>H_P/4+L;
M0NJ[=K+3E-=[4_,<@Y9(B?2AD'PF.]8_6,'O7+.E+%0ZE\H&^VB[1=K1U-9<
M6O'>#]L(<#W$$ CV*?:*Z]<!^(\M'7B2ILM21VG*,-J(<[2-[@]OA[1T.5:8
MV,Q\L;^0TG^=5?1$MS\+_O<:7_U93_NVK1OE8W&DNUFT57VZ=E11U J9(I6'
M(<TB);RX7_>XTO\ ZLI_W;5'N&KM9>3X-2:INEY^N3S?SV=TW9>9<_)GNSSC
M/R+1FG- _5GBI-HWZH]CV=144_G?8\V>R#SGDYN_D\=LKNM<F\.O^=/6?ZQN
M/[,J1(V;POX(C0VK(KU]7O/>2)\?8^:=GGF&,YYS]"W*B* 7*/&R\7C7/%J/
M15%5=A0Q3QTT<;G%K'2$ ND?XXR0/4-MR<]7+GSCKPDN]RU$=6:-+GUKN1\]
M.Q_)*)&# DC.V^ -NN1D9SM,"VW/R99([=SVK48EN#6Y#)Z?DC>?S@XEOR%;
MVT%9*K3ND[=:[A<)KC5P1XEJ)7%Q+CN0"=^4=!GN 7.^F./.I],UC;9KJUR5
M0CPU[GQF"J8/$@@!WO SXKI/3%_MVIK)376S5 GHYQEKL8((V+2.X@[$).QI
MCROON1L?QX_NW+8G!#[U&F?B@_:*UWY7WW(V/X\?W;EL3@A]ZC3/Q0?M%/<-
M;>6!]SNGOC<G["D^3;Q3\]BATEJ&?_*HQRV^H>?Y1H_Z(GQ'=XC;N&9WE@?<
M[I[XW)^PL%U3PSE^QEIO6FF6/950T44E=%#D.V&T[<=XP,X\,]Q2/ ZQNG^;
M*O\ 0O\ H*Y?\D#[K+[\1;^\"V5P;XG1ZWTG5T%SD:W4%'3.[4=/.&8QV@'C
MXCN/M6M?) ^ZR^_$6_O D>)'45?5P4%%45E9(V*FIXW2RR.Z-:T9)^0+DJ]Z
MAU;QOU=+:+"Y]-96$N;"7ED;(P<=I,1\(GPW\ .I6]/*)JY:3A#?70$M=((H
MB1W-=*T.^49'O6,>25;Z>#0-?7,:TU-37.9([OY6-;RM_P"\X_UDCM&Q88_)
MBA\RQ)J>3SO'5M&.0'V<V57\']#\0=%:W?;IZR)^EV,+Y7.>7Q2@YP(VG=K\
M]>@\<[9W\BC8IKI_FRK_ $+_ *"N(N#_  \^R)=J^B^J7U/\U@$W/V':\V7
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MSC8G*VI2:EL5941T])>K9//(<,CBJHW.<?  ')6C/^3%2?THJ/F8_OJ]Z)X
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MAU-8IZ/SN&]6U]+C/:BJ9RX]N5@,_'+3'UZT5AHC-6PSN[)U=3CFC;*2 UH
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MM0UX@ES,9 Z=Q^ W/0-Z$GOSX+K#AGH^FT1I*DM%-ROF [2IF _E93\)WLV
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MYH7*'E8??+M/^KHOWLJZQ8WE8UO7 PM6<4N#\&OM1TMVFO$M"Z"G;3B)M.)
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M!FBOM[JX:B22H:UE3!.^5S)&CF;S%S0?P=O8NW5CVO\ 2M+K/2M;9*UYB9.
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M!4QXEP X^ILG^]'\%@=6[<JWN=A4_JLGQ=,</%KO#9#^)\#?_P ER_[X?P4
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MB6^4-1G_ /-ZH^<C^ZHQY05&?_S?J/G(_NKG:,*<T*)S6^*8Q5=#-X_T9_\
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M/YJ[_;_\EY]=$?\ [J[_ &__ "6+ER\!5/ZS+\4^QI\&3OU5&W_\4?\ [?\
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M6ZO*6_GE@_1S?2Q:56%_+Y'U+ZS?\OV$1%5PB(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M5ICJAK*'1U;,\OE<((!U=("#\BM-YH8Z*<10ND>P?A/9RY6>WG4DE0__ "<
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M,,E2)I,%4QJPUN 523U.<X*F]HTMCKJ5;+."W!*MM5(,$Y5)4UG(.JMT]87
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MZ^*,;@N *M;Y'/ZE55D/_M&$_P"D$M3599QEW:--JTT<4,31&QK=NX*IA?\
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M(#JBH<,B,'H .]Q[@L;J_P"=3?GN^E=,\(Z:#3W"R.X.9ETD4M=,1U=C./\
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M:57Z6']H+!/)H_SU>OB[/VE>N+VL]/7G0=116RZ05%4Z2(B-H=D@.!/4+$.
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M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%NKR:?YY?_ -'#]+UI5;J\FG^>7_\
M1P_2]6IY=WIOUFGY_M+>J(BW?7"(B B(@(B("(B B(@(B("(B B(@(B("(B
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M#@,*I;?*2+#8IWAQ[WY./8I=@TI1U31)="(&.WR9 ,++HM-Z3C8&PU3)7XW
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M4$O:W+M"T-R[.!W;JLTA3MJ;@]CC@<A]^Q5,Z(4UQEC<,%KU%OHK5\LN;)Z
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MG5/=XJ4!TDKV,\"_=3I-84'+("'$=V>\K HXWRNR\.<2KG2,AI6A\]"V;?\
M")W6$X:5[^]>+VE=I]9U4A,='#%!$>_D ]ZM\FIYHB.R].;O=W*]PWRVRQ=@
MZQ4H)^$3D'Z56P14533#S&TB-Q/I$@XPJ_,_]53JWNEB=-<;U>:@1BIFY2>@
M)#0MH:5I8K:UA?SRS8SSNV#5B5,UMJF;'3@OJ7["-H\5DL%WH]/OC?>"*JM<
M,B%I]%@\"L<WSXU6-0TI'3YEG]'!!78DGDKI]LGL^8-;^M6K4,=HD?Z4,Y+1
M@<[.<8]ZHQQ-<^C+#03=CCX$#,#Y5AE5KBBGJ7XCJJ4^!(_M7-CX]IEI.2(5
M=3;*0E[X9("S/P2"TM]N%[1PNCPV)V!ZSS-*M4EXBK" V3![B\8)]A"BMYED
MED%.XQ3MWP[H]=,4FGE6)B5_D9$79= 891T(^ Y8U=9,2$Q2ECA^"XXS["LV
ML\IJ?M4_VBI<-@?@O6/ZAB[-[HYZ0EN?A,']BTU$H8C+5"9A;,1VG=GO5!*Y
MKF\S TM&Q;X*HN%.P2DQY+!^,,%JD3TH:UL\/PG;'!5ZQ6%)F5(98F'H#E1&
MI:0>7T?852U+".8.8 0>H4GLN=I<S\'J%O%(EE-IA7"J#3GM#CP.ZG0W!T<A
MY<$GQ[U244#*ACV$8D RTJ8^C=V[-L>*K-:>)6BUO,*ZHJ9PZ,N<W!Z@E9+9
MIX97M;([D:0 <>*PRX$F0<P] ;9579B75+&L=@DX]2PR8HFFVE;_ #M-A7:B
M?"U@#VNB(R.3HK6(E6<LC6-;(XD@*  +.G>"WE3B,+T1JH#4Y5>$)'9^*=F%
M/+4 1"G[-.S51RKSEZH*?LT[,*HY5[RIH4W9J$Q*J+5YRIH4O9+SLE5\NR (
M*41+WLE4\J<J"E,2\[)5>-EYR[H*3LD[)57*$PI%-V7J40BVZ*?RKW&% D"+
M"B#,*<$PI1M*Y%YR*=A>%!(+%"6*H(4)"@2.3JH',SLJDA0 >F$(270>CT5&
M^G]+HK[V66CV*FEBW.RC;6(VMK(<*?&S'<JEL.3L%,9"<]%SWL[L4=D5*JYO
M14<+"UQ55N L=M)A<J/H%>*-JL]#\%7RWC.%/N8QVE>J(;*Y,V"HJ79JJ\[*
MF]-XC:J8[T5ZX[*F9(&M.5+DJ/6D2B<:>YX *MM4_<X44E1MU5!439[U2]NS
M2E$J:8X*ME0XDDY53-)L5;:B3<KCKN9=71&DJ>0-!5N?("3E15<V 5:)JL ]
M5UXZ=F%M1*XNF &RE/F5K=5^M0-J<]ZVC&IU+@^12)90,^*IG5&0>4J#FSU*
MM%5M]A[BX[J4XJ='$Z0X:"KG16DO(+AE3-HKY93W6F&GDF=AH.%>[;92YP+F
MY]ROUMM &/161TE$R(#;=<]\\SVA-<?Q6NV69K ,M'R+(*:E9&   ID8#0H9
M:AK =URVOIM6BK#FQM5+45X:TC*ME57]<%6N:J+B<E9?.NVBD1Y5U76EQ."K
M=+58SDJEFGZ[JVU-4&YRY;8\);)%5PDK/1("M-;6AH))W5OJJXG/*<!6"X7(
M-R <E=N+!N7%ESKK/<P >9V%::N[]1'N?%6*>H?*XDE2<E>C3C1'EY]L\RJY
MJE\A)<25':W$U2H-U6V<?Y4%TUK$.>U]JN]'E9'XY4ZGF#*>9I[PH[C!VT7K
M!5,(RV*0'P7N\?P\[+Y6J09<XCIE0C.%&!\,>M>8PMF:$LY@52RLQE5H.RE5
M(]'(5,E=UE,+01EQ"F1PN?T7K1]L*GQDL=D+R^F9B6L3&^ZDD88S@KQJJJOT
M\'O5.&X"K"9C4KIIQLAK'&(D.#"<CNV4+0'/E>]Q,G-U*FZ8E=#6O<T9] Y^
M12)/MKYI,8])3,=BJJ$QPHJ>7[?'O^$/I5 ';*93N/;Q_G#Z5S=#HZWT=1$5
MV#17E+?SRP?HYOI8M*K=7E+?SRP?HYOI8M*K"_E\CZE]9O\ E^PB(JN$1$0$
M1$!732U!%==2VJWU)>V"JJHX7EAPX-<X XSG?=6M7_A_]W6GO]80?O&J8\KX
MHB;Q$_%O%_!'2S!E];=6CUSQC_@5%<N!EFFI7&TW2MBGQZ)G+)&$^O#0?UJ[
M<=;!==062VPV:CDJI8J@O>UA P.4C.Y"LW W2.I;!=:VHO$3Z2@DAY! ^0.[
M1^1AV 3C !W]:Z.F-ZT^@MAQ>V]C['M\?]_EH^_6FKL5WJ;;<8^SJ:=W*X#<
M'O!!\",$>U;?X><*;%J+1UNNM?47%E14!Y>(I6!HY9'-& 6$] .]8OQ]JJ>I
MX@RMIBTN@IXXI2W\?<_00%M[A1$^?A!;XHAF22"H:T9QDF20!4I6.J8<?#X^
M/^IOCM&XC?[K3]A+2O\ []=/]_'_ '%JOBYI*W:1O%%2VF:HEBF@[5QG>UQ!
MYB-L >"F?8FUI^36_.H_[RPBOIIJ.MJ*6J'+/!(Z*1N<X<TD$9]H5;3V\:8\
MJ]>C7L>B?C_L-[::X.Z=N6F[9<*JJN;9:FECFDY9F!H+F@G&6=-U7/X(:9E8
M13W&YA_<>UC<![1R*\U,,M1P09#3QOEF?9HPUC&ESG'LQL .JT)IO36K/JS2
M&UVVYTU4V1I;,Z%\;6;]7.(  ]JO.HUV=N:,.'HK[+JW$*KB/H"MT74Q.?**
MJWSDB*H:WEW'X+AW'Z?E5LT7I&YZNN1I;9& QF#-._9D0]9\? #=;ZX_R0,X
M>O94%IF?41"+\X$DX_JARJ='04NA.%3*Z2,&1M+Y[/W&21PR&Y][6J/9QU?<
MRMZ?C_J9KO5(C<_PLE!P5TW04S77BX54\G1SS(V%F?4,9_6J6^\#[94TKI=.
MW*>*;&6MJ")(W>K( (]NZTKJ2_W'45RDK;K4OFD<3RM)]&,?BM'<%>^&^M*[
M2EZ@<)Y'6R1X;4TY.6EI.[@.YPZY]RCJI/;3..3Q+6Z)QZK\??\ [^;'KY:*
MVQW.:WW2!T%5$<.:>A'<0>\'Q6R>$7#JT:OL-76W2:NCEBJ3"T02-:.7D:=\
MM.^Y68^4/8X:S3-/>HVCSBCD:QSQ^%$\XQ[G8Q[3XJ+R;?N/N/Q]W[MBF*1%
M]2OAX=<?+]E?O&MH_L):5)+17W3FZ;3QY_86 <2^%4VEZ!USME2^LMS"!*V1
MH$D63@$XV(SW[=52W_AWJZKU/<IZ2TSF.6KEDCD[1C007D@Y+MEN?5'/:.$5
M9#?9VS53+;YO(\G//*6\HW/4\Q&_O4],3$]M-?8X\U+Q.+HUXEJ[A/PZLFK-
M-SU]UJ:V*=E4Z$-AE8UO*&L/0M._I%9JW@?I=PRVLNQ'JFC_ +BYP#B.A(73
M7D_$GA\S)S_E4O\ 8HQ]-NVF?I\X<TQBMCC<1Y4$O!32S(GN%;=,M!/\O'_<
M6N.#NB;;K*>ZLNLM7&*5L99YN]K<\Q=G.6GP"P*L>[SN?TC\-W?ZRMR^3+_.
M]0?F0?2]168M:(TRPVP\CD4K&.(COO[^S(CP1TL#@UMU!]<\?]Q8KQ,X96'3
M.DZBYVVJKI*F-[&ALLK'-P7 '8-!_6O.)/#O5%ZUM=+A;:$2TD[F&-_G#&YP
MQH.Q.>H*UIJ?3MUTU61TEZA[">2,2M:)&ORW)&<@GO!4VU&_FK\J:4BU?8:]
MV_\ /AGO"'A[:-86:MJ[I-6QR0U'9-$#VM&.4'?+3ONLX=P1TN<M%==0[]/'
M_<5/Y-?W,77XY_P-6F-=O<-;ZAPXC_VC4=__ ,5R=JUB9A;_ (<'&I>V.+3+
M9VI>!DD5.^;3MQ=/(T9%/5 -+O4'C;/M ]JTQ5TTU'52TU5$^&>)Q8^-XP6D
M=00ME\'->7"VZAH[3<*J6HME6\0M;*XN[%YV:6D]!G (Z;Y5\\H^P10S6^^P
M,#7S$TTY ^$0,L/MP'#W!1-8FO55CFPX<V&<^"-:\PTDMC<'=$VW64UU9=9:
MN,4K8RSS=[6YYB[.<M/XH6N5NWR9?YUJ'\R#Z7JN.-VU+GX%*Y,]:VC<?_3(
M7<$M+9Y//KH'^';QY_86"<2>$TNFK<^Z6FJDK*&+^69(T"2,=.;(V</'8859
MQ)T#JB\:\NE=;+8^2EF>PQR]LQH.&-&=W C<%;-O)DL'"*IAU!.)ZF.W.IY'
M$\W/(YI:&Y[]R!GWK7IB=]M/4GCXLL9*SCZ>G>I:SX8: TMK+3YGDJKE%<8'
M<E3$R5F ?P7 %F<$?K!6M=56*JTY?JNUUH^V0.PUV-GM/P7#U$*X\.M4RZ2U
M+!7-+G4K_M53&/PXR=_>.H]GK70.NM#V_7?U'N$4[&B-S7.F9OVU.=RT'Q[P
M>[)5(K%Z]O+DQX*<O!_QQJ]?/WM:\+N%5+J&PONNH):NGAE=_DS87-82P=7G
M+3L3T]GK6M]4Q6J"^U<%@?/);HG<D<DS@YTF.KM@-B>GJ6]N-VJHM.Z=BT]:
M2V*IJHNS+8]NQ@&V!X9Q@>H%<YJ+Q$=H9\ZN+#K#2.\>9%F?#[A]<]8RND@+
M:6W1NY9*J09&?!H_"/ZO6L3H:9]96T]+%_*3R-C;[7' ^E=1:PN4/#GAVQEK
MC:)(FMI:8$;&0@Y>?$[.<?$I2L3WGPKPN-3+U9,OT:K)!P:TG0PM%QK:N21V
MW/).V,$^H ?VE675' Z'S5\^EZ^1T@',*>J((?Z@\ 8]X]ZTK<KA5W.KDJKC
M4RU-0\Y=)*XN)_\ 7@KUIK6U^TY35%/:Z^1D$S"WLW^DUA/X30?@N]84]59[
M::_U7%M\VV+4?&/*+1NG&W/7-'8;PV>GYY7Q3M80U["UKCC<$=1X+(N,6A[9
MHTVH6J6KD\Z[7G\X>UV.7EQC#1^,5;.$,CY>)MFDE<Y\CY7N<YQR22QV22L\
M\IKX6GO9/_X:B(CHF5<>*D\.^37>)[?HT<M@<']'6[6-RN%/=):J-E/"V1AI
MWM:22[&^05K];D\FG_/MY^+,_:44C=M2PX5*WSUK:-PP/B58*73.L*RU6]\S
MZ>%L9:Z9P+O28'')  ZGP6UM,\'=.W/3=LN%357-LU331S/#)6!H+F@G&6=-
MUK_CI]\NZ?F0_NFK=L-!4W/@W3T-"SGJI[1''&WF#<N,8QN=@KUK'5+OXN#'
M;/EB:[B-ZC\UC^PEI7_WZZ?[^/\ N+3O%#3M%I?53[;;))I*=L+'ATS@YV3U
MW  5Q/"?68!)MK<#_P#6H_[RP)V<GF.ZK:>WC3FY5Z],5]CT3\?]AO'5W!>E
MI]//J]-S5LU=$T2&"=[7"1N-PW#1Z7AX]%HX@@D$$$;$%=J55QI;904\U=,V
M&%SHXN=W0.=L,^&Y"TOQRX?=BZ;4EEA^UN/-6PL'P3_U@'@>_P"7Q5\F/WPZ
M^?P*Q7VF&/'F/\K#P>T#:M8T5RFNLU9&ZFD8QGF[VM!!!)SEI\%16'1MLKN*
M==IRHFJFV^"29K7M>T289G&26X_4L[\F?_-=]_31?LN6I^))(U]J#!Q_EDG[
M2K,1%8ESWICQ\;%EZ=SOO]_ENMO!'2SCAM;=2?5/'_<1W!'2S3AU;=0?7/'_
M '%K[R>7$Z]?DD_Y')W_ .DU3?*,<1KFEP2/\@C_ 'DBMNO3U:=/7Q_Z?V_L
MH\ZTQGBCIRBTOJEUNMDDTE.(62<TS@YV3G.X '<L17I)/4Y7BQGR\;):+6FU
M8U'P7[0U@?J;5%!:VES8Y7YE>WJV,;N/MP-O60LWXN<-:/2=JI+A9Y:N6G=(
M8IQ.YKBTD9:1AHVV(^19/Y..G^QH*Z_SLP^<^;P$_B Y<?><#^J5G+JBW<1=
M%W6GI7 PROEI@X[\KV.]!W[#O>MJTB:_>]?C<&E^/\[Z=N\?DY*6X>'7#*S7
MK17U=O\ 4UM."9'@PR-:UL3-B3EI[VN6HZFGEI:J6GG8631/,;VGJUP."/E"
MW7Q#U+;K/PPMFG+'<:2KJ)HF0SFEF;)R-: 7YY2<<SOE!*SI$=YEQ<.N..N^
M6-Q6/'WM*U9@-7,:02-IN<]D)""X-SMDCOQA25F_#CAY7:T?-,R9M);H7<CZ
MAS>8EW7E:-LG&._;(6P+CP(IA2N=0WR1L[1G[?$"P^T@Y'ZTBEIC<*X^#GS5
MZZU[-$(IM3%V%1+$)&2B-Y;SQG+78.,@^"E*CD;KN'!^CFT+!<[)-6275]+'
M4]C(]I8_+0YS6@-!!WVW]2TJ002""".H*[)TO-'!I"ROF>V-GF=.WF<<#):T
M >\D!:0X[Z)^I5Q-_ML6*&K?BH8T;12GO]COISXA;7IVW#V>=P:UQQEQ1XCO
M_+65DM=5>KK36Z@C,E34/#&#Z2?4!N5M#B9PRM6D]'QW"EJ:R:M$L<3S(YO9
MDD') #<C<;;K+>"6CX]/6234-X#8JNICYF&3;L(.N3X$]3ZL>M5WE"?>_/QN
M+Z')%-5F9,7!K3BVR9(^=,;C[FJN#NBK;K*HND=UEJHVTK(W,\W>UN>8NSG+
M3X!;+/!'2P.#6W4'USQ_W%CGDR_SV_\ Z.'Z7J3Q+X=ZHO6MKG<+90B6DF+#
M&_MV-SAC0=B<]04K$=.];6P8Z5XM<GL^N9G^7G$SAE8=,Z3J+G;:JNDJ8Y&-
M#996.;@NP=@T']:MW"+A[:=8V:OJKG/6QRPS]DSL'M:,<H.^6GQ6"ZHT[==-
M5<5)>X.PFEC[5K1(U^6Y(SL3W@K=?DU?<U=OC8_8"BL1-M:9<>N/-RHK./IC
M7AI+5M@J],WZIME</3B.6/QM(P_!</4?XA6==0\6M(Q:QT\:NV<DESHN;L7,
MW[0 D/C/KR#CUC'>5J3@UHDZDOQJ[A$?J70.!D#AM+)W1_VGU;=ZBV.8MJ&.
M?@7IGC'3Q/C_ '[F3</>#U)=M.PW#44M;!/4^G%% YK>6/N+LM.YZ^S"U3I.
MW0W;4UKM]2Y[8*JICA>6$!P#G '&0=UV7#+%+SB%[7"-Q8[E.<$=RY X=?=Y
MI_X]#^V%:]8C6G1S>+CPSBK6//G[_#=S^".EF#+ZVZM]L\8_X%:[YP+H'43W
MV"YU(J0,L95%KV//AEH&/;NKYQSTY=M16FV0V2D=5213N>\->UN 6XSN0H>!
M^E[]INBN(OV88IG,,-,9 _E(SS.V) SD?(K],;UIV6X^*<WL?9=OBYPK:6:B
MK)Z6KC=%40O,<C'=6N!P0MXZ-X1:?O.E;9<JNIN39ZF!LKQ'*P-!/AEAV]ZU
MCQ2K::X:_O511%I@,W('-Z.+6AI/O(*W]INDFK^"T-'2-YZFHM#XHFY RYT;
M@!D]-R%G2L;F'!P<&.V7)6T=41O7]UF^PEI7_P!^NG^_C_N+47%73-!I34S+
M?:Y9Y8#3LEYIG!SN8EP.X VV"K?L3:T_)K?G4?\ >6!S,?'*]DGPV$M.^=PH
MM/;QIERKUZ->QZ)^/^PZ%M_!;34]MI:F:KNC721,>[$T8 ) /XBBFX'Z<FB<
M*2Y7)DG<XR1O ]H#1]*R+6UMK+MPHEH;;"Z>KEI:?DC:0"[#F$]?4"M8\+M!
MZNMFL*&MJ*66@I(G9G>^5N'LQNW .^5I,1$ZT]+)BQ4O7'&'<3KNP77>D:W1
M]Y\RK7-EC>WGAG8,-D;TZ=Q'>%<^&?#^JUI4S2&;S6VTY#99N7)<X[\K1XX^
M399WY3%53GZATH+35M[64CO:P\H'RD'Y%?O)UKJ:71M11QN:*J"I<Z5G>0X#
ME=[-B/<JQ2.O3CIP\7]9.&?HQ_NGOV&](-:*5U56^<D;$U+><^O'+C]2U+Q1
MT1#HNXT\,%R95LJ&E[8W-Q+& <9=C;![CMT.RKM>\.]46RZUEP,4US@?(Z7S
MJ#+W[G.7-^$#^KUK [A6U=?4=M7U$U1/RAG/,\N=@# &3X*MYCQK3+EWQQ$T
MG%TS[E,B(LWG"(B B(@(B("W5Y-/\\O_ .CA^EZTJMU>33_/+_\ HX?I>K4\
MN[TWZS3\_P!I;U1$6[ZX1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MMIAS\'!;!R;TGX=O[PU9]G'4_P#[K:?]S)_?6M;G627&XU=;.&B6IE?,\,&
M'.))QZMUT-]A?27_ +Y<?G#/[BUIQ@T=:M(U%K99YJB5M2V0R=M(U^.4MQC
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MI:F6=OGA:1SSO$E0\?BM:,8SZ@/64]E/O3'I>2)W>T17XM*<'?ODV/\ 2/\
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M?YY?_P!'#]+U:GEW>F_6:?G^TMZHB+=]<(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("Y-XYOQQ2O8\.P_<1KK)<B\=R1Q6OG_8?N
M(US\GZ#NX$ZR3^'\,+Y\KSJI#7>*C#_6N'3UXMM-"C#W#O4H.7H*+;5$4[@5
M60U"MK3NIS'!5F(3$KQ%,2JF.0X5I@D V56V7"QFK2MESCEP.JC[;UJU>< )
MYR%3H3-UT$V^Q4^*7)ZJRMJ,]ZJH)E$UF%*RO;7[*-KU;8Y]E,$X\4B5YGLN
M7:!>&0*W.J .]>><>M7<617.D&%(=(-U2NJ.NZE&=-LHA.E?D%4;SN4?,/%4
M[I05>&L0]E?EI5OF=DE5$CQ@JAE=N5M26=ZI4KME22'.5.D.Q4AYZK6KGO"4
MY0@;J)W>H1U6T,91A>X[UXO0I5>(1LO4[D0 +Q>IT1#Q>+T)L@(F,+W&4 ($
M0("=R]\5X@A1>E>>*#P>I1!>+T*1ZWH5$"O H@% 87OBF-DP,(D1!T7N$0\0
M="O44CP;(O3T3"#P)XIE$!>+T+Q0/ O%$@W.ZF!<;&W[>7N&0 J>Z3FHJ1@'
M&<*[6^-D-$^3IMU5IDC[%G:<W-)*[#&^I9>;;;5[0]IRV!KGN'>&^U1W(NBI
M'/+LG^WP44A+)8HBT8CW=GQ*F3Q,JZ@<N>6,=/$JU8[DK3*YKFP-QA^.9Q\2
MJ"O<]V[SZ3C\@5UGI1+5<S3AK,_J5MJHWOE# TYSDE6B.ZLJ&6$!V,]1LID0
MQ0Y'X+CD>I51B)ASR@\@)RJ:(N\V<6X](;CP5]]E=:4C06GF )'>IIJ0_DRT
MY QD=ZE-+XG\Q.6'<+UY:VH<&'+#XJ^MJQ.EPIZMQ#@1S-< ' _2LKL[(8Z%
M[R&DC!()6+V>E;.^4/=AC1S./@JP5#V4$S>;T@[N[PN>\?!O2?BOD],U]()&
ML+ =G,S^M6.X0BFC.83S>/@LNLDS*RW2N<27EHQZBK/<@):=T$C!VI=\(+*)
MU+:8W#%8 R;M YN/#"N5M;)1XD [1O>T]P5#2PF*JECER-\*^4$!='EV3MN%
MIDMI3'7;(K6ZEJI&"%SHP[ <#MA5]UIV00=G$PR/DV&-E+H+?$*6*2&0=H1N
MID3)O.G=K(&OV#2[H%SS9OI8Y;1-1B.62,3L.[P/P53:DIJ:6B+Z*=W+C/9N
M.<>I9!6U%11/DC,C7E[<.!'7Q6)00?;GM<<1/R0JTMN=LK1[E+;J;MF1.S@#
MKZE)N&*6OYC%SD=Q6;:9LHJ*25\;<L8[IZE;=;VU\,]0V =0U_N(712?G;4F
M.S%&UD]36!Y)+.@(_!]6%E%INM52M/+RU#&_@M/I ?VK%*;MWP/BIY@W!R<;
M;J=%5RC#9?MC^; (!:[V@KHF(GLQC;+8KS123/>R-\9/6)X^@J&H=:ZQ[>5K
M(W=,8P0K;35%-<8G4]:T>< Y9)T=[U2UEOG8TF)W,W. 5C-6D6VA%+#25$C7
MO;- YQP,=%*GH(Y).:',;,;8W 5'.RKC#N9KL#OQLJ*.KD8_ <2/ *8I:>\2
MCJK'9D5+1QB(&HD8&9V)ZA2+C<&-C,-)DL&Q)[_6HJ4&JMSG%I$KM@J:2DAI
M:?GG?AQZ;9641'5\Y:9[=GMG<89"]T8D<[ID+(Z45<#^:/D9*[9K0=QZR59;
M,8W.YFDO([L+(J*$B3GDV>[8+/-;4RFD;7..1S*=SY7<Q&[G?C+#;A*VJJWO
MR=SL%D=[FBIZ9\;G%O*WTOX+$(7L+PX?"><#U+/#2>]FENW966MWVUT=0?1&
MQ"O5IMM*TE])4<CLG#'=/E6,E_92N#-WDY44=0^,P=JX->YQ! /3P*VG'-MZ
ME3JB/+/*BM\VI(HR "U^#CO62WI\$MFBD#V\P:.7QRL'IY#+$(IP""-G*OCY
MJ? J'N,3]VXW7+6NK+V\*1W4^**?4L:W')G<94@!=T.8&P0+TC!12"\7J("(
MB B(@($"("(G<@\ZA>+WN7B O.]>H@\[EXHO%>(AXO0$7H1#Q>*)$$*A.Q41
M4LG=0M"I:_ 7K)-U3%_HJ!LFZK+:J\0/R57-DPW"LE/,JQLVW59;=%549-RH
M9'^B52]INCY!CJLY:QV03.V4@O\ 6H9Y0 =U1OF641M/4JG38SNI;JC;JJ)T
MQ\5)?-ZU>*'4JY)^N2J66?KNJ:2;).ZD<Y>=EI%%)NGNFR>JN]L<3A6BGIG.
M()&5?[?#R@*N28B%\6]LBH1EHRKO"T!JM='Z+0KC&_#5Y63O+TZSV3CA2G$*
M!\F!U5+)4!H.Z4VPO*J+AA29*AK!UW5LJ:\-! *M%3<.N2MZX[68]6E]GN &
M<%6Z:X==U8*BX]=U;9[D-_2713CLKY8AD<]P&_I95NJ*\[[JPR7#.=U1S5SG
M9Y5U4XTN6_(7>IKP,\Q5IJ*Y\F0S(5(2Z0DN.5,9&NFN*M6$WM9 &EQR=RIT
M47BIC& *8#A6FWP1$:&QX4?10<R\#U3NMM'E%!S+PN31M&2FR@+ME#S)I&T9
MQA29& J(N\%YS*T1,(4DL2]H8!),6D=RGO(P5.M4?/58'7"Z,5N\,KU7*WQ]
ME 6Y4<# ^"JYNY3(F<H<%)B>1'4[KV\$[EP9>T,<F'+*X>M0D MPHIMY7>U0
MK=E"A?3'M-NA5XM<[+;"\EG,7=?6J<-RI=0/16$8*UF;0MU3X2:F5LU4Z1K>
M4$]%64<+IY6L8"2XX&%;H03)@>*WSP&T%]4ZH7:X1_Y- \<C3^$Y4QWBE)M*
MT5ZI9UP8X;06Z@@NMTB:^ID:',8YOP/_ #6X"0T8:, >"AC CC#&[- P%+>Y
M>=>]LMNJS;Q"+F7JEM*B#E"'N5"3@J&1X"II*EK.I09"B(JH:*\I;^>6#]'-
M]+%I5;J\I;^>6#]'-]+%I587\OD?4OK-_P OV$1%5PB(B B(@*NL5O==KU06
MZ.01OJYV0!Y&0TN<!G]:H5?^'_W=:>_UA!^\:ICROCB+7B)^*^<0^'-3HN@I
M:JHN$-4V>4Q!K(RW&V<[^Q></>'53K2@JZFFKX:44\@C+9&%W,2,]RV5Y2OW
M.VGXV?V"H?)I_P P7CXTW]A:]$=>GJ_TF+^L]CKYNO\ #1E\M-99+K46ZXQ&
M*I@=RN'<? @]X(W!4-EH'72\4-O8\1NJIV0!Y&0TN<!G]:Z6XKZ'AUA:#56[
ML_JO2APB>"/MH!.8W'VYQX'VE<^:*BD@UW9(IF.CE9<86N8X8+2)!D$*MJ=,
MZ<O(X<X,L5GO6?"]\0^'53HNAI:FHN$-4*B0QAK(RW&!G.ZP1=!^4K]S]H^-
M._8*Y\47B(G4*\_#3#FFE/ LMX>:'K-:UE7%2SLIHJ9@<^5[2X9)P&[=YP3[
MEB2Z?X56VFT=PX;7W-P@=.WSVH>X;M:1Z(_V<;>)*8Z]4]T\#CQGR:O]&.\N
M?-9Z<J=*W^>UUCVR.C#7-E:,![2,@C]8]Q5C707E%6 5=FHK]3-#GTI[&8CO
MC<?1/N=^TN?4O7IG2G,P>PRS2/'N_ 67Z%X?W?6!?)1"."BC=ROJ9LAN?!H&
MY/\ ZRL075N@V21\)J#ZWQ$:PT#G0YQRF<@YS_7RIQUBT]VG XU>1>8OXB-M
M>5/ 6K;3DTM]@DFQ\&2G+&GW@GZ%JO4^G[AIJZ.M]VB;'4!H>.5P<US3G!!'
M=L5D-1K+7%@O#OJA<;E#5-=ET-7DL/\ 4=MCV>Y8O?;M5WR[5-QN,G:5,[N9
MQ[AX >  V"BW3[H5Y%N/-=8JS6S.;GPJJZ#1AU"ZYP/B%,RI[$1D.PX XSGU
MK6ZZAU7]XY_^JX/H8N7E-ZQ'A?GX*8;5BD>8VS;AUH"HUM%7OIZZ*E%(6 B1
MA=S<V?#\U8[J6SOL6H*RU22MF?32=F9&C =Z\+<GDR_S74/Y\'T/6M.*7WQ[
MY\9_L"36.F),N"E>+3+$=YG^6<,X#U[FAWU;I=QG^1=_%2JO@3=XX7.I;K0S
M2 ;,>US,^_=;,XN7"NMF@*BIM4\T%4U\0:^(^D 7#*UQP?U/K"Y:OIZ:LJ*R
MLMKFN\X,[<MC'*<'FQL<X]N5>:UB=:=^7C\3'EC#-)W/WM:?6]54VIXK)=__
M &?4.F;"]T@R&<QP';=1N-QW+)=?\,J[1]JAN$M9%60/E$3NS86EA()!.>[8
MK*?*6BIV7:QS1X%6Z&02$=>4.;R_K+UGMHDCXB<)^RF<UU3/3F&0G\&=G1Q]
MX#O85$4C<U84X6.;Y,'FT=X<M+86@N%]=JZS/N4=;#1P"4QL$C"XOP!DC'=D
MX]Q6"-I)W5HHQ$[SDR=EV>-^?.,>W*Z9U5/'P_X3>:4SPVH9 *2)PVYI7@\S
MA_WG>Y5I6)W,N?A<>F3JOE^C6&C-):,=J;55;9:*X1-%.V1XJ"PEL@:X-R!Z
M\Y6=?8&K_P MTO\ N7?Q5J\G/[NZGXA)^VQ9)QEO&K*'5L<6GYKDRC-*QQ%-
M&YS>;F=GH.NP4UBO3N8;X,.#^G]MDK,]_<QW4O!RML=BKKG)=J>9E+&9"QL3
M@78[LY5!H;AB_5]E%?17FGB<UYCEA?$2Z-P\=^\8.59KWJ?6#J-]+>:ZYMIJ
MAI:8ZAI:)!WC<;]RJ.%.KG:2U+'),X_4ZJQ%5-\!G9_M:?U9\5'S=^&$6XLY
MHCIF*^_?[L:OEKJK+=JJW5[.2IIWECAW'P(]1&"/:LIX>\.KAK.GJJF&HCI*
M6%P8)9&%P>[J0,> QGVA;:XO: ?JPV^Y67LS6\S(979'*^)QV?GOY<Y]A/@%
M7ZNNE%PRX?PT=LY15<G84H/5TGX4A]F<GUD#O5HQZF=^'37TZN/):V7Z%?U<
M\:OLD>G;[/;&5T=:^##9)(VEK0_O;OUQW^O;N5E4<LCY97R2N<^1Y+G.<<DD
M]25" 20 ,DK)Y-IB9F:QJ%ST[8+GJ*O%'9Z5]1-U=C9K!XN)V 6TK?P'KY(0
MZX7JF@D(W9%"9 />2WZ%L&QT=OX9<.GU-1&#/'$):DC9TTQV#<^&3RCP&_BM
M%W[B7JB[UCYA=*BBB)]"&D>8FM'AD;GWE:=-:Q\YZ<X./Q:Q[>)M:?=\%\U-
MP9OUJIWU%NEAND3!DLB!9+CU-/7W$GU+63FN8XM>"UP."",$%;)TIQAOUH9)
M%<R+K$6'LS,</8[&QYAN1GJ#OZPJ/AW:I->\1'3WC$L>75E6 WE#P",-P.XD
M@>S*B8K/T6&3'@RVK''WN?=/N2=%\,K]JB!M5$R.CH'?!GJ,CG_-:-S[=AZU
MF<O 6H$.8K]"Z7'P74Q#?EYC]"R3C%Q!ETI'!:+$(X[A)&'NDY01!'T #>F3
MCW >M:8I>(.JZ:K%2R^USW@YY9).=A_JG;]2M,4KVET9*</C3[.\3:??*7K'
M15ZTG,T76G'8/.(ZB(\T;SX9[CZC@JS6>A=<[M0T#'B-U5.R /(R&ES@W/ZU
MTWHJ^T7$O1=3!=*>/M<=A5PCH'8R'M\/$>!'J6@[7:Y++Q.M]MG.7TMUABYO
MQ@)1@^\8/O5;4B-3'ACR.)2DTOCG=++EK[AG<](4,5<^>.MHW.Y))(F$=D>[
M(/<?'Q]RP)=MW"GI:VFDH:YD<L-2QS'1/_#&-QA<K<3=%3Z.O18WFDME02ZF
MF/AWL=_I#]?53DQ]/>&OJ' C!_R8_H_LN>A.%M5JZQ"YP7*"F8971\CXRX[8
MWR#ZUA-JMSKC>Z2VLD#'U%0VG#R,@%S@W/ZUT7Y/GWOF_&I?[%H71_W>V?\
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M*VW5&\M+*Z)Q\<'&??U5"LGE3$Q.I$1$0(B("(B B(@(B("(B B(@(B("(B
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MJA\Y<XG=4CWDJ&-V^Z[JXHK'9Y]LTVE<&.+NJJ(QE443E61OPJ6AI28E4-:
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M>I]6!W!<]Z5J9:S7MGJ:EY?/-<X9'N/X3C*"3\JFW:(JOR-8<>/C;W,3N?\
M?S;QX^7*JL]ML5?;YG0U4%=SL>/S';'Q!Z$*[6>OM'%71$L%4QK9<!L\8^%3
MRXV>WU=X/>,@]ZQWRE/N:M7QL_L.6F=$ZHK-)WV*X41YF_!FA)P)6=[3_8>X
MJ;6Z;:GPVY'*]ARK5OWK.MNDN$]@J],Z:GME>!VL57(6O;TD:<8</40N;M'_
M '>V?_6,7[P+K/3UYH[_ &BGN5ME[2GF;D>+3WM([B#LN3-'_=[9_P#6,7[P
M)?MK2.?6M8PUIX]WZ-S>4I]S-J^.']ARYY76/%#1DNM+524D%8RD,$W:ESV%
MV?1(QL?6L%M' >-E4Q]VO)FIVG)C@AY"[U<Q)Q\B7I,V[*\_A9LV>;4CMV7_
M ,G>GF@T%+)-D1SUDDD6?Q>5K<_*URU]PCFBGXR5,L!'92NJG,QX$DC]2SOB
MAK6VZ2TZ[3]@=$*]T78,CA.12LQ@D_Z6.@ZYW/KT7HJ^NTWJBWW4-+VP2?;&
MCJYA!#@/7@E1:8B8CX*\C+3#?%BWOH\M@>4F#]==L.-C1 9_[1ZU&NI=8Z7M
M'$VPT=;;Z]K9& FGJF#F&#U8]ON&W4'WK#=.<#'PW*.6_7*&:DC<'&&G:[,F
M.XDXP/9E+4F9W"O+X.;+GF^.-Q/O9=K[T>"M0';$4-.-_:Q67R;)8W:7ND3<
M=JRLYG>PL;CZ"J/C[J^C9:1IJWRLDJ)'M=4AAR(F-.0T^LD X[@/6M=\)M9#
M2&H3)5<QMM4T1U :,EN#Z+P._&_N)4S:(NWR\FF/F5W/:(U*S:]IYJ76M]BJ
M01+YY*[?O!<2#[P0585T[KC0%HX@0PW:V5T<-6Y@#:F(!\<S>X. [QTSU'0Y
M6$V_@/7FJ'U1O%*RF!W[!CG/(]^ /UJLXYWV<>;T[-[2>B-Q/B6F%<]+_=+:
M?C</[86T>,=@T?IZQ4=%;AV=[AP&-C=S.>W.2Z;^P]?#;IJ[2_W2VGXW#^V%
M2:],Z<V3!.#+%)G<]O#??E'_ '%47Q]G[N1<XKH[RC_N*HOC[/W<BYQ5LOTG
M3ZK]8G\(=<6>Z-LO"ZW7*2)TK*6UQ2EC3@NQ&-LK!'<>* M(^HE5N,?RS?X+
M-[=:W7OA10VQDHB=56J*(2$9#<QC?"UI]@6M_+M/\W=_%:VZNW2]3//*B*_T
M\=M?=_EI=QRXGQ*Z@XV_>NK?;!^VU:#U_I231][9;9JIE4YT+9N=C"T;EPQC
M/^BNF=;Z=?JG1\MIBJ&T[YNS<)'-Y@.5P/3W*F.)U:'#P,5XIFQZ[ZU^[D%;
MW\F:GG;37ZI<"*=[X8V^!< XG]3A\JD47 5_;M-=?6F 'TA#3^D?82<#Y"LP
MU+J"Q\,=+-MMK$9K&L(IZ;FYGN<?^DD]7?Z^@]2E)K/59/#XE^/?V^?YL0T;
MQ;ECFXC7UT)!:)PPX\6M /ZP5B*F5$TE342SSO+YI7%[W'JYQ.25+64SN=O)
MR7Z[S;XR(B*%!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 6ZO)
MI_GE_P#T</TO6E5NKR:?YY?_ -'#]+U:GEW>F_6:?G^TMZHB+=]<(B("(B B
M(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("T)Q1:#K>Y_]E^Z
M:M]K0/%&0#75S![NR_=,7G^I?]4?C_B7I>F?]L_A_F&(R1 JEFA'@JTO'BI3
MR,%>-69A[G2M,U."#LK=-2#? 5_D:"%2R1YRMZ75Z&/OI=SLI9IL9V5^="/!
M2S!ZEK&1G-%@?39'14TE,03LLD=3CP4B2F![E>,C.<;&WQ$=REEI"OLE+ZE2
MR4O79:1=E-%K&0G.1WJJ?3D=RD.B(RM(F)4F)A*,FQ4ISR>]1O;A2G!:5B&<
MS(7GQ4)>5X<X4)RKQ$*;1=H0O>U..JDE0Y[E/3".J85;9CXJ+M_6J+)09*=$
M'M)5HER>JC:_94+,J8'$!1TG6JP[91M*I(WE3F'91K2DSM/!435*!4;%,*2F
M_2B\:O5*CT# *("B($*(@+W"!$!$\40 O0O$"D1=^R>*!,;*!"F%ZB#P=%ZO
M1WH@];LH@O&J) 3" ;+U!YW(O0BD>(O0F$'B87N$0>=$[EZF$'B\*B 3&R"$
M#.%?H@8K;SN=L1AHRK)$WFD:.[*O-3%F&)H.(@-RJ7E>D+5-(]SHXVNVSOA1
M25+YNV+,M8TXQXJ96,;3L,H_E#L/4%:P',: '\S<Y.%$3M=<N6+GC+QD-W/J
M4<+1YR)9  2-@%1$EH+<$EQ!44;9)::>0-=GH#E:*KQ:9FB>J :,L;S>]8W<
M";A=@QY#69QE3+9.89YY"23RAN">J]= *FI=R##6XW'>K(\K_0=E2S&%F1&Q
MH</8KCVKJV3#&@0QD.<?4K=$V,T)Y6Y<  XGKZE<K:[,[F#9KL%WL 54PD7E
MCJJ!HB:23(,-]7<K?+2R EIVE) QXJ^6KD;4S/G<UP:?UYV59<8FBXPO+<%S
M 1CN597AB,]O<_M#WYR?!3HJ/SBC,8:!,S<?Z066BU&=D3 ,<^<D>"N<=KBA
M8T%K0V,@<QZE9Z76O3U(V)E.PC :W<J_5%J=+51R1@'EWRIE/"P-RT -<>Y5
MTL@A+>SR<JDRTK'9/HJ .;'EH+@.Y5TME$L)Y0 >JJK(T.;EW4!7N!HR<A9^
M6\=F,TM%*P<I9@]#ZU(GM[R7!W3N68B('N4F:E!.Z14ZFJ;[;.2H:6##V_!*
MMM5)S,;Z6 YI8?4MBWZW<_I8)PL O% X!SF @Y])5G<(UM8GQN+^P<[#G##3
MW9[E8JB.6EJ>TC')/$?38KT\%SAS$\[3MZU75=M9=PR:.7LJN,8R?PQZU;'W
M9WC2R4<_:RMFBEY7G;!&WL*R&FJ6R1]A."PY',T]!ZPL:K**JHIP\P.A.<'/
MP'>]72W3&:-K:AKFXZ._\UK%M>64UVNCJ2KHGE],\&(G('4!2989'1SS5<79
MR/&X;N#ZU?*5YY6QL^V-(W',"/:JB:F@%._MW!K<>(*M-XTITL2H[.RH^V0Q
M\@(SDG8K*;13101/?(0(V[G"IH*ADA$4)#(6;.>>F%:=1W^*" QP;1]!OU]9
M6-KS;M"\5UY4VIKFZNN4=/ 3RC'MPH::2*IJ7NE?F)NQ(\/!8M;JJ2>J?.(G
M/YMLG9H]I5\IIF=GS.:6,!S@_A'V>"VBG1'=2;=4JZ\U[6P0P4S.4.!+6^([
MLK%S'-/(V$#F8P[X[RKM>YS#$QS6%]=58Y6?B-[O8KC:K=YE;&&IP:B0]!]"
MSF/>M"P.IB*DN.0&C_T5B5_J1)5.:'9:TX"S;4,@HJ9\?,.T<.9^_P $#N6M
M9)1-.]SAUW"VXN/<]4LL]]1J'C6^ENIU1+G B.W0J0]^7;]RJ[?2F65OHDMS
MNNRVHC<N:NY[0S/2=*&4K'XRYS<A5%+/R5<[F_R8! /K4=,YM%;7[AKBW ]2
MHG.$%M8_\-[.8[^M>1WO:;/0CYL:95::HU%"YXQS 8PO*V$L!<T8!PK%IFN8
MRE#7.](G;=95$\5# UW+GJ2HBW1;IE$UZHW"RKU3JF$1R.:T[!25U1W8"81
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M=3VR''_Q'C"GV/34E=4]O7RDQ#TCRGKZE,S[Y1"78:"HNMQFN5>YS8AZ63]
M5\N5=%2-GJ9N5LK&_:X\_ '\53ZBN]/;X8H(L1Q1[-:/'Q*PJY5$E9('N>6M
M>?1:[J?65$1U3OW&]0LU\N4U7*X%Q+G[NW[O!6IK7,Z#TCT"OL%L[65PB:Z1
MQ/PSL%7MM4%( ^9X,G?X+H]M3''3##V=KSN5DMUJ?/Z<GHL]?>K]2Q04P]!P
M)'4GH%+GJF]F6M]"-O4^*MAG-3SQQ-(CQ@>U8VF^7SVAK6*X_'E=8JP5U7R
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M,L?B@>>Y5D5%(X="K]'3-;T:JAD8;T"QMR/@UKACWL>^I[QU4I]*6K))LX(
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M,YQOXJ]:TEU<?B\3-69B;;B-SX_ASG>N'.I[+;)[A<K<V&D@ ,C_ #B-V,D
M;!Q/4A8BMA:EXL7S4-CJK56TUO93U  >Z*-X<,.#MLN/>%KU9VU[GG\B,,6_
MX9F8^]L:@X3W>32U7>[A/#11Q4[JF. CG?(T-+M\'#<CVGU+7*W9PPN=;=-
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MRW*LUR>.S=E7FMD&#NL3O-6 '-RN'DVC3;'#!]9L[:ED:.JTLY[FW1C'[$2
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M?%3'AXT4O?IFW=?^+-I9JOASY]31.[>GC;70M<W#@WERYI'CRD[>("YHMO\
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M:(>TD 6=VJB :!A8?IL9E6R;1$"&KR.;>8G3OX\;A64=""!LKO2T(&-E4T,
MP-E<XH@U>1.279%84D%(!W*X0P!O<@('136.5)O,I2Y6#"I'- RJR4JD?U5J
MRB4K RF!X)WKPE60\(;X*'E;X)E>%!"0WP7G*W'1,KS*D0O8TCHJ&I@:<[*O
M)4IXR"D=AC]33C?96V: #N625$605:YXL96U;(65\0QT4ET8\%<)8\95.YJV
MB55$Z,>"DNB&^RK7-4IS5>)0H7Q#P4KL.8X:,D] J\1E[@UHR3L%?X8(+9'S
MO#73D=XZ).3I=7$XEN3;4>%BI--2S /G+8F>L[J[4ECME+S%[W/)VZJ%]9+4
M28C])0R4DI)+W.=C\%J1.2>^WN4X?%PQWC<_>B-#:H2[DC(SW\RMU1;:!P>(
MRYI=X%5#Z$S/Y6QD-539]-RU-Q8.61K [8=>9=6/-GI.XM+*^'B9?FQ2LLKX
M-:3IX[HZKD:7\@YFD^U= 1CE  ZE8WH:Q&UVT=JP-E> 2,=!W!9.!RGUKT:V
MO:-WGN^4YLX_:S7%]&/!A>')\/<O7'N0#92XWK!S CO[E$W<8.Q"-V.0ICF@
MCG:-^\(+?/EKCE6BNJ@S.ZN]Q=RL)"Q"[//(]Q/N7+FOTPVI&UMN]W9&UP#M
MUB%=7&9Y(*7)[GRNZJW X=NO$RYIR2ZJUB$^)O.[)5@U]3!U#1NQNV=GTA9#
M$X9ZJRZRE:ZFIX\C)F9^T%G@F8RUF%I\.MT1%].\QHKREOYY8/T<WTL6E5NK
MREOYY8/T<WTL6E5A?R^1]2^LW_+]A$15<(B(@(B("(B#(=*:RO>EI'&T5CF0
MN.7P/'/&X_FGH?6,%9S]G2_]CR_4ZV=ICX?*_'R<RU*BM%ICQ+HQ\K-BCII:
M8AD.J]8WO5,K3=ZQTD33ED#!RQM/J:._UG)5@C<6/:X=6D$*%%$SMC:]KSU6
MG<LXU?Q+O6JK0;;<H:%D!D;)F&-S79&<=7'Q6#HB3,SY3DRWRSU7G<LNT5Q
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M2 D;9V5+3V7I"Y4L7+ "[=[E7B#T,!>B,<VW0;!5+#MA9:;I,409Z/3Q52[
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M#]'-]+%I5;J\I;^>6#]'-]+%I587\OD?4OK-_P OV$1%5PB(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M("(B B(@(B("(B N4>.(_P#PGWK_ +']S&NKERIQN&>)]Z'Z']RQ8<CZ+O\
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M?Q$1%B\<7:.EZ?S335IIL8[&DB9\C %QK10&IK((&]99&L'O.%VXUH:T-:,
M# "WP^][GHM>][?A_E*K*JGHJ=]163Q4\#,<TDKPUK<G&Y.W56SZZM/_ )=M
M?SN/^*Q+C]4]AP\GCSCSBHBC_7S?\*YA5KY.F=.GF^HSQLG1%=]G9?UU:?\
MR[:_G<?\4^NK3_Y=M?SN/^*XT14]M/P<GRS?[,,_XX5M+7Z\GGH:F&IA,$0$
MD+P]N0/$+,O)IN<+77FUO<!._DJ(Q^,!EKODRWY5HY5MFN=79KE!7VV9T%5"
M[F8]OT'Q!Z85(MJW4X<7+Z.1[>8]_P"[?O&S0-TU-645RL;&3SQ1=A) Z0,)
M;S$@@N('X1SOX*]<&M'5FDK'5"Z%@K:N0/=&QW,(V@8 R-B=ST]2Q:Q\=J0T
MS6WRUU#*@#!?2$.:X^.'$$>S)5'JCCD9J5\&F[?)#*\8%14D$L]C!D9]I]RU
MW2)ZGK1FX=<D\F+=_@G:]M0UUQ?H[13DFEH*=HK9&_@#F+G#/B>9K?:?4LDX
MSZHCTMI-EJMI;%65D?81-9MV4(&'$>&V&CV^I5G#&Q-TEI*HNE[D+;A5M-97
M32G+F#!(:3ZADGUDK7]MTG<.*U_J]172:2ALSG]G3@#+W1M. UN=@/$^).W@
M[Z[>9+1>M)Z(_P"3)^D?[^K32+IH\%M*>;]GBOY\?RO;^E]&/U+5'$OAG5Z1
M8*ZDF=66ISN4R%N'Q$] \#;!\1^K;.<X[1&WEYO3LV&O7:-Q]S7B(BS<(B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B MU>
M33_/+_\ HX?I>M*K=7DT_P \O_Z.'Z7JU/+N]-^LT_/]I;U1$6[ZX1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%S_P 4F$Z[NA'_
M ,+]TQ= +0O$X@:XN>?_ (7[IJYN5&Z?F[_3YUDG\/\ ,,1:W'7JHL A>2/
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M-GC<1'XPXLOMEN%BN#Z*[4LE-4-WY7C8CQ!Z$>L*W+L/6^E*#5MFDHJY@;*
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M6<D$*BFFZJ1+/L=U1R5"[8JX9E.DDZ[JGD?ZU3OGZJ3)-D=5I%59E.Y_253
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M+1[X5EHN=7:*^.MMLQ@JH\\D@:"6Y&#C(\%<;_JV^Z@IXX+Q<IJJ&-W.UC@
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M1AP<_H0K#!4_:#G?DV(6D=X<UHU+(*-W*_[4[.!E7.V'E<7OV<X'HK):W=I
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M.[NBFQQC!<[H%*,O/)Z/0+Z/TGTJ<O\ RY8[/.YG+]G'33RK(V,C9DA2I)@
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MB("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@+=7DT_SR_\
MZ.'Z7K2JW5Y-/\\O_P"CA^EZM3R[O3?K-/S_ &EO5$1;OKA$1 1$0$1$!$1
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MR&N:TYR1GU+"8:5ED[JPO#PW\+ (5<UH;'&7''@K5:F -+I?:%>HX#4,:X]
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M(@(B("(B B(@(B("(B B(@(B("(B N,?**C_ /PMWUWB(/W$:[.7'7E%L_\
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MSR__ *.'Z7JU/+N]-^LT_/\ :6]41%N^N$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!<@^46W_\ "/>3ZH?W+%U\N1/**^^)>?9#
M^Y8LLON_%MA\S^#33^I5++U54\[E4LAR5O5G:7M/_*!9A8G8 6'0_#646*3T
M@"L.3]%T\/Z38EG.>5991G "PVT/P&K*J1^6A>9,O<I&UUYLA2)0""H6R*%[
M]BJ;VM:NH4=1ME4?>JN?TE3\JF'+=!A0X4S"8V5H86>-"J(V[*2P*HC26F-'
M@*GG PJA2)^BI+KJM-0,$^*M51WJ[5'X2M=1WJJ+J)GPE61]%2,^$561]%K5
MQ71$*$A3"-E!W+1G"BJ1Z)5JD&ZNU5T*M,I&2K0("H2O<KQ:PRL]:HQT4(42
MNS>A>A>!>A$/5X]%X[H@I)^A5OE8Y[N5C2XGIA7RCM\U?*&1-..\K,;3IR&F
M'\D))?$CHNWB\2^;QX89<L4AA%KT?67 ATGVEAWW"V!IO2MJL^))F-GF'>X*
M]06Z8 $[#P"K([>7'IE>YBXF+%]\O.OFM96T]VB:T,CC#&^H*J\]C<!TR53Q
M6H$# &5.-M.-EM\UGNTO1,P[G&RB;*U[MAE2HK>]I/,<A3.2*-KN5W*X>.RC
MLCNFR01RLY7@;JS^8R6:J-729,)V<S^U1S7,1DL&9'=W*I,DM9/&0]X9&>Y1
M;%UQTV\)K?IG<,FAJ(ZNG;(P@Y"MU9$&N):L>M%P-NK12RR\T<A]$Y[UDTQ#
MFYZ@KQ,N"<-^F7J8\D9*[2*6I(&"=U5.D$C2"K6]I8XD*=$\N&,JO3$K1;28
M=LA2GC!)4YV",]ZDN)W2OP6OW[PENZ=5!&[LWY[E$=RHNR.RO$Z46J[4W92]
MHT?:W_2K41C*RJ6#MH712>X^"QF>,QR.8X8(*]OB9O:5U/F'F<C%T6W'B5*#
M@E7*US]A/'*#@M*MQ'53:<KJO6+5FLL:6FL[AMNF>)H&N!V(RO)!A672%;V]
M&8GN]./;W*^O&^5\+R<,X<DTGW/KL&6,E(O'O4Y'>H!D J<[&%(P=QE<SI@Q
MGJ5$.B\QMNHF_*@@<.\*7(P$9"GEN=E 6^B0AM;:N+F:=LK!]14(+9/0R"MB
M/BRT@%6"\4G,QP(42EH*[TSXJIS<.Z]?!6U[0P$'<N\5L#4%$&R2%PWWW6#5
MD8;(\X)QTPNC%??9QY::[O.8PQ-Y "P=25ZVX<LK6,P&=^.]6V221Y:PDAN>
MBA8.61SSW+?V<>]S=<^YFEJJ&"(R%VY/0A9?:[CEOHOSGN6L*>I/9-C;GG)Z
M]RRJTS&)S"XX&,87->FG12^VT+5<"T<K2.4=3ZUE%JJ<M<][@<C;*UI;:LEA
M/-AN<;+*:2L C8UI)P-URS&I=-;=F=0U0>UI/BDT[>4D#& K!2UG*QH<>_92
MZ^L>V X/?A3M,)EYF+XQR].JPZ^3<QCB_ SDJ]U];R4[1CTG!8Q75+'RAG>?
MU*FY7G6E7)''/$Z M')@%6BXV^1DAD8,LQT5SHYN=^XVZ*LE=V8 P'-/BGE6
M8B(:]K'N$8+A@CJK>WFD>"!D96:WBVQ2QET;1AWAW*R4-N>QSX]L@[9[PM*4
MESWLJ8M.QU$;7LW#AG(6.:ET9<Z*/SBEYY(SW#N6S;%&(6LC."W&6_VK(HG1
M5$1B<T$>!"[<62:=X<66G5VESE]4IX:!T$P<UXVPY6:XS&2-I)6Y=?Z4@J('
MR4L;62C?8+3=SHIZ67LIFD'.R]*F>,E=.*V.:SW9?H.F(I.TQN2K_77B>BSD
M'E"MFEXWT] P X5==*>2HB.6\PQW+NI&JZ82F6W5@,GI.W]JRVBU''(T!P:5
MJ&HH)('ES,A3:.NGA."XJ]:[\H\-UB]0<OHAN5,BN0D/XJU=07-Q())62VVX
M@D!^X6M<4*=<L\IP)!DOR%Y4RQ0M)V.%:J>MC;#D%6RX5YD)#2<*]<6Y5FZ=
M77(S/Y&.Q[%<K72A\0=("[*QB@87U67],K+H+C!30@'&,+2U->%8G?E=(*"F
M,>^/85B^JM*053'2TN!(/ =5>HZQU2?M32&GO5PCHY'Q<Q>"L+X8M&K+5R36
M=PTT+5502.8Z%^QQT4YE/*S9T;A[EMGS:$2$2,:3XX7DENI7]8F_(O,OZ9'_
M )EVTY?Q:OC:1U!53&L^ELM$\$=FT*G.G*8CT<!<]O3<D>&L<JLL."B633Z:
MY1ECE;I;+41DXW7/?AY:^YK&:D^]:>Y%6OMU0S.8R5(=3R-^%&[Y%C.*\>87
MB]9]Z2O4((SD$*KI+?/5#,;=O%5K2UIU$)FT1Y4:\*KYK74Q2!KF')55]0*G
ML.TV]F%K''R3VTI[6OQ64J5)T*J9XGQ.+7C!"I9.A6,Q,=I7B=J&HZ%6JJZ'
M=72H[U:ZG?*F"5EK.A5GE&ZO-8.JM4C=RNFC"R2P;JXTK51Q-])7VSVVHK7X
MA82/'"M,3;M"(F(\IU(WIE7: ;*\4.C*Q\/:<PV'3"IY[744DO(]A<?4%3)Q
M\E8W,+5R5GWI<?13VJHH[55S?!B('K"O-'IN5V\S@/8E.-ER>(3;+6/,K" O
M"TK+X[/1T^\F'$>*K*2CMU5S1AC<^Q==?2\LQN6,\JF],,H:1U5*&-Z=Y65-
MTY3,I,R'TB.I5;#98J-Y<W&,J5=II.RPTD !=O%]/K6/G]Y89>3,^%II=-TL
M\K@9,X/17VFL5-2MRR,$COPL7H*R47#E#CU6=T3W=F.?==D<7'B[Q#"<UK>]
M2M:YFS6X"J8.8M.56!C2"2!A2)'M!(:M-[9]U%<:@10G=:WK'FX7@ [L85F6
MHI^6G=NL)LS@99I'=2Y=&.O9G:5]AYII8XV_!"S"G @IP/ +%[7R]L"JZ^W0
M4D(9GTG)>-SJ"L^]B^N*SMJN&('(+L?K7K:IL=5#'GHWHK/>7F:NIG'O=E0U
MLW)<8W9Z!7B-(F=L@KW>FUP[U25WI1<P[E##5-K*0EI])J\:_GC+3X*\=T2M
MTC^9G7<*JI9?M9;WJC>P,E<T^U0&4M=Z"1&D*^:3E(?GH5-<X/CR.A5M?SO:
M0[H5-H)?1+"=VJ1#.T G)5-G/?LJJK'4JVO>6YQT420F2]"%)9+DEI/51!_,
MWUJ2X;Y&Q54PEO)@GYL[%79LC9(!G?;JK7-]LAWZA14,Y ,;O<HK.ITM,;C9
M4L](G&P4REE("F/P[(*HWN,3\]WJ43V[D=U<X!^XZJBJH^9I=C<*J@?VC<@[
MKV2/;.R3&X([2H:2?!Y257$-E9UP5:ZB+E?S-V/>JFDG:X 'J%2+>Z5IC?>$
M#B^-Y W4QLS)&8<W!4VHC#@7#P5"2 2#\JB>Q!/  >9G12><@=5/R3G!R%(E
MC(/,/>%G/W+0BC=SG#MAXJ<7L!#<C&%1MDY00.JAD!+<YW5)MI;2"KC$CSAR
MMQ^$0#L%5U$A8SE'PBJ0MSZLKS.3DW.H=&.NH3*1N0YQZ=%F>@K ;K<!),T^
M;18)VV*QNT4;ZNHBIX6Y+B M]:;M,=IM44+&@/Y1S$=Y7SOJG,]C3ICS+NX^
M'KG<^%R@C9$QK(P&M&P 6/7T@UA]2R1HW6,W<9KGKYOC][[>E[EN+?4I]''S
M2X/@O -E56UF9B%V6MV&3LEADHXF=LZ,M'<JBCDBCB<Q]27Y[R=U:2W Z+U@
M"VQ^K9:1K4,9XU9E>Z..&&3F;4N>",8<[*EMMS'7'MC,TQ\A&!U!*M[,;*HB
MV!6OR[>/-5/Z./BN5;@!C6G. KY8QB@9[UB[,XZK*[.,4,?L7RGK&?V\SDGW
MRZL=.BO2JRH"%&5"5X2\)3^A5EK8N6</!ZC&/>KT_H59+@'^= _@$ ?K7J>G
MS])%VU41%^JO":*\I;^>6#]'-]+%I5;J\I;^>6#]'-]+%I587\OD?4OK-_R_
M81$57"(B("(B BV-PFT/;M7TMZEN4]5$ZB$9C[!S1GF#\YR#^*%KE3,:C;2V
M*U*5O/BWC\A$10S$1$!$1 1%L;7'#F#3>CK=>8KJ*F6H+&OCY0&GF:798<[@
M8_MV4Q$RTIAODK:U8[1Y:Y1$4,Q$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MIE?-0&F,S8Y#S!A#@T@9Z AVX]23TS;2V6O'S<BV&:SN9\[]_P"'P:7 +B
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M]P;C.WKQU6"Z ^[>P?'H?VPMA>45>+@W4=-:V54K*#S5LIA8[#7.+G@DXZ[
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M['7OW^FA$158"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@+=7DT_SR_\
MZ.'Z7K2JW5Y-/\\O_P"CA^EZM3R[O3?K-/S_ &EO5$1;OKA$1 1$0$1$!$1
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MRO1C40Y>\^5.6N=T&RFLBVR5.8&AJ!W7=-FGC&]1C91^B =EX!G/5>G9P.%
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MID4AQ+%Z+@5F-)'OD+65$]UHOQY7#L9SW=,K85#6=,E>1GQ>SO,.W%?JJO\
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MLU_NME9,VTU]12-FQVG8NY>;&<9^4_*K6B*4S:9C4R(B*$"(B B(@(B("(B
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M$[+UX>:O.DKNZWUHBE=BGE.#ZCXK8[7M<,@Y!&05IU[1C(ZK,-(7WF#:&L<
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MR'=2FG#E>!-?)@+T.V4LC(40;MNI0F%_3"\><M]:@Z KQQVP@C:_+?4HG/\
MM9WV4EIV.ZA<=CNH(6YK^6X./J5RCGP.JM8:7U;R.X*H9D'<I'@7!TY<WJI
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MKREOYY8/T<WTL6E5NKREOYY8/T<WTL6E5A?R^1]2^LW_ "_81$57"(B("(B
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M%"/65 2,^Q0EV#N/>ITA'S G=1<S=P#T4H.[^J-=S;)I"9MC*@+\]#MZUYD
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MS5%3(9'D=,GN'J'142YK3N=OG<]XR9+7CWR(B*&0B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@+=7DT_SR_\ Z.'Z7K2JW5Y-/\\O
M_P"CA^EZM3R[O3?K-/S_ &EO5$1;OKA$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 7-_%NF#^(EW?CKV/[EBZ07/W%)H.N[H?T7[I
MBX?4)UCC\?Y=_IT;R3^'^88*VF [E,$('<JH@!2GNPO&ZIE[45B$GD [E 0
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MH@]:[;8J)ISD@[J26@;@J(#9!&<C?N40P6J7G;&5$",@%!$ST3^M1<XS@A"
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M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%NKR:?YY?\
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M0.]9V0NP=NB\W(SURK0AZ#C*B'K4(+2#S+TMRW8H/.IW&%YD8(_6O<[;YRH
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M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!<?\?ZHQ\5;XS/3L/W$:[
M7%7E%REO&'4#?#S?_P"SQJF2G7&F_'R>SM,L)EJR>]4SZ@[[JB=+ZU+,F5%<
M40UOR)E5/F)4ETI\5(+RH"5K%(ASSDF4UTJEEQ*@RO,J\1IG,[1+S*ARO0B'
MN$ 7H436H#6^*F-:HFMV48:JS*\0\:U3(V%S@T=2<(T*ZZ<I?.;K$TCT6GF/
MN41\Z=+ZU#8%AI?,+5%%WN <2JYK\G=2>?.PZ=%Z#A?28*=-8B'FY9W*87#F
M)RO,G&W10/'I;*!SL]%U0YY1AV^Y7N/ ^]0]!OU\5#Z6>N%95,*]/+C8E0C8
MD=Z]SG!*F$/<$G(&1WJ,.P#A>-V;D+S.=ACV(#W#H>H4&W4=Z$'!&%#T&%(F
M1DEV"HG;9R>JE1R'\(*8[T_D4#UI!Z*<TD9RJ0D 'Q4=/,<<KD%4!ZU$#R]Z
M\!R/!!UP>B@2Y@>1W*=^OM5=3/:X1O:UQR._HJ9V&@$=!NE$_E8]G.X!KL@>
MU)05.63N:0 ,Y 4(=WA3ZP ACP,#IGQ5*7X/BD)'/=GQRO0=N\+PX</!>-R#
MOT4B;&2 5.;C&Y4@;G?HIT;FXPX*)$P' 4;' 8.539!/?A1-V/51I*L:[JHS
MES>BD,.1X*8PG;TME4AZ&'&_5><NQ49.W50N/R((>7!W"B(VR.B\SUW7O3V(
MEYSJ)I^108!S@+T#&<(AZYVRD2C(.,J<>G<%YL0[N2!;:JDAK(C'41B1A[BL
M2NVAH) 7VZ0Q/_$<=EG) [E!G;HJWQ4R1JT+5O:OAI2NH:FUU?953>65IR/6
MLOF[.\6)EQHV@5,(#*M@_4X>K97;7%E%PI#51 F>%O0#J%@>GKJ^T7$2$%T+
MQV<T9Z.:>H7C<KC=$ZAW8<O5&T-1.YK_ $0%)DF?+NX[JZZAM[:6IYJ=W:4L
MH#XI/QFJRY(R%YVG7L[]U.@?R.VZ'8J6QA(.R]$9&,E!FW#.I=%<JFGS\)F0
M%LADI+3URM.:2N'U/O\ 3RO/H$\CCZBMR$!K@YO1VX6])[$0D<CG/R?%3G1
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M8]?R.;(V0 M)[U89;33F=DL8Y2TYV7T?%S17'TRRO&Y5K#A@ 4^E_EV?G!2
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M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@+B/RDA_\
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M3G=05+ R4X?S94VE;S2/:6<Q&"-U-K8P(@2UHP<;=5&^Z5K,9Y\#O4QC.53
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MDW[E"4B0G. O'GE:IO*7C8+Q\>6X(W4"TWB-LU&6R#+21D*VT\+8JJ)L3<-
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MN,=I&<X./'8@^L*UV%[HKW;I(R6O;41N!'<0X+:_E+- O=F=CTC3O!/J#O\
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M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 7.?%P?\
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M8ZO("1VA,/;"S%*YYZO/,KF>G54E$PQT\;&]P53U&ZG0\+CW;H'$YSU7K1W
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M_2=ZU?6M#6X:,+Y[F^HS?YM'IX.+$=[((HVQ-Y6# 4:]7B\>9V[D!7AZ*(J
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M #R__HX?I>M*K=7DT_SR_P#Z.'Z7JU/+N]-^LT_/]I;U1$6[ZX1$0$1$!$1
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M" >J]+VY(*@<_'0(+EIBJ<]LM/(<EAY<_0KI([J,X6,VR1T-XB(8XLE]$D=
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MEBTJL+^7R/J7UF_Y?L(B*KA$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M>Q^\^19^W^G_ -N)$70GE&TT$.E+:Z&&*-QK0"6, _Z-ZY[65J],Z>7RN/\
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M9$1%FX!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MG?QPH*J0-(P<!2'.?S@C(*I+A(>U8"3S97CQY>I/>J[4\N0"IKW;[;JDHFG
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M5^K+I6'[9._(;G9C>C6CU 8"M2ZZLFAM,:>H@V*VTCN0>G4536O>?67.Z>[
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MSR__ *.'Z7JU/+N]-^LT_/\ :6]41%N^N$1$!$1 1$0$1$!$1 1$0$1$!$1
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ML=U @YNXA0$@GT5/E8'9QU4DL+=^J#S8=3[U-9(XC<A2"TN/13(AC92A4LD
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M4\E152LA@C;S/DD<&M:/$DJU:15U\7AX^+6>GS\5OU3>(;!IZON=01RT\1<
M?PG=&M]YP%QG-*^::265Q=(]Q<XGO).2MC<8.(/UU5;;?:W.%GIW<P<1@SOZ
M<Q'<!W#W^S6RQR6ZI[/"]2Y49\G33Q#8? [43;%K.."H?RTEP;YN\GH'YRP_
M+M_674*X<!(((."%TMP@XB0ZAH(K7=9FLO,+>5I<<><M'X0_TO$>_P <6Q6_
M\RZO2>5$1[&\_A_"Z\5]#MUC9F>;%D=TI<NIWNV#@>K"? X&_<?>N:+GIZ[V
MNK=35]MJX9@<8=$<'V'H?<NST5[8XMW=O+].IR+=>]2YPX5\,*^Z7."XW^ED
MI;7"X/$4S>5\Y'0<IW#?$GKT'B.CT5!?+O0V.VS5]TJ&04T0R7.ZD^ '>3X*
MU:Q2&_&XV/B4F(_.6)<:=1-L.BJJ-C\5E>#31#OP1Z;O<W/O(7*ZRCB'JVHU
MA?Y*V4&.EC'9TT)/P&>OUGJ?_)8NN:]NJ7SG/Y/]1EW'B.T"(BHXA$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!;J\FG^>7_ /1P_2]:56ZO)I_GE_\ T</TO5J>7=Z;]9I^?[2WJB(MWUPB
M(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@+0?%%N=;
MW,_HOW35OQ:'XH#.M+E_V?[MJY>7]"/Q=_I\ZR3^'^88/,W&X5#-WJY5& "K
M7-WKSK>';?RMM5OE6:L[U>*CO5GK.]3C4GPQ^N.Y5CJ/A*]UW4JR5/PEZ^#P
M\W.AIVE\S&CO(6R*2,10,: !LL%T]!V]SB&-FG*S_.Y\ O6X5=S,N/).H>/<
M6^Q>1MR?:HPTN/<IT<8'5>U6-."9VC9&&C8J,#TAGO3&W484;7 '?HKPJ]QR
M@%30\=W<J>:=N,-5,*@@[H*\R=<[J$R'*H!*2?A%3#,0P'JIVJJ#-G^*][3U
MJD:X/8>Y2WEP.,J1<G%KV>ON4+!D8*HX9'<V"54QRM!R$V*AK1D]Z\>P=X1I
M).QPHR<C!&ZF$)(;R@@!0B+.<*J;@=0CACILI2I"TM/I97K7$'U*:<DGF&RA
M('J"(1,+2W?902MPT\IW7HQT*@<1D@#*"F<3@@CWJ6P$GN4<O,.;'<I,7I/Z
M_*JI5;&.&XPH'G8@]>Y1M!!W.5Z6]3W*4+;.<M(*L<^&SAP5_J2-QLK%4M])
MWJ6&?PWPSY3HR?40HI" "#U4F#('7930SF.Y643V7F.Z=04$<TW:N:"['>KU
M#2B,; 84JTM C)[E<]B-L>U=6.D5ASVM,RACA:6Y"FAGAW*$.QZL=5Z)@W<G
M(5U4\-P/6O#@'.,%4QJ TD\RDRUP )*@5S9N7<E03R029RX<RLTMP:0<'JK9
M/6R%QPJ6R1"]:3*]5-2UC3R.R05;Y+N8\^D=E9I3.\D@D'Q5.ZFEE/I/*PMF
MM[H:UQ1[Y5]5?'.SL7#Q"@BND;MW8RJ>*W'?)./6H76AI.0X^Q9]67ROTT\+
MM'<H>BF&MA?TSGU*W4]I:T9+B?:JV*B;'U:M:SDGRSF*0FQU3!GKE3.WR?0)
M]BCCIF.&S0/6JRGI&9 (&5M$6][.9CW)--+(_;TE<8@1CFZE1M9'&W&&KWF;
MT ]ZO"B-C<;@_(O'.'>$:? *%P)R=U(ER'(/@JRTMY+3*0#]L?U5ME?CF'57
MJW ,L\33T<23E<'J$ZQZ=7#CY^T#(VM;MU573 %H). %)R""1OCN4<;OM8SW
M+PO>]>/H2J207['91#+G]X\%+B#>3F.5-8X8.%=DFDX;@J61MT4LN<YRG,;G
MKT0>Q^D?!53&9;@'N4MG*/@]5'SA@&ZE*>T-Y<94+GXZ=.BIG3'E.Y4N28#!
M#ME&Q4S2!C<CJ52<_,3]*DOD+]@O.;E/I8"@1OFY#MU*JK>>>(EW4^*M7:!T
MPPX;%7:$L>W#7 ;) KX81R9ZJ?S@-]BL[JU\ Y79]JF"N;C?<JPJIG%V=MU0
M3G+E.-=&0=U0SU,?-U4"JC!QUV2?^2('54GGL8;@'HJ>2YM<X!@)38N='$&C
M<9/>JKF .,JUP5KW-PUCO:5$)GYYWN;@==U'4F*S*KF?AVRAIX'3/W"E13Q.
MR#EW?L%41U;]FQ1XSWG9.J%XQ6E7QMCIVDN(5IN%?SO(9D@*552U,AWY "<$
M=<*CD9)S>E+C?? QD*LWVF,6O,HV.E<=AR^LJ8Z9C1AT@+O5N5)A:WF',YSR
M.N3U7A:QA!#1MWJ-R=-(2^U:]SL->_ SX*4][^1Q8QC-_:HW2 $X.%3/+CEH
M!59^^5XCX0ES<SVCGD/KP=BI3VL&2&CVJ86.<,'&%XZ%N-W'(5/P3W]\J.=X
M'@HXI7=G@';P4JM:WHT*%_.(@!G'15[P1%9]Z<T\\>1GKU7O-Z>.]>4;_-RU
MKV<X<-QX*7*\&<D;#N4PI?RMEZ>6S-!/HD96/U#S), .BO&H7'G81X*R4H+Y
MM_%='5K'IS3&[KBUO+$T8[E*>,Y54\8&%3N:O.WN6^E._8KV%_4*&08RI#'$
M.5D0O%.[*N,/16>E=T5U@=LL,CKQ+E ["K(W\H5OA("J6NRN6TNZD=E8V1>E
MV0J4.3M$KM%X5':83G5+S%1MYB%T5JXLDZ37/4MYV0@A2GNQU5^EAM35!V*M
M-5OE7*=V050F(O(<?@9W5J^2>Y8-/5U]J^RHHR<;EQ&P60RZ6=:Y.2LF:'>I
M;%T?JO2^GM,EICA;48])QP7.*TYJS54MTN51+"YS82X\H]2UGOVHCHUWLOL\
M=- WT)05Y"6O;EK@5@K*ZHDV)<5D.FVU$LF3GDZ8*K%9B.\FXGPOO<J:8J]4
MEFK:O^0@>X>.%=:?A]>:O?LN0>O*GHF4,*:=U4Q=%>[YHZXV>8-G:UV>]I5)
M':I6C,KV-'M6-IBO:5HC:E:5,:JL4M-'\.H!/J"IGAK7'D.6]RK6>KPF8T*!
MW11*%SF@;N"TC'97JA"O0I#ZF%F>:1ORJEEO%)'D&4;>!43@M+7'EK"X84R,
M%8_-J6E9GERXJBDU9C:.,_*J_P!+\9=$<RL,QZ!2GN'BL&FU/5/SR^B%12WN
ML?UE</8KQQZQY5MS?@SR5S#\)[1[2J8S4T9].9ORK W5]1)\*5Y]ZE&:1QW<
M3[U?V-?@QGEW]S/772AB_P"D+O8IE+>*:69K& [K!Z*DGK) U@)SWK-[!9&4
MH#Y<.DQWK'+T5C7O;8;Y+SN?#):;H"%7QG9440#1@*H:]<VW97NGN.RI*CH5
M.+]E*>,@JDNND:A8KA\%RQ"[GX2S"Y#',L.O)Z@+NXOEQ\OZ,L6F^&5 HY?A
ME0+V7SD^7B] 7B]'15(5=#CG666OH/!8C1'TPLLM9V"\WF^'?QE^C^"HVJ5&
M?14QI7CNU50]57P*WPE7"!966A5#HO'!1-Z(>BK5,J5P4MS54.;U4LM5E5(]
MFQ5!4Q=5=G-V*I)V9!5JR2H+-'_[5BR-LK9T#@T-)V"UW:8\7*-9Q<7.CH ]
MIP0L.7\Z:U5CMM? X%FQRI;^BQ*BODD;PV7."< K*F/YXP?%>?DPVQSW3%HE
M$R3&0O)"#C/12G=5(J'N$3\'N*4K\Z)+>%P/+V>=B,+%3>:9U2^*0%A#B.;N
M5XT](^:WGM3D\Q"LMVT^Z,S24XYP\Y+5]/?C4RQ\Z'#%YCPAN-/53O;)1S\C
M6CF:1N'*^:<J#41ASARNZ.'@0K?2U+*&EBBF80,#W*[6ML3:R3L<<K@';+R.
M=QYQ8_N=.._5*^Z>&*ZO \1E7KO5ML,?*:Y^-W2]?<KFT;KY?D6WDG\OV;QX
M>GHG0(5X5SPEXB+Q6%/4Q\S2L:NU)S@[+*WC+2K7719:5V<7)-91+55_MO*7
M/8-PK!"")F#_ $@ME72D#@X$!837T1@JFN:-N8?2OI>-FZXU+*8T[#1$7TKR
M6BO*6_GE@_1S?2Q:56ZO*6_GE@_1S?2Q:56%_+Y'U+ZS?\OV$1%5PB(B B(@
M*LM5RK;36,J[;52TM2SI)$[E/L]8]2HT0B9B=PV[8>.-WI(VQWB@I[@!MVC'
M=B\^LX!'R +)XN.]H+,RVBO:[P:YCA\N0N>T6D9+0[J>I<BD:ZM_BWE=.//H
M.;:K)A_<^IFR!_5:/[5K'5FM;YJE_P#[5K'& '+:>,<D3?ZHZ^TY*QM%$WF?
M++-S,V:-7MV$1%1S"BCD?%(V2)[F/:06N:<$'Q!4*(-GZ7XS7ZU1,@N<<5U@
M;L'2N+)<?GC.?>"5FD''>U.CS/9ZYC_!CV.'RDCZ%SXBO&2T.W'ZCR,<:BW]
MV\+OQX>Z-S;196L?W25,O,!_5:!]*U3J?4]WU-5B>\5CYRWX$?P61_FM&P^E
M65%$WF?++-R\V>-7MV$1%5SB(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B("(B MU>33_/+_\ HX?I>M*K=7DT
M_P \O_Z.'Z7JU/+N]-^LT_/]I;U1$6[ZX1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0%H3BD_&M;D/T?[MJWVN>^*[L:[N@_1?NF+
MDYLZQQ^+N]/_ .R?P_AB4KLY5!-OE5+W[%4TA7E]3T[56ZH&Q5FK!U5[J=LJ
MRU[7'. M,;"\:8[7=2K'4]5?:V-P)5DJ6G.%Z^#P\S,R'1U,0R6H(]063L',
M-PK=9(NPMD#,8)&2KM$"!C&%]%PZ=-8>=FGW(HFX.<*H&.792F$D;X461G&Z
M]&'(<V^,*4]SMUZ7>"B:W+5*%/C)7@82#G8*IY1C'>HVMRW!":1M2MCVW43(
MW=,*I[+Y5,8W!QWJ8A"G#1C?KWJ$QD9VRJAPZKP.4BB<T\V=U40$@C(PHRP;
MNRI1>[FV[E"55NUVXV4YDN!N,J7&[G9W+WIU4H1EV_@F>;"II9"#@'*ABJ,'
M=3M"I?S '&X4ISFG8C<*(2C?H5+(&23LI$3>7EV*=ZE<H.XV46#C!/O02Y6\
MQ._12R&-R6C!4QS7 YRI+R<J!&W/+U]BD3SOB:=_<I[20T@^Y6^M<2<9RJVG
M4)B-R@A<Y[27CKWJW5! G(/0JXL/H85MK&_; Y89/HPVQ_2EY%MZP%-:?2\%
M(CZE3@,-)*RJUE?[9(SL3S;'Q58)V-Z;A8U23EK<@[*I[?UKJKDC3FM28E=G
M5+2XYR I#YPW/*[(5 Z4D84IW-X[*9NB*[3I:AQ)P["HYYY#XJ:R-SB<E3&0
M\W4+*>JS2.FJU.D>=M]UYE[#C?*OC:1OXH*F-I0!DMSZE7V$S[UO;1\%CB=*
MXX[E5,R/A*\>9,(!:W!\$;09.X5XPS'O5G+$^Y10L<X*<V XSRJJ<V.#(SA2
M^V&=B%K%=,IG:,0$#U*+LAMO[%(-7R]^ZD/JWNSNFX@BLRN#3'&-R%ZZN8&$
M-:,^*L[I'.!!4G+L]56<BT47,U7,[+@0JB&LC P7*R\S\8RHAVIV 41D3-&1
M13MQEKA[TEJ&M:?2'K5C$DK1Z3<@+PR<SCU5NM7I5D\Q=\$@K)I6NCHX8P,$
M-"Q>F/-+&.4]0LPG',]N2, !>;ZC;Q#MX<>94+&O!SS8"-,CYPUA&.]3IRUI
MQG93K9"7<TA&W<O*CO+T?%$PDEXB;UQDJI:S$>_4+TL8'DD@N\5+DK*=E/(]
MX<2PX \5?PSCN]! .Y"%[FCT03A4#:V28#LX&1L/>=RJ;FGD<.UG>?$-V!5.
MKX-.C7F5T>Z9IV&Q[U++G#X;VY]JH W=K<D\NV3WJMB:QD;6\OP3E.YJKT/P
M<F5F".\KWF81GMHS[UZ.3<<H )YNG>O?0WPUHR<G91N4Q%/O0]I$W_I6 ]%*
M>YCL\TK3X84YSV'.0WKG.%#VC0P<H&,J.ZT17X*2.-@)Q(![BJJ)H:<]J<]=
M@I9F Z8PIC9QWD;;*(F?BGICX*M\C3'RR%YQZE3F!O4&7??H$=4-).<;;*)L
MCCCE!)]BMO[S4?92W4[, _;"';=R]$#!D\F1TP7*(\Y</0/*>APA;(02UARW
M8J/S3K_^E Z/!>8XXQC8=Z\ (:[+PT]V O"V4.(( P,]>J&!Q_#;N,[]RC2=
MS'NAXQK7<W,YQSMU5=&UC< -'3"IJ>)N&]HXGQPKC!!"[H23GJ5,1]RLVGWV
M2F%K!TQW+T2AH.ZFF%@>\-9L[J%,+6C)Y0#C"MJ5?F^^5L?(Z1Y#-W'<>M26
MLD<[+FXR-B5<RX;8:!A4DQ(<=U'3*.JL>(2((7%V7.#01OXA#$T#TW$[;A3
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MCF^EBTJMU>4M_/+!^CF^EBTJL+^7R/J7UF_Y?L(B*KA$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MI+B?$JM8K7Q")M,^]FL^H8(VX9DGVJVSZE><AC2L;4.5?KGW*KI/>JF7(YB
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MHO5XJN<1%Z@\1%Z@\1$0$7J\0$6R^"ND+3JN>[MO,4L@IF1F/DD+,%Q=GI[
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M9/;/"Q2P4KJRJ:QO0'=;)>^.V6\[X.%OQ<?_ +EEFM[H4&J+EV,)AB.^,;+
MY<O>7'<E5-RKS4U#G$]ZHS(L\^2;V6Q4Z80.]%[?:J'447:0'UM(55/)]MC
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MF/$=TE1P-T_-=236\T!:Y_PB2QW7UENY35CI:?R?+,+7D0/;"*DL_%.2[/\
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MDA>P2EXP?%5#V=^/D1,+;6-] <O7(V4BXPMFH98W_AC'L*KIAR@'&<GJ535
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MD[<I4SDC8WFV4V@B,DA/X(Z+P+=^SV<<:^<J1"WL>7H3W*&*G/CD>Q5HC#B
M-L*JBI\@=%:(9S.^ZV.BV& ?6I(8]DA(5\[# .V5 :9IS@;^Q3I"V2ASF;YP
M0J 1$R'!(W61"F/3KGU*$4(R<-'M4:3$K8&D,8"Y3.0^"G5L'9\@([U)9(6^
MCA>+S8_Y7VOHFOZ:-_&7KVD$!NX4<3R-G*8UO.?!'0]X7&]N*S'>$UO*0O"
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M*^'C'->,M.5[CT5:RV:FD+FDEO@JZGJ.WCYB,+*::[PM$I<JIG[JJD[U2O\
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MA&\9P%CC*P9V/ZU415GK6D9(E6:S"[NIXCL!U4IU TC(*IVU669!W'<O35N
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MA[EXG,[Y9?;^B]N+'YJAI+'8*G!^1T5+GP.1XJ)K_6N6'M5MI4$9[@A 4GM
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M-V7+,]UO<D'H53R.PJEP5'-WJU65GH=XJ<P^BJ1AR55Q=%,JP.D("N-JF+G
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M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M@*/F\%+&ZBSA0E$%Y@E>!P"]YRH MQWJ%1%RA4@H@%X O5 ]0+Q0DE!&2,*
MNRO FRDV)A HL(/,+T !>@*)K<[8W4"#"K:&B,Y!(PU3Z*@+B'2#;N"O4408
MWE P%2;_  6B$AD0C:&L& %*DV5>6*FG8,%4B5UOF>J21V3A3ZC(RJ-QW6D0
MSVC:=U/C.2J5I4^'=)3"X4ZN$"M]/W*X0_J65EX5L715,?14T?15$?19K0GM
M404#5&.BJE[W*%W11*%W0H*6;O5#+WJOEZ*AF&QRJS"]94KRI+MRICRI21"\
M2]QA3&94(Z*./JDIB.ZKAV"N5-C"M\?15M-G*YK.[%"N8,A1AJ\CZ*;MA1$;
M:6G2#H%"TJ)P7@V6M:N>V1.C"CRI,;L*,NR%$U37*F-<IT1R51!^,J;#*,[K
MCM#LK?LO-,,JZ4L?,K11OSA9!0@+EM7<ELJ/S8$*EGHN;.ROD3 0HG4^1T45
MIIC.698FZW GHC: #N64&E'@I;J8>"TWV8;8VZEP.BHYXBW/@LGEIQ@[*V5<
M&QV58F86VQ][>JHIAU5UJ(^4E6Z8=5T4E25,P;JK@Z*G:U5,(V5K*P]F;Z*C
MIALHGC+5,I6Y"G'/=2[(]/P&I> >@6636&">#THFG;O"QO34HAD![LK8-%.'
MQ@=05VQ6KFM:6FM::4C8U\D,8:1X!:U%L!K&M([UU!?[4*B!V!L0M)W^SOH;
MW%Z/H.?_ &J-S3>D1,>]8):>IMT?/ ]P;X*"WZE<RH$52#GUK/;A;HWVO.-P
M%JR[TS8;B,C9RIQIKR(F++9)FGAL2BECJXR^%W3NRJIKG-&'+#[9'/3$/IGG
MEQDM5]MU^IZEY@J/0E&VZYLN&:S.N[2MHE?:24-D!)V4V5_I9^"<[.;T5N<T
M@<T9RU>15IC?RN^0JW'S>R_!%Z=3(:5S^S':')\5.EYS&1&0'>M6^&9E1%R<
MQ:?4HJB2:"WRNYP7MW!]2].EZWC<.>8TKX''SB$N&#ME9F=^Q]BP:&7FDIWC
MOW6;M.>Q_-7Q_JM=9O[NW%]%-7B]7B\B&CPJ%>]Z\5@RO"44*F![E&GTA[5Y
MT1OPA[5:#3:Z(B_3GB-%>4M_/+!^CF^EBTJMU>4M_/+!^CF^EBTJL+^7R/J7
MUF_Y?L(B*KA$1$!$1 1$09)PWIO.M>6&+&1YY&\^QKN;^Q=@+E?@=3><<2;8
M2,B)LLA]T;@/UD+JA=.'P^C]&KK%:?O$6':_U]0:+DHF5U-4U#JH/<T0\OHA
MN.N2.N?U+$_L[63\EW+_ +G]Y7F\1VEW9.9AQVFM[:F&W46HOL[63\EW+_N?
MWD^SM9/R7<O^Y_>4>TK\5/Z_C_;:<XD_=]J#X[+^T5C:NVJ[G'>=27.Y0,?'
M%53OE:U^,@$YP<*TKEGR^4RS$WM,?%'#&^:5D43'/D>X-:UHR7$]  N@^&W"
M*CH*>*X:HB;55S@'-I7;QQ?G#\)WZO;U5B\GK23*FHFU'71AS('=E2-<-N?\
M)_NZ#UD^"WVML=/?+V_3>#6:^VR1OX1_E#%&R*-L<3&LC:,-:T8 'J"B6+:Z
MUQ:M'4K'U[G2U4HS%31?#?ZSX#UGW96M(>/3_.OMUA:*;/X%3EX'^S@_J6LW
MK':7I9>;@PVZ+V[MW5E)3UM.^GK((JB!XPZ.5@<T^T%:.XH\)&4M/-=M*QN[
M-@+YJ+)=@=[H^_\ J_)X+;NDM3VW55K%;:9BYH/+)&\8?&[P</\ T%>DFL6@
MS8,7+IW[_"7#:RSA5;XKGQ LM/4-#HNV,A:>AY&EX'RM"OO''23-/:C;6T4?
M);[CF1K6C:.0?":/ ;@CVGP6&Z2O#K!J2W71K2X4TP>YHZN;T</>"5RZZ;:E
M\Q[/^GSQ7)[IAU3Q&OLVF]&W*YTC6NJ(FM;'S#(#G.#03[,Y]RTOPQXCZAGU
MG0T=TKI*VDKI>R>R0#T2>CFX&V#W=,+>L\5KU=II\9>VJME?%\)AZCJ"/ @C
MW$+$M&\)[1IF]MN;:FIK)XL]@V4-#8\[9V&YQ_\ H71:+3,3#Z#D8L^3-2^*
MWS?Q_P!VKN,]!%7\.[KVK074[6SQN/X+FN']A(]ZT[P,TC]7M1?5*LCYK?;G
M!^"-I)>K6^[J?=XK9G&R]<UIATO;<37>[2,C$33NUG-G)\,D >S/@KU3QV_A
MIP]/.6N;21\SB-C/,[^)V]0]BB8B;;^#/-AIEY7M+?1I'?\ %A'E":N["FCT
MW0R?;)0):L@]&=6L]_4^H#Q6A%67>XU%VN=57UK^TJ:B0R/=ZSW#U=RHUA:W
M5.WA<KD3R,DWG\OP$1%5SB(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@+=7DT_SR__ *.'Z7K2JW5Y-/\ /+_^CA^EZM3R[O3?
MK-/S_:6]41%N^N$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!<F<<H.?BI>W>/8?N(UUFN8.,D'/Q+O+L=>Q_<L7+RYU3\W;P?^R?
MP:^I:;U*YQ18[E,BA#1T4W "\JUMO6K5+Y<!2)I T;J9/(&@JRU]6!G=32LR
MM,Q$,:N;N>Z3%W3*GTT73&X4GE$U;*3WG*N=+%R;'<%?<<*O_%7\'R?(GY]D
M)V( 4LYSMXJ8X@/4+,%SCT"ZI8PJ82(8^9W56&OFDKJGLV$\@.ZN=1(7,+05
M(C@;"W+1Z3NI5;QU1T^Y->W=7VR%D,08W8>*K6NY02>Y4,#\- 4[F+G8[EO2
M8B-0SF-RFM!<2<*8._?JO8F^CLI@:!N=UK$,9E"QN2%&2 3ZE!VF">52W.).
MYZJVXA&DWM06X'5.T/0;*3L-L[J8T>";3I,8 ""2IA<7 M W4,0+E.;L3@*8
M5E[#$T#?KU4[G#&D@#=4[9LG ZHQKG.]+<9Z*T">USY#ML%$20?%> \@Z)$,
MG.<HA,!VRO(8N<ESEZX9V)V7G:[\K>@[U(G\P8TA6NMKG$F.#)=TV2LJ3NR/
M<E3+=2M9]MDQS'?=5G<]H3&H[RE4%M,A[2I)]BO,3(X&@,  4J)V2X[X7I/,
M,;J8K$>"9VJ!)L<()"0<].Y2VM)!\%-#0T>D?<B$#F"0%KV@@K&[QI*&I#Y:
M=QCFZXQL5DLD[&#T=E)=4.<"!G/BJ7Q5R1JT+5M-9W#7@TO<AS8B!QZQNJ&J
MH*JDVGA>SUXV6TV,D(&$EIVRQED[&O!V((7-_14K'S9;1R+>]J:-Q<TMRI4C
M"%G=1I&(U+I(I0R,_@XZ*BK-/=@QQR) .N.JY[<6\QJ6L9JL-PKC:K8^N#B"
M0UJN#;5'U V5RM@;3=I$WJ5GAXD1;Y_A:^3M\U46JPT[(#VK>8GO*F2Z<I)#
ML.7V*\TS<0MV[E-8!W]5ZL8<>M:<7M+;WMB51I1N#V4ARK'76:JI''FC<YOB
M MDDMW"<K9&D/:'#UA8Y.%COX[-*Y[1Y:PH*V2DDP2>7O!686NZ-G (.?%17
M;3D%2"Z$".3U!8O+15MKFSAW*.\#985C+QIU/>&LS3+'WMA,<'MR-PH7L[V[
M+'+3>1* Q[B'=X*R&.H'8EYZ=RZYY%8IU,*XK3;I4U?.8V<F1N.]6AS6,#I7
M$>Q07"J+I79.V5;9:HN'(-\GHO!S99O,VEZN+'$1TPJFN=-)CH!^M3W $=-A
MWJCC>8F<N-U6TL$L^ [9I]2RK&FE[;[0B@A9@]Y57%3-.,#!Z+WS1T6S!D>Q
M5,43^;<'"LHIWV[M6G(W'J43;4-LY!5[I@WEPX;J8[D\-U.D+5#:@]@&"5.%
MAC.%=H3AN5.$N3C")6J&SLA(.?159)1,<S8G8=5[+(2" <*G;4<@ZJ$PHYH0
MR? /<O"W"AJ90Z=Q;G..]2Q*25X7)[Y9?<>G3%>-2)^"8<XW*\SA7.V6"Z7=
MX;0T4SP?PN4\ORK8>F^$<[W-EO50T,[XF _2HQX+W6Y'/P8/I6:QH:2IK9A%
M2023/.P#6Y6PM+\+J^N+9;JXTT1WY!@N*W#8M,6^TQ!E#21Q_P"EC<^]7^.!
MK1T793C5KY[O!Y/K>2_S<4:C]6,:?T9:K3&T04L;GC\-[02LGBIVL;AH 'J"
MF  *8.BZ8[/$ODMDG=IW* ,7H:HD4LT.%Z$3N0 O5XO0I0]"E5,\=-"Z69[6
M,:,DDKRLJH:.G?-4/:R-HR23A<[<6>)DMP=)0VR5T5*-G/!^$D=UZ4WY\(^,
M/%)]2)K;99,0@%KY6DC*YZK9W2R.<]Q<XG))[U47*N,SW;[*UOD!5;3OLTM;
MMJ/ 2I9*\+PH#(%$0SVCRF0I/:$]%$V*5_P6D^Y$(N<*$R*HAML\G48]RKJ>
MR$[OW5)R4KYE:*6E9^<GHO0R5WP6N*RFGL\;?P KA#;6#'HCY%C;E5CPTC#,
M^6(4MNGF/0@I-3RTS^25I!6?4]&QG1H4B^6P55&2QH[5FX.%E',W;4^%_8:C
MLP8!1@+US2QQ:1@A>+KVQB!$7JA(B(@\7O>B (/5Z@"B 0>#8(O3@*'*@>$K
MSJO2@"D>846 O>B84!C9>@+T#*KJ*@?/Z1&&*)G1$;4L$#Y78:,J\T5 V,<S
M]W*KAIV1,PP!5$;>JRF^UXJ11 84[EQ[%&QNRC(&%1>%,Y4]1T*J)3U5'4/V
M*F"5JK-@50%5M4[J%0GJMJL91-51$J=JJ85,IA7TZKX%0TX5?"L+-(5D2JHU
M2Q*JC6<K0G!1!0-4;>BA+U0GH5$H7'8H*6;;*HIMP55S;95OE=C*G1$J=YW*
MDD]5%*Y2"]-+Q*H9NIT8W"I87;JK9U6=NS:G=6PC*KH&^"HX!T)Z*Y0C9<UI
M=V)-8IN5+8%&1LK4J9;0] R%"[91M.RER]%UUJ\V]NZ$/P5'SY"I"3S==E-8
M,A1>NH3CF9EZ7J!LO*X[J/DV*IY6X7![WJTK.EZM]1N-UD]NGSC=8#23%C^J
MR6VU.XW6&2FIVSO&F;TT@(5:W!"L5!/D#=7B!^1A8Z82G@;*%S05$.B)I7:D
MFCP"K36,ZJ_2C+2K/6MZJ)6B6.5;-RK7*SJKU5MW*M\D>5?'9,PH S"FQC"G
M=D0H>7!6F]HT.^"O:9^#A>/^"5! "7J^/RRNR:RNW]ZS:S38P''98/91@^]9
M=1GE:"O0JY;,RB#9HN4XW6&ZKL+)G!W+N-P<+(+95Y&"54W0LDHWN/4!7RQ%
MJ2SCRU=5P<M(^,] %K'5=(#-$]H[^Y;9JQS=L/:M?W6$/>X$9P5YGIEOG3#H
MS1VA[I.!LE?!'+T(PJ/BKIMU"UEPHN9ISOR[*_Z7A!JF$C=N-UDE^HGW6!M&
M]O,TGJHS\B</+BT3V]Y6G5CTU!IW5$\$+6UHRSQ*S=DM-<J02T[VEV,[*[7;
M0MEIK>?.G1QM ]BUY<+7<+.#4VGMG4@_!P=PKUR8>5/5B[3^A\ZD:MW9=3O<
MW8G<*YQU(DC,<XYFD=5B=GN[:QC!+&^&4C</&,E7YF2-E69OAM\%HZ;PN<#A
M"^$-WCYMCX+841R(<?B+5M+*3(QA./2&RV?3[LA_1A>/ZI/5:+3][3'&HTJ5
MYD(2H%X\0T>KS**$*T0/4!7F5XI(>HWX0]J\"];\(>U3!IM=$1?ISQ&BO*6_
MGE@_1S?2Q:56ZO*6_GE@_1S?2Q:56%_+Y'U+ZS?\OV$1%5PB(B B(@(B(-J^
M3E3]KK6KF(VAHGD'UE[!]&5T>M$>3-3YJK_4D?!9#&#[2\GZ M[KJQ?1?4^E
MUUQHGX[<Z^4A5=IJVWTX.T-&''U%SW?V +4J[(K])6*XW5UQN%LIZNL<T,YY
MV\X '0!IV'R*>[3ED='V;K-;2S\4TK,?0JVQ3,[<N?TN^;);)-HC;C!%U3?^
M%.EKM&[LZ'S"<]):0\F/ZOP?U+1?$#AW=-'O[:3%7;''#*J-N,'N#Q^"?U>M
M9VQS5YW(]/S8(ZI[Q]S"EZ 20 ,DKQ7G1=(*_5UEI7#+9:R)KAZN<9_4J1W<
M5:]4Q6/>ZRT9:&V+2ULMK6@.@@:'X[WG=Q_VB5=:J>.EIIJB=P9#$PR/<>YH
M&2?U*8L-XPUSJ#AS>9&'#Y(VP#^NX-/ZB5V>(?:6F,.*9CQ6/V<RZNOM1J34
M%9<ZHG,SSR,)^ P?!:/8%9T1<;XNUIM,VGS+-.$FI9-.:QI'ND(HJMPIZAN=
MN5QP'>XX/LSXKK!<.#;HNT=,5IN6G+76N.75%+%*X^LM!/ZUOAGS#WO1LLS6
MV.?=W8QQILXN^@+@0W,U&!5QGPY?A?\ =+ERHNW+C3-K+?54L@RR>)T1'J<"
M/[5Q*]I8]S7=6G!5<T=]L?6<>KUO\8_9?M+ZPOFF'.^H]?)%$XY="X!\;CX\
MIVSZQNLEK>,>K:FG,3*BEIR1@OA@'-^O*UTK[HG3L^J-1TELI\ALCN:60#^3
MC'PG?)T]9"SB;>(>=BS9^V/':>[;G ;3<]94U.KKRZ2>HE+HZ9\Q+G./1\F3
M_LCWJHU:V3B3KUNG*2=T=DM/VRLE9^%)T('K_!'AZ1W64<1M04V@]$,@MH;%
M4.8*6BC'X.!@N_JC?VD>*Q7R:>S=:[[(3FH=/'SD]2.4X_7S+;41JCVNBM;4
MX?Q[V^_W_K^S9%LLFG]+4 \UI:*A@8 '32<K2?SGG<GVE2KYI?3^J[>?.Z2E
MJ&2#T*F''./6UX__ $+4WE+2UGU2LT1+Q0=B]S1^"9.;!]X'+\JNGDTRUCK9
M>HY"\T+)8S%GH'D.Y\>[D5NJ.KITUCD4MG_I>CM_];\-1Z[TQ/I/44]MG=VD
M8 DAEQCM(SG!]NQ!]8*QY;J\IAL0N%A<W';&*4.\>7+<?K+EI5<]XU.G@\O%
M&'-:E?$"(BJYA$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 6ZO)I_GE__ $</TO6E5NKR:?YY?_T</TO5J>7=Z;]9I^?[2WJB(MWU
MPB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@+FWBXW
M_P#")=S^A_<L722YLXNN XB78?H?W+%Q\[_KC\?Y=_I__9/X?YAB1  5-/*&
MM*CJ)@UO56*OK0,[KS*4V]69T\KJS .ZQNOK"YQW2OK>8D JRSRY)W7IX,'O
MEP9^1KM"[T#N>0NSOA7</+&@^"QVU2;CY%?.;FC(7TW#M_QQ#PLT;MM&>7M#
MXE2I7@# /11,.69/5JMDTA=*2/@KHM9G$*B)W--@=%.FSS85.U@+N;O[BHW/
MY\#O&Q41/995PGT00JF$@'?O5+",!1<^YP5K6=,YC:Y-D '52WU#6@[JWB5S
MA@KT0EXR2K^TF?"GLXCRJ14<YPU19<79[E*AA##LJEH'/CU*:[GRB=1X&^D#
MD;*>W;"E9#1A>M<21A:1V9RJ6NY03ZEZ'%QV4K.RF-=@9&^5?:KV$ $GP53'
MT! SE4K>;F)&ZJ&.]#93"$;CS9P%$UW(W.RE%P:PY.%(YG3. ;LU2*@RN>[E
M;T[RO)I&QQ\H[U!(6Q- :=^]2X8S,_F=T"@1T<!+R]XV[E/>[M)>1F,=Z2RB
M*/E'7N7E(WD)<[J5;P*Z./T0/!-@H6R['&%"Y^W7J@J [8G*DO>7;-ZJ$>D=
MSA3FN8T;8V[T$+(B1EYZ*<',8"0![U2RS^GZ*@])XW059F+L!JF-..]4?,(F
MYR,I'(7[@H*PMYL^ELJ6HAYVD,<,A>/>X#;JD,+WG?.Z:%KFM<W-F/D(/=E6
MN:WUL%8UYB/)WD+,(Z<@^L*<(CGX6RRMCB5ZWF%BFK131-YAOA6R:\[G#L+*
MZFDBJ!RRQAWKPK)6Z4AG)=#*Z,^&,A+]?_E-.C_TH(;J'=7!7.FN$;@&\V%B
M=SLM;;^9P':1C\(=RHJ2KF=(V-F2\G "PCD6K.K0U]C6T;K+8S96NZ.4$K(Y
M6D/ .5#:+0_S4/JI'!Y[AW*&:GEIZ@>GS1=Y/<NGKU&Y817<ZA1.L=-VGG#6
MEG*<G!ZJDN%2Y[N6' :.Y+O>6L=V41R!L5:):YHC)QZ2\/D9HR6GI\/3Q4Z8
M[IE:YC8R7XYE34=,Z4AY;[%[2V^KKG]J^-_9CID=5EMHMQBC;(]F_</!9XN/
M?+;QV7OEKCJH:6TR\G:OA/+XJLC#&C V(\5E;'F)@^A6NXQ02G+F<C_$+LOP
MM1\V7-3D[GNHXFM>,Y4]QC:S;JJ)_P!J=@N]$]#XJ6)&EQ#7$N7%-9K.I=43
MN-PJFS]Y!'L4]LL9P1E4GF\O*#('-'L513VR:;'*<-\5,8[S.HA7KB.\HG5#
M=]R"I9J0#\)5[;*]IR90554]I@:/MAYRMJ\3);RSG/6%H9(97>CDE5<%GK*M
MX;! Z0N[@%G&C],?5:L;'#'RPM/IO Z+=%GL5%:H&L@B:' ;NQN5EFK7#\V>
M\KTO-^\-#V;A7>:^3M*HQTT)_&.7+96F^&EFM9;))$:F<;\TAR/D6>D#.Z#T
MMF]%Y_17?5KN[YYN::1CZM1"33TL-.P,@C:T#;#1A54<8SEW5>L:&CUJ(^I6
M<DSM%L!LH03T4(.>B/SC#41$(LAHW*"=G3*I)*9\G63"I9+;+UCG(/K")U"[
MM>T]"HCT6/N-;2GTH^U:.]JG4MWC=)V;G<K_  =LATKRO X*!D@>W((4#W ;
MY4H3LX5/7UT%!2R3U+PR-@R25Z)!RDYR5KO6^G+UJMSH!6-H:,;8'I%WZU,1
MM,1'O:UXL<3#<GR4M)+R4;"1L,%ZT5<[P9Y#@[+?5;Y/CZCF<;U)(\]Q9LL.
MOO ZY6KF?E\\0[V *;3$1V6WOM#3[Z@N*A8))#Z+25G;]*14Y+)&.#AUY@O8
MK*R$^B-O8N.W*K5:,4SY8;%;:B3J,*K@LSB?367MHVM&,*8RF#=P%SVY<SX:
MQAA8*>T1L'P=U6,HVM&S5=VQ#'11MIP5A.:T^9:12(6Z*F]2JH8,=0JML7*H
MPSU+*;S*T0EMB:/:IHC"!N%& J;6&M 4P-!&/%0M"F-ZJJ88CJNUMA'G,0QD
MX<%C"S[5KP+0X'J7!8"O4XMIMC[N7+$1;L+W"!>GHNEB\0(%$$2\ 46$RO"4
M'N4RO.J\PH'I*\0!>@( &R] \$7H0 %$UI<< 9*BAC=([#0KY;Z1D(R=W>*K
M:W2M%=I5NM?1\WMPKRU@:S & H6]%$';+GZIMY:1$0A(V1NQ43>BA=@%$)T;
MME$Y^RIP_'>H'R;*4O)Y-B5;JB3JIT\FQ5MGDZJ]85F4B9V253$[J-[MRI:V
MB&4IC%50=52,57!U42F%QIPJ^%4-.JZ)82UA5Q*JCZ*EB55&J+0FM484#5&J
MREZH7=%Z5"[H@I*GH<*U3NW*NE3T*LM4<$J]594\CO%4SG[I*_&5(<_=:15,
M2KZ=V5<H/25FIG]RO%(<X7-EC3JQ2N$ P%7PG;!5'&!A5,:Y=;==;:A61]%$
M5*8<*8%TXZN?+<"EOZ*:%+>NND.*TI')DE5$+,A>1-R57118:L\O:'5QZ[2!
M'MNJ:ICP"KD&8RJ:J82%Y._G/:I7LLI/(Y72W56_54$T)W4,!+'+28BT,,L,
M]M=1D#=9+1R9 6O[34X(W696V8$!<DQJ=.25_9NU>X4%,[+54 )IFDN;LK;5
MQY!5XY533Q9!43"8EBU7 =U;W1$$Y635$&<[*W34_794UI>)68QJ3(W&5<)6
M<I(*HY1U4UE*D<-BO:8>DHGC8J"%W*Y;TG4[96AD5G^& LJA/+$%B%G?]M"R
MGFQ&/#"]'%.X<MX5\$I8>9I5155V:209[E;(),M("IJIY$;QW%6R?0EG6.ZW
MO>"7$]Y6'WR+DJG8&RRP-YAUW5LNMO,^"!NO#XF6,63<NK)7JJI]+PD,DD/?
MT6;V>$N':.]@6/6^G;3TS6-]ZO\ ;:^-C1&X@$>*Y.=>V6;6JO2.F-+1JVRO
MN]?2Q.+NP:X.< <953?S'24$<$,323AK01T60Y:\9"Q2Z5?G5;+&T>C$>7/K
M6&#);)-:SXJ3&N_Q4E/'15M(*2YPL:>C7M&,%6FZVJML+^U -5;_ ,=N[F^U
M5T_0@JX66\&D/8U/VRG.V^^%V[O3YU.\?#^%=1+'V0B:-E1 >:,X((6R*!W-
M2T[O_A-5BN.GXY&FNL4@8\^D8A\!_M"M,.J)XI8J&II>QJ6GD#2?A>Q<^6/Z
MNL>S]W]X3'S?+/,DHK9#67'D&: G/BY1^>5V^: ^YP7G>RM]W]X:*]%0-K*T
MGTJ!X_K!>&LJQ_\ B,GRI[*WW?W@5Z*@-;5?^XRKSSVIQ_,95/LK?[,)B5P7
MK?A#VJW"NJ.^BE44=9.7C-'*-_!(Q6-MS(B+]*>&T5Y2W\\L'Z.;Z6+2JW5Y
M2W\\L'Z.;Z6+2JPOY?(^I?6;_E^PB(JN$1$0$1$!$1!T-Y-=/R:9NM3C^4JP
MS/YK ?\ B6W7.#6ESB T#))Z!<4V^ZW"W?YOKZNEWS]HF<S?W%5]QU;J"Y4'
MF5?>*VHI2<F.24D.]OC[UM7+%8T]GC>J4PXHQ]/>'2UXXFZ3M4KHIKM'-*W8
MMIFNE_6!C]:D6GBKI*XSMA;<C32..!YS&Z,'^MT'O*Y41/;2I\L9M[U&G<;'
M->QKV.#FN&00<@A2JVD@KJ2:EK(F34\S2R2-XR' ]RT-P UC4170:;KI724L
M[7.I>8Y[-X&2T>H@$X\1ZUO];5M%HV]OC<BO)Q]<?FY$XDZ6?I+4\]"WF=2/
M':TSW=71G.Q]8((]WK4?"=H=Q$L0/_O&?D!*VWY2%L;-INW7)K1VM-4=D3_H
M/!_M:/E6GN&<PI]?V!Y. :MC/]H\O]JYYCIN^>S88P<N*QXW$NOEK;R@7%O#
MV0#HZJB!_6?[%LE:^X\4YFX<5K@,]C+%)_WPW_B71?Z,OH>9&\%_PERXB(N-
M\<+KOA:XOX>V$GKYJT?)LN1%V'PZIS3:%L,3A@BCB<1[6@_VK;#YE['HT?\
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M@A3 \1LP,94GG$;,#JH8@9'9*C9I/B;SY<\>Q39'=BT<NV5+,@:TM&X4))D
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MKF',5&PAV05,2JGQ;>Q)) PY4#G\HV4G>0[E6WH3& RR9=T"K"[; V"IHCR
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M!V48=GJKQ*FD3<NR,[*:,-&1U4H2!OAE&NYS_8FS2>TEQ[E,+L,.1L5!TC!
M4J>3( &ROO2L1MYSN>[E'13@0P8[U*AQ$PEW5&N$CMBHVF4YOH-R5)<[M7@
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MO5/8-PJD=%(8%-YL!9+I;U23;%53RJ.<]5>OE25.\[%4LSLJ?(=E2O6L*2A
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M/'JS^O*IW5O":_3&Y5\;Z&I?Z<M.6RL!=W[,RWY%9^(_$B@K+$-.:0IS36H
M-DDY.3F:#GE:WJ 3N2=S],5B*]]L<-*<69RVO$]IU$>],\FS[K+G\1/[QBUW
MK)[I-6WMSW%SC6S;DY/PW+*N"FI;7I?4%=57J=T$,M*8FN;&Y^7<[3C ![@5
MANHJF*LO]SJJ=W-#/52RL<1C+7/)!Q["JS/S8ASY+UGC4K$]]RWOPPJ;?1<%
M:FHK:62KI6.F-7#",N<.;![Q^#C._18S]=?"_P#HI5?[MO\ _<6.\*]??6E-
M44=Q@=4V>K.98V@$L=C', =CD;$=^WAOELD/""2<UYJ)6@GF-*T3!N?#EQG]
M>%>)W$:=M,WM<5(I-8F(U/4L_%'7]CU3IFBMMJHZV&6EF:YAF:T ,#7-QD.)
M[Q\BJ](\2+)4:7I].ZVMSJBE@:(XYF-YQRC9N1D$$#;+5B/$O4=GU!<J;Z@6
MF.@I:6/L6O#0UTH'3+1L .[OW]PRFPUW#.[6&BHKU23VNMIXPQT[>8F0]Y+F
M@YR?QAMT&RB)F;>65<U[9[3%Z^-=_$JR_<.-.WK3E7>]!7!\C:=KGNIW.+FG
M R6CF',UV/'.5BO"S7OUG5%7#64IJK;5X[5C<<S2,C(SL=C@@^I9A<-::1TC
MI6NM&B#+5U56'!T[@[#21R\Q+@,D#H ,+#N'%TT?24U=1:OMLDQJ2.6J +NS
M:.X 8<TY[QG/3N2=1,:3>:5S4G%:*V]^OH[9U3Z<X=:\D?'I^HEMET<TO$+0
M6_\ <=Z)'J:5KBU6:HT_Q0MMKK"TS4UR@:7-Z.'.T@CV@@^];&LURX8:0JS=
M[35U596M:X11\KW%N1@XRT ;;9)6MGZG%SXD4^H;B.PB-=%,\-R[LXVN;@;=
M<- ]J6UV^*.1[.(I,]/7O_SXU][+/*/^[6A^(,_>2+(>.9D'#[33:#/U,RSF
MY>G\G]K]V.98-QHU';-3ZFI:RS3NFIV4C8G.=&YF'![SC! [B%?.'_$BVLT]
M];>M*8U-M#>2.;EY\,[FN'7;N(W&WAE3N)F8^*\Y<=LN6DVU%O$^YJFE,PJ8
M33<_;AX[/D^%S9VQZ\K=WE'8^I.FS4\OGV9.;'ARLYOUX4RAN7"G3-0+G;.>
MKK&>E$P-ED+3_HA^&@^L[A:NX@:MJM87UU=4,[&!C>S@@!R(V9\>\GJ2J]JU
MF-L9BO&P7I-HF;:\=]:;,O)(\G"AP>O9_OBM'-<6N#FDAP.01W+:5SU?9I^"
M])I^*I<;K'R<T79. &)"X^EC'3UK5BB\[TRYMZVFG3.]5AO+RACVVG=+U$F\
MIY\N]K&$_0M&K:?%W5]FU%I^PTMIJ7334F>U:8G-Y?0:.I&^X6K$O.['/O6^
M>;5G?C]A$14<8B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("W5Y-/\\O\ ^CA^EZTJMU>33_/+_P#HX?I>K4\N[TWZS3\_VEO5
M$1;OKA$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 7
M'/']I^RY?C\7_P#L\:[&7''E .QQ;OP^+_\ V>-4OX=7$^G/X,#:"T*I@)+M
MU3P>D<*OABP.FZYI>I64^)JJ8V*7"W?=5T,>53;2)T0QDG?HJ^)N O(X\#HI
MH:0LYAM6VTQC\#<J=&_)Z[*C().RGL!#5EMKJ%:UP(PA^52&$A3XQS*8EG,:
M0\N?8O9&>CT4]K,!0R[-*:.M:*EN#LK9.<Y\%=:PYSA6J88RH1;O"F#=]E4-
MB;(SED8'-/<1E26_"57!NKUER66:X::AG:74I[*3P[BL7KK=4T3BVHC./QAT
M6RVCN7DL3)6.;(T.:>H*Z\?)M7M;NX\G'K;O7LU5[%"0LUN.FZ:4N= 3$_P[
MECE7::JF)RSG;XM7;3/2_O<5L%J^Y:R"BC(P2""#ZU"0MF+P$INO<8"A1#W*
M]&ZARO4'HZ+T+P%%(]!7N5"BG<H>KT$^*APO0<*8E*HBE$9]-N2HI*GF& ,>
MQ4I=E>+3VLQVA7IA-?(7=7$J6O%Z!E4ZILG6GH)"]#W=02IL-+))T&RKH+6Y
MW4[K>F*\^%9M"A;(]VV5=:&*1S6\QR%64MN:T9+&E5H@CA:7-&,!=V/#,1N6
M-LD>(6ZK(&&^"M-:0>]5=9([G=OU*M4A.3DK#-=>D)'X2O-AJS#(6YZJR@[E
M3X'<CP0>BXL%^BVVEJ[C38,<A?$%4Q]P5FM52)80"=U=XR!C?JOH<5^J-O-M
M7IG1+$"#LK+6Q 9SU"R#;E.5;+A%L7#HIRUW!CMJ6.R.#B,;8*O%LD /I=%:
MRQKG'VJKI3RMV7'CG5MNJ\;KID\#@1MT4<\@#5:Z2JP.5PV5>Z1CV'E.Z[:S
MN'+K3QIYV@CHI$^6$;X:3X*;%(UBAJ7##2W&Y[U.T*%PY)P 01ZE-<_E=@]Z
M\JH^61IY,9\%,+ ^,'O"HE[(06 X4F-P$H.5/8P]GC'14TK!')D'JHLFOE[5
M1L;4O);L[?*DO('>,#UJ;=90R*%^=B,*PU59R@@%?%\W#->1:(??</E5_I:V
MGX*JIJL$AKE2NGSC&5;73ESSNHXY>4[]52,.H8SSNNRXMG<>A(4^&1SB!DDJ
MV]LHV3D'*SG'+:O)KORN9?L0>J,?_IY5!%-C.2<J(2@'*ITRWC-$]U?S]<!!
M("? JE;4#& IG.",CJHTTB\3X3Y1S-'+U5+(>HW!55'D@GN4M[,]!DJ(3:-J
M%_/L-U)W5Q##C<;*4^,D_!V6D6<U\4RIV-R"=ME,C<,J4]A85!G"G6V?5T>5
M<*AC=B%0U0C<[+#A29IL# ZJ2TN>5K3'KNYL_*B_S=;3H6NE>&1]3LL@M]"R
MG;S/])Y5!;&,A])WPE7^<9Z%8Y;S/:/#MX>&M(Z[^59S#.Z\?*T>"M[ZC?JJ
M:6H/>5E%=NRV>(5[Y^NZI9)<YW5$Z8YZJ6Z3O)6L8Y<E^5"H=(,G=2N?'>J=
MTO7"A[0^*UC&Y+<J%1S9*J(9,$'.ZH&OZJ;&]1:ABS]^ZZ"8G&ZFE^0 K6R4
MJOIHY)3G8-\2L9C3T,>3K\*H#(Y1N2HJB=U.WL8,N>?A$=R\C<&OY(/3D[W=
MP5;'3MA83U<>I4X\<V[SX<_,YD88Z*?2G]%HJX^THGY&7#=8X>]9;.ST)0.\
M%8G(,/(]:Z,7;</%Y/SJUL\9U53&J9O55,:UER0J&J:P;J5&JF,864M(>XV4
M+U,(VW4J11!*1(5+\5&[JH'=-E>%)!U48Z*6.JB1,)\953&<!449W53$=U64
MPN$&ZG@;*GI^Y5F-EDO"2X;*FE'55C@J>4;%3 MTHZA4<HW5;-ME44JUJSD:
M/14#AU4;#Z*A>KPJD$+T(Y> JR$9Z**/JH,J./JJRF%9"JR)442K(EE*\*Z'
MN59&J*%5D96<KPJF%1J4Q3!T5$HE"O5XH2II^A5FK.]7FH[U9JL=5K16RR5?
M4JTS_"5VJ^]6F?X2[,;FNDHB+11ZU5$#L*G:IL>Q42FO9=:63"N$9SWJS4[L
M%76F/, N/+7WN_#;?97T[BURNL+^ARK3$%<8/@KBN[*QV7:EFQWJY0U&W56!
MA(53'*0/6N>U-JSV7T5.W5/.?6K*)SXIV_K5/9FUX-0/%0.J!XJT]N?%0F<J
M8QHVJZR0%IPK'/+R..ZK7S$@[JU5F^5KCK[D3*?#58>-UD-NJ>8#?=80)"'*
M\VFK.0"5;+B[-<.3?9G,;@YFZMMPBZ[*.CJ YHW53,SG82N&/FR[=;AAERA.
M3A06N<AW*3N%>;A3YSLL<F!IYPX+MI/5&F%HU+9&G:W):TG=9[;G\S0M066L
MP6/!6RM/U@DC;NN.]>FREH908PYBMU=!Z)5TIG<S5+K8_1.RKTL=L*JV<LA5
M#*%>KC%AQ("M$PP2M*"3$SF)*M]^B[2E)'4*YP?A85+70F2*1H[PLXMK)M6T
M;AB-OC_RM@_T@MA4)):&^.RPNVTCQ<3SC9I674,G),W/1:<RW7/9EBC4,OIX
MNQMQB:=^546F;&3-+-6U$CG..6M+C@*L@E#XP05%)5^;1.<.N-EX/5DB)K7S
M+HU'O4MXTZRYO?32AACQG)6J]6<+ZZUO=7VF4X9Z6&9R%L>BN,W;E[GY<LCI
M:]L[>5_?L0>]=F/F\GBS\896Q5R, T7<&7.T0Q23<U7$WEE#CN"K\;8XC/,%
M'<M&TLE<ZXVEYI:T[N&?1?[0J:XW]MABC9=89&O<<$M;EH]>56V6,UM\?S/N
M]ZU?FQJSR1LD9$<F^#U61VH?:(O4"K7VD%?3"6G<'@C+2%=;9M#$#UP5S\F\
MVK\[RO$1'A7A"A. H<KS5@KP!1(I3$/ F4[EYA2EZ-T;\,>U>!>M'I#VJ8\H
M;61$7Z<\-HKREOYY8/T<WTL6E5NKREOYY8/T<WTL6E5A?R^1]2^LW_+]A$15
M<(B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B MW>3M/##:M3":6.,GLL<S@,^B]:116K;IG;?C9O89(R:WH1$
M56 B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B MU>33_/+_\ HX?I>M*K=7DT_P \
MO_Z.'Z7JU/+N]-^LT_/]I;U1$6[ZX1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1
M$0$1$!$1 1$0$1$!$1 1$0%QMY0#2>+M_P#7YO\ _9XUV2N0^.\7-Q7OKOT'
M[B-4R3J'3Q8W>6O:6/!&5=8F^BI$,6,*NC9E<LR]..R.G9D[!7.ECV5-3-PK
MI T86>U]ID<>RF=CGN44854QNR>2+3"D$'J40A540%Y@GHLYAK%YE($2GQLY
M5&UFR\<2-E&B;/7$ ;*EG=UPHGR=5(>[8[HK$J.H[U;IQU5=4.ZJWS.]$XZJ
M%MJ4[.V592@DJF:W)W5;3GE*0RNJPW 4+NA40=D*%Q&%I#GE2R'JJ"H."572
MGJK94G!*)KW4=32T]0TA\;<GO W5IJK-RY-._(\"KOS84#I%K3->GB46PTOY
MABLE/+$2)&$*46K(ZAP=U"I3#&_.6A=E>3V[PX[<3[,K&0@"NTE"QWP#@JCF
MHY8OP21XA;4RULYKX;4\J9!U7N%Z&K:(VR0Y3JIK8B5,92/?TZK2,5I5ZH4Z
M*K%!(JRDM[#M-U5Z\>UD3>(6?"B#7'H"5DT5II\<P *GMHH&?!8%T5X-O?*D
MYH8Y3T,LIW:0/6KQ2VV-K?2;DJX!K6C&,84;<.;D=RZL7'K1G;),I$=*&##0
MJAC.4=%&TX]B@=)RG).Q71%8JRW,I@.&[=53U[^6+ <%#-.(QDD85FK[CVA+
M0/>LLN6M:K4I,RDUTN^V,JVO?G*]DD+NIRI1W7CY<O5/9UUKIXWJIH*E#91M
M*RK*R_V68 =^W@LCAJ&AN^2L.M<XBDR3LLHIWB1H<W&/ +V>+?=7)FKW5WGN
MV SHH*B1SXR>4 =ZCB#0#S *54.+8B!T7=WUW<L1W6OLV\KW]^5+I<[CNRI=
M;5"!@'>51-NG)GT?D7!;)6L]Y=D5F89!'D#=3>V#,;K'/JT<'#?UJ0^Z2/)V
M 3^LQQXE7V-I\LL$[7 Y*D5$X8 .<8!\5B;JZ8DX>1E2'U$KCN]Q]ZSMSXUV
MA:..S:2KB="".;G'CT7L5='V1])JPL5DW(6F1W+X)%.YI/I'=1'.W*?Z=E[;
MQ#ES2X J4^YP/SAPV6)OD.>;*@[0JL\V?"8P0RFOJ6SV^1K#ES=PL9?*7'<J
M?153F2 $Y:=B/4I%PA,,Y+=XW;M*XN3,9)ZX=6*\TKT/&DDJIC&1E4<;LJNI
MY"TYP#[5Q6=F&8F>Z+E.$WQNHN;)7A.RS=6H]SW) V4<;N922?! <?!*=)%]
M2J6O *J(9VXP>JMQRTKP2$=%2<<2VIRIHO;)NYI&%5P^EOG(6/13EAZJLAKB
M&^I8VQ3'AWX>92WE>#$#L2H96M9&<D*VFX%H..JIYJM\N[G>Y5C':6E^7CB.
MWE,FE],C (5+([ ('>H>8GO7A'BMZUT\W)EFZ5RY)R@D#3@),\ 8"D+:(WY<
M5K=,]E<R?UJ<VH/BK:#A1->J3CAO3E6CLKC-GJY2GS>"IG.*\;N5,8XA6W)M
M/9-,A4/,2I9ZE1#HK:8]<R]1$R!U*D1M^53&9QX!4W:X^"%X'.<>JK,)C+6J
MM;41Q'.SCX+R:NGF'*PEK<] J=D8ZE5C!&V/;"ITQ'=:.3DM\V)U#([.8HZ,
M].?KE3^W#\A6.CJ"P<N=E'%4_;",[*M)[-.9$1?<*RL=RAQ[L+%93EY60W"3
M-/G/<L;<=R5>GF9<F6WS8AZWJJB-4S#NJF+JKRPA51=55L&RI8U51C98RTJB
M/0J5(-E./129%$)E3N"DO.%/<J:0[K2&<C2HP5*!\%$#LIDA-8>JJ(#EP5(T
MJHICZ2K/A,+K!T58WX*I(/@Y50#LL&L/3C=4\QV*FD]5(F/HE6A$K=4.P2J*
M0JJJ#U5&];592B8=E"XKP'90.<K0A \KQA4+BO6*R$X*;$%*&X51"-U25HA4
M1-V53'W*7$WQ4YHQNLIE>%7"561JC@ZJLC5)3"H8IC2,*4PJ:U561+PKU>%0
ME35'0JS5G0J\5'P2K16="M**RL57WJU3_"5VJ^]6F?X2[*.:Z2O5XG<M%'K5
M,8I;5-:H3"?$=U=:%WI!6AG55U&_#ANL,E=PZ,-M2R"(;*Y4S?15NHSS-5TI
MM@%Y=^SU:SV3@W9.BG 9"EO&%G$J60$[*$+U>*5'F5"HE"5,"$E4M0W+2JD]
M5*D&05,"S3 M=E14TQ8\'*F5;-BK?DAV%UUB+0RB>F6:VBJY@-UD=.\.:M?6
MFJY' $K,*"HYFC=>=GQZEZF"_5"HKX=CA8Q<:?K@+,'CM8U9JZGR#LJ8KZ:9
M*L?ME08)N1QV6?:;N/(]C2[8K7E9$8Y,C97JQUA]$$[A;9:=4;AS1\&[[75!
M[ <JYRX?&L&TY< ^, G=9A2S<S<97-#"\:E:;C%\)8Y5##B%E5SV:["Q"MF:
M)7 G"FO9$(8G8)7A&7%263-YL @J89&AW*2,E86CYTHE 8FAQ<!@J*+>4-'4
MJ)_12CLX$=4CNJNENKGTTW93?!)V*N%REYH!R[CJL7GF<R7EEZ]SE6059D;R
M%Q.&K*V'O%X3OW)T4GI*Z4=5C',=^XJP%Q#ME403>)2^.+0F)9I0UP<0QYP>
MX^*K:Z*GJ*-XJVQF/&Y>,A8;%.0!N?455UU747"RST+/Y=WP7>(7GVXLQ>+5
MG2V^S%*J>2R5WG5IE;56USL21,.>3UC^"V'8JV&NM\-1 X%KA\BL>@K-V-J=
M%<*1K9>;TFO&?>LLAH*:",LAB;&W.<-VW5_4,^*9]G'>8]_Q4QQ/E&/:FWB%
M"*<<NY=GVJ$TC3WN_P!I>9'3\6NTS(\0F1XA2?,V]Q?_ +2>9M!V+O\ :4ZK
M\4[3LCQ3;Q4KS-N.K_\ :04K?QG?[2?-^)M,V\5$TCF&_>I7FK?%_P#M+UM*
MT.'I/Z^*F-?%&VV41%^FO$:*\I;^>6#]'-]+%I5;J\I;^>6#]'-]+%I587\O
MD?4OK-_R_81$57"(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB MU>33_ #R__HX?I>M*K=7DT_SR_P#Z.'Z7JU/+N]-^LT_/]I;U1$6[ZX1$
M0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%RAQRB=]E
M"\DC <("/6.Q8/["NKUH/RB]/OCNM#?86$PS,%/,X#H]N2TGV@X_JK/+]%U\
M.8C)J?>TK&S'<JZ!BA8P$*I@;RE<<R];2="P!5L0P,]RDQ#*J@-E1,0BC=NJ
MN-VRMY/*5/A?E5ZEO9^]6L;S*8V/Q4$3AA532"U(4\)?( %3RC"JGG 5+,[8
MJ42M\QP3A4LDNQW4VJ=UPK7++U 5)36">7J%2DYZHXY.5X"H2]R IL+LE4SC
ML<J93'+ME:(96E< A*-W"$;+2(8RIY3@%6NJ/I%7.?H5:*MVY32:SJ%,]W54
MKW]5%(_JJ=QZJ]:G4AE<H.9)#NI9.ZUB&4V5$9RJF(9]85'$560]RK,(V\EM
M\,XW;RGQ"H)[1,S)A(>/UJ]L*GQK7%FO1SY<=98>\20NQ(TM*KJ.9IZ]5D<D
M4<K<2-#AZPK=46>)_I1$L/J7H8N=KZ3DM@^"#M&$'N*D"=N<$[A2JBWU<0V'
M./$*WR"6-WI-<#[%WQRJVC<,?9S'E>VU7*.9AV[PJRFJ(IV['#N\+%FSN:>J
M]$[@>I'L6E>5$*3BVRF<@;^"D><M:'#*LL5RD Y7^D/6I4L_.<M)"M/)K/>"
M,4^)7IUQ:SOR5)DN;',(.Q5C<\^*@))6%N7/N6C%"MJ*QTFP.RH7.SE>$Y7A
M7)?)-_+6*Q#Q"%ZO%FD"+W"\1"9&[=9#:)SRX.<+&QLKG:I0) "3U77Q<FK:
M9Y*[AE3).[!*]J'<T)4%.YNV.]>U?HLR.A7LQ/S7#KYS&+Q(#*&CN"M3U<;D
M0Z9Q5O<O$Y/>TO0IX2EZ#A>D*'E[UR+I@=E%!A>@^M3L1 X7J\&_1>]$V:,[
M+SN1%(!7*EC%92F#_I&[L]?J5M4R&1T3PYAP0IK.O)IZR)P>6D8(56R+E;G*
MK.:*Z,&7-AJA^%W.5KJC/2R]G*!GN(.05EDQSYCPZ<66E?/E5%Q4#CNI,4Q<
MW=3&D'O6.M.CKZGJ)E>H/%XHEYA#0F4P@"#W*B:5#@J,  9*B5J[3&]-U*DD
MPH9)NX*1G)RE:^^4WR>Z DN*]7F5[@E78"]:H<8[PO0X#O0WI$=RC 5+,H&P
M7A>3WII$WB$XX'4J$R =-U)ZKT)I3VL^Y&7DKP+P+U%9F9\O5Z#A>+PJ!,Y]
MD[4@*#N4#CLD0;TN%--L>]3F28<5;*9_HN]JJ@Y4M74M[9.JL+DY_:4[AUV5
ME=U*N5.[.V>JH*AO)(X**>9A2\;KM"SJJF)4K.JJHU>64*N,X55&=E21]%5Q
M]%C+2$1*E/*F.Z*4Y1!*2\[%4TG55+^A5+*=UK524(47<H 5$"IE"(%5%-\)
M4V544W54GPM"[0G95#3L51Q.V4]KL#98Z:[1DJ1*[8J)SB<J1(=BK1"LJ&HZ
MJD?T55-N53O&RUAG*7W*6\J: I;QU5X0DDJ.-2R,*;!OE2A/C"JX0I$057$-
MUE:6D*F)JFAJAC"G-"RE9'#U59&J.,>)57%T4)3V*:U2FJ8U5$?<O,[(G<H2
MIZCH59JS.ZO,_0JS5G>M*(LL=7OE6J?X2NM5U*M4_P )=M'-=)7H7B]5U'K5
M-:I35.:H3"(*?"[!4E1,."J3W:5G3([;)D!7R!VRQ:WRX(5_II<@;KS,U-2]
M'%?<+O$[9>/W5/$_/>II=LN;329VA*A7I[U"I5%XF5Y[U(A*ED;*,J$J8%%5
M-R"K/.WE)(5^G;D*TU3,Y71ALSO"G@E+'@Y64V:JR!DK#B>4JZ6FIY) "5;/
MCZHVTXV7IG4MD44@(&4K(,M)5NM<_,T'*OK&]K'NO'M\RSU8GJAAESI_A*UT
MDIIY_>LPN-+\+98I<:<QO+@,877BM%HTYKUU.V6V2X<CFN!V/5;'L]8)6 @K
M2-IJN1X:X[=RV%IFX%K@QSMECDITSM2U>J-L\JV=I$[V+![[1RN<XM"SNC>V
M5@[U[46YDAR1U58[]W-/9J:DIJCS@%V<!2M1U,E%(R5I[NBV3<K2R&%TC ,A
M:_U-;W5<?H'=J5O'M-2K,3I%9[JRL@:''#U<7^(6%4<;X+C$S=N#@^M9F>@4
M9:16>R*SN.Z;(QE5"6/ZXV*E6^"2'M6/WQT/J0''3JJNFEYB >H5*5FT],>]
M,SJ-J=V04:565,(>WF;L[P5"06G!V2])I.I*VVJH)<$ K([(T=LPK%6;K)M/
M.//'GIE<?)CYDZ:591!\)_CE3^Y4].<NDQXJ?W+P;>5S*(BJ:,IW+W"\PH2\
M1%XK0/<X43-WM &22I95RT_2&LN<+<98P\[_ &!;8,<Y<E:5\S*EYBL3+82(
MB_3'C-%^4LT^<Z?=CT2R<9][/XK2BZ6X\V"2[:0%93,+Y[<_MB -S&1A_P F
MQ]@*YI6-X[OE/5:37D3,^_0B(J/.$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 6Z_)H:?.=0.QZ(9 ,^]_\%I1=+<!K!):=(.K*EA9/<7B8
M C<1@89\NY]A"O2.[T?2J3;D1,>[;9*(BV?5B(B B(@(B("(B B(@(B("(B
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M.-T79'ULV'\B6OYI'_!/K9L/Y$M?S2/^">S/D6_VX<;HNR/K9L/Y$M?S2/\
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MJX_V>H!:;\G6PMJKS77F=F6T;!%#G\=W4^YNW]9= )CCMM'I'&BM/;3YGQ^
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MSV@@J0PM=+^"[( Q@[XWWQOMON%)T"(B@$1$!$1 1$0$1$!$1 1$0$1$!$1
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MAIA>W8==R,*IU1K&S:7DIV7JHD@,X+HR(7O#L==P#XCY5%=1'9GQJ\?CXO\
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M[1DM#IBTD>O==NZ9TG8]-6Z.BLMMIJ>)HP7!@+W^MSCNX^U3.H&$\8*J6MX
MW"JJ"#-/0TTKR!C+G/C)V]I6J/) ^ZR^_$6_O MS>4  .#VH@  !'$ !^F8N
M2] :YK]$,O$MH8T5U=3BG9,[?L?2R7 =YVV[DCP.E>-W&&'1C3:;"8:J_NP7
MEWI,I6_Z0[W'N;[SW V[@KJCB)KFJ%PN<])2Z>B=AT@I '5!'5C/5XN[NG7I
MJG@?PV=Q$O%3=+W5<UKIILU+>US-42'?!WR >]QZ]!ODCL*AI*>@HX:2BAC@
MIH6!D<4;<-8T=  HGL.;>*/%[6FGM>WBU6GS?S&FD:V+FI><X+ >O?N2M$:<
MO%;8[_276V<OGU-)VD7,SF'-OW=_5?1!<+<%OONZ=^.?V.4Q(V9PUXPZUONN
M;-:[IYOYE53B.7EI.4XP>_N6[>)O$"UZ LS:RX\TU3,2VFI(SA\SAUW[FC;)
M]?>=EF"XG\H.\U-]XK72 N<Z*B>VBIX_Q>4;_*XN*B.XN-XX^ZYN=6XVV>GM
MT6?1AIZ=LAQZR\.)_4KEI+RB=2VZL8S4D,%UH\X>6QB&9H\06X:?81OXA=%<
M.=$6O1-@IJ&@IXO.N0><U7+Z<S\;DGKC/0=P6 ^4GH2VW/1M9J&FIHH;M;P)
M'2L:&F:/(#FNQUP#D$^&.]-P-JZ8OUOU-9*:ZV><3T=0W+7="#WM<.X@[$+4
M_E#<1K_H:X66&P24[&544CY.UB#]VEH&/E*Q#R0;W.+E?+$]Y=3NA;6QM/1K
M@X,=CVAS?]E0>6'_ )WTU^@F_::D1W%OKO*-OWU!H::AI*7ZJ<A\ZK)69:7<
MQP&,!P,-Y=SG?.RV;Y.>N+[K6@ODFHJB.=]++$V(LA;'@.#B>@WZ!6KR:=!6
M,:-I=25E'%67.K?)ROG8'"!K7EH# =@3RYSUW6V]77%NG])WJZP1L;)24DLS
M0&@ N:TEH/OPDZ\#67&#C?3:1K9;/8*>*OO$>TSY">QIS^*<;N=ZLC'CW+2D
MG''B%+*Z>.ZL9$#DL91Q<@]6[2?UJW<&=,,UWQ'@IKN]\U, ^LJ\N/-* =P3
MZW.&?42NVJ*WT=#1,HZ.E@@I&-Y6PQQAK /# V4]H&@N%WE!FXW""UZSIX8'
MS.$<5=3@M9S'8"1N^,_C#;U=ZW]<JZFMEOJ*ZOF9!24[#)+(\X#6@9)6*T7#
M+2E%JYVHZ6U11W M]%K1B)C_ /K&LZ!WK]_7)6!^5E>9J'0M#;H'EHN%6!+C
M\)C!S8_VBP^Y1Y&":T\H:^W&XOI=&4S**DYN6.62(2SR^OE.6MSX8)]:M%!Q
MQX@V&O9]7>6JC.Y@K*00DM]1:&D>W=6W@OK_ $_H'SRKN-DJ*^[3.Y8ZACF@
M11XZ-ST).<GPPLOXB<:],:TTO66JMTY6]J]A-/.Y["89<>BX=_7KXC(4Z&^^
M'&M[;KO3[;G;,QO:>SJ*=YR^%_@?$>![_E RE<@^2G>)J+B+);FN/F]PI7M<
MSNYF>FUWN </>NOE68T"UIQ?XL6_0$3*6*(5U[F9SQTW-AL;>YSSW#P'4^KJ
MMEK@_P#RCB1Q6#9YG!UWN'+S]>SB+L#'YK!M[%,1L9#6\=>(%;4/EIKA#31C
M?LJ>D86M'M<''Y2LNT!Y1=PAK8J;6E/%44;R&FLIV<DD?K<T;.'L /MZ+HW3
MM@M>G+5%;K-1PTM+&T-Y6-W=ZW'JXGQ*Y[\JC0MNMU)1ZGM5-'2RRU'FU6R)
MO*V0EKG-?@; ^B0?'(2-2-^:@JJVLTA65FE*B&2M?3=O12<HD9(<<S1ZPX;>
M]:'X0\;K[>=<TEHU5)2^:UF8(W,A$99-^#G?O(Y<>)"RCR4+Y-<="5ENJ'E_
MU-JN6(D](WCF ]SN?Y5IGC]IF31_$N:KH Z&FKG>?TKV;<C^;+@/8_?U A(C
MW#M)<W<7N-=]LVNZJS:4?3&GI V"0OA$A?-^$![,AN/$%;+BXE4QX-?7D2SM
MA2X,7_ZS\#DQX<_ZMUSSY/6FI=7\2VW*X<TU/;W&NJ'OWYY2?0!]9=Z7]4I$
M?$=7VVOJ+3HV"X:NJH8ZF"E$U=*&\K&.QEP 'AT'CCUKG'67E"W^Y7)]-HZF
M90TG-RQ2/B$L\OKP<M&?#!]JSCRM;Q-1Z,MMLA>6MN%43+C\)D8SC_:<T^Y:
MBX+\0M/: CJZFOLE177>9_*RH8YH[*+ ]%N>A)SD^Q(CWBX6_CEQ L-P8+\&
MU<9W=3UE((7%OJ+0TCV[KIGAWK2VZYT]'=+62P@\D].\^G"_O:?'Q![PN?\
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MQ^,?!EG"71KM5W\.JF'ZETA#Z@]SSW1CV]_JSZEC&I6M9J*ZL8T-:VKE  &
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M15L=+;J>HKJAK UK1OR-&PR3LT>W 672\(-6LI^U%)3O=C/9-J&\W\/UK<'
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M&2KQ>.%FJ[93.G=0-J8VC+O-I ]P_J]3[@5T[;:&FME!!14,38::%H8QC1L
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M^?BL7_$LK\FC^;ZA_.@^AZQ3R@/N_/Q6+_B65^31_-]0_G0?0]91]-\Y@_\
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MY>':])W$_P L0X!??!B^+2_0%TPN9^ 7WP8OBTOT!=,*,?A7T?ZO^<M6<?\
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MP."F13UJL]5+?B[/MG^;:3]$SZ%4K1.G>-C:*R4]+<;5)/501MC$D4H#9,#
M)!&Q^5;'X::SCUG:9Z@PMIZJ"4LDA:[FPT[M.?6-O:"KQ:)>I@YN'-,4I/=E
MZXEJ_P"=3?GGZ5VTN.]:VJ6RZJNE#,TM[.=Q9G\)A)+3[P0J9'G^MUGII;\7
M3O##[@+#\5:LG7/6@N+HT_I^"U7&W/J6TP+8I8I "6Y) <#X9Z^'<MD<-.(<
M6LZFX0/I6T<\&'QQ\_.71G8G.!N#](5JVCP[.)S<-ZTQQ/?7^%A\I#[E[9\<
M_P"!RUMP0^^5:OS9OW3ULGRD/N7MGQS_ ('+6W!#[Y5J_-F_=/5+?2>9RO\
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MF [@/&[3XM/4'UA:JO/ NDDD<^SW:6!IZ15$8D _K CZ"MS(DUB?)FXN'/\
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MQ_T;UK#@Q+([B1: Z1Y&9-B?_A/59MJ=/.S>H>RSQ@Z?.N^_BZF1$5GHB(B
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MKFH#WN</,9-B<_AL5>KOIYUO4.GD_P!/T_GMT:B(K/1$1$!$1 1$0$1$!$1
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M0,D>LX"N>H>#-]ME$^IH9Z>XB,9=%&"V3'J!Z_+GU)NWE:>3S[Q[2L:C\/\
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MD8]I&_ZELVDJ8:NGCJ*6:.:"0<S)(W!S7#Q!"Y0UKH.\Z2+7W"-DM(\\K:F
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MH;31NY#7U31EY[CZ6PSU#0"<;E1H;]1:/TMQ-U/8=8TFF.)]O@@EK2&TM?
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M*NMX<6]K!$1"T_A2N]%@_P!HC/JRK?PVX<VK0$5:RTU5?4&K+3(:J4.^#G&
M  .I5;Q T1;==6RGM]YGK8Z6&7M@RFD#.9V"!S9:<XR?E4#GSAEPOUW66%E_
MLFIFV<W8=J]O/(V20!SN5SBT;YR2/:J?B'HK6NAZFVZVN]\CO-10U,3!)S/<
M]@!) <7#X).1_6]:ZMHJ6&BHX*6E8(Z>"-L4;!T:UHP!\@5%J:QT6I+#6VBY
ML<ZCJX^SDY3AP[P0>X@@$>Q3L3;%=*>]6:AN=$[FIJN%LT9]3AG!]:TEY7'^
M8=-_'G?LK;^B]-4FD=/P6>VS54M' 7&/SEX>YH<<D9 &V2?E5!Q T':==4M%
M3WI]6R.DE,L?F[PTEQ&-\@[*([2*'BOI73>KK;0V[4M:RAJ'2GS&82M9)VF-
MVM#MG9 &1Z@M1:EGUCP5K+5-]='U>LM1+V?F55GM.4;D $D@8Z%IQG&0MUZ^
MT!8=<TL,5^IY'209[&>&0LDCSUP>AZ#8@K$]-<"-*62[P7&62XW.6!P=$RME
M:YC"-P<-:,X\#MZE,#:S3S-!Z9&5SYQ>J(]-\?-'ZBO+3]1NP$7:D9;&X&0$
M_P!7M&N70BLVK-,VG5=H?;;[2,J:5QYAG9S'=SFN&X/L40(+SJ2S4.GI[I57
M2C90=D7"<2@M<,''+CX1/<!U6J/)%WT->/\ 63OW4:K[?Y.VCJ6N$\TUUJX6
MG(IYIVAGOY6@GY5GG#[0]KT):ZF@LCZI\$\QG=YP\./-RANV -L-"#*%H'R>
MOOG<2OCCOW\JW\L3TAH*TZ5O=ZNML?5NJ;M(9:@32!S0>9SO1  QNX^*"[:N
MHY[AI2]45'_.:FBFABWQZ;F. _65J+R6+];&:0JK#++'37>FJY))8)"&O>#C
MT@#UQCE/A@>(6\UK37'!;2NK;E)<9HZFWU\IYI9:)X9VA\7-((SZQ@GO2!@/
ME'7&DU%JC26F['+'57EE62XPD.,/,6@ D=#MS$=P;DJMX^_?6X8_'6?OXEL#
MA]PJTUH>H=56N":HN!!;YW5O#Y&@]0W  ;[AE7'5F@[3J>_62[W)]6VJM$HE
MIQ$\-:2'M=Z0(.1EH[PIV,K6@M'/93>55JME0]L;IJ,MC#CCG); [ \=@3[E
MOU:^XA\)M.ZYKXZ^X^=4EP8T,-12/#7/:.@<""#CQZJ(%C\I^G?6\*)IJ8=I
M'3U<4KRW<!N7-S\K@LNX?:DM%9P^L]?%<*5M-#11,F>^5K1$YK '!V3L00>J
MK=,Z0M=@TDS3D+9:NV!CV.96.[0O:XDN!VQ@Y.P&%KVI\G;1LUQ-1'-=8*<N
MYC2QSMY/8"6EV/>@L/ 6OIKIQ@XA5U!*)J2H>Z2*0='M,QP0I_#O_G.:W^*O
M_:A6Q]#<-;!HFZU]=86U4;JQ@8Z*23F8QH.0&[9^4E5-GT':;3K>YZJI7U9N
M=PC,<S7R Q@$M.PQD? '>IV,9\I=K7<(;L2 2V6 CU'M6C^U:]XLT=56^3=H
MRIA#GQ4C*22?'<TPE@)][FCWK>^M-,T.K]/5%FNKIVTDY8YY@<&O]%P<,$@]
MX\%.MVG[?1:8I[!V7G-MAIA2]G48?SQ@8P[;!V]2B)&D],\*[=?M/4UUMG$.
M^NHGQ!Q(J !%MNUV_HD=""LLX)Z.L%AJ[S<M.:EDOOG#O-ZAQ<UP;(UQ))(Z
MG?KWYRJ"M\G;2$]:^6"IN]) \Y--%.TL'J!<TG'M)6R-'Z4L^D+4+?8*-M-
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M?A;]?7OE=&67@MI^BF;+7S5=P+?^C>X,8?:&[_K5ZU-PSL&H*JFGJ65%.*>
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M67'RIS3XG?ZK7QE^]K>OS8_WK%S1I;[IK1\<A_;"ZYU'9J;4%EJ;77&04U0
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M1WPWBNFJS"8>S[0CT<\^<?(%7J[Z<->?2V?^GU.VV$1%9W"(B B(@(B("(B
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M(H(XWC.<$- *K$0<_P"E^"M3;.,TMVFAB&F::9U91^F#F0X+6<O4<KCU_P!
M>*VYQ"TG2ZTTI666L>8A, Z*8#)BD;NUV._UCO!*R1$V-!6AO&K2EOCL5%:[
M5>*6!O94];)*TEK!L!O(PX Z<S?E6R^%]KU7;;35.UO=H[A7U,W;-CC:.6G!
M&[0X 9]@&!W969(FP6J.!NC;UI2XZOEO=,R!EPJVRTY;*U_,T&0YV)Q\(=5M
M=$&N>,G#V;6E%05EGJA1:@M<G:TDY) .X/*2-QN 0>X^U8>:[CG64OU+-IM-
M&\CD=<^>/FQ^-L\C/L9[@M[(FQ9])T%QMVFZ&BOEP%RN$409-4\O+VA_MVVS
MU.,]ZT=8M*<3>&]SNMOT9;[==+/73]K'/.]H[/N!(+VD'& =B-MET2B;&I^+
M?#BXZK=:M0V"HCMVK+>QO+Z?HOQZ7+S8ZM<3@XP<D'U8Q5Q\;M1VZ6RUU);+
M7 ]ACFKFOC#Y&XW'HO=U_P!%HZ]0M_HFQK#@'I*[Z1T+5VV_4[(*R2KDE:QL
MC7@M+& '+21U:53^3MHV]:,TU<Z/4-,RGGGJ^U8ULK9,MY&C.6D]X*VNB;&I
MN 6C+WI :E^KU,R#SVJ;+!RRM?S-'-OZ)..HZK:\G-R.[,@/QZ)<,C/K42(-
M)2UO&VRS5%,RV66_1O>XQ50<UG+DY QSL.!ZP?:5=.#O#2KL%EU"[5CH)JV_
MDBJIXCZ#&$.RW(VR>=W38;86V438Y^M.F>)_#*:JH-&P4.H+!+(9(8ZE[6NB
MSX@O80>F<$@]=LK-^&EOXAR7RKN^NZ^E@II8NSCM5.&N:PYR'9!(;C?O<3G?
MH%LI$V-*:[X<ZEMFMI=9<-*J%E?4C_*Z*5P:V4GKCF]$AV 2"1@[@^% ZV<8
MM:U=+3WR2ETO;896R224<C0]Y:<[!KW$GU$AJWTB;&)<2])OU?H*OL3*GEJ9
M6,,4\O?(QP<"[ [R,' [^BPCA6.*%JJ[58M06:W,T]0QF!U6)6F1S W#,8><
MXP/P1MU6Y$0:)U%P]U?I'6==J7A?)3S17!Q?4VV=S6@N)R1Z1 +<DD;@C.!L
MJ*;0_$+B9=J%W$;S6TV*ED[0T=,]I,A[\!KG;D9&7.V!.!NN@T38U1Y0.BKM
MJS2%KMNF:2.62EJVR&,R-C#8Q&YHQS$#O&RV-7Q5HT]4PVU[([EYJYE.Y^[6
MR\A#2?5S85Q1!K7@A0ZYHK;=&\09WR2.F::5LLK)7@8/,>9I(Y3M@9[BME(B
M B(H!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$
M0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$
M0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$
M0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%H#RDO\_6CXL[]LK?ZT!Y27^?K1\6
M=^V56_AYWJOU:WY?N\\FW[H+O\5;^V%T N8^#FJ+=I2MNU;=7O#74X9''&W+
MI'<P.!W?*K[=..ET?,[ZEVJCAB[O."Z1Q^0M"K6T1#DX/-P\?CQ%Y[]V_P!%
MH:S\=*QLS1>;33R1$[NI7.81[G$Y^4+<.E]26S4UO%7:*@2L&SV'9\9\'#N^
MCP5XM$^'I8.9AY':D]UX1%)K*J"BI9:FLF9#3Q-YGR/.&M'B2I=4SKO*<BTU
MJ7C?2T\SX=/T!J@TX\XJ"6-/L:-R/:0L=@XY7YLV9[=;'Q?BL;(T_*7'Z%7K
MAY]_5.-6==6W0Z+5$7&BUSZ=K*N.E,5U@:US:.9^&RY< >5X&^ 2<8!V5#IK
MC+47C4%NMKK-%$VJG9"9!4$EO,<9QRIU0T^4./N(ZO+<J(J6Z7&DM5#+67&H
MCIZ:(9=(\X _B?4K.R9B(W*J1:6U#QRABE=%8+89V@X$]2XM!]C!OCVD>Q6"
M+CCJ 2YEM]J?'^*UDC3\O.?H5>N'GV]4XU9UU;=$(M9Z.XOV>]SLI;G&;75O
M.&F1_-$X^'-MCWCWK9@WZ*T3$^'7ASX\T=6.=N<?*)^[FE^(1_MR*^^31\/4
M/L@_XU8O*)^[FE^(1_MR*^^31\/4/L@_XUE'TWA8O_DI_&?V;Q103S1T\,DT
M\C8XHVESWO. T#J25IJ]\<8J>YSPVFUMJZ1AY63R3%AD]8&#@>"TF8CR]O/R
M<7'B)R3K;="+6W#W7UXUC7.;%8HJ>WQ'[=5.G) /XK1R[N]7<LAXC:I?I'3X
MN4=*VJ<9FQ=FY_(-P3G.#X)N-;*\G';'.6)^;'W,H1:<TUQJCN%WBI[K006^
MB+7NDJ#.7<O*TD;<NY) &/6J+4''-S9G1V"UL=&#M-5N/I?U&D8^51UPPGU+
MC=/5U-X(N?*'CG>62@UUKM\T>=Q#SQN^4N=]"VKH?7]GU:TQTCW4]<T9=2S8
M#L>+3T</9\@4Q:)6P<_!GGIK/=ER(BEV"+66L^+UILD\E):XC<ZMAY7%C^6)
MA\.;?)]@QZU@C^..H#+EEOM0C_%+)"?EY_[%6;Q#AR^I<?'/3-MS]SHA%J?2
M7&>VW*5M-?*;ZG3.V;,'<T1/K[V_K'K5A/'>I!(^H,)_^9/]U.N"?4N-$1;J
M\_BWLBIK94FLMU+5%O(9XF2<H.<<P!PJA[FL8YSW!K6C)).  K.Z)W&WJ+5>
MK.,UIM<TE-9H'7.9AP90[DB!]1W+O<,>M84_CCJ$RY906IL?XI9(3\O.JS>(
M<&3U+CXYZ9MO\'1*+3FFN-]'43,AU!0.HP3CSB!Q>P>UO4#V96W**KIZZEBJ
M:.:.>GE',R2-V6N'J*F)B?#HP<G%GC>.=M5^4A]S%K^.?\#EK3@E]\FT^R7]
MTY;+\I#[F+7\<_X'+6G!+[Y-I]DO[IRSM])X?+_^0K^-74R(M7Z\XN4>GKI]
M3[92LN,\1(G=VG*R,_B@@')\?#Z-9F(\O>S9\>"O5DG4-H(M.::XM7G4=UBM
M]KTW#),_<DU)#6-[W./+L MPLYN1O/CGQOCIE1$Q/A7!R,>>-X^\.5.,7WR+
MW^>S]VU;;\G3[B:OX\_]ABU-QE86<2;UGO=&?_V;5MOR=V%NAZAQZ/K7D?[+
M LZ_2>)POKU_S_=M!$1:OHA<Z>47]VM'\09^W(NBUSIY1?W:T?Q!G[<BK?P\
MSU;ZO/XPK/)M_P _W?XJW]L+?ZT!Y-O^?[O\5;^V%O\ 2GA;TKZM'Y_N(B*S
MT1%3W"MIK=1RU==/'!31#F?)(< !:BU'QPI8)GQ6"W.J@#@3U#BQI]C1N1[2
M%$S$>6&?DXL$?\DZ;E1<[1\<=0B7,E!:G1_BAD@/R\ZSC2'&.T7:=E-=X3:Z
MAYPV1S^>(GUNVY?>,>M1%XESX_4N/DGIBVOQ;11>-(<T%I!!W!'>H*F>*EIY
M)ZF1D4,;2Y[WG#6@=22K.],1:>U1QMHJ2=\&GZ(UO*<><3.+&'V-ZD>W"QB'
MCE?Q-F:WVM\7XK62-/R\Y^A5ZX>??U/CTG75MT0BU30\9[756.LG=2FGND$?
M.REE?Z$Q\&O Z^H@>]6RQ<:JBYWNWT#K+#&*JHC@+Q4$\O,X-SCE]:=4+_*/
M'[?.\MTHBU+K?BW/IK4];:8[1%4-IRW$CIRTNRT.Z8]:F9B/+?/R,>"O5DG4
M-M(M44W&>V-TXRMKJ8BXO>YK**!_,<#HYSB!R@_+ZEB-7QROCYB:.VVV*+.S
M90^1WRAP^A1UPYK^I<>D1/5MT*BTQIKCA!/.R'4-O\V:XX-13$N:WVL.^/83
M[%N"BJZ>NI(JJCF9/3RMYF2,.0X>I3$Q/AT8.3BY$;QSM/1$4MQ<X^43]W-+
M\0C_ &Y%T<N<?*)^[FE^(1_MR*M_#S/5OJ_YPOGDT?RVH/S8/I>MY+FK@]K"
MVZ0IK[47,R.DE$(AAC;ETA'/GU #(W*NEQXYW=\Q^IUKH(8L["<OD=\H+1^I
M5K:(AAPN=AP<>M;SW[_O+H%%HVP\<Y#,UE^M4?9D[RTCB"W^JXG/RK<=DN]#
M>[='76NI944TG1S>X^!'4'U%7BT3X>E@Y>+D?]<J]$5/<*VFMU'+5UT\<%-$
M.9\DAP&A2Z)G7>50BTSJ/CA303/BT_;C4M!P)ZAQ8T^QHWQ[2%CD?''4 ES)
M;[4Z/\5K) ?EYS]"KUP\^_JG&K.NK;HE%J_2'&*T7B=E+=H3:ZEYPU[G\T3C
M^=MR^\8]:V@"" 0<@]ZM$Q/AUX<^//'5CG8BH+_7FUV*Y7!L8D=24TDX83CF
MY&EV,]V<+3<''6HDGC8^QP,:YP!<:D[#/7X*B;1'EGGY>+!,1DG6V\T6H]6<
M:J"@G?3V"E^J#VG!GD<619]0ZN_4L4AXY7]LV9K=:WQ9^"ULC3\O.?H4=<,;
M^I\>ENGJW^#H=%@&A>*-HU/,RCF:ZWW%VS8979;(?!KN\^H@'VK/U:)WX=>+
M-3-7JQSN!$6"ZZXF6?2LKJ3#JZY#K3Q$ ,_/=W>S<^I)G1ERTQ5ZKSJ&=(N>
M:KCE?72DTMNMD4>=FR->\_*'#Z%>].\<F23MBU!;1"QQP9Z5Q(;[6'?'L/N5
M>N''7U3C6G74W6BIK;74MRHHJR@G9/32MYF2,.00JE6>A$Q,;@1:RUOQ=MEA
MJI:*V0&Y5D9+7N#^6)A\.;?)]GRK W<<=0]KEM!:A'^*62$_+S_V*LWB'#E]
M2X^.W3,[G[G1*+3^F>-U!53,AO\ 0NHBXX[>%QD8/:.H'LRLRXA:P^M;3=/=
MJ2GCK63S,C:.TY06N:YP<#@^'ZU/5'EK3F8;TG)6W:/*'B]][F^?HF_MM7,&
MG?\ /]L^-1?MA;"U9Q>GU#IZMM3[/% VI:&F03EQ;AP/3E]2UK;ZDT=?35(;
MSF&5LG+G&<'./U+*TQ,]GS_J')QYLU;TG<1'^7:Z+1'V>*K\@P_.3_=6S.&V
MJWZPL,MQEI&TKF5#H.1K^<'#6G.<#\9:Q:)\/>P\[#GMT8YW/X2TSY0OW=Q?
M$H_VGK)/)G_DM1>VG_\ $6-^4+]W<7Q*/]IZR3R9_P"2U%[:?_Q%G'TWD8?_
M )*?QG]I;M1:QXB\2:_1U\%$ZS15%/)&)(9S.6\XZ$8Y>H.?U>*J>&?$IFL+
MA54-31LHJF-@DB:V3G$C<X=W#<9'_H+3JC>GL1S,,Y/8[^<V*B(I=0BU'K/C
M"+%J.KME#;8ZQE,0Q\KIBW+_ ,(8P>AV]Q65\--65FL+94U]3;F45.R3LHBV
M0O[0@9=W#89'Z_!1%HF=.:G,PY,GLJSN68HB*72(B("(B B(@(B("(B B(@(
MB("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(
MB("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(
MB("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(
MB("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(
MB("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(
MB("(B B(@(B("(B B(@+0'E)?Y^M'Q9W[96_UH#RDO\ /UH^+._;*K?P\[U7
MZM;\OW:RT]9*_4%SCH+5 Z:H?OX!H[W./<%N*U\"H/-@;I>934$;MIXP&M/M
M=N?D"M/DV_=!=_BK?VPN@%6E8F-RXO3>!ARXO:9(W,N:M>\*+AINBDN%!4"X
M4$>\F&<LD0\2-\CUCY%B>B=2U>E;]!<*1SC&"&SQ9VECSNT_V>!77\D;)8WQ
MR-#V/!:YI&00>H*XVU10LMFI+K0Q?R=-52Q,_-:X@?J46KT]X8>H<6.):N7#
MV_Q+L2AJH:ZB@JZ9X?!/&V1CAWM(R"N>^.NL);G>WV.CE(H*)V)0T[2R]^?4
MWICQSZEM#@O6NGX:VY\I+C!VD>?4U[L?JP%S#65$E75SU,QS+,]TCCXDG)^E
M3>>SI]2Y4SQZ1'_KNR30FB+GK&K>RBY8:2(CMJF0>BWU =Y]7RX6T?L$T'FW
M+]6JKM\?#[%O+G\W.?UK..%5MAMF@;,R%H!G@;4O(ZN<\<V3\H'N66*:TC7=
MMQ?3,,8XG)&YER9KO0EUT?,TU@;/12'$=5$#RD^!'X)]7R95+PY^[NP?'8OV
M@M\<>_O>U'QB+Z5H?AS]W=@^.Q?M!4F-2\OD\>O'Y5:4\=I_5UZN6^+>LIM3
MZ@E@@E/U*I'F.!@.SR-C(?'/=ZO>NC-8U3Z'2=YJHB1)%1RO:1W$,."N.0,G
M 5LD^YW>LYK5BN*/?Y9OP]X<W+5[75(D;16UKN4U#V\Q>>\,;MGVY 6PY^!-
M 8,4]ZJFSX^$^)KFY]@P?UK:FGK;#:+'0V^F:&Q4\+8QCO(&Y]I.3[U<%,4C
M7=TX/2\%:1%XW+E*]\.-0VN_06L4AJGU)Q!-#O&\#J2?P<=^>BZ/T-9ZRPZ:
MH[?<:YU;41-W>>C1^(#U('0$_JZ"_(IK6(:\7@8^->;UGRYQ\HG[N:7XA'^W
M(KSY.$\5-'J6>HD9%#&R%SWO. T#M,DE6;RB?NYI?B$?[<BUQ!7U4%#4T<,S
MV4U2YCIF-. _ESRY]0R=EG,ZMMX>7-[#FVR:WJ9_9L#BOQ'EU-,^VVISXK-&
M[<]'5!'>?!O@/>?5:N&N@JO6%?SOYZ>U0N^W5&/A?Z#/%WT?(#:M"6F@O>IZ
M*@NM:*.EE=@N[WGN8#T!/3)76MLH*6UT,-'00,@IH6\K(V#8#_UWJ:QU3N6_
M$X]N=DG-FGM'^Z_!#9[91V>W0T-M@9!2PC#6-'ZSXD^*U_Y0?W!,^.1_0Y;,
M6L_*#^X)GQR/Z'+2WA[',B(XUXCX.<*>&6IGCAIXWRS2.#6,8,EQ/0 +<6F>
M"%14TK)]07#S1[AGS>!H>YOM<=L^H ^U8'PL^^%8OC ^@KK59TK$]Y>/Z7PL
M6>LWR=]-"ZGX(U%+223V"X&K>P9\WG8&N=^:X;$^H@>U:DI9ZNU7%DT#Y*:L
MII,@CT7,<#_ZV7:JYEX\VV&WZ]DD@:&BL@94. _&RYI/OY<^]+UUWA;U+@TP
M5C+B[-[\/=2,U5I>EN.&MGWBG8WHV1O7W'8^PA87QXU?+:+;%9;=*8ZNM873
M/:<%D73 _..1[ ?%6KR:JIYAOU(2>S:Z*5H\">8'Z!\BP3C35/JN(UU#R>6'
MLXF#P 8/[2?E4S;YK;/S+3P:W]]NW[[_ &8UIVQU^H;K%;[7"9:B3?P:UO>Y
MQ[@%N2W<":84P^J5YF=4$;B"(!K3[\D_J53Y.%MACL-SN7*#435'8<W>&M:T
MX]Y=^H+;Z5I&MR>G^G8K8HR9(W,N:-=\*+GINEDKJ&87&WQC,CFLY9(QXEN^
M1ZQ\@6MUV=J3[G;I\5E_8*XQ5;UB/#A]3XM./>/9^)=G:<^YZU_%8OV M0<?
M=93,F&F[=*6,Y0^L<T[NSNV/V8W/CD>M;?TY]SUK^*Q?L!<FZYJGUNLKW/(2
M7.K)0,]P#B /D 5[SJ'I>IYK8^/%:_\ K]D>C=*7+5ES\SMC&@,'-+,_9D3?
M$GZ!WK;E/P)H!3@5%ZJG3X^$R)K6Y]AR?UK(>!%MAHM 4U2QH[:MDDED=WG#
MBP#Y&_K*V&E:1KNCA>FXIQ1?)&YGNY@USPNN^F6BHIC]4J N#>TA80]A)P.9
MF_7Q!*VSP6TK=M-V:9]WJ7L%5A[*$[B'_2)[G'O ]^_38R*8I$3MTX?3L6'+
M[6G]FI/*0^YBU_'/^!RUIP2^^3:?9+^Z<ME^4A]S%K^.?\#EH2W5U3;JD5%#
M,^"<-<P2,." X%IP>[8E4MVL\CGWC'S8O/NU+>'%WB:*03633D_^4[LJ:MA_
MD_%C#^-XGN]O33^EM/7#4]WCH+9$7R.W?([X,;>]SCW#Z5:Z9C):F)DTHAC>
M\!TK@2& G=Q W..JZXT)IVU:=L,$-E+)HYFB1]4,$SDCX6?#P'<D?/GNG#2_
MJ6:;9)U6/][?R:'TC;](VH4M"WGG?@SU#AZ4KO[!X#N^4K(D1:Q&GT=*5QUB
MM8U$.8^/,/9<1*I__6P1/_[O+_PK;G F'LN'5$['\K+*_P#[Y']BUKY1D/)K
M*BE'22A;\H>__P EMOA'#V'#JR-\8G/_ -I[C_:LZ_2EXW$IKG9/S_>&7HB+
M1[8N=/*+^[6C^(,_;D71:YT\HO[M:/X@S]N15OX>9ZM]7G\85GDV_P"?[O\
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M:>&&D[9*V6.UMJ)&[AU2]T@_V3Z/ZEFB*.F&$<3!$[BD?V0QL;&QK(VAK&C
M:T8 "B1%+=CE^T1IR^R.DN5J@?,[K*S,;R?$N:03[UC[>#NDA)S&FJG#/P34
M.Q_%;#11J&%N-AO.[4B9_!:;!IRT:?B,=GM\%*';.<T9<[VN.Y]Y5V1%+:M8
MK&JQJ!674>E[-J.-K+S015):,-D.6O;['#!]V5>D0M6MXZ;1N&O8>#^D8Y0]
MU)4R-S\!U0['ZL']:S2SVFWV:D%-:J.&E@&_+$W&3XGQ/K*KD2(B&>/!BQ3N
ME8AC]^T98+]6BKN]M94U(8(P]SWCT1D@;$>)51IW3-HTX*@66B92B?E[3E<Y
MW-RYQU)\2KPB:A,8L<6ZXK&_CH5-<ZZ"VVZIK:M_)3T\;I7GU 952M/^4-J3
MS6U4UAIWXEJR)I\'I&T^B/>X?]U1,ZC:G)S1@Q3DGW-):BNT]]OE;<JG/:U,
MI?CKRCN:/4!@>Y=/<*M.?6UHZDIY6<M9./.*CQYW=WN&![BM#\'=.?7#K&G[
M9G-1T6*F;(V.#Z+?><>X%=3JF./>\KTC#-IMR+^9_P!D1$6CW!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!8UQ TL-7V$6TUAI )FR]H(^TZ C&,CQ62HFMJWI7)6:6\2U-I;
M@XVPZ@H;H+XZ<TLG:=GYKR\WJSSG'R+;*(HB(CPSP\?'@CIQQJ!$12V$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!%XYS6-+GD-:!DDG "@IYX:B/GIY8Y69
MQS,<'#Y0AM,1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!:JU=PDDU+J"K
MNE5J!S'3.]&,4F1&T# :#S]P6U428B?+'-@QYXZ<D;AB?#K1=/HNVU%/%4>=
M3U$G/).8^0D 8:W&3L-^_O*RQ$2(TOCQUQ5BE(U$"(B+B(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B L>
MU%K2P:=K64EYN IJA\8E:PQ/=EI) .6M(ZM/R+(5SIY1OW;4/^KF?O95%IU&
MW)SN1;CXO:5\MWZ;U79=2NJ&V2M%48 TR8C>SESG'P@/ J^+1?DT?SG4'YD'
MTO6]$K.XVGAY[9\,9+>9_E17LEMFKW-)#A3R$$=WHE<>?5BY_E&L_P!^[^*[
M"OO^9+A\7D_9*XN5,CRO6IF+4U]_^'9FF'.?IJTN>XN<ZDA)).23R!7-6O2O
MW,6?XG#^P%=%I#W<?T8$1$6$1$!$1 1$0%C%[UYINQW&2@NMS$%7& 71F&1V
M,C(W#2.A63KE[CE]\BX_F0_NVJMIU#BY_)MQL<7I'??O=%Z<U':M1T\L]EJQ
M511/Y'N#',P[&<>D KLM1>3=]SEV^-C]@+;JFL[C;7BY9S8JY+>9$1%+H%S)
MKW66HZ+6=ZIJ2\UL-/%5/8R-DA : >@73:Y$XD_=[?\ XY)]*I?P\CUB]J8Z
MS6==V^N!]UK[QHZ:INE7-53BK>P22NYCRAK-OUE;!6L?)X^X6?X])^RQ;.5J
M^';PIF<%)GX"M^H97P6"YRPO+)8Z:5[7#J"&$@A7!6S4_P!S5V^*2_L.4NB_
MT9<L_7YJG\O7#_>E=2:2GEJ=*V:>HD=)-+10O>]QR7.+ 23[UQJNQM$_<;8?
MB%/^[:L\<O"]'R7O>W5.^S4WE'76MCJ+9:XWOCH)(C,\-.!([FQ@^.,9QZUA
M/!V[5UNUU;8:-[S#5R"&>('T7M/>1ZNN?4NC-6Z6M>JJ!M+=X2X,/-'(P\KX
MSWX/]G16O1W#NQ:4JG5= R:>L(+6S5#@YS >H;@ #VXRIFL]6V^7@YK\J,T3
MV[?_ *,P1$5WL"(B B(@(B("(B B(@(B("(B B(@(B(-$\<]37JSZOIJ>U7.
MJI('43'ED3RT%Q>\9^0#Y%6\!=17>]7>Z1W:XU-7'' US&ROY@T\W4+&_**^
M[BE^(1_O)%7^39_GR\_%F?M++?SGSU<E_E#IW.M_X;^1$6KZ$7+>K=:ZDI=4
MWB"GO=='#%62L8QLI :T/( "ZD7'6MONROOQZ?\ ;<J7>/ZQ>U*5Z9UW=%<%
MKG6W;1+*JYU4M54&HD;VDKLG Q@+.UKC@#][]GQF7^Q;'5J^'?PYF<%)GX"(
MBETB(B B(@(B("(B#$>+4LD'#R\R02/CD:QF',<01]L;WA<UV&[W)U[MS77"
ML+341@@S.P?2'K72/&'[V][_ $;/WC5S!I__ #[;?C,?[065_+Y[U:TQR*Z^
M$?O+M!4]PK(+?0U%962=G30,,DC\$\K0,DX&ZJ%CW$/[A=0?$9OV2M7OY+=-
M)M'N6L<4M'$@"]-R?_U>7^ZLU!R,A<11?RC?:%VXSX#?8J4M-GG>G<V_*ZNN
M([:\?F]6A?*'KJNEU%;&TM5/"TTF2(Y"T$\[O K?2Y]\I#[I;5\4_P"-RF_A
M;U69CC3K[E7Y.U=5U5\NS:JJGF:VF:0))"X#TO65O=: \FW_ #]>/BS?VUO]
M*>$^E3,\:-_?^XB(K/0$1$!:@\HNKJ:2W64TM1-"72R F-Y;G8>"V^M,^4I_
MFRQ_II?H:JV\.+U&=<:^O][L6X%7&MJ=>Q1U%94RQ^;R'EDE<X=!W$KH]<S<
M OO@Q?%Y?H"Z948_##TB9G!W^(B(KO4$1$!$1 1$0$1$!$1 1$0$1$!$1 1$
M0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$
M0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$
M0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$
M0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$
M0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$
M0$1$!$1 1$0$1$!$1 1$0$1$!8GQ UQ;]'43'5+345LP/8TS#@N]9/<WUK+%
MRIQBK)JSB'=NW)Q"]L,8/X+6M&,>W<^]5M.H</J')MQL753S/9<;KQAU55S.
M=25%/0QYV9#"UVWK+\I;.,.JZ20&IJ*:N9WMF@:W];,*]<%=$Z?U%;JJLN[O
M.ZJ.7D%)VA:&-P,.(&"<Y/JV6=WS@_IBX0.%%#+;I\>C)#(7#/K:XG(]F%2(
MM/?;R\6#FY:1FKD\_?\ ["Z\.-<0:TH9Y(Z.:EJ*<M$K7>DS)Z<KN_ITZK,%
M9-&Z=I=+V"GME'Z7(.:23&#*\]7'_P!;# 6,<:]4R:=TN(**0LKK@XPQN!P6
M, ]-P]>X'];*TWJ.[V8R6P8.O//>([K?K_BY1V*IEH+)"ROKHSRR2./VJ,^&
MV[C[,>U:OJN+>L)Y2Z.Y1T[<YY(J:/ _V@3^M8A9+75WNZT]OM\9EJIW<K1]
M))[@!N2M]V#@I9*:E9]69ZBMJB/3Y']G&#Z@-_>3[EGNUO#Q*9.9SK3..=1^
M.H8AIKC7=J6=C+_3Q5U,3Z4D31'*/6,>B?9@>U+WQHO3;M5BT"B?;Q(>P=+
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MEJ*2OL=0\N%,!/3Y/1I.'#V9P?ZQ4UM.]2WX'-RQE_I\_EN985Q XAVW2#!
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M_P#Z2'Z'I6TS/<X7*SY.5%<D_'M^3=*UGQ!XKT6G*B2WVN)M?<F;2$NQ%$?
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M(O.Y]XB(BXB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MZ"LO\FG^97_])#]#UKSBW?*+4&M*FKMCS)3-8R%LF,!Y:-R/4MA^33_,K_\
MI(?H>LJ_2?.<:T6]0F8\;G]I2_*7F>(M/P@^@XSO/K(Y /I/RK3-KKZZVU/G
M%LJ9Z:H#2WM('EKL'J,A;]\H>T/K-+4EPB:7&@F//CN8_8GY0WY5JCA1J:'2
M^K(JFL_F4[#3SG&>5I((=CU$#W946^DISZ?_ +SYTZB==UO^O'5/Y=NWSE_\
M5+J-5:DJ8)(*B\W26&1I8]CYWEKFD8((SN%UW32P5,$<],^.6&0!S'L(+7#Q
M!"BF=#!$^69T<<;!S.>\@!H\25;HGXNWY*O,?]L_[^;B<,>""&N!'J7:END=
M-04TLGPWQ-<[VD*SZ<U98]15=936BKCFEI78<,8YA^,WQ;G;/\1G(%:E=.GT
M_B5X\6M6_5$_X_,1$5GHN<O**^[BE^(1_O)%7^39_GR\_%F?M*@\HK[N*7XA
M'^\D5?Y-G^?+S\69^TLO_;YNG_R/YS^S?R(BU?2"XZUM]V5]^/3_ +;EV*N.
MM;?=E??CT_[;EGD>)ZU]"OXM_< ?O?L^,R_V+7'E$3/?K>GC=GECHF<H]KGD
MK8_ '[W[/C,O]BP_RD+1(VNM=X8TF)\9I9".YP)<WY07?(D_1.169]/KKW::
MHM%WNEI,KK375=(9,!YIY',YL=,X]JN/UXZI_+MV^<O_ (K+>!>K*2Q7BIM]
MTD;%25_+RRO^"R09QD]P()&?4%T<&L(! :0>A"BM=QY<O"X4\C'U5RZ^[X?J
MX\N&H[_<:5]-<+K<:FG?@NBEF<YIP<C8GQ46BG2P:PL<D;7<S:V'N_TPNN;C
M64=MHY*JOFAIZ:,9=)(0 %;]+:CM.IJ)]59YVRL8\L>TMY7L/=D=1GJ%/1W\
MNCY+UDCJR]_P[_NU[Y2$SVZ:M<+2>22K+G>T,./I*UIP6I(JOB+:VS@.;%SR
MM![W-82/D.#[EN3CK9WW30LLT#2Z6AE;4X'4MP6N^0.S[ESUI.]2:>U%072)
MO,::0.<W\9IV</>"0HMVLPY__'S:WOX[2[(16^Q7BAOMMBKK74,GIY!G(.[3
MX$=Q'@JNJJ8*2GDJ*J:.&",<SY)'!K6CQ)*U?1Q:)CJB>SF/CE]\BX_F0_NV
MK87DV_<_=_C3?V M5<4;U27_ %M<*^W.<^E=R,8]PQS<K0W('@<;+:ODV_<_
M=_C3?V LJ_2?.<.T6Y\S'C<_Y9=QA^]O>_T;/WC5S!I__/MM^,Q_M!=/\8?O
M;WO]&S]XU<P:?_S[;?C,?[02_E/JWUBOX1^\NT%CW$/[A=0?$9OV2LA5@X@,
M+]#W]K1D^8S?L%:SX>_F_P"NWX2Y!B_E&^T+MQGP&^Q<1L.'M)[BNV*29E12
MPS1.#HY&->UP.001D%9X_>\7T3_W^7^4U<^^4A]TMJ^*?\;ET$N??*0^Z6U?
M%/\ C<K7\.WU7ZM/Y(_)M_S]>/BS?VUO]: \FW_/UX^+-_;6_P!*>#TKZM'Y
M_NL6NXVRZ*O['C(\PG/O#'$?K"X^&W1=BZU^XV_?$)_W;EQRJ9'G>M?3K^#M
MFC>9:2"1W5S&N/O"G*GMO^;Z7]$WZ%4+5]#'@6F?*4_S98_TTOT-6YEIGRE/
M\V6/]-+]#56_AQ>I?5K_ )?NPS@%]\&+XO+] 73*YFX!??!B^+R_0%TRHQ^&
M'H_U?\Y02QMEB?&\9:]I:1ZBN)9!RR. Z D+MU<1S?RS_P XJ,CF];_\?G_A
MUWP\>Z30M@<XY/F40^1H"Y;UK,^HUA?)9">9U;-^V0 NHN&_W!V#XG'^RN=N
M+]G?9]>7(.:1%5/\ZB/<0_<_([F'N2_B#U.LSQL=OP_9NW@7214W#JADB YZ
MB2660CO=SEOT-"S]:/X!ZRI:>E?IVY3-A?VADI'O. [FZLSXYW'CDK>"O6=P
M]+@9*WP5Z?=&F*<5OO>7W]!_Q!<K6?\ SM1?IV?M!=(\:=1VVW:1K[9-4-=7
MUD89' PY<!D'F([ALN;K/_G:B_3L_:"SOY>/ZM:)SUB)\1_EVHM!\6^&=>+M
M57JP0.JJ>H<99J>,9DC>>I _"!.^VXRM^*@^K-N^JYM1K8!<0P2>;EX#^4^K
MW=%I,1/E[?*X^/D4Z,G;X?BX[HJVOM%69*.HJ:*I8<$QO=&X>HX6PM,\9+];
M7L9=A'<Z8;'G 9(!ZG#8^\%;[O>F[/?&%MVMM-4DC'.]GICV.&X]Q7.W&+1U
MOTE=Z1MJF<8*MCG]@]W,Z+!QUZD'.V? K.:S7O#Q,W%Y'!CVF._;_?<Z'TIJ
M.WZGM++A:Y2Z,GE>QVSHW=[7#Q5X7/?DXUDS-3W*C:X^;RTG:N;W<S7M /R.
M*Z$6E9W#VN%R)Y&&+SY$1%+J$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1%I_P J>>:GX:1/IY9(G_5"(<S'%IQRR>"F!N!%R[Y,W$J2DN1TM?:E[Z>K
M?S44LKL\DIZQY/<[N]?M7423&@1%S!Y37$F2HN(TK8JE[(:5_-72Q.P7RCI'
MD=S>_P!?L2(V.GT6G?)5GFJ.&U2^HEDE?]491S/<7'')'XJMX^<2Y="6:GI;
M2&&]5X=V3GCF$#!U>1WG)P =NOA@M>X;3DD9&W,CVL'BXX7K'->T.8X.:>\'
M*X2M6GM;\2JF>LIH:^[N:[#ZB>8!C3X!SR&^X=%42V7B%PXK(9FP76UO>\,8
M^!W/$]Q.S3RDM<3^*>O@IZ1W,BLNBW7I^F+<_5 @%Y=$#4"%N&@^&/'&,XVS
MG&RY@\J6NJZ?B8QE/53Q,\PB/*R0M&>9_@5$1L=<HL.X.2/EX7Z:?*]SWNHF
M$N<<D^]8-QZXNLTK3RV+3TK7WZ5N)96[BD:?^,CH.[J>Y-#=2+D;@=P\O&MJ
MT7>^5M?%8(GY),SPZK<#NUIS\'Q=[AODCK:"*."&.*%@9%&T-:UHP !L $F-
M"-$10"(B I3:F!S@ULT1<=@ \94U<)\*_OOV#_6;?VE,1L=V(B* 1$0$1$!0
M2S1Q8[61C,].9P&5&N:O+'_EM)_FU7TQ*8C8Z3C>R1O-&YKF^+3D*&2>*)W+
M)+&PXSAS@%J_R9/O1VW]//\ O"M.>5S]\>V_ZIC_ 'TR:[Z'6S7![0YI#FGH
M0<@KU8;P9^]9ICXBQ9D@(B* 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0%RUQ5LNI8-15=PU! Z1DKOM=1""Z$-_!:#^#@=QW^E=
M2KQ[6O:6O:'-(P01D%1:NW)S.)'*ITS.M.1+9K?4MMA$5'>JQD0& QS^< >H
M.SA6R[7:Y7VL;-<JNHK:@^BTR.+B/4!W>P+JVLT1IFLD+Y[%;R\[DMA#"?;C
M"J[3IFR6A_/;+514TG_6,B'/_M=53HGXO,^2<UOFVR=OS_9K3@?H*KM,S[]>
MH705#XRRF@>,.:#U>X=Q(V ]JVK>K72WFU5-OKX^TIJAA8\=_J(\"#N/8JU%
M>(U&GKX.-3#C]E7Q^[D[7F@[II*L?VT3Y[<7?:JMC<M([@[\4^H^Y6*V7RZV
MIKFVRY5E(QVY;#,Y@/N!79CV-D8YDC0YCA@M<,@A8[5:%TO4RF26Q4'.=R6Q
M!N?<,*DX_@\K+Z/,6ZL-M?[\7*_/=]1W".(R5MRK'[,#G.E?^O.RIKI05%KN
M%10UK RI@>62-!!PX=1D+L>U6>W6F,QVN@I:1IZB&(,S[<#=2Y[#9ZB9\U1:
MK?+*\\SGOIF.<X^))&Z>S5GT:9C<W[L;X+?>UL_LE_>N6;*52TT%) V"DAB@
MA;\&.)@:T=^P&RFK2(U#VL-/9XZT^$1"ENM#3W*VU5%6M#J:HC='(/40N,:Z
M*."MJ(89FS11R.8R5HP'@$@.'MZKISC/J3Z@:.FC@?RUM?FGBP=PTCTW>X;>
MTA<[:,L4FH]2T-LBR!-)]L</P6#=Q^0'WX65^\Z>%ZO:,F6N*L?._GQ#>G +
M3GU,TU)=:AF*FXD%F1N(F_!^4Y/LPMHJ7301TM-%!3L#(8F!C&CHUH& %,6L
M1J-/;X^&,&.,<>X1$1L+6''+1]3J"U4UPM<1FK:'F#HF_"DC/7'B01G'K*V>
MB3&XTRSX:Y\<X[>)<54-966NM;/13S4M5&2 ^-Q8YOB%D5LUSJ!FH+=7U-QK
M*UU/*'"%\A(>.A;R],D$CWKIF[:5L5WE,MRM-%43'K(Z(<Y]KANHK1IBQV>3
MM+9:J.FE_P"L9$.?_:ZK/HF/>\:GI.:EOFY-1_ON3[K*)].UDK0X-DI'N >T
MM(!83N#T/J7&*[>>UKV.:]H<UPP01D$*U?6W8_R+;/FK/X*UJ[=G.X-N5-9B
MVM(M*_<Q9_B</[ 5T4,;&11MCC:UC&@-:UHP !T "B5GHUC41#GORC_NIMGQ
M+_C>I_DV?YZO/Q=G[2WA76FW5\C9*^@I*E[1RATT+7D#PR0O:&UV^WO<Z@H:
M6E<\8<886L)'KP%7I[[>;' M'*_J.KM\/R3JNFAK*6:FJHVRP3,+)&.Z.:1@
MA<R<1^'-PTO5RU%'%)569Q)9,T9,0_%?CICQZ']2ZA0@$$'<%3:NW1R^'3E5
MU;M,>)<76R[W&U.<ZV5]52%WPNPE<S/MP=U,JJ^[7ZIBCJ:JNN,[CB-CWNE=
MGP W_4NK*[16FJZ4RU-CH'2'<N;$&D^W&,JOM%AM-G!^I=MI*0G8NBB#7'VG
MJ53V<O+KZ/E^C-_FN0;W::RR5YHKG#V-4UC7NC)!+0X C.._!707D\?<+/\
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MY%>F_;X2XZM]QK;;-VMOJZBEEZ%\,A8?U*HN%ZN]WY8Z^XUM8,^BR69SQGU
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M):=M^E;!26>T1EE)3MP"[=SR=RYQ[R3NDZ%W1$501$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MHWC%=[=41PW\_5&B)PY^ )F#Q!&SO8?E705LKZ:Z4$%;03-FIIFA['MZ$?\
MKN5HM$NWC<S'R8^9Y^"J1$4NH1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 6@/*2_S]:/BSOVRM_K0'E)?Y^M'Q9W[95;^'G>J_5K?E^[7FC-,5NJ[
MU';Z !NW/+*[X,3.]Q_L'>5T#9.$>EK?3M;54LEPGQZ4L\CAD^IK2 !\OM6
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M;5\GC4LE32U=@JGEQIV]O39/1A.'-]@)!]Y3RE(XC;;)*<=N)9&M\>4@9_6
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MMHO57)8Z^WQV^/F='5MQVP+7$@?[/ZU'P@U/:-3Z3GK[!9F6BBBJ7PFF8QC
M7!K7%V&@#?F'R*!G2+1</E&VFJI *#3UTJ;DZ0M92,(.6@ \Q<,^)& #T63<
M.^,5HU==S9ZJCJ;/>=^6FJMQ(0,D-=MOC?! ]64U(V<BL&M]76G1ED?<[Y.8
MX0>2.-@R^5_XK1WG;V>*U72>4/1ND9/7:6N]-:'NP*T$/'MQ@#Y'%-#>:+">
M%W$*CX@T5PJJ"CGI8Z281'M7 \^1G(PLV0$1% (B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B K#J/2%CU)/#->J'SJ2%I8PF:1H:"<G9K@%?D16]*WCIM&X8]IW1E@T[
M5OJK-;FTU0]G9N?VCWGER#CTB<= LA1$UHI2M(U6-0(B(L(B("(B B(@(B("
M(B B(@(B("(B#$:_AOI2OKJBLJ[2V2IGD=+(_MY1S.)R3@.QU5_L=GH;%;F4
M-JIQ3TC"7-C#G.P2<G<DE5%;504-'-55<C8J>%A?(]W1K1U*QL<1-)DX%\I?
M^]_!1VAAK!AMOM$S^$,K1 <C(Z*QWO5ECL=6VENUR@I:AS!(&/SDM)(!V'J*
MEK:]:1NTZ7Q%:;#J.T7\S"SU\57V..T[//HYSCK["KLB:VBT;K.X$1$2(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(L;N&N=-6^MFI*
MV\4T-3"[EDC=G+3X=%=;+=Z"]4?G=JJHZFGYBSM&9QD=1^M-J5RTM/3$QM7H
MB(N(B("(B K9J&PVW4-$VCO%,*FF:\2!A>YOI $ Y:0>\JYHB+5BT:M&X8K:
M>'NE[3<(*ZWVIL-5">:.3MI'<IQCH7$=ZRI$2(TK3'3'&J1$?@(BI+I<:2U4
M,M;<9V4]+%CGD?T;DX'ZR$7F8B-RJT6,4VOM+U-1%!3WJF?-*\,8T9RYQ. .
MGBLG3>U:9*W^C.Q$1%A$1 1$0$1$!$1 1$0$7CW-8QSGN#6M&22< !8/]E72
M7U2\S^J)^%R]OV3NRS^=X>OIZTF8AGDRTQZZYB-LY10L>V1C7L<',<,AP.01
MXJ)&@B(@(B("(B B(@(B("*S7W4]FL,T45XN$-))*WF8V3/I#IG8+RQZHLM]
MGDAM%QAJY8V\[FLSD#.,[A-PI[6G5T[C?P7I$1%Q$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!<[:[J6Z&\I"UZCN0++3<X0Q\V/19]K[)W^R0QQ]171*Q[7.D+3
MK2QOME[A+XR>:.5AQ)"_\9I[C^HJ8%_BD9+&R2)[7QO <US3D.!Z$%4EPNUO
MMT])#7UM/32U<G94[)9 TROQGE;GJ?\ R\5HNGX5<2=,M-)H[6T7U-!^UQU+
MG-Y!ZFEKP/=A7/3/!*JJK[%>^(U]DOM9$0YE.'.,8(.1ESMRW_1  ]O1-"BU
MG_SJM)?$1^S4)Q7_ .<1P_\ S(_WKUF5^X?UUQXR636,573,HJ&G$+X'<W:.
M.)!D;8_Z0=_<4UGP_KK[Q0TSJ>GJZ6.DM36B2)_-SOP]SO1P,?A=Y4[&L.,L
M5YN7E 62CM0HW5D5)&^A97?R)<.=Q)'0G(./6 KUJG3?%_5%CJ;3>&Z;FHYP
M.8# <T@Y!:<;$>*SWBQPV@US#1U5+6OMM\H#S4M8P';?/*[&^,[@C<%85/P_
MXK7RG%KU%K:CCM)')(ZE:>UD;X'#&$^]WRIL2M9V2ZZ<\F&IM%^=$ZMI#&S,
M;^<<GG+2T9]0('N6QN"])3TG"_38I8(XA+1QROY&@<SW#)<?$D]Z@UYHJIOW
M#&72U#7N=.8X8VU5:XN<[D>TDO(&22&^"ONB+/+I_2%GM%3)'+-14K('OCSR
MN+1C(SOA0-.:7IX[/Y5%]I+>QL--4T9D?&P8;ET<;R<?G9/O4?&_[]7#/XU%
M_P#:&+-*;0-=%QJJM:&KIC0S4P@$ YNT![-K<],8RWQ3C%PZGUM%:ZVT5[;?
M?+7(9*:9X/*<D'!(W!!:"#OW[;J=C8ZMNI+O3V"P7"[5IQ3T<+IG>O V ]9.
M![UC7#.UZUMT=<[7=YH[F^4L[!M.S'98R#ORM&^W=W=5*XR:3O&M=*MLMFK:
M6CCEF:^I=/S>FQNX:, _A8/N"@<^\,[KKVCNMUU;9-*F[S7ASB:J6)Y:/3)<
M&8<-N8 ?U0E]OVK;)Q+M6O-2Z;?9AVL=/.8XW-9.WE+7#<GTC'D?U1X+JO3%
MFI]/:>MUHHQ]HHX&PM./A8&[CZR<D^U6GB;I./6FC*^RN>R.:4!\$KQM'(TY
M:?9W'U$J=C)H)HZB".:![7Q2-#V/:<AP(R"%IGB)H'5=-Q#^OC04U)-7NB$<
MU)4X&<-Y?1SL06@=X([CNMA\-K+=-.Z-MUHO=3!555&TPMFA+L.C!] ;@'(&
M![EBFN-'Z[FU/->M&:O%,)6-8:"L;F%@:/P?1<#OD[MSOU40*7A[Q3N%QU<-
M*:TL1L]_>PNB<S/9RX!=C!SC8$@@D'!6VUJ+0?#*^Q:W;K#7MZAN5XAC,=/'
M3MQ''D%N<\K>@<[  &YRMNI(Y1T[#K&OXT:VK-+?4PWBGJIF.-PW+(NT+1R9
M\ UHSX$>*OVN=!<5=:P4D=[%@+Z63M(987]G(PXW',!TZ''B LVXA<*Z^X:I
M&J]#W@6;4!&)N8'LYML9. <'  (((.![Z"V<.^(%YO5!6:YUF/-J*5LT<%L]
M N<.F<,:![2#MGQ4[%E\I>&62CX?PW(,DG=4EE0!NUSB(P[W9RM[S6ZCDM4E
MN?2P^8.B,)@# &<F,<N.F,+!.,&@:[6\VGGT%734XMM2Z>3MN;TP>788!W]%
M;&(R"% T!Y(]+3LM6I)1!'V[*ML8FY1S\G+\'/7&1G"B\HF".CX@\.[G3,;'
M6NK.1TK1@N#9(BT'V<SOE6;<%- 5V@:"[P7&KIJEU94"9A@YL- &,'("]XL:
M KM97G2U90U=- RTU)FE;-S9>"Z,X;@'\0]?%3ON,)\J2*.>ZZ!BG:U\4E;*
MU[7=""Z$$%;V-)3&C\T\WB\TY.S['D')R8QR\O3&.Y:$\J^E%=5Z'I'/+!/5
M31%P&XYC$,_K4ZHX;\532&S1ZZIWV7'9]H]SVS<G3!/(7=.[G3W"5Y.(CH^(
M&O[=:'%UBBJ,PX.6C$CVLP?S<[]^ O/)F=(S[(3X!S3-JFE@\7?;<?K6T^&&
M@[?H#3_U/H'NGGE=VE34O&'2OQCIW-'</;WDJR\'>']=H>HU%)<*NEJ!<ZAL
MT8@YO0 +]CD#\8)L85Y)=+1SVC4%UFY9;Y)6=G-(_=[8RT.'K&7%^?''J47E
M:4M%#8K%=(^6*]QU@CAD9L\Q\KG'UG#@PCPSZU<-2\(;U;]456H.&E^99ZFK
M)=/2S9$1).3C <""=^4M.#T/<O-.<(;W<]3TM_XF7YEXGI"'04D.3$"#D9R&
M@#._*&[]Y[D^\3>/^FZRY:+M>J:)KHK]8@RJ<Y@](,V+_P#9< [U .\5B7$/
M6KN*-MT7I:PO#:B\N9/<&LW['E)!:?4"U[_8UI[UT3>JBDI+/75%S+!0Q0/?
M/SC+>S#279]V5H'R5])PNJKQJWS=T5.^1]+;V/.2UF<N.>\_!;GU.2![Y4%$
M;=IO1=CMH9#:V3.B#7G# 6-:UG,?87;^U7<6WC*;;Y@&:6\Q,78]AR#D[/&.
M7&,8QMA;,XAZ-M^N--S6BYET8+A)#.P9=#(,X</'J01W@GVK5M-H'BW0T;;/
M0ZWH1:6#LV2N![9K.@ )C+AM_I;>*0+?9=):HT!P8UY37-T#3-%VM.VFE+^4
M.'+*>FWHX^16OA!0\2Z?0]')HPZ?;:JASY Z7':.=S$'G..HQCV +>.A]',T
M[H[Z@W"OJ+PR42=N^J.0_G^$T#N;N=LGJ?%:SAX5ZYT?653.&^JJ>GM-0\O\
MUKAGLR?:QP)Z;@ G 38:"T%KJBXLQZKU VTQ1SL?'6^9OY>T!80#RXW/,&D^
MS*E7#16N]":TO>H- LHKK0W24S34D^ \9<78W(Z%QP6NW[PLVX8Z%OM@NM=>
MM5:EJ+M=*R,1/B8X]@T Y&QZD;XP&@9.VZL5WT7Q-H+U7U>E-;0RTM7*Z7L;
MBS/99[FCD> !ZN7V(+WPHXEC659<;5<[7):;_0>E44SB2'#/*2,@$$' (/B-
MRL_N;YH[=5R4PYIVQ/=&/%P!Q^M:\X3<-ZO2ESNE]U#<Q<]0W(8FE8"&,;G)
M S@G) [AC  "V8HD:$\DJEHIK!?+H_EEO4E:8YI'[O$?*UPWZ@%Q>?61ZE!Y
M6=-1T]KT_=8.6*^1UG)#(S9[F!I<?6>5P9CPYO6KCJ+A#?+7J>JOW#*_,L\U
M62Z>DFR(LDY.,!P(SORENW<>Y1:9X0WJOU12ZAXEWYMXJJ0AT%+%DQ @Y&<@
M  '?E#1D]3W&?O%?Y2+I'\&JATXQ*Z6F+QX'F&5F_#+[W.E_]64W[IJH>+FD
MJK6NBJFRT%1!3SRRQO$DV>4!KLGH"5?=(VR2RZ6L]KG>R26BI(J=[V9Y7%C
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M_P U;3U+>VIXZ>4O#7<CP_NVV#/D5MI- <6K91ML]LUM0BT,'9QR/![9C.X
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MO'.:P9<X-'B3A!ZB @C(.0B B(@(B("(B B(=AN@(O&.:\98X.'B#E>H"(B
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MI+_/EG^+._:4KR;ONFNOQ/\ XVK+_P!OG)_^2_/_  Z#1$6KZ,1$0$1$!$1
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MBX'$>1NV)IV^4Y/L 6U4I&H/3,,X\/5;S;O_  *":1D,3Y9GM9&QI<YSC@-
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MCWJ-37PC)3)Z?:+X[[C_ 'S#LU:#\H&YU]%JNACHJZJIV&B:XMBE<P$\[]\
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MAQ6S4=@M<0GJA$=Y#AI<['0G+VM&<@;E-#>=%?[/7-E-#=K?4B$%TAAJ6/Y
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MII)9"YK@02 3WM/*00<X."/5.A?O*U_S-ICX\[]E;FJ-06:DJFTE5=K?#5G
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M(WF:,9R1G(&%5+EW5>DX]:>4I>+/45DU)2O@CDG=#\)[&PQGD'=N<=<].B1
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MY.)/UZUP[OJ>_P#>1KHM<Z>3E]VU=_JY_P"]B71:4\*>D_5X_&6-\2?N"O\
M\3D^A<CP[2LQ^,%UQQ)^X*__ !.3Z%R/%_*,]H5,GEY_K/\ VU_#_+LZ_![K
M'<1%_*&FD#?;RG"XN7;Q (((R"N0M>Z?ETUJFNM\C2(@\O@<?PHR<M/]GM!4
MY(;>M8YF*W]W>%WBX5:OEB9)':V.8]H<TBJBW!Z?A*/[$VLOR4WYU%_>6?\
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MMMY(K=IVNJ+G9**NK*44DU1&)3!S\_(#N!G WQCN5Q4MZS%HW K%KW[B;_\
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M..=]+%\*0[$AI.PSZU.ADB*DM%?#=;317&EYO-ZN!E1'SC#N5[0X9'C@JK4
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M9M_UJ]I!RAF.UY\-]^.?F]RNWDE_YLU5\>9]#EDOE.L<[A+7EH)#:B GU#G
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M17>N(B("(B B(@(B("(B B(@(B("(B B(@(B("(K%KF\5%ATI<KG1LB?44S
MYC902TGF W (/?XHK>T4K-I\0OJ+GRW\:M15-?30/HK0&2RM82(I,X)Q_P!8
MN@U$6B?##C\K'R=SC]PL(UWQ(M6D:EE'-'-5USFAYABP.1IZ%Q/3/ANLW7-7
M'#3MQI-8UET=!++0UG(YDS6DAI#0TM)[CM\BBTS$=F7J&?)@Q=6.._[-V:%U
MQ:]8T\SJ#M(:F'':T\H',T'H1C8A92M$>3UIVXPW:KO-1#+!1&G,$9>"WM7%
MS3D ]0.7KZ_:M[J:S,QW7X66^;#%\D=Q$12ZQ$1 1$0$1$!$1 1$0$1$!$1
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MY4)( K:8D_\ Q6_Q7(MGU)=K-2UE'254C:2IB?#-3OW80X$$X/0[]0K=;/\
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M*:BIV\D<;!L!_:3U).Y5=T4 BU9J3COHNQW"2C\XJ[A)&[E>ZBB#V-/AS.<
M?=E9;H?7-@UK223V"M$SHL=K"]O)+'GIEI[O6,CUIH9,BP/7?%;2VBJKS.ZU
M<LU> '.I:5G:/:#TYMP!["<KS0G%G2NM*SS*UU4L%>02VFJV=F]X'7EP2#[
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MSR%<=*<C3UJT[I7W=W3/"#0U'8K'2W*K@9)=ZJ,2F1XR86D9#6^!QU/BMC$
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M?#'2$+7'_P!JF*6HP<![A&'!I]7,[/N'@MB<=M+W/5^A'VNQQ,EK#4QR<KY
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MG.,6HK_?M>VWAYI.L=0/J(Q+6U3"6N#2"[&1N &C)QUR![8&\002<'HM3>5
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MV255&UIE;(X!C.S>7D 'KR@^'M"BUMPJN'#JPRZJTIJBY&NH"V2H;*0.U:7
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M\16.>YS6R28!.0/MRWR"#T.5R?:M)7+67&G7%MH;S-:J/SJ9]8^$GGE9VNS
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M((R"J)MGMK7\[;=1A_7F$#<_0JY$1,1/EX    , =P7J(B1$1 1$0$1$!$1
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M6ZBT7QEEU'J>QLNVEKO&&O<^$2B"3E:#@';F!9GUAQQT71?U/HS7"M\TI_/
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M;6P4P9;:)HICF "!@[(YSZ.WH[@'93L7!$15!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!:1\I?X.G_;/_P "W<M(^4O\'3_MG_X%6_T7!ZG]5O\
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MV7C'KS5E"QVD=&05$D614SO+C%S9.&MRYHSC'>3OT5WL/_-4E_U34_M/5_\
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MK>L8IB]<NMQX;:^P/!_2"3YH/[Z?8'@_I!)\T']]6W0W&5]OH8J'4E--5-B
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M)N^YJZ_&Q^PU;<6H_)N^YJZ_&Q^PU;<6E/#U/3_JU!$12[!$1 1$0$1$!$1
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M2!T0( '*!C?V+-D416(G;EIP\5,LYHCYT_Y8QQ&TY/JG3$MLI9XX)7R,>'R
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M[+57^K9_V'+ .%'_ #:*CXA7_3*MC\2*.HN&@-14=%"^>JGH)HXHF#)>XL(
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MB5PLI)=.QZ6=?[<R1SJ2HIPYS0'')W;G )WPX @D[J/0]AUW6<<;;J;6%H?
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MU9MMWU#:JFTW:@L<G^54;*Z%[>S/-CEYB "2TMSC\7*Q_@-H>Q:HU1JZNO\
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M^PGIC_K[I_OF?W%[]A/3'_7W3_?,_N*=7=?L_4?M1^G\.<'EI>XL!#<[ G.
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M##6R. '@,KK'AA][^P_%6KD^O(-=4D'(,CM_>5UAPP^]_8?BK5EC\OG/1O\
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M?K':]04)HKW04]=3$Y[.9@< ?$>!]86.6[A5HBWLG92Z<HP)V%CS)S2'E/4
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M.Q(P<'O[EERLNEM*V32M)-3:>M\5##,_M) PDESO622?=W*]("(B@$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MT+85AX'6ZFF;)>;E-6@'/91,[)I]1.22/9A;6MU#2VVCBI*"".GIHAAD<;<
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M"CNL-TJ)GTSBX1NC: [+2.OO5)K,VV\;D\/+DY5<M8[1K]&S41%=[+B!=?\
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M(?I>LXU]PVI=87:&OJ+A/3.CA$(8Q@<" YQSO^<JGAYH&GT7+7/IJZ:J\Z#
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M,VJIJEK6S1%W*3RYP0=\$9/=WK9UFXTQW+4EOHGVQM'0SR=G)+)+SN!.S3T
M SC/794]VX%0OG<^TWE\41.T51#SD?U@1]"GV/@;103MDO%UEJF Y[*"/L@?
M:XDG'LPLXBT=GD8,//PZQU^C'X?_ *MQHH6-#&-8W.&C R<GY2HEJ^@$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!AO$_6@T=
M9F2Q4[IJVI)9!EI[-I W+C_9U/RK4^B.,%QMD\D6H^TN-)*\O[08$L1)R<=
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M1 1%KSBYKBX:-%K-NIZ6;SKM.?MPXXY>7&,$?C%)G7=GFRUPTF]_$-AHM/\
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MXD@=/#'5;<6N=&\5*'5%_@M5/;JF"25KG![WM('*TGN]BV,E=:[,N'7!&/\
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MM+0"YKLC &_H_K4_B?PTM_$"2V/N%?64CJ#G[,TW+OS<O7(/3E"SQ$V-)?\
M)YM7])K_ /[UG]U;@MUN9166FMK9))(X*=M.)'_"<&M#<GU[*M1-C1T/DYV6
M!I;!J*^1M)SACV 9]S5F/#CAC1Z&N5764EVN5<ZHB[(LJG@M:,@Y& -]EL!$
MV,(XG\.J#B#3V^*XUM72"B>]['4_+DEP WR#X+"1Y.MBD<!67^_5$6<EAE8,
M_P#=*W:B;%@T;I"R:.MIHM/T3::-QYI'DESY3XN<=S] [E?T1 6(670=%:M?
MW?5D-54OK+E%V4D+N7LV#T-QMG\ =_>LO1!8=<Z:I]7Z7K;'6S304]5R<TD.
M.8<KPX8R".K56:;M,5AT_;K33R/DAHH&4['OQS.#0 "<=^RN2(,/XD\/K1K^
MV0TMV[2&:!_/#4PX$C,]1N""#X>H+*J*G;24<%.PES88VQ@GJ0!A3D0%B'$+
M0=%K?ZD^?U533_4ZH\XC['E]([;'(.VRR]$!8AJO0=%J356G[[5553%46:3M
M(HX^7E>>8.]+(SW=RR]$$,C!)&]A. X$+$^&>A:+0%EJ;;;JJIJ8IZ@U+G3\
MN02UK<# &WHA9<B#$-=Z$HM8U]BJJZJJ8'VBH-1$(>7#SEIP[(.WH#IXK+T1
M!A-[X;6:Z:ZMFK,S4USHW!SNRP&U&/@\X(Z@;9'=CP6;(B#7&O.#VF]75YN3
MA46VZDY=543@TO/BYI!!/K&#ZU8;;P!LWGL51J*]7:]MB.60U$O*SV'J<>PA
M;E1-B31TL%%2PTU'#'!3PM#(XXVAK6-'0 #H%J[6/!.U:GU577Z:\72DJJOE
MYVT[F!HY6ANVV?P0MKH@U%IW@;;K)?:"Z1:AO<\E',V9L<LC2QY:<X.W1;=1
M$!8?I?05#I[6%^U%35=3+4W=Q=+%)R\C,NYO1P,_*LP1 6(</]!T6BIKS)0U
M534&YU'G$@FY?0/I;# &WI=ZR]$&'\3=!T6O[/2VZXU=32QP3BH:ZGY<D\KF
MX.0=O26 _P#)YM7])K__ +UG]U;N1-BP6?3;;3HV/3]+7U7+'3NIV5;B#*,Y
M]+IC(SX=RIN'6BK?H33YM5KDEF8Z5TTDTV.=[C@;X &P 'N64(@H+_:J:^62
MNM=>TNI:R%T,@'4 C&1ZQU"M>@-*Q:-TW#9::MJ:RFA>YT;JC',T..>78#;.
M3[UD:(-1:FX&6F_:EN-Z?>KM2U%;)VCV0.8&CIL/1SC93M)\%+?IO45#=X+_
M 'FIDI7E[8II&ECMB,' ]:VNB;%GUA8(-3Z:K[+5RRPP5C.S?)%CF:,@[9V[
ME[I*Q0Z9TW;[-2RR304<?9,?)CF<,D[XV[U=T06?5]A@U/INOLU7+)#!61]F
M^2+',T9!VSMW)I"PP:8TW06:DEDF@HX^S9)+CF<,D[XV[U>$08WQ!TC2ZVTW
M+9J^HGIX))&2&2'',"TY'4$*\6:@9:K10V^%[GQTD$<#7.ZN#&AH)]>RK$0$
M1% (B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M%).WGBE9T</$*J0$1$!%;KS>[=9O,_JG4MI_/*AE)!S-)YY79Y6[#OP>JN*
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M5U773%D,;G#+8VANY.._V^"DZ2U_>;G#K5E[L]-;Z[3T37=BR4R![C&]V[O
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M+2M%4SF[$N<_[8SP<,;>U9%K/B1546KI].:>%D95TD39:NJO%9YO"PN&6QM
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M1^8SVFKC:R"2+.6]ED$,+23C/=\AK=):;N3;??I:W2^G;!-5TKJ>E@MS6F4
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MI"6TV:2,4WFOU3\[QVT;1@ ,ZAY  R=EMW3-)+0:<M5'4@">GI(HI #D!S6
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M.TAJ(3MSL)W&^Q!_CBGUAI[4-!KB'5^CH:2NJ'TGF-;;ZF3LA*P.YFN8_H'
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M:F$GEYF$[C!VP?[%;=0Z1O=CU':=1:&BI:N:DMS;344%5)V?;0-(+2U_0.!
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MH9V,-4)9&E\9;S./0Y., =,'*VVHD$1% (B("(B B(@(B("(B B(@(B("(B
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M"YHK%I35UBU93RS:>N4-:V(@2!N6N9GIEK@"/D5B/%S0HE@C.I*3FF.&^B_
MWQZ1QANX_"QX]$&=(L-J.)^BZ>\"URZBH16%W)@.)8#X%X'*/>59>+&HG:?U
M1H6:6YOH+9)5S>>'M2R-[!&".<#J,]R:&S$6-:4UUIK5DLL.G[O!631#F?$
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M$O*<AKMCEN<$CU!7IH#0 T  ; !8SI;7NF-55<M+8+Q3U=3&.9T0#F.QX@.
M)'K"R<[#)Z("+!YN+.AH:Z>DDU)1B:$'GP'%NW4!P'*3Z@2LQH:N"OHJ>KI)
M!+35$;98GC8.:X9!W]103T6(WOB1I&R7DVJZ7RFIZX$!T9#G<A/0.< 0WWD*
MYZGU78]+T4=5?[E!10RG$?.272?FM&2>[H.]!>T5ETWJFR:EM\E=8[G3U=-'
MM(YKL&/O]('!;[U:+=Q.T;<KRVUT6H*.6M<[D8WT@U[O!KR.4GV'=!F*+'M1
MZTT[IJJ;3WVZT]#,Z$SM;+GTF XR,#??NZJ3>-?:8LUHH+G<KQ!!1U\8EI7$
M.+I6$ @M8!S8P1W;909.BMNG[Y;-16UEPLE;#6T;R0)(CG!'4$=0?4=UYJ*_
MVK3EN=7WRNAHJ0'EYY3U/@!U)VZ!!<T6,V#7>F=06^LK;1=Z>I@HV&6HP'-=
M&P DN+2 [&QWPM4:=UI;-6<6*Z2IUC<*:E@JJ>&ST-)(Z.&K!'I![>7TLN\<
M=?!-#?J+%>(XU(ZP.&DJJDHJ@<SIZFH;SF.(-))8WH7$@#?9:]MVNKQ;?)]L
M]X$[ZS4%?(:.GEG/,3*^9[6DYZX:TX]@30V5K31UJU?24\5U;.R6F?VE/4TT
MIBE@=XM</[50Z/X>VG3-RFN;*BXW.ZRQ]D:VY5!GE:S\4$@8"P+45-JGAG26
M[4M3JROOE(*B.*ZTE6 8^1YP71?BX/3VCNR%NP$$ CH4'J+#[QQ,T=9KNZUW
M*_TD-:UW*]GI.##X.< 0T^TJ\7O4UFL=#2UMVN-/34=5(V*&=QRQ[G D>D-L
M$ G/1!>$5JTWJ&U:EH'5UBK&5E(V0Q&5@(',,9&X'B%;=5:]TQI6ICIK_>*>
MDJ)!S-B(<]^/$AH) ]909.BQZVZTT[<[7<;E;[K!44%N!=53QAQ;& WF)Z;[
M;[94%CUSIJ^U-1!:+Q2U4E/ *F;D)#8X]O2+B,#KN,Y'>@R1%B5BXCZ1OMW^
MI=JOM+45Q)#8QS-Y\=>4D .]Q*JM6:XTWI-\+-0W:"CEE&61D.>\CIGE:"<>
MOH@R-%BE/Q$TI46NX7*GO=-+0T'9^<S,#BV/M-F9P.\[;=.]6#A/Q1H-91OI
M*NKI&WHS3=G30,>.:%I]%^^1N-^ON30V4K;J2SP7^QUMJJY9XJ:KC,4KH'!K
M^4]0#@]1L?42K#/Q,T=!?#:)=04;:\/[,MR>4/Z<I?CE!SW95RU'J^P::G@A
MOUT@H9)V/DC$N1S-;UP<8[QMU/<@NMLH:>V6ZEH:*,14M-$V&)@_!:T8 ^0*
MI5'9[G1WFV4UPMDXGHZAG/%* 0'-\<'=8Y>^)6C['=C;+I?J6"M:>5\?I.Y#
MX.+00T^TA!EZ*SWK4UELMMIKC=+E3T]!4O9'%4%V6/+@2W#AM@@$YZ*W:8X@
M:6U/7R45BO-/55; 28@'-<0.I:' <P]F4&4JUZGL=)J2PUMHN)E%)5LY)#$[
ME=C(.QP?!3+_ 'JWZ?M4URO%2VEH8>422N!(;S.#1T!/4@+ ^$O%"BUI0FFK
M*JD9?BZ5WFL#'C[4T^B[?/=CO0;&HJ9E'1P4T.>SAC;&WF.3@# RIRTIPEXJ
M6&DT5:Z;5FIFF\R23<YJGOD>!VKN7G=@\NV,9(VPMN72\6ZU6E]SN-;!3V]C
M0\U#WCDP>F#WYVQCJ@KT6.:3UOIS5CYF:?NL%9+".9\8#F/ \>5P!QZ^BI.+
M=?56SAOJ"MM]1)3U<-,71RQG#F'(W!09<BY]O,=ZTYH.+55+Q)KIJZ.GBJ?,
MJQ[)(Y7.#28^7KWD?^LK:-;Q$L%DLUHJM3W"&VU5?31U'FS@Y[V\S03Z+03@
M'(R?!-#,45DDU98H],G4)N=.ZRAH<:MA+F %P;W;YR<8[E14FO\ 2M717.LI
MKY224ELY?.Y@3R1\V0WTL8.2"!C*#*$6.Z2UKI[5O;C3UTBK'08,C US'-!Z
M'#@#CUJW2\4-%Q7DVJ345$*P/[,C)Y [I@OQR_K09FBL>I=66+3)IOJ]<H*$
M5/.83+G#^4 NW ]8]N=E)TGK73NK>V&GKK!6OAWD8T%KVCQY7 ''KQA!D2+$
M]1\1=)Z<N8M]YO=-35IQF+#GEF>G-R@\OOPK!Q-U;35_"#45XTG=G.-/RQ-J
MZ5[F%KQ*P.Y7;'H>H\4T-EHJ6U/=):Z-[W%SW0L)).23RC=:UT)J^./6>O*3
M4-]@BBIKBV.DBK*EK QF#D,#B-NG1!M1%JW5&K65'%#05#8;Y#/1U,E4*R&D
MJ6O:_$8+.<-)[\XSZUE6I^(&E]+UK*.^WFGI:IX#A%ASW 'H7!H/*/;A-#*$
M5N??+6RR?5A]PIA:NS[7SHR#L^3QYNBQJU\5-%72IAIJ&_T\M1-,VGCCY'M<
M][CAH +>A/?T09LBUC3ZADH.,&K6W2XS1V6AM$-28WO<8HNG,\-[CCP"AX=<
M6K5J>]W.V55=1MJ3<)8+9'%&\&HIVC+7G.1D@'PZ=$T-H(M+Z%XFV>RRZJIM
M8:B+*D:BK(J:.H<^5S(!R!H  /*P'FQT'5;AH:RGKZ.&KH9XZBFF:'QRQN#F
MO:>\$()Z+6W$&_WRNU=;]%:/J64-?44YK*VX.8'^:TX/+Z+3U<3M[QTSD6B_
M:8UCHVUSWZPZQN5Y?1,,]3073$D<\;=W!IZM. 2,?*FAN!%C5GUK9[C:=/5K
MZ@4[KXT>:1/!)<_&7,R!C(W'N5UJ[U;Z2\4%JJ:EL=PK@]U-"0<R!@R[!QC8
M>*"'4EEI=0V*MM-P,@I:N,QR=F[E=CU'=55OI(Z"@IJ.#F[*GB;$SF.3RM&!
MGY%CFI.(>E--W%M!>KU3TU80"8L.>6 ].;E!Y??A7&\ZIL=FL<=XN5SIH;9(
M&F.HYN9LG,,CEQGFR-]LH+TBPJ?B;I5VEJJ^4=YIY*2)W8AY8_:8M):QS<<P
MSCP5HX=\1Z+6VCI>UNE/1Z@;12S53:>)V*4 EHD =D' +3C)30V8BQ+2]XH;
M7P]H;E==2,N-''#S/NT[>R$PYC@X._J ZG'>5.TIKW3.JZB6GL%X@JZB,<SH
M@',?CQ#7 $CUA!DZ+#;UQ.T=9:RHI+G?:>"JIY.REB+'N<UV,] #MZ^BO?UR
MV?ZW'7YMP@?9VQ]J:IAYF!HV)VWZ]W5!=T6&VWB?HRY7>.V46H*.6LD(:QGI
M!KR>@#B.4GU9RKSJC4]ETM1-J]07&"B@<>5AD))>?!K1DGW!!>46,Z:UYIG4
MU8VDL5W@K*DPF?LV!P<& \I)R-MR-CONK7I*]45GTK=[G=]5F[T5/72B2ME@
M+/-_2#>RP!D\I(W]?@@SI%CEJUOIJ[17.6WWFDFAMH#JN4.Q'$#G!+CL1Z)Z
M'N4G3/$'2VIZ]]%8[S3U56P%W98<QS@.I:' <P]F4&4HB* 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 6O>
M/=%75_#&Z16Z*68M=%)/#%\.2%KP7@>X9]@*V$BD: XC:BTEJG25EL^ANPJ+
M\^I@-LAI82V2DY7 ESMO0  (/R]V5E,-%3U7E&U3JN"*=\&GF/C+V!W([ML<
MPST."1GUE;+IK;0TM1)/2T5-#/)\.2.)K7.]I R5.%/"*@U AC$Y;R&3E',6
M]<9ZX]2;&L]'T\5!QSUI3T<;8*>:AI:A\<8Y6F3IS8\=S\I51Y1%*ZHX37HQ
M1=H^/L9#AN2&B5I<?8!NMB-IX6SOG;%&)W@-=(&CF<!T!/53'-#FEK@'-(P0
M1D$)L:5XS7RRZ@X,UDUAK*:LIF55-'(8#L'<[3@^O!"N7'2WT=NT[IJJH*2"
MFGHKS2-IWQ1AAC;DY:,=!L-O4MFQVJWQ4IIHZ"D93%W,8FPM#"?'&,94^HIX
M:E@940QRM#@X"1H< 1T._>FQH360J+7QMNE;<=4-TRRJHHA;ZV:B941O8T8D
MC#G[,(=D^O/LS3_4ZAIN#G$6MM6H'7NFK).9\@H?-8Q*"WG+ -B#ENX&/170
M%;14M?#V5=305,6<\DT8>,^."O324QI?-33P^;8Y>RY!R8\,=,)L:;U'14UP
MU3P:IJZ".HIW03.='(T.:2VG8X9!\" ?<M@ZRNFF+/-8HM20TY?/6-CH ^F[
M3DF[G-V/+C(WVZK)#2TY?"\P1%\(Q$XL&8]L>CX;>"]GIH*@Q&HABE,3P^,O
M8'<CAT(ST/K012AQB>(SAY:>4^M:V\G L^Q+:HP,2Q2SLF!ZA_;/)SZ\$+9B
MP;0^F+EI?5NI60F%VFKC**^G;S>G#4.VD8&X^"< Y]GKP%HX-?='Q'_U])]"
M]X&$/.N9H?YI)J2K,..A'HY(6:ZDIZ^'3UV.F*>E;>)HG&$OQ&UTI&.9Q W(
MZ[]3C)'54G#G3#-(:/M]G#Q+-$TOGE_ZR5QYGN^4[>H!!KSB;=++9^-FDJS4
MAA90,H)@))H^=D;RXAKCL<;]_=E>6BMH-2\;!<M#ECZ2FM<D-QKH6<L,LCC]
MK;G&'.!P<^ ]2S"^Z7J[CQ3LMZ=!!+::>WSTTXD(.7..PY3U"S*CHZ:AA$-%
M3PT\(.0R)@8WY @T+PWU'H_3G#^X6/5XIZ6_Q23MN5-5P%\M3(7N+2-CSY!:
M!_Z)M5-_S9]+?ZUC_P#M3UT7/;:&>K953T5-)4L^!,^)I>WV.(R%$*"C%,VG
M%)3^;L/,V+LQR@YSD#&.J;&M*^CIJORCJ/SJGBF['3IEC[1@=R/[<CF&>AP3
MOZU'8*>*@\H'4,-'&V"&JLT-3,R,<K7R"3EYB!WXS\JV9YO#YSYQV,?;\O)V
MG*.;ESG&>N/4@IX14&H$48G+>0R<HYBWPSUPFQK?RA/N'I/]:TG[:Q'B&RHM
MW&L7"OU&-.4\]N9'07":B9419!]./+]F.SDY\#Z]][5%/#4L#*B*.5@(<&O:
M'#(Z'=0UE'35T)AK:>&HA)SR2L#V_(4V-,Z#TA:M1V'7-/3:E-]@N[FQS3-H
M/-HF5#6DB1F/1=N6DEHZM]:I>$\MVUKJV@J=1P/C;HZE-"YK]^TK22QS_60Q
MH]AP>];SIX(J:%L-/$R*)@PUC&AK0/4 D4,4)D,4;&&1W.\M:!S.\3XE-CF2
MS#ZE5>L*#4&N(=.5DM?.^KI:NUQ3^=1N.6O:]^[VD=&CIX;K(KA;8+5H?A32
MT=PFN-(-0TSX*B: PN+'&1P!83D8S@>I;RK+;0ULL<M914U1)'\!\L37EOL)
M&RG34\,_9]M#')V;@]G.T'E<.A&>A]:;"K_FLWYCOH*YM;$R;R:=)Q2M#XWW
M9C7-/0@U,@(72Y&1@]%3"@HQ3,IQ24_F[#S-B[,<K3G.0,8!RD2-9<:*"DH&
M:&JZ&FAIZBGU#201/B8&ED;N;F8,?@G V]2VJ]K7M+7M#FGJ",A2YZ>&H#!/
M%'*&.#V\[0[E<.A&>A]:FH-.\";K:J WK3]94P07X7FK+:1_HRENQR!WC /R
M*/@#9K;6\/[HVKH::7SNX54<Y?&"9&\V ">\86UA04@K36"E@\[(Y3/V8Y\>
M'-C.%,IZ>&FC+*:&.%A)=RQM#1D]3@(.8>RK:_R=-'3NFE;045T+ZV1L/;]E
M V60!YC.SVM)'HG;HLLTU!07KB/IVJ;Q$COMRHV2/BCI;4R,=ERX<Q\D>S1C
MH'=#T&ZWC!2P4]/V$$$44&_VMC UN_78;*70VZBH.?S&CIJ;G.7=C$UG,?7@
M;IL8KQG^]7J?XD]:JU#JC1%SX+4MBM;:>JO,M+%!2T%/3D3LJL-'-C&QYLDG
MOWZY6Y>)%HJK]H6]VNW-:ZKJZ9T40<[E!<?$]RJ-,6*FMUJMAFHJ5ERAI(H9
M9FQMY^9K TCFQD]$@:UN-K\XXK\.*2_PQ5=3!9Y3,)0'@S-8,NWZGFR5;.)L
M4UNXR4%PJ[\-.T,EL[&AN$E$RHB9('DOC]/9CB#GF\-N];T=3PNG9.Z*,S,!
M#9"T<S0>H!ZA>5E)3UL!AK*>&HA/5DK ]I]Q38T':[(ZOTEQ(J=*ZGDU!7U\
M+8YC!0"FC?(T9/)R^BYSFES3R]2=^JO=BUOPU9HNQT$D%--+%V,;;8*,RSLG
M! /H8R7!V27=_KSON*FIX:6%L-+#'#"WX+(VAK1[ %)9;*!E::QE%2MJSUG$
M30\_UL938T-J3M[7QIU#57'5;=,&LIH#05=10QSLFA# 'L:Y^S"'#<=_R*EJ
M+"'<&=42Z:O%1J"BJ;DVIJ1#1&E#VL<TS"-HV(( /H[>B5T+74%)7QB.NI8*
MF,'(;-&'@'QP5.BC9#&V.)C61M&&M:, #P 38YXXNZOT+>M 6RCTY-1258J*
M=U-!%!ROIV!PY@=O0VVQW^M9[</^<3:O_P#7I/WQ6?-LUL8Z5S;;1-,IS(1
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M $&F* <2F3<E1":&A@LD;9J>0'8>AZ3,=Y.W?NNE8HV0QLCB8UD; &M:T8
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MP.D,,4<9D=SO+&@<SO$^)38T#8J"R5'"K6UIO]>ZUV:GU'4003,:7"GQ(PL
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MM<#/-C Q[-UDRT7;K_4:7M'&"\43&OJJ:[/,0<,@.=RM!([P"[/N5BH:_6=
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MYLJHVCHTS,+G ?(%4Z\NU7I;B!IB[S5LS-/5W/;*R)TA[&.0Y=%)CH#D$$^
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MW'!D9@DL+<YQX=_C=:6T7;6'$W6]#/JR^VVUVZ6G$5/05'9GF?%G9Q!P!@[
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M<;I(+S,^2H9)C 8X$=D,#X(YG8]JJ=$Z(M>D](G3U*'5-&\R&8S@$S<_7FP
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MI*ZD?R30./7!\#@9'J64(@UYI_ADVVZLH=1W#45WN]SI8Y(@ZK>TL+7-+<
M>B!DG;J2O+KPOBEOE=<K#J&\V W!W/6P4$H;',[O> 1Z+CXA;$1-C$=&:8MO
M#K3-P@BK9Y*%LLM=+-4D%S!RCFR0!D -ZK%^ 5@ABM]WU7YFVDEU#5OJ((0/
MY*FYR6-]^2[V86TYHHYHGQ3,;)&\8<QXR"/ A>Q1LBC;'$QK(V@-:UHP !W
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MI9RB;&+ZXT70ZLBHGSS3T5QH91-25]*0V:%P.^"1T/>"LDIV/C@C9+(99&M
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ME:^0!_*TGN!.!E2J^FU;Q!OE@@N^FSIZS6JNCN,\DU4R9\TD>>5C.7NW._\
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M?V9<,M<UPV<T@'!]7L)P[RA[UJ"V6&".T6^44+IH'/N,5:(G-D[3 BY/A$'
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MU/G$\TH&0 ,,C&/P6C./:LB12*:EH:6EGJ9Z:GBBFJGB2=[&@.E<  "X]YP
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2 B(@(B("(B B(@(B("(B#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g829170g70a03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g829170g70a03.jpg
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M'CRP.HR[NIK(VG5^*79.[-7-7+BW0C17.XRUEEK_ '/$KBY\#XM=@)WZN1!
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M6'09:*>%KKW75-9/EX382(HQS;B3TYCH71N.A3"U1 6TO?M'+EL>R;7&?.'
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MAK]X[<^E4QB3#EUPW6BEO-&^FD<"6$D%KQRM(V%;15&\)R :F'Z@#;G,PG^
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MP7I1>82/(4:=/N12\D$1%Z2!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M0AE+5R'PFNXF//&#Q'_^%\*:+4D6*UNH7,.. 1%"])V.Z;!EK&J&SW2H!%/
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MIR?34CQ_F\CWCXO(./HWQO0O@H8IOQJJ^/6M5"0Z4'=*_P#59T<9YMG&M1M
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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$(#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g829170g70a04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g829170g70a04.jpg
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M @(#      $" P01!3$2(1,R-$%1<8&Q(F&1T? 4,Z'!%>%2\2-R)$)B_]H
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M$]D@N=N?G'(,GL/OHWC>UW2/_P!4T9<1:+#4(W:P^4E^<CL(B+,Z(1$0!$1
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M)5]-C4_4QX.[?R[R\T1%L%R"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M!I DFB:&MK:=E0<MVMM:?5S[5I]9XX2X'XS6D\IHR/XW+"IL<K6(IVS?@T5
MQSF/:]A(<TY@CD*VY:*KNVU455_UX62_M-!]JQ"MG8').#+"3O[@@^[:L*7>
M:&A/XIKR(II\N+J#1[411NR=63QT^8YLRX^AF7:LN+1G"5:XX1MI'O17#/\
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M_:?_ 'J(_B!BOZ N'^T4_$#%?T!</]HK/,C?_47WC+Z$N]W/$WYI:O\ :?\
MWJ+XYQY<L90TK+K344;J9SC&^!CFNV[P<W'9L'F7Q_$#%?T!</\ :*?B!BOZ
M N'^T5XW)F%2I>5(N$^)I_(BZU)H#KW5NCNFC>=8TDTD&9YL]8>AX5!_B!BO
MZ N'^T5>^@6S7&RX4K:>[4DU),^M<]L<K<B6ZC!GEV'S+*FFF;>D4ZE.XYQ:
M33[BR41%,6@(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B \5YM-
M#>J"2BNE+'4TS]['CT@[P>D;506/=#-=;3+688+Z^C]\:9W^<P='SQZ>@K12
M+%Q3W-2ZLJ5RL37/Q[S#4L;X9'1RL<R1AR<UPR(/,0OPM@8OP)8L5,)N5(&U
M663:J'O)1V\O4<U2&+M#-]M)?-:"VZT@VY1C5E:.EG+V$]2B<&BMW.E5J/./
MQ+Y?8JY%]*B"6FF?#41/BF8<G,D:6N:>8@KYK YA>W!DKN\OM X[C%.T?M-=
M_*KR6(K9<JVUU(J+;5STDXV:\,A8<N;8I]9=,V*;>&MJI*:XQC9_B(LG9?6;
MEZ<U+&:2PSOV&JTZ-)4JB?+O-/HJ5MNGNC< +G9*B(\KJ>5LF?8[5^U2&DTT
M82G XV6MI_&TY.7[)*SXT=:&HVT]IKV]RE-,DW'Z2KX[//*1C/V8VCV*%KNX
MYN,%VQ?>*^D?QE-/4O?&_(C6;GL.1VC8N$H'N4^XEQ5927>W[EG\':'C<?O?
ME_E4<CO.6CVK3*REH@Q9;L'WNMK[I'42,DIC"QL#0XDES3RD<RGEUT]L +;3
M9'$\CZF;+^%H]JDA))<SO:;>4+>WQ4EAY9>*X.)\7V/#4)==[A%%)EF(6G6D
M=U-&WMW+-]_TJXKO#7,-P[BA=_RZ-O%_Q;7>E0B61\LCI)7N>]QS<YQS)/24
M=3P%?7(KE1CZLM3'6F6YW=LE)8&/MM$=AES_ "[QUCWO9MZ55+B7.+G$DDYD
MGE7\4APE@^]8JJ1'::1SH@<GU#^]B9UN]@S/0H\N1Q*E6M=S^+,F<!C'2/:Q
MC2Y[CD&@9DGF5]:)-%)I'PWK%$(X]N3Z>B</>'D<_IYF\G+MV"6Z/-&-JPF&
M54^5==LO]0]O>QG]!O)U[^K<I^I8PQS9W;#2>C:J5]_ (B*0[H1$0!$1 %Q\
M:?$^^^03_=N787'QI\3[[Y!/]VY#"KU)>1B]69P>O"$WR67V*LU9G!Z\(3?)
M9?8M:.Y2K'M$/-&G$1%LEX"(B *&Z8_!K??%L^\:IDH;IC\&M]\6S[QJ\>Q!
M=?L3\G[&25<O!F^';UY,SUE32N7@S?#MZ\F9ZR@AN5+3.U0_.XT&H9IE\&E\
M\6S[QJF:AFF7P:7SQ;/O&J=[,MMU^Q/R?L9*5\<&'_3XC^M3_9(J'5\<&'_3
MXC^M3_9(H*?6*KI/:H^OLR\%7.G_ ,'-3X^+UE8RKG3_ .#FI\?%ZRFELRSW
MO9Y^3,NK1O!J^)]R\O/W;%G):-X-7Q/N7EY^[8HJ>Y6]'[2O)EMHB*<MP6>>
M$O\ &2T^2'URM#+//"7^,EI\D/KE83ZIS-7[++T]RG5LW WQ+L/D$'W;5C);
M-P-\2[#Y!!]VU84CFZ%^Y/R([IPM3KIH\KS$W6DI'-JFCH:<G?PEQ65%N6>*
M.>&2&9@?%(TL>T[G C(A9!TB86GPEB6HH9&N-*XF2FD/RXR=G:-QZ0O:B[S+
M6[=\2K+;9D^X.N*8J&X55@K) QE8X2TQ<<AQ@&1;UD 9?5Z5H-89C>^*1LD3
MG,>TAS7-.1!&X@J\,":;&Q4\='BV*1[F#5%;"W,D?IMY^D>9(3QR9[I>I0A#
MH:KQC9E[(HE3Z2,(SQ![+[2-'-)FP^8@%</$6F/#-LA?W!+)<ZG+O60M+6Y]
M+G#=U9J3B1VI7="*XG-?4_>GZ:./1U5,?(UKY9HFL:3D7$.!.7/L!*RZI#C7
M%MSQ=<^Z[G( QF8A@9L9$WF Y^<[RH\H)/+*GJ%U&YK<<=MC1/!H^*]U\L_D
M:K;J865%/+#(,V2,+'#H(R*J3@T?%>Z^6?R-5OJ:'5+-IW98>1B*[T,MLNM9
M0U REIIG0NZVDCV*8Z%<11X>QM ZJ>&4E8PTLKB=C<R"UQ_6 ["5*^$)A!]-
M<6XDHHR::HRCJM4>\D&QKCT$9#K'2J84+^%E7J0G97'+N?+R-T(J T9Z8!;Z
M6&UXJXR2",!D5:T:SFMY \;R!SC;T'>KFM^*;#<8A)17B@E:1GD)V@CK!.8[
M5,I)EKM[VC<1S%\_#O.RAV#,J/7?&N&[1$Y]=>:)I'R&2B1Y_5;F52.DG2[4
M7V"6VX?9+1VYX+9)G;)9AS;/>M])Z-R.21C<W]&WCEO+\$:,@FCJ(62P2,EB
M>,VO8X.:X<X(WK]K+NBK21483J6T-P+Y[+([OF;W0$_*;T<X]N_3E#5P5U'#
M54<K9J>9@?'(TYAS3N*1EQ'ME>PNX9CR:W1]D1%D;@1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 9BX0E/Q.D)[P/\ /I8I/M;_ "JM
M%;?"49EC"W/ ]]0M'FD>JD6O+=E)OUBYFOF?>BI*BNJHZ:CADGJ)#DR.-I<Y
MQZ -Z5=)44<IBK*>:"4;V2L+3YBI%HM?Q>D*P'GJFM\^SVK7-724U9$8ZNGA
MGC/R96!P\Q7L8<2-BQTY7=-R4L-,PZBUY<-'.$JXDS6*D83RP@Q>H0N#5:%L
M)3$\7'70>+J,_6!7O1LDEHE=;-/\\C,*+HXBHH[;B"YT,!<8J:IDA87G,EK7
M$#/IV+G*,Y$EPO#"*RM"6$+5BRON<=YCED931L<QK)"S:20<\NI7?;]&N$:$
M@Q6.FD(Y9RZ7T.)"SC!M9.C:Z75N8*I%I)F3:2DJ*R814D$L\IW,B87$]@4X
MP_HEQ5=RUTM&VWP'_F5;M0_LC-WG 6HJ*BI:&+BZ*F@IX_FPQA@\P7W6:IKO
M.G2T.FN=26?+D57A70K8[8637B62ZU VZKAJ1 _5&T]IRZ%9]+3PTD#(*6&.
M&%@R;'&T-:T<P 7U19I);'7HV]*@L4XX"(B])@B(@"(B (B( N/C3XGWWR"?
M[MR["^%?215U#4TE2"Z"HC=%( <B6N!!V]10QFN*+2,/*S.#UX0F^2R^Q6S[
MCF#_ ,RJ/WE_]5U<,:/,/X:N8N%IIYHZD,,>LZ9SAD=^PJ%4VF5VVTFO2JQG
M)K"?YW$N1$4Q9 B(@"ANF/P:WWQ;/O&J9+PWVTTE\M-1;;@QSZ6H ;(UKBTD
M @[QTA>/8BK0=2G*"W::,2JY>#-\.WKR9GK*P/<<P?\ F51^\O\ ZKNX2P/9
M,*5-1/9H)8I)V!CR^5S\P#GRJ.,&GDX5GI5:A6C4DUA?G@290S3+X-+YXMGW
MC5,UX+[::2^6FHMMQ8Y]+. 'M:XM) (.\=("D?-'=K0=2G*"W::,3*^.##_I
M\1_6I_LD4M]QS!_YE4?O+_ZJ1X1P?:,)MJFV6&2(5):9->0OSU<\M^[>5'&#
M3R<2QTNM;UXU)M86?;R) JYT_P#@YJ?'Q>LK&7+Q+8:#$=J?;KK&^2E<YKRU
MKRTY@YC:%(UE8.U<TW5I2A'=HQ6M&\&KXGW+R\_=L78]QS!_YE4?O+_ZJ4X3
MPQ;,*T,M)9HGQ02R<:X/>7DNR WGH 4<(-/)Q]/TVM;5E4FU@[2(BE.\%GGA
M+_&2T^2'URM#*,8LP+8\55<%3>8)9986<6PLE<S(9Y\G6L9+*P:=_;RN*+IP
MW,?+9N!OB78?((/NVJ+^XY@_\RJ/WE_]5.[=1PV^@IJ.F!;!3QMBC!.9#6C(
M;>H+&$7'<T],L*MK*3J8Y^!Z%',=81H,86=U%7#4E9FZ"H:,W1.YQS@\HY?,
M5(T4F,G5G"-2+C)93,<8QP?=L)UQ@NE.>*)RBJ&#..0=!Y^@[5'EN*LI*>MI
MGT]9!%40/&3HY6!S7=8*KR]:&<+7"1TE,RJM[SMRIY,V^9P/HR4+I^!7KC1)
MIYHO*\&9@1:"]P2VZ^?X;K-7FXIN?G7>LFAK"UND;)4QU-P>-N53)WO[+0/3
MFO.C9JQT>YD\-)>IFR&UULUMJ+A%32FAIRULD^63&DG(#/E.W<O$M-:=VT]N
MT9NI*6**"%U1%%''&T-:,B79 #ZJS*O)1P\&O>VJM:BIYSR-$\&CXKW7RS^1
MJM]5+P:XBW!]QE.Y]<0.QC/ZJVE-#8M.G=FAY'PKJ2GKZ.:DK(F34TS2R2-X
MS#@>19JTE:*Z_#DTM;9V25MG)+LVC6D@',X#>/TAVY+3B)**D>W=E3NHXEOW
M,PNBUOB/1MAB_2/EJK<V"H=M,U*>*<3SD#83UA0ZIT#6AS\Z:[U\;>9[&//G
M "B=-E?J:-<1?PX9GE?T D@ $D[@%HFCT$62-P-7=+A,!R,#&9^@J;X;P%AS
M#KVR6VV1=T-W3S?E) ><$[NS)%39[2T6O)_'A+ZE,:,]$E9=IX;AB2)]);6D
M.;3N[V2?K&]K?2>3G6BX(HX(8X8&-CBC:&L8T9!H&X +]HI8Q42PVEG3M8\,
M-^]A$19&T$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M&=>$J[_Y9;&\U"#_ /T?_15"K2X1DW&8[AC'_*HHV^=SS[55JUY;LI.H/-S/
MS)/HQ!=I P^!^>1GTK8*R/H@BX[218FCDF+_ -ECC[%KA24]CMZ&O_#)_/\
MH(B*0[9C7'K=7'&(1S7"?[QRX*DVDN/B\?X@;SUDCO.XGVJ,K5>Y0:RQ4DOF
MRZ.#*?\ C-\'+W/'ZQ6@%G?@T298HNL?SJ/6\SV_U6B%/3ZI:](?_P 5>ON$
M1%F=,(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M_F5GX;QQA[$6JVV7.%T[O^1(>+D_9._LS6:DF=.C?4*_*$N?T)(B(LC;"(B
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MUAJN+>3J6,%JO05X,K5]:;[UZPA)M\SEZ9?UKBJX5'RQ]B>HB*4[P1$0!$1
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M"627FI:3&T[1"W=KN'V#E/4LPUU945]7+55LTD]3*[6?)(<W.*CE/')'(O\
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
>1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g829170g90e80.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g829170g90e80.jpg
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M*"@H*"@H*"@H*"C_P  1" SD"?8# 2(  A$! Q$!_\0 '0 !  $% 0$!
M          <#! 4&" (!"?_$ &00  $# P(#! 4$# D)!08 #P$  @,$!1$&
M(0<2,1-!46$((G&!D10RH;$5%R,V0E)5<G-TLM$6,S4W4Y.BL\$D-&)U@I+"
MX? X0U24XAAC@X2TP]+Q)41DHR8G5M-E=M25Q/_$ !L! 0$  P$! 0
M       ! @,$!08'_\0 .A$!  $$  0#!0<$ @,  P$!  $" P01!1(A,1-!
M4112<9&Q%2)A@:'!\#(S--$UX2-"\21#@B4&_]H # ,!  (1 Q$ /P#JE$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MVE_M?N3[8^D?R[2_VOW)S1ZGM%KWX^<-M1:E]L?2/Y=I?[7[D^V/I'\NTO\
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MGAT^A]GXWN?5#OVA[7^6*W^K:GVA[7^6*W^K:IB1/#I]#[/QO<^J'?M#VO\
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MGAT^A]GXWN?5#OVA[7^6*W^K:GVA[7^6*W^K:IB1/#I]#[/QO<^J'?M#VO\
M+%;_ %;4^T/:_P L5O\ 5M4Q(GAT^A]GXWN?5#OVA[7^6*W^K:GVA[7^6*W^
MK:IB1/#I]#[/QO<^J'?M#VO\L5O]6U/M#VO\L5O]6U3$B>'3Z'V?C>Y]4._:
M'M?Y8K?ZMJ?:'M?Y8K?ZMJF)$\.GT/L_&]SZH=^T/:_RQ6_U;4^T/:_RQ6_U
M;5,2)X=/H?9^-[GU0[]H>U_EBM_JVI]H>U_EBM_JVJ8D3PZ?0^S\;W/JAW[0
M]K_+%;_5M3[0]K_+%;_5M4Q(GAT^A]GXWN?5#OVA[7^6*W^K:GVA[7^6*W^K
M:IB1/#I]#[/QO<^J'?M#VO\ +%;_ %;4^T/:_P L5O\ 5M4Q(GAT^A]GXWN?
M5#OVA[7^6*W^K:GVA[7^6*W^K:IB1/#I]#[/QO<^J'?M#VO\L5O]6U/M#VO\
ML5O]6U3$B>'3Z'V?C>Y]4._:'M?Y8K?ZMJ?:'M?Y8K?ZMJF)$\.GT/L_&]SZ
MH=^T/:_RQ6_U;4^T/:_RQ6_U;5,2)X=/H?9^-[GU0[]H>U_EBM_JVI]H>U_E
MBM_JVJ8D3PZ?0^S\;W/JAW[0]K_+%;_5M3[0]K_+%;_5M4Q(GAT^A]GXWN?5
M#OVA[7^6*W^K:GVA[7^6*W^K:IB1/#I]#[/QO<^J'?M#VO\ +%;_ %;4^T/:
M_P L5O\ 5M4Q(GAT^A]GXWN?5#OVA[7^6*W^K:GVA[7^6*W^K:IB1/#I]#[/
MQO<^J'?M#VO\L5O]6U/M#VO\L5O]6U3$B>'3Z'V?C>Y]4._:'M?Y8K?ZMJ?:
M'M?Y8K?ZMJF)$\.GT/L_&]SZH=^T/:_RQ6_U;4^T/:_RQ6_U;5,2)X=/H?9^
M-[GU0[]H>U_EBM_JVI]H>U_EBM_JVJ8D3PZ?0^S\;W/JAW[0]K_+%;_5M3[0
M]K_+%;_5M4Q(GAT^A]GXWN?5#OVA[7^6*W^K:GVA[7^6*W^K:IB1/#I]#[/Q
MO<^J'?M#VO\ +%;_ %;4^T/:_P L5O\ 5M4Q(GAT^A]GXWN?5#OVA[7^6*W^
MK:GVA[7^6*W^K:IB1/#I]#[/QO<^J'?M#VO\L5O]6U/M#VO\L5O]6U3$B>'3
MZ'V?C>Y]4._:'M?Y8K?ZMJ?:'M?Y8K?ZMJF)$\.GT/L_&]SZH=^T/:_RQ6_U
M;4^T/:_RQ6_U;5,2)X=/H?9^-[GU0[]H>U_EBM_JVI]H>U_EBM_JVJ8D3PZ?
M0^S\;W/JAW[0]K_+%;_5M3[0]K_+%;_5M4Q(GAT^A]GXWN?5#OVA[7^6*W^K
M:GVA[7^6*W^K:IB1/#I]#[/QO<^J'?M#VO\ +%;_ %;4^T/:_P L5O\ 5M4Q
M(GAT^A]GXWN?5#OVA[7^6*W^K:GVA[7^6*W^K:IB1/#I]#[/QO<^J'?M#VO\
ML5O]6U/M#VO\L5O]6U3$B>'3Z'V?C>Y]4._:'M?Y8K?ZMJ?:'M?Y8K?ZMJF)
M$\.GT/L_&]SZH=^T/:_RQ6_U;4^T/:_RQ6_U;5,2)X=/H?9^-[GU0[]H>U_E
MBM_JVI]H>U_EBM_JVJ8D3PZ?0^S\;W/JAW[0]K_+%;_5M3[0]K_+%;_5M4Q(
MGAT^A]GXWN?5#OVA[7^6*W^K:GVA[7^6*W^K:IB1/#I]#[/QO<^J'?M#VO\
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M<0<$[Y<-MD&VHH7A](_1;Y&M?3WB-IZN=3L('P>2I.TGJJRZLMWR[3]?%60
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MHQE6ENI\#)"KUTXBC(!W64,5A=:K.6@[+!.))5Q42%[SDJW4'E5((S+(  O
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M$1%$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M [E[@)8X$Y7@'*^GF09 3M<-L KP2TYWW5E@C)7J)Q+@-T5>AID='%$W+WG
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M(H02T]3X!8T-=/*&,&>[92]H6Q"@HVRRM^ZNWW"RB-L9G3/VFA90T;(HVX
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M45.EWIHOS0JBT2Z($1% 1$0$1$!$1 1$0%S5Z8&GO6L>HHF=0ZAG<![7Q_\
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M_P#!ZI_K)?WI_!?BM_X/5/\ 62_O7;Z(;?G-?Z:YTEWJ8+ZRI9<F$"9M229
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MG<H'!8*\MB51L(\$#PO0E17IL(7L1!>.V7SM3W(*HC"]!@5OVA7WM'(+D (
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MPST8;IV^'ZCHA!GYPIWEV/S<X^E=2(AM&_"_A!8=!R_+(G27"[EO+\KG:!R
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MOW]B]Y!C<,;G'3=9(';<XSC.5YDR"<AHZC.-_P#KZEZY0UI)!Z;$A>A@Q[@
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M%7<3@,X.3G'7_KJO;B#N-W?'Z3_UW*V$A<6@'KM@#J/^OBKAGJ'E]7K[<_\
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M&WP"LS%$=98Q$U=E,3"F>&8)W!QU/=MGQPKF.J]79LCNX^J=_8HON]_=+/\
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M'#2? (/J*.>".O:_7]DN5;<J6EII*6K-.UM/S8(Y0<G).^ZD9 1$0$1$!$1
M1$0$4;:JU_7V?B]IW24%+2OHKE )9)G\W:-)=(-L''X ZCO*DE 1$0$1$!$1
M 1$0$4<<(=?5^MJ[4\%PI:6G;:JH01&#FR\$O&79)W]4=%(Z B*.':^KQQL;
MHOY+2_(#2]OV_K=KGD+L=<8SY()'1$0$1$!$1 1%I'&/6%9H?1<EYM]/3U$[
M9XX@R?/+AQ.>A![D&[HK#3U:^Y6&VU\K6LDJJ:*=S6] 7-!('ENK] 1%''%7
M7U?H_46CK?0TM+/%>JIT$SIN;+ 'Q-RW!&_W0]<] @D=$5M<ZEU';JNJC@DJ
M'P1/D;#'\Z0M!/*/,XP@N46B\(=;UNNK#55]PLTEKDAJ#"UI)+9  #D$@';.
M#[/<-5UUQ-U+_#R?2/#VR4]RN-)$):J2H/JMV!P/6: !S-&2>IQA!,B+7+3?
M*NDT3%>=:PP6JIC@,U9'&2]L(SY9/3&1OCS64L-XH+_::>YVBH%30U )BE#2
MT. )!V(!Z@H+]$1 1%B]57&2SZ8O%S@8Q\M%1S5+&OSRN<QA< <=VR#*(M*X
M/ZNJ];Z)I[U<*>"GGDEDC+(,\H#78'4DK=4!%A-+ZJLNJ8ZI]AKFUC:63LIB
MUCF\CO#U@/H6;0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!<C^D)I2>NXD7
MFOI]S((<@;G:%@_P77"AWB';6U&JJZ7<./)N/S&JQ&V-4Z<@5E#/1R%L\9;C
MOPK9="WK3%/5M<)X0X_C-V/O4?WKA](UKI*'#AX ]/<DTS!%42CI%?5]JJJ)
MY$T1 '>K%11$1 1$0?02%[8_ .ZI^]$%8 D' ROA:?@J;'.:=B54#L#=4?0S
M+L [KTXMC!'5_P!2IF3\08/BO+1GJ@]$D[DJGWJHXX"IJ B(@($0;%!>P'E<
M';[#9>YCSM . 1U'>2J+),C/>!LOF#U)W5#/4]Z$]Z\Y3.0@'<(#MU0=Z #J
M@^9SG*^X*^=<KT#L@^8*9(V7O'J]<DI@C)P@\ +Z,)U\D QE QX%?,$+TT#/
M5#C*#X"5Z8,G=&@E5XF9.!U05:2!TLK8XVESG' PI=T1IYMNIFS2M!G>!G;H
ML7H/3;6-;653/6V+0>Y2-3Q;  ;+932UU5*E/%E92GB[@J5+%C&RRM/$ ,E9
ML(C;U!&&#)7BHFQD!?9Y0T8"L7NRAM]+LKXT9.R\C=7M)!G<A$A4I(<;E96E
MFY#CH%:L&%["C-GZ:I:6[E6=?5=J[E9T"U2]WB6EQ' #YE?;3>63@-D.'*&V
M>ROH=RG*HB1KAD%6]74!HP#N@^W*L+FEH*L:. R/YG= O$;'3R+(.+8(L#P0
M>*J9L,> L*.:JF+C\T+U52NJ9N1I]57D$0C9L%)(ZO0 B8>Y8>MK ]Y8T[*I
M=ZSE:8V'<K! G.25CMFO9(FR-.0%A+E; YI(;]"S,#\A7)B$C%1&5?0.B<=M
MEC'-QL5)%RMP>UV M/N-N,;B0-E$83&/8O0\E[<PM)!7CH41[8\CV*O'(0>N
MRM?8C7$'?HL9AE$LI%)GO5RQ^W58J*3E/797<4H/>HR9!K\ J'KN\/NE6X=#
M*['Q*E6:81TTSST:PGZ%$,KN>5[CWDE6!X1$5!?0O*]!6![YMNIRJY>'.8X=
MXP?)6JK4K'3.[,#)SME;*9ZZ8S"Y:,NP=SXYPO?+@8.2/'"^-&7!S0? GH54
M;E[-P<-[O+_KX+HAJ>6L!R-CGSZ?]?2O33R8W WROC@6Y !&"?\ K_KJO)'X
M(.ZO85XY00<D<QZ#P5<D$C)SGSS]'_65C@>4@@>:N:=X+2'M)P-O^O\ KR64
M5),+D@!XVP0.N?A_U[BO#@P$Y[O#_K9>6.,A(:<G/>%]'K,>YV01OG/399(!
MK@X8SGP/FJS7/8 \@<O0]X5-DT&.S!>]^?P1GZE<LCJ WLVQM:W\9[\_0,^2
M1^"3^+[S/#.<-<X=^!^]5\R&%KF-Y3GHX]1WKU2T<VPGJWM VY86@'O[]_-7
M\-I@ER',,A9LWM'9'_7[ULBF98[B%@)F!C@9V,>,8Y=_<JKG]HS,4=0]X&W*
MSE]V2LK3T+H,-9"R-O@W 580N#VN.!D=<^__ )_%;(HGS8\T,0*>MG#0VF#7
M>,K_ / *Z%LJ70@25+&GP8S/TE9-IG8TD _B@#?'_65]/:.'K @#??;O6440
MQYI8Z"VO+'&HE?.T[>L>7X8]BN8;?2P OBA@!&V2.8_2KCUC(3&QI)ZGS]ZO
M:6@=,T%X:.\N/16*83<J,4;G%O9X#<;AHPLM0V^IGC :<,W',6G+CY#O_P":
MS=BT])40B9K&]EC:6489T[F_O5_=KS9],4Y<QYGK''#7'?+O!O39:;F531TH
MZRW6\>JKK5TACKE)2:7L;KA<P'2MWBI^;#Y']P)RH&OMTK;_ '62KK7.+Y#Z
MK0/5:.X!9W5%WK=5W(SUCG!L;^5D>PY03]:HP4D+6ASP6Y!WR=CG]X7F7+E5
MRK=4NJ(BF-4PP4-"Z5C08^5Q. [Q_P"O\52J:9M._E=@[9Z]5M5#&Z:JCI8(
MGRSSO#61-;N7'(V\-UM=]X37R.S1U;XX))7$ \LF"SK\[. !TWRE%J:DFN(1
M<9HZ9N8'-DST5];JZHKJN.GABYWO)QMG"P\U+)%*8W-/,'<NWBIPX5Z+CH98
MYZM@?4. ))[O)<]VN;4?BZL>SXU6O)M7#;1--04INEZ9#]S;SESV[-[ULC=5
MZ1NT[J"IH&=F-FR.:&Y/B"-PLY=;5]D[6V@:XLCQS/ .,^ 43:GTN^VSNQD
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M.'S1#Z4>N8HO5C=0&0M'0N+J<Y^+C\59\ *RELW$O7=GO;V0WRIK"Z(RG!F
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M=4WUM-0L9VSINSSR,9&XC.Y)Z!1_!Q7U[JZHJ9^'>D(9[1"\L%16G>3'GSM
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MURXA3W:^VX"<4M0P.F,()R-Y"0WUCW=ZQG#>LI;%Z1&MZ6_O9!7U\CS123'
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MN6A=8VNTT-HAN4573"7D!<)7/+GM#6X\VCN/58"NXI\2-,QQW;5^BZ:*PO>
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M5EK8-@L_3# *PEN'19^ ?<UMI:Y6=>_#'+6WN#I79\5G[F<,<M;P<DJU)"L
M"G*J8RO0<5K9NH=%?>A9/U.']@+,K#:*WTA9/U*']@+,K!M@1$0$1$!$1 1$
M0$1$!:IKOA_I[7%.R._47/-&,15,1Y)8QX!W>/(Y'DMK1!!D'HUZ9;4!TUWO
M,M,#D0E\8]Q/+]6%*5IT;9+-IBIL-GHVT5!41/BD[+Y[N9I:7%QR2[!ZG*V%
M$&J:-T+;=)Z2J-/6^>KDHYC(7/F<TR#G&#@AH'T*KP]T9;]"V!UHM4U3-3&9
MT_-4N:YV7  C8 8V'<MF1!$>HN VF[G=YKC;*RXV6:<DRQT,@;&[/7 (VSX
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M%;->T%'27>>KACI9NW8:9S6DNP1OS-.VZSE^LEOO]FJ+5=Z9E50SMY7QO[_
M@]00=P1T611!"E/Z.6EHZX/EN-XFH6OYQ1NF:&GR)#<X]F#YK?>'&@;7H&AK
M:2S35<L55-VSOE#FN+3C&!AHVV6W(@BS5_!#3E_O4MWI*BOL]?,XNE?0O#6R
M./5Q:1L3WX(RLMP[X5:>T/4R5MO;45=SD:6NK*MX>\ ]0W  &?9GS6^H@(1E
MI![]D1!"\GHYZ3^2%D%==XJKM#(*H3-YP"!ZN.7&._IG?JMAX><'M-Z*N'V1
MIOE-?=,$-J:QP<8\]>4   GQW/FI'1!KVM]'6;6EH^Q]^INVB:>:.1AY9(G?
MC-=W?4>\*-:#T<M+PS$UEQN]; T$1PR2M:UN>_9N^/<IK1!ING.'-DLFAZG2
MC355=IJ"\RB>3#W<V,CF8&XZ!:.[T=]/E_9-O=^;;2[F-'V[>3V?-_PRIJ1!
MAZ73%FIM+MT['00_880F#Y,X9:6GKGO)).<]<[]5%D_HZZ=,\@I;Q>Z6@D=S
M.I(YFEOLR6_7DJ:T08/1VE;1I"S-MEAI13TP/.XD\SI''8N<3U.P4?:GX!Z7
MO%VEN-#/7V>:5Q=(RC>T1DGJ0T@\N? ''DI=1!%FFN!VE].WZU7>W37(5= 2
MX%\K7"9QSZSQR^!QM@;*4T1!J5\T';;SKBT:IJ9ZMM?;&=G#'&YHC<,N/K M
M)_"/0A9S4EG@O]AN%IK'R,IZV%T$CHB X-<,'&01GW+(H@PFB=-4FD--4=CM
MLD\M+2\_(^<@O/,\N.2 !U<>Y8UF@[:SB))K(3U?V3?!V!BYF]ER\H;G'+G.
M!XK;40:/Q&X7Z>UYV<MUBE@KXF\K*RF<&R!OXIR"'#VC;NPM>TCP(TQ8+M%<
MZN:MN]5"X.B^6N:6,(Z'E &2/,D>2EE$&.U#9+?J&T5%LO-*RJHIQA\;_H(/
M4$=Q"B./T<-+LJ\FZ7EU#S<WR4RL#3Y$AN<?3YJ;40:;PZX=VC0/V3%DDJW1
MU\C9'LG>'!G+S8#< ''K=^5A-<<%].ZHO+[O'-6VFZ2',D]"\-$A_&((._F,
M9[\J3401YP_X1Z=T9<3<J;Y57W4@@5=8\/<S(P>4  #(VSN?-98Z"MAXBC6?
M;U?V3$/8=ES-[+EY>7..7.<>:VU$!:9Q%X;6#7L$0O,,D=7".6*KIW!LK!UY
M<D$$>1!\L+<T00I2^CGI9L$[:ZXW>LE>T,CE?*T&$9!RT<N,]V^1OT4@5FA;
M;5</&Z-DGJQ;&P,I^U:YO:\K' @YY<9]4=RVM$&+TO9*?3FGZ"ST3Y9*:CB$
M4;I2"X@>. !GW+"TF@;93<1*O63)ZPW.IA[%\1<WL@.5K=ARYSA@[UMR(-$X
MC\+-.Z\?'47..:FN$;>5M72N#9"WN#L@AP]HR.XK4(?1RTJ:65E;<+Q55,F,
M5#IFAS #T Y<;^>?<IJ1!;6JBCMMLHZ&!SG14L+(6%_4M:T 9\]E@M?Z(L^N
M;5'07UDQ9$_M(I(9"Q\;L8R.X[>(*V9$$/VC@%IVEN=-572Y7:\14Q!BIJR4
M&,8[B ,D>6P\5N>M=!6S5UUL%?<9ZN*6RS&>G; YH:YQ<QV'9:<C[F.F.];:
MB#S*P21/8[.' M.%J6@- 6S1&GJVSVJ>LFIJJ5TSW5#FEX+F-8<8:!C#1W+;
MT0:MPYT1;M!62:UVB>JF@EG-075+FN=S%K1CU0!CU0J=DT%;+/KJ[ZKIIZMU
MPN<?9S1O<TQM&6GU0&Y_ '4GO6VH@HUM+!6T<]+5Q-EIYV.CDC<,A[2,$'V@
MJ*]/\"[%8-3TUVMMUO$4=-.*B*D$S>0.\">7)&-O''>I:1!H7$3A5I_7-3%6
M5XJ*.YQ@-;64C@UY Z!V00<?'S6)TAP1TY8+S%=JRHK[S<(7!\3ZZ0.:QPZ.
M#0-R.[).%*:(-<UUHNRZVM(H+]3&1C#S12L/+)"[Q:[_  W![PHWH/1RTQ#(
M[Y=<KQ6PAKFQ122M:V/(Z[-W(Z^'B"IK1!KV@M)4.BM.Q6:URU$M-&]\@=4.
M!?EQR=P /H6PHB")-3\!].7N_P!3=(*VY6QU6\OJ8:21H9(2<DC(.,G?O'DM
MSU?H2R:NL$%JOT,E2R!H$507XG80,<P?XG&_<?!;0B"%K7Z.NEZ:NBFK[A=K
MC3Q'+*::5K68\#R@''L(4RTM/#24T5/2Q,A@B:&1QL;RM:T#  '<%41!3JJ>
M&JII:>IB9-!*TLDC>WF:YI&""#U"AJX^CKI>>X23T-PNUOIY3E]-#*TLQX N
M:3CVY4TH@CW0_"/3NB]2/O-D?7,F=3_)NQDE#X\'ER[YN<DMSUQN=NBRM+H.
MVTW$2LUDR>K-SJ8! ^(N;V0:&M;D#ESG#!W^*VU$&"UOIBCUAIJKLEREGBI:
MDL+WP$!XY7!PP2".H'<KS3=G@L%AM]IHWR/IZ*%L$;I2"XM:,#. !GW+(H@(
MB("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(
MB("(B B(@(B("(B B(@*)-=M_P#VIKC^9^PU2VHKUM@ZGK0?]#]AJSM]VNYV
M:L6^LOC6M#^8M!=C&5>/A'4*B6'/1;6I\$H&2-E<02[;=#NK0MZH'%H\D&48
MYK^N%[%.''("QC)3XJ[AJ".J"_A[2,<IPYO@5A;[HFPW]KOE=&V.8_\ >1[%
M9N"=KNJNV!I"3&UA VJ.#MPH^>:T2"JA&X82 X*,[C:ZJWSNBK('PO:<$."[
M+9S-Z'(\%9W>S6V\TYBN%)%)D=7-!(6N:/1G%4N,BT(&$E3SJG@U32<TMFG=
M&>HC=C"BZ\Z-O-F<XU=)(8Q^&P9"PF)AG%4-:$6!XKR_ 8<*I(7-/+C!\U0/
M>2HR>$7KE.,CHO*((B(/46SE4."TDG=4@<+[G(5'SNPG1?5\45Z:O;6DM*\-
M7O/@J@!A?=QT7PG?=?01X( [TP/%"1GJAY>Y &,>: +ZT H?) QA-^Y,E>V[
MH# 3W+*62V27&LCBC:2,[E6M%3NJ96Q1 N<3MA3'HVP,MM(USV_=G8).%E3&
MV-4Z9/3MHBMU&R.-N'8W*V2FB5*FASA96FA\EM[-7=4IHL]RO2X1L7D8B9OU
M5I-(7DHO8EDYB50)RF55IX2]WDC%ZI82\Y(V67@C#&]%YIX@QJN HR[&,C!Z
M+U T->"1L$:W/5>NBBPS5-5L< WHJTT39(R5@&.(.RO&5;FL(<=E-,HEC+EZ
MCW#S6*>>JO:^;M)7$*A!"9';]%6+Y2P\QYG+U65 BC("K32-AC("Q#B:F8_B
M@H?@\01NFD[1X5_M%&2>Y?8V!C5A[S7X!C8=UC,LJ84[C7<[RUIV6*?*23NJ
M1>3G)7DNZK#;)[SXIE4\E?-T5[+E2<_JAP!N52?(T9WR@]<Y[E<4U20=U8&<
M=V%X[<GHFTTVB&02-PJ-93,D:5A(*U[3@E92FJA(W<K*)&M7:V8+B&K6JB Q
MD@A2=- V9I&%K5VM>SL!5AIH\KBT[+U$_*N:RD=$\Y"MV,P<C9184+X.:T5.
M<_-S]*T ]5(M>!)05#,XS&1]"CMPW*>3*'E$18J+XB]1QND<&QM+G'H ,E6.
MH\KW%&^1X:QI<XG8 =5L-ITM4U/KU(+&C\!N[O?X+::2U04$( =' \[%SG@$
MKIMXM576>C35>B.D-2H[#53Q S<E.UN^2=\+-4%FH8<R<CI"T_.<.;_DLC*^
MCB]1];3 9R07 Y5%EUM3-G5QR#ORM)773;MT=VGFJJ7G*P0\[6>J-AOGZ/BO
MC7/,)(D!D/<!@CX^:LW7NW;F)M3,_.Q;$O0N-3+DTUHG<QNV9'<JRF_;I[U$
M6JY[0NHW,?$>;M#*<\V-O/S\U6I::40XC9L3[#A6$9O9SRT%-"T_A/?GE/\
MU]:N8Z>[S1CY5<H*:+;F$3-\]P]JU3F68\VR,:[/DRS80(@!ZISN<?NQWKR^
M*G8P![^7E/4D >U8TVB)V!4WJMF:\Y^YNY?<!WJI#;+% _[JR>H#^Z63/P_>
MM4\1MQVALC!KGO*M/=[73CD=4,YATR"Y6\=[CJ"UM+254[R<#DC(S[\*Y%UL
M5$UWR:FHHNC0<#)QW9\/'Q5.363&1.,1)Y=@7-(#OCMCR6N>(7*OZ*6<85NG
M^NI5IHK[4<A911TT3B2'32;AOB<'*O:>PU,PYKM=^3#ASQ4S<;>TYW./<M:K
M-:32%PC=EQ.S\Y]^ L74ZCK)Y >=Y[L \OO\=UIJR+]7]56FVFU9I_IC:0&V
M[3U#B26/M9A(2'3R<X/E[!].53J-6PPCLK>QHB ]4<H:,Y[P%'L<LLKB7.=N
M<$C]ZR-+"72M#O85S55T1WF:I=---<]HB&Q_9JX5_,V>7U2" (\MV\^\]RR%
MHMK'\KB-FC(;Y_\ 6?H7BS6][WCE8<@#&&K>;;;P&-=ZKB!OD]#C'=[@L8NU
M51JGI'X,_"ICK/65_9J1K8FM#2, 9\-O)9^CC#7<@W& ,XQ]/AC_ *[E;V5K
M#$6NPW'3N..BS<>.0X=DG\4D_P"*SICHE56NBWD<(V9 +<;#OVRL!J6^06ZV
MSU51)RQQ_B]2?#SW5_<9@Z4L]9KAU:=]E!G$:\5%RK>R^4TL-/$>1L?:\[R<
M_.+6Y718L\]77LU7+L44[\VJ7^Y56J;X><GLVDX8/P&YZ#SZ>]=5<-[ S2.C
M:6*5@94/;VLXQOS'HWW# ]Q*B#@=HAE7=V7*JE9-2T\C9<@$%T@.6M(/<-S\
M%/\ ?XI3#&\?Q+?G8Z@]Q7H7*XF(MQ^?^GF]9F:I8*L;\M[4U#6R&0;@]'#P
M6MZ:O\ND]6_8>X/>ZT7!P-,]V_8O)QU_%).#X;'HMI &".G><?6M<UI88KY:
M9&O>&3Q9,#\@>M@Y'L(Z_P#)94ZF)HJ[-77?-'=)EZIVU%  X#+7AP]O3_%1
M_ SY/?G1' (.=O!9?A=<ZRY:'8RZY-723.I'N.>9W(1@N\\$*QOT(CU9$<EH
M?"#[=R%X'$:)HCKY/?X77O<>J*#JFZ?*IC42%S"XXV[LE9[3^JG-G:7/WRJ]
M3IN"I@D<YIBE:,X:/G>[N6L76P5%$T3L#@T+RZK<QUB7T-%=NO[LQI*>LJ87
MK3YN--ATD3.64?Z/C\5@9B6</JS'3FC'TJKPVO#G/%+4@/CD'(YKNAR%D;];
MVTNG=2T0)+8&"5F?Q00[/P6ZQ//<IN><=)<>7$VL>Y8_./@BV.5JN(WM*Q,;
MM]BKECR!YKUGS#*1N:56;RE8R-Y"N&O38OVL"]MC"LF28[U69*?%7:+GLU\,
M?DJ8F..J]=M["KLT^AJ]!I 7@3>2J-F:>J&GS=,E>^=IZH.4]Z)IY#BON5ZP
MT]Z^<H\4'PX7G9?7,7G&Z#[R[+R6K[OA>"XJ@0O)7WG\5\Y@@\DKR2O9(*\$
M(CSE?%]PO)"*^%>2OIRO!*J/#E1<JSBJ+T10>J+ 3(JSEY@_C%%VS-N;@!9M
MOJQ+%V]NP65?M&MM+"6%NK_4<L(W?JLI=G;$>*QK6J24O0 7SE7W"^K%DZ>T
M5]Z%D_4H?V LRL-HK[T+)^IP_L!9E:VV!$1 1$0$1$!$1 1$0#L,GHM4T-K^
MP:W?<&Z?J9)C0O#9>>,LR#GE<,]0>4_!;6H\X17;25TEU -'68VQU/4AE83"
MUG:O];!&''88.VV,]$$AHH@N'I!:2H9*^&2GNCJNEG-/V#86\TI!():>;& 1
MWD'<;+,</N,.FM:W'[&TIJ:"YD$LIJQH:9,=>4@D$^6Q02.2 ,D@!.O1<[>D
MOQ#MDMINNC8X*YMTAF@>Z8L:(2-G[.YL]#X=5M7!KBK9;_!8]+TE+<F7"GH&
M1ODEC:(B8XP'8(<3W;;()?11OKKC%IS25V-I<VLN=U;\^FH8P\QGKAQ) SY#
M)5]P[XHZ?US--2VYU12W*$<SZ.K8&28'4C!(('D<CO"#>D6H<0N(E@T'2Q27
MR=YGFR8:6!H?+(!U.,@ >9("T6C](S24L$[JNCNU)+&WF9')"TF7?HTAV,]^
M^!YH)I1:I/KJV0\/1K%T-7]C# VH[,-;VO*YP VSC._BM0@X^:2JJ^UT=%%<
MZFHKG1LY60MQ"7D !Y+N[(SRY02TBT3B+Q3T[H-\=/=)9JBX2-YFTE*T.DY>
MXNR0&CVG/@M2@](S2+J*66II+O3U$9 %,Z%I<\'O:>;&WF1[T$T("",@@CR4
M4\6^)UGL>EQ25--<'RWRUR/IG11M(8'L('/EPQ\X=,J/?1^XJV:QZ>M>EZVE
MN4EPJ:XQLECC:8@9'@-R2X'OWV0TZ81:9Q#XD:?T''"+S-+)63CFBI*9H?*\
M9QG!( &>\D9[LK!Z-XUZ;U)>H[1+#7VFX3$-ACKXPP2D] ""=SW XSW902>J
M=1*V"GEF>"6QM+SCK@#*Q6K=3VG25FDN=]JVTU*P\HVRY[CT:T#<G910/2(T
MI7MGI9J.[4<,S'1LJ9H6EF2"-^5Q(]P*"1^'.N+;KVRSW.SPU<,$,YIW-J6M
M:[F#6NR,..V'!;2H/]$3^;JY?ZT?_=1*<$!%%&K^.^E=/7>6VPLK;K50N+)3
M1,:YC'#J.8N&2/+(\U[L''/2M]O%IME!'<C67"3L@U\+6]B[/1YYOV<H)41:
M/KWB;8M#W:WT%]%6PUC#(V:*,.8QH."7;Y^ *TV#TCM)OKFQ2T-XAI'.Y15/
MA:6^W <3CV GR034BQ<E]H/X-RWVFF%5;F4SJL20$.YV-:7'E\\#XJ*ZCTC-
M(MHX9::DN]1429S3MA:', .,N/-C?KL3[D$T(M'X<\4-.Z\,L5IEE@KHF\SZ
M2I:&R<OXPP2'#V';O5+6G%73VCM2P66^FKBEEIOE/;MC#HVM]? ._-DEA  !
MW(0;ZBT?A_Q-LFMZ>[5-NCJZ2EMH:Z::M:V-I:X./,"''8!ISG"U"Z^D5I*D
MKY(*.ENMPAC.'5$$30SVCF<"1[0$$SHM>T1K*RZUM1K[!5=M&P\LL;ARR1.\
M'-[O;T/<5KW$3BYIO0]8VAKGU%9<B XTM(T.<P'IS$D 9\.OD@D)%"[/2,TA
M\@,TU+=XJAKPPTI@;SX(/K9YL8VQUSN-E*]\O=OL5GFNEWJF4M#"WG?))W>
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M.[8J1T!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M@D]!S;CZ5C-JG6V45RN19*C?FFA ]_[E\MUE=<)9HH*NG[2(9=SY ^*Q>O\
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MA[<CKDL:WW^:G'45FMM;I>LMU504TE"*=S1 8QR- :<8'=CNQT6O<6>'-'Q
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MFGIV/C%0")8&N:#R@\CB ,X&'?!%>^%M/!8?2,U?9;!AMG=3&1\+/F1O'9G
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MZFT=<K?4TD,-FJC/.V8N#G@OB=AN =\,/7'4+=M46&AU-8:VSW6,R4=4SD>
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M-@IHT)H"FMC6U%4T2S['+AT5B-I,Z87AUH0Q\E;<X_7V+6$=%*D<#8V!K&@
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MY<#<OCSM@>(S]*W]_*US98\.AF SCIOT*UTS-JO<>3&JF)C4M"X0_>94=_\
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M?)7* B*V%?1FO-"*NG^6AG:&G[0=IR_C<N<X\T%RB(@(B("(B B(@(B("(B
MB(@(B(-$XTZ-KM<Z,-GM<]-!4&HCFYZ@N#,-SGYH)SOX+;K%2/M]DM]',YKI
M*>GCA<6]"6M ./+97J("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B HNUGDZFK1W>I^PU2BHNUI]\M:/S/V&K.WW87.S#A.@1J^DX"W-+YE!OE?
M%]"#[A>2WP7U.Y!3];.R] YZKWW+R1GH@\EGXI7S)Z%?>4C<+[L1AW0HCQD%
M.7O7UD36LY6[ +[NU!3<S(QDA?1D=%4!!ZKR0 BOK)2"KF&H5GA.G1!F8I@X
M+V6M=TZK#&=T3"[&<=RK4=0[/._(+N[P45DPZ2/H=O->96T]7&8ZJ($'Q"^1
MSM=UPO1#7-)14<ZSX64E?&^IM6(Y=SRYV*AJ]Z<KK/.Z*K@<W!QGN*ZKB+VM
MR,@*PO5KIKM3F*IA:[SPM<T^C*)TY%J8\.PT*S+3DJ>KQPJCGD<ZE>6YZ# 6
MO2<(J[F);+M[%AJ67-")@"O36J6X.#U6XCM:@@>06QV?A#10$.JY'R^1 3ED
MYT)6VU55PD#*.)TA/P"D/2_#"HG+9;F<,Z\@*FBTZ<H+9'R4L#&X_P!$+*")
MK1@#"SBCU3FEK5CT[36^-L=/$&M'>MB9$&-P J@ :%Y<]9Q&F+R0%Y) ".=L
MK2HESL%0GFR2 K9VXZH3WKX/6.R,7IH+CA9&CI\;E>*.G[R%DV-P%%B'U@P-
ME6AC=([#!NJ866MCXHVX..8J+'5BZB%[#AP5F\>*VN>)DS3T6&K:(MR0$B5T
MP%1$'@Y&RU^Y4+"20%LM4"TD+&S1\X*K"6L,>^F=ZI6QV2J=4D-/<K.>WF0^
MJ-UEK)0?(XR]_4I$$,LYXC8L3/(:B;E;T7NMJ"YW(SJ55HX.1F3U*=E[O448
M8Q65QJQ"T@'UBKBOJ6P1$D[K5IYW3R%SC[EA5+.F%5SRYQ).Y0=51:5[:5@S
M5F@*HW&%2:%5!P$'I O',@.4%3*\$INO)!0>@Y?<JEE?.;""MG94GNZKYSCQ
M5)[T1]+SNO!=E>2Y><E17HKP<+YDE?.5 )"B/B#J5UVK?L?0O/R.(^L1^&X=
M_L6R<1M3"W4KK=129K)1B0@[QM/^)460_<6%[AD]?;NK,ZA:8W+W*6PQM;&?
M6< ?9U5H=A@+ZXG<GJ5X5B.6"9YI%\1%$$1?%!]"]-7@+T%&4*K5]'1>&%>A
MT6+9$JC3A>HSNJ>=EZ8<'HL=,XE=#YN>BIO/5?6G /BO#P5C#.>RFXYVSLO=
M/&7.. D+.9RR5/3X:?+=*JM)33OJ^Q4WJY\ED:"+ +CU"]4[ Z,$?-[W'8 K
MY55+(1EH#G#Q&!\%A$3+;,Q2NZNL$+/5/+C&YW"U^LN'-+]R ?+GYSAL/8/W
MY7R05%<3(XAD(_#<<#W>*KTT$4);V3.T<?PWCZ0%NIIBESU534LX:>6=W:5#
MW8=WGJ5L%KAC@<TMC;[';E4A (PZ1SBYW>X]RL:F^1TS2RD:)),_./0?O6,U
M3,ZI9TTTTQNM($]=2.H872TL,$D..::,\H>WNR/'S52;6C9&1MIJDEK6AI83
M@''?\,*.J)XN,D(K:@N>\Y#<Y&-]L?X+<9-,T?R)M931B(8/.T_3[/\ KW9>
M'/>J2+VYU1#*Q71]PB,;G-#P,M>UN[2K-D]4)NQKF\KLX#@/5=[%YL5#-%;>
MT&1GN=N#[._Z56@@D9.YTG+DD8/+E:YC79NC<]V9MU"\-$D9+7'KX+-1ES&X
MF;RDG',>BKV(DP 2<IP ,X62EC+6?Q?4] U;+<PQJIE>Z2O,MNK(VE^8I#C'
M=U_Q_P"N]9;6- *B!MRHAECQS#&QQW@^S?Z5I=4QP!Y6EG?X+;]"70UE,ZWU
MY <[OVPUWX)]_0^>/QEW43TVY*Z==6)TIR?+F.C?B0GE:UQV(QO]&5)NGZQK
MGRVRH.Y:7PY;C+>\>>YS[SX+0*2UFVZC=%R9C>.=O<0,]/K^A:^WB1'7ZI-/
M0Q%D%#F2*8$DRN:=P[P8=_\ H[)IFY,Z2K41N4T5E2&1PT\CONCINS]N&N=G
MX-1C\]^ZU6.]1WW5%)+2$&GIZ<S../PG# R>AV)^!6Q-D]BY;DZG39:I^ZQ^
MI.5D(E=CU<Y6-LE5$]V-B#WJKKJ1S=/54C/G-83[=E'EEU-!#%'F1N<>*\R_
M<Y*XF'L8MGQ+4I7N--VL8P#RG;9:YKV=UMT!?7NR2:*5K<==V$+S0ZUI7LY'
MR1GR)7S452+[9JF(M^X20O:/,$$96ZB]15.X[M%=BY1'+5'1QW01B2-W-OA6
MDPP\CS61H&=E/-"\'+"6^\*QK&XE.V%ZLQ_XXT\2/ZENB%%SLWICBT@@[A9F
MQ5G9R%KN_"PBJTK^29I\UMM5S35#&JG<)2IYF31#)('=ME?<$M.VP^E8>SS.
M,+02.F=BLL*C<>J"0<X/0KV*:MPX)C4K*J9CF\ L6^-Q&X66J) XG(#<G8!6
M<NV1W>)6NJ&<2LFQEK0<X7G. 1C_ !59[G;AH!*L*N9[CR@C.,;+7/1E'5Y$
MWW;+>[O5*61Q+G..?#VI"UK<Y/D2O%3\T@?-6MG$+2>0@D Y5JYR]2;;8PJ+
MBM-53;3#(6B$/F#G9Z]RVV"E<Y@Y1L M2M]2*<9QGR61=>IWM:QIPT=P*W6J
MJ:8ZM-<3,MECHCLYY:&^:^BEC;\X/?D]PV6&MM;),[!?AWCE9J:L;2-$DU;R
MLQ\UYZ^P=ZZ::HF-M4Q/96:QPVC:WDZ<H(5K4.DB=ED8Y<[;;A8^IU"Z?F^Q
M],UY.W.X\H5F67&X,+9ZB6%W3D PT^758S<B?Z>K**9CN^W*NAB+FE@=-W +
M6JV1[Y#SX [@.@5[6TKJ5Q#PX/[\G.5CG$O?@E<=ZJ9C4M]N(CK#[$W;NWV6
M7I)W,8&AW*01C_KW+&1-)) S\5E*6'LVB21QP/%+4:*YVR+.>9F'AS6GO!ZJ
MA//3T;22.9YZ;+&5=VD=ED(#6#8$=ZQSG/E.^2LJ\B.U/=C3:]60FN\TFP(
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M@UE_VK-(?J/_  U""X](;B4^R6BCBT=J.DCNL=:8JJ*GDCED8T-=D.:<\N'
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M<'O6*LTR?'>J\=1YK$,D&%<1R#Q5&:CJ,JNV7*P\4H5S',$&48[(51I6/CJ
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M:J3AI65KG0M. TXZ+?Z(-D:.8#Q \O\ HJ*]*5 +1@YWQG/DI*M\N"R0MZ@
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M2IWZCX KJ("-A<[JJ,+<NR3@)._F=@= LH^[&TGJ\/<7NRKF"%KH_6.'=RM
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MW:]<9-'VXZAOGV'N=LBP^IHH6@/A9WDEK1T\078ZG9$3ZBT6Z<3+/1<,H]:
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M%!K=D@I8+I1-:V@A?%RB&1W:8:_O."UHW\%&E1'Q$^WI2MDEM?\ ##Y*>S<
M.P[/LW==NO+E%TZ5XD72]V;1]?7:7MWV2NL7+V5/R.?D%P!/*W=V!DX"N=#7
M"ZW32=LK=0T/V/NLT7-/38+>0Y.-CN,C!P=QG"TG45]UCI;@W=+O?I:'^$E,
MX%KX6!T7*96M&VW<2LA;M?-MW!VAU?J)PDE=2,E>V(!O:R..&M:.[)Q[.J(D
M)%S[:[[QGU?0B^V.&UVVV2CGIJ65K.:9G=@O!._B2T'J-ENG!WB34ZMJ+C8]
M1T(M^IK9_'PM!#9&@\I< 22""0",GJ".NP2<BYVFXB\1KMQ"U-IC2E+15)I:
MJ2.*:6( 4L;7D<SCG!)V&^?85>,X@:]X?7^W4W$Z&CK+/7R=FVOI6M'9'O/J
M@#;.2"W)'0[(:3ZB Y&1N%HO%[B!!P_TZRJ$'RJY53^QHZ;. ]W>YV-^4;=.
MI('?E!O2*!*>NXYMI!>I*:U2PD=K]BG,8).7KC WSCNY\^65L/H_:[O6N*;4
M$M_[)KJ2H8R*-D?(6 AQ+3XD8""6D7-=@XF\2]3WJ\V33=%0U-13U+A\KEC#
M64T0<X '?!)QWY.QP%N^MN(-_P!&Z<T]:9:6"YZ[N@[,11C[D'<V.? QG)(
M&W?X;C2744!7>^\8-$T O^H?L1=K5&0ZJI(&@/@:3XAH^(+@._933I>^4FI-
M/T%XMSB:6LB$K.;JWQ:?,'(/F$%:_76FL=EKKI7%XI:.%T\O(W+N5HR<#OZ*
MUTAJ*AU7IZDO5I,IHJGG[,RMY7>J]S#D>UI4<>D S6ILMS=89+>W3(MK_E[9
M@.U)]?GY=OQ>7WK5. $?$0Z<TVZ@EM8T?VS^9KP.W[/MG]IW=>;FQ[D'12*&
M->\2=15FMI-&<-J&&HN<#<U=9, 60GO SL,9&2<[G &5A:K7G$?AQ7T<O$6E
MH[G8JF01OJJ1K0Z(^1:&C.,G!&^-BAIT"BBOCSKJY:3T/:[SIBH@YJNKCC$C
MXQ(UT3HGO! /CRM6L"X\;[Q1B]4%-:Z"E>WM(K<]K.T>SJ,\P)R1XN:?(()[
M11UP;XC'7-!6T]RI!0WZVO$=93@$#J1S-!W&X((/0CS4BH"+FZQ\0^)^JK]?
M;-IFGH)#253F&MEB#6TT8<X '.Q)QX$[';JLK3<1=<:!U'04'%&GI:BU5S^1
MEQIF@",]Y]4 $#.X(!QN,H:3XO,I<V-Y8WG> 2&YQD^"B7C_ *_O&A6:<FLA
MB<RKGD$['L#C(UO(< ]V<G?S5]PUK.)-TO7V0UC2T%OLDT#G1T<8 E8XD<N>
MI&V<Y/N""^X1:CU=J&"[NUI8?L0Z"<,ION3X^T:<\PPXG(&!ZPV.?)2 HJX$
M:XNVK[=J"HU!- [Y#5]E&YD8C#68).5JWVPM>\0[U7P\,::DHK+1O[,W"K:"
M9#_M @9Z\H:2!C)W14_(H1TCQ(U38M;4FD^)]'3QSUV&T=P@ #7N)P <;$$[
M9 !!(R-\CUQHXDZCT?KVR6RP4\59%5TP?\D,?,Z64O>UH!&_4-V"(EO4=56T
M5@N-5::45EPAIWOIZ<G^,>&DM;[RM?X47O45_P!*"LUA:?L7<NW>P1&)T1?&
M,8<6.)+=R1OX9[UK^F:[B)1Z>U-=-;"WPNBH7U%##3AI[)[6/<0[&<]&]Y6-
MT7J?7&LN$<5TLDU!_")U8Z/GFC#(^R:=]M]^B#?=-:WM&H[_ 'NSVTSFLM$A
MBJ1)'RMY@YS?5.=]VE8;B[J+5FGJ&V2:+L?V6EFG+*@=D^7LVXVV:01G?UCL
M,>:@7AM'Q%=KW6@TW+:VWD5)^R9G Y"_M'YY-NG-S?0I6XRZUU/HC16F:F&:
ME;>*B1D-:[L@]A?V>7<H[AS!%3! Y[X(W2L[.0M!<S.>4XW&>]>UHG%_7[-!
MV*"6GIOEEVKI.PHJ;?#G=[CC? R-AN20._*C^ON7&NQVI^HKA]AJJCB;VT]L
M9&.TCC&YS@ [#P>3[41/:*,KCQ7I&\'W:VMU+VCRT1MI7N^9.7<A:XCN!W\Q
MCIE:I8JWC5<K70Z@I:C3]31UC631V]S0T]F[<'( QL<_/)]Z">%@-?:C9I+1
M]TODD7;?(XN9L><<[R0UH)[AS$+.0]IV+.VY>UY1S\G3/?CR4$>DFS6OV"O3
MH9+?_ [LX.T8<=OS<[>FWX^._H@R?"JY\4=0UULOEYJ+4S3-<'2.@;&T/8S!
MY>4#?<XQEQVZA3.H.X'MXALM^FI+C/:AHT4F0&X[81]F>3.W7FY<[^*LW\0]
M=\0;[7TO#"FI*2ST3^S=<*IH/:'N/K @9Z@!I.-SC**GU%!^E>)&JM/:UH]*
M\4*.G;)7D-I+A3@!KW$X&<>J03ML 02,C=5^-G$?4.C=:V"WV&"*KBK(>9U*
M8^9TTA>6M:"-QOCHB)I7B>6."&2:=[8XHVE[WN. T#<DGN"T3A@_7\TU=4:_
M900PRL8ZEIZ;ES$<GF#L9[L=Y6)])FZSVSA37-IG%CJR:.E<X=0QQ)</>&D>
M]!K-RXP:FU7>JBV<*; VNA@.'U]2WU3YC):UH/=S')\ J-7KOBSHQOR[5^FJ
M2X6EIS+)2XYHQX\S''E]KFX\U)W!ZP4FG>'5CIJ.-K734T=3,\#>21[0YQ)[
M^N!Y +<B 000"#L045%G%[7ESL?"ZAU)8(WT53530@1UD YV->UQ(<T]#L%D
MM;ZEU/;N&UMN^EK4+K=YV0.EC;"Z3E:YF7/#&D$[X&!TSGN6N>E=_-:W_6$/
M[+U>\1=4W/1_!>U76R/C96-BI(P9&!XPY@SL41(^G:FMK;#;JFZTHH[A-3QR
M5%.#_%2%H+F^XY606@:DX@QZ5X66_4MT8*BLJ:6 QPM]7MIY(P['D.I/D%HD
M5=QOJ[4-0PML\<#F=LRT&(=JYG4#!&<X[N<'WH)Z11WHOB*S5_#6Y7ZCB%+<
MJ*"9L\!]81S,87 C/5IV(]X[E&&B];<7=?6GGT_';::*%[FR7&:)K1([KR $
M$;#'1I\R@Z36L:WUQ9]&?8[[-.J!\OE,,/91\_K#'7?;J%H?#;B+J%NM7Z*X
MB4<,%Z+#)35,( ;. ,X.-CD D$8Z$$948>D S73;E:3J66W.HC7R?8P0 <P]
M88Y]O#E^E%=9(M%X;,U\RHKOX?2VU\/*SY-\C R'9/-G '=A;TB([XXZ^ET#
MI)E70-@DNE5,V&F9,"YNV[W$ @D #'7JX+,\+M5MUIHBVWDAC:B1G)4L9T9*
MW9P [AWCR(427J-G$[TAH;9(T3V'349,[3NQ\@/K ^UY:TCP855X(RR:&XI:
MFT#5O<*6=YJJ N/7 R,>9C(SYL**Z!1$1!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 7'O
M'N4?;<O[#U'8?_3QKL)<9^D-&YO%R_2#H?D_]Q&K"2T*JC#AS!6;'&-RNHIN
M88*HSLW)"K%D:*HW!SNMPL%RY'-&>BCV"0L<LW;ZGE<T@JPQTG"SU;:B( G)
M65:T-&RCO3-QP6CF6^T\G:1@@K9$[8:>Y'D'E'7Q7N'/+ON5X:WUR2O;7@;=
M%15 \4'5>&G)*]JPD!.Z9POF<'"^A0-RO0V7G<95C7US:9AYCW*BXEJ6M=C.
MZNJ6L#1MU6EP7 U-1AISDJ^O]TBL=CDK)SAV,-'B5COS6(9:_P"J:2T4YDK)
MVM_T<C*UO3/$*COMV-'!&\'N<>]0/>;K67RO=),]SRX^JSP4M\(M(R6]IN%:
MW$S\<H\ L8JF993&DS6Z<PPO<X]VRL7R<\CG'O7F27+0QO0+QG 6;%[+L#*M
MY9.J2R8"MQEQ17UN2Y7D$15-H;&WG?T"K6RI;4U $8RP%1&4I:*21N6M)]R]
MR0.BV<,%9=LTT4 Y(\-QU6,JJDRGUL94VR6[AMA4Q&%Z!)*]!4>&A[#EKBKF
M"L>PX<2J.52>=]DT,JVJ;+ZKN]4JJWME:2T;K$DO:\.:LM;ZT$!KSNHN]L)/
M2.A<0X*F(EN$M+'51Y&,K"U= 82<=$A)AC6TX=U"]$-B:0W95GD,:1WK&U,Q
M)Y6]2LF*E*3/+R-Z=ZR-+ &-  Z*E14_(W)ZE7;WMC;U6._-E$*G-A>>;S5M
MVP)R2OHF;ONL-[;(C2YSYKTUY'>K3MVA?/E 45D!)GJCF-<.Y8[Y3X!!5.[D
MV*L]('>"Q=7;6.!RT+(MJ2?G97TXD5B4F(:=76C!);A8*JM[FDY:I*DI0[N5
MA4VYKP<M5Z2QU,(PJ*'.?56/EHW-S@*1*VS=2T+!U5O<PG+5C-"Q+3^0C8A>
M"P%9ZHHLYV6.EI7-Z!8]87NQ4L&Q5A-#C.0LT]I'56DT8.5=IIA^RP3A5(R6
M]ZNS3[E>3"KHVJ4\N,+*4]1CO6%Y"T[*HR4M[UCI6S0U(/>KV*<'O6J157M5
M_351QA16R,>"KF&4!82"<'O5_#*U49VGJ0%?Q5&>BUZ.H Z!74561T09]KR5
M]._4K$1U3BJ[9R>]78OP6ISM'0*T$F1U7WF4%R9?!>3*K?F7T%!5[0KYSE>-
MT#24&,J*+L*A]33-:8W_ ,=#C9_GY%8^\6YCJ$55'E\0.2,;L\BMDY2J!ADA
MD?+2AI[0<LL;NDC?W]?BMMNYRM=='-"&-51R2.$1P6]6DC<%:Q('15(/0C?*
ME?5UD;54SJFW_@'#HW[.:? _O46W(ELS@]I:X>K@KKFY1KFCNTVXJIGEGLS5
M/R5-(^7\/;/F2L=+O*0=@O>F::LK9*EM*TN;%$9'CR!^M>I8B2=@N#(K\2N:
M_5WV.E.GEK1@Y7W.#@[HUO+U)7TC?*Y77$*;HP3MT5*1F#EI5T/6;U5*4$C9
M2))A=6>]S6]S@UK'DC YVAV-QN,]^RKV\F=LLI&Y>7$-]JP3QAQ(^<MITW U
MD;&2_A D#Q6V:MTZ:J8U5MNFD*OUV%[C@'=N5*MLKHS"0]^SB"=_/90!9JMT
M,[AS8&5)E@NC'!H=DY '5<=6Z9W#U[<Q73J4H,N#1$ R38#'58VNNG*TA[R>
M7?)6%@JG'+6';P/<M2U[6U$S&T-/*Z(.;E[AU(\ I-=5?1EX=%N-MI=K:@CE
M,1JXS*-BT/!(6%OUV%\^X1$B-OK$]<K2+!IDR3,$<.1GYQ*D"AMD5'3M!=D9
M((4BG758JW#$T%L+ 06D'.VRN)+2UX.&[]^RV"/D$32 <DC&#UVS_@K9U7&V
M/G87$D.QGIT4U+&JJ&KR60<^WJ>8"N(:%T)]8APZ[=ZNIK@P$M>0'8!SU[N_
M'7W*TAN#N:3G=#)^+R>K]95Y):O$B&2IFF-QY1MUPLK0Y."3@ K777)D9/.#
M'OCU\;GW+,VZH;+$UP.<CPZK55$PV4U1+8(9"UP <.7P5_#,''E&Q[PL2V0$
M!S<>!5[ X'/<5(DF%YVO+UZE>'29!!*HO. 03YJV9(6GUAE93+#3[(]Q)!.R
MQ%TJ R-QST'57]1+R1N+N@[UI.K[AV5*Y@^>\@!8TQN2J>6EI=WJ^UDJ:AQS
MDG'L[E&U>\R5+W'Q6[W^01T;@W;(6A2G,CCYKOQX[R\W*GI$/4(W51YROD'0
MI(=PO1IZ4O/GNI%?%]182RAY1"BP41$4'MFRK DA6[>JKL&1E;J)Z,9?7;JD
M=G*MCSV5*39RRJ[$/9P1A4NB]M.5\/52>I %]<,A?&HYQ!.>J>0^.VA;YE4U
M[D.6M7A:JN[*%2$9<E0[F?Y!>H3RM<51\59Z1I/-]"#=? JD0W)/0*1Z++V\
M\D?*#N50&Z]/<7N)*8PK/64CH=V G1?"OJ"O!(6;M)5_'+VC<'KXK%Q[%7<.
M6NR%OMU-=4+]K2&@8V0D ';<*I&1R8)[E2<2 =L9*W-;P^7#=U;=KEV$G?N0
M52B!<_;JL)EG$=&7H<D@YV6:A(P 1L5C;;'A@R#@]<+)@ #N6^CLU2";Y)6Q
MS#)&<.'EWK?*9P^2[8((R"/!1M5G,1&X 6WZ:KA4V=O.<N8.3WA;[-768:KD
M=-NLM&'.D;*?_P!#B_8"S"PNB/O.L>/_  4/[ 6:7C5_U2]"GM B(L5$1$!$
M1 1$0$1$!0%Z.W\Y7$[]>_\ O3*?5K>F-%633-UNUQM%/)%5W23M:ISI7/#G
M<SG; G;=QZ(-D7*^OM.VN3TA;C!K&Y5UJMUTA9+25M/*V(<W(QH#G.:0&Y8]
MOMY5U0L!K'1]CUC0-I-0T$=5&PDQOR6OC/BUPW'U'O00?J3A?PUM$, O>NKL
MUD[VL8QU=%)S$G .!&< =[CL/%5O28M\-IT5H:VTTDDL%'.RGCDD(+GM9&&@
MDC )('<I TWP3T38;A'6P6U]541NYHS5RF5K#XAO0^\%;-K31=EUE!1PW^GD
MFCI).UB#)7,P[&.X[HK8)S&V"0SE@A#27E^.7EQOG/=A<\5?#O3C::LU'PSU
M]]A6AKI2QE4#",9/*2"'-'D[F]BZ'J(8JF"2"HC9+#(TL?&]H<US2,$$'J"H
MOK^ N@ZNM-0+=44X)R8H*E[6'W;X]Q"(CV6^7[B3Z-U[FK6&>XV^J:'21LP:
MB.,L>78&V0''./Q5)7![7>G*_AY9V"YT-)/0TD=/4033-C=&YC0TG!(]4XR#
MTW\<K>[%9;=8;3#;+1214M#",,B8-O,GO)/>3N5H5\X&Z&N]P?6/MLM+)([F
M>REF,;''\WH/=A%:-I2O@UIZ3-3?-/\ W6U6VD,<M2T>K*>S,8.>_)=MXAF5
M><-_^TYKO]4=^W IATIIBSZ4M@H-/T$5'39YG!N2Y[O%SCNX^TJUM6B[+:]6
M7'4E'3R,NU>PQSR&5Q#@2T[-)P/F-0:+Z4S0[A1.2,EM7"1Y;D?XK3N.5%4N
MX6\/;TR%U126UE.ZI9U&'1,P3Y9;C/\ I!3IJ_3%LU;9GVJ^0OFHG/;(6LD+
M#EO3<;J\CM-$RRQVAU.R6WL@;3=C*.=KHPWE#3GKL.]$8.V<0M*7"PLN\5]M
M\=(6![NUG:Q\>WS7-)R'>2B;T9ZV"Y:ZXC5U&XOIJFI9-$XC&6NEF(.#TV(6
MX/X":"=</E7V-J SFYODXJG]G]><>];9H_0FG](5MQJ=/T1I'UY:9FA[BW8D
M@-:=F@<QV"*BO@1_/#Q._6W?W\B]\%OY\.)GZ=W]\Y2KIW1=ET]?+M=[73R1
MUUT>9*I[I7.#B7%VP)P-R>B6+1EEL=_NUYMU/)'7W1Q=5/=*YP<2XNV!.!N>
MY$0QQ4U8.(>L(]"6:Z4]#8H'\UTN$DK6-?RG=C22.8 [8[W>0RIFTL[3=OM-
M+8=-W"W]E#$8X88*ACW]"2[ .2>I)]JU!W /0+G%QME3DG)_RR3]ZRVD^$ND
MM*WN&[66AGAKH0YK'NJ'O #@6G8G'0E%1AZ-]^MVD:K4>DM23PVV[LKC(UU0
MX,$N &EH<=MN7(\0[94_2AU-9KG_  <M=MN-/5UD%9VTK('AXC;C R1L#Y=5
M+NN.&6EM:3MJ+W;\UC1RBI@>8Y"/ D?.]X.%A:?@9H2"DB@;:I7.9()>V=4/
M[0D= 3GIY#9!E..4;Y>$VIVQM+B*7FP/ .!)^ *QO .]6V;AAIJD97TIJQ$Z
M'L.U;VG.USB1RYSG S[-U)%1#%4020U$;)89&ECV/&6N:1@@CO"CVR\&=&V7
M4D-[MU#4154$G:Q,%2_LXW>(&<^XDA$:;IS_ +6VJ?\ 5S/[FF6,T+=:/0W'
MO6=%J>5E']EI#-2U4YY6$.>7M',=@"'8STRW'5312Z-LU+K2LU5#3R"]5<0A
MEE,KBTM#6MQRYP-F-^"\:UT+I[6E/'%J&WLJ'1;13-)9)'['#?'ET14:^DIK
M&QRZ"FL5'6TU?=+A+$(H:=XD<P->'<QQG'3 [SG;O6!XZVVHL_H]:1M]<"*J
MFGI8I6G\%P@DR/=T]RDS2'!_1VE;BROM]N=-6QG,<M5(93&?%H.P/GC*V+6N
MD;1K.U1VV_P/GI(YA.UK)',/. X Y'DXH,I9_P"2:+] S]D*$?1[')Q+XIL;
MLP7'8#IM-.IV@B;!#'%&,,8T-:/(;+ ::T99M-W:\7*TT\D57=I>VJW.E<X/
M=S.=D G W>[HB,U<8'55OJJ=C^1\L3F!WXI((RH ]&;4ELTW07G2>H)H;9>8
M*]\A;4N$8D]5K2T$[9!8=O C'>NAUI&M^%NE-958J[S;R*[ ::FG>8WN Z!V
M-G>\$H(D](W4MGN^IM%V^UW"GK*FDK2^<0/#Q&'.C !<-L[';JLWZ4_S=%?Z
MR/\ PK;:/@CH:DBI6Q6J3M*>43-F-0_M'.'3)STVZ=%M&L-&V;5WR#[.4\DW
MR&7MH.25S.5VV^QWZ!%;$N;?1]H9[IP_XD6RC/+-5&6"'N >^)[1].%TDM<T
M9HNRZ.CK66&GDA;62"6;GE<_+O>=NJ(BGT9M7V:ATA)INYU4%MN]%4RE\-2X
M1&0%V<CFQDC=I'48"Q7%C4=IOG&WAY3V>O@K7T5=$V=T#N=C7.F9@<PV)VWQ
MT4H:RX1Z0U;<'5]SMSHZY_\ &3TTAB=)YN V)\\95*U\&]%6NKM=50VM\=5;
MIA/#+V[RYSP007;^M@M&W3KXHJ0U O'O^=GAA^NM_OXE/2US4>B[+J*\VBZW
M6GDDK;5():5[97-#'<P=N <'=HZHB*/2,_G!X7_ZP=_>P*<KBT/M]4UPRUT3
M@1XC!6$U1HNRZFN=HK[Q3R2U-JD[6E<V5S QW,UV2 =]V-ZK89&"2-S';M<"
M#[$$(>B(3]KRY#.PN;\?U4:Q_!6XT=KXM\38;E504DDM8Z1@GD#.9HFE)(SY
M.:?>IAT3H^SZ+MDM!I^!\%-+*9W-?(YY+B ,Y/DT+ ZSX2:2U?=?LE=:&1M<
MX 22T\IC,N-AS ;$XVSU\T5%?I)VZEFUYH^[7:HJ8M.5$0II:NC<.:+UR[F!
MP1T>#T.0TX5Q=>%W#JALK[C7:\NWV/+.8.%PA?V@QT: PEQ/@,J;I])V2ITO
M%IVJH(ZBSQ1-A9!,XOY6M&&X<3D$=QSD+1Z+@)H.EKA4FW5$X!YA#-4N=&/=
MU(]I*#0^+.CJ.@X 6QFD*RHN5FI*P5_:R.#G.B>'@N]4#8.>.[;?/12YH_B'
MI>\:6I;A#=[?2QLA;VL,T[8W4Y W:X$[8^![EE=5WBRZ0TI45=VC9#:*>,1&
M&.'F:0?5$88-L'ICHHH9H'@W>8/L[3UE)#1.':OC9<.R8WO(<PGF9^;L@QO!
M.Z4EZX^:XN-ME[:CJ('NBDP1SM[6,9W60X=?]IK7?ZJ?KA6/]'&DHZSB/K2]
M6&E%/8&CY+2<K2&EI>",9[^5@)[_ %AGJIFM>C+-;-67'4E'3R-NU>SLYY#*
MXAP]7HTG ^:$$5^E/2SPP:1OP@=44%JKB:F,#((<6$9\CV9&?](>*DVCX@Z4
MJ[$V[LO]O;1%G.3).UKF_P"B6DY#O+&5L5?1TUPHIJ2N@BJ*69I9)%*T.:]I
M[B"HS' 300N'RG[&U')S<WR?Y4_L_KSCWHC4/1;JXJ_47$*LIB705%7%+&2,
M$M<^8C;V%>[_ %,%L]*^U5%PFCIH):##9)7!K23%(T#)VW(Q[5+.CM#6'1]1
M<IM/T9I3<'M?,T/);L7$!H.S0.8[!4M=\/M.ZXB@%_HS)-!D13Q/+)& ]1D=
M1Y'**U[CY5T];P7U%-1SQ5$.(V\\3P]N1.P$9'@1A1]K2U55S]%:P.HF.?\
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ME[G +*&FZ@'IS'?&>X $^2UJR<>8!>*>WZRTS<=,FH.(IJDN<S?O=S,80/,
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MU1+32MDA>6N!SD*33ME35-+:*B/E)&,85C4O[.([XR%?T5?%<H@TX95#YPZ
M^Q6EPIR^%P[PM'+J>KJBKFIZ,$'EQW.5>TH#I 1T5GV9:3GN5U3D@@$@'&5L
MJ[-5N>O5>%Q&W?C8KV96PX+Y@UW58^HJGE_W,#;O7R*FDG=S2')*PBGU;XKF
M9U#)PW21K_N1D>#W#H5G+:VKJ,NJ<,A[V#;/=^Y6%IAAC+01[UL/;,$8]49Q
MRD^(_P"OK6,ZAW6:>FZF;MU-'%,T,#6A[ YG*?\ KO"V!U=),\-!.!MRE:2V
MX]CCUL ;[?2KQM]9&>:)V78&3CHM<U:[.JJNG75ND;8VM&7 <V,YW5V'!KB8
MW @GJ%H;+N^0>KG?H2K^@KZASPYI+0.H=WK15N>LM7B;[-KG?X- /AA6TC'R
M'<'?Z%1IJJ24C.,GO*RE*UP9AXR[N\E@+*GI'@Y&<>"RE-&6,^O*K1MC:SK@
MA4JBH$32!\4TQVH5DPR3DMQX;*.M>WC[F8(W^L_;;P[RMAU!=Q#$_+@ !G/@
MH8O-V?75KY2?5Z >2WV;<SU<UZ[%,:7-34AL?+&?6[\+%54WJ!H/M/B52,IW
MWR3WJ@YQ<=UUTT:<-=S;X%6C& J356&W1=5N/-RR^..<KPO97DK*2'E$0+%3
MN7E>E\[EA*P^(B+$$1$!$1 1$"L B(H"(BH!$1 *(B@^C9.Y?,(J 52/JO "
M]@X"RI25<28&%Y)R52SA?6N[UMYF.GQZIJH3E>"M=3*!>H7\KP5Y5:GAYG;C
M9*8G?0G6NK9K8\F!KNO17CW$*PMQ#(^1RO"2YJ]"GLY7HO&-^[S7@.];P"-P
M1[=EY=L,8V\E1VMPY^\'3G^KH/[L+85KO#<YX?Z;/_\ 3J?^[:MB7EU=Y=<=
MA$111$1 1$0$1$!$1 4,:FX)2?PCJ+YH7453IRKJ27311 \A).3REI! )WY3
MD>&%,Z(()I^ E6^^6J]W75]7<+K353*B>2HA+Q(UCFN:QI+LCH=R3U&PQONO
M$GA_7ZIN5%=++JBXV.Y4<9BC[(DQ%I.3EH(.3MDY.<#;92"B"(=+\(J]NK:+
M46M]3U%_K:$@TL986L8X;@G)/0[X &_7*EY$0:#)P\+^+T6M_LD &4_8?(^Q
MZ_<RS//S>>>BQ&K^&5]K=3U=^TMK:XVFIJ^7MH'@R1' P  ", #N(/?NI51!
M&O#3A=_!:^5NH+W>)[WJ&K9V;JF5O*&-VR "22=@,YZ#  4E(B#0] </CI/5
M6JKR;B*K[-U';]EV/)V/KO=C/,>;Y^.@Z+)<1]#6O7EB^QUVYXWQN[2"HBQS
MPOQC(SU![QW^W!6U(@@L\&M6U=,+7=>(UPFL@'*86L=S/9^*<OZ8\<CR4@:A
MT#3W#AC+HR@K)J:F[&.&.HFS,YH8]KM\D9^;CN [MAA;HB#":(L1TSI.UV4U
M'RDT4(B[;DY.?'?C)Q\5KFGN'IM'%2^:R-R$HN=.8/DG8\O9Y,9SS\V_\7X#
MJM^1!I?%K0YU_I9EG%>* MJ65':F+M/FAPQC(_&\5>ZDT5;-2Z.CT]>FNE@C
MB8ULK/5>Q[6X#V]<'KX]2%LZ((#^T=J=M(;1'Q#KAI_YOR;D?\S\7EY\8\NG
MDI;T'I"UZ)L$=ILT;A$'%\DLAR^5YZN<?'8>P +8401GQ(X26_6^K+->ZFJ[
M#Y)RLJH1%S?*HVNY@W.1R_A#.^Q\E)@    P!W(B#0>#_#T\/+7<:,W(5_RN
MH[?G$/9\OJXQCF.>B^\)>'QT!2W:$W(5_P NJ?E&1#V?)MC'SCE;ZB#0>)_#
MTZWN6FZL7(47V'J'3\O8]IVN7,.,\PQ\SSZJMQ5T58=;VNDM][J6T=89"*&H
M#FB02$9+6@_.! W;Y=V,K>%HW%'AM;=?4U*:FIJ*&Y49)IJR Y+,[X+>\9 /
M4'P*"+[_ ,([]2::KW:GXAW"JL%!3OF-,.<<X8TD-/,\@=!W'R6S^BE"^+A9
MSO:0V6OF>P^(PQN?BTK$R\$]47<1T6J.(5PKK,QP)@ >72 =,\SB ?,\V%-&
MG[/1:?LU):K5"(**E8(XV#?;O)/>2<DGO)15Q<*?Y705--S<G;1.CYL9QD$9
M^E:CPBT*>'VF9K2;@*_M*EU1VHB[/&6M&,9/XOTK=D1&@<4N&%MUZRFJ'U,M
MNO%)M3UT RYHSD-<-L@'<;@@]#USI$? Z\WBJIVZXUQ<+O;:=P<VE'/ZV/-S
MCCVX)\U.R(,/<M,VFXZ8?IZIHXS:'0BG$#=@U@'J\O@1@$'Q"AZ#@=J*TF6A
MTYQ!N-#9)'$]@&O#F@]?FO )\QC*GE$$6<*^$,7#_4]PNE-=Y*V&IIODXBEA
MY7M/,UQ<7 [[M.V._P"/SB/P?I]2WYFH;!=JBPW\8YZB $MD(& 3@@AV-L@[
MCJ%*B(( NG &[:@IS+J;7-97W!I A?)$Z2.-O>,.?G)VZ8]ZD7B%H ZNT#2Z
M:%Q%(8#"?E'8\^>S;CYN1U]JWI$$##@?J.VTYM^G.(-QH[2\8?3D/'+GYV.5
MX&^_A[U(O"_AW:N'UJEI[>Y]365!#JFKE #Y2.@ [FC)P//J5NB(-"T-P^.E
M]9ZHOQN0J1>I3+V/8\G8Y>YV.;F.?G8Z!8+7?!QEVU(_4>E+W4Z>O<AS-) #
MR2GO.Q!:3W]0?#.2I:1!#NDN"SH-207_ %MJ"IU'<:<AT#)0>S80<@GF))P=
MP-AGQ6Z\2-!6G7UE;0W8/CEB<7T]3%CGA=WXSU![QW^W!6VH@@4\$=45<#;7
M=>(EPGL0PTTX:_+F#\'!>1\<CR6[:FX74%PX91Z,L]2;=21/8]LKV=JXD.YB
M3N,DDE2(B#4KAH.UW?0%%I:]M%5!2TL5.V=K>5[7L8&B1G7E.WGUP<A:[I_A
MC<J'0UQTE<]55-5:YV<E/)##V4U.,YY XN=EA_%QXC."I/1!!=5P:U;<*3[$
MW3B+6U5B) ?"Z)Q>]H.P.7GZ21Y*8]-V6CT[8J*T6QA91TD8BC#CDD=Y)\2<
MD^9611!87ZTTM]LM=:K@POI*R%T,@!P<$8R#W'O"BS0O"C4>DKW0_)M<54FG
MZ.8R,MYB.'@YRTCFY1G)WQUWQE3$B"*^(?""#4.H!J+3MWJ+!?\ \.> 'ED.
M,9.""#C;(._>%B].\$II-04UYU[J2JU'/3$.A@D#NS!!R.8N))&=^48'CGHI
MH1 6L<0]$6K75B-MO#7MY7=I#/&</A?TR/\ $'K\%LZ((%^TAJF6F%IJN(M>
M^P@<GR<-?DL_%P7XQCNW'DI+H>'>GJ30;M(BE=+:'-(?VCLO<XG/:<W<[.^W
M3"V]$$"T_ [4=L;);[%Q"N-'8WD_< UX<T'J,->!GS&,^"VKA1PEBX>W^YU]
M-=I*V&KA$+8Y(>5S,$')<#OT\ I01!H6E^'QL?$K4&K#<A,+K&6?)NQY>SW:
M<\W,<_-\!U6<UYI"V:UT]-:+RQQB<0^.5AP^)XSAS3X[GV@E;"B""F<&=7BD
M%I/$>O%B Y!"V-X=V?XGS^F-L9QY*7-&Z=I-*:<HK+;Y*B2FI6EK7SOYW')R
M3Y;GH, +,H@\S,[2%[,XYFD96C\(- GAYI^LMAN(K_E%6ZI[00]GRY8UN,9/
MXO7S6](@C3B;PFH]872"]6VXU%EU#" &UE.,\X'3F (.1T#@0<>.V-;MO ZM
MN5WIJWB#JRLU!#3',=*[F##Y$N<=CW@ 9\5-Z(-)XL:$&O-*0V6*M;;FQU#)
MQ((>T&&M<.7ER/QOH6W6ZG^1T%-3<W/V,38^;&,X&,JX1 4;\3.$-DUO5-N/
M:S6R]- Q6TP'KXZ<[>_'<00?/920B" G\$-65T?R*[\1[C46L[.B^ZNYV^!#
MI,?'*D2P\,[+IW15UT_8VNA=<::2":LE'/*\N86ASNF0,[-&!\5O*(-&T3H$
MZ:X;U&E#<14F6.=GRGL>3':YWY<GIGQ5;ACH=FB]&'3]15,N43I)'/>Z'D#F
MOZM+<G9;FB"$)>"EWLE?5/T!K.MLE!4NYGTC@YS6GR((SX#(SCO*W'AAPY9H
MJ6OKJN\UUXN]PQ\IJ9WD-=CIAN3OYDD^&-UOR(-!T-P].E]:ZHOYN0J1>IG2
M]AV/)V.9'/QS<QYOG8Z!5N+V@SQ"TW3VH7 4'953:GM3#VF<->W&,C\;KY+>
M$08B]6"DO6F*FQW'F?25%/\ )Y"W8],<P\"#@CS"C?0'"S4FDKW0F/6]3/8*
M-[G1V\Q$->UP.6D<V!US[=\!2^B"PU!1U-PLE?1T-4*.IJ(711U')S]D7#'-
MC(R1GQ6M\)]!T_#_ $R;7%4_*YY)G3S5'9\G.XX VR<   =?'Q6YH@HUM+#6
MT<]+51B2GGC=%(P]'-<,$? K2.$6@9^'UMN%N-W-PH9Y^WA8Z'LS"<8=OS'.
M0&^'0^*WU$$?\2>']=JFX4-SLVI[C8[E1QNCC,))B()R<M!!R=LG)R -ME@-
M,\(;A_"RBU#KC4]1?ZN@(=2Q%A8QC@<@G)/0[X &^,Y4OH@*-^)O"NEU?<J:
M]6VY5%EU#3 -CK:<9Y@.G, 0<C.Q!&WCLI(1!"]NX.7JX7:BK-<:VN-WAHY&
MRPTT1=&.<'8\W-M[0 ?,+:N*7#TZYJ]/S"Y"B^Q50Z?!A[3M<EAQ\X8^9Y]5
MOR(-!XK\/3KUME N0H?L=4&?>'M.TSC;YPQT60XFZ5L6KM/MMNHYF4[7RM%+
M4<X8]DQR&\A/4GIR]ZVY:=Q-X?VS7]HBI+E)-3ST[C)35,)]:)QZ[="#MMY;
M$((QEX,7^GMLM'>>(MP=I>G8720-#VYB:,EN[RT# \P/!7/HA0N9HF]2\I$3
M[B0PGOQ&S]X5.7@IJVOA%MO'$:OJ;)L'0\LA<]H[B"_'Q) \%,6D=.6[2E@I
M;/9XC'24XP.8Y<]QW+G'O)**UOA/P^.@:>[Q&XBN^7U/RC(A[/DV.WSCE:!%
MP KJ"NK+G9=9U=!=I9G2,E@A+&ACB26.P_)W[\X\E/:(B'='<%C2:EAU#K2_
MU.HKG 0Z 2@\C' Y!/,278.X&P!\5LG$_AZ=;W+3=6+D*+[#U#I^7L>T[7+F
M'&>88^9Y]5OR(-1XE:"M>OK(VAN9?#-"[M*:JBQSPN[_ &@]X[_(@%1R[@SJ
MRO@;;;WQ&N%19!ZKH&,=S2,_%.7$?'F]BG1$%C8;73V2S45LHW2NIJ2)L,9E
M>7N( P,D]5AN)>E3K31E?815_(S5&,]MV?:<O)(U_P W(SGEQU[ULZ(-$O>@
M#<^$T6BOLB(S'2P4WROL<Y[)S3GDSW\O3/>MBT;9/X.:5M5F,_R@T-.V#M>7
MEY\#&<9./BLRB",W<([<[BT-:_*?5![;Y%V6QGY>7M.;/^UC'7?*WZ^VBBOM
MGJ[7=(!/1549CEC/>/(]Q!W![B%?(@@N#@OJ>S-DH-+\0J^@LKW$M@<QW-&#
MUP6N SYCE6^Z)X=TFE=)U]EI[G<9I*_G=45AEY9.=PP7,&X8?/<YZDK=T00:
M_@YJZ"C?:;?Q&KV6-[3&8)8G%S8SMRCU^F-ML#R6[T'#>AM?#&LT=:JN>G94
MPO8^K.[W2/ZO(&-N@QX;>:WM$&C\'M#2</\ 2K[3/<37R25#J@O#2UK,AHY6
M@D[>KGVDK>$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!>'=2O:\.ZI ^!4ZFGCJ:
M=\,S0YCA@@[JKNOBJ.7N*NC9=/W,RTS7?)9"71NQTW^:M(=&RNICD?=!U'FN
MO]6V*"_V:HI)V-)<T\KB/FGN*Y1O]IJ=/7N>&=I]1Y:[;J.XK*>L;:H^[.FF
MU$):71/&XZ+$RL+7$+<KU2![!-$//9:U5LYAS ;K&&QC2%6HYS#*""J3NJ\J
ML4N:*O@DC$4CLG9;;/6LB:7$A0?8;@ZGJ&D.(W4B053ZV!I:[.RRB49*2\$S
MX!6R6F],:P#F&5I;:!P.3N57@@FYP&9!5B91)])=V<OK.&?:J%RN[>R+6'WK
M4J.-\+,R/)*QU\N@B86M<KM&2J;D'R$<RKTM4'8&5HL-<7/SS;K.VZJ#6\SC
MT2)&TU%;%20F25P"]6.XLJ)@][AN=@HXOMWDK:@QQN/9,ZK[I74C*:X-;4AW
M(3C/@IS=5TZ+M44-53'DP3A:=?:"9ER=&]I$?4%?6WJHI*)M3;V%S7C/DK"*
M]5ER<7U@#7> 5\R>JZ#&QLY6K[34QFDW'JA(@Z9V&=5E:=@BAP1@]Z$/I :W
ME'0*EU*\2S-;U*LY:X-V;N41?[-ZE4I:J.,=0L8Z>:;9N0%[AI'/.7E72;>I
M*Q\AQ&%]AIGR'FD*OJ>B ^:WWJ^BI<;N*&MK2GA#1AH]ZNV1!HRY>WNCB;MA
M>Z&BJ[D_$#"(^][ALB](475#6# QLL9772&/)+QGVK;I]*?Y,YID)D(ZK2+O
MH>O:]SXI>T\B"I\$FK7>&OW.5MQ>>?YJQ$UG#LF-Q'DLG46NOHB1+"\ =^%1
M9.YIPX$+!E$TSV82:WS19RTD>2M3&0<$'WK;&S,<-\+S)3P3#UFA%TU(Q KP
M6.'0K8Y[2TY,;L+'S4$T>?5)'D@Q62.H08*NG1XSS-5%T0[E%VID*F<]R]EK
MFY[PO'-UR%%4WL:X$$*TEI&G/*<*^V*\N9NH,/+3/;W9"MG M.^05G2TA6TT
M3' Y:BL2*A[.A7MET>P[E>JBE SRD+&3,+"<J:5G8+R[O*R,%W)[_I6HPC)V
M5]#S#O45N5-<W'\)9.GKB[J5I-/-R]2LI2UG3=$;>R<D=579)GO6N05>?PED
M8*D'O1698'$*H&.*MZ29I[UE*<L?C*HMA&XKT(W+)LIVGO"J"F8@Q;8W*JQA
M[UDA Q?1%&%19L@ROKJ;(Z*]'(WO7KM8QUPD2FF$J+>UP.0L/5VHX):%N#I(
ML=RMI7Q$= LMQ*:1[5VT[@M6&J[<X9P"I.GIX90=@L566D.!+,$>"G*(OJ*=
MS,Y!5DYG7(6^5]KZ\S?H6NUEN+">4+'K"L&(M]E[8TM*KOC,9W"H/F ZHJ[@
ME+2,E96EJ ,;K6C4XZ%?8ZXM/4H-ZIJEI[U?Q5+/$+0X+D1WE7T=S/B5-C>X
M:MH[PHPXDWXU]:*6)V8HNN#U*R=QO1I:*23F]8[-4;SRNFE<]YRYQR2LZ>VT
M_!X1$4!$1 1$0?6N+2"TD$=X6:HKP'M;'6]PP)!U]ZPB*3&UBJ:>S9):*.1O
M/$YKV9ZMW"M32X=O[%BJ>IFISF&1S?+N62@NC)"!4-Y3^,WHM<T3'9NIN1/=
M5BI0!T57LW#YNV%[8YKAF-P</$%>P\9ZK#<PW1KR?(1(-NY7AG>UF"\;=V51
M;(,8V5,MSDG!RL);Z;DQ&H4*JMF+CR[-SCV*M;C)VK<D[]0JC8FN[AG"R%#"
MQI+L#;&W@L9JC6DBF9G<RR]K@>XCE^:MIH*-SI0W&,#)!'<L%;)HVQ$X69IZ
MUT;B_H!WK1/5U41$0V:DI88S@/"KF6.-P:'#FZ!:ZZ\<CB000=B">BQ]9<V3
M%_9RN#QZPP<>:11LJN1#;ZBI:QA:XX=X^*UV^7=L,3CV@PT'&^Y6#FOWJRMF
MDYG 9#AMMO\ 2M%U%?GR@P1D\PR"[*V46IF6BY?BF'G4EZDK9'0->2TX+SGZ
M%KDG*W9IR5XYCON=U\7;31R]'FUW.;K+Y[5]1%FUO<:J>2\1JIC8K?3'1A+R
MO+EZ/1>2$E8>47H+YXJ:'E.Y?5\6N64/B(B@(B* B(@($0*P"(B B $G &2K
MF*BF>\-<WL\C.7[;*"V192IM@90MEA<7RQY$S,=-]B/)8M76B!$10 B+[WJP
M/H7U?$6<=$$"(H"^+ZOK&YZ]$[]#L^Q-SU66HX?5)"Q;2 [<;+/6P QX)W71
M9IAJN2^L)8[<[*]A(<=R2#TPK:9HW&R\0S]GZIWPNB.C6O)7 ;!6\T[6M)SN
MOCG.ESRGN6+EYW/(\%*JM$1MWAPR/-P[TP?&VTY__5M6RK6>%^W#C2_^K*?^
M[:MF7G3W=4=A$111$1 1$0$1$!$1!:7:XTEHMU17W*=L%'3MYY97 D,'B<+Q
M8[O07VV0W&T54=7139Y)H^CL$@_2"%ZO-OANUIK;=5C-/5PO@D'^BYI!^M0M
MZ+5PFHJ34FD;@<5=HK7.#3X$EK@/(.9G_:03!?=1VBPRT4=XKX:1];+V-.)#
MCM'[;#XCXK*KD_TCJNNU7Q K*&T R0:8H#43%I^826F1P\QS1C_9*Z$T/JR"
M\\-[?J2JD C^1&:I=^*Z,$2? M<@R=)JFRU>HJFPTMQAEN],TOFIFY+F 8W.
MV/PA\5F5 WHP4<UVJM5ZTKV_Y1<ZMT49/<,\[\>67-'^RMYO?&/0MFN3Z&LO
ML;JB-W+)V$,DS6'P+FM(^!02 BL;)=[??+;%<+/60UE'*/4EB=D'R\CY'=7R
M#!:8U;9=3S7"*QUHJGT$@BJ1V;V<CB2,>L!GYIZ+.KF?@AK*P:/KM>SZCN45
M&V6X@1M(<]\F'2YY6M!)ZC?&-U->CN(VEM83N@L%VBGJFCF,#V.BDQXAK@"1
M[,H-M16=XNE#9K?-7W6KAI*.$9?+,X-:/^?DM)M/&70EUN3*&EOT;9GNY6&:
M&2)CCY.<T#XX0;?J2^V[35GGNMZJ/DU! 6B27D<[',X-&S03U(5*74UGATU'
MJ"HKXH;/)$R9M3+EC2QV.4X.^^1MUW6D^DI_,W??SJ?^_8J,5)IVK]'ZRLUG
M(Z*R-MM(Z:5O-S1G# TCE!.>8CN/7P027;*^ENE!!6VZHCJ:2=H?'+&[+7@]
MX*N5@=#066BT=:X]-.__ "(V .IGNYAEAWYCS8.^2=_%:S7\:= T5Q=1RW^-
MTC7<KGQ0R21@_GM:0?:"4$B(L#=-7V&V:;;J"KN,?V&=RXJXFNE8>8X'S 3U
MV]JRMKKZ6ZVZFK[?,V>CJ8VRQ2-Z.:X9!WW07*+ VS5UCNFHZ^PV^N$]UH03
M4PMB?B/! W?CESDC8'Q\"L'J7BUHO3EQ?07.]QBKC/+)'#$^;LSX.+ 0#Y=4
M&](L7IS4%JU+;6U]BKH:VD<<<\9Z'P(.[3Y$ JO>[K162U5-RNDW845,SGEE
MY2[E;XX )/N07JQ>I;_;=,V>:Z7NI^34,1:'R\CG8+B -F@GJ0N?Z7BY:V\=
M*NX2ZEJOX'NI0V-I$QA[3LVC:+&0>8.WY5N''6^VW4G >XW2R5(JJ":6$1RA
MCF<W+.UIV< >H/<AI+=LKJ>YVZEKZ&3M:6IB;-$_!',QPR#@[C8]ZN5#VDN+
MFBM/:-TU;KG>V-K(K;3,E9%#)+V9[-N0XM:0".\=0I2L=XM]]ML5PL]9#64<
MOS98G9'L\CY'=!?HM;UCKG3FCHXW:BND5(^09CBPY\CQXAC03CSQA8"#C1H&
M:WNK/X0Q,B:\,<U\$HD!.<>IR\Q&W4#'F@D-%''%WB!9-/Z8N5#)=W4=YK;;
M++0"..3F<7-<&.#FC#3S#O(PM6X$\4K+-I6S6>_W^:HU+43OBY)V2R/>YTAY
M 7\I'0COV03@B+"ZJU59-*4+:O4-RAHH7'#.?)<\^#6C+G>X(,TBT?2W%;1N
MIK@VAM5ZC=6/.&0S1OA+SX-Y@ 3Y#=9[5FJ+/I*VLK]0UHHZ1\HA;(8WOR\@
MD##03T:?@@S2+S#(R:)DL9YF/:'-/B#T6$TUJVR:EJ+C!8ZX54MOD$54T1O9
MV;B7#'K 9^:[IGH@SJ+2*GBMHFE^R'RB_P $3J";L*AKHY YLF7#E:.7+]VG
MYN5L^GKS0ZAL]-=;1/V]#4M+HI.1S.8 D=' $;@]0@R"+7]2ZST_IFMH*2_7
M*.BGKB13B1CN5V" <N PT>L-W$!:RSC9H!UP^1C4$8?S<O:&"41Y_/Y<8\^G
MF@D9%;NK:9M ZM[9CJ01F;M6'F:68SS#'48WV6DS<8M!PVV.N?J*#L)'%C (
M92\D=?4Y>;'GC"#?D6&OFJ++8K,RZWBXP4=#( YDDI(+\C(#6]2<=P&5K>GN
M+^B+_<64-!?(Q52'EC9/$^$//< 7@#/EG*#?47Q[FL8Y[W!K6C)). !XJ.ZO
MC5H&EN!HY-01ND:[E=)'!(^,'\]K2#[1L@D5%KFG=<:<U'=:FVV.ZPUM731B
M61L37%H:<8(=CE/4="59W#B5I"W7&Y4%??(*>KMPS4QR,>WDZ; XPX[C9N2@
MV]%@M/ZMLFH+ ^]VNO9):F%X?42-=$UO+\XGG ( \5JS.-F@'7#Y&-0,#^;E
M[0P2B//Y_+C'GT\T$C(L#I?6%AU3/<(M/W%E:^@>(ZCD8X!A)<!@D .!Y7;C
M(V6#K>+>B*(U[:F_PLDH93!/&8I.</!((:WER[=IW;D#WA!O2+3]+\2](ZFC
MJ'6F]T[C3L,DK)@87,8.KL/ V'>1L%B1QLT ;A\C_A SGYN7M.PE[//Y_+C'
MGT\T$C(J<$\-13LJ()8Y('M#V2,<"US2,@@]"%']=QJT#17%U'-?XW2-=RN?
M%!))&#^>UI!]HR$$B(K:UW"DNM!!76VIBJJ.=O-'-$X.:X>15R@(BTS5O$_2
M&E*PT=ZO,4=8/G01,=*]OYP:#R^_"#<T6OZ1UEI_5],^;3MSAK!'_&,&6O9^
M<QP#A[<*CK'7>F]'MC_A#=8:62099" Y\CAXAC03CSZ(-F1:EH[B-I76$SH+
M!=XIZIHR8'M=%)CQ#7 $CV95_JG5]BTJZA;J"X,HOEKS' 7L>X.<,9W:"!U&
MYP$&>11V>-.@1<_D7\((NTYN7M.QD[+/Y_+RX\\X\UD]5<3-(Z7,+;O>H&RR
ML$C(X0Z9Q:=P[# < C<$]4&XK W/5UDMFI:"P5M:(KM7-#Z>#LWGG!)'S@,#
M=IZGN7C1^M-/ZPII)M.W.*L$>.T8 6/9[6. ('GC"AWBY6TUN](K1-97SQT]
M+!2-?)+([E:QH?-N2@Z#5"X5M-;J*>LKIXZ>E@89))9'8:QHZDE:%0\:= UE
MQ%%%?XVR.=RM?+#)'&3^>YH ]I("VK6,-HK-)75FH' V5U,YU2\9.(P,EPY=
M]L9V07=CO%OOUMBN%GK(:RCDR&RQ.R"0<$>WR5^M(X=.TE8>'3:S2]2XZ;A;
M-4.J7M>7'E)[1Q! =MRGN[ME95G&G0-+1P5+M01R,GSR-C@E<_8D'+>7+=QW
MXSW()$1872FJK)JR@-9IZXPUL#3A_)D.8?!S3@M]X7W5.J++I6@%9J"XPT4!
M.&E^2YY\&M&2X^P(,RBTK27%'2&JZ\4-FO$<E:?FPRQOB<_\WF YO8-UMERK
MZ2V4,U;<:F*EI(6\TDLK@UK1YDH+DG )/0+!:1U;9=74<]5IZM%7!!)V,CNS
M>SE?@'&' =Q"U:DXTZ"K:TT4-_C;(X\K7RPR1QD_GN: /:<+3_1$^\Z^_P"L
MC_=L03LBL+[=Z*PVFIN=UF,%#3-YI9 QS^49QG#03W^"6&\4%^M--<[14-J:
M&H:712M! < 2#L0"-P>J"_182PZJLE_N-SH;1<(ZJKMDG95<;6N'9NR1C) !
MW:1D9&R\W?5UCM%_M]DN%<(KI<,?)J<1/>Y^3C.6@@#(.YQT*"M2ZELU7?JF
MR4USI9;M3-YY:5K\O8-N[WCV9674:V*W:#AXN7FHMLSSK!L+I*N$]IRQM(9S
M.&1RY/,WH3U]JC7B3Q;ME7Q!T;4:<U+5-LM/4--S$(FC86=JTGG80.<<H=W%
M!T;75<-!0U%75/[.GIXW2R/P3RM:"2<#?H%8:6U':]4VEMRL55\JHG/<P2<C
MF;CJ,. *UFLUE8=8:!U5-INO%;%3T$[)7")[.4F)Q ]8!1CP+XCZ6T=POHZ:
M_P!U9!5/J9G"!C'2/QS=2&@X'MP@Z*18/26K;'JVB=5:=N,-;$P@/#<M>PGI
MS-< 1[PLX@(L3J;4=HTQ;S77^X04--GE#I#NX^#6C=Q\@"M9T[Q=T3J"XLH;
M=?(Q52.Y8V3Q/AYSW %X )\LY0;XBQ.J-16K2]J=<K]5BDHFO:PRECG^L>@P
MT$J_H*N"X4--64<G:4U1&V:)^".9CAD'!W&Q'5!718.QZMLE\N]TM=JKA45]
ML>8ZN(1O;V3@XMQD@ [M/0GHL36\4-&T-5<Z>LOL$$]M?V=2R2-X+79(Y1ZO
MKG8_-ST0;DBQ>F-06W4]FANMCJ#4T$Q<&2&-S,EKBT[. /4'N4.^D5Q(H*.P
MU-EL%]J*74=-5Q]K'3]K$]K.4DCG  (W;T*"=D6A\..(VF]304%JMMW^67=E
M&Q\T;HI0[+6M#R7.: =SXJ]UAQ)TII"I%-?;O%#5D ]A&QTL@!Z$AH/+[\(-
MO18#2&L;#J^D?4:=N4-8R/ D: 6O9GIS-< 1\%4U7JNQZ3HFU6H;E!11..&!
M^2YY_P!%HRYWN"#-K W_ %=9-/W2UVZ[UHIZRYR=E21]F]W:.Y@W&0"!NX=<
M=5AM+<5=&ZGKVT-IO4;JQYPR&:-\+GGP;S@ GR&ZCCTB9XJ;B7PRGJ9&1015
MH?)(\X:QHFA)))Z !!/R*.X.-6@9KE\B;J"(2%W*)'PR-B)_/+>7'GG'FM^E
MJH(J-]6^1OR9D9E,C?6'*!G(QUV\$%9%'E3QHT#!01U9U!$^.1Q:UK()2\D=
M?4Y<@>9 !6R:0UC8-7TKZC3MRAK&QX[1H!:]F>G,UP!'MP@SZ+&:AOUKTY;7
MU]\KH**D:<=I*[&3X =2?(;K4K%QBT->K@RBHK[&VHD=RQB>*2%KSW .<T#/
MD2@V_4-ZH-/6>HNEXJ/D]#3@&27E+N7)#1L 3U(52RW2CO5JI;E;)NVHJE@D
MBDY2WF:>_!P0M&](?^9[47YD7]\Q9'@L0.%.F"3@"B9_B@W5%'EUXSZ#MEP=
M1U%^C?*QW*]T$,DK&G\YK2#[B5NECO-NOUNCK[-6P5E')\V6%V1GP/@?([H+
M]%K&L=?::T=V;=0W6*EFD',R$-=)(X>/*T$@>9V6$BXSZ!DH!6?PAB;'V@CY
M70R]H'$$CU.7FQL=\8\T$A(M?NFLK#:K_;[+<+@(+E< #31/B?B7)(&'XY<Y
M&,$^'B%GWN:QCG/(:UHR23@ (/J+!:3U;9-6TU14:=K?EL$$G922")[&AV,X
M!<!G;'3Q"SJ B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B O#NI7M>''UBD#YE?5\7U5!1AQCTH
MVXT!N--'F>('M,?A-PI05&HB;/"^)XRUPP5:9TQJIW#C.&-[3)33=V[?,+7[
ME2F*9S<>J5)W$^P/L-\>8VGLL\[#C\$]1\5IUS@%13B1F"<92J-)1.X:)4,Y
M7E4%E+C 1DX]JQF-TA9?8W%CP0MZT;<@)&QR'9:'A9S3K)!4-< 0T*PQE-,;
M6.8' =5\!;'OC=8"CN_(P-)Z*Z%R9(-R%EL75=5%K"5I%U?+/*2#LL]7U7.P
M@%8-L,LLA &RQF46,;G0'+BJDEU?(WL*?)>>JSU+IUU0,RDAO>KJVZ?@BJ'N
MC;G'?A-2=F#HZ-S(</'K'JO3:&%CLEO?E;'/1'FY6A6LE$>F^5=#9X-3":SP
MT,$/*6-#23T5S;HY'!H R\K VNE$."0MNT[4L@N$;GMYFD<JRA%:GE%(27?.
M2:ODD)Y LA>K8]M:9 WU9-QY*E#08W=LK"=6-$<DI]8JZIK>7?@Y639'!#N2
M%]=7Q1[,P3Y(:]7RGMV .;97C*>&+JJ,#+E6G%-22$'HXC 66HM)5U1O63=D
M#W,W39$QY,9)5Q19 7VFAKKB[%)">4_A.V"W.W:6H*0ASF=J\=[]UG(HF1-
M8T #P"PYH9135/X-5M.DF-(DN#NU?^*/FK:88(X6!D;0UH[@JB+":IELIIBE
MY+ 51DIFN!R%<(D3I=,14VF&4$.8"M=N6C**IYCV(!/>-EO*\E@*RBMA-J)0
MY<] O82:5Y]CEK5;8+C19YXB6CO!RNA'P-=W*SGM\<@.6@^Y7<2PY*H[2YU,
MLD9P]I"]MJ6NZJ:;GI2DJP>>%N?$ +4+IP^'K.IGN:? A.7T.>8[PT1\4,P.
M6A64UL8<]F<+8ZG2]=1N/-&Y[?%NZMFTIC.'M<#YJ=5B8GLU6:AE9G;(\E8R
M1X^<,%;V8(R-PK.JHJ=X.0$9=8:0Z/P5)W.W/>MDJ;2S<QNPL9/;YF9P,CR4
MT;8OM!W[*C,X8*O)H"-G-(/F%85,)QL5%VM)=U;/AYP55>79P0O<43G= M<R
MSA8MI^4JYCP-E<&E>>XKS\DDST*D2//,U>V3<O0I\DD\"OHHW^!5V=%>*K(.
MV5>15SV^Q6+*23P*]NI9 -@4VC-4UYY7#UMUFJ.]# W6CFGD/<<JXIXIV],D
M*;5(L%Z'+U57[-M_&*T%AG [U]S4'Q5V;;RZ^#\94G7T>*TL,J3WE.PJ#U)4
MW)MMSK]YJB^_?Z2U84DQ[RGR"4]24W(V!^H2W\)>!J($^LY:W-0/SC=>([<\
MGO4ZC=::[A^,.RLO358D&ZTJBH9(L%I/L6?H'N;@/&"ME,RQ9N:".9IR 5@[
MC:QN6C*SD+O57R;#FG*V(CRXV[KZJU:OI7,)P%*%PIVNS@!:Q7437..0L)A8
MEHC8)"[ "NHJ![NXK:J:UASMFY]RRT%HP/F*12NVE0VR3P5]#;'XW6XQVO'5
MN%B=75<=GM;G9':/!:T*Q0FT<ZEJ@^?L8SZK.JPB]2/,CW.<<DG*\JS) B(H
MHB(@(B("(B B(@]PS20NYHW%I\EDJ>X-DPV<<ISU'18I;!IO1]XU T26^E<Z
M'GY#(2 %)IVRIJFGLJ1P.E!<S?E&=CW+;=,\/[W?J(5E)''\G.>4ND:"3TZ=
MWO6_Z$X;45ADIZNJF?-5MY7%LK08VN\-O\5*%#"VGC,?9"%C!E\3!@ >+2%C
M%N/-M\6?)"U/P@OAB8\3TA<2=N8_#HL5>]&7BTW!T#:=TC9#B)S=P?+/O[UT
M=&2UK7/^:3RY'>T]'>W.![U7CD:0&N:T]"6XSCN/T[J3:IE8O5PY-=*^C)@D
MC,4P=RN:X=#G?_%5&73D)Q\T=5T3J31=LU"YSYHVPU$9($H;U[OW*(=2\*KQ
M33%U!RNA)Z/.^<[Y6N;&NS=3D[CJU*LNG.QO9X!.P/CE8:JN;6.;@D<IQ\.B
M]ZNLUST]RLK(2(B_E;(WYI/79:C+*^0DN/5946]-=R]MD:VZR2O?V9(#L_!8
MLDDDG<E$6V(B'--4U=Q$15! B^M5@5(PO97R,#'FO0Q[ET1V:WG"^87L;KR1
MYH0\A?,+[WKX0L63ROG<O2\K7*P^(B+%1$10$1$!$16%@5S;Z*>OJ6P4K.>0
M_0/$KU:[?47&I$-,PN.1S.[FCQ*E&PV6GM=)R0@/<\?=)3U<?W+.FGF855:8
M6TZ?AH(P2WGJ,;RGH#X!4KG0#'.T8D;T*VJ2,-&&@ > 6/J8\@K9RZAKVU!C
M7AQDA/W4 M<T]X\"L-<*5K09Z<$19PYIZL/@MEN-.^&4RPDC\8 =0L35QMGC
M>87/YW#!!Z%:YAG$L"B^N:6N+7#!&Q7Q:V8OH\%\1('M>2OH=D8*^%9RD 7U
M?%Z:,[GHD*-&5['@O)/@F5G'1B^E7E)4F,8WR/J5EE?0["SIJU*3&X9ME:'L
MPXKQ),TY.!S>:QC79&0O7-D+;SM?*NQ4EC@6G&"JO-\H<9,#F/798TG?=5Z2
M;D<,]$BK9,:=Z\,QCAWI@?\ ]-I_[MJV1:WPS(/#O3)'0VVG_NVK9%Q3W;X[
M"(BBB(B B(@(B("(B N=-65T/#7TB1>Z@F.T7JB<Z<CIS<I!'MYXV'_;71:B
M7TB] W#6^GK<ZPTS:BZ4502UAD:S,3QZV[B!U##\4(8+T<;(;Y9-5ZEO<?:2
MZCJ)8G!W?%OSX\BYY'^R%%XU3/HOASKC057*17LN IZ?/4QO)$A'ERQ__K%U
M7H:Q,TSI&T6:/'^1T[(WD='/QE[O>XD^]1+Q&X1UNH.,UHOM+31OLLQBDN+S
M(T8=&=QRDY/,UK1L#WHJ[U'3U7#WT:#347-!7MI(F2O;LYCYI!VASXCG< ?8
MH^X=SUMGTC34\/!Q]Z;51"22OF/.:D.&01F(X;@C !^G==*ZNL%+JC35PLMP
MR*>LB,;G-ZM/5KAY@@'W*%K#3<7] T/V!MEIMNH+;"2VDJ7R %C<[#=[3CR(
MVZ X0??1UMVHK-J_4%/5Z=N-ET]6QFI@@J>9S(9 ]H# X@9/*X]V2&CP4_K1
M^%U%K2GI:^JU[<*:>IJY!)#20-&*48P6\PVWVVWZ9R22MX1'-'H_Z0L>H-6:
MTK[Y;H*^6CKN2%E0T/C;S/D)/*=B?5'57OI%Z4M>CZ6S:PTI3P6BZ4]<R(MI
M6B-DF6N<#RC;(Y,''4$Y5EIG1_%;1=[OUVT[04;X:NJ<YU#43QN%0SF<6O&'
M#!&?Q@=^A659H?7O$O4=!5\2HZ:UV*A?VC:"!P/:GO& YW7&"7'8=!NBL3Z1
M-VK;UJW1=F9;JFOI):9EP=;87ECJA[BX%F0#N&L(SC(YBK36 N>H=,R6F'@K
M-;I&LQ355-ZKX'#H=H@7#Q!._MW4K\9>'M9JMEKNVFZIE%J.T/YZ61QPUXR#
MRDXV((!'=U!ZY&K2W/C?=J;[%BR6JU2.'9R7(2,R!T+AZ[L'V-/EA!C]5F\C
MT59X-34U33W.F,,#VU#2'EC:E@83G_1Q\%E-:_\ 90@_U70?WD2VKBCIF_WW
M@[4V*)[+I?GLIP^1O+")G-E8YSO6( V!/7]RL]3Z2O-=Z/T6F*:D#[TV@I(#
M!VK .=CXRX<Q/+L&GO0:5KN\55I]%S3S:)[HW5T%-22/:<$1ECG.'OY<>PE8
M;3,M;;-*06H<$I*^)\($M3,[F?4$C=_-V1(SU&#MW*68] .O?!:W:2OH^2UD
M=%$PN!#^PF8-CL<'!ZX.X)6EV>;C1I6VQV&GL=LO$-.WLJ:N?*W9@V&<O:2
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MHM5+05QK64SC2QB)CV.9([=HVSE@WZK,:GT#K#2&N*[5/#$T]3%<7%]7;9G
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MAIVADL,A#6U#0"!N=LX]4@[$8W!&^L7JV<7^(E*VQWZAMU@M#W-^531N'W0
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MLZ"!LLP,N>R'4K?[5,# WDV8!AH6=,;8S.GNV4\="T10,:UG0X&[O,E9JGG
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M#T<UTE0"/@5<>C[63Z5U5J;AW=)"74<SJJB<[\-AQG'M:6.QYN14[%S00"X
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M+&>CF.#@?>%R3J/5=AUOQ'NYX@WNMH].V^5T-#0TK'N$G*XMYCR@@9QDGKN
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M47"E932OIGSG+XXC!/AA[MB'=,#?H$5U$B(B"(B B(@(B("(B B(@(B("(B
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M(<_+>08R-QASB3TR[ [\%3VB(B"(B B(@(B("(B B(@(B("(B B(@(B("(B
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M>FWBTD>Y6-;)\GDA/)*74\G*>7N8>8Y_P^"HS5#+&Z7.^:B/EYB=C("=O/\
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M?8,J':&N$#'<KHRR7U\]>[O\%OE'6%U9 UTW98CSS2'8 AH]WL6$,VWO/91
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MSMX[X(PM[U/][=V_5)?V'(CE[@E9^(5_TE)2Z7O4%CL4-2]SIRW[I-*0W(&
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M)6SMA;,^*)^7,:=O6'=OM@H-"]'O5%YU*-5?9RODK/DE<(H.=K1R-];88 \
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MGV=%J.F[WK?BKJ&]NM>KX=.TU#,604+&@R%N3@D;$]-R2=^@4_:8(;IBTEQ
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MC8TN .2WU2<%QR ".7?8H.J5"G$W7&IKGKMF@^'9C@N+6"2LKG@$1 @' )!
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M[;EH=%_VMJ__ %</[EB"KK?6>K-5\0*G17#F:.B%"/\ +[B\#U2,<PS@X )
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MMY%9PT-7 3/;)'1N</P3L5$C'%IR"MUT;K>6T2-AK6B>E.!ZW5JSIF)832R
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M\KW/<>\G*U55QY,Z:5W<ZWY5+ZGS1W^*L41:IG;,1$0$1%01$4!$1 1$0%]
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M_P!NDH+U105M&_<Q3-R,]Q'@?,;K((@P&E-&Z?TFR=NG;7!0]OCM',RYS\=
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M8':=M+M._8$T$)M'9B+Y+@\G)G.%E406EHMM'9[=!06RG934<#>6.)G1HSG
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M 1$0$1$!$1 1$0$1$!<N<9[M\FXFWJ'/S>Q^F%A74:XG](LSLXQZA<P.Y/\
M)\$?J\:RIG23&US!>F$[]0L@;W%*1G (&,J(67"=G>?>KF*]3-Z[K/G8<B7&
M5T+NA'Q5PR5CV$@C'?NHH@U!CYW,KV&_Y<.67E'>"%8JA-2D,VR60"2$@M/@
MJ]-%40M+902U:=1ZEEB!$,H]BRC-35,T1;(YH!66X8ZEL8PX8<QCAY@%4)+9
M;YSS34,+CTRT<OU+"PWOE.YV5[!=V./K'9%T\UNEK=5,8R)\M.&] #D?2L56
M:$J2T_(KA$X'N>"WZ1E;-'71.!P0J\=1&3EI&3TRB:19<M#7RF!=V#9VCOB=
MGZ\+"RV:X4YS4453&T=2Z,@?%3M',]OS7_2JS*QP^>QCATW6/*RVB/2] #(U
M[F@K.:CLE#74A?RMBJ&CYX_Q6^N%#(_,M, XG<@ K%WBWVZ>+D:V8!WSN4X(
M5U&M,>O=!,\1BD<TG.#C(5,;*3Y] T=2YWV/KY&?Z,X!^D86%N'#RZ0Y-.^"
M89Z!W+]>WTK5-$MD50UZR7JJM52V2FD<!WLSL5)VG]6Q7%H];LJ@=6D]5&%=
M8+I0NQ4T4H\VCG'Q&58QR2T\H<TN8]I]A"L5:[DQ$]G1-->F2M#)CRN\<KY6
MO!C)!!"B[2&I:9];%%>B1&<#M&J69HJ&H@-/029=C+79R"MD=6J8TK:)_P F
M@KJP[<K205C+!Q2=!=:B"OYNS[0AKP1C&5[O=2;'I2HC)Q+("%#;CS$D]2<J
M35J33K:@NU%>J8%DC'!P\0K"XVNHAS)3/+F=>5<XV#45?9)@ZEE/(.K#T4U:
M*XATUS:R&H=R3; M<M]J_-/9A71%?=E:;M'.Q)D$=05G[=3EQ"NV4U-7-$C,
M<QWR%7IX'4Q((V[BLLG)CD^ZT1:FF>JOV($>!U6,KX/4/BLFV3)/BK"L)+]_
M%<>%>FJ6RJ.C#,M7;/S([ \E=LL=,!OD^TK(!O*,JE-5-B9EQPO2F[5ZD6J=
M;F%)MJI6#^+!7QU%3L'JL:J;[E%CY[?BL=57JGC!YIV#WK'Q/65Y*?1E&0PM
M.S6_!73.S:W8 +39=3T<9WF:J1UK;F##I_@TK";M/JL4Z\FZ2N9@]%:.G8.\
M+1JO7=!@B-[S_LK%3:Y@&>1DCC[,*Q=HCO)RSY0DIU4T95%]8T9W46RZY<<\
MD#O>583ZSK'9Y(V#VY*>T6X/#KGR2V;@P?A?2J3[K& ?6'Q4-RZIN3\X<QO^
MRK.2^W)^<U!'L&%KG+I\H7P*I3+)=XQW_2K9]\C&<N'Q4,27"MD^?4R'WJVD
MEE=\^5Q]ZQ]L](7V:?.4RS:DIV?.E8/:X*SEU92-SFHC_P!X*'W.\795)SVA
M8SF5>C+V:/5+<FN*./;M>;V+'U6O:<@AO:'V *,73-"I.J&CO6/M5?DOL]/J
MD&?7(((9'(1YX"QD^L)G_-C(]I6ENJ1XJ@^K SNL9R;L^:Q8HAML^J:MX(&
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M2W]_L66J*R0T[>T^Z,:T .!Z;8QGK\5I?RAS&O@YP03ZS2U565\T)#H'D/
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MD)B;A^.A\/?WI V^LKI7V6E?',YLK6,<.:(;%CL$D^)"US4MQ:^K[5G9[MW
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MOK'M.)6GV'*NZ:\9.SQOW$IN$TIU>F+1.3BD,/G$XA7MGI'6AP%)5S.@_$F
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M]"J3JIQ[U;($%4SN/>O!D=XKRB!S%? 25\7IH05&=%]>[9?.@5-ZJ/).41%
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M78&L:&M%!!@ 8 ^YM42U?"K45BO-RN_"O545)'4S.?+03X='S@G+,X<TX.0
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MHU55-/PCM$5/-$^6G=,R9C7 ECC*X@.'<<$'WK?=46:+4.GKC:*F22*&M@=
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M' FT4MXI[EJ"\72_ST[@Z)E7)Z@(.1D;D[]V<>(*E]$<^\7IH+9Z06B+E?\
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M=-6T+5^%?\VFE/\ 5=-_=-6T+%1$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M<?$1%B@B(@(B("(BJB!$"#Z%49WY5,*I&ME#"7M>@$ 7UH[UNTP?,87D+TF
M4'P>U>FG"^ 9=A?7-P?%(%8,+F9"HY/BO44W9M(*].:Q[&EG4G=9=^R1T43(
MYL;@3D$*V5:=O)G*HKGN3UU+;3V$&R(M;)^@7"K^;/2G^JZ;^Z:MH6K<*OYL
M]*?ZKIO[IJVE0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MRM$]V<"(BQ'Z \*OYL]*?ZKIO[IJVE:MPJ_FSTI_JNF_NFK:441$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%P_Z2'\\^HO\ Y?\
M^GB7<"X?])#^>?47_P O_P#3Q((U1$1!$1 7MH7AO550BOH&5Z'0KX.B^YQT
M047+RO;N]>$!%]'1,(/B(41!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!?6-YG
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M0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!</^DA_//J+_Y?_P"GB7<"X?\
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M,]R]S7^I.S6L:L.Z1[NKW'WKSU5\&B9W,-5/$\BW1X=NN8B%U/<*F;//*<>
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M6Y%EJ#3URK8Q+'2RB(_AEIPK6B:(96RRLY@T@AOBI*L_$V2FA;#4TT3HVC
M;A;8B/-IF9\FJ4VGHH,?* Y[O C"R+*1C&\L30UO@%O=-K#3-S %93=FX]X"
MOX[-IVZ>M;ZL,<>@)3DGRE(J]4:_)/)>32>2D:IT-4AI=2RQRCNW6&JM.7"G
MSSTSL#P6$T3#.*H:@:3R7@TGDL_)2OC.'L+?:%2,(\%CI88,TODO!I?)9PPA
M>#"$TK"M@+2MGT16OH[M%RN(WW]BQ[H1X)!S4\S96?.:5G1.I1UMI6N9-1QD
M$8("V7(<S=<Z:)UP:5\4,A]4D @CHIJH;TV>G8YIV(RMTT[ZPP[=WB[V6*XO
M<)8PYG@0M%U'PWM531R@4D;9,'#FC!4HP5+'1YSU7BM$?R=Y/@K%4]I3X.3:
MW0<M)62L<\AH/J['HKBTBHL54QLCB8CT*EZ]QPUE8\L P-E'6NV10-;$TCM#
MZWL5FB(ZPG/,U3#<+1?62,:TN'Q60K(8JUN=B2H+BU ^BF;S.V!WPI&TKJ6.
MI:PE^05C$I-/3;SJC3;ZJ$AHP<;$!1;7V^HMU4Z*=I!!V.-BNGZ"&&OA#AAP
M*Q.J="4UWI'-#>64 ECO J5414RHKGM+GNEJ7L;C)7RIJ"YI65OFGZNRUCZ>
MKC(P=G#H5C.PRM,Q,=&UC PDG9>A&?!9,4Z]"FSW*:&-$?DO38O)92.EWZ+V
M*;R5TC%MCQW+VZ%LC',>,M.Q"R7R7?HJC:7;H@CB[4+J&I<TC[F=VGR5FTJ2
MKG:&5]*Z-PPX#+3X%1Y7T<U#4NAG:6N;]*J+JS7:JM-6V>ED<T@[@'JN@>'W
M$B.LIA'-)RR@ $$A<W=0JE-42TT@?"\M<.\+.FN8Z+WC4NPJO5$+H2[M1CVJ
M)]57N*:ID(>,'S46?PHN1CY#+D*QEN-1,27O.ZLUQ/9CRQ#;ZN\,:3RD9]JQ
MLMTDG.&DK ,)<<N.5>PD-PL=HOV],N.253<3G9>0_(7UFY5VFF2MC0T.)ZX2
MND#6N)V"N;7 9(R>Y66H('QP.+0<#JHNFI53^TG>[S5)#U*+!D(B("(B OH7
MP+ZK ^H@/BOO?LLX0 ).R]# .#NO3HRP O. 53)'X*S[)W56N R7;^ 5('/5
M?,+Z F]FGL=%]QNO@V7INZSAB#S7UPRPA>@T87T=-UEK?1-K,C!PBKS1YW:J
M"Y:J9IELB=B(BQ5^@/"K^;/2G^JZ;^Z:MI6K<*OYL]*?ZKIO[IJVE%$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!</\ I(?SSZB_
M^7_^GB7<"X?])#^>?47_ ,O_ /3Q((U1$1!$1 1$0$1$!$'FO;0P]7$>Y!<T
M$_9R,ST;E;S8*MLCV$%VQ'3N4>'#7>J25LVGZ]L9:"/<LJ1)]R>V:T29)RUA
MYL#UL86@6:MM=?)-07=D;HV^M%*[8]VV5MUJJ150.B+'DN;N>O5:92Z$NDEQ
M>QX:R('9^^X6.O*1K-;!'0W22(/$T+';.:?G-6S:H921::H9+?4/>R=PYFN(
MR-L]WFM@=H&FC [1QDDQOU5O6:,8Z%D0+@UIR!NLHIF6/-$(UR?%5Z=\G-ZC
M23Y!2!;M'T5.[FJ6NF=W YPLRVAH86N#*=C=L##>B<M1S0C 54K7<I:>9?*N
M6>2+#F. SX*0'6B@+R\1^N=\E6=1;L/PQC2SS"RY93FAKULKYXX0U['/P, .
MZ*]8!)S2S>IGHUJRU);#+* &<QSC8;+9H-,TK:8R5;F@@9#5)Z=R.K0I(I0,
MTX<__1'5??DMQY2?DDWPZ+-U]1;J. Q%S1)S9R#T"UBOODKYGBC?+RGSSE2)
M9:E6D;<(03)25 :.I,95.&LF=*(^1S7_ .D,%6D%UNLT_9B64YVY2LB]M3VK
M9*DY<%8ZI+[+62P'$K3CQ7R.[9/7/@K^&4.BYGM:X^87EU/+(]O)%'R..22P
M;#O51;_98;#F7H7)I<23E4)G,/,74D7SN4>KC*]MBH@)724@Y68;ZKB,E45Q
M7Q'P5:F=',[N [RK<4UJ=)(US)HBV,.(:_.#[U5AIJ'U&LDJ 7-YBW(SCQ2)
M-,B^_P -"SDIFM<X=ZQTVK*YQV:P#/<K8T5!),T"LD'/XL'[UZ?9P]KC2U3)
M,' !&,GP"<TFE>+4U6X^M&S;O 59FJYV;OB8X#KE:_V;XY',>,.S@KQ5'D!:
M#L1N%.:33:6:PB<")*=A]B5&I*.:![60!LA&Q\UHN2"<+VUY!.>H5YI-0D&&
MK?)34\SADO9D^9R1_@J\-=2\V9"&N'BL%!.?L+;^3/-RN!W\'E6$KSS/P<C*
MG,NH;HZXTX!<R1I*Q%9=FACNRE+7^1ZK5Y'DEW*YRL*R1S3S!QR%.<Y4BV\W
M9U(VH;.\-[L'"R4&I+_2-'9U<CVC8-<[(4<4FH:QD+8^V=RCNRKJ/4LP^<<K
M/<)J4GT>O[HQP-12P3'O!9C/P4?ZLIWWN[35SI!$Z0Y$;F[#RRJ,.I@'#M&;
M>2O(]0TDS0V:)I]JDQ$G5JTMDK&_,:V0?Z#PK>2"MHQS2PS1CQ<T@?%;M'5T
M$HSLTGI@]%4=V3VD1S^P$Y"G*O,T2&L>UV2XY]JOZ:]SQ?-D</>M@FML4K<2
M0P2>8;@_$*QJ-/4[QF)KXCY'F'TIJ8-P^-OD<[<5,4;_ #Q@K[3/H'S9DDD8
MSPZJQGTU5,W@E;(/ @M*L9Z&OIB>UIY<#O R/H4-;;G#;+?.X.I;@S.<\LFR
MV)D4\<(:81(P=[=U$C*ES#@EP(63H[]64Q!@JI6>7-D)N$TWRIBIY 1+%R^U
MJPU;8J*=I<QH:?)>*'6\H ;7T\52WO. "LK%>K%7##FOI7GQ.R:$>WRWB@D8
M&DEKEC%NFMZ&(TT,]%.VHC!P>4Y(ZK2U@R@1$11?,+ZB#YT1?5\PBB91,("^
MA?!LF4'H+VTJF"O0*BQ*O&5685;,.ZN&#?983#;3*XCZ@+W6U7R:$Q1.^ZO&
M_P#HA6[ZAL+2&;R=Q\%CW.+G%SB23U)2FGSE*J_*'Q5F4\G+S\AQW*G&[D>'
M8!QW%92.[ X$L((\MEMAI8]O:@G/,O4KS)@D8(6695T,PP<L/F%Z?14[QF.6
M-WO30PK7.'0E7--<*BG.8I'-/D5=NMIP2T9"I&VR $@$^Y$Z,U:]<7:B(Y:F
M0@=Q<5O5EXIU B/RYL<C>_/4J(Y*29O_ ';C[EY':MC+>1P]RO-,&H3_ &W7
MFG+P'1U4$<;^_(526V:>N!)I*UD;CT&0N>H^U:<M#P?)7;*ZLCP6OD'Q5BK?
M>&/+Z)HK=)3,:74LS)F]V"%@:FV55.2)87C'?A:70ZLN]+C%1-@>)6RV[B).
M,,KHNU;WY 5U3)%4P]N81L1NJ;F+8*6^V"ZC[JP02'OZ*N[3S*EI?05,<C?#
M.ZQFW/DRBN):LUKF.#V$M(WR%NU@UQ4T5,V"<@AHP#NM;JK;4TSRV2)VW> K
M,LZY2FJ:6724PZ<XAQ.<8JIP!SL<K)7S75.*9S89 YSAC8]%!C06G+2O9GDQ
MN25GXJ:;\_4D,;"XR9*T._7-U;423/=UV \ K:1SR.]6%0Q[MMTFOF8Q3I@[
MB_G<["K6"Z36V<'F)CS\%]J*4Y)*M71@;$*0F].@>&^K87R-B?(.S>>\]"IH
MI',FB!!!!"XAM5RFMT[71O/*#TRITX=\2V%C*>ND)&P#B1M[5L[G+OLE74FF
MZ.\TSHZB)I)Z' R%!^K-"UEFE?) Q\U-UR!N%T!;;G3UT+7PR-<#X%5JFEBJ
M8RV1C7-/4$*?A4RBK727)@9@X(P54:P*8]9<.HJCGJ+8UL4NY+0#@J*:^WU-
MOJ'0U43HW ]XZK7-&NL,^_6%LU@7L,"\A5 L4&L"KLC"I-*N8\GH"@-B"L;S
M8::ZTY9*,2#YKP-PLJQIQT*]C(ZJB'+Q8JVUR.[:)SHNZ0#(6+"GE\4<S"R9
MC7M/<X96I7S0T%5S2VYPAD._(>A32(X8T%7+(6$+W<K766J4LJXG-&<!P&Q]
MZH13M 4%<1<G3<*JQ4/E (7J*4.58KQ@V5=@V5M$]5P54;?I)K:B L[PLO=;
M.):9XY<Y'@M7TA5_)[ARN/JN4JMA9/3@C!!"RB$JG75SA<*9U+5RQ/!'*XX5
MNM_XC6,P3FHC;MN3@+0%A,:;(G8B(%%%]1?$1]1$5!%]"^A6(3;YDGJ5] W3
M"] +.(3;Z!LOO+A O8]BV1#%XQ@KUA$5'H'N7UNX7D#=?1TZ[JPCWMRD^"HO
M8UPSWK[S=R=VR3J8ZD=%NYI:=U\5R6Y;N-E2?'C<=%SU6]=89Q5MW[PJ_FST
MI_JNF_NFK:5JW"K^;/2G^JZ;^Z:MI6MF(B("(B B(@(B("(B B**..O%5F@Z
M".@M8CFO]6SFC#]VP,W':.'><@@#R)/3!"2KK=K=:*?M[M7TM%#^/43-C;\2
M0M?AXE:+FF[*/5-HY\XWJF@'WDX7(6GM*:TXKW:>M89ZTAV):ZLD(B8?Q0?^
M%HV\%NU5Z-&IXZ4OI[K:9IP,]ES2-SY EOUX1=.L*:>&J@9-32QS0O&6OC<'
M-</(A5%PK:KUK3A%J4TS_E%#(TATM%.>:"H;XXS@@X^<W?S78?#C6=!KG3$%
MWMWW-Q/9SP..70R#JT^/4$'O!"&FSHB(@B(@(O,SBV%[AU#20N8.$G&+5^I.
M(]GL]UK*>2AJ9)&R-;3,:2!&YPW SU 0=0HB("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B N'_20_GGU
M%_\ +_\ T\2[@7'O'6P_+N,5_FFDY(G?)\8[\4\8_P %)G0A<#/175';ZFLE
M$<$1+CX[+>K;16R@J.4-8]S>I< 5D(ZVF-[B[$L&W0+&*]SHY9:8S1]V=_W+
M1[U5&BKJ?P&?%3!-5$8Y0-PJ'RA_DMG++%%+-#W1W<P>]5F:"N9ZNC"E#MG^
M("^=L>]Z<J;1LSA[7GK+&%<1<.:IWSIVA2!\H ZO0U;&M)Y_I5Y3<M'9PW</
MXRIQ[PKF+AQ3_AU+C["LA4W266K[.(DC/BLQ;[@R$AM0\ _Z2123MAZ?A[:V
M?QCW.]ZS5OTI::3!C@R0KJ:YTV?5+05\;=X!U>WXIRQ!'5D(::&$ 0Q-: KE
MC'.ZG"Q+;U3_ ([54%XAQ_&-^*;9:9=L#50FA#G8:%9B^4K0<R-S[5C:[4T;
M<]B6E;+=7JPKI]&8DIH8VDR86"N5321DX 6"N-^GE!P21Y+6ZVMJ9">6.1WN
M*SFN&N*)9VNN433ZF%CWW3+< K7)Q7R$\L$GP5L:>X_T$GP6N;D-D4)'IKS3
MT-"USRT/QDK6;[K&>K>8:1V =LK69:>X3$-?%,?+"R5GTY532!\T;V#PPM7=
MLWID[-;::IB+ZQO:S'O)61BHH:8GLX@3W;+9;!IP\K0YI \2%LD=AIH1S/&0
M/)9TT>K"9]$:QT\\DY=#3>N>_"O38*N0<]3A@\RMQK;C#0@LIH6!PVR0M7N5
MZ+G'MI02>X'99ZII81S2QYHXX3R,]9WBKVKY*:R29D';.V: L34UD4K7!LP#
MCWA6KFNGDA:Q_,&G<K#>V<='BO;+$R%C3Z[MU;M?5.=V;FL+ >8[=2LW4GEK
M6R.C#F,: %:]LT4D\Y!#G''3HD2:8IDY>*DNB'*\CG/><%5&U8<:B1OJ.DB$
M+<]&CILJTC6,MOJ_.D=NK=L#9'QL'7O"J:#RBH#VQ@L; 8VX_&\5=45U9!;H
M*2:$M8/6<\#?G)V/T!>HZ)TU1R<I:UO4J]-'S L[/+!U)"$+&AK::5M=#40L
M=R.+V._" S@[JPN%M<^)\])*V:/J0.H"RC[$R0F:GYFR$$'P(*Q]-;[I:7B1
ML9EB'4#=16NDX7IF#E9N[6OY1#\MHHW;_P 9&!\TK$04E1*S,<,CAWD!09V@
M>[[%P#\1SP/K_P 50(V+B1MWJXH^S9:!#)+&R;M'>J7@'& ODU-3MC#I[A W
M_0C/,?H1DQL\H;D!8V=Y=MC<K>(J*SNAB$5IN4^"'/F(=CE[]L=%M5NHK'5T
MC#1AE&3U>V,9/ES$;)%.S:(Z2W5E20V"GD>3_HK-4>C;O4?.A;$/](Y^I2K0
MT4EIJA(*B2>$M/J2L&/<<+(,N<QE<UL#0T#((&Q644L-HUH>'[^8?+JD@$9P
MP8/TK*4^D;73O]>)\GY[O\%NT]5VN6O:&NQW]50,D/.0]H(QU641";EA8;):
M0SD?1-QT!;@*TK=+VQ\1,#IJ=X'7FS\5L<TU(SF#&M:['4=5855]MT,8$TM*
MQP=S'!QGNWPKJ!'EWIZZS<KC,V6(G >W]RLX-03,=ON%LFI;W;KO V@MT!FJ
M'>I&& DY[L>)RL"-&WP<CI[?)31/(:))L,:,^.5A,Z9:9:+4D+Z0<^SQUR%=
M4UXHY&$O]4@9!"Q=XT+>J&W,J1":B-PV[)I).YZ>/1:6YTD;G-)<TC8@K&:E
MB&^3U-MJG#MJ>.;/0D8*]1:4M%PC>:>IDI)?P0X\S/?WK0HYY&.!#CLLG27J
M6/ =@C*L3":EFJW0=V@;STKH:MO_ +MV#]*UZKI:RA>YE73R1%O7(V^/1;7;
M=1D.:1*6$=X*S])?WUDIC=!\I &2YHWQYJ\L>1M&+*IP:1D@%4GL8[=NQ4EU
MEIL-P8>: 4\I_"8WD^I8FLT"YX#K16MFR,\K\?6/W*33)N&AN:1U7Q9FXZ>N
MU!S_ "FAEY&]7L',,>.RPYQ[%BR?$3"84!$1 1$0?,(OJ(/@7H+XB+M4:0WJ
M5],SL$-V"I(IHYI.]%])&, >]?%E*"(B@("1T)"(@N8:ZHB^9*<>!5Y%?*EH
MP[E/N6*1-C.,OTO>&^\+[]FYB=HXG>Y8)%=C867Z5GSJ6,^Y>VZD;^%1QGW+
M7HYGL/JN*J?*<GUV-/N38S[=2P_A4,9]R^C45(3ZU"P#R"UQ[HW9(;RKQRY&
MQ39IM#[U1O'W.G:T^Q>Z:_5-,\.I'F/'XI6IX7IDCF?-<0K%2<J0:?B%<82&
MS,CE9W\PW60CU;9Z\_Y73NIY.]S1LHR%0[\+=>VR-=MT*O-M-)7BIX*O>AJ&
M2 ] 3NJ<]#40YYXSCQ"C>BFGIY!)#(]A'>#A;7:M95U,"R?EF8!OS*<L2O,R
MF/%?"P$'(5]3:BLMP8!5Q]A(?P@%</MT$[>:V5D4X_%)&4Y)\CGCS8&:E#@5
MB:NC(S@+9:B">GS\HIY&@?A 9"M3V,VS7M)\$ZQW.D]FG31NC*IP54E/)SQ.
M+2#E;+5V_F!V6!K*%["<!91+'6F_:'XB5-MD8Q\AY>]IZ+H/2.LZ.\P-Y9 )
M.\%<6N#FGO!6<T]J*LM<[71R.P#U!.RSBKU9;B>[N5KF2L\5@=1Z7H[Q YL\
M0)[CWA1GH'BA'4-CAKWM!V =E3#;KC#60M?$]K@1W%-3'6$U-* M5:,K+-(Z
M2-IEIQWCJ%JW3.5U95T<55$6R-#@?$*,=8\.V3&2IMPY)=R6@;%8\L3V9Q,2
MB6G'/(&K8Z"D:< K"U%%4VNL,=7$Z-P.-QU6:H:MC<$E8Q&IZI+)FW-8 <#!
M5A6TS6M.%?NN4;F 9Z+%UU8TM(!64Z8PL6NP558]60?NO8D6&V:K7TM/7TSX
M:E@>QPQNH:U%:)+/<7T[]XSZT;O%JF#MEAM16V"\4O9R^K(WYCQU"2(ESA>F
M.P54KZ26BJ7P3M+7-/Q'BK=I41DH9<C*OH9.98:)Y"NH9>4A9,69IY'12MD9
MU:<J6M)W-E52-!.ZB"E>) ,K<=+2&EJ&C/J%94IWC3<=46YE;12-(SL<*![U
M0OH:U\;AAN=ETDV,3TH<-P0HTXAZ?[2-TT3=^NP5JC;&B=3I%*+ZYI:XM<,$
M+XM3<^HO@7U$$1?5D"]-7E?0?%90Q5 U>N3JJ;7X5>-P/1;(TQE3((0%>Y!L
M50S@J[T1U5<[+[W*EGJOG,4YETJ]5\\<KR"2O31GN5B=II\QNOH"]]F<;!?.
M4YV0!X+RXY)7HC RJ9V!(22'?G"O^;32O^JZ;^[:MH6K\*_YM-*_ZKIO[MJV
MA<C:(B("(B B(@(B("(B N#=2U-5Q#XLU')(2^YW 4T!.X9'S<C/<&X7>2X*
MX<2MT]Q:LOV0]04ES;#*7?@GGY"3[.J+#N/3EEH=.V2CM5JA$-'2QB-C1U/B
M3XDG<GQ*R2(B(VX_:/IM5</[A+V3?LC;8G5=++CUARC+F>QS01CQP>Y0;Z)U
M_EH->U%G+S\FN=.[U,[=I'ZS3_N\X]ZZ>UY7PVS15]K:D@10T4SCGO/(<#WG
M ]ZY$]&>EDJ.+UI?&"6T\<\KSX#LG-^MP18[)\]('B1>>'T5C=9(:&4UQG$O
MRJ-S\<G)C'*YOXQ6R\&M5U^L]"4EYNL=/'5RRR,<VG:6LPUY P"2>[Q42^F5
M_$:2_.JOJB6]^C#_ #16[]//_>%#R;;Q1U!5Z6T%=[U;F0OJZ1C71MF:7,)+
MVMW (/0^*C[@%Q2OG$"[7:FO<%OBCI8&2,-+&]I)+L;\SBMI](#^:#4GZ*/^
M]8H:]#K[X]1?JD?[:'DR7%;CAJ;2^N[S8K=2VE]'2N:QCIH7N>0Z-KCDAX'5
MQ[E >D-15FE=24=[MK('U=*YSF-F:7,)<TM.0"#T<>]?H54QL,$I+&D\IW(\
MEQ#Z/X!XQZ>! ([678_H7H0EGA!QLU+K#7]MLETI;5'25(E+W00O:\<L;G#!
M+R.K1W*:==ZPM6B;%)=+U*6Q@\D43-Y)G]S6CQ^@+8&QL:<M8T'Q 7'?I3WZ
M>Y<27VQSS\EM<#(V,[N=[0]SO:>9H_V0AW7NH/20U1653_L+1T%NI<^H',,T
MF/-Q./@%?:1]).\TU7''JFWTU;1DX=+2M[*5H\<$\KO9M[5-G"/AY:=':9H0
MVC@DNTL39*JJ>P.>7D9+03T:.@ \,]5<ZVX7Z6U@^"2ZVYL=1%(']O38B>\
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M[] <GP4J(@B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MJA< 9XRUX'7"V1,,=2LZND;2/:P-YML+WDTTK!"Z1C\9/*2%D(;G0U=4'DL
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M* ]4:.K;/(][&.EIQ^$!N%JA'DNJZVCBJHG-D8UP/B%$FM]!ECI*JVM ZDL
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MRX9)*G56AF_:IJ@6LGJRWP 6,KJ2\50+JRFEDQDY<Q3*ZXQQL/,(X0"!W!6
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MS!<#GV+(U%K:7_=%*8JWU*JH6&C[&ZJF;),,^U2S16Z." -8WN6K6">"C :
M MQI*Z.1@Y2NBF&B5G4T(=G+5@+G:F/#LM&?8MU+FO'18^M@Y@<++2(9U%9.
M4N=&T@^2UADT]%)@DX"F&\T!<'>JH_OMK.7$-^A8:79;+Z1CF=]*V^TWEKP,
MN^E15V3XI,;@+9++/R8R58$F1NCK!AP#@5K>I]%T]="YS& N/@%?V:IW!!6T
M4\C96X/59:1S1J#3-7:Y''D<Z(=^.BP():5U/=;'3W")S7L;DCP40ZTT&^E<
M^:D &Y. -BL>PCIK\]5[:\L.6Y5-T,C)3&6'G&V,+,VJQ5%81SM+6^&%%?+;
M7N#@PG<[+88[>^ICYP#G"R=FTDQDC26 D>(6V-L[(H#W$!(G8TFVPU$,F,$A
M9]M*^0-=ONLI%2Q0.:YV"P[%5S-!"V1FVVX*VTQ#7,RHT-/*1V;R=EF8+<PM
MR0"#W%8!]ZBC(((!"]#4S6CYVWM2:J5IIJEL#K)3DDEH'N5C4Z=I'Y<YC2?8
M%A*K5P8#Z_TK&RZN+ACG.?:L8KAE-+/OL%(T[-;\ J4EGI0,<K?!8$:F'+ES
M]_:L?5:L#2</^E9<\:8>'N6V-ME.P;85C>(&04Y>#@+ T=]J:Y^(@[E\5L<5
M-)50<L@)SXK'K/9ETI[L3IZIBGJ0UWK8*E6SQ4WR=H;@'"TVSZ;CBDYV[$G.
MRV:.GDIP"';!;Z:)B.K3573,]&1JK>'GF&"%K]]MG+"7L&,=RS$=>[E+23D+
M'W"621CFD9"US;G?1MBN-=4>5[*F6;DB!/=G*J4U%)%'V;6!V-\]Y*V-S(XP
MXD-!]B^"H8 .5N_L3K"=U.@B9",R$;>"OG5 D<SJ .H5B'EW,.0JH [.P[E%
M>:NI:7/8.<,.^WBL;5RRO>1ORD9)_P %DVQO(P6[Y504PP[+=CY*Q)IA7UI$
M436^KRCJ.I56GJJF5A#']DP#J>JR#J"%SN8M&?8K.X6J9\'^3/+23W*Q*:E:
M5M?2TSB]SNTDQU)ZE6K;U43,'R>+ .P(& KF+30@/:U1-1-L0.YJNYXH((VO
MJ0 UOS0-@%8EBM:5M;5 B6I;'CJ ,E7,-!,9.5T\W+W.PL5/J6..?LZ2+F[O
M55:&JN%9*/N@A:.H)5&?IG/HGO#)WN;CH1L5J^L]/&ZN=74(:VHP.:$  . [
MQYK,PVV=YS\J>[ W)&,JM%$(78?(YS>_?HI,;6):=IUKX;=V4["R1I(Y7!8G
M632(XB>@?CZ%(\[*:6,"4#/02 ;M]JT36]*Z*G< "]K9!AXZ8P5A5&H91+2D
M1%K9"N*9X&>?IXJW50/:&8#/6\2@]5$;1Z\9RT]=NBHJHQV1@Y(\ O#A@D(/
MB(B -EFZ>J=54@;-)'%%"-FC8N_>L(JM,_DE!Y>;R5B=),-FLU8[[K02.$=%
M5-Y7%XV![B L)4VR6.>2.-S)"TD8:=_@OLYD8X=K(T8.0UIROMV>V2:*H@:Y
M@D: =^KAL59(6,D4D1Q(QS3YA>-UD*=UQ<S+(9IF><1</J51QC<,5-OEC=^,
MP$?0L63&MZJK2#FJFJ[9112G[A. ?Q91RE9G36F*JJK<N?"V,?A<X*J,75R%
M@?Y;+$.R22>]27=K38K7&YU5.)I@,\@.=_BM%NU?%4NY*:G;%$T[;;JRD,:B
M(L5%>S\S+?&W!Y2>JMJ9_)*TEH< >A5[<*E]2 #@,'1H& %1CVO<TY:XCV%7
M4-RJH?FRN/M*M",(H,U#J&H9\]C'*\AU%&?XV(CV%:RB#<XKU1R?]YRGS"R$
M<C9&\S#D>.%'@ZK,V]TLD?+SREOD5#3;@X$;%?<XW!6@FJJ8)7,;,\<IQU5S
M#>ZQA',_G [B%1O#<.(SU53NZK4X=3.:/ND&3Y%9"FU%2R-^Z!T;O H:;"W&
M.JJ,QT[EC:>XTTP]29A\LJ]8\%N00?8FTTN!@+ZT@=%0:_.3E>VN&/%7::57
M>TJK&T8)RJ >,X50.(.R0*P.%4:2>BMVN5>+H58%4%R<WDO!>&G?HAE;XY62
M/?/W(UP*I<XP=D!'0(BJ2O<?7P5%N0JT9VZ;H+CLVO;@[K$7.VA['8;E9B(^
M:]N&0!C(*:$67JV.826C!"P!E?$>4G92Q>+:V5KB %H-XM!C<7-"QGHSB=L?
M1U[XGAT;BTA;WIK5YC BJ7#'CE1I)&Z,E>HIW-/4JTU:)A.\ETAJH,L>' A:
M;J"CBGRYN Y:I;;U-3[<Y+5E_LLV>/=VZ3.V,4Z[,!5Q/A<<=RITSGN?@Y62
MJ'"8G RJE!19<"0M<MD*]#2=J!D96R4%K:&C+5YME*UC1LL_2M [EBKS3P=D
MW8+(4TO+C*!@(V7EK,=5%9VWSY6>IYMEJU$[!PLY2/('590C/4SP>I62I69W
M6%HW9QXK.40SU*R@9&*/9>BW'<JD1 '1>W#(*J*#2<KVUQ7W 7S&R"HUP[RO
MKI0!LJ!.!N5:SS\H.$%P^09ZKR7C&5B35.,G797$4AD07(DW.548[/16Q'BJ
MT"0+@'9?<[+X>B\Y5'U Y>2<!4RY!O%O.:&G/_NV_4JZM[;_ "?3?HV_4KA8
M@B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@+DWCM>
M'T?%&\Q-.S>Q_N6%=9+E+CA:#6<4;S+CKV/]RQ85]F5'=H$=]E>1U6?ME=-(
MWO5K0Z=]89'T+:[790P#9:=2W<T::[6TLE0[H<+8-+T(B#21A9^.SLY?FY]R
MJ,HS"[U0MM,-,SMEV2M9" WP6O7FK>&NP5EP"&8*P5X;D.*VL6@Z@J7DNW6E
M3P/E<78RMVN\//*1A4J&T]H#D+$:?2M,,@SLMPLE0 &[K&WRU.IVEP'3=6]I
MJBW'BK$HEBT5 <T?XK+24+*L8(!6D6:LZ;Y6\VBK#L<Q"HMFZ;CR3R;*ZATY
M -RP+9Z;D<Q>)CRG9-0+""U1Q1'E:.BT[4[WT\Q#1WK?Q*X-(QNM3O\ :Y*J
M8NP<9RFM]CLU6G942R-Y'*1M,T+Q".U*UR@M_8O (6[VD$1 !6*9DVO^Q;&.
MJH/P<[*M*QQ"I,C)^<FM$2QU92-D:<!:S=+(Z7FPQ;^V%N-PO$T3,;M"J(7K
M=)S.<2&X5H-.STWK'. IHE;%CYK<^Q86Y,B(<,#X+&5A&ORV2WMW'1651KZ2
MG/*T'/L6>OE*PE_J[*/+I;3).>5NRQVL2VRW:[J:IX: =]NBVFDJG7&F+:C!
M!"CW3=HY7APSU6_4<;88@"<%2>J]V$J-*T[JHO#!GQ64I+7!3,Z#(5::L:,Y
M/18FXWID33AW1"&8$T<(VP,+'W&]1Q;9&.BTJXZC)<X,=]*P%7=GRYYG'XI!
M+:ZR_P"6O8T[9V6(JKU*XD\V-L+6G5OK'F*H/K<@A9[8Z9@ULCW>LX[KV^J+
M6D$]%KYJG'HO3&U,^S0XIT.JYJZQSL[[JQ,\A=D$K,T.G*JJ(+\@%;;9M%L!
M:9&<Q\PD035$-!IJ:LJSRQ,<5L-JT?43O:Z?./!2O:M,P0M!+ /<L_36Z*/9
MC1\%C,2L3MJ-@TPRFA;EF,!9Z.A##C& MEIJ5C6[JQN8$0)"RHN<LZ2JWS0L
MV.; %1J;BWD(6(N5>&9W6MUU[9&TCFW77XL:<OA2O;GJ 4DQYCLK4ZK9)"2"
M<K0;[<W5,IY,E6M)#4RM &0"M/BMWA]&[0WSY1.X9VRLD+HQFP&_L6LVF@$+
M'&1WK'Q63:Z!H&2"/J6.YEETAE&W?F!PT_#HO7R^9WS1^XK$NK8(P2W'M5/[
M,QL)P![%1FS5U( QLO0KJH#S/@M>-^;W=!WKXV^NR?5)[U!L;+A4LSEN5<Q7
MGDY1(P@>*UAE_P D\S%Z;>X7G#P-T&Z17"&;=C@25YO5"RNI6MQTW*U6$QRE
MKH)"W!R<*_AK*B,N#GY;T""QAL\4,KG28CC\NJJ372DHF$1-R[XJXJ[777&#
MFIGX;U.5C:>RNAD(D:>;O<]9Q+&8TR^G67"_U99 #%$&\SG'P5S561\4KLU;
MI #N&+(:2JXJ"&Y=F[+FQ=?<5B-+SR7"IN$C>;LPPG?Q0A<P6RF#1S.E.3OE
MRR;=.Q2PD-(,3ANU^^5J-!-4BN:)9>;)R %G)I:CUBZ5[<#U<.V1--(UIHA]
M#)V]L;S1GYT0.2/8M$>QT;BU[2UPZ@J;[97?*H'_ "TX>T['/56&HM-6Z]4W
M- \1UC6^J\ >L?-833YPRB==)0\BREZL5;:)>6JB/)W/&X*Q:ULWJ/K@YQY+
M[(,9V PO 51PVZ 9'CE!31$0%>V^VU5=DT\9+!U>=@%:1@%X!Z+:J"L=V 8T
M!K!W#HL*Z^5U8N-X]76=0N;78:"%[36YG>.HSAJW&BN%'211QP4E*&L^:.3H
MM+=*3XCV+RR5V<<Q^*T375/F]NWC6*(URI(CU6]@P&1 >051FJFO/W2"-WN4
M:B5X=U*]B>0#9Q4YZ_5L\"Q/_JDO[.T4F>UHHB,> 7P7.SG)=;F9\L*-OEDH
MZ.*^MK9=_6*OB5I[)8G_ -4B25.GJC^,M<9]K0K.2CTJ\GFM<8SX-6E"OE!Z
MKT;C+WE/%K3V*QZ-KFLFE)(W<E$&N[NN/K5F_2^FWDXBY0>F'.6#%RD#<'HO
M3;F\#!W2;M24X5CT9Z#2&EL R=LUV.Z0XS\%YET=IY^T=4^,?G$_X+"BZ2#H
MOK;F[O&5/$J7V&QZ,LWAU:)8B65T[G9VY<=/@K*MX8M[,FCK7!W<)!M]"RMK
MNT3P&DEC_$+::"K=(UH> YFWK^'M6<79\VFKAUOO3U05?-/7"S2\M9">0G#9
M&[M<L68W@X+79]BZ?FMU/40N94B.2)PW:X @J)=?Z;CL)%RL[BVF<[DD8[?L
MR<XQY+=35ON\J_B^']ZF>B/HS)$PCD.">\=5N6FZB)UL:)H86/:\@R2'J/(+
M /JI;A"QM5.YSFCU0KBDIJ<-Y7329Z8RLG(N]<L8749I(@(7,+LM;U*U7D?^
M*[X+<B)ODN8.5\,+^4.<=P/ !8^NN99'D0\H<, D=Z)$-<+2.H(]J^*YJZQ]
M2U@>!ZO?XJV0 <=%7BK*B'^+F>WV%4$096&_U\6W:AP_T@K^GU5,W^.B:[\W
M9:VB#=8-54KMI&/9]*R%/?J*8^K, ?!P(4=(@E>&JBD;EDC2#X%7#)0&C=1$
MR1[#ZCW#V%7D%VKH2.2HDV[B<HFDH/EYMEY[3;'@M!@U161G,C8Y/:K^GU7&
M=IZ<C/>TY5V:;G&[)\E4;G)P>JUZCU+;GCUI7,/@X+*TE?33Y,4['>]6)33(
MC.2JD;]\8*H-<'#(.56B<0?)5-+UA 7MYP"K<%>\X'7*NT>91S,(&5@[C2!S
M#S#/FLRY_JGR5F^0$D.&05)6&AW2UYYBT+7)Z=\3B"%)U;3M=G&X*P-?;F$%
MQ"QTRB6D@D*M'*X="KRNHNSDV[U:LIW!_11896VESR,[K:[?""T;+6[9$6X6
MST1( 6,LF7@:&M&.JO*=^^%:P_-&5>4[<D+%896G;S-7U\1[ME6I!AHP%=&,
M.&4%E3DA_19BD<3UW5FR 9R%D*6, ;JPC+T)SC=;%1' &%K%/*V-9."O#6]5
ME$HV1L@ Z[H9PL']D1A4);F #NKS&FPFH '54):YC027+6)[N&M/K+ W"]2.
M)#'+&:EBEN55>6-!&5C9+QVIP%I\+ZBID'K.W6S6NVN#07[E(F9740R5+S2$
M+,4[.0*A24XB&ZNBX-:LH8JA /1>HM@508_F5P,851][3 1K\YPK>4_!>&OP
M$5<ERI\^!LJ;I-MU1?)ZJ"1;7O;:7]$WZE<JTLYS:J,^,+?J5VH"(B B(@(B
M("(B B(@+0>.>J_X)<.KE50R<E=4CY)2D'!#WY!</S6ASO<%ORYKXQ7RV:FX
MU6+3MVN%-2V"SN$M9)/(&L=(1SN:2>N0&,\B7(0S/HN:HKI8KQI6_23_ &1H
MW"JA%0XE_9NP'-WWV/*?]M3VN8>(VJ;#8>,>G]9Z9N]#6P3X@N4=+*'D-&&%
MQ \6$8\V*6^.MUNEOX672NTY)(V<MCS/ ?69$YPYGM(Z;'KW Y14A!S2XM!'
M,.HSN%]7+/#G1'#_ %'06V>@UK<J35;@R2;-0V*3M=BYK6D GO (<?'?HNI(
MV=G&U@+G!H RXY)]I[T1I?%W7D&@-*/N)C;/73.[&D@<=GR$$Y/^B ,GW#O4
M5V3A7J_7]*R]:_U174GRD"2*@A'\6T[C+<AK/8 3X[Y5QZ2 ;)Q"X<Q7#^3'
M57W3F^:<RQ!^?]G"Z"14$VKAEKO1-^H)-'ZJ-?:7S!M337#(:QG>>7)!V[V\
MKLX[LE?>-LLC.,7#)K)'M:ZJ;S $@'[LSJIU4#\</YY>&/ZTW^^8A#=N(NBK
M]J/5&G;C9M12VRDM\@=/ TN'/ZP.0!L21ZN';8]ZD)05Q\FDCXF\,&QR/:UU
M=AP:X@'[M#U5#TC]:U-)>[/I*FNSK-1UC!/<*Y@<7,B+BT <OK8]5Q('78=,
MH)[#FN)#7 D=0#T7U<=7Z#0&G;:VZ\.]=7-FI*7#VB6.0"HWW&>S:![R0>AZ
MY4E\2]4RZJ]&J*^_Q-34.A$O9D@"1LW(_'EEI0TGDN:T@$@$[#)ZKZN=-)\"
M*?4^E+9>-2ZCNLURJZ2*6 Q/!9 PL!8WU@2<#'0M_P 5DN#M;=:Z;6?#34]P
MFJC0Q20PUC7?=!$[+'8)S^,TMSG&<>"(W"XZ]N--QOMFC&4U(;=54AG?,0[M
M0X,D=@'.,98.[Q4DKD:X\++;3\<[7I!MTNCJ.II#.ZI=(WMFD1R.P#RXQZ@[
MN\KI7A_I&ET58/L50U=75P]JZ;M*IP<_+L;9 &VR*V1<O^DAK6ZOUQ3VW3=1
M4L98(A5U+H'$ 2.<TY=CJ&@QC?O<5T=J:\T^G]/W"[UIQ3T<+IG#..; V:/,
MG 'M7./!*X:7JK;JV[ZXOEMAN6H7R0213SM:]L+LEQ /3+G;?F!"'0^C+]!J
M?2ULO-+CLZR!LA:#\QW1S?<X$>Y17&RLUEZ1-48ZFH;9-,P1MD8R0M9)/N0T
M@=3S..?T>%BO1:U RFGO^C9*R*I;13.J*.:-W,V6/FY7EI\,\KA^<5.=OM-!
M:W5LMLHH*>:KD,\YC:&F:0_A./>?-$7Q<UI ) )V&3U7U<=Z0I=-:SO=XDXL
MZCN-!J'Y08XXI)!$R,=XYG-(;@Y'+L !W]W4'#RPPZ<TM2V^FNU3=H 7/CJI
MY>T+FD[!IR1R@8 QM\4&R+XYS6D!S@,G R>JUOB5J0Z2T/=[VQC7RTL7W)KN
MAD<0UN?+F<,KE^P1Z#U-0/NW$K7-R?J"I)<8XHY"*<9V&>S<#XX& .B#L507
MZ.\LDFNN)HDD>X-N(#0XYQ]UGZ*U]''6<T^H+QI"6[NO5OI6&>W5SVN:YT8<
M 6D.];'K-.#TP1TPJ_HY_?WQ/_UB/[V=%;KPYT5?M-ZGU%<;SJ*2YTEPD+H(
M'%QY/6)YB#L" <8;MCW*0B0T$N( '4E0/P!GD?Q,XH"65[F,KS@.<2&CMIEK
M]DM-QX]:EO%PO%UJZ+2E!/V%+2TY +N\;'(YL8)<0?G #;H'3 ((!!R#WK0N
M+VC[WK"UV^GT_?7VB6GJ.UD(<]HD&-MV[Y'4#INH#XS\.Y>'5):39[]<)[+5
M58:*2HDWCD )YARX:<C/</>I(]+:62'15E,4CV$W)H):XC_NY$'STJ^WI.&5
MH9\HD?*RX1,=+GE+R(I,DX\>JFJA<!14H+AS&-N 3N=E"OI:_P VMJ_UE'_=
M2JUI_1ZIKI;&5U]U/=I]02QAYJ6N:8V.QD##@7$#\X>Y!/B@CT:99)-3<1Q)
M(]X;7Q@!Q)QZ\ZO^ FI;TR\W_0^J:AU7<+,<PU+G%SGQAW*02=R-VD$[X=Y+
M%>C5(V+47$R20X8RN8YQ\ 'SH)\<X-:7.(#1U)7T;C9<?1:DT]Q'U%<KGQ,U
M35VVVQR<M!;*=DA 9W$D,<T;8SWDYZ !9OAQJNW:/XHVVQZ2U'47K25U<V'L
MJACVNII7'#<<S6C.>7<  @G(R 4-.IE!4LLG_M8PQ]H_L_L=GESM_$GN4ZJ!
MY?\ M;0_ZN_^R42&[5>BK]+Q=I]41ZBD998X>1UNR[?U"WEQ\W!/K9.^?<5(
M2@JZ32#TL;/$)']F;<XEG,<?Q,O<J+9I>'?I#&*61[;%JIN6!SCRLF+N[_;V
M\A($$]HH(XPU$VM>*6F]!4$TC:6G<*VY.C<1@8S@D="&9QYR!:[QFU;!=^)
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MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M])>(^9A:^F#9SCYOW0%K@?([#S6T^BS;[M0Z(K77**H@H)ZHR4$4^>81X&7
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MLT=4Z+]&^_V^O %PJ*.>JJ& YY'N: &Y[\-:T'SRFBFG_P!E&<8.?L77;?\
MQ)E.!&1@]$P,8P,>""">'FF9-6^C!'9(G!E14,G,1=L.T;4N>T'P!+0/>M6T
M9K[2FEK+'8>(6C&T][MS>Q<_[&Q/,[1L"2[!SCOW!ZYW73X  P!@*E-303N:
M9H8Y"WYI>T''LR@C3A+<[?JV"[5E-HB*PV]P[&FJNP9&ZIB</6&P!ZCNR.F^
M0HTT9J:MX%7.YZ;U7;*RHL<]0:BDKJ=@/-D 9&2 <AK<C.6D'KE=-KQ-%'-&
M631LD8>K7C(/N0<F<5>(;>(-_P!*R6JTUM/:*.N 955#,=M(YS,@8R!@-'>3
MOW+K9>6QL8QK6L:UK>@ P O2"%>/^G+S'=]/ZXTS3.JZVRNQ/3M:7.=&'<P(
M W(W<#C?#L]Q5E)Z1-LKK9\GL^G[M47^9O9LH^0%@D.WS@2XC/@W)\E.ZI,I
MX62NE9#&V1WSGAH!/M*"$O1$:YF@KL'-(/V2=L1_[J-4_1&:6Z2O_,"/_P H
M]X_]VU3L !T 'L0 #H /8@@CTB&D\0N%Q )Q<3G _P#?4Z]\;[/>M/ZZLG$7
M3M&ZO%#'V-93L!)#/6'-MO@M>X$]V 5.A .,@'"(.?=1\?K9?--5MNT[8KM4
MW:KIY(C$^,<L0+2'.):22 "3T'3?"V/T5P6\*F!P(/RV;K_LJ6HJ>&)[W10Q
ML<_YQ:T GVJJ  ,  #R08G5WWJ7K]2F_8<N:."/%BFT'I3[':BM%P^02SOEI
MZVGCY@\G <TAQ V([CW]%U:J<L$4L9CEB8]A_!<T$?!!SE3UMQXV\2[%<*2V
M5%%I.Q2]L)IQ@R.YFN(R-N9Q8T8!. "<[J\XN6F;2'%2/74]B9?-/UD+8:^%
MT+9>R(:&<V""!LUA!.V01D970C&-8P-8T-:-@ , +Z1D8/1%<[R\3M$W.>EH
MM&\/67BY3/:#";=#&&MSZVX#M\>X=25L/'C1]SJK?IO46D:$"X:>D$K**)@S
MR9:X!K6['E+!ZHZ@G"F*"F@I^;L(8XN;<\C0W/P55$02STD+-]C0UUBNOV;Q
MR_(PUO)VGASYSC/^CGR5]JZR:EXH<%@;Q:8[;J&.85=/2AQ':!N0 0[=A<US
MMB>H&<9VF/Y-!V_;=C%VW])R#F^*JH.?M->D#1VBRQ6S5]FNL%]HXQ!(R.(?
M=7-&,D.(+2<;C"QW BYU=[X[ZJNM?;Y;?-5V]TOR:0$&-IDAY0<@?@X/O71S
MZ>&25LKX8W2-^:\M!(]A53 SG SXH(&T4TCTJM8G!Q\@ZX\J=9?TJVEW"W#0
M2?E\/3V/4Q8&<X&?%" 1@@$>:##Z,VTA8OU"#^[:H=X"P";B%Q6BE:>SEKW-
M/F#-."IZ0  G  R@Y7TQ4VWA'=KGI_B'IB.NM\DYEH;G\B9,7MZ8RX;@@ X!
MRTYVW6_\/-7:?U=K*.'3.@(H[3 PO==WT<41BE&[<8&WN/-DYQ@%3--#%/&6
M31LD8>K7M!'P*^QL9&P,C:UC!T:T8 0>E O*?_:WYL''R#KC_P!PIZ3 SG S
MXH(R]),$\'+Z "3S4_3].Q;#PD!'#'2P.Q^QL'[ 6V$ C!&0@&!L@@CA4TCT
MAN(9((!8=\?^\8M4HVT/"+6=ZH=::99<].U\YGH:_P"2,F+!DX;EP\" 1G((
MS@@KJ(  Y &5YEC9*PLE8U[#U:X9!00AH[6FF=6:RHZ#2G#Z*:W-RZHN3Z&*
M/Y.1NUPV(Z^8/@-E1UVTGTHM%$ X^0]<?K"G2**.%@9"QL;!T:T8 7O SG S
MXH-+XT GA7J@ 9/R)ZL?1]!'!_3@((/9R=?TSU(1&1@]$  & ,!!!%G:?_:S
MO1P<?8X;X_\ =1+4]0:IGT9Z2>I;RVUU%QI8Z>-E4V 'FCB,4.7CNV(;UVWZ
MA=1X&<X&?%?.49)P,E%<WZ_XNGB)9I-*:!LURJ*NY8CFDFC#>1F<D  GKT+B
M0 ,^[/\ $3A96NX*V2S6@"JNMB+:@,:,]NX\QE:T'KNXD#OQCO4W0T\,'-V$
M4<?,<GD:!GX*HB.;[?Q:X?16IK+UH>."^1MY):2.V0X,@ZX)P0,]Q&1YJ1=-
MU N/"B]W$Z5BTU/4TE1FF9$UAD8&.Y'[ 'H>\#O[B%(SJ:!TPF=#$9AT>6#F
M'O55!$'HK@MX5,#@0?ELW7_97OBCQ"TW:K\^Q:XTM5U5J[-KXJV2E;+$]Y&X
M:'>&PR#G.=N\RX  ,  #R7F6-DK"R5C7L/5KAD%!S-P;@I*_C9+=.'U!7T.D
M8Z=[*KMLACW%APT9)_#Y2&Y)V)VZ*6J+B)+<.+%9HVWVD30447:55P^48$?J
M@XY.7<\SFM^=X^"W^*-D3 R)C6,'1K1@!:/PQT1-I:HU!<;K40U5XO-:^IFE
MBSRM9DEK!D9V+G?$>"*WI$1$$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!1#
MKII.KJ__ .'_ ';5+RB'7)QJZO\ _A_W;5)C:PQ#8]MUZ;@*D2<*ESD'"PAD
MOVD851KQW*SC<<;+WZPW6<0FU:5^Q6&K9B&NR5?RO."L-7NR"I)# W28N#MU
MJ]0SM)<+8+CN2L9%!S2=%()9.PTX;C992YVD5$!Y6]0O5FI^7&5M5+#&8\.(
M6V.S7* =36&6ED=+$T^:PU%6NC=AQP5/FH[53R0N.Q]RA75%I%/.Z2 'KX*3
M&EB=LG:[G@==UMEMN> /6R5$M-5/B=AVQ"SMONI;@\RL5),)DM]T&P)&5GH*
MMKV]<J(K?=QL2[?VK9+?>, 9=]*V1.V,PV^OY7YY>J^6\<A&5B8;@V1N[A\5
M=Q5&!L>JJ-KIYV!G5>:BH9RDY6"AD<[O59S7$829(>*R[OA!$>5B*B[5CP2
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M%L-VJ=>Z.X1:EN6H[[2U5^B<R6EJ*>)A;"TN8TMY3&UIZN[CU6&A_P"UM/\
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MC9G7]W.<O^E4?L\[?UOI6*@M,\FY!W\E?1Z>F(W!^"L"JV_. /K?2O3;^[&
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M\LX6Q(@P@TI91JDZD%"W[-F/LC5<[L\N,8QGEZ>2O+[:*&_6FHMEVIQ4T-0
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ME%6C.#L%GU/#J'45_N&H[M3C%/)59#8_ X+G$D9.-\#.<94JH@B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MJG1$%I:+;1V>V4UNMD#*>CIF".*)G1K1_P!=>]7:(@+Q##'!&&0QLC8.C6-
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M7#7]%Y$8#=E[:SI@;H)[TQ][EK_5H_V0LDL;IC;3ML_5H_V0LDMD((B("(B
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MZ#T+IJTZ.H*.FM=!4Q2T['332PMD-07-!+G$C?.>G0!1=PCM-%9/2,UI;K9
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M]YMK:W/+\G-4P29\.7.<K*H"+%5>H[)1UOR.KO-M@J\X["6J8U_^Z3E94$$
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M-(&-'O)PK.#4-EJ*-U73WBW2TK7!KIF5+',!/0%P.,H,G(]L;"Z1S6M'4N.
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MP,_GFXH?KDG]_(IVJ)XJ:%\U1*R*%@RY[W!K6CQ)/1!45&KJJ>BIW3UD\5/
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M*U5P .!W=ZR$=0V>!C'.Y9&C&?%16WW.S]M5QSL=RL(S(U6E/?::BKQ2M9B
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MMN=)**FEYC@/< 06$]V03OX@+0+?QGU7:K8RU7K0=UJ-00L$0>UKPR9PV#B
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M9)F,2\I#XP[P.3@^('M6F6WC-JJS6^.UZAT'=:B^0-$0?&US6SD;!Q'(>O\
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M4-551T]P>Z9T,3GB,<\&[B!L-CU\"@P/I,1R-UCI>IU#!7SZ+C;_ )0VE/\
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MK_TI_P"SMKG\2V?^:_\ 2@AY%,/_ +.VN?Q+9_YK_P!*?^SMKG\2V?\ FO\
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MU_Z5BR[(A; YS<@%>'1EO4*>Z;@)JID>)&6_/E4?\E0J^ &K) >S;;_?4?\
M)9:ACN4$(IC?Z.VM\^JVV8_6?_2O/_L[:Y_$MG_FO_2L62'E[;*]O1Q4O?\
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M=U7()"/N3-R?$^"Q>G>'[Z5S7W2K:\C_ +J '!_VC^Y;Y!#'3PMBA8&1M&
MI-2TT^KVB(M;8(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MXH)H14ZHEM-,6G!#"0?<H?\ 1COUUO\ HN[U-[N-57SQU[HV25$A>YK>S8<
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M+IYE)KBW,MVH*/,54*A]0WM"#\X<IP#XMV.<[*3>"[.'=QU!=*S0EDJJ::A
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M_0V"Y3%U#?J*)I>?F]OC;X2![1Y/"ESC=8+UJK2,-BL,0<*VLB;62ND:T0P
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M=35UDNU/</E-+$V3GBC:YLA<T.#6^MG.#WX&QW6*T[Q_TY<;M#0W2AN%F,Y
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MKM5?5P5<LU:^J#X00T LC;C?O]0_%6W$#1^LKAJ%EYT9J]UMD$0A-%4,YH,
MDYQ@@DY[VD^>-D&+T'Q3KZW6,6EM;Z>-EO\ -&3#(TYCF !.!G. <.P07 D$
M*75$.BN&%_&N(=7<0;]#=;K2QF.FBIF<L;-B,_-;L.9VP:-SG*EY$<]\#Z:F
MNW&3B#<;VUDMZI*IS:9LHR8V=H]KBT'P#8VY[@?-9KTL*&DDX<Q5DE/$ZKAK
M(V1S%HYV@AV0#UP<=/)7O$3A)5W/5 U3HF\FQW]P^[$Y$<IQC)(R02,9&"#X
M=<ZIJ'@QKS5U&':LUG3555$1V$+6N[%OBXX:W?'^C[T5E^.O_9[M_P"91?LA
M8+CS4U$?!#0].QSV4=0VE;4.;X"#+0?I/^R%)O$30E7JCAG3:9IJNG@J8FTX
M,T@)8>S !Z;[X64N6B**]\/*72U\^ZQQ4D4!EBV+)(V@![,]#D?#8HC,Z>M5
MKMNGZ.@M$$#;8V%K8VL +7L(ZGQSU)[\J$N!%+3T/&?B-2T4,<--#*]D<<8P
MUC1,< #N"J4'"WB;9J?[$637D$5B'JL+@X2L9X-'*>7V!X6R<'>%59H#4-YK
M:FZ15\%;&V-CN5PD)#LESL[;^THJ65S]PHH*6J](/7]14T\4LU-(]T+WM!,9
M,F"6^!QME= J.M#Z K-/<1]5:CJ*RGEI[NXF.)@=SQY?S>MG;X(C4?2UM]-_
M JV79L;6W&FKV1QSM&'AKF/)&?#+6GW+%>D95/N-/PWIKE*Z.TU\XDK'9P,_
M<AD^&&OD^E29QHT15Z^TE%:*"J@I965;*@OF!+<-:\8V[_65UK'0%!J[1%/8
M+NXM?3QL[&IB'K12-;R\PSU'7([P?>BMD;:;<+.+6VBIOL9V78_)NS'9\F,<
MO+TPH0]%YPIKUKVVV^1TMDIJYII79R/G2-!!\VM9\ O@X7\46T'V$;KVG^P7
M+V6?7[;L^F/FYQC;'/CN4J<-M$6[0>G66NV%TKG.[2>H>,.FDQC)\!L !W?$
MD(OX/?S^\1_SG_WH4]*&=7<+M30ZZK=4</-04]KJK@WEJHJEN6]V2/5<#G .
M"-CT*E/3%+<:+3]!37RL977**(,GJ6-Y1(X=^/\ K/DB(>]+W[P+5_K)O]U(
MIDMELH*6R06^EI*>.@;$(Q U@[/EQTQT(4-^E[]X%J_UDW^ZD5N.&7$ZDH6V
MFS:]B%B+>1G;<S9F,_%!#21@;;/'N16.X/N-FXC\3K=IKUK73Q2R01L]9C96
MN(8T?%P\P%EO1+H;?+I6ZW<\DUZFK71U$S]Y&LY6D#/7!)<<]Y]BD/A7P]M_
M#ZR24E)*ZJK*AP?55;VX,KAT '<T9.!OU/BM#OG!V^VC4M7>>&&H664U9+IJ
M2;(B!SG;#7 C)V!;MW%!C/25H:6+6O#VLBIXF5<]:62RM: Y[6R0\H)[\<QQ
M[5MOI%Z3EOVBQ=;:'-N]D?\ +('L^=R#=X'N =[6^:U*IX)ZLNU[M5[U'JR"
MX7*GJ&22->UW9LC:X.Y8]AUW[FA3[6S04U'//6/8RFBC<^5S_FA@!))\L90<
MVZ]U_+Q*TEH_2]D>T72^R,^R+&_]UR.P01^*7 O]C!XKHJQ6NFLEFHK90,Y*
M6DA;#&/)HQD^9ZE<_P#HQ:5I*S45_P!8T]*Z"WMGDIK9&_<L:XY<?<TM;GS<
MNCD$=>D/_,]J+\R+^^8LGP9_FLTO^HQ_4LUJ^P4VJ-,W&RUSG,@K(C&7MZL/
M4.'L(!]RC;AOH/B!I2Z6ZDJM5T-3I:B+@VE$1+WM(.V[01N<CUR B-<]&JFI
MKEJW6]XNK62Z@96<I,@R^)KG/YN7/3)&/]D!7GI:4-!%I:TW=H9#>H:YL<$S
M-I',Y7.(SUP"&GR/M66UKPCN3]63:HX?7W[!W>H)-1&_/92N/5V0#U.Y!!!.
M^RL['P?OMWU)27GB?J)EZ=1D.AHX >RR#G?+6@#(&0&[]Y14QVB6::TT4M4.
M6H? QT@QC#BT$_2N>O2,9<KCQ7T9;*)E++F(24T5:?N#YC(<AWCGD8,=^0.]
M=(+1^*W#RCU]:J>.2H?17.C>9*.LC&3&X]01MD' [P<@%$A'FJ+%Q=U-8*FS
MW:ATK)13MY2 2"PCHYISL1W%4M9V.[Z;]%RMM&H71NK:1T3 8W\XY/E3"T9\
M@<>Y7<O#OBK=:;[%7O7M*+.1R/=3L)F>SP)Y&DY'B\^];UKC0T]\X6RZ2HK@
M]TW9P1MJZUQ>YW9R-=EQ W)#457X-6^DHN%^G&TE-%")Z&*:7D:!VCW,!<YW
MB22HTX6P167TD-;VFW,$% ^E,W8LV:'<T+A@> [1^/:IFT9:)+#I*SVF>1DL
MM#21T[WLSRN+6@$C/=LM2T_P_K+9QCONL9:RG?1W"F[!D#0[M&G[EN>[_NS\
M0B- T5:Z*X^D_K"2OIHJAU)"9H.T;S!C_N0Y@/'!/Q5UZ54AD.BJ"KD=%9ZF
MN>:MP. ,<@!/L:^0K=M+Z K+/Q9U%JV:LIY*6YP]E' T.YV'+#D]WX!^*S_$
M/1ENUSIR6TW3F8.820SL^=#(,X</'J01W@E%9B&TVZ.SMM<5%3"V"+LA3=F#
M'R8QCEZ84&^C3RTFI.(5LMDADL=-5@TQSEH]>1H(/FUK=^_ 7IG"_BC#0?82
M#7M.+$&]D"><3"/I@>KD#&V.?'<I1X;:%MV@]-_8NVN=+)([M*BID&'3/QC.
M.X#H!W>W)(1IZ(?WIW__ %C_ /;:O/HE?R3JK_6#?V2MUX)Z K.']EN5%7UE
M/5OJJKMVNA#@ .4#!S[%\X+\/ZS0-%>(:^LIZHUU2)V&$.'*,8P<H)&4#^BG
M_FVL?]8CZG*>%'7!S0%9H2*^,KJRGJC<*H3L[$.'*-]CGVHC1/1BH*62_P"N
M:Z2GB=615W9QS.:"YC2Z0D ]P.!GV!>O25IH;?JC0M\HXVQ7(5W9NF:,.>&N
M86@GOQO\2MYX1:!K-$5.I):VLIZD72J%1&(@X<@!=L<]_K)Q?T!6:X?I]U%6
M4]-]C:HSO[8././5V&/S45(JY_\ 2_ -@TV#T-8_]E= *-N-O#RMX@VZU4]!
M6T](ZCG=*XS!Q#@1C P$2%]]J'0?_P##-%\7_O41^DQH736F-%VZKL%HIZ&I
MDN#8GR1EV2PQR'&Y\0/@NEU'O&W0=9Q!TS1VR@JZ>DD@K&U)?,"00&/;C;O]
M8(K7O2+_ )D#^?2_6%8\6O\ LQT/ZE;_ /[:WCBAHNJUAP__ (/TE5!3U'-"
M>UE!+?4(STW5OK30E7?^$M/I*"K@BJXZ>EA,[P>0F+DR=M]^5!DN$MOHZ/AE
MIF.DIH863VVGFE#& <[WQ-+G.\223E1CP>IX[/Q^U]:+>P0V_LC,(6##6D/8
M1@=P':. 4T:2MDEDTK9K5-(V26AHH:5[V?-<6,#21GN.%I^E= 5EFXL:CU9-
M64\E+<X3%' T.YV',9R>[\ _%$:!Z.5-3737.N;O=VLEU!%6%H[49=$USW\Q
M;GIN WR  [U>^EW0TCM$6VN=3Q?+65[8FS<HYPPLD);GKC(!QY+)ZYX2UM3J
MZ;4W#^^MLE[DWJ8W$]G(3U<< XSC<$$$[J)N.>DM5VRPT%TUQJAEVKY:H4]/
M2P ]FQO*XN<-FC.S1LWOZHK<_2??536#0M!$Y@I:F8E_:N+8^<-8&<Q[AA[_
M '967J[9Q?JK+):9K;H\VV2'L#3AI# S&, 9V4AZUT10:VT7%9;MS1.8QCXI
MV#+H90W </'J01W@^]1S#P\XLP4;;/%KZD;9VCLVR!A^4!G38\G,-O\ 3]Z#
M:^ >D[]HS253:M1.@)%4Z6G$4O.&L<UN1TV]8$^];;Q ^\/4G^K:G^Z<ONAM
M._P5TQ16?Y?4U_R=I!GJ#ESB3G;P'@-\!7FI;>^[:=NMNB>V.2LI):=KW=&E
M["T$^6Z(@GT>.'^EM1\.HZ^]V6FK*PU4K#+(79Y1C V*WZ_<)]#4]CN,T.FZ
M-DL=-(]C@7;$-)!ZK)<'M&U6A=&LLU=4PU,PGDE[2$$-P[&V_L6VW:F=6VNL
MI6.#73POB#CT!<TC/THKGO@+45-)Z/VLJBA+FU44E6^(MZAPIV$$>86'X'4G
M$.FT:*G1%-IQU%4S/,DM3GMG/:<8><]V-AX'/>IDX+Z"J=":2K+/<ZFFK75%
M4^<F)IY>5S&-Y2"/]$_%:<_A+J[2MUK)N%^J8;=;JM_.ZBK6\S8SY98\'R.
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MP,E3-75E-;Z26JKZF&EI8AS233/#&,'B7'8+ _P^T?\ _P 6:?\ _P#8P_\
MX2#946-LU^M%\$ILMUH+B(<=H:2H9-R9SC/*3C.#\%DD!$1 1$0$6+&H;0Z_
MNL8N%.;NUG:&DYON@;C.<>&%E$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M28WN:' -&< #./$HB1=2ZIL>F862W^Z4M"V3Y@E?AS_8WJ?<%BXN).C9;?\
M+F:DMOR;M!$7&8 AQ!(!!W&0#U'<5"_";3E'Q7U=J75>L6NKHH*D04U&]Y#&
M#<@$#N:W  Z$DDY5EZ2W#S3NF;3:[Q8*(4,TU6*:6*)Q[-P+7.S@]".7NVW1
M74#Y&,B=*][6QM;S%[C@ >)/@M0BXGZ*EN'R*/4UM-07<H^ZX:3X<_S?I4>>
MDE<JZ>ETEI.AJ#31WVI$<\@VRT.8T-/EE^2/]$+:HN".A66,6YUG#W<G*:LR
M.[<N_&YL]>_&,>2(W:R:AM%\DJV6>XTU8^D?V<XA?S=F[?8_ _!6FIM9:=TP
MYC;_ 'BDHI'C+8Y'Y>1X\HR<>>%"WHO-998.(#6\TD=#4, SU<&"7Z=E'>@K
MW1U]SNVHM6:-NVK*^LG);)'$9((AWMQ@@G<#!Z #"+IUQI[4%IU'1FKL5QIJ
MZ '#G0O#N4^!'4'R*RBY5T/55%OXRVNX:4TG?+'9J]S::NI9X']D.8D<P.,!
MH/*[?H0>XX752(Y/](2XW*T<<*.Y6,O%?1T,4["P9V;VA=D=[>4'/EE=&\/=
M6T6M=+4EYH"&]H.6:+.3#*/G,/\ AX@@]ZB/4[&2^EA8(Y&M>QU 6N:X9!!B
MFR"%J>L(]0<$]572#2K'/LNH8W-HVX+NQE)P T?CMSMX@CKA%5/2:UY-?*ZH
MTQ9"]]MM9$EQECW:Z7F#0TGP:7 ?G'R4AW6YU]H]%^DK+0Y[*MEGI6B1GSF-
M=R-<X>!#2=^[JM,U3H$:(]':[NKASWRX2TT];(3D@]JTB//^CDY\23Y*9N%]
M/#5\*--4U5$R:GFM4,<D;QEKVF, @CO!""*N#7"K0>I] 4M?6QFYW*=I^4R"
MJ>QU/)D^IRM( QY@YZ]"IAX?:-MVAK!]B;2^HDA,KIB^=_,XEQ]P&  -@.F>
MI45:CX$5%JK9;OPSOE5::X9<VE?(0P_Z+7C<#R<'#Q*V7@-Q N6K:.ZVO4D3
M8[[9Y!%.X-#>T!+AD@;!P+2#C;H@C?@'JNUZ.L.N[M>I^S@961AC&[OE?]TP
MQH[R<?XG99?16E[OQ<U''K+7<9BT_"?_ ,FVLYY9&YV)'XOB?PB/Q1A1'IO0
MEQU-:M27BRCY366>M;(:%S>9L["7$X'>1RCU>\9'7KU1PAX@6_7>G&2TS8Z6
MXTK6QU5&W;LCW%H_$.-O#IW(-Y8QL;&L8T-8T8#0, #P5"X5U+;J.6KN%3#2
MTL0R^69X8QH\R=E<+GWBQ#+KOC?8M$5E3+#9((?E,T;'8,CN5SR?;R@-'ADH
MB5+5Q*T==J]M%0:BM\M4X\K6&3EYSX-)P"?8H_\ 2Y_FWH/]9Q_W<JV&^\#M
M#W.U"DI[7]CI&XY*FE>1(/;S9#O?E:KZ4U%';N$UGHH'2OBIZ^&)KI7E[R&Q
M2 $N.Y.W5%3397-98J%SR&M;31DDG  Y0M<'$_1)N'R(:FMG;\W+_&^IG\_Y
MOTJ-_2$N]='HW2&G+=.:?[.O9#-(#C+&M8.4^1+P3^:MNHN"&AJ>Q-MTMH;.
M_DY7U;Y'"9SL?.Y@=O8-O)$;M9=16B]U%;!:+C35DU$\,J&0OYC$XD@ ^]KO
M@M*X8Z7TA9=6:FJM,75];<I9"VL@=,'_ "8E[B6X !^<#UR=O:M&]%B@CM>H
MN(MOA<Y\5)500,<[J0Q]0T$^>RN_1^_G/XI?K_\ ]Z9%2G5Z\TK2.KVU5_MT
M3Z%_9U+7S &-^2.4CKG(.P\%5TUK/3FINU%BO%'6OB',]C'X>T>):<''GA0#
MH#1%FUCQLUX[4$#JF"@K97L@YBUCW.E<,NQN0,=,^U4?2/T'9-*"RW33D#K9
M\KF?25,=.\AKFEO4#NVY@1T.>GB$YR<3]%1W#Y$_4UM%0'<I^ZY8#^?\WZ5M
M\;VR1M?&YKV. +7-.00>\%1H[@=H;^#[[8RU8D,?**TR.,X=CY_-G&<[XQCR
M6I>CC772[\*=0V:.J=\JHY)J:BE<X_<N>/U1GP#LGWHB3+GQ*T;;+BZ@KM1V
M^*J8[E>SM.;D/@XC8'VE;115=/74L5313Q5%-*.9DL3P]KAX@C8KDC0U3I/1
ME+46/BEHJI9<'S.S7S0=H"WRW! &^[,YZKI_08L(TG;FZ1="ZR-CQ3F(DC&3
MG.=^;.<YWSG*#/+4;MQ)T=::]U%<-16^*J:[E?&).;D/@XMR ?:L#Z16HJS3
MG#*LFMLCH:FKE92"5APZ,.R7$'N/*TC/FL;P]X+Z0@T=0&[6N*Y5]73LEGJ)
MG.SS.:"0S!'*!G (W02M;JZDN5'%5VZIAJJ6499-"\/8X>1&RP6H]>:7TW4B
MFO=\HJ2IQGL7/YG@>):,D>]:LS35#PBX?:KK=.2U<CNSDJHV5$G.V-V"& -Z
M8&V3U.-SL%IW KAC8;]I"/4VJJ87BYW6224NJ7EP8 \MZ9W<2"23X_$)NL5\
MM=_HA5V6OIJZFS@R02!P!\#CH?(JTU-JZP:7;&;_ ':DH3)NQDK_ %W#Q#1N
M1YX4&U-HBX5\>-/0Z:?)%9[_ ,L,U&7ES6DNY>_? ):X9W&XZ*RXF4+M.\9Z
M[4NLM-5-_P!,U$+6P.8WGCAPUHW'S<@M?ZKL \V472?+7K+3EUM55<K=>J*H
MHJ5ADJ)&2C[DT#)+AU;L.]1#-Q7IOMY01,U/!_ _Y)EY#V]CVG([OQG/-A;-
MPM/#/4M->FZ1H*>%]="(Z^B>PQO[/<8Y<X#3G?D.,X[U'E1H?3;?22IK VT4
MXLSJ$RFEWY"[LW'/7/4!!T/;=06FYVAUUH+C2S6UO,75+9!V8Y?G9=T&%@J#
MB;HNNKQ14NI;<^H+N5K3)RAQ\ XX!]Q6J<9=#S#A'46/0U!V4<=0R=]'3YS*
MP$EP )W.<.QW\JCO1]]X43T]MLVJM*&QW2G[,/EJH2 Z1N-WO'K8)&X>,;[[
M(.GT7QA:6-,9!81L1TQY+ZB-&XY?S3:F_5?^(*,^#?"'1VI>&]FN]XMTLU=4
MME,CVU,C >65[1L#@; *3..7\TVIOU7_ (@H4X7<#J#5NA;7>Y[[<:62K$A,
M,36EK>61S=L_FY]Z*FRR:>T=PJMU95TSF6FCJWQMFEJ*ASFEPYN49<3CJY;K
M3S1U$$<\#VR12-#V/;T<TC((4$\>[%'IK@-0V:&>2HCHZJ&,2R?.=\\Y/Q4Q
MZ0WTG9<?^"@_NPB/5IU#:+O6UU';+A3U550O[.IBB?ET+LD8<.XY:1[E8S:X
MTQ ZX-GOUNB=;W]E5!\P;V3\D<ISWY:=O(J*?1]_G.XJ?ZQ/]_.M5T'H6T:T
MXUZ]=?V23TM!7S2"G#BULCG3/ YB-\#!V'C[B5*W$/B78:;0MQGLVHZ-ERGH
MI)J L>.=Y!<T%H/7UF.'M!5KP7XCVV[Z/L=+?-0TT^I:@O9)%(\"5[NU?RC
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M0NNBYA04LCHI;B'X:V,EQY@?FG!/<=P.F5.J(+.\U4U%::RII*9]740PN?%
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M:,N&[,GO'AX$J3$0<_,UMQDMU)]BZK1K*RX-'9MKFQES3W<QY7<A/O \EMO
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M>*+DIP?PI7>JSZ3D^0*#:47/'HO:SN537W33FHZJKFJWQLKZ5U6]SGEI:.8
MNWP6ECAY$E=#H"*-/2.J)J7A'>):6:2&5KX,/C<6N'W9G>%L?"R5\W#;2\DS
MW/D?;H"YSCDN/(-R4&T(B("(H/XF5E3%Z0>@J>*IF9!)$.>-KR&N]>3J.A03
M@BCW6FE-4W;B!IZ[V741H+-1<ORJC$CV]IAY+O5'JOYFD-];IA2$@(B("(B
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M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M;BGNOR2./M''9S1@;'!Z G;.<; A',%@OFM^-&M++3ZCK;9:XIW/J1'(XES
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M,;QESAC?YI ]K@M4XD7RY\,>&.F-,T%>^*]W($5-?+(7.BZ&0AQR1ZSP >X
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M-9.P4KH:IO5KC)DR >67$+FFS:5O%=Q BX6U50Z:PVRY/KI<'_NN4')/=EI
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M#WD95XB!@8QW+Q##%"PLAB9&TG)#&@ KVB"G#!% TMAB9&TG)#&@ _!(8(H
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M-6UKKFTZ/K+/379M4Z2ZS&"G[&,. <"T>MDC ]<>*V.L>Z*CGD8<.;&YP/F
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MBOFH-(674&G8K'=J0SVR+DY(A*]F.08;ZS2#M[41ZT)]Y&GO]74_]TU1'PA
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M-&/?)8+8R&I>.5U1(XR2$>',XG \AA9R^V6W7^VRV^\T<-91R?.BE;D9[B/
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M';Z/CJ6LK+C:M7U]!=I9G2QU%/%R!C7$DM(#\GVY'L4\(@B'1?!2"UZCBO\
MJJ^5>H[K"0Z%U0"&L<.CCS.<7$=V^!X+<N)&@K3KVS,H;L)(Y87%]/4Q8#X7
M=^,]0=L@]<#O *VQ$$&_:/OE=%'07_B'=ZZRL(!I0UPYFCH"7/</B"IBM]FH
MJ&PPV:&-SK?% *81R/+R8\<N"3N=ED$00M8^"EQT[>HWZ>UO<Z&R-J6U/R ,
M)#B"#RN/.&NZ 9+>G7*WSB;H6@U]IW[&7"62G?'()H*B,9=$\ C..\8)!"VU
M$$?<--"WK2U16/ONKJR_PSPMA9!4,/)&&G8CF<[N)&V.N^5J]?P/J*"[U59H
M35MPTY#5'FDI8@YS![,.;MX YQXJ:401_P ,^&=/HNLK;E47:NN]ZK6AD]74
M/(#AG..7)\.I)/AC=5M*\/FV#B#J'5 N+IW7<$&F,/*(O6!^=DYZ> 6](@+0
M^)?#U^L:B@K:._W*RW*A#A!+3/)8.;J2T$'.PW!&RWQ$$/Z=X-5#=3T-\UGJ
MFMU'44#@^EBE:6L8X'()RYV=P#@8W SE;#Q.X86W7,E+6_*I[9>J08@KZ?YP
M .0'#(R =Q@@CQ6_H@A2EX)7"X5]++K76]VOE)3/#XZ;+HP2.A+B]V/:,'S6
MX<5>'K-?6ZV4CKBZ@%#4=N'"+M>?;&-W#XK>T0%'_%OAE1<1::W-J*MU%444
MA<V9D8>7,</69C([P#GNQYJ0$04+?206^AIZ.DC$=-3QMBB8.C6M& /@%IFA
M^'S=+:PU1?6W%U2;W,9C"8>3L<O<[&<GF^=CH.BWI$$4Z]X-4=_O[K_I^[U6
MGKX\YDGI@2V0_C8!:0X]Y!W\,JUTIP3CI=0T]\UAJ&NU+7TS@^ 5',&,(.03
MS.<3@[XR!Y%3 B".^)G"RWZTK::Z4]=46>_4P BKJ;J0.@<,C..X@@K7+;P4
MK:N[4=;K76=UOT=(\20TY+HVAPZ')>XCW8/FIG1 6 UUI6AUGIFJLMT+VP38
M<V2/YT;P<M</^NF5GT01CPTX;WS2%V9/6ZTKKK;H8'4\-#)&X1M:<8ZO<!C
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MC_BG;R_TC_BJ:)N32IV\O](_XIV\O](_XJFB;DTJ=O+_ $C_ (IV\O\ 2/\
MBJ:)N32IV\O](_XIV\O](_XJFB;DTJ=O+_2/^*=O+_2/^*IHFY-*G;R_TC_B
MG;R_TC_BJ:)N32IV\O\ 2/\ BG;R_P!(_P"*IHFY-*G;R_TC_BG;R_TC_BJ:
M)N32IV\O](_XIV\O](_XJFB;DTJ=O+_2/^*=O+_2/^*IHFY-*G;R_P!(_P"*
M=O+_ $C_ (JFB;DTJ=O+_2/^*=O+_2/^*IHFY-*G;R_TC_BG;R_TC_BJ:)N3
M2IV\O](_XIV\O](_XJFB;DTJ=O+_ $C_ (IV\O\ 2/\ BJ:)N32IV\O](_XI
MV\O](_XJFB;DTJ=O+_2/^*=O+_2/^*IHFY-*G;R_TC_BG;R_TC_BJ:)N32IV
M\O\ 2/\ BG;R_P!(_P"*IHFY-*G;R_TC_BG;R_TC_BJ:)N32IV\O](_XIV\O
M](_XJFB;DTJ=O+_2/^*=O+_2/^*IHFY-*G;R_P!(_P"*=O+_ $C_ (JFB;DT
MJ=O+_2/^*=O+_2/^*IHFY-*G;R_TC_BG;R_TC_BJ:)N32IV\O](_XIV\O](_
MXJFB;DTJ=O+_ $C_ (IV\O\ 2/\ BJ:)N32IV\O](_XIV\O](_XJFB;DTJ=O
M+_2/^*=O+_2/^*IHFY-*G;R_TC_BG;R_TC_BJ:)N32IV\O\ 2/\ BG;R_P!(
M_P"*IHFY-*G;R_TC_BG;R_TC_BJ:)N32IV\O](_XIV\O](_XJFB;DTJ=O+_2
M/^*=O+_2/^*IHFY-*G;R_P!(_P"*=O+_ $C_ (JFB;DTJ=O+_2/^*=O+_2/^
M*IHFY-*G;R_TC_BG;R_TC_BJ:)N32IV\O](_XIV\O](_XJFB;DTJ=O+_ $C_
M (IV\O\ 2/\ BJ:)N32IV\O](_XIV\O](_XJFB;DTJ=O+_2/^*=O+_2/^*IH
MFY-*G;R_TC_BG;R_TC_BJ:)N32IV\O\ 2/\ BG;R_P!(_P"*IHFY-*G;R_TC
M_BG;R_TC_BJ:)N32IV\O](_XIV\O](_XJFB;DTJ=O+_2/^*=O+_2/^*IHFY-
M*G;R_P!(_P"*=O+_ $C_ (JFB;DTJ=O+_2/^*=O+_2/^*IHFY-*G;R_TC_BG
M;R_TC_BJ:)N32IV\O](_XIV\O](_XJFB;DTJ=O+_ $C_ (IV\O\ 2/\ BJ:)
MN32IV\O](_XIV\O](_XJFB;DTJ=O+_2/^*=O+_2/^*IHFY-*G;R_TC_BG;R_
MTC_BJ:)N32IV\O\ 2/\ BG;R_P!(_P"*IHFY-*G;R_TC_BG;R_TC_BJ:)N32
MIV\O](_XIV\O](_XJFB;DTJ=O+_2/^*=O+_2/^*IHFY-*G;R_P!(_P"*=O+_
M $C_ (JFB;DTJ=O+_2/^*=O+_2/^*IHFY-*G;R_TC_BG;R_TC_BJ:)N32IV\
MO](_XIV\O](_XJFB;DTJ=O+_ $C_ (IV\O\ 2/\ BJ:)N32IV\O](_XIV\O]
M(_XJFB;DTJ=O+_2/^*=O+_2/^*IHFY-*G;R_TC_BG;R_TC_BJ:)N32IV\O\
M2/\ BG;R_P!(_P"*IHFY-*G;R_TC_BG;R_TC_BJ:)N32IV\O](_XIV\O](_X
MJFB;DTJ=O+_2/^*=O+_2/^*IHFY-*G;R_P!(_P"*=O+_ $C_ (JFB;DTJ=O+
M_2/^*=O+_2/^*IHFY-*G;R_TC_BG;R_TC_BJ:)N32IV\O](_XIV\O](_XJFB
M;DTJ=O+_ $C_ (IV\O\ 2/\ BJ:)N32IV\O](_XIV\O](_XJFB;DTJ=O+_2/
M^*=O+_2/^*IHFY-*G;R_TC_BG;R_TC_BJ:)N32IV\O\ 2/\ BG;R_P!(_P"*
MIHFY-*G;R_TC_BG;R_TC_BJ:)N32IV\O](_XIV\O](_XJFB;DTJ=O+_2/^*=
MO+_2/^*IHFY-*G;R_P!(_P"*=O+_ $C_ (JFB;DTJ=O+_2/^*=O+_2/^*IHF
MY-*G;R_TC_BG;R_TC_BJ:)N32IV\O](_XIV\O](_XJFB;DTJ=O+_ $C_ (IV
M\O\ 2/\ BJ:)N32IV\O](_XIV\O](_XJFB;DTJ=O+_2/^*=O+_2/^*IHFY-*
MG;R_TC_BG;R_TC_BJ:)N32IV\O\ 2/\ BG;R_P!(_P"*IHFY-*G;R_TC_BG;
MR_TC_BJ:)N32IV\O](_XIV\O](_XJFB;DTJ=O+_2/^*=O+_2/^*IHFY-*G;R
M_P!(_P"*=O+_ $C_ (JFB;DTJ=O+_2/^*=O+_2/^*IHFY-*G;R_TC_BG;R_T
MC_BJ:)N32IV\O](_XIV\O](_XJFB;DTJ=O+_ $C_ (IV\O\ 2/\ BJ:)N32I
MV\O](_XIV\O](_XJFB;DTJ=O+_2/^*=O+_2/^*IHFY-*G;R_TC_BG;R_TC_B
MJ:)N32IV\O\ 2/\ BG;R_P!(_P"*IHFY-*G;R_TC_BG;R_TC_BJ:)N32IV\O
M](_XIV\O](_XJFB;DTJ=O+_2/^*=O+_2/^*IHFY-*G;R_P!(_P"*=O+_ $C_
M (JFB;DTJ=O+_2/^*=O+_2/^*IHFY-*G;R_TC_BG;R_TC_BJ:)N32IV\O](_
MXIV\O](_XJFB;DTJ=O+_ $C_ (IV\O\ 2/\ BJ:)N32IV\O](_XIV\O](_XJ
MFB;DTJ=O+_2/^*=O+_2/^*IHFY-*G;R_TC_BG;R_TC_BJ:)N32IV\O\ 2/\
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MEC ]I48:2LLFH-04=NB) E?]T</P6#=Q^'TX74]%2PT5)#2TL8C@A8&,8.@
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M_2 _E^V?JI_;*N_1Z_SF^?F0_6]8^;YNG_D_S_9-"(BR?2"(B B(@(B("(B
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MG<>XJ:[/P\TW;:=L?V-BJGXPZ6I':.=Y[[#W!:7Q4X?6^CL\UXLD/R9T&#-
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M\CA_@,?$K(<!+#SU%7?)V>K&/D\&?QCNX_# ]Y4<M^]<R<R+-NJ8B.^I^?\
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MN?8)9J.K9+$YT51"\.:1L6N!_>$[-E5>3PVY'/5NF?Y^4NP$5A8*\72R4%>
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M *0X.#8]6ZLBKSZ1^[G'C-]_]?\ F1?L!2#P ^]>X?KA_88M5X\VQ]/J2FN
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M7O\  35'Y&J_@/WK.<)M;0Z;J)J*YEPMU2X.[0#/9/Z9QX$8S[ IVH[O;JR
M34E?2S1$9YF2M(^M(AAA8&/DVXJYYWYQT<V_P$U/^1JKX#]ZW/A)I>^6C5S*
MFX6Z>FI^P>QSWXQOC ^A;QJWB+9K% ]M//'7UW1L,#P0#_I.&P^M9C1^IZ'5
M%K;543N61N!- X^M$[P/EX'O5TZ\?!Q:+\11<W5'771#7'4N.M6<W04D?+[.
M9W^.5J5FT[=[S!)-:J&:IB8[D<Z/&QQG"E'CY9))8:&]0L+FPCY/,1W G+3[
M,DCWA:=PLUBS2USFCK0XVZJP)"T9,;AT<!W]3G_DH\_*LT>VS3>G43/?XL=_
M 35'Y&J_@/WI_ 35'Y&J_@/WKI"WWJV7" 345?2S1D9RR0;>T=WO6!U5Q LE
MAIWXJ8ZRLQZE/ \..?\ 2(V:/;OY)IVU\*Q:*>>JY.OR1KPRTG?[7K6WU=;;
M*B"F9V@?(\# !8X#Z<*0.,_W@5OZ2+]L+*:'U=1:KMW;4^(JN, 3TY.[#XCQ
M;YK%\9_O K?TD7[85=5-FW9PJ_"JW$Q,_HA+A[]^UD_6F?6NI5RUP]^_:R?K
M3/K74J0U<#_M5?']A<DZA %_N8 P!52@?[Y76RY*U']\%T_6I?VRDL..?TT?
MFZ.X9$G0=FR?^Y_XBMG6K\,?O#LWZ'_B*VA(>OC?V:/A'T%J^OM(4VK+:R*1
M_85D))@FQGESU!'>#@+:%KFK]86W2WR47$R.?4.P&1 %S6][R/ (N1X<VYB]
M_3YH#O\ H74%D>\U-ODEA;_WU..T9CQVW'O 6,LU_NMDEYK97U%-@[L:[U3[
M6G8^\+IVT:@M-WB;);KA33@_@AX#A[6G<?!1WQOBL M(D IFWLR-Y.RQSN;^
M%SX[L>/?[U-/ R.&T6:)OV+G2/YTF&6X9<01J5YM]S8R*YL;S-<S9LP'7 [B
M/!:QZ0A?\NLP.>S[.3'MRW/^"TGAIVO\.K-V&>?MQG'XN#S?1E2YQML<ESTS
M'6T["Z:WO,C@.O9D8=\,-/L!3R;*;MS+P*XJZS'ZZU+3_1_;&=0W(NQVHI?5
M]G.,_P""G1<IZ/O\VF[]3W&!O.&9;)'G'.P]1_C[0%T79=96&[TK9J:Y4\;B
M,F*9XC>WR()^K96&[@^3;\'PIG4PV%<AW/\ E*K_ $S_ -HKHG5/$2QV2ED[
M"JBKZS'J0T[PX9_TG#8#Z?)<X3RF:>25P <]Q<<>).5)<W&KU%<TTTSN8VZB
MX??>39/U5GU+8%K_  ^^\FR?JK/J6P*O?L?VJ?A#C^K_ ,[G_/=]:ZCT)]YE
MC_4XOV0N8;M"ZGNE9"\8?',]A'F'$+HKAM?K=5:-MK&UD#9::!L,L;G@.86C
M&X/=MG*D/GN#513>KB?3]VXJ'/2&ZV+_ .-_P*6;?<*.XQODH*F&IC8\QN=$
M\. <.HR/:%$WI#=;%_\ &_X%9>KQ28G$JF/P^L,3P!^^NN_4G?WC%-]SH:>Y
M6^HHJR,24\["Q[3W@_XJ$. /WUUWZD[^\8IMN]QIK3;:BNKI!'3P-YG'_ >9
MZ)#5PK7LGWNW5 ^JN%EYM<TDEJ8;C1YRWL_XUH\"WO\ =GW+26NK[369::FB
MJF>'-&]OU%='Z:U[8;]$WLJQE-4GK!4.#' ^6=C[E>ZL98*BT2NU":1U(&D\
MTA&1^8>N?9NFG+<X99N1XN/7KZ?](IT/Q4K:6JBI-1O^4T;R&_*",21^9Q\X
M?3[5.;2'-#FD%I&01WKCR3E[1W9YY,GESUPNJ]%]K_!&S?*,]K\DBYL]?FA(
M;.#Y5R[S6ZYWII/'_P"]BW_K@_8>M X,??\ T/Z.7]@K?^/_ -[%O_7!^P]:
M!P8^_P#H?T<O[!4\W-E_\C3\:71R(BR?2N1+M_*E;^F?^T5TSP[^\BR?JK%S
M-=OY4K?TS_VBNF>'?WD63]58L8?-<%_O5_#]W/O$0O.N+WVG7Y2[X=WT85*V
MZ2OURHHZN@ME1/329Y)&8P<$@]_B"MIXWV22@U.+DQA^35[0>8=!(T8(^ !]
MY5[PCUW36:!UGO+^RI"\O@G.XC)ZM=Y$[Y\RCD\"W.75;OSJ-SU^C4OX":H_
M(U7\!^]/X":G_(U5\!^]=*17.@F@[:*MI7PXSSME:6_'*T[5O$ZSV4"*@<VY
M5?,,MA?ZC1G?+^F?(933T+O"\6U3S5W)B/R8#@MIZ\66\7"2Z4,U+#) &M+\
M>LX.'^&5HO%PO/$&[<^>L>/9V;<+H/3M[HM06R.NMLO/$[9S3\YCN]KAW%1%
MQYL;X;I37F)A,$[!#*1W/;G&?:/V5?)<W&IHPHBU.XB=_7_;9^ K8AI"I+,=
MH:QW/X_-;A22N<.%VLFZ6N,L5:'.MM5CM.49,;AT<!W^8_<IWI=36.JIQ/!=
MZ$Q$9R9VMQ[03D>](=?#,FW58IHWJ86W$'[R+W^JO^I<R6K^4Z/],S]H*9N)
MO$*UNLU7:;3(VMGJ6&-\C/XN-IZ[]Y]FWU*&;5_*='^F9^T%)>5Q:]1<OT\D
M[U_MUXB(LGU(H0](+^6+3^@=^TIO4(>D%_+%I_0._:4EYO%O\6K\OJ]>CY_*
MEX_0L_:*E+6_WFWW]1F_8<HM]'S^5+Q^A9^T5*6M_O-OOZC-^PY(:N'_ .#\
M_P!W+$'\?'^</K782X]@_CX_SA]:["4AS<"[7/R_<7,W%< <0+Q@8]=A_P#U
M;5TRN9^+'\X-X_.9_=M5EOXW_8I^/[2E3@22=%2 GI5R ?[K5(BCK@1]Y4OZ
MX_\ 9:I%2'=@?XU'P%IO%_\ F[N__P '^^8MR6F\7_YN[O\ _!_OF(SR_P"Q
M<^$_1 VB/ORL7Z]#^V%U6N5-$??E8OUZ']L+JM(>7P/^W7\1<>U(Q42@=.8_
M6NPEQ]4_YS+^>?K4EKX[VM_G^SJ;1!)T;8R>OR*']@+-K":'^\VQ_J4/[ 6;
M5>W9_MT_"'.?&D :^J\=\47[(6]^C^3_  ;N([A5_P# U:)QI^_VK_11?LA;
MWZ/_ -[MR_6_^!JGF\#$_P"1J^,M+XY%YUN>?/**:/E]GK?XY6U^CVV/['7E
MPQVQEC#OS<''T\RI<>[')+%17J%A<V(?)YR!T!)+3[,DCWA:'PYU6[2EZ,TC
M7244[1'4,;UQG9P\Q_B4\V%548O$)KN=M_5TVL?J+[W[G^JR_L%6MOU58KA3
M">FNU&6$9(?*&.'M!P0M2U_Q%M%':JJBML\=?6SQNB^Y',; 0027#8^P*O>O
M9-JBW-4U1I "Z_H/\QI_T;?J7("Z_H/\QI_T;?J4AXW N]S\OW0+QV^_2/\
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M8L_ 'OZ^X+6^"U@^RNI_ETS,TMO DW&QD/S!]9]P6@R222N:9'N>0T-',<X
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MX4V#[.ZLI^U9S4E)_E$V>AP?5;[SCW KI5:+P>L'V&TI'/,SEJZ_$[\C<-_
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MX/DQL7,@>1]2@?5&HKAJ2XOJ[C*7;_<X@?4C'@T?X]ZO[/H/4=VIFU%);)!
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M/J4!VBU734=R=#00RU=4\\[W$YQXN<X]/:5M%;PJU-34IF;#35! R8X9<O\
M@0,^Y3;ACB>7=W5:M_=^$RG^VW&CNE,*BW54-3"?PXG!P]A\"KM<HZ>OERTQ
M=A443WQ2L=RRPOR&O .[7#_HA=-Z;O%/?K+2W&DVCF;DM)W8[H6GV%6)>A@\
M0IRHFF8U5#)HB*O11_QP^\9_ZS'_ (J(N%_W^V;]*?V2I=XX?>,_]9C_ ,5S
M[#-)!()()'QR#.',.",C!W6+Y?BE?AYE-?IJ?U=.7G7.G;/,Z&LN<1F:<&.(
M&0@^!Y0<>]6UNXCZ7KI1&RYMA>=@)XW1C_>(Q]*@FQZ,O][A$UOMLKX#TE>1
M&UWL+B,^Y4=0:6O.GPUUUH9(8W'#9 0YA/AS#(SY)MMGBN5KQ/#^[\)^KJF-
M[9&-?&YKF.&0YIR"%Z7.W"[6U18+G#0UDSGVF=X8YKCM"2?G#P'B%T2J]?#S
M*<NCFIZ3'>!8.^:LL=C>67.XPQ2C_NAE[_\ =;DA:AQ>UM+8X66JU2<EPG9S
M22CK"SNQ_I'Z![0H:L=DNFI*]\-MIY*F8^M(\G9N>]SCT3;DS.)S:K\&S3S5
M)Z@XH:5EE##7R1YV#GP/ ^I;;;ZZEN-,VHH*B*H@=T?$X.'T+GRX\+-2T5*Z
M<005(:,ED$G,_P"! S[LK Z5U'<-+W1M11/< '8F@<<-D Z@CQ\^H3;GIXI?
MLUQ&31J)_GYNJD5C8[G3WFTTMPHW9@G8'C/4>(/F#D>Y:KQ1UE_!>VLAHRUU
MSJ0>RSN(V][R/H'G[$>S<OT6[?BU3T;'>]16FQM!NM?!3$C(8XY>1Y-&2?@M
M=9Q1TJZ7D-?(T?CNIWX^K*YZ>^LNM>7/,]763N\WO>X_25LT7#754E/VHM9
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MG!S>_E<>8'XDCW*1DAV<.IIC&HY/3]?-HW&6AIJC0]9430L?/3%CHI"-V$O
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MN>*I8\20S.>T\A[_ '$9^A;A]IJQ?^.N?^_'_P#@)]IJQ?\ CKG_ +\?_P"
MKU=ERUQ&Y3-%6M3\$4\.*]]OUM:)6$@/G;"[S:_U3]?T+J)1W;>$MEH+A35D
M59<724\K96ASV8):<C/J=-E(B0Z^&8UW&HJIN>HB(J],1$0%S5Q9M/V*UM7!
MK<156*EG^UGF_M!RZ544\?;3VUIH+I&WUJ>0PR$?BNZ9]A']I27E\6L^)CS5
M'>GJQ?#/58M?#Z^LD>.UM^9( ?\ WFS1_O\ UJ+*"FFN-P@I8<NGJ)6QMSWN
M<<?XJBR5[&/8Q[@QX < =G '._O"W_@C:/LAJWY9(W,-!&9/+G/JM_Q/N4>!
M175EU6K$^73^?DGJV445OMU-10#$5/$V)OL PN8M>6C[!ZLN-$UO+$).>+\Q
MWK#X9Q[EU.H=X_V?+;=>(V],TTI^+F_\7T*R]SB]B*\?FI_]?HM].:M^3\'K
ME$Z3%72DT<>^^)/FGW O_P!U1E8;<^[7JBH(\\U1,V/([@3N?<-U9B1XB=&'
MN$;B'%N=B1G!^D_%21P(M/RO4M1<'MS'11>J?]-^0/H#E'B45U9ERW:J\NG\
M_).\$3(((X8FAL<;0QH'< , +F/B37ON&M[O*\Y$<Q@:/ ,]7_#Z5U N5]>T
MSZ36=ZBD!!-5(\>QQ+A]!"LO7XWN+5,1VVVKA]KZV:4LKJ4VR>:JE>7S3->T
M<W@/8!]96S_;HH/R35?UC5BM"<.K#J73=-<'UM>V=V63,C>S#'@]-VGNP?>M
M@^TU8O\ QUS_ -^/_P# 4ZM./3GQ:I\*8Y==.R*->7NBU#?77&@HWTG:, E:
MX@\SQGUMO+'P4C^C[7O?17>@<261/9,P?G @_LA9#[35B_\ '7/_ 'X__P !
M;'HS1-OTG+526^>JE=4-:UW;N:<8STPT>*L,L3"R:,F+US7GMM*(BKWT?\</
MO&?^LQ_XJ&N'M'3U^L[535D398'R^LQW1V 3O\%,O'#[QG_K,?\ BHBX7_?[
M9OTI_9*Q\WS7$8B<ZB)_#ZNG&M#&AK0&M P !@ *TO%O@NMLJ:&K8'PSL+'
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MG/T2^HOX]W%]/I^AH8W$"KF+GX[VL&<?$@^Y2@HF](*D>^V6FK:"612OC<?
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MZBLGTE=,54S3/9R"TEK@6D@@Y!"Z\MDYJK;25#NLL3'GW@%<A+K73GWO6O\
M58OV L8?/<"G[U<?#]T$<;OOZE_01_4MK]'^AIG4=SKG0L-6V41-D(R6MQG
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MQ2M+9&.+7 ]Q&Q"QEX''9G[D>77]G2_#+3T%ATO2<L;?E=5&V:>3&Y)&0WV
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M:-E+;::.GIV]&,&/>?$^95=&-BYE5V+M^K6O+_YT8[7?WF7S]3E_9*Y<H_\
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MG)<>I)/B2D//X;B9%F[55=[?'>V01$5>V+$:NM8O6FKC;\ NFA(9GN>-V_2
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MBPNL[G-9]+7*OI6AT\,1+,C(!)P#[LY]RYH9J*\,N'RYMSJ_E?-S=H922?\
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M0ULTHZ6:E=+45<C>5TTN,AO@ .@6UJ-^%VN;EJJZ5E-<(:2-D,(D:86N!SS
M;Y<?%;U?*M]#9;A5PAIDIZ>25H=T):TD9\MD8XMRS-GFLQJE?(H&AXPWYTK&
MOI;:&EP!/9OV'^^L]JGB_'35$E/I^E94AAQ\IG)Y"?\ 1:-R/,D)MHCBN--,
MU;[);11)PWX@WG4.J(Z"X"E[!\;W_<XRT@@9&^5+:.K&R:,FCGH["@WT@?Y=
MM?ZL?VBIR4&^D#_+MK_5C^T4ER<6_P 6K\OJK^CW_G]Z_11?6Y3%<:*GN-#/
M1UL0EIYFECV'O"AWT>_\_O7Z*+ZW*6M1UTEMT_<JZ ,=+34\DK \9!+6DC/E
MLD)PR8C#B:NW7ZRT>BX062GN(GEJ:N>G:[F%.\@ ^1(&2/@I(:T-:&M #0,
M#H H'AXP7]\S&FEMN'. _BW_ /X:F'5M97V_3U;66F.&2KIV=H&2M)#FC=W0
MC?&498=[&Y:ZL>-:[LPB@BDXQWGY5#\KI* T_..TY&/#N7.^/6ZX4YP2QU$$
M<T+@^*1H>QPZ$$9!1T8V9:R=^'/941%$NO>)];9=1SVZT0TDL5. V1\S7.)D
MZD##AL-A[<HRR,FWC4\]SLEI%IG#'4-VU-;*FONL-+% ).S@$+'-+L?.)R3M
MN!\5?ZSUA;M*TK7UKC+4R#,5/'\Y_F? >?UHM.3;FUXTSJG\6R(N?[GQ=O\
M42N-%'2T<7< SG=[R=OH"6SB[?Z:4&M92UD7>"SD=[BW;Z"FW#]L8V]=?DZ
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M:ZJS7.HH*^/DJ(78< <@]X(/@1NILX!?>G6_KKOV&*.N,7\X%R_-B_NVJ1>
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ME;+3RM#V/;T<"K#Z# N8U<3./&O6%=$15Z"&O2&_C+#[)_\ [:QG #[Z:_\
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M=A,T=J6DEA P6D'ZT+-ZFG+IKLTS$3,=/CW=+(B+)]>(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M9V3;'-SZ\NC44ZIA+_H__>[<OUO_ (&J0KU=J*RT+JRYU#8*=K@WF()W)P
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MN$DA=]:V_1?#FZW^>.6LBDH;=D%TLC<.>/!C3U]O3VIMT3Q6_D513CT?O_\
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MZ_Y//@>TL/UCX)+HXQC^):\2.]/T1-6U=3<:MT]5(^:HDP"X[DX  ^@!=-Z
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M[NE-26JGU)IRIHG.:Z.ICS%(-P'=6N'OQ[ERW(RIMEQ<QW-#5TLN#W%CVG_
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M]VY'+-FNQET6ZYWJ8^6W2J(BR?7HGXZVJX7)]E^QM!5U?9B;G["%TG+GDQG
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M$A'K.:"2,^)WZKJ^JIX:J!\%3$R:%XPYCVAS7#S!7,W$JS4MBU=5T5O:YM,
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M<UPBD/-R$';E\/9T6>X/_P X-L]DO]VY;GQTT];Z:WT]XIH&PUDDXAD+!@2
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MO]ZY8'T@/O>MOZU_P.6>X.?S>VS\Z7^]<L#Z0'WO6W]:_P"!ROD]B]_QW_\
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MU8_M%67I<6_Q:OR^JOZ/?^?WK]%%];EZ](2%PJ[+-CU"R5F?,%I_Q7GT>_\
M/[U^BB^MRWWBAIM^H],214S>:MIW=M /QB <M]X^G">3DLVIO<-Y*>_7])0=
MH32;M6U=5315T=++"P2 /87<XS@XW[MOBMS^TM5_EFG_ *D_O4<6*ZUNGKQ%
M6T1,53 X@M>-B.A:X>"FBT<7[+44[?LE!4T<X'K!K>T83Y$;_$*0XL&G#KIY
M;_2KXRU[[2U7^6:?^I/[U?6+A'56V]6^N?=H9&TM1',6"$@NY7 XZ^2JZBXQ
M4<<#X[!22S3D8$U0.5C?/ESD_0JG";7M;>:QUIN[9*BH(=)'4M9W=2'XV \#
M[DZ.RBCAWC1;HZS\9UMNO$#[R;W^J2?4N8K;_*-+^E9]:Z=X@?>3>_U23ZES
M%;?Y1I?TK/K26KC7]ZCX?NZ]7-W&/^<&Y?FQ?W;5TBN;N,?\X-R_-B_NVJR[
M.-?X\?&/I*1> /WIUWZ\[^[8I,49\ ?O3KOUYW]VQ28D.OAW^-1\!$15VM7X
MG?>'>?T/_$%SEIS[X;7^M1?MA=&\3OO#O/Z'_B"YRTY]\-K_ %J+]L+&7S?%
M_P#(H^$?5UJN:.+?\X5W_.C_ +IJZ77-'%O^<*[_ )T?]TU677QO^Q3\?VE*
M/ ?[RYOUQ_[+%(I (((R#L05'7 ?[RYOUQ_[+%(R0[<#_&H^#ESB!8CI[5-9
M1M;BG<[M8/T;MP/=N/<M@9KES>%KK+VA^7]I\F![^P.^?^'V+=^.=A^76&*Z
MP,S/0NP_ W,;C_@<'WE0*H^<RJ:\*_731TBJ/TEM/#6P_P (-64E/(WFIH3V
M\_AR-[O><#WKIU1SP1L/V-TV^XS,Q45[N89&XC&S?B<GWA2,K#W.%8_@V(JG
MO5U_TY:X@PN@UM>V2 @FJ>_W./,/H(6Q:3X92ZCL=/<J>ZP1MEY@8S$26$$C
M!W\L^]9KCGIF5M6R_P!)&70O:(ZGE'S7#9KCY$8'N'BM2X?ZXJM)SR1F/Y3;
MYG<TD/-@@_C-/<?K4>)5:M6<NJG)C[L_OVEM7VEJO\LT_P#4G]Z?:6J_RS3_
M -2?WK:X^+>FG0<[G5C'X_BS#D_0<?2M,U9Q<K:PB'3T3J*%K@XS28=(_!Z8
MW 'Q3H[;MOAMNGF[_"9;OPXT'-I*NK*B:NCJ1/&(PUC"W&#G/5;3J&Q6_4%O
M=1W2 2Q$Y:1LYA\6GN*QG#[4_P#"FQ"K?3O@GC=V<HP>1SL=6GO'EW+5>('$
MQ]COL5!:(X:CY.?\K+^A/X@(Z$=Y\=O%5Z$7,7'QHG_TG\^[ 7[@Y70N<^R5
ML53'U$4_J/\ 9D;'Z%'=ZLMRL54(;I22TLO5I=T=YM<-C[E-UKXNV"IB!KF5
M5%+WM+.T;[BW<_ +3.*^NK=J2AI[?:HI'LCE[5U1(WE[B,-'7OWSCH%'D9=C
M"\.;EFO4^G\ZLWP9UI5UM6;'=9G3GD+J:5YR[;JPGOVW'L*EY<Z<%J":JUS3
M3QM/94C'R2.[@"TM ^+OK71:L/5X3<KN8^Z_*=?D**O2!A>ZQVN8 \C*AS3[
M2W;]DJ55@M:V)NHM-UEN)#97MYH7'\&0;C]WL)1U9EJ;UBJBGO,(0X+5<5+K
MJG;,0.WB?$TG\;&1]6/>NC%R'+'5VJXN9()*:LII/8YCP5+^G.,5.*1D=_HY
MOE#1@S4P!#_,M)&#[,^Y2'B\*S;=FF;-V==4NKE;7GWZ7S]<E_:*DK47&.$T
MSX[!12]NX8$U3@!GF&@G/O(]ZAVJJ):JIEJ*F1TDTKB][W')<XG))26'%LRU
M?BFBW.].C>#G\WML_.E_O7+ ^D!][UM_6O\ @<L]P<_F]MGYTO\ >N6!](#[
MWK;^M?\  Y7R>A>_X[_^8_9H_!/[_*?]#)^RNBESKP3^_P I_P!#)^RNBDA.
M"_X\_&?V6MU_DNL_0O\ V2N0UUY=/Y,K/T+_ -DKD-27)QWO1^?[.MK6TR6"
MD:#NZE8,^U@7)DK'12OC>"'L):0>XA=;63^1J#]7C_9"@3B_IB2S:BEKX8S\
M@KGF1K@-F2'=S3[\D>1\DELXQ9JJM47(\OW3=HNKBK=)VB> @L-+&W;N(;@C
MW$$+-+G#A]K^JTJ'4LT1J[:]W,8N;#HSWEI_P^I2)-QCL38"Z*DN#Y<;,+&M
M&?,\RNW5C<3L56HYZM3'=;>D#_(5K_63^R5I?!'[^H?T$GU+$:XUC7:LJV.J
M6M@I(B>RIV'(;GO)[SYK+\$?OZA_02?4IYO(JOTW\^FNCMN'1"(BR?5L/K"%
M]1I2\Q1@E[Z24- [SR%<J0O[.9CR,AK@<>.Z["(!!!&0>Y<P\0],RZ9U!-!R
M'Y%,3)3/QL6Y^;[1T^'BI+P.-V:IY;L=HZ.F:.HCJZ2&H@<'13,;(QP[P1D*
MLN?N'_$N?3M(VWW*!]70,_BRPXDB'@,[$>6RW.MXQV6. FCHJZ>;&S7AK&^\
MY/U)MVV>*8]='-55J?.&"](3_/[-^BD^MJH>C]_+MT_5A^T%HVK=2UVI[G\K
MN#F@-'+%$SYL;? ?O6\^C]_+MT_5A^T%/-X]F]3?XA%RGM,_LV#C_"YVGK=,
M!ZC*KE/O:<?4HHT9I\ZFO3;<VK92R.C<]CGMYN8C?&/9D^Y=&ZTL;=1:;K+<
M2&R/;S1./X+QNW]WL*YDC?76&\!S>TI:^DD[Q@L</^O>DMG%;449,7:XW3.O
MT27]I:K_ "S3_P!2?WI]I:K_ "S3_P!2?WK-6#C!;9J9C;W334U2!ASX6\\;
MO,;Y'LW]J]7OC#:H('"T4L]74$>J91V;![>\^S'O3HW^%PSEYM_K._DPL?!>
MK:]I-Y@V.?XD_O4T@8 "ASAMQ(N-??OL=>6NJ6UDF8GQ,WA/A@?@?5U4R*P[
MN'1C\DUX\:WW01Q_^^:W_J8_;>LCZ//\=??S8?K>J?I!4,@KK57AI,3HW0$^
M!!YA\<GX+6>%NKZ?2ESJC712/I*IC6N,8RYA:3@X[QN5/-Y-5=-GB4U5](W]
M8=((M%MG$ZQW.^4=MI&U&:AW()I&AK0[&PZYW.WO6]*OHK5ZW>B9MSO2"_2
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MY,'AW:@G/-R],>Q;VB.J]9IO43;K[2CKAKH&LTG=JFKJJRGG9+!V0;&""#S
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MS)" UV2&N!\/)32BCDOX5J_5%=<=8%%&M>&%??\ 4U;<X*^EBCG+2&/#LC#
MWN'DI71&S(QK>13R7(Z-7X=:;GTM89*"JGBGD=.Z7FC! P0T8W]BVA$1LMVZ
M;5$44]H4:VFBK*.>EJ&A\,S#&]I[VD8/UJ&&<&*WY4WGNE,:;GWPUW-RY]F,
MX4VHC1D8=K(F)N1O2G30QTU/%! P,BB:&,:.@ & %41%75'13GBCGA?%,QLD
M3P6N8X9#@>XA19J7@_2U4SY[#5_)"XY["8%S!['=0/BI711SW\:UD1JY&W/I
MX0ZC$G*'V\C\83.Q^SE;+IS@Y%%*V6_UPG W["FR&GVN.^/8![5+J)IRV^$X
MU$[UOXJ%%2P4-+'34<+(8(QRLC8, !:?K#AQ:-12OJ6<U#7NW=-$,M>?%S>\
M^8P5NZ([;EBW=IY*XW" ZW@[?8GGY+54%1'W$O<QWO!&/I5>U\&[M+*TW*NI
M*:'O[+,C_A@#Z5.J)IP1P?&B=ZGYL+I73=OTS;_DMMC(YMY)7[OD/B3_ (=%
MFD1'I444T4Q33&H@1$59-1UKH2V:I';2YIJ]HPVIC&21X.'X0^GS485G!Z_1
M2D4U10SQ]SN=S#[P1_B5/J*:<-_AUB_5S51U_!"MBX-5+IFOOEPB9$#DQTN7
M.=Y<Q  ^!5:]\'YZBZ3RVNKI*:B.!%$\.):  -SW[C*F1$TP^RL;EY>5@=#6
M273NF:2V5$K)I(2\E[,X/,\N[_:L;Q*TI4:LME)34M1% Z&;M"9 2".4CN]J
MW!$=56/15:\&?Z=:1?H'AO7::U'%<:FNIIHV,>SDC#L[C'>%*"(A8QZ,>GDM
M]E&LB,])/"T@&1CF GNR"%"?VF+I^5*+_==^Y3DB,,C#M9.O$CLM[? ::@IH
M'$.=%&UA(Z' PO%TMU)=:&6CN$#)Z:48<QWU^1\U=HJZ.6-<L]D+W_@U-VSI
M+#7QF(G(BJL@M\N8 Y^ 6)I.#]_EE J)Z""/.[NT<X^X!O[E/R*:>=5PC&JJ
MWK7YHGK.#].VQ-IZ&K:ZY&5KGU,X(;R@'+6M'3<CQZ*YT!PXKM,ZB9<:FNII
MHVQN9R1AV=QYA2>B:;:>'8]-<5TTZF!$15W"QNH+)07^WOH[I )83N#T<P^+
M3W%9)0YK/BO+3WF.GT\V.2FIY/NTDC<B<C8M'@WSZY\NL<N5D6K%'_F[3Y>J
MSO7!JOCE<ZS5\$T.=F5&6/'ED @_0K.@X.WR:4"LJJ&FB[R'.>[W# 'TJ1M/
M<2=/7:!AGJVT%3CUHJD\H!\G="/^L+)7'6VG+?3NEFN]))@9#(9!(X^P-RFH
M>=&%@5_^2)Z?%"?$[2]#I66UT=$^269\3I)I9#NXYP-N@&Q6P>CZPF\79_<V
M!C?B[_DM(USJ.34^H)J]S#'" (X8SU:P9QGSW)]ZES@799*#3M3<)V%KZ]X+
M >O9MR ?>2[Z%(<.'33<SMVH^['TUI)2U36>A;5J@=K4-=3UP&&U,0WQX.'X
M0^GS6UHJ^EN6J+M/)7&X0+7\';W%(?D=70U$?<7.<QWPP1]*]VW@Y=YI!]D*
MVCIHN_LRZ1WPP!]*G=$T\_['QM[U/S:WI#1MJTO"?D,9DJ7C#ZF7=[O(> \A
M]*V1$1Z-NW3;IY:(U#&ZALM%?[7+07&/GA?N"#AS'#HX'N(4-W;@Y=H9W?8R
MLI:F#/J]J3&\>T8(^E3LB.?)P;.3UN1U]4(6'@_=!5Q37*XT]*QC@X?)R7R9
M![B0 /;NIN:,- ))('4]Z^HC+&Q+>-$Q;CNQU_LU'?K7-07&/G@D[P<.:1T<
M#W$*&[MP<NL4[C:ZVEJ8,^KVI,;Q[=B/I4ZHC')PK.3UN1U]4'V/@]=/E4<M
MRN%/2QL<'?Y.2^3(\,@ >W=3!>Z%]PL5=0,D DJ*=\(>_P 7-(R<+((A8PK6
M/3--$=^Z#F<&;HU[3]DZ+8Y^:[]RG%$1ECXEK&WX<=T7Z^X;UVI=1RW&FKJ:
M&-[&,#) [.PQW!;!PUTI4:3ME72U51%.Z:;M 8P0 .4#O]BW!$8T85JB[-Z(
M^](M8XAZ<GU/8!;Z:>.&3MFR<T@)& #X>U;.B.BY;IN4S15VE$NCN%UPL6I*
M&Y3U]++'3N+BQ@=DY:1MD>:EI%1JZB*DI9JBI>(X(F%[WGHUH&24:K&/;QJ9
MIM]([L+J[2=LU12"*X1ELS!]RGCV>S]X\BHGN7!R\0RG['UE'4Q=Q>3&[X8(
M^E7E=Q@J1J1LE'3-=9F988G##Y!^/GN/@/CY2%9]?Z;ND+7LN<-.\C>.I/9.
M:?#?8^XE.CSJ_8<VJ=SUC\M_[1K:>#=TEE:;I74M/#WB+,C_ *@/I6I<1+11
MV+5%1;;=S]C!'&"7NR2XM!)/Q4Z7[B#IZTTCY!<(:R8#U(:9X>7'PR-A[USI
M>KE/>+M55]3CMJB0O('0> 'D!LH\[B%K%L41;L]:M_'HFG@ PC3%P>>CJP@>
MYC5)ZU3AA99+'HZBIZAI942YGE:>H+N@/F!@+:U7T&%1-O'HIGOH1$5=0B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@BWC';;_?9J.@M-NFFH81VKWM<T!TAR
M -SW#]I6'"+0UPMM\EN5\HW4YIV<M.UY!RYVQ=L>X9'O4PHIIP3P^W5?]HJF
M9G]!$15WB(B B(@(B("(B B(@+4.*++M5:9DH;%225$]4[LY"P@<D?4]3W[#
MV$K;T4:[MOQ*)HWK;GO2'#B\S:BHOLS;GP6]C^TE<]S2"!OR['O.![UT&-AL
MOJ(T8F'1B4S31YB(BKK$1$!$1 1$0$1$!$1 1$0%K7$>@JKGHRY4=!"Z:IE#
M R-I )P]I/7R"V5%&%RB+E$T3YQISKIG0NI*74=KJ*BTS,ABJHGO<7-]5H<"
M3U712(CGQ,.C$B::)F=^HB(JZQ$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1
M$0%IVN]!T&JF=MS?);BQN&U#6YYAX.'>/I"W%%&N[:HNT\E<;AS5>>&^I;;(
MX"@-9$.DE*>?/N^=]"Q$>E-02/Y&V.YY\Z5X'Q(75B)IY%7!+4SNFJ80'I?A
M-=:Z9DE[(H*4')8'!TKAX #8>T_!3C:K=2VJWPT5!$V&FA;RM:/K/B3XJ[1'
MH8N%:Q8^Y'7U$1%76(B("(B B(@(B("(B B(@(B("(B B(@(B("A'BGI&^W?
M6%15VVW2STSHXP'M<T D-P>I4W(HYLK%IRJ.2N=0C_@U9+C8[)70W6E?32R5
M'.UKB#D<H&=CY*0$1&RQ9BQ;BW3V@1$5;1$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$$.<6K-J345^C906R>2WTC.6-P<T![CNYVY]@]RR?!O1M79'UMQO%,8*M^
M(86.():SJX[>)P/<5*"*:<%/#[<7_:)F9D1$5=XB(@(B("(B B(@(B("(B B
M(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B
M(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("CG7G#&EOL\E=:I
M&4=P?N]I'W.4^)Q\T^8^'>I&11IOV+=^GDN1N',-ST#J:WR%LEIJ)@.CJ<=J
M#_NY*M*;2&HJEX9%9+CD][X','Q< %U2B:>5/ [6^E4Z0MHSA).:B.JU,YC(
MFG(I(W<Q=Y.<-@/(9]H4S11LBC9'$UK(V -:UHP !T 7M$>EC8EO&IY;<"(B
MKI$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%\<T.:6N +2,$'O7U$$2:SX2LJ9I
M*O34D<+G'+J239F?] ]WL.WF%&U=HG4E$\MFLM:['?#&91\6Y74B*:>5?X18
MNSS4_=^'9RW0Z*U)6R!D-EK6D]\T9B'Q=A2CH'A:RUU,5PO[XYZF,AT=.S=C
M#XN/X1\NGM4IHFC'X39LU<T_>G\1$15ZHB(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@+RYS6_.<![2O2A
M'T@21=K3@D?<'_M*.;+R/9K4W-;TFQKFN^:X'V%>E"/H^DF[W;))^X,_:4W)
M!B9'M-J+FM;65[J9*.RW"IAQVL-/)(S(R,AI(^I0+]MG4W])2?U'_-3IJC[V
M;O\ J<W[#ER8I+RN,9%VU53%NJ8=APN+HF./4M!*]JG3?YO%^:/J519/=CL(
MB(HB(@(B("(B B(@(B("(B B(@(B(-;XAW>JL6DJVX4!8*F(QAI>WF&[V@[>
MPJ,-+<3-0W+4=LHJE]*8*BH9$_EAP<%P!P<K?^,7\WMS_.B_O6J"M!_?I8_U
MR+]H*/ XCD7;>51115,1.OK+JE$15[XB(@(B("(B B(@(B("(B H/U=Q*U!:
M]37*AI'TP@IYG,9S0Y.!YY4X+EOB)]_%[_67*2\CB]ZNU;IFW.NJ?>'%ZJ[_
M *4I[A<"PU#WO:2QO*,!Q V6SK1N"WW@T?Z27]LK>4=^)5-5BBJKO,0(B*N@
M1$0?"0T9<0!YKX)&$X#VD^U:%QO.-#/Q_P"(C_Q40\,'$Z\LVY_CC^R5-O,R
M.(>#?IL\N]ZZ[]73J(BKTQ$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$$(:PXDW^U:GN5#2/IA!!,6,YHLG'MRI'X;7JKO^E8*^XEAJ'R/:2QO*,!V!
MLH$XC??S>OUERFG@K]X5+^EE_:6,/ P,B[7EUT553,1OZMZ1$63WQ$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!1+K+BA<
M;%J6NMM/0TDD5.YH:]_-DY:#O@^:EI<R\5OYP+Q^>S]AJDO+XM?N6;456YU.
M_P!I3[HO4=/J>Q0UT&&2_,FBS_%O'4>SO'D5G5S+PWU4_2]];)(YQH)\1U+!
MX=SAYCZLA=+PR,FB9+"]KXWM#FN:<@@]"$ALX?F1E6^O]4=_]O:(O$LC(HGR
M2N:R-@+G.<<  =257H,+K34<&F+%-7SX?+\R&(G^,>>@]G>?(+0M&<3[C?M3
M4-MJ*&DBBJ'.#GLYLC#2=LGR6@<2=5/U1?G/B<1;Z?,=,T]X[WGS/U83A1_.
M!9_SW_W;ECM\Y<XE7<RJ:+4ZIW$?'JZ91$63Z,1$0$1$!$1 1$0$1$!$1 1$
M0$1$!1SQ;U==-,2VQMJ="!4-D+^T9S?-+<8^)4C*&/2%_P XL?YLWUL4EP\2
MN56\:JJB=3T^K+<*-:W?4UYJZ:Z.@,45/VC>SCY3GF:/\5**@G@!]\MQ_4S^
MVU3LD,>%W*KF/%5<[GJ(B*O0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M!Y<]K3AS@#YE&N:[YK@?85 ?'@D:Q@P3_F;/VGK8?1Z)-+?,G/KP_4]3;S:.
M(<V5[-R^O7:741%7I"(B B(@(B("(B"!+SQ1U'27>NIX7TO9PSOC;F')P'$#
MO\E,.B[C/=M+VZOK"TU$\7,\M&!G)[ES+J3[XKK^M2_ME=&\,_O$LWZ#_$K&
M'@<+R+MR_7375,Q$?NV=$19/?$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0:#K?B-%I:\BWR6U]23$V7G;,&]2=L8/@HFXBZO9JZLHYXZ-U*((RPAT
MG/S9.? *7-:<.J?5%X%PFN$U.X1-BY&1APV)WZ^:B3B1I&'2591P05<E2)XW
M/)>P-Q@X[EB^<XG[7JKF_M[_  _+\7GAUJ]FD:RLGDHW50GC# &R<F,'.>A4
M@4O&6"HJH81996F1X9GY0-LG'XJT'AOI&'5M;603U<E,((P\%C [.3CO4A4O
M!RCIZF&87>H<8WAX!B&^#GQ2&O"]N\*/!_I_)(.J/O9N_P"IS?L.7)BZSU1]
M[-W_ %.;]ARY,26?'/ZZ/A*>;]Q:M=L I[7 ^XS,: YX=R1@^1W)^&/-8*#C
M34B4?*+-"Z//1DQ!^D%8/2'"^Z7VF95UDK;?2/&6%[.:1X\0W; ]I6;O/!J>
M&D?):;D*F=HSV,L?)S>0=D[^WXIU7Q>)7(\2F-1^7[]4AZ0UO:-4 QT<CH:Q
MHRZFFP'X\1W$>Q;0N0H):JUW!LD3I*>LII-CT<QP*ZCT;>AJ#3=#<< 22LQ(
MT= \'#OI"L2[N&\0G)W1<_JC]6:6B:LXFV>Q3OI8 ^X5C#AS(2 QA\"[Q]@*
MM^,FJ9;'9HZ&AD+*VNR.=IWCC'4CP)S@>]0SH_35;JFZBCHN5C6CGEF?\V-O
MB?$^ 3;#.XA71<\"Q&ZF^GC36=ID6>G[/P,QS\<?X+;=)\4+1>YV4M6Q]NJW
MG#1*X.C<? .\?: L6W@Q:ODO*ZYUQJ,?/ 8&9_-QGZ5%FL]+UFE;H*6L+9(W
MCFAF:,-D;_@1WA3JY*[^?B:N7>L?E^SJ98'6FH6Z8LCKB^F=4ALC6<@?R]>_
M."M7X+ZHEO-GEMU=(9*NA Y7N.[XSTSXD=/@KCC?]XLOZQ']95>M7E<^+-^W
MZ+'3_%JAN=R;355%\@@Y'/=/)."UH:TGI@=<85C>^,M+#,Z.SVY]2T'':SOY
M ?8T9./;A0O!%)/,R*!CI)7N#6L:,EQ/0 *4;!P=K:JF;->*YM$YPR(8V=HX
M>TY !]F5'BV<W.R(Y+?6?74?_&0M?&AKI@VZ6DLB)W?3R<Q'^R>OQ4FVN_6R
MYVHW*CK(G4;02^1QY>3'7FSTQYJ#=;\,ZW3M$^OI:D5U$S^,(9R/C'B1DY'F
MM%CJ9XZ>6".:1L$I!DC#B&OQTR._";91Q+)Q:IHR(W_/P3?J#C!;J.9T-HHY
M*\M..U<[LV'V;$GX!8:FXTU E'RFS0NC_P#=S$'Z05K^C.&ESU#3,K*B1M!0
MOW8][>9\@\0W;;S)"SUZX-U$%&^6TW(54[1GL98^3F]AR=_;\4ZK%WB5V/%I
MC4?E])ZI&TCK6T:H:64,KHJIHRZGF&'@>([B/9]"V9<ATM156NX,F@?)3U=/
M)D'HYC@?^MEU+I*[MOVG*"Y !KIX\O:.@>#AP^(*L2[^&Y\Y.Z*_ZH_5ET1%
M7JM+XQ?S>W/\Z+^]:H&T9/%2ZKM$]3(V.&*JC>][C@- <,DJ>>,7\WMS_.B_
MO6KF]C'2/:QC2Y[C@ #))\%C+YCC%7+E4U1Y1'UE-U]XQT5/,Z*ST#ZL-..V
ME=V;3[!@DCVX6.HN-,PE K;/&8^\PS$$>XC=6.G.$%?74S)[Q5MH.89$+6<[
MP/\ 2W 'LW7W4?""NHJ5\]GK!7%@R87,Y'D?Z.Y!/ELG5LFYQ.8\36H].GT[
MI5TKJRU:G@<^V3GM6#+X)!RR,]H[QYC(6?7(UJN%79KG%644CH:J!V0?K!'A
MW$+J/2MZBU!8:2Y0CE[9GKL_$>-G#XA6)=_#N(>U1-%?2J/U94D $DX [U'>
MIN*]HM4SZ>W1/N4[#@N8X-B!_.WS[ACS6(XW:LEI6LL-!(6.E9SU3VG?E/1G
MOZGRQXJ+M+:<N&I;C\DMD8) YI)'G#(QXD_X=4VY\WB-RFYX&/'7^=D@Q\::
ML2YDL\!C\&S$'XX_P6TTG%6S5-FJJID<D=;3LY_DDK@TR;@>J[H>OM\E@8N"
MK/D_W6]N$^/P:?U0?][*T+6>B;II61KJMK9J-YPRIB^:3X$=Q4ZM%5_B./3-
M=R-Q^73Y)/L/%J&[7FBM[;1)$:F5L0>9P>7)QG'*I/7+&@/OULGZW'^TNIB<
M#)Z*P[^%9-S(HJJN3O4K>X5U-;J22JKIXX*>,9=(\X 497KC)0P2NCM%OEJP
M-NUE?V;3[!@GXX6@\3=6S:EO4D<,A%LIG%L# =G8V+SYGN\![U[T1P\N6IX?
ME1D;1V_.!,]O,7GOY6]_MR%-N._Q*]>N^%B1^?\ .FFST_&FI$@^46:%T??V
M<Q!^D%;]I'7EFU*X0TTCJ>MQ_F\^ X_FGH[Z_):16<%L0$T5YYI@-FRP8:3[
M0=O@5HU-HK4+-3LM4=+)%6L(D$P.&-;G^,#QW?3G;JG5(R,_'JCQ:>:)^'UA
MTXN6^(GW\7O]9<NFK9#/3V^GAK*CY34,8&R3<O+SD#<X7,O$3[^+W^LN5EMX
MW.[-,_C^R:^"WW@T?Z27]LK:KY=J.R6V:NN,HB@C&Y[W'N '>2M%X:7BCL7"
MZ"NN,HC@CDE]KCSG#0.\E1-KC5M9JJY&:<F*DC)$%.#LP>)\7'O*,ZL^G%Q:
M(CK5,1J$C.XU4V3RV68CN)J /^%;]HZ^56H+;\NGMCZ"!_\ $]I+S.D'XV,#
M \/%1=PMX=&M[*[W^(BEV?!3.'\;X.</Q? =_LZS<      -@ D-W#YRKD>)
M?JZ>4:A]6KZ]U:S25#35,E(ZJ$\ACY6R<F-LYZ%;0M9UUI*+5M%34T]5)3"&
M0R!S&AV=L8W1VY'B>'/A?U>2)M=\2(M3V%UN9;7TQ,C9.<S!W3.V,!:=I6ZM
ML>H**Y/B,S:=_,8P[EYMB.OO6Z:]X<4VF+ ZXPW":H<)6Q\CHPT;YWZ^2TO2
M=J9?-0T-MDE=$RH?RE[1DC8GI[E'R>3[3[13XO\ 7TUV_+\$I_;JI_R)+_Y@
M?_@J2]-W47NQT=R;$86U#.<1EW-R[XZ^Y1Q]I:B_+%1_4M_>I#LU#!IO3D-*
M^<NIZ*(\TKQCU1DDE6'T&'[9%4^T]M?A^RO>;M0V6A?5W.I93P-VR[J3X =2
M?(*,;MQG@9*YEJM3Y6#I)/)R9_V1GZU&^M]3U.J+S)53.<VF:2VGASM&S]Y[
MRM@T9PPN%_HV5U9.*"CD&8RYG,^0>(;D8'F2IMY]SB.1DW)MXL=/YZ]F>H^-
M,HD K;/&8^\Q3$$>XC=2-I36%HU/&?L=.1.T9?3RCED;YX[QYC*C.]\&ZF"E
M=+:+BVJE:,]C+'V9=['9(S[<>U1E33UEGN;98724M;32=>CF.'4$?1A&/MV9
MB51&1&XGX?I,.ND6 T-J%FIM.T]> &S?Q<[!^#(.ON.Q'D5GU7T-NNFY3%=/
M:11GJ'BJVQWJLMM199724\A;S"H YAU#OF]XP?>I,4*<?+-V5;0WB)OJS-^3
MRD?C#=I]XR/]E''Q&Y=M6?$M3K7?X)+T3J:#55F-=!$8'-D,;XB[F+2//S!!
M6P*!N!%Y^1Z@J+9*[$5;'E@/](S?Z6\WP"G*NJHJ*BGJJAW+# QTCSX #)^I
M(98&3[18BNKO'=H^M.)5+IF]&W"A?5R,8UTCFRA@:3OCH>[!]ZV31VH8-36.
M*XT\9BYG.8^(NYBQP/3/LP?>N8KW<9;M=ZROG_C*B5TA'AD[#W# 4B\!KW\F
MO%5:)G8CJV]I$#_2-ZCWMS_NJ;>9B\4KN9/+5/W9[?LG-1]K/B92Z;O;[:*!
M]7)&QKGN;*&!I.^.A[L'WK>JVIBHZ.>JJ'<L,+'2//@ ,GZER=>:^6[7>KKI
MLF6IE=(1X9.P]W1677Q3,JQJ:8MS]Z?HZ0T'JLZMHJFJ;0/I(8I!&TNDY^<X
MR>X=,CXK.W2XTEJHI*NX5$=/3L^<]YQ[AXGR6*T/:&Z?TG0T<F&2,C[28G\<
M^L[/LZ>Y0)Q$U9/J>]2.:]PMT+BVFB[L?C$>)_Y(M_,JQ,>F;G6N?Y^B0KQQ
MFI(I7,M-MDJ&C;M9G]F#[  3\<+'TO&FH$@^56:)T??V<Q!'Q!6N:(X<7'4M
M,*R:5M#0./J2/;S.D\VMVV\R5L=VX,31TSGVNZ-GF:,B*:+D#O8X$X^"G5Y]
M-WB5VGQ:>WY?1(6DM;6?4X[.BF=%5@9--,.5_M'<1[%LZY$D966>YEKA+2UU
M-)[',<%TEPXU-_"?3L=3-RBLA/95 &WK ?.'D1O\58EW</XC.1,VKD:JC]7K
M7FK&:2M]/524CJH32]ERM?R8V)ST/@L#I?BG17FNEAJ:/['P10NF?/+."T $
M#'0>*LO2 ^]VV_K7_ Y0;&Q\CVLC:YSW$-#6C))\$VY<[B%['R.6F>G3HG"[
M\9+=!,YEKMT]6T'':2/$0/F!@GXX6V\/]4G5EHFK32"E,<QAY!)SYP <YP/%
M198>$-VKJ9LURJHK>'#(C+>T>/: 0!\5*?#_ $L=)VF>B-6*KM)S-SB/DQEK
M1C&3X)#HPJ\VY<YKT:I_+_Z@/B-]_-Z_67*:>"OWA4OZ67]I0MQ&^_F]?K+E
M+'#*\45CX815URF$4$<LOM<>8X:!WDJ0X>'513F7)GMU^K?+W=J.R6V6NN,P
MBIXQN>]Q[@!WDJ,G<:J;F/+99B.XFH _X5'6N-6UNJKB9:@F*DC)$%.#LP>)
M\7'O*W+A;PZ-;V5WO\1%+LZ"F</XWP<X?B^ [_9UNV^K/OY5[P\7I'K^Z4='
M7VJU#;?ET]L?00/_ (GM)>9T@_&Q@8'AXK/+XT!H :  -@ OJ/<HB::8BJ=S
MZBP>J=46S3-()[G,0Y^>SA8,OD]@_P 3LLXN7.(5TFNVL+I-.XEL<SH(VG\%
MC"0!]&?:2CBXCF3BV]TQUEOE;QIE,I%%9XQ'W&:8DGW ;*\M'&:FDE:R[6N2
M!IZR02<^/]DX^M8?07#"GOMC@N=RKY8V3Y,<5.!D $C<D'?;IA7MZX,O:6NL
MURYP7 .94MP0,[D.'7V8"G5YM%7$IIB['6)^"6;/=**\4+*RVU#*BG?L'-[C
MX$=0?(J]6.T_:*:QVBFM]$W$,+<9/5Q[W'S)W4><:M72VZGCLEND+*BH9SU$
MC3NV,[!H\SO[O:J]F[D>SV?$N]_P]67U3Q0LMEF?34P?<:IFSFPD!C3X%_[@
M5J#N--9VF6V>G#/ S.)^./\ !1YIC3U?J2Y"CMD8<_',][CAD;?%Q4G1\%6?
M)_NM[<)\?@T_J@_[V5.KQ*<G/RMUV>D?E^[,Z<XMVBXRM@N<,EME=L'N=SQ^
M]VQ'O&/-2,Q[9&-?&X.8X9#FG((\5R[K+2-QTK5LCK@V2"3/93Q_-?Y>1\EN
M_!/5LL5:VP5TA?3R@FE+C\QPW+?81GW^U6);\/B5R+O@9,=?5-JQ6HM06W3U
M'\INM2V%IV8WJ]Y\&CJ5<7FXP6BU55?5'$-/&7NQU..@'F3@>]<MZEOE9J&[
M35]>\N>\X8P'U8V]S1Y!'7Q#/C%IB*>M4I/N7&AHD+;;:"Z,='U$N"?]D#;X
MKS;^-)[0"XV<"/O=!-N/<1O\5B=*\):^Z4<=7=:H6^.0<S(NSYY"/$C(#?K5
M74O"&NH*1]3:*P5_(.9T+H^1Y'^CN03Y;*=7F^)Q*:?%\OR^G=+FFM2VO4E*
M9K54"0M^?&X<KV>T?X]%F5R38[M66*Z15U!(8JB(]#T<.]KAW@KJ33EWAOMD
MI+E3;1SLYBW.>5W0M]Q!"L2]'AV?[5$TU=*H:UKS7T>DJ^FI9+>^J,T7:<S9
M0S&Y&.A\%96?BM::NVU=9<(G478.:UD0?VCY20?FC Z8]FZT_P!(#[X;;^J_
M\;E']@LM??K@RBM<!FF=N>YK1XN/<%-O/R.(9%O)JMT=8\HU_)2=7<:9.V(H
M+.SLAT,TVY]P&WQ*R-BXQT-1,V*\4$E&"<=M$[M&CVC ('LRK"BX+$TX-=>>
M6<C=L,&6@^TD9^ 6D:YT37Z3EC=.]M11RGECJ&# SX.'<4ZL:[W$;$>+7V_+
M]G2M)4P5E-'44DK)H)!S,D8<AP\BJR@?@CJ6:CO?V%GD+J.KR8P3\R0#.WM
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MU1[S] *E_BGJ9^F].$TKN6NJG=E"?Q=O6=[A])"0\_!R[LV:LC(GI';I'\_
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MX]_??2_J3/VWJO3XAD56L?Q+4^C>+9Q6M$]GJ*ZOB?2.CD[-E.UXDDEVSD#
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MKAH-36JKJG<D$-3'(]V,X:' DK%\UQ68C+HF?2/K+K!%3IYXJF".:GD9+#(
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MCFA@:"TCW9!5TZ(X9=\6FNNYN8Z_CT1_Z0E2\066E!/9O=+(X>) :!^T5K?
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M:IP]4#O#?$^7Q4ZT?#_2])('Q6>!SA_2N=(/@XD+9HHV11MCB8UD;1AK6C
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MAC&-Z- & %[: UH#0 !L %]5AZ^'A48E.J>LSWE!?I ??#;?U7_C<KOT>O\
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MWVB)KC_1O>P? $!8Z>%5PB[;JFK'KU\X^CGZ^:EO-_(;=*^:H;G:/YK,_FC
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M<U.8&!Y,C@<Y..Y;@A:NT7J>>B=P\R/9%&Z25S61L!<YSC@ #J25C/X1V/\
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M /?)<?U3_C:IV7(5%75=!(Y]#53TSW#E+H9"PD>&05?P:BO1FC!O%QQS#_\
M.G^/M2):,+BE.-:BW-.W5R+X=AD]%#>O^*DK*F6@TRYK6L):^L(#N8_Z Z8\
M^_N\57T&3E6\:GFN2F5%R-776X5\ADKJZIJ'GODE<[ZRJUKO]VM4H?;[C50$
M'.&R'E/M;T/O3;R8X[3OK1T^+K-%&7#?B4+U/';+V&15[MHIF[-F/@1W.^@^
M2DU'L6,BC(HY[<]!$15N0SZ0O\=8_P V;ZV+'< /OFN'ZF?VVK(^D+_'6/\
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M#&OU]:FO:'-+GY!&1_%N4J<=_O+B_7(_V7J+>$O\X%I_.?\ W;ECYOFLZ/\
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MO%8CV6K\OK#'<!(HY=1W$2L:\"DSAPS^&U3C\CIO_#P_[@4(>C_]\EQ_5/\
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M4-.<9?A@^).%'E6<C-Q8\+DWKMTF?HS?$_7[-3QQV^W0NCM\4G:%\@]>1P!
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M^IN-3%3PM&2Y[L?#Q/D%R?54E9;YRRJ@GI9F_@R,+'#XKPQM36S!K!-42G8
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M3UAL2(BKJ$1$!$1 1$0$1$!$1 1$0$1$!$1 1?''#2? *%SQIJ 2/L+#M_\
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M$5?3V+%%BCDH["P6M-0PZ9L$]PE ?(/4AC/X<AZ#V=Y\@5G5"GI!5KW5]IH
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M*7MZ."8]9(VO^(RJZKZ::**YBN8C:WKX75%#4P,(#I(W,!/3)!"@[[35\_\
M'6[_ 'G_ /X*GE$:,G#M9,Q-SR<>U$1@GDB<071N+21Y'"WVS<*[O=K525\%
M90,BJ(Q(UKW/R ?'#5I%S_E*K_3/_:*Z<X??>39/U5GU*0^=X;BV\BY53<[0
MUOA?H>OTG75TU?44LK9XVL:(2XD$'.^0%(B(J^GL6*+%'AT=A$15N$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!:_J/1]DU#EURHF.GQ@3QGDD^(Z^_*PO%Z
M_5UETV6VV&;GJ28WU+1M"WOW[B>@]_>HGTWQ)O\ 9(6P"9E93-&&QU(+BT>
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MG(!=[6G;/L/N4V\6KB&)?KFW>IZ1VF8_DPV.W\(=/4TH?4R5M6!^!)(&M/\
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M>:.LN,;/Q ]A^DM4EHHY[N+9O3NNF)EJNF] V"P2MGI:0S5+?FS5!YW-\QW
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M.FO]7P_L!:WZ1G\U5Q_30?W@6$?U+Y-QT/\ >7I__5]/_=M6;6$T/]Y>G_\
M5]/_ ';5FUC*PHUE3%1TD]34O$<$+'22//1K0,D_ +GC2>FV<2+=KC4=S,;*
MJZ.=!;NU< 8^3#F]>[U8VY\ Y;SZ0E\FI-*TUAMV77*^SBEC8WJ69'-\26M_
MVBK*D]'[2K:6$551<WU 8!(YDS0TNQN0.7896=/2-L9ZLQP"U&Z^Z#@IJIQ^
M7VIWR.9KOG8;\PG_ &=O:TK;*S3%#6:LH-0U+IGU=# ^&",D=FSFZOQC/-@X
MSGHHBTY;8N%7&.FM-/),;#?J=L<3IG D2@[ D 9/-MTZ2!3TI5TG<+#$:MLD
M6H]-W&T5#S''5Q&/G R6'J'8[\$ J&;/J367"BBBM>I[(;GIZF/)%74AR8V9
MVWZ8\ [E/FIBUG<;G:=-UM;8[;]DJ^)N8Z?FQS>)QU.!O@;E1G)QZTY)99FU
M]LKVW$L,<E ^(%KG8P6\Q/S?:,^2M.]=B4HZ7U!;]3V6"Z6>;M:67Q&'-<.K
M7#N(6646>CK8;A9-$3R7.%],ZNJG5,4#P06,+6@$@],X^&%*:QF-20B'TH?Y
MN:?_ %A%^Q(I3M'\E47Z%G[(46>E#_-S3_ZPB_8D5O2\?-*T]N@B;2W>6:.-
MK.1L#-R!CJ7K+4S3T3S4..<++3KG0]^H ([DZL$#RW8RL#F['QV<X>QRDOB-
M_-_J7_5U1_=N48Z;MU]XE:\H-4Z@M\ELL%K/-04LN>:1^<AV_7< DXQL ,[E
M2=Q&_F_U+_JZH_NW)/E"PUST?/YI[+[9O[YZT3BG67:@X^6*IT]0,N%S9;?N
M5.\X#\]N#OD=!D]>Y;WZ/G\T]E]LW]\]:[J3_M.:8_U:[]FH5C^J4\FHU5XU
M9Q?NITG74M!:(:*<35K02)6\I+3LXDNQD[ 8R1DKI"FA934T4$0Q'$P,:/
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& 1$0?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
